P00001606T0076|14 33|alkaline phosphatases
P00001606T0076|37 50|5-nucleotidase
P00008171T0000|30 47|hyperbilirubinemia
P00013683A0210|40 52|CO2 production
P00015731A0090|11 24|administration
P00015731A0090|42 60|anhydrase inhibitors
P00015731A0090|61 73|acetazolamide
P00015731A0090|74 86|methazolamide
P00015731A0090|87 102|dichlorphenamide
P00024600A0522|11 26|HMG dosage regimen
P00024600A0522|86 98|dosage regimen
P00027739T0000|0 28|Serum gamma glutamyltransferase
P00027739T0000|45 56|liver disease
P00027967A0207|19 30|HI antibodies
P00029555A0861|31 42|quantitation
P00029555A0861|101 133|shellfish microbiology laboratories
P00029953T0045|0 14|Characteristics
P00029953T0045|17 30|lipase activity
P00030937A0119|11 43|alkaline phosphatase concentrations
P00033873T0001|0 26|Gamma glutamyl transpeptidase
P00034935A0545|76 88|drug treatment
P00038408T0000|29 47|alpha-autoreceptors
P00038408T0000|70 85|alpha-methyldopa
P00052597T0000|9 23|immunoglobulin E
P00052597T0000|47 60|Professor Dan H.
P00054900A0226|10 23|reaction stains
P00055040A0000|3 14|out-patients
P00055040A0000|19 36|pustulosis palmaris
P00055040A0000|70 87|immunofluorescence
P00055040A0000|135 153|degradation products
P00055040A0000|234 245|cryoglobulin
P00055040A0000|254 269|plasma fibrinogen
P00056837A0000|5 21|mediastinoscopies
P00056901A0308|26 45|hydroxy-ethyl-starch
P00060529A0695|12 23|control group
P00060529A0695|27 42|acquisition-rate
P00060529A0695|143 160|practice population
P00061478T0000|4 16|complications
P00061478T0000|19 33|catheterisation
P00063680T0000|19 31|galactosaemia
P00064414A1098|36 49|erythropoiesis
P00066874T0000|21 47|fluid alpha fetoprotein levels
P00066874T0000|61 73|contamination
P00072928T0000|0 13|Serum-ferritin
P00072928T0000|27 42|haemochromatosis
P00073344A0367|14 35|phytomitogen reactivity
P00074758T0000|16 29|hypothyroidism
P00086313A0000|20 31|Legionnaires
P00086313A0000|32 46|disease bacteria
P00086313A0000|142 156|antibody testing
P00088391A0181|43 59|coumarin treatment
P00089778A0000|3 15|concentration
P00089778A0000|18 37|alpha 2-macroglobulin
P00089778A0000|38 55|alpha 1-antitrypsin
P00089778A0000|67 79|C3-complement
P00089778A0000|80 108|fibrinogen degradation products
P00089778A0000|289 304|cataract patients
P00096241A0087|141 151|term infants
P00097989A0106|23 36|treatment plans
P00100540T0000|0 17|Aspirin intolerance
P00100540T0000|27 40|susceptibility
P00100540T0000|43 65|platelet cyclo-oxygenase
P00100791A0425|24 40|cynomolgus monkeys
P00100791A0425|87 99|rhesus monkeys
P00105401A0635|36 47|interference
P00105401A0635|52 72|thyroid hormone binding
P00105401A0635|122 134|clearance rate
P00105401A0635|137 151|thyroid hormones
P00105401A0635|183 201|premedication levels
P00105903A0288|45 62|polyethylene glycol
P00112627A0542|0 12|Pentobarbital
P00112627A0542|81 93|normeperidine
P00112627A0542|121 132|alphaprodine
P00114144A0189|56 69|result emphasis
P00114144A0189|114 125|similarities
P00114144A0189|136 157|glycogen storage disease
P00114144A0189|215 226|enzyme defect
P00117748T0000|0 11|Erythromycin
P00117748T0000|15 35|clindamycin resistance
P00117748T0000|38 63|Corynebacterium diphtheriae
P00117748T0000|68 78|skin lesions
P00118044A0000|14 26|displacements
P00118044A0000|110 120|EMG activity
P00119339A0400|74 86|T. cruzi stocks
P00119339A0400|135 146|degeneration
P00129659T0000|59 72|sex differences
P00137671A0896|5 16|observations
P00139624A0318|18 31|administration
P00139624A0318|47 69|serum ceruloplasmin level
P00139827A0000|0 16|Radioimmunoassays
P00139827A0000|19 30|pregnenolone
P00139827A0000|31 42|progesterone
P00139827A0000|43 64|dehydroepiandrosterone
P00139827A0000|70 86|alpha-hydroxy-DHA
P00142718A0156|115 130|chest radiographs
P00146327A0147|108 118|stem bronchi
P00150066A0554|16 27|haemorrhages
P00154430A0906|3 19|Southern technique
P00154430A0906|35 46|localization
P00154430A0906|73 85|transcription
P00155973A0387|112 137|carbon dioxide concentration
P00155973A0387|202 213|gas flow rates
P00155973A0387|239 255|minute ventilation
P00163384A0000|27 41|Bubo virginianus
P00167544A0067|25 39|microdissection
P00167544A0067|110 127|electron microscopy
P00167544A0067|155 178|surface specimen technique
P00168176A0000|22 39|apple butter samples
P00168176A0000|44 55|ethyl acetate
P00168176A0000|83 97|silica gel column
P00168431T0000|0 18|Steroid glucuronides
P00172199A0270|100 114|cross striations
P00173860A0475|80 96|excretion patterns
P00173860A0475|128 139|disturbances
P00176742T0000|14 29|suture absorption
P00183063A0300|14 26|DNCB reactions
P00188387A0975|9 20|lipoproteins
P00188387A0975|90 101|heart disease
P00193587T0000|0 12|EEG theta waves
P00196255A0000|0 14|REM dream content
P00196255A0000|111 123|verbalization
P00198510T0000|43 59|Locusta migratoria
P00199012T0000|7 18|ACTH syndrome
P00199012T0000|31 46|thyroid carcinoma
P00201881A0487|72 82|MSH contents
P00205074A0000|7 22|hypophosphatemia
P00209664A0836|131 147|parallel phenomena
P00210220X0000|9 22|neurochemistry
P00211881A0602|52 64|kidney lesions
P00216939T0001|45 70|acid dehydrogenase reactions
P00219533T0001|0 11|Distribution
P00219533T0001|15 26|correlations
P00219533T0001|29 42|serum uric-acid
P00219565A0172|14 30|hepatitis B antigen
P00219674A0000|0 13|Technetium-99m
P00219674A0000|22 34|pyrophosphate
P00221725A0523|25 41|cytochrome oxidase
P00221725A0523|60 71|lipid content
P00222102A0227|24 51|pseudohypoparathyroidism type
P00222102A0227|72 99|alpha-Hydroxycholecalciferol
P00222102A0227|157 169|normalisation
P00222102A0227|172 184|serum-calcium
P00222827A0000|31 42|diisocyanate
P00222827A0000|103 117|hyperreactivity
P00224013A0661|313 328|extraction ratios
P00224013A0661|401 425|beta-Vasodilator receptors
P00224013A0661|458 471|vasodilatation
P00227393T0000|12 45|25-hydroxyvitamin D3-24-hydroxylase
P00227393T0000|48 60|aminophylline
P00227393T0000|62 95|cytochrome P-450 monooxygenase system
P00227610A1593|71 84|polyoma viruses
P00231555T0001|46 61|combination drugs
P00231555T0001|81 98|cortisol production
P00232456T0000|18 29|gene products
P00232456T0000|59 70|tumor viruses
P00234206T0000|28 42|Bunyamwera group
P00234264A0164|0 34|Gamma glutamyl transpeptidase activity
P00239014A0000|38 50|determination
P00239014A0000|88 98|blood plasma
P00239169T0000|0 23|Dopamine receptor blockade
P00239169T0000|30 41|neuroleptics
P00240518A0000|33 45|determination
P00240518A0000|51 75|fungicide 5-fluorocytosine
P00254537T0000|49 59|state boards
P00261981A0434|17 33|serum somatomedin A
P00264240A1843|24 39|X. borealis oocyte
P00264240A1843|151 169|X. laevis oocyte 5S DNA
P00265964A0562|34 46|grain boundary
P00267764A0651|40 56|treatment failures
P00294502T0001|12 28|treatment planning
P00300314A0132|53 73|degrees F. granulocytes
P00300314A0132|92 106|hospitalization
P00300314A0132|143 159|calcium leucovorin
P00300314A0132|195 206|methotrexate
P00300314A0132|219 233|treatment cycles
P00303189A0247|44 57|serum chemistry
P00304310A0000|76 88|stabilization
P00304806A0760|12 36|serum alpha1AT quantitation
P00304806A0760|105 118|concentrations
P00321261A0104|20 34|prostaglandin E2
P00321261A0104|42 61|prostaglandin F2alpha
P00330364A0132|135 149|BCG-vaccination
P00330364A0132|180 194|BCG-vaccination
P00330364A0132|226 237|laboratories
P00331128A0000|12 26|serum calcitonin
P00331936T0000|44 78|immunoperoxidase antiglobulin technic
P00336354A0543|22 37|arginine infusion
P00336354A0543|73 84|hypoglycemia
P00336547A0000|3 15|mortality rate
P00336547A0000|46 63|Nocardia asteroides
P00336547A0000|67 96|Nocardia brasiliensis infections
P00336547A0000|134 146|C3H/eB origins
P00336547A0000|211 222|mouse strains
P00336547A0000|238 252|New Zealand Black
P00340692T0033|8 35|John Henri Roosegaarde Bisschop
P00342623A0228|20 38|whole-virus vaccines
P00342623A0228|49 60|type B antigen
P00352569A0000|7 18|oxygen supply
P00352569A0000|30 44|blood parameters
P00354315T0000|32 51|ataxia telangiectasia
P00361059T0000|32 53|diflucortolone valerate
P00361059T0000|68 87|clobetasol propionate
P00361340A0529|29 42|osteodystrophy
P00361340A0529|65 82|vitamin D deficiency
P00361340A0529|112 140|1,25-dihydroxycholecalciferol
P00361340A0529|155 166|significance
P00361340A0529|185 203|hyperparathyroidism
P00369397A0280|55 69|GnRH stimulation
P00369683T0000|72 83|breast cancer
P00377466A0188|39 64|follicle stimulating hormone
P00377466A0188|93 104|progesterone
P00377466A0188|109 120|testosterone
P00377466A0188|139 150|healing phase
P00378492A0475|0 11|Renin studies
P00378492A0475|51 62|control group
P00378492A0475|98 116|plasma renin activity
P00378492A0475|122 143|plasma aldosterone level
P00378492A0475|199 212|artery stenosis
P00378735A0000|89 101|marrow culture
P00378735A0000|126 139|dosage schedule
P00378735A0000|186 200|chloramphenicol
P00378735A0000|224 242|temperature response
P00378735A0000|268 279|relapse rates
P00381783T0000|0 29|Bone marrow transplantation-1979
P00383169A0000|45 60|dopamine receptor
P00383169A0000|115 134|rye-ergot derivatives
P00384744T0000|23 34|hypofunction
P00386251A0899|3 19|IDF standard method
P00386251A0899|83 102|sulphonamide residues
P00393598A0198|11 24|endotoxin fever
P00397806T0039|4 16|Algerian cases
P00401676A0414|71 82|radiotherapy
P00409927A0570|32 44|staphylococci
P00409927A0570|65 76|streptococci
P00415543A0320|132 142|lung disease
P00416758T0001|11 28|T. gambiense strains
P00416758T0001|56 72|laboratory animals
P00417166T0000|36 48|rhesus monkeys
P00420460A0291|34 46|drug treatment
P00420460A0291|47 76|log baseline plasma renin activity
P00420460A0291|92 104|blood pressure
P00425547A0000|21 33|osteomyelitis
P00427715A0000|95 110|radiation therapy
P00429151T0000|24 35|practitioner
P00429151T0000|59 69|Glasgow area
P00429893A0000|30 40|round window
P00429893A0000|49 60|implantation
P00429893A0000|108 119|scala tympani
P00429949A0000|17 39|World Health Organization
P00429949A0000|44 58|Expert Committee
P00429949A0000|61 85|Biological Standardization
P00429949A0000|160 192|International Reference Preparation
P00431832T0001|0 15|Plasma ion changes
P00431832T0001|42 61|beta receptor blockers
P00432615A0541|56 76|heterophile antibodies
P00432615A0541|90 102|gammaglobulin
P00432615A0541|133 144|interference
P00432615A0541|150 163|Sephadex system
P00435187T0000|13 24|flowers bloom
P00437749A0242|7 25|treatment modalities
P00439618T0001|0 15|Lethal Tachmalcor
P00439618T0001|16 29|diethylamino-2
P00439618T0001|29 41|hydroxypropyl
P00439716T0001|32 48|blood flow velocity
P00445259T0000|0 25|Serum ferritin concentration
P00445259T0000|29 48|bone marrow iron stores
P00445720A0263|11 26|pressure gradient
P00445720A0263|85 116|high-fidelity pressure transducers
P00450367T0000|26 37|hysterectomy
P00450367T0000|38 49|hysterectomy
P00450367T0000|87 98|hysterectomy
P00450760T0001|0 15|Cryoglobulinemia
P00451192A0248|36 50|computer program
P00451192A0248|100 119|LV region-of-interest
P00453780A0430|15 30|serum IgA response
P00453780A0430|44 60|patient population
P00454780A0340|0 17|Ultimate strengthes
P00454780A0340|36 51|cast cobalt alloys
P00454780A0340|59 72|titanium alloys
P00454780A0340|98 109|fatigue limit
P00456424A0000|53 65|microgram kg-1
P00456424A0000|68 80|blood pressure
P00456424A0000|150 162|cisterna magna
P00463973A0000|0 13|Platelet number
P00463973A0000|164 175|birth weights
P00464387A1185|6 17|measurements
P00464387A1185|58 72|disease activity
P00465223A0373|17 34|difference betweent
P00465681A0000|7 29|hemoglobin concentration
P00465681A0000|106 119|oxygen pressure
P00465829T0000|6 26|Planck analog equations
P00465829T0000|40 52|state membrane
P00473229T0000|9 25|methylene chloride
P00473229T0000|26 40|trichloroethane
P00473229T0000|41 57|trichloroethylene
P00473229T0000|58 76|tetrachloroethylene
P00473229T0000|105 116|chick embryos
P00473249T0000|24 37|administration
P00473249T0000|40 52|streptolysin O
P00473249T0000|58 77|electroencephalogram
P00474064A0205|18 36|convlusion threshold
P00474064A0205|76 86|mg.kg-1 I.V.
P00474064A0205|111 123|phenoperidine
P00476020T0000|3 14|biochemistry
P00476572A0139|109 120|radiodensity
P00477794T0000|41 56|response patterns
P00477794T0000|81 97|nuclei principalis
P00478714T0000|32 54|alcohol treatment program
P00479222A0682|101 114|immersion times
P00479246T0000|28 40|osteomyelitis
P00483716A0366|57 69|carotid artery
P00484177A0242|23 40|laminar flow regimen
P00485615A0935|158 169|pancreatitis
P00488534A0308|22 48|Treatment X Strain interaction
P00488534A0308|66 82|defecation numbers
P00490336A0181|5 22|conduction velocity
P00493818A0422|34 51|patient intolerance
P00494659A0391|30 44|3-carboxyphenyl
P00494659A0391|45 73|hydroxymethyl-2-oxazolidinone
P00495097A0663|5 19|characteristics
P00495097A0663|63 76|fiber synthesis
P00499588T0000|0 21|Carbohydrate metabolism
P00499588T0000|28 39|semen profile
P00499588T0000|57 68|sperm studies
P00503336A0285|81 99|alkaline phosphatase
P00503336A0285|103 115|transaminases
P00506559A0000|12 29|inhalation toxicity
P00506649T0000|19 40|serum protein components
P00512215A0000|38 56|difference tone level
P00513284A0000|70 81|tetracycline
P00513284A0000|105 116|drip infusion
P00513284A0000|139 153|pediatrics field
P00513284A0000|212 226|glucose solution
P00513284A1255|22 33|DOTC infusion
P00513284A1255|34 48|laboratory tests
P00516545T0001|10 24|characteristics
P00516545T0001|30 48|erythrocyte membrane
P00516545T0001|49 69|peroxidation processes
P00516545T0001|113 130|glomerulonephritis
P00517890A0468|35 46|transmission
P00517890A0468|78 101|hepatitis A virus excretion
P00519173A0126|39 50|oesophagitis
P00521732T0000|26 42|oestradiol-17 beta
P00521732T0000|80 106|steroid sulphatase deficiency
P00524451A0136|22 38|locomotor activity
P00524451A0136|106 118|hexobarbitone
P00524451A0136|152 165|catecholamines
P00534613A0000|18 31|blood platelets
P00535520A0239|74 88|cholangiography
P00540707A0255|58 70|complications
P00540707A0255|107 121|tip displacement
P00540707A0255|125 138|pouch haematoma
P00540707A0255|212 226|PMK implantation
P00540707A0255|254 266|vena cephalica
P00541752A1032|7 20|determinations
P00553858A0000|108 119|publications
P00555492A1034|149 161|blood pressure
P00555495T0000|7 22|re-establishment
P00555495T0000|87 99|re-appearance
P00555583T0000|0 15|Pharmacokinetics
P00555583T0000|18 30|Carbamazepine
P00557559A0170|46 71|N-methylnitrone 1,4-dioxide
P00564943A0444|38 53|blood cholesterol
P00569989A0239|5 23|halothane anesthesia
P00569989A0239|27 46|flow pneumocardiogram
P00569989A0239|71 98|acceleration pneumocardiogram
P00569989A0239|149 164|pneumotachograph
P00574222T0000|15 26|implications
P00574956A0304|251 263|manifestation
P00575231A0422|9 23|cystometrograms
P00575231A0422|41 60|detrusor contractions
P00577440A0298|60 81|3H-alpha-acetyldigoxin
P00578648T0048|34 47|administration
P00580151A0706|61 72|testosterone
P00583004A0445|10 33|1,8-dihydroxy-9-anthrone
P00583004A0445|34 59|1,8,9-triacetoxyanthracene
P00583004A0445|63 86|1,8-diacetoxy-9-anthrone
P00583004A0445|141 153|inflammations
P00583522T0001|52 63|inflammation
P00589073A0000|15 43|plasma prolactin concentrations
P00590594T0000|7 25|allotransplantation
P00592887T0000|18 33|Patent Blue Violet
P00592887T0000|40 51|lymphography
P00593119T0001|11 24|asthma patients
P00593119T0001|27 39|determination
P00593119T0001|50 62|comprehension
P00593119T0001|90 102|IgE antibodies
P00594466T0001|43 54|allylglycine
P00594617A0192|69 87|degradation products
P00594617A0192|127 139|insufficiency
P00594617A0192|188 211|ethanol-gelification test
P00597715A0256|39 50|sperm density
P00597715A0256|79 90|FSH elevation
P00598012A0174|2 21|girls prolactin levels
P00598012A0174|82 96|prolactin levels
P00599601A0260|64 75|pinealectomy
P00600943T0001|13 31|lymphomononucleosis
P00601401A0181|6 23|hemoglobin solution
P00601401A0181|95 118|delta log Po2/delta pH ratio
P00602622A0362|9 20|ulcer therapy
P00602702A0309|33 52|estriol concentration
P00602702A0309|108 127|estriol concentration
P00603783A0647|0 10|Serum levels
P00603783A0647|67 84|observers IgA levels
P00606849T0000|20 31|heart disease
P00606849T0000|41 53|thromboxane A2
P00614915T0001|18 29|traumatology
P00616575A0000|34 48|brain structures
P00616575A0000|86 99|decimeter waves
P00616575A0000|115 127|investigation
P00616575A0000|136 147|unit activity
P00617815A0215|12 25|L-R differences
P00618078A0367|14 29|lysozyme activity
P00619782A0058|73 92|ultraviolet radiation
P00619948A0000|72 83|fluphenazine
P00619948A0000|92 104|nortriptyline
P00619948A0000|144 155|reaction time
P00619948A0000|165 177|blood pressure
P00621626T0000|0 12|Stress effects
P00621626T0000|15 36|affiliation preferences
P00621626T0000|82 96|behavior pattern
P00623361A0221|28 39|contribution
P00627039T0000|25 63|Louisiana paper manufacturing plant workers
P00627129A0944|174 191|beta-adrenoceptors
P00627202T0000|22 33|pharmacology
P00628990A0000|63 76|reconstruction
P00628990A0000|86 104|ureteroureterostomy
P00628990A0000|119 138|ureteroneocystostomy
P00628990A0000|170 181|ureterostomy
P00630713T0000|15 39|Du Pont aca ammonia procedure
P00633909A0000|41 62|Internal-External Locus
P00633909A0000|65 76|Control Scale
P00635143T0001|8 19|strontium-90
P00635143T0001|33 46|Cyprinus carpio
P00635194A0093|0 12|Kodak XV-2 film
P00635194A0093|65 80|dose distribution
P00637637T0000|27 45|plasma renin activity
P00637637T0000|57 68|hypertension
P00639410T0000|16 26|bone changes
P00639410T0000|43 61|lipid clearing agents
P00641395A0441|4 15|blood samples
P00641395A0441|30 47|hyperbilirubinemia
P00641395A0441|149 164|extraction method
P00644314T0000|7 22|hypersensitivity
P00644314T0000|45 59|anticoagulation
P00644539A0783|124 136|test solutions
P00646023T0058|21 34|virus excretion
P00646023T0058|51 62|transmission
P00656008T0000|17 32|paraquat toxicity
P00656008T0000|41 59|superoxide dismutase
P00657551T0000|13 31|magnesium absorption
P00659962T0000|16 34|riboflavin excretion
P00659962T0000|53 65|acid ingestion
P00663166A0000|37 47|body imaging
P00663166A0000|83 94|particulates
P00663166A0000|150 171|patent ductus arteriosus
P00663166A0000|179 199|Eisenmenger physiology
P00665053A0276|63 76|group affection
P00665336A0908|43 57|EEG-information
P00668122A0414|10 29|liver biopsy specimens
P00668122A0414|81 95|mean iron content
P00668122A0414|101 122|liver ferritin molecules
P00676416A0320|43 55|liver biopsies
P00676790T0000|0 16|Angiotensin effect
P00681550A0000|51 64|auditory fibers
P00681550A0000|92 103|relationship
P00681550A0000|114 125|response type
P00681571T0028|54 74|eccrine sweat duct units
P00682762T0001|0 17|Silicosis mortality
P00686836A0000|32 48|lipid peroxidation
P00686836A0000|69 85|gas chromatography
P00686836A0000|88 100|breath samples
P00686836A0000|168 184|IU vitamin E acetate
P00693987T0001|0 13|Thromboplastic
P00693987T0001|52 65|administration
P00696680A0000|71 87|rhabdomyosarcomas
P00696858A0000|22 36|porcine secretin
P00696858A0000|116 130|porcine pancreas
P00701462A0722|0 14|Urine antibodies
P00703350A0418|0 11|99mTc phytate
P00703350A0418|12 23|198Au colloid
P00703932A0000|15 32|glomerulonephritis
P00710372A0302|82 93|GH deficiency
P00712117A0521|104 115|A/Victoria/3
P00713525A0268|21 35|disfluency rates
P00713525A0268|69 80|presentation
P00713525A0268|91 103|stimulus words
P00715180T0074|53 79|plutonium-239 dioxide aerosol
P00715753A0241|2 22|biopsies CK-MB fraction
P00715753A0241|51 67|total-CPK activity
P00716366T0001|7 19|determination
P00716366T0001|22 50|alkaline phosphatase isoenzymes
P00716366T0001|106 119|liver cirrhosis
P00722298A0619|101 115|field dependence
P00722298A0619|122 133|significance
P00722652A0118|11 33|2nd-generation schizonts
P00725336T0000|0 32|Newcastle disease virus surveillance
P00725534A0888|66 79|IgA immunocytes
P00725534A0888|139 151|IgA deficiency
P00725752T0001|11 22|hypertension
P00725752T0001|54 74|beta receptor blockader
P00728718T0000|0 13|Thyroid disease
P00733067A0188|127 138|construction
P00733067A0188|199 209|valve system
P00733067A0188|238 255|spiral introflexion
P00740409A0000|3 16|histochemistry
P00740409A0000|20 33|ultrastructure
P00740409A0000|45 62|cerebellar deposits
P00741476A0000|24 41|Ergotamine Tartrate
P00743335T0001|0 12|Reaction times
P00745775A0170|45 57|arteriography
P00745775A0170|88 100|complications
P00747722A0486|40 50|B1 injection
P00748978T0000|0 17|Serum relaxin levels
P00748978T0000|20 34|prostaglandin E2
P00753237A0000|205 217|INSENSITIVITY
P00753237A0000|328 342|PNEUMATIC INSOLE
P00753237A0000|435 450|blood circulation
P00755245A0000|41 53|vasomotor loci
P00755671A0485|39 58|recalcification times
P00755869A0216|0 21|Contingency contracting
P00755869A0216|44 61|parents/caregivers
P00755869A0216|78 89|consequences
P00755869A0216|98 112|self-monitoring
P00759049A0185|18 30|microcuvettes
P00759049A0185|60 87|bathophenanthroline chromogen
P00759400T0000|0 16|Platelet serotonin
P00764737X0000|3 15|vigilance task
P00767161A0837|26 45|serum E2 concentration
P00767161A0837|85 98|administration
P00779272T0001|61 73|mononucleosis
P00792847A0000|21 42|antilymphocyte globulin
P00799988A0554|19 36|assessment patients
P00807356T0001|40 59|hydroxy-9 ellipticine
P00808266T0000|42 57|radiation therapy
P00811852T0001|8 19|satisfaction
P00812183T0000|10 23|transfer factor
P00818380A0239|30 42|antibody tests
P00818380A0239|79 89|gold therapy
P00819176T0001|35 50|swimming activity
P00819176T0001|80 99|Anomalocera patersoni
P00819176T0001|100 119|Pontella mediterranea
P00819176T0001|120 139|Labidocera wollastoni
P00821833A0000|50 62|howler monkeys
P00821833A0000|63 78|Alouatta palliata
P00822611A0467|76 88|binephrectomy
P00827364A0000|32 48|freeze-fracturing
P00830568A0000|39 51|emptying rates
P00830568A0000|138 155|gastroduodenostomy
P00830568A0000|168 184|gastrojejunostomy
P00830568A0000|227 238|pyloroplasty
P00832096T0000|8 24|calcium metabolism
P00833472A0907|88 102|gallbladder bile
P00836637A0000|63 77|music-listening
P00836637A0000|109 129|arithmetic performance
P00836637A0000|132 142|EMR children
P00836637A0000|168 180|reinforcement
P00837262A0000|3 16|responsiveness
P00837262A0000|90 101|conditioning
P00837811A0675|55 82|fluid gamma globulin elevations
P00837811A0675|86 98|abnormalities
P00838152A0863|12 30|mean temperature rise
P00838152A0863|104 116|disappearance
P00838152A0863|127 140|qualifications
P00838152A0863|146 158|triplet groups
P00838152A0863|168 179|predominance
P00838152A0863|194 207|qualifications
P00839378A0649|54 69|airway resistance
P00842406A0771|56 77|visuomotor coordination
P00842406A0771|82 96|recognition task
P00846559A0000|15 26|Fusarium poae
P00846559A0000|30 47|F. sporotrichioides
P00846559A0000|96 116|F. sporotrichioides var
P00851286A0375|25 44|copper concentrations
P00857024A0888|12 24|bladder tumors
P00857024A0888|76 90|properdin levels
P00863184T0043|24 39|transport maximum
P00863773T0000|14 31|live-virus vaccines
P00866577A0579|20 40|plasminogen activators
P00868301A0043|2 21|diethyl ether solution
P00868301A0043|41 72|2-benzylidenamio-1-phenylpropane
P00868301A0043|82 94|retention time
P00870859A0121|71 83|recirculation
P00872442T0000|44 66|LKB reaction rate analyser
P00875778T0000|18 38|Gravigard IUCD inserter
P00877857A0763|0 11|Serum amylase
P00879329A0176|5 22|control preparation
P00879829A0564|59 71|birth asphyxia
P00881630A0000|28 38|snake venoms
P00881630A0000|48 59|A. piscivorus
P00881630A0000|88 102|Phospholipase-A
P00881630A0000|165 180|cremaster vessels
P00885562A0281|27 41|cartilage matrix
P00885562A0281|77 90|osteoarthrosis
P00885562A0281|119 130|GAG synthesis
P00890028A0507|3 14|length scales
P00890028A0507|50 63|Reynolds number
P00890028A0507|102 117|Taylor microscale
P00890028A0507|137 152|Kolmogoroff scale
P00891370A0000|15 26|arteriograms
P00891370A0000|52 66|xeroradiography
P00891370A0000|94 108|contrast-medium
P00898500A0246|59 71|mites skin test
P00898500A0246|139 157|IgE antibody activity
P00903772A0359|20 42|conditioning stimulation
P00903772A0359|48 60|modifications
P00909114A0000|0 17|Diallylnitrosamine
P00909114A0000|32 43|nitrosamines
P00909114A0000|122 132|tract tumors
P00911590T0000|35 49|bocurarine block
P00911590T0000|54 80|atropine-neostigmine mixture
P00913623A0242|42 54|diphosphonate
P00913623A0242|87 99|pyrophosphate
P00913623A0242|132 147|passive diffusion
P00916099A0000|0 16|Self-emasculation
P00917572T0001|47 60|hypothyroidism
P00917721A0484|52 70|presleep suggestions
P00917721A0484|93 104|dream content
P00918556A0000|15 38|hepatitis B surface antigen
P00918556A0000|95 120|radio-immunoassay technique
P00918556A0000|151 163|liver diseases
P00918965A0728|90 101|componenents
P00926272A0000|25 37|deterioration
P00926604A0504|155 167|strophanthin K
P00927633T0001|27 40|investigations
P00927633T0001|73 84|Rattus rattus
P00928529T0001|0 14|Feeding behavior
P00928529T0001|38 55|hibernation rhythms
P00929418T0001|9 36|infectious-disease specialist
P00930947A0629|13 28|drug interactions
P00931089T0001|22 34|operating room
P00932738A0116|11 23|blood pressure
P00932738A0116|34 50|C02 responsiveness
P00932817A0499|50 67|pinhole collimators
P00935526A0000|3 14|difficulties
P00935526A0000|24 37|prostaglandins
P00935526A0000|52 65|chromatography
P00938594A0149|13 26|steroid therapy
P00938594A0149|61 74|manifestations
P00938594A0149|89 104|osteoarthropathy
P00938594A0149|127 144|laboratory features
P00941050T0000|17 38|procainamide absorption
P00947327A0000|121 136|sulfamethoxazole
P00947327A0000|140 151|trimethoprim
P00947327A0000|284 296|sulfanilamide
P00947327A0000|311 323|2,4-diamino-5
P00947327A0000|323 345|3,4,5-trimethoxy-benzyl
P00947327A0000|355 366|trimethoprim
P00951909X0001|12 23|loop syndrome
P00951909X0001|83 94|loop syndrome
P00951909X0001|137 158|Billroth-II gastrectomy
P00954819A1041|72 83|intoxication
P00954819A1041|128 139|AChE activity
P00956364A0138|0 12|Batch cultures
P00956364A0138|15 30|S. mutans serotype
P00956554A0414|44 63|solid-phase allergens
P00956554A0414|94 106|IgE antibodies
P00959656A0250|39 50|antithrombin
P00961711T0000|0 16|Hematology problem
P00962222A0633|34 45|heme turnover
P00962222A0633|67 92|erythrocyte characteristics
P00962222A0633|102 118|progesterone phase
P00962277T0000|0 12|Haemodilution
P00962277T0000|42 59|gelatine derivative
P00964758T0001|14 25|plasmacytoma
P00964758T0001|31 42|parotid gland
P00970320A0000|33 60|chemical cartridge respirators
P00970320A0000|103 115|copper smelter
P00970488A0105|74 91|DA receptor blocking
P00970488A0105|150 161|neuroleptics
P00970839A0118|0 11|Rainbow trout
P00974901A0080|13 30|macrophage function
P00974901A0080|39 62|Bordetella pertussis cells
P00974901A0080|105 118|susceptibility
P00975314T0001|81 94|gonadoblastoma
P00975540T0000|53 71|mass fragmentography
P00975540T0000|74 94|high-accuracy analyses
P00980255T0000|16 38|2-deoxy-D-glucose method
P00984209A0614|0 17|Serum gastrin levels
P00984209A0614|50 85|background serum gastrin concentrations
P00984209A0614|113 123|V&P patients
P00984209A0614|128 138|V&A patients
P00985276A0000|20 50|postflight exercise response tests
P00985276A0000|90 102|Skylab mission
P00985276A0000|166 179|weightlessness
P00985279A0493|15 38|hemoglobin concentrations
P00986800A0325|55 69|saturation level
P00986800A0325|73 83|mug Cu/g diet
P00986925A0002|53 64|pentagastrin
P00986925A0002|78 106|plasma 47Ca radioactivity curves
P00988572A0000|0 12|Oxygen tension
P00988572A0000|23 34|lymph vessels
P00988572A0000|44 57|rabbit hind limb
P00988572A0000|119 145|catheter-tip oxygen electrode
P00989973A0000|16 36|plasma fibrinogen level
P00992316A0178|21 34|pressure curves
P00993176A0066|49 60|heme pigments
P00993176A0066|133 144|2SO4 solution
P00996272A0397|62 74|investigation
P00996272A0397|101 112|instructions
P00999494A0000|91 106|agent propranolol
P01000378T0000|16 29|plasma glucagon
P01000378T0000|33 53|insulin concentrations
P01003819A0498|14 24|nomogram one
P01003819A0498|65 80|corneal curvature
P01004298A0744|34 44|CA component
P01009451A0728|88 99|nocturnality
P01009739T0001|8 19|indomethacin
P01009841T0001|29 40|trunk muscles
P01009841T0001|43 55|lamprey larvae
P01012640T0001|7 21|characteristics
P01012640T0001|48 63|pheochromocytoma
P01012904A0333|13 30|interference effect
P01019207A0232|73 83|betaI% value
P01019207A0232|110 122|mug ruscogenin
P01021091T0000|45 56|blood vessels
P01035457A0623|20 34|nipple discharge
P01036714A0072|121 134|cell population
P01044338A0240|8 19|measurements
P01044338A0240|22 39|temperature changes
P01047417T0000|7 31|National Health Dis-service
P01047895T0001|13 23|patient care
P01047895T0001|113 123|patient care
P01048020T0000|30 40|Test Anxiety
P01048020T0000|44 58|Credit/No Credit
P01048020T0000|61 77|A-F Grade Condition
P01048020T0000|112 128|Course Information
P01048968A0152|44 56|staphylococci
P01048968A0152|72 82|penicillin G
P01048968A0152|83 94|erythromycin
P01048968A0152|106 119|beta-lactamase
P01050400T0000|13 30|nursing instruction
P01057137A0192|25 37|acceptability
P01071715A0903|36 58|blood pressure recordings
P01078982A0227|52 67|cyclophosphamide
P01078982A0227|69 90|antilymphocyte globulin
P01078982A0227|107 123|ALG administration
P01078982A0227|148 163|cyclophosphamide
P01080374A0709|37 53|aneurysm retinitis
P01081904A0198|59 79|pull-out arteriography
P01082833A0000|82 93|indomethacin
P01082833A0000|173 188|carrageenin edema
P01083321X0000|46 57|subalpine fir
P01083321X0000|114 125|productivity
P01083375T0000|0 17|Alpha-1 antitrypsin
P01083375T0000|27 44|childhood cirrhosis
P01083784T0000|0 23|Lymphocyte subpopulations
P01083784T0000|40 55|eosinophil counts
P01084413A0271|25 36|measurements
P01087288T0000|46 58|radiation dose
P01087288T0000|93 108|thyroid carcinoma
P01090210A0417|9 20|lung capacity
P01090210A0417|92 108|mean closing volume
P01090210A0417|212 225|airway pressure
P01092248T0000|15 28|zinc deficiency
P01092248T0000|34 45|pathogenesis
P01093055T0000|10 29|phosphorus metabolism
P01093845A0208|0 12|Modern studies
P01093845A0208|104 116|modifications
P01093847A0000|21 44|tropatepine hydrochloride
P01093847A0000|82 93|neuroleptics
P01096741X0000|54 66|chickpea haulm
P01096741X0000|82 96|supplementation
P01098179A0167|44 55|preparations
P01098179A0167|75 91|dissolution curves
P01098179A0167|125 139|chloramphenicol
P01099693T0000|6 17|Perspectives
P01099693T0000|20 44|bone marrow transplantation
P01101272T0000|15 29|carcinogenicity
P01101272T0000|69 83|cyclohexylamine
P01107226A0808|8 20|amphotericin B
P01107226A0808|83 96|mg/ml dose level
P01116254A0000|20 33|administration
P01116254A0000|47 59|concentration
P01116254A0000|62 79|tracer thallium-201
P01116254A0000|80 91|potassium-43
P01116254A0000|157 169|concentration
P01116466A0185|0 17|Thromboplastin time
P01116466A0185|25 42|thromboplastin time
P01116466A0185|43 54|thrombin time
P01116466A0185|75 88|clot retraction
P01116466A0185|92 106|clotting factors
P01116466A0185|123 135|platelet count
P01119586A0337|0 18|Glycogen utilization
P01119586A0337|34 45|tissue levels
P01119586A0337|48 64|creatine phosphate
P01119658A0000|73 85|cell carcinoma
P01119658A0000|175 193|lymph node metastases
P01119658A0000|225 237|neck treatment
P01119658A0000|257 272|radiation therapy
P01124944A0830|27 37|protein diet
P01130186A0568|47 60|insulin release
P01130531A0224|0 15|Nerve stimulation
P01138330A0204|101 121|acetylcholine chloride
P01140184A0342|0 14|Liver microsomes
P01140184A0342|47 68|epoxide hydrase activity
P01140184A0342|113 127|liver microsomes
P01147436T0000|11 33|Burkitt Lymphoma Registry
P01147436T0000|35 48|progress report
P01147502T0000|27 42|instrument system
P01148868A0284|12 24|clearance rate
P01148868A0284|27 38|progesterone
P01156631A0658|3 31|mean plasma sodium concentration
P01156814T0000|48 68|thromboembolic disease
P01157191A0536|27 41|sodium saccharin
P01157191A0536|45 59|sodium cyclamate
P01157191A0536|109 122|bladder tumours
P01157614T0000|32 52|matrix task performance
P01158512T0000|19 31|dehydrogenase
P01159822A0353|70 83|ultrastructure
P01159822A0353|90 102|invaginations
P01168607A0672|10 23|administration
P01168607A0672|86 100|prothrombin time
P01168607A0672|104 116|serum vitamins
P01168908A0000|0 14|Prostaglandins F
P01168908A0000|170 193|plasma progesterone levels
P01168956A0552|119 139|maximum weight decrease
P01171020A0711|26 46|nucleus accumbens septi
P01171935A0313|25 41|movement disorders
P01171935A0313|101 113|manifestation
P01171935A0313|134 164|dopamine receptor site sensitivity
P01172917T0000|6 26|Lactose tolerance tests
P01172917T0000|41 53|milk tolerance
P01174873T0000|0 13|Retinoblastoma
P01176905A0094|19 32|serum melatonin
P01178637T0001|0 14|Atherosclerosis
P01185956A0722|33 52|Doppler-cardiography
P01185956A0722|97 108|stroke volume
P01186344A0303|53 67|characteristics
P01190120A0832|11 22|% lengthening
P01190120A0832|35 52|thromboplastin time
P01191955A0077|36 47|incompetence
P01191964A0000|44 56|thyroidectomy
P01191964A0000|159 172|serum thyroxine
P01191964A0000|248 277|serum thyrotrophin concentration
P01193458T0001|7 24|isotope cystography
P01193458T0001|33 47|Tc sulfur colloid
P01193770T0000|0 11|Air ion action
P01201977T0000|3 16|interpretation
P01201977T0000|29 45|disc sensitivities
P01202616A0466|9 21|retransfusion
P01202616A0466|90 102|lamina propria
P01206896T0001|0 14|Characteristics
P01206896T0001|30 42|resuscitation
P01206896T0001|45 64|emergency lung surgery
P01208811T0001|33 45|plutonium-239
P01208811T0001|49 75|citrate solution-blood system
P01209618A0409|75 92|potentiating effect
P01209618A0409|106 119|d-tubocurarine
P01215067A0000|74 86|conductometry
P01215067A0000|98 116|meningitis purulenta
P01215067A0000|126 141|meningitis serosa
P01215067A0000|151 162|encephalitis
P01217450A0295|2 18|Chemical occlusion
P01224116A0576|34 53|serum immunoglobulins
P01228258A0000|130 148|Cytosine arabinoside
P01228882A0437|46 59|concentrations
P01228882A0437|62 79|CSF immunoglobulins
P01235347T0001|12 25|cardiotoxicity
P01237206A0199|0 12|Demonstration
P01237206A0199|95 110|auramine staining
P01237206A0199|122 138|antibody technique
P01237206A0199|142 156|Coxiella content
P01241588A1470|23 34|5-HIAA levels
P01241588A1470|107 119|neurotoxicity
P01241866A0682|13 28|leukocyte-counts
P01241866A0682|42 55|administration
P01242636A0678|81 98|beryllium retention
P01243628A0286|43 64|blood carboxyhemoglobin
P01244236A1122|165 183|vasomotor reactivity
P01245162A0262|108 125|transaminase levels
P01246210A0648|3 14|calcium ratio
P01247475A0000|16 29|retinoblastoma
P01247475A0000|82 94|deterioration
P01249198A1097|3 23|serum FT3 concentration
P01249198A1097|78 88|GTD patients
P01249198A1097|104 118|hyperthyroidism
P01252223A0347|59 75|trait correlations
P01252223A0347|122 136|complementarity
P01253191T0000|10 43|phase-plane technique representation
P01253191T0000|53 68|action potentials
P01259027A0416|22 36|identifiability
P01259027A0416|77 91|model parameters
P01259027A0416|265 277|design problem
P01261005A0711|92 117|bandpass spectrophotometers
P01265443A0159|45 63|Heidenhain pouch dogs
P01265443A0159|113 125|acid secretion
P01265887T0001|8 26|factor VIII inhibitor
P01267446A0210|0 15|Biohydrogenation
P01272816A0000|10 26|calcium metabolism
P01272816A0000|86 99|administration
P01275541A0405|21 31|CPK activity
P01276105A0313|13 27|insulin response
P01278251A0000|82 93|polyethylene
P01278251A0000|107 126|tetraphenylbutadiene
P01279197T0000|28 41|homology region
P01279197T0000|44 66|Mason-Pfizer monkey virus
P01279197T0000|74 94|saturation mutagenesis
P01279352A0297|27 46|bp sequence GGGGAGGAGG
P01279352A0473|129 140|PAL sequences
P01279352A0473|179 193|target sequences
P01279352A1197|107 120|promoter region
P01279352A1197|130 159|beta-galactosidase reporter gene
P01280413T0001|53 66|microorganisms
P01280807A0575|18 41|MetRS/CAU operator complex
P01280807A0575|47 60|order magnitude
P01280807A0575|80 103|ThrRS/CGU operator complex
P01281322A0604|18 29|relationship
P01281322A0604|51 68|percent area density
P01281322A0604|89 101|percent change
P01281472T0000|14 29|muscle glycogenin
P01281771T0000|0 15|Characterization
P01281771T0000|57 73|expression pattern
P01282014A0275|51 63|motor recovery
P01282014A0275|79 89|saline group
P01282638A0934|3 17|prophylactic use
P01282638A0934|75 86|chemotherapy
P01282638A0934|135 149|health care costs
P01282638A0934|206 217|continuation
P01282638A0934|247 258|interruption
P01282638A0934|277 290|life expectancy
P01284032A0213|47 60|concentrations
P01284595A0102|35 48|identification
P01284595A0102|54 64|Y-231 cosmid
P01284828T0001|0 25|Tissue plasminogen activator
P01284828T0001|58 69|fibrinolysis
P01285009A0000|0 13|Gene constructs
P01285009A0000|31 43|growth hormone
P01285009A0000|88 107|mouse metallothionein
P01285009A0000|116 130|thymidine kinase
P01285009A0000|134 151|rat cholecystokinin
P01285009A0000|158 174|chicken beta-actin
P01285358A0396|0 11|Serum gastrin
P01286732A0572|6 17|hepatomegaly
P01286732A0572|133 149|liver cell necrosis
P01286732A0572|171 182|complication
P01286732A0572|185 203|P. falciparum malaria
P01287197A0761|36 50|plasma potassium
P01294345A0591|44 57|administration
P01294345A0591|104 119|overreactiveness
P01294345A0591|128 142|prolactin levels
P01294345A0591|181 196|breast tenderness
P01295373A0651|42 52|% baseline RL
P01296815A0059|56 71|sequence analysis
P01297332A0983|25 37|consideration
P01297332A0983|116 132|consensus sequence
P01297332T0000|21 31|DNA sequence
P01297332T0000|49 62|gene expression
P01298173A0153|96 107|chemotherapy
P01298398A0461|25 37|determination
P01298398A0461|40 55|nadolol racemate A
P01298398A0461|73 88|phase composition
P01299489A0788|60 74|supplementation
P01300914A1066|437 452|amplification ECG
P01300914A1066|594 608|RV abnormalities
P01301171A0979|34 54|c-myc bearing sequences
P01304515A0178|34 45|control group
P01304809T0001|24 50|Friedrich Schiller University
P01309587A0715|11 25|transactivation
P01309587A0715|31 43|BMRF1 promoter
P01309587A0715|49 66|Z/c-myb combination
P01309587A0715|118 129|c-myb protein
P01309593A0095|3 17|UCR core sequence
P01309593A0095|87 106|MuLV promoter activity
P01309593A1092|39 50|target motifs
P01309593A1092|100 114|virus P5 promoter
P01309593A1092|131 149|immunoglobulin light
P01309593A1092|196 207|protein genes
P01309815A0972|11 24|scr1-1 mutation
P01309815A0972|38 54|signal recognition
P01309815A0972|129 140|AEP synthesis
P01309860A0559|31 45|integration site
P01309860A0559|101 113|mouse L1 family
P01309894A0807|31 41|AAV sequence
P01309910A0428|0 25|Nucleotide sequence analysis
P01309910A0428|74 85|CREB2 protein
P01310154A0879|71 85|transrepression
P01310154A0879|162 180|protein modification
P01310154A0879|186 199|gene regulation
P01310178A0876|3 27|JS78 mutation changes Gln243
P01310178A0876|158 182|host transcription shut-off
P01310879A0000|1 16|patient suffering
P01310879A0000|39 54|thrombocytopenia
P01310879A0000|67 83|arteriothromboses
P01310899A0339|12 28|receptor structure
P01310899A0339|88 106|transmembrane domain
P01310899A0339|131 158|serine/threonine kinase domain
P01310935T0000|84 101|protein degradation
P01312005A0600|127 137|target sites
P01313715A0461|170 189|B-lymphocyte cell line
P01313846A0850|17 33|sequence databanks
P01313846A0850|63 91|immunoglobulin gene superfamily
P01313846A0850|128 143|melanoma Ag MUC-18
P01313846A0850|183 200|poliovirus receptor
P01313846A0850|213 232|cell adhesion molecule
P01313894A1179|54 72|LMP2B mRNA expression
P01313909A0526|18 36|ICP0 nonsense mutants
P01313909A0526|140 153|nonsense mutant
P01314457T0000|10 27|nucleotide sequence
P01314457T0000|49 66|herpesvirus saimiri
P01314457T0000|82 93|conservation
P01314457T0000|103 114|organization
P01314841A0724|27 42|burst suppression
P01314953A1266|10 36|gel mobility shift experiments
P01314953A1266|89 101|hap3 mutations
P01315706A0000|8 22|differentiation
P01315706A0000|42 61|adenovirus E1a protein
P01315706A0000|67 85|rat L6 muscle cell line
P01316476A0842|13 25|TATA sequences
P01316680A0643|61 73|CAYWCCLGHAFAC
P01316680A0643|98 121|consensus zinc finger motif
P01316680A0643|122 137|C-X2-4-C-X2-15-C
P01316900A0000|3 13|DNA sequence
P01316900A0000|19 40|sulfate activation locus
P01316903A0296|25 37|RNA polymerase
P01316903A1040|0 15|RNA polymerase IIA
P01316903A1040|83 93|input enzyme
P01316903A1040|97 112|RNA polymerase IIA
P01317376A0981|0 19|Fructokinase activity
P01317376A0981|118 130|frk mRNA levels
P01318310A0000|0 14|Plasma membranes
P01318310A0000|41 57|affinity receptors
P01318310A0000|65 82|density lipoprotein
P01318739A0410|15 33|patients vincristine
P01318739A0410|67 79|neurotoxicity
P01320255A0795|96 108|factor binding
P01320255A0795|142 154|transcription
P01321277A0342|67 90|chicken embryo fibroblasts
P01321277A0342|97 118|spindle shape morphology
P01321280A0494|36 49|E7 gene products
P01321280A0494|94 123|immunoprecipitation experiments
P01321280A0494|174 189|E7 fusion proteins
P01321332A0970|9 26|transfection assays
P01321332A0970|86 100|transactivation
P01321332A0970|135 152|hepatoma HepG2 cells
P01321332A0970|181 195|transactivation
P01321336A0000|3 16|enhancer region
P01321336A0000|28 40|leukemia virus
P01321336A0000|52 72|sequence motif ACAGATGG
P01321336A0731|3 16|splice variants
P01321337A1161|26 37|MATa cna1 cna2
P01321337A1161|51 65|MATa cnb1 mutants
P01321337A1161|126 137|growth arrest
P01324172A0880|50 61|mitochondria
P01324385A0329|7 19|IgG antibodies
P01324385A0329|27 40|anti-HHV-6-IgG
P01324385A0329|65 82|immunofluorescence
P01324385A0329|94 105|seronegative
P01324385A0329|211 222|control group
P01324404A0813|21 36|activation domain
P01324404A0813|93 108|carboxyl terminus
P01324404A0813|114 129|HNF-3 beta protein
P01324404A1208|75 89|transactivation
P01324404A1208|120 132|participation
P01324404A1208|138 155|region II-III domain
P01324406A1250|27 52|ATPase/DNA helicase activity
P01324639T0000|0 15|Susceptibilities
P01324639T0000|63 77|amoxicillin-BRL
P01324639T0000|83 105|amoxicillin-clavulanate
P01324639T0000|106 117|temafloxacin
P01325221A0870|104 115|p41 MAP kinase
P01325221A0870|133 146|chromatography
P01325386A0766|3 16|hit1-1 mutation
P01325386A0766|49 64|heat shock protein
P01326329A0703|6 19|base pair region
P01326329A0703|154 169|activator protein
P01326329A0703|187 216|glucocorticoid response elements
P01326329A0703|237 255|AMP response elements
P01326557T0000|72 101|chondroitin sulfate proteoglycan
P01327280A0000|72 85|cord dorsal horn
P01327758A0000|19 34|papillomavirus-1
P01327758A0000|59 70|gene products
P01327967A0668|11 22|inactivation
P01327967A0668|68 94|agent methylmethane sulfonate
P01328197A0985|27 60|MAP kinase activator/MAP kinase system
P01328197A0985|91 119|ras signal transduction pathways
P01328681A0149|47 66|c-myc hyperexpression
P01328681A0149|88 100|transcription
P01328681A0149|179 194|protein synthesis
P01328854T0000|60 72|transcription
P01328854T0000|110 135|phosphoglycerate mutase gene
P01328854T0000|156 166|muscle cells
P01328884T0000|0 17|Truncation variants
P01328884T0000|66 79|sequence motifs
P01329039A0239|11 24|E-box consensus
P01329039A0951|0 17|Intermediate levels
P01329039A0951|20 31|gene activity
P01329039A0951|47 58|TnI enhancers
P01329039A0951|115 128|Ig kappa E2 E-box
P01330077A0000|0 17|T-cell receptor beta
P01330077A0000|25 42|gene rearrangements
P01330309A1134|3 14|CANNTG motifs
P01330309A1134|37 58|myogenin fusion proteins
P01330975T0000|10 23|polyneuropathy
P01331057A0000|81 98|cytochrome c oxidase
P01331060A0768|17 32|calcineurin A gene
P01331060A0768|73 85|cDNA sequences
P01331086T0000|8 23|promoter elements
P01331086T0000|32 56|cytochrome c oxidase subunit
P01331086T0000|121 140|transcription factors
P01331292A1425|43 57|oligonucleotide
P01331292A1425|108 120|vaccinia virus
P01331516A0103|26 48|3T6 mouse fibroblast cells
P01331516A0103|90 111|coinfection experiments
P01331516A0103|114 124|C2 myoblasts
P01332589A0666|122 134|micrograms/ml
P01332964A0247|23 33|RII beta gene
P01333035T0000|10 39|cAMP receptor protein contact site
P01333035T0000|45 56|alpha subunit
P01333035T0000|74 86|RNA polymerase
P01333047A0404|23 34|growth factor
P01333047A0404|53 75|growth factor stimulation
P01333047A0404|109 123|phosphorylation
P01333047A0404|155 171|threonine residues
P01333053A0110|22 56|steroid hydroxylase gene transcription
P01333053A0110|106 119|peptide hormone
P01333125A0000|25 40|sequence analysis
P01333125A0000|74 85|conservation
P01333125A0000|96 112|structure elements
P01333125A0000|147 159|enteroviruses
P01333125A0000|163 174|rhinoviruses
P01334428A1102|73 86|mumol min-1 mg-1
P01334428A1102|102 115|mumol min-1 mg-1
P01334518T0000|13 26|blood screening
P01334518T0000|33 47|hepatitis C virus
P01334518T0000|62 82|immunodeficiency virus
P01337142A2043|12 44|glycoprotein alpha-subunit promoter
P01338867A0503|130 142|fatiguability
P01339125A0153|0 16|Laboratory studies
P01339125A0153|114 124|bleach teeth
P01339373T0000|33 51|Arabidopsis thaliana
P01339373T0000|77 93|SNF1 protein kinase
P01339391A0000|42 60|DNA surrounding HRAS1
P01339468A0272|3 13|ORF1 protein
P01339468A0272|55 77|potexvirus RNA replicases
P01339773A0778|3 15|relationships
P01339773A0778|115 140|ventilation-perfusion ratio
P01339815A1545|13 24|correlations
P01340470A0000|13 23|protein gene
P01340470A0000|64 82|RNA recognition motif
P01341119A0450|4 18|research studies
P01341119A0450|70 81|H2 inhibitors
P01341119A0450|85 97|others antacid
P01346262A0377|27 41|protein profiles
P01346262A0377|53 68|S. entomophila UC9
P01346534T0000|0 15|Characterization
P01347476T0000|12 25|mouse ornithine
P01347476T0000|47 60|sequence family
P01347944A0964|37 58|homeodomain binding site
P01348504A0757|7 29|pol alpha-primase complex
P01348590A0000|185 196|radiotherapy
P01349705T0000|18 32|thyroid function
P01349837T0000|18 36|Arabidopsis thaliana
P01349837T0000|60 74|chaperonin HSP60
P01349837T0000|78 91|gene expression
P01349837T0000|98 112|seed germination
P01350780A0184|0 26|Amino acid sequence comparison
P01350780A0184|87 107|gamma-glutamyl kinases
P01350932A1123|15 27|glycosylation
P01350932A1123|59 79|N-glycosylation sequon
P01350932A1123|113 128|disulphide bridge
P01352113A0002|37 51|nitrogen dioxide
P01352113A0002|92 106|inhalation model
P01352113A0231|61 77|NO2 concentrations
P01352113A0231|120 132|exposure times
P01353478T0000|24 41|IAP retrotransposon
P01353478T0000|47 65|A20/2J B cell lymphoma
P01354506T0000|51 63|understanding
P01354506T0000|66 77|cytogenetics
P01354506T0000|78 91|histopathology
P01357190A0726|38 57|membrane anchor domain
P01357190A0726|72 84|glycoproteins
P01357528A0084|3 16|subunit protein
P01357528A0084|48 60|amino terminus
P01357528A0084|72 85|subunit protein
P01357528A0084|189 205|surface organelles
P01357528A0084|208 221|enterobacteria
P01358190A0654|0 11|Substitution
P01358190A0654|17 28|DR1 beta chain
P01358190A0654|73 94|alpha chain substitution
P01358758A0000|21 35|rat insulin I gene
P01358758A0000|58 73|sequence elements
P01358758A0000|83 94|FLAT elements
P01358880A0251|10 26|amino acid sequence
P01358880A0251|64 87|transglutaminase sequence
P01360180A0513|35 47|baculoviruses
P01360180A0513|87 98|recombinants
P01360180A1568|26 41|P68 amino terminus
P01360180A1568|134 152|reporter gene product
P01360294A0000|103 114|antithrombin
P01363080A0710|69 80|sulfonamides
P01363080A0710|94 111|agent metronidazole
P01363080A0710|140 158|anhydrase inhibitors
P01363166T0001|0 14|Currents aspects
P01363166T0001|17 37|H2 receptor antagonists
P01364100A0377|17 34|subrepeat structure
P01370281A0461|30 41|reading frame
P01370446A0818|26 54|keratan sulfate attachment sites
P01371181A0688|83 97|characteristics
P01371181A0688|121 131|copy numbers
P01371272A1167|0 11|Perturbation
P01371272A1167|38 55|frameshift fidelity
P01371272A1167|72 94|yeast DNA polymerase alpha
P01371413A0742|50 69|Southern blot analysis
P01371413A0742|75 92|segregation pattern
P01371413A0742|103 124|rodent-human hybrid DNAs
P01371863A0000|70 96|protozoan parasite Leishmania
P01372365A1202|34 47|concentrations
P01372802A1481|37 53|amino acid residues
P01372802A1481|149 159|C3 fragments
P01372802A1481|184 202|fluid-phase fragment
P01372900A0448|61 77|amino acid residues
P01372900A0448|87 108|alpha s1-casein variant A
P01372900A1017|37 48|organization
P01372900A1017|54 88|goat alpha s1-casein transcription unit
P01372900A1017|100 133|polymerase chain reaction experiments
P01373374A0735|73 83|GBF3 binding
P01374331A0636|62 79|nuclease S1 analysis
P01374392A0341|3 20|hydrophobicity plot
P01374398A0951|10 27|translation protein
P01374398A0951|79 98|amino acid composition
P01374398A0951|137 153|amino acid residues
P01374688A0471|32 45|% pentafraction
P01374688A0471|46 57|% pentastarch
P01374688A0471|92 106|micrograms/kg/0
P01375224A0152|55 68|transformation
P01375224A0152|71 94|chicken embryo fibroblasts
P01375224A0152|147 162|growth regulation
P01375913A0484|31 49|DNA oligonucleotides
P01375913A0484|51 62|U14 snRNA gene
P01375913A0484|92 118|T7 RNA polymerase promoter site
P01376319T0000|43 68|mannose 6-phosphate receptor
P01377696A0000|23 52|surface glycoprotein neurofascin
P01377696A0000|82 94|fasciculation
P01377696A0000|107 137|antibody perturbation experiments
P01377962A1012|10 20|tobacco GS-2
P01378052A0594|156 173|activator sequences
P01378127A0841|23 39|calcium supplement
P01378127A0841|42 58|calcium antagonist
P01378431A0202|15 29|Vallejo-Ramirez
P01378506A0884|15 33|full-deletion mutant
P01378506A0884|54 65|virus release
P01378506A0884|94 106|virus assembly
P01378526A0535|29 45|FK506 plasma levels
P01379032A0495|61 71|steroid dose
P01379150A0996|156 170|risk arrhythmias
P01380062A0097|45 55|T lymphocyte
P01380062A0097|59 77|recognition epitopes
P01380062A0097|95 106|CTL clones Y-1
P01380076A0165|42 60|paired-ion technique
P01380076A0165|71 84|docusate sodium
P01380454A0451|24 37|protein product
P01380454A0451|65 82|DNA binding activity
P01380454A0451|85 103|Fos-Jun heterodimers
P01380454A0451|104 120|Jun-Jun homodimers
P01380454A0451|124 143|Hela cell AP-1 proteins
P01380454A0451|170 189|transcription factors
P01380454A0451|226 239|ATF/CREB family
P01380716A0174|77 90|calcium hydrate
P01380825A0622|0 19|Northern blot analyses
P01383690A1023|3 14|ARG SH2 domain
P01383690A1023|105 116|ABL SH2 domain
P01383695A0100|12 25|EBV B-cell clone
P01384165A0000|49 63|vascularization
P01384165A0000|81 92|regeneration
P01384165A0000|143 158|tracheal grafting
P01384229A0175|56 70|oligonucleotide
P01384229A0175|162 177|herpes TK promoter
P01384229A0175|192 223|chloramphenicol acetyl transferase
P01385462A0151|101 117|acid determination
P01385462A0151|130 142|determination
P01386210A0293|100 116|GM2 gangliosidosis
P01386897A0000|63 73|CDC28 kinase
P01387105A0933|7 26|Southern blot analyses
P01387105A0933|93 103|cell hybrids
P01387105A0933|167 179|loci Cycb1-rs1
P01387105A0933|203 218|mouse chromosomes
P01388160A1102|5 18|residue Glu-381
P01388160A1102|68 81|epsilon peptide
P01388160A1102|105 119|peptide sequence
P01389362T0000|17 28|bond strength
P01389362T0000|34 47|dentin adhesive
P01389585A0825|32 50|Prisma Universal Bond
P01389585A0825|73 92|dentine bonding agents
P01391001A0583|26 38|yeasts species
P01392012A0228|33 47|oxytocin content
P01392012A0228|63 75|pressor effect
P01392277A0000|64 76|swimming pools
P01392277A0000|108 121|KOK regulations
P01392358A0389|20 35|telephone contact
P01394200A0592|3 16|treatment group
P01394200A0592|33 48|T-cell activation
P01394200A0592|84 103|rebound lymphocytosis
P01394200A0592|107 118|upregulation
P01394200A0592|124 140|subset markers CD25
P01394655A0615b|0 13|Urease activity
P01394655A0615b|33 49|ammonia production
P01394655A0615b|97 114|Jack bean meal urease
P01395755A1023|83 94|oxygen uptake
P01395755A1023|128 141|oxygen delivery
P01396432A0388|93 109|memory performance
P01396444A0934|94 109|activation states
P01396572A0320|21 32|plasmid pUC19
P01396572A0320|73 84|plasmid pUC19
P01396583A0204|1 11|cDNA library
P01396583A0204|14 24|tumour cells
P01396592A1113|62 86|transcription factor GATA-1
P01396592A1113|97 110|SCL gene product
P01396592A1113|148 162|differentiation
P01398068A0948|57 67|p53 proteins
P01398068A0948|98 111|RGC DNA sequence
P01398071A0526|76 87|BRF1 activity
P01398071A0526|129 142|RNA polymerases
P01398073A0986|54 65|TFIID protein
P01398073A0986|109 125|activation domains
P01398074A0697|3 14|gene sequence
P01398074A0697|75 100|RNase MRP enzyme preparations
P01398074A1081|3 17|RNase MRP RNA gene
P01398098A0770|0 17|Clone pSRc200 hybrid
P01398106A0754|60 78|intron insertion site
P01398140A0488|15 27|Xenopus U7 gene
P01399206A0375|35 55|collagenase inhibitors
P01399206A0375|78 93|blister formation
P01399206A0375|115 134|epidermolysis bullosa
P01400217T0000|29 61|IncP alpha plasmid transfer genes traF
P01400217T0000|91 106|phage sensitivity
P01400396A1265|35 47|phorbol esters
P01400396A1265|109 126|protein kinase C beta
P01400401A0065|12 31|AMP deaminase variants
P01400401A0854|0 18|Western blot analyses
P01400401A0854|40 55|immunoreactivity
P01400775A0435|37 49|N-methylation
P01400775A0435|66 83|N-methylsalsolinol
P01402647A0114|0 11|DR1 molecules
P01402647A0114|80 95|peptide sequences
P01402647A0114|110 121|phage surface
P01403222A0391|73 85|blood donation
P01404401A0740|9 21|ATPase cluster
P01404401A0740|29 41|reading frames
P01404401A0740|84 98|chloroplast gene
P01404612A0303|92 108|vaccine candidates
P01406630A0545|50 66|consensus sequence
P01406630A0545|136 150|binding analysis
P01406630A0545|164 175|DNA sequences
P01406630A0545|184 202|sequence specificity
P01406630A0965|29 39|kappa B motif
P01406630A0965|149 164|NF-kappa B complex
P01406677A0000|23 37|control elements
P01406677A0000|87 99|myoglobin gene
P01406677A0000|148 166|nucleotide positions
P01406677A0000|228 241|luciferase gene
P01406688A0898|0 17|Sequencing analysis
P01406688A0898|34 44|rap1t allele
P01406688A0898|54 69|nonsense mutation
P01406703A1435|12 28|Y1 cell cDNA library
P01406703A1435|73 91|hormone receptor cDNA
P01407286A0427|146 164|tyrosine hydroxylase
P01408090A0572|17 32|TEE visualization
P01408219A0670|43 58|lymph-adenopathy
P01408474A0531|0 12|PaO2 threshold
P01408474A0531|47 60|sensor catheter
P01409643A0618|7 26|lambda gt11 expression
P01409643A0618|38 53|oligonucleotides
P01409643A0618|77 97|immunodeficiency virus
P01409643A0618|99 109|TATA element
P01409643A0618|121 134|identification
P01409643A0618|204 214|TATA element
P01410071T0000|0 10|Blood levels
P01410071T0000|83 105|platelet serotonin uptake
P01413984A0737|29 45|FA supplementation
P01413984A0737|64 77|HDL cholesterol
P01413984A0737|78 91|LDL cholesterol
P01413984A0737|131 142|antithrombin
P01413984A0737|146 174|plasminogen activator inhibitor
P01413984A0737|175 200|tissue plasminogen activator
P01413984A0737|204 235|von Willebrand factor concentration
P01413984A0737|273 285|blood pressure
P01414219A0319|58 81|peak plasma concentrations
P01414219A0319|94 106|concentration
P01418542A0000|19 36|beta-glycyrrhetate
P01418834A0987|11 28|hematocrit decrease
P01418834A0987|70 82|blood pressure
P01418860A0797|47 58|potentiation
P01418860A0797|163 184|calcium channel blockade
P01418860A0797|202 213|interactions
P01419945A1386|0 11|Localization
P01419945A1386|38 52|nerve stimulator
P01419945A1386|76 87|interscalene
P01420177A1065|0 11|Substitution
P01420177A1065|76 89|protein kinases
P01420223T0000|0 11|Significance
P01420223T0000|32 52|latissimus dorsi muscle
P01420223T0000|56 66|fiber typing
P01420363A0818|46 59|c-Fos/c-Jun AP1
P01420363A0818|137 148|consensus TRE
P01420363A0818|201 212|consensus TRE
P01420363T0000|19 34|PEA3 binding sites
P01420363T0000|58 72|tissue inhibitor
P01420363T0000|75 94|metalloproteinases-1
P01420363T0000|101 113|transcription
P01420579A0292|5 21|serum neutralizing
P01421145A1190|0 12|Fractionation
P01421145A1190|37 65|heparin-agarose chromatography
P01421390T0000|90 104|body irradiation
P01421390T0000|114 125|chemotherapy
P01421390T0000|139 163|bone marrow transplantation
P01422265A0263|3 20|IgG subclass profile
P01422265A0263|32 45|coeliac disease
P01422265A0263|150 166|subclass responses
P01422265A0263|183 197|coeliac patients
P01423454A0309|38 49|contribution
P01423454A0309|151 163|effectiveness
P01423738A0639|19 30|pinealectomy
P01423738A0639|103 114|deceleration
P01423738A0639|127 138|mean delta tau
P01424674A0000|84 96|cicatrization
P01425653T0000|23 39|caffeine ingestion
P01425653T0000|60 76|oxygen consumption
P01425921A1286|38 53|amino acid changes
P01425921A1286|70 83|lysine deletion
P01425921A1286|102 118|consensus sequence
P01426635A0496|88 102|dopamine neurons
P01427034A0440|42 53|protein genes
P01427034A0440|119 130|DNA sequences
P01427457A0000|95 108|calcium heparin
P01427457A0000|124 136|sodium heparin
P01429596A1669|54 66|hemagglutinin
P01429596A1669|87 120|18K agglutination-aggregation factor
P01429624A0328|97 111|adenylylcyclase
P01429768T0000|5 22|neutrophil response
P01429836A0457|12 23|microtubules
P01429836A0457|67 80|protein sorting
P01429836A0457|95 107|Vps1p function
P01429836A0457|124 135|microtubules
P01429836A1205|73 86|protein sorting
P01431380A0244|14 26|field research
P01431380A0244|144 159|group rickettsiae
P01431380A0244|196 208|tick emulsions
P01431380A0244|240 250|patient sera
P01431380A0244|299 312|hemolymph cells
P01431380A0244|348 359|observations
P01431602A0229|32 47|sensitivity range
P01431602A0229|57 76|micrograms phosphorus
P01431602A0229|88 103|microliters HClO4
P01431809T0000|0 17|Nucleotide sequence
P01431809T0000|49 62|polyhedrin gene
P01431809T0000|65 80|Spodoptera exigua
P01431809T0000|88 104|polyhedrosis virus
P01432453T0000|28 43|system definition
P01433502A1163|38 53|enhancer activity
P01435698A0000|23 40|blood compatibility
P01435698A0000|74 85|prostacyclin
P01435698A0000|130 141|implantation
P01436261A0145|0 25|Subcutaneous administration
P01436261A0145|31 50|somatostatin analogue
P01436261A0145|130 142|disappearance
P01436261A0145|151 162|incontinence
P01436261A0145|178 193|calcitonin levels
P01437562A0462|49 61|C.fasciculata
P01437562A0462|99 116|nucleotide sequence
P01438287T0000|14 27|vaccinia vector
P01441818T0001|0 13|Interferon type
P01441818T0001|27 39|body reactions
P01441818T0001|56 74|Klebsiella infection
P01443047A0773|29 49|differentiation status
P01443047A0773|79 94|Id-SCL expression
P01443748A1190|42 53|excitability
P01446132A0328|3 13|air embolism
P01446132A0328|61 72|complication
P01446828A1088|24 44|consensus binding sites
P01447189A1546|33 46|serine protease
P01447189T0000|0 11|Purification
P01447189T0000|30 43|serine protease
P01447189T0000|81 98|killer cell leukemia
P01448107A0361|24 36|GCN2 mutations
P01448107A0361|47 58|derepression
P01448107A0361|61 74|GCN4 expression
P01448107A0361|89 107|amino acid starvation
P01448806A0135|0 13|Administration
P01448806A0135|16 28|growth hormone
P01448806A0135|61 74|bone maturation
P01448917A0775|27 42|amino acid residue
P01448917A0775|45 63|sequence information
P01448917A0775|121 140|clover mottle virus RNA
P01448917A0775|208 225|proteinase cofactor
P01448917A0775|277 289|24K proteinase
P01448917A0775|329 341|cleavage sites
P01448932T0000|0 41|Rice dwarf phytoreovirus segment S12 transcript
P01449183A0795|27 42|transferrin assay
P01449183A0795|72 84|fluid otorrhea
P01449301A0710|0 15|Cold cardioplegia
P01451771A0619|27 41|family variables
P01451771A0619|94 111|components analysis
P01451771A0619|134 148|scaling analysis
P01451771A0619|169 180|health scores
P01452037A0000|26 64|glyceraldehyde-3-phosphate dehydrogenase
P01452037A0000|119 142|triosephosphate isomerase
P01452037A0000|160 183|Bacillus megaterium DSM319
P01452037A0000|201 211|gene cluster
P01452037A0000|223 237|complementation
P01452037A0000|257 270|gap amber mutant
P01452584T0000|52 63|wound healing
P01452584T0000|71 83|Lindberg Award
P01452703A0782|0 16|Laboratory studies
P01454518A0336|10 21|significance
P01454518A0336|61 72|conservation
P01454518A0336|134 157|stringency hybridizations
P01454819A0000|0 20|Mono-ADP-ribosylation
P01454819A0000|34 45|modification
P01454819A0000|62 92|arginine ADP-ribosyltransferases
P01454819A0000|179 199|ADP-ribosylation cycle
P01456888A0074|75 91|core antigen p55 gag
P01456888A0074|131 147|expression systems
P01456888A0074|178 190|baculoviruses
P01456888A0074|223 236|core protein p55
P01456888A0074|277 304|myristylation consensus signal
P01457380A0000|99 111|ttk transcript
P01457695T0000a|9 27|beta 2-microglobulin
P01457695T0000a|30 41|hemodialysis
P01457695T0000a|45 58|hemofiltration
P01457695T0000b|9 27|beta 2-microglobulin
P01457695T0000b|30 41|hemodialysis
P01457695T0000b|45 58|hemofiltration
P01458170A0155|82 95|theta-activity
P01458170A0155|98 109|power spectra
P01458170A0155|162 173|wave activity
P01459451A0478|18 31|antirepression
P01459451A0478|67 82|co-antirepressor
P01459885A0705|13 32|haloperidol treatment
P01459921A0000|36 51|Hampshire wethers
P01459921A0000|105 123|linoleoyl methionine
P01459921A0000|127 142|calcium linoleate
P01460054A0478|104 119|DNA binding domain
P01460054A0478|151 163|amino terminus
P01460772T0001|35 48|hypothyroidism
P01460772T0001|65 83|interferon treatment
P01462786T0000|0 20|Dynamic decision making
P01462786T0000|35 48|complex systems
P01464329T0000|61 79|prophase chromosomes
P01464606A0344|66 79|chromatography
P01464606A0344|82 98|detergent extracts
P01464606A0344|125 146|fragment affinity column
P01467828A0542|52 65|opioid peptides
P01469042A0355|47 57|CENP-B boxes
P01469042A0355|72 98|mouse centromere satellite DNA
P01469042A0355|189 206|centromere function
P01469047A1606|55 80|% amino acid sequence identity
P01469047A1606|134 150|acid decarboxylase
P01470243A0871|140 151|independence
P01470243A0871|215 227|haemodilution
P01470243A0871|248 262|viscosity effect
P01470741T0062|0 11|Distribution
P01471602A0362|30 49|bile acid sequestrants
P01471602A0362|116 134|reductase inhibitors
P01473196A1016|19 30|reabsorption
P01473207A0582|45 57|prematuration
P01473234A1001|0 10|Green pepper
P01473234A1001|65 77|acid formation
P01474990A0000|82 96|trypomastigotes
P01474990A0000|152 165|trypomastigote
P01474990A0000|169 184|epimastigote cDNA
P01477021A0394|40 66|serum prolactin concentration
P01478672A0795|37 53|alpha satellite DNA
P01480183A0000|27 41|lactoferrin gene
P01480183A1689|36 49|estrogen action
P01480183A1689|63 87|lactoferrin gene expression
P01482912A0617|14 32|registration updates
P01482912A0617|60 75|data dependencies
P01482912A0617|102 119|relational database
P01483755A0000|8 28|resonance spectroscopy
P01483771A1335|46 70|plasma epinephrine response
P01485648A0000|49 66|Pharmacia CAP System
P01485648A0000|67 88|Pharmacia Diagnostics AB
P01485648A0000|150 162|IgE antibodies
P01486836A0774|48 68|visuomotor performance
P01486836A0774|89 107|discrimination tasks
P01486836A0774|114 134|visuomotor performance
P01487144A0505|14 24|gene segment
P01487144A0505|102 124|transcription terminator
P01487144A0505|131 142|myeloma cells
P01487144A0505|146 161|L cell fibroblasts
P01490493A0416|38 53|serum cholesterol
P01490493A0416|67 84|triglyceride levels
P01493864A0619|0 14|Dopamine neurons
P01493864A0619|58 70|pre-treatment
P01496348A0000|9 20|parodontitis
P01496784A0939|36 51|strongyloidiasis
P01498607A0000|9 27|nucleotide sequences
P01498607A0000|58 71|responsiveness
P01498607A0000|77 107|parsley chalcone synthase promoter
P01499213A0185|65 84|hyperextension injury
P01499213A0185|140 153|L2-L3 disk space
P01499616A0136|166 177|foreskin flap
P01502157A0000|25 41|factor binding site
P01502157A0000|70 99|P2 transcription initiation sites
P01504853A0299|36 49|mating behavior
P01505516A0928|56 68|valine residue
P01506705A0282|15 26|hemodynamics
P01506746A0476|0 18|Greater rupture force
P01511231A0085|17 29|smoking habits
P01511231A0085|62 82|smoking cessation trial
P01511231A0085|98 111|placebo patches
P01511950T0000|10 24|hepatitis B virus
P01511950T0000|62 73|significance
P01511950T0000|94 117|hepatitis B surface antigen
P01512259A0867|60 72|cysteine motif
P01512654A0503|38 52|saline injection
P01512654A0503|72 84|KLH challenges
P01512654A0503|117 130|threshold level
P01512941A0000|44 55|levofloxacin
P01512941A0000|111 123|ciprofloxacin
P01513114A1133|7 27|serum creatinine levels
P01513213A0231|0 15|Model predictions
P01513213A0231|44 61|survival experience
P01516427T0000|56 67|tuberculosis
P01516829A0113|33 44|SNF6 function
P01516829A0460|33 46|fusion proteins
P01516829A0460|95 105|target genes
P01516829A0460|129 141|lexA operators
P01518833A0397|1 21|lambda gt10 cDNA library
P01518849A0165|44 57|microorganisms
P01518849A0165|93 106|protein elastin
P01518849A0165|148 182|alpha 1-proteinase inhibitor complexes
P01518849A0165|186 200|elastin peptides
P01518926T0000|25 39|ultrasonography
P01522699A0092|35 45|menu weights
P01522699A0092|49 62|recipe analysis
P01524549A0241|4 15|GH deficiency
P01524549A0241|113 124|GH deficiency
P01525153A0359|47 63|monomer structures
P01525153A0359|77 96|K cation concentration
P01527020A0511|33 59|rat AdoMet decarboxylase genes
P01529530T0000|24 37|gene expression
P01529530T0000|91 115|ISGF3 transcription complex
P01531086A0127|16 27|reading frame
P01531214A0885|66 79|administration
P01531632A0000|175 190|arginine residues
P01532229A1264|64 75|muscle factor
P01532229A1264|170 180|muscle cells
P01532796A0107|77 88|beta subunits
P01532796A0107|103 114|mitochondria
P01532914A0067|21 38|hepatitis B vaccines
P01532914A0067|61 72|immunization
P01533760T0000|0 25|Estrogen replacement therapy
P01533760T0000|35 46|breast cancer
P01533760T0000|59 71|meta-analyses
P01535242A0557|100 114|factor switching
P01536153A0574|88 104|animal food workers
P01536575A1213|133 145|transcription
P01536575A1213|151 171|cytochrome P450IA1 gene
P01536575A1213|201 225|detoxification/activation
P01536575A1213|246 257|hydrocarbons
P01537334A0507|26 40|mouse chromosome
P01537334A0507|59 81|coat colour mutation slaty
P01537845A0571|20 30|c-myb clones
P01537845A0571|50 71|c-myb gene transcription
P01537845A0571|74 86|mRNA stability
P01538401A1244|3 26|base-pair oligonucleotide
P01538401A1244|157 168|DNA fragments
P01538403A1058|11 24|reconstitution
P01538403A1058|48 69|transcription complexes
P01538403A1058|82 97|protein fractions
P01538403A1058|161 176|complex formation
P01538403A1058|183 201|H5 promoter mutations
P01539996A0588|16 32|amino acid sequence
P01539996A0588|38 57|T. thermophilus enzyme
P01539996A0588|124 135|conservation
P01539996A0588|279 298|T. thermophilus enzyme
P01541556A1040|72 88|lipid modification
P01541556A1040|100 112|Cys-22 residue
P01541577A0000|35 52|volunteer hearing Ss
P01541577A0000|58 73|Stanford Hypnotic
P01542565A0220|6 22|tobacco L12 protein
P01542565A0220|27 44|% amino acid identity
P01542565A0220|58 70|protein L7/L12
P01542565T0000|47 62|Nicotiana tabacum
P01542565T0000|63 78|characterization
P01542565T0000|109 124|sequence analysis
P01542667A0125|61 75|enhancer element
P01542686A0000|21 40|polypeptide component
P01542686A0000|62 84|p75 nucleoprotein complex
P01542730A1982|184 195|dual-chamber
P01543909A0787|114 128|characteristics
P01543909A0787|197 211|ferritin subunit
P01544918A1240|0 15|Characterization
P01544918A1240|39 71|8-azido-cAMP photoaffinity labeling
P01544918A1240|75 90|immunoreactivity
P01544918A1240|127 139|mobility shift
P01544918A1240|142 154|sodium dodecyl
P01544918A1240|177 194|gel electrophoresis
P01544918A1240|212 223|subunit sizes
P01544918A1240|249 269|RII alpha dephosphoform
P01544928A1252|22 32|DNA sequence
P01544928A1252|156 168|cassette model
P01545523A0000|14 28|quantifications
P01545523A0000|101 117|antistreptolysin O
P01545792A0000|10 27|myosin light chain-2
P01545792A0000|33 44|gene promoter
P01545792A0492|0 18|Deletion mutagenesis
P01545792A0492|87 108|MLC-2 gene transcription
P01545797A0587|0 18|Disruption mutations
P01545806T0000|49 72|recombination genes REC102
P01545818A0696|158 171|v-Src SH2 domain
P01546522A0000|29 47|leukoencephalopathy
P01546522A0000|101 116|resonance imaging
P01547775A1024|35 46|significance
P01547775A1024|150 162|PLRV replicase
P01547775A1024|168 195|ORF2a/ORF2b transframe protein
P01547787A0548|0 19|Proprotein processing
P01547942A0120|29 46|dimerization domain
P01547942A0120|47 57|zipper probe
P01547957A1083|16 39|oligodeoxyribonucleotide
P01547957A1083|194 204|DNA fragment
P01547957A1083|222 244|polymerase chain reaction
P01548756A1102|9 21|hybridization
P01548756A1102|108 118|band pattern
P01548756A1102|121 133|chimpanzee DNA
P01548756A1102|151 165|rhesus monkey DNA
P01548891A0635|62 77|thyroid carcinoma
P01548891A0635|115 130|thyroid carcinoma
P01549118A0000|3 40|Caenorhabditis elegans vitellogenin genes
P01549118A0000|121 142|hermaphrodite intestine
P01549125A0140|49 63|beta GK promoters
P01549125A0140|104 119|DNA binding assays
P01549129A0356|75 86|interactions
P01549346A0000|3 20|c-Ets-1 oncoprotein
P01549346A0000|24 45|transcription activator
P01549465A0122|8 33|transactivation experiments
P01549465A0122|126 139|discrimination
P01551176A0000|57 70|pyrroloquinone
P01551568A1476|0 19|Marker rescue analysis
P01551898A1084|128 140|culture medium
P01551910A0313|0 18|Competition analysis
P01551910A0313|21 51|gel mobility shift electrophoresis
P01551910A0313|117 136|transcription factors
P01552052A0139|68 82|serum creatinine
P01552052A0139|127 138|cyclosporine
P01552457T0000|0 22|Intrapocket chemotherapy
P01552457T0000|30 42|periodontitis
P01553407T0000|49 62|risk assessment
P01554334A0000|20 35|gamma-interferon
P01554334A0000|45 55|assay system
P01554334A0000|79 90|tuberculosis
P01555556A0565|0 13|Control Tmuscle
P01556068A0000|3 29|Klebsiella aerogenes gene maoA
P01556068A0000|61 76|monoamine oxidase
P01556068A0000|143 163|ammonium ion repression
P01558942A1369|7 18|observations
P01559209T0000|0 12|Preceptorship
P01559209T0000|15 25|CNS students
P01560021A0379|63 78|brain AE3 variants
P01562659A0676|45 58|administration
P01562659A0676|61 73|amphotericin B
P01562659A0676|107 120|administration
P01562659A0676|123 135|dexamethasone
P01562659A0676|198 210|CNS vasculitis
P01562659A0676|213 224|encephalitis
P01562659A0676|263 274|confirmation
P01562659A0676|277 294|C. immitis infection
P01563343A0548|0 11|Lac operators
P01563343A0548|55 65|CAB promoter
P01563635T0000|0 13|Overproduction
P01563635T0000|14 25|purification
P01563635T0000|29 44|characterization
P01563635T0000|47 70|M.HinfI methyltransferase
P01563635T0000|76 89|deletion mutant
P01565093A0179|67 81|blood lead levels
P01565093A0179|132 156|disease surveillance system
P01565093A0179|172 188|Alabama Department
P01565093A0179|191 202|Public Health
P01565882A0737|23 38|perfusion defects
P01565882A0737|95 109|perfusion defect
P01565882A0737|182 196|perfusion defect
P01568960A1129|95 107|corner vessels
P01568960A1129|126 136|VA/Q regions
P01569015A0120|51 63|reading frames
P01569102A0708|31 41|LDL receptor
P01569102A0708|75 86|conservation
P01569344A0404|66 78|New Orleans age
P01569344A0404|94 112|HTLV-I/II prevalence
P01569581A0482|134 160|translation initiation region
P01569581A0482|181 210|translation initiation frequency
P01569584A0672|0 16|Hybridization data
P01569584A0672|72 84|m6F6 cDNA clone
P01569945A0529|37 48|reading frame
P01572549A0000|0 21|Protein tyrosine kinases
P01572549A0000|142 158|signal transducers
P01572549A0000|164 184|growth factor receptors
P01573270A0000|69 80|immunization
P01573270A0000|147 165|EBV-B lymphocyte line
P01577056A0178|59 70|theophylline
P01577056A0178|166 178|washout period
P01577740A1111|0 14|Primer extension
P01577740A1111|29 45|S1 nuclease mapping
P01577740A1111|63 90|transcription initiation sites
P01577740A1111|112 127|Northern analyses
P01577819A0709|10 29|PRP-precursor alleles
P01579472A1018|16 30|enhancer element
P01579537A0000|36 49|botulinum toxin
P01581409A0398|45 62|Pharmacia CAP System
P01581409A0398|69 84|DPC AlaSTAT System
P01581577A1186|37 51|gene duplication
P01581965A0388|85 118|breakpoint cluster region gene product
P01581965A0388|179 189|GAP activity
P01582413A0192|186 207|hetero-oligomerization
P01582413A0759|0 11|Dimerization
P01582413A0759|111 125|transactivation
P01583819A0377|64 75|Simson method
P01584812T0000|55 66|localization
P01584812T0000|98 122|transcription factor NGFI-C
P01585014A0000|45 57|gonadotrophin
P01585014A0000|77 90|micrograms GnRH
P01585014A0000|107 130|progestagen sponge removal
P01585014A0000|250 262|sponge removal
P01585014A0000|350 371|mare serum gonadotrophin
P01585014A0000|381 408|mg follicle stimulating hormone
P01586901A0000|9 20|interactions
P01587267A1144|3 14|sequence data
P01587267A1144|33 46|interpretation
P01587763A0402|5 19|body irradiation
P01588270A1029|12 24|blood pressure
P01588315A0356|9 31|Orgyia pseudotsugata MNPV
P01588315A0356|57 73|promoter structure
P01588315A0356|108 121|polyhedrin gene
P01588913A0000|81 93|transcription
P01588963A1153|76 87|Cdc25 protein
P01588965A0000|0 15|GCR1 gene function
P01588965A0000|49 62|gene expression
P01589576A0170|3 13|decay curves
P01589576A0170|16 38|chlorophyll fluorescence
P01589576A0170|46 58|superposition
P01589576A0170|101 113|time constants
P01592545A0726|20 32|blood pressure
P01594554A0845|47 63|trypsin inhibitors
P01594554A0845|94 108|feedback control
P01596007A0908|81 92|gamma OH study
P01596007A0908|114 127|control studies
P01597170A0000|131 142|control group
P01597272A0077|40 57|withdrawal symptoms
P01600531A0483|31 45|phosphocreatine
P01600531A0483|58 69|control group
P01601181A0842|3 16|60A transcripts
P01601181A0842|55 66|gastrulation
P01601869A1389|172 185|BC3H1 myoblasts
P01607223A0000|6 19|investigations
P01607223A0000|45 60|release technique
P01611699A0000|5 25|pyridoxine derivatives
P01611699A0000|64 88|Albizzia julibrissin DURAZZ
P01612085A0624|3 21|serum erythropoietin
P01612085A0624|25 38|concentrations
P01612085A0624|107 121|distance runners
P01613640A0158|3 18|coating materials
P01615049A0000|12 27|drinking patterns
P01615049A0000|60 69|h light/12 h
P01615182A0206|41 57|sputum amoxycillin
P01615182A0206|74 90|combination tablet
P01615493A0408|18 30|antigen levels
P01615493A0975|80 95|thrombin activity
P01616475A0756|48 61|CP/NCA patients
P01616475A0756|85 97|family history
P01616475A0756|100 112|panic disorder
P01616475A0756|148 172|panic disorder presentation
P01617242T0000|0 13|FDA regulations
P01617242T0000|17 29|growth factors
P01617801A0088|6 21|Serum aldosterone
P01617801A0088|25 43|plasma renin activity
P01618027A1108|103 113|E10 fragment
P01618243T0000|11 27|amine pressor tests
P01618256A0521|26 38|concentration
P01618256A0521|60 73|micrograms.l-1
P01618256A0521|114 127|micrograms.l-1
P01619114A0383|67 85|Mini Speech Processor
P01620118A0470|109 129|immunodeficiency virus
P01620129A0417|40 51|factor HiNF-D
P01620129A0417|71 85|promoter element
P01620129A0417|91 102|H4-FO108 gene
P01620610A1070|44 61|expression problems
P01620610A1070|183 194|MTI subregion
P01621584A0183|92 103|IOP reduction
P01623900A0670|5 17|blood pressure
P01623900A0670|64 75|plasma levels
P01623900A0670|97 110|norepinephrine
P01623900A0670|188 201|blood pressures
P01623900A0670|228 246|norepinephrine level
P01623900A0670|259 281|norepinephrine excretion
P01623900A0670|310 325|dF administration
P01624425A0907|48 60|substitutions
P01624425A0907|66 84|consensus amino acids
P01625527A0000|5 24|blood serotonin levels
P01625527A0000|44 55|control group
P01625527A0000|85 99|failure patients
P01625527A0000|114 129|treatment regimen
P01625527A0000|159 182|maintenance haemodialysis
P01625527A0000|200 214|transplantation
P01626372T0000|105 133|trimethoprim-sulfamethoxazole
P01626430A1112|93 107|Drosophila genes
P01626440A0449|6 25|application solutions
P01626440A0449|28 50|instrument disinfectants
P01626631A0557|5 16|Rett syndrome
P01626631A0557|43 54|disturbances
P01627106A0320|32 58|nitrofurazone administration
P01627106A0320|62 83|S. enteritidis challenge
P01627106A0320|133 150|isolation frequency
P01627830A0000|16 29|casein kinase-1
P01627830A0000|51 66|yeast cDNA library
P01628201A0824|0 12|Incidence rate
P01628806A1347|11 27|sequence variation
P01628806A1347|98 111|helicase region
P01629768A0131|17 33|pressure injection
P01629768A0131|89 105|glass micropipette
P01630454A0635|52 71|Act1 promoter activity
P01630455A0448|26 36|NFIL-1 beta A
P01630455A0448|76 86|DNA sequence
P01630455A0448|115 126|TATA box motif
P01630455A0448|150 162|IL-1 beta genes
P01630569A0605|7 19|amphotericin B
P01631229T0000|0 11|Cutis aplasia
P01633435A0743|25 39|characteristics
P01633816A0667|22 34|EcoRI fragment
P01633816A0667|155 177|primer extension analysis
P01633816A0667|181 197|S1 nuclease mapping
P01634308A0191|0 24|Cardiovascular risk factors
P01634400A1101|0 14|Production costs
P01634400A1101|52 72|replacement stock costs
P01634464A0163|26 43|factor VII inhibitor
P01634464A0163|65 88|penicillin administration
P01634861A1336|32 51|oxygen debt hypothesis
P01634861A1336|83 98|lactate clearance
P01636339A0200|97 108|pollen grains
P01639724A0452|1 12|control group
P01639724A0452|43 56|contraceptives
P01641628A0869|21 35|reference values
P01641628A0869|156 170|reference values
P01642060A0471|44 57|Phthalocyanine
P01643943A0300|11 27|lung cancer tissues
P01644751A0590|8 19|reading frame
P01644751A0590|67 82|sequence analysis
P01644751A0590|100 114|msgB gene product
P01644814A0068|53 67|immortalization
P01644821A1259|57 67|CAT activity
P01644821A1259|70 80|fusion genes
P01644821A1259|213 228|butyrate response
P01644831A0824|27 42|carboxyl terminus
P01644831A0824|160 175|carboxyl terminus
P01645902A1462|137 147|syn mutation
P01645905A0341|0 12|Nucleoprotein
P01645905A0341|40 52|vaccinia virus
P01645905A0341|156 172|breakdown products
P01646157A0414|28 51|alpha-GalNAc cDNA sequence
P01646157A0414|109 125|amino acid homology
P01646157A0414|161 180|alpha-galactosidase A
P01646487A0874|84 95|B lymphocytes
P01646753A0336|39 54|hydroxyl radicals
P01646753A0336|88 104|reduction proceeds
P01647070A0232|9 20|JCV T antigens
P01647070A0232|34 44|SV40 origins
P01647070A0232|47 60|DNA replication
P01647656A0000|129 144|LV volume overload
P01647656A0000|169 181|regurgitation
P01648530A0000|54 70|actin gene promoter
P01648530A0000|131 159|actin-beta-globin reporter gene
P01649173A0160|109 130|transcription start site
P01649318A0734|22 32|CD23 element
P01649318A0734|74 123|herpes simplex virus TK promoter transcription start site
P01649318A1222|49 63|cell DNA fragment
P01649318A1222|110 122|transcription
P01649539T0000|0 13|Plasma vitamin E
P01649539T0000|28 48|myeloperoxidase levels
P01649835A0822|27 37|PBR/IBP cDNA
P01649835A0822|113 124|binding sites
P01650524A0837|34 45|permeability
P01650524A0837|70 83|LTB4 production
P01650524A0837|116 138|5-LO inhibitors phenidone
P01650524A0837|170 182|dexamethasone
P01650557T0000|22 43|latex agglutination test
P01650557T0000|61 89|cytomegalovirus antibody status
P01650557T0000|99 114|transplant donors
P01651232A0152|34 48|uridine residues
P01651918A0000|40 52|cDNA fragments
P01651918A0000|80 96|amino acid sequence
P01651918A0000|99 127|rat testis fructose-6-phosphate
P01651918A0000|143 156|bisphosphatase
P01652372A0153|28 45|localization signal
P01652515A0379|34 54|avoidance conditioning
P01652515A0379|86 100|microinjections
P01652755A1492|18 40|transfection experiments
P01652755A1492|52 65|overexpression
P01652755A1492|78 116|retinoblastoma susceptibility gene product
P01653173A0619|85 103|P105 promoter TATA box
P01653173A0619|125 137|preincubation
P01653173A0619|143 168|HPV-18 P105 promoter template
P01653173A0619|215 234|preinitiation complex
P01653236A0895|40 61|glucocorticoid receptor
P01653236A0895|92 113|glucocorticoid receptor
P01653236A0895|123 139|hamster ovary cells
P01653238A1062|11 47|12-O-tetradecanoyl-phorbol-13-acetate
P01653238A1062|51 66|response elements
P01653238A1062|101 123|transcription factor AP-1
P01653238A1062|128 144|consensus sequence
P01653238A1062|160 175|growth factor beta
P01653238A1062|217 230|promoter region
P01653918A0286|105 124|corneal pain threshold
P01654349A0327|38 58|NaHCO3 supplementation
P01655126T0000|0 18|Extraction procedure
P01655126T0000|38 54|butyltin compounds
P01656220T0000|51 63|leukemia cells
P01656220T0000|77 98|receptor tyrosine kinase
P01656221A1319|14 31|amino acid sequences
P01656221A1319|103 118|tyrosine residues
P01656675A0236|0 16|Capnography curves
P01656675A0236|21 31|HVS patients
P01657246A0325|3 29|transcription initiation site
P01657249A1019|114 130|region determinant
P01657415A0837|0 13|Intron K1 cox1.2
P01657594A0472|39 59|complementation groups
P01657969A1420|47 58|interactions
P01657969A1420|76 97|amino acid substitutions
P01657969A1420|156 172|calmodulin binding
P01658356A1369|19 30|coexpression
P01658356A1369|67 82|FeLV recombinants
P01658356A1369|117 129|3201B cell line
P01658356T0000|0 12|Recombination
P01658356T0000|26 47|leukemia virus subgroup B
P01658356T0000|64 74|env elements
P01658375A0854|3 21|nucleotide sequences
P01658375A0854|191 209|consensus sequence GT
P01658468A0123|37 47|C. kutscheri
P01658741A1047|47 64|nucleotide sequence
P01659685T0000|59 73|Dd ras expression
P01659685T0000|76 88|Dictyostelium
P01660486A1756|47 60|gene cotransfer
P01660486A1756|66 89|aminoglycoside resistance
P01660486A1756|145 161|control mechanisms
P01660486A1756|202 215|gene expression
P01660925T0000|0 15|Transfer RNA genes
P01660925T0000|20 42|Dictyostelium discoideum
P01660925T0000|98 111|consensus boxes
P01662609A0398|18 29|polypeptides
P01662794A0640|34 45|transfection
P01662807A1182|51 65|SV40 chromosomes
P01662884A1029|0 11|Temafloxacin
P01669611A0142|71 85|pleuropneumonia
P01671675A0483|96 115|hybridization methods
P01671675A0483|119 134|sequence analysis
P01671675A0483|161 172|cDNA sequence
P01671675A0483|192 205|CAD polypeptide
P01671675A0905|28 51|Northern blotting analysis
P01674177T0001|0 18|Histamine-2 blockade
P01674242A0358|75 86|erythromycin
P01674242A0358|87 100|troleandomycin
P01674242A0358|101 121|triacetyloleandomycin
P01674242A0358|122 134|roxithromycin
P01674242A0358|143 155|ciprofloxacin
P01674242A0358|356 367|idrocilamide
P01674242A0358|368 380|thiabendazole
P01674242A0358|403 417|BCG-vaccination
P01674242A0358|439 455|half-life increase
P01674369A0417|53 67|restriction site
P01674662A0000|33 45|heroin addicts
P01674662A0000|102 116|lymphadenopathy
P01674817T0000|55 67|mRNA decay rate
P01674817T0000|68 83|sequence analysis
P01674817T0000|115 126|RNA15 protein
P01675154T0000|42 54|bypass surgery
P01675424A0991|37 48|H-NR sequence
P01675424A0991|63 78|NADH-NR sequences
P01675424A0991|100 117|pyridine nucleotide
P01675637T0033|7 25|amino acid difference
P01675637T0033|84 105|receptor dimer formation
P01678287A1308|15 37|Antp TATAA binding protein
P01678287A1308|100 111|homeobox gene
P01678392A0648|4 20|% confidence values
P01679068A0000|160 174|Enterobacter spp
P01679124A1368|43 54|ChAT activity
P01679124A1368|128 141|norepinephrine
P01679124A1368|149 165|dorsal hippocampus
P01679124A1368|168 180|MS/HSI animals
P01679749A1171|3 14|localization
P01679749A1171|21 37|proteoglycan locus
P01679749A1171|60 71|availability
P01679749A1171|136 156|HSPG2 proteoglycan gene
P01681075A0429|11 29|dobutamine injection
P01681075A0429|44 62|pimobendan injection
P01681075A0429|96 108|determination
P01681075A0429|114 125|tissue levels
P01681075A0429|150 171|carbohydrate metabolism
P01682484A0680|153 164|hemodynamics
P01682484A0680|175 191|lactate metabolism
P01682509A0539|32 43|proteins IE86
P01682542A0690|22 34|HIV prevalence
P01684791A0000|29 54|glucocorticoid inducibility
P01684791A0000|60 89|chicken glutamine synthetase gene
P01687050T0000|30 49|fluid immunoglobulin G
P01688841A0430|82 94|regulator virF
P01690728A1166|35 49|mRNA transcripts
P01690728A1166|56 68|kilobase pairs
P01690728A1166|99 123|Northern blot hybridization
P01690728A1166|124 148|S1 nuclease protection assay
P01690728A1166|155 177|polymerase chain reaction
P01690812A0000|108 121|gene insertions
P01691184A0995|18 34|polypeptide chains
P01691184A0995|78 93|cleavage products
P01691184A0995|105 118|disulfide bonds
P01691184A0995|124 139|precursor protein
P01692135A0783|10 33|rtFc gamma R alpha cDNA clone
P01692135A0783|92 103|CRNK-16 cells
P01692135A0783|140 150|mRNA species
P01692135A0783|182 192|killer cells
P01692837A0390|76 88|kilobase pairs
P01692962A0980|35 46|s polypeptide
P01692962A0980|56 67|hamster ovary
P01692962A0980|103 115|cAMP synthesis
P01692962A0980|133 153|protein kinase activity
P01694009A0112|75 88|signal sequence
P01694014A0716|23 36|cell lines HL-60
P01694014A0716|48 76|phorbol 12-myristate 13-acetate
P01694014A0716|116 130|RNA hybridizable
P01694280A0000|22 36|ventriculoscope
P01694525A0000|0 22|Isopenicillin N isomerase
P01694525A0000|81 97|amino acid sequence
P01695116A0078|63 74|chemotherapy
P01695314A0762|13 25|glucose levels
P01695314T0000|0 18|Platelet aggregation
P01695314T0000|54 79|calcium antagonist treatment
P01695314T0000|88 103|diabetes mellitus
P01695378A1406|35 63|phorbol 12-myristate 13-acetate
P01695905A0480|96 108|adipose tissue
P01697683T0000|0 13|Identification
P01697683T0000|17 32|characterization
P01697683T0000|52 65|cytotactin gene
P01697928A1214|21 36|sequence homology
P01697928A1214|114 128|response element
P01698761A1059|15 31|DNA rearrangements
P01699944A1538|57 78|CArG box binding proteins
P01699944A1538|115 129|promoter element
P01700272A0838|0 14|Polyadenylation
P01701088A1335|0 11|Co-existence
P01701088A1335|63 73|AP-2 element
P01702361A0621|34 50|collagen synthesis
P01702361A0621|85 106|angiogenesis inhibitors
P01702426A0196|134 149|acid synthase gene
P01702426A1006|61 91|lambda-ZAP goose liver cDNA library
P01702432A1296|0 23|Northern blotting analysis
P01702432A1296|95 106|pollen tissue
P01702972A0613|7 23|cDNA hybridization
P01703335T0000|40 56|immunosuppression
P01703335T0000|73 84|observations
P01703335T0000|93 112|transplant population
P01707659A0458|69 82|chimpanzee gene
P01707800A0354|11 34|N13-N20 interpeak interval
P01707800A0354|61 73|parallel shift
P01707800A0354|95 108|conduction time
P01707800A0354|121 134|onset latencies
P01708098A0922|18 40|complex DNA binding assays
P01708098A0922|61 85|alpha promoter DNA sequences
P01708771A1215|0 20|Sequence determination
P01708774A0203|3 13|DNA sequence
P01708774A0203|24 35|AP-1 activity
P01708774A0203|59 72|promoter region
P01709486A0000|46 59|proto-oncogene
P01709933T0000|12 27|characterization
P01710766A0349|72 90|amino acids C terminal
P01710766A0349|109 123|initiation codon
P01710768A1172|167 181|gamma interferon
P01710979T0000|77 88|proteins p130
P01711041A0348|69 81|C5 alpha-chain
P01711041A0962|3 15|C5 alpha-chain
P01711048T0000|88 98|RNA splicing
P01711048T0000|108 129|osteogenesis imperfecta
P01712296A0157|3 21|nucleotide sequences
P01712296A0157|75 94|amino acid differences
P01713213A0000|42 66|pim-1 proto-oncogene shares
P01713213A0000|93 122|serine/threonine protein kinases
P01713213A0000|137 147|Pim-1 enzyme
P01713213A0000|182 210|protein tyrosine kinase activity
P01713213A0488|54 66|vector pGEX-2T
P01713213A0488|73 84|Pim-1 protein
P01713213A0488|97 109|fusion product
P01713213A0488|123 146|glutathione S-transferase
P01714358A0990|5 18|kDa polypeptide
P01714358A0990|55 77|wheat etioplast membranes
P01714452A0559|46 57|repeat domain
P01714452A0559|71 82|conservation
P01714452A0559|128 149|carbohydrate attachment
P01714902A0221|39 82|Ti alpha-beta CD3 gamma delta epsilon TCR complexes
P01714902A0221|88 98|cell surface
P01714902A0221|129 151|interleukin-2 production
P01714902A0221|157 170|TCR stimulation
P01714902A0221|188 212|histocompatibility complex
P01715593A0838|36 54|fluoxetine injection
P01715593A0838|55 65|brain levels
P01716292A0000|53 72|T cell allorecognition
P01716629A0000|52 76|matrix glycoprotein undulin
P01717718A1255|11 24|point mutations
P01717718A1255|30 44|Gag-Pol PR domain
P01717718A1255|113 124|conformation
P01717718A1255|149 160|prerequisite
P01717833A1223|3 22|alpha inhibin promoter
P01717833A1223|72 85|granulosa cells
P01717833A1223|102 112|CREB protein
P01717833T0000|15 30|alpha inhibin gene
P01717833T0000|49 61|monophosphate
P01717833T0000|67 78|transfection
P01717833T0000|83 99|rat granulosa cells
P01717925A0477|15 33|nucleotide sequences
P01717925A0477|74 91|sequence similarity
P01717994T0000|48 62|complementation
P01718043A0384|14 26|osteomyelitis
P01718043A0384|46 56|PMN elastase
P01718043A0384|117 144|erythrocyte sedimentation rate
P01719684A0494|145 161|sphincter function
P01720555A1087|25 36|B2 transcript
P01720555A1087|54 66|alfalfa organs
P01720843A1506|27 41|sulfhydryl group
P01720843A1506|72 87|enzyme inhibitors
P01720843A1506|127 146|nitrovasodilator EDRF
P01721261T0000|0 15|Pharmacokinetics
P01721261T0000|25 42|transplant patients
P01721884A0962|72 84|ribonuclease H
P01721884A0962|157 169|investigators
P01721884A0962|251 272|RNase H crystal structure
P01722319A0849|20 36|amino acid sequence
P01722319A0849|49 61|CHIP28 protein
P01722319A0849|117 136|N-glycosylation sites
P01722479A0302|14 27|concentrations
P01723619A0766|16 26|F absorption
P01723619A0766|42 61|plasma F concentration
P01723619A0766|162 172|F absorption
P01723962A0165|13 23|serum lipase
P01724982A0237|60 71|North Chicago
P01725622A0292|30 46|platelet increment
P01726211A0502|5 15|risk factors
P01726631T0001|0 11|Epidemiology
P01726631T0001|27 44|hospital infections
P01726631T0001|50 64|Local Health Unit
P01727488A1146|82 95|gene expression
P01727494A0000|0 12|Vaccinia virus
P01731107A0928|0 12|Substitutions
P01731107A0928|68 82|pRNA replication
P01731933T0000a|3 27|coordination domain mutants
P01731933T0000b|3 27|coordination domain mutants
P01731979A1408|3 19|tissue specificity
P01731979A1408|22 35|gene expression
P01731979A1408|79 107|CaMV 35S domain B enhancer element
P01732033A0000|3 17|pathophysiology
P01732033A0000|46 56|brain injury
P01732033A0000|109 119|brain injury
P01732736A1076|22 35|POU-domain gene
P01732736A1076|129 140|gastrulation
P01732752A0156|58 72|pre-B-cell lines
P01733105A0127|11 22|Thogoto virus
P01733358A0240|59 76|cystadenocarcinoma
P01733358A0240|83 96|adenocarcinoma
P01733358A0240|101 115|mucin production
P01734020A1318|0 13|Immunostaining
P01734283A0817|27 38|RAP74 protein
P01734283A0817|100 117|translation product
P01734570T0000|9 39|thromboxane synthetase inhibition
P01734570T0000|99 111|translocation
P01734570T0000|122 133|porcine model
P01735347A0482|83 94|plasma lipase
P01735447A0271|73 89|pre-super-pro-PrB
P01735447A0271|102 113|sec61 mutants
P01735447A0271|118 130|translocation
P01735447A0833|7 25|active-site mutation
P01735721A0185|12 28|amino acid sequence
P01735721A0185|56 86|Bacillus stearothermophilus TyrTS
P01735721A0185|148 166|B. subtilis TyrTS gene
P01736093A0731|14 24|CAT activity
P01736093A0731|136 148|constructions
P01736651A0104|22 36|Children clinics
P01736844T0000|0 11|Testosterone
P01736844T0000|16 27|testosterone
P01736844T0000|64 75|testosterone
P01736844T0000|83 95|androgen index
P01736844T0000|101 123|testosterone measurement
P01737741A0000|13 25|effectiveness
P01737741A0000|28 53|monoamine oxidase inhibitors
P01737789A0800|64 81|acceptor splice site
P01737789A0800|92 123|down-stream alpha-delta breakpoint
P01738470A0441|86 102|recognition memory
P01738936A0292|14 28|plasma C-peptide
P01739439A0257|96 108|abnormalities
P01739439A0257|138 148|control mice
P01739956A0638|30 43|calcium channel
P01740121A0136|53 90|baculovirus/insect cell expression system
P01740437A0851|14 24|core protein
P01740437A0851|30 49|liver HSPG preparation
P01740448A1735|14 33|transmembrane regions
P01740448A1735|71 88|amino acid stretches
P01740682A0703|80 102|World Health Organization
P01740682A0703|147 162|thrombocytopenia
P01742341A0499|64 77|transportation
P01742606A0000|1 23|mouse brain beta-spectrin
P01742606A0000|50 76|lambda Gt11 expression library
P01742606A0000|124 146|kDa spectrin beta-subunit
P01742879A0471|7 24|Plasma AVP responses
P01742879A0471|113 125|water drinking
P01744039A0511|39 61|polymerase chain reaction
P01744039A0511|75 92|gel electrophoresis
P01744039A0511|114 137|conformation polymorphism
P01744119A0757|16 42|primase recognition sequences
P01744119A0757|43 73|nucleotide substrate requirements
P01744119A0757|109 136|oligoribonucleotide synthesis
P01747972T0000|40 55|artery dissection
P01748194A0767|34 45|hemisections
P01748194A0767|122 136|cord transection
P01748292A0000|37 56|G protein alpha subunit
P01748292A0000|67 88|Lycopersicon esculentum
P01748630A0125|0 22|Growth factor stimulation
P01748630A0125|39 53|phosphorylation
P01748630A0125|79 94|activation domain
P01751163A0000|44 56|complications
P01751163A0000|68 79|implantation
P01751163A0000|106 117|Sarns/3M-VAD
P01751970A0209|0 16|Amino acid residues
P01752441A0000|30 44|HIV-1 Tat protein
P01752441A0000|74 91|hexanucleotide loop
P01752441A0000|95 112|trinucleotide bulge
P01752441A0000|118 141|TAR RNA stem-loop structure
P01752792A0000|53 67|time differences
P01753317A0879|81 93|bone formation
P01753317A0879|116 126|bone defects
P01754381A0000|25 40|characterization
P01754381A0000|54 67|DNA polymerases
P01754381A0000|70 81|trypanosomes
P01754381A0000|184 201|DNA polymerase alpha
P01756195A1117|65 78|concentrations
P01756539A0354|9 20|hypertension
P01757341A0591|3 16|volume fraction
P01757341A0591|121 139|alkaline phosphatase
P01758750A0000|0 13|Airway pressure
P01759282A0000|8 19|distribution
P01759282A0000|63 80|contact interaction
P01759282A0000|127 138|biomechanics
P01761736A0158|26 38|body clearance
P01761736A0158|94 113|elimination half-life
P01761736A0158|192 203|distribution
P01762914A1218|8 18|uPA promoter
P01762914A1218|83 102|translation start site
P01762917A0615|52 67|TGEK tetrapeptide
P01763106A0070|81 91|test session
P01764899A0399|40 56|water fluoridation
P01764899A0399|59 74|caries prevalence
P01764899A0399|114 124|cavity level
P01765095A0680|0 34|12-O-Tetradecanoylphorbol 13-acetate
P01765095A0680|110 123|regulators CMD1
P01765266A0000|2 14|Xenopus laevis
P01765266A0000|33 55|elongation factor 1-alpha
P01765266A0000|63 72|EF-1 alpha O
P01765269A0308|37 51|pre-mRNA introns
P01765269A0308|73 90|consensus sequences
P01765375A0290|51 63|clathrin clone
P01765386A0305|23 33|DNA sequence
P01765407A0866|52 70|plasma concentration
P01765407A0866|77 88|postexposure
P01765407A0866|122 139|mmol/mol creatinine
P01766666A0788|41 62|nucleoprotein complexes
P01766876A0000|78 90|co-conversion
P01766876A0000|107 119|point mutation
P01766876A0000|153 169|replacement vector
P01766999A0000|20 49|allergen extract Ambrosia elatior
P01767060A0000|35 53|c-DDP administration
P01767060A0000|71 82|radiotherapy
P01767592A0682|34 51|DNA binding proteins
P01767592A0682|84 120|HAP2/HAP3 consensus recognition sequence
P01767592A0682|123 136|nucleotide-154
P01767592A0682|141 172|BAF1 consensus recognition sequence
P01767592A0682|175 188|nucleotide-136
P01767899A0136|6 21|thrombocytopenia
P01767899A0136|33 47|serum fibrinogen
P01767899A0136|90 107|thromboplastin time
P01767899A0136|159 170|envenomation
P01768648A0853|24 41|LexA fusion proteins
P01768648A0853|52 63|dimerization
P01769189A0000|0 10|Plasma lipid
P01769189A0000|14 32|lipoprotein profiles
P01769189A0000|97 112|training distance
P01769189A0000|136 146|ml kg-1 min-1
P01769189A0000|218 228|ml kg-1 min-1
P01769919A0393|8 22|threshold shifts
P01769919A0393|52 68|brainstem response
P01770651T0001|34 52|equilibrium dialysis
P01770651T0001|53 74|radioimmunoassay system
P01771959A0442|9 24|ejection fraction
P01772201T0001|32 43|subjectivity
P01772341A0852|45 74|thromboxane synthetase inhibitor
P01772341A0852|79 107|thromboxane receptor antagonist
P01772341A0852|140 158|digoxin intoxication
P01774062A0257|30 42|HLA-DQA1 locus
P01774063A0161|13 29|backcross analysis
P01774063A0161|62 80|C57BL/6J x Mus spretus
P01774063A0161|84 95|C57BL/6J mice
P01774063A0161|112 129|thrombospondin gene
P01774093T0000|41 69|Chlamydia trachomatis infection
P01774822A0289|39 58|LV time-density curves
P01776715A0489|25 38|centrifugation
P01776715A0489|83 95|equilibration
P01779299A0000|50 67|Periplaneta brunnea
P01779299A0000|83 97|acanthocephalan
P01779299A0000|98 121|Moniliformis moniliformis
P01779433A0694|27 41|Alu family repeat
P01779433A0694|163 177|Alu family repeat
P01779433A0694|248 262|Alu family repeat
P01779433A0694|294 308|Alu family repeat
P01779769A0000|16 29|repressor locus
P01779769A0000|36 47|Streptomyces
P01779769A0000|101 112|reading frame
P01781923A0744|49 61|concentration
P01781923A0744|137 164|barbiturate brain distribution
P01782424A0278|14 36|threshold concentrations
P01782669A0496|29 40|temperatures
P01782982A0155|24 35|baseline FEV1
P01782982A0155|104 122|bronchoconstriction
P01783088A1136|107 120|micrograms.l-1
P01783088A1136|158 171|micrograms.l-1
P01783375A1066|114 137|translocation breakpoints
P01784589A0000|41 61|5-HT2 receptor activity
P01787085A0331|38 48|control rats
P01788002T0001|0 13|Magnetotherapy
P01791754T0000|75 89|secretion signal
P01792580A0198|5 15|blood donors
P01792580A0198|58 71|blood donations
P01792580A0198|148 158|blood donors
P01792914T0000|23 39|childhood leukemia
P01798407A1011|18 30|abnormalities
P01798407A1011|142 157|laughing seizures
P01804671A1001|137 169|ventilation/perfusion distribution
P01806314A0322|91 101|muscle actin
P01808049A0262|0 14|CT abnormalities
P01808136T0000|12 24|contrast media
P01808136T0000|27 46|coagulation factor XII
P01808602A0000|38 49|hypertension
P01808602A0000|68 86|nifedipine treatment
P01808829A0510|12 26|brain congestion
P01809854A0106|40 53|research design
P01809854A0106|64 82|consensus statements
P01809854A0106|90 102|meta-analysis
P01810108A0000|4 16|phase slug flow
P01810108A0000|24 36|heat exchanger
P01810108A0000|57 68|inactivation
P01810108A0000|71 91|Listeria monocytogenes
P01811243A0000|29 40|measurements
P01811243A0000|210 222|rCBF technique
P01811948A0289|84 99|LpS1 beta promoter
P01812102A0101|10 21|study reports
P01812102A0101|54 68|pattern reversal
P01814182A0000|16 34|15-methyl-PGF2 alpha
P01822581A0533|25 40|alcohol responses
P01822581A0533|81 95|microgram/100ml
P01822581A0533|99 111|breath samples
P01822995T0000|0 24|Maize rbcS promoter activity
P01822995T0000|34 49|sequence elements
P01822995T0000|60 77|dicot rbcS promoters
P01823520A0183|0 11|Measurements
P01823520A0183|35 61|haematofluorometer Buchler ZF
P01823520A0183|92 107|haematocrit value
P01823524A0238|191 204|susceptibility
P01823524A0238|207 225|xenobiotics toxicity
P01824713A0964|3 15|12S E1A product
P01824713A0964|32 42|TRE sequence
P01824713A0964|46 59|cotransfection
P01824944A0988|32 44|transfectants
P01824944A0988|73 84|polypeptides
P01825027T0000|25 44|peroxisome biogenesis
P01826003A0694|65 74|beta TG gene
P01826043A0431|3 31|pp90rsk-protein kinase activity
P01826043A0431|90 120|signal transducing protein kinases
P01826043A0431|149 162|protein kinases
P01826043A0431|175 194|protein kinase C family
P01826043A0431|213 226|protein kinases
P01827068T0000|30 48|transcription factor
P01827068T0000|80 101|T cell receptor alpha gene
P01827203A0136|18 37|transcription factors
P01828248A0189|14 24|UvrA protein
P01828248A0189|41 51|UvrB protein
P01828248A0189|120 131|UvrAB complex
P01828248A0189|142 157|helicase activity
P01829460A0329|0 23|Southwestern blot analysis
P01829460A0329|44 57|phosphoprotein
P01829460A0329|68 80|kappa B element
P01830114A1587|51 63|P4 transcripts
P01830114A1587|76 88|amplification
P01830114A1587|91 104|gene copy number
P01830928A0361|21 37|microtubule motors
P01830928A0361|115 131|attachment domains
P01832152A0000|3 33|incompatibility group W plasmid pSa
P01832152A0000|44 79|Agrobacterium tumefaciens oncogenicity
P01832152A0902|22 33|start signals
P01832197T0001|9 26|D2 dopamine receptor
P01833185A0547|3 19|Thr161Val mutation
P01833185A0547|47 58|fission yeast
P01833185A0547|143 157|phosphorylation
P01833185A0547|164 177|uncoordination
P01833716A0990|0 11|Deregulation
P01833716A0990|53 66|transformation
P01833716A0990|81 95|HTLV-1 infection
P01837787T0000|44 55|organization
P01837842A1410|27 43|protein components
P01837842A1410|58 74|gel shift complexes
P01840513A1019|38 48|pCAT plasmid
P01840513A1019|111 150|chloramphenicol acetyltransferase activity
P01840513A1019|187 198|8-bromo-cAMP
P01840608A0823|26 37|reading frame
P01840608A0823|87 113|amino acid sequence comparison
P01840711A0000|31 42|disease virus
P01840902A1089|94 111|transport machinery
P01842498A0000|47 59|hybridization
P01842498A0000|63 73|cDNA library
P01842498A0000|76 93|phytohemagglutinin
P01842498A0000|96 111|phorbol myristate
P01842498A0000|130 140|Jurkat cells
P01842498A0000|158 168|cDNA library
P01842498A0000|195 210|blood lymphocytes
P01842867A0696|28 46|regeneration ability
P01844017A0410|20 31|relationship
P01844017A0410|48 89|glucose-6-phosphatase dehydrogenase activity
P01844017A0410|95 107|vitamin E level
P01844017A0410|146 158|sodium nitrite
P01844878A0000|43 68|neomycin phosphotransferase
P01844878A0000|90 106|promoter sequences
P01844878A0000|131 142|DNA fragments
P01844982A0324|21 33|leishmaniasis
P01844982A0324|52 66|schistosomiasis
P01845885A1003|182 212|UL26 transcription initiation site
P01845885A1003|235 259|methionine initiation codon
P01845899A0000|87 103|AAV DNA replication
P01845899A0000|107 123|AAV gene regulation
P01846489A1119|34 47|protease domain
P01846489A1119|65 79|protease domains
P01846491A0459|39 56|genus Orthopoxvirus
P01846491A0459|105 123|genus Leporipoxvirus
P01846491A0459|134 154|complex rearrangements
P01846803A0688|22 36|phosphorylation
P01846803A0688|63 83|p34cdc2 kinase activity
P01846803A0688|137 150|ATP binding site
P01847464A0856|12 26|cotransfections
P01847464A0856|28 42|pFRTK-CAT target
P01847464A0856|90 107|plasmid replication
P01847464A0856|149 166|EBNA-1 construction
P01847464A0856|213 230|localization signal
P01847665A1079|55 67|PDGF receptors
P01847665A1079|70 80|glioma cells
P01847665A1079|177 192|glia cell lineages
P01848300A0910|49 66|peptide utilization
P01848871A0392|32 44|sodium channel
P01848871A0392|105 119|amplitude signal
P01848871A0392|164 175|prolongation
P01849509T0000|0 13|Identification
P01849509T0000|17 34|nucleotide sequence
P01849509T0000|37 75|Rhizobium meliloti insertion sequence ISRm3
P01849509T0000|174 201|Thiobacillus ferrooxidans IST2
P01849675A0167|14 25|relationship
P01849675A0167|51 61|DNA sequence
P01849734A1063|8 25|PR55 beta transcript
P01849734A1063|66 78|neuroblastoma
P01849734A1063|86 99|cell line LA-N-1
P01850096A0662|0 11|Heterodimers
P01850096A0662|58 76|restriction fragment
P01850096A0662|127 150|alpha-actin transcription
P01850105A1093|65 79|differentiation
P01850105A1093|117 137|muscle differentiation
P01850127A0000|33 51|branchpoint sequence
P01850127A0000|111 129|polypyrimidine tract
P01851386T0092|10 28|Lung Cancer Task Force
P01851527T0000|3 18|promoter activity
P01851527T0000|36 72|Alzheimer beta-amyloid precursor protein
P01851862A0273|0 18|Nucleotide sequences
P01852603A0000|10 24|DNA repair mutant
P01852603A0000|32 43|fission yeast
P01853796T0000|6 18|deterioration
P01853796T0000|21 36|glucose tolerance
P01853796T0000|53 69|insulin resistance
P01854339A0221|21 38|sequence similarity
P01854339A0221|56 73|consensus promoters
P01857143A0351|35 45|skin lesions
P01857143A0351|68 80|myelofibrosis
P01857326A0160|24 46|resolution imaging boards
P01860846A0663|36 60|tumor necrosis factor-alpha
P01860846A0663|82 104|MARCKS gene transcription
P01860846A0663|128 147|leukemia cell line HL60
P01861034A0798|46 56|contact area
P01861034A0798|86 101|scaphoid fragment
P01861188A0000|0 10|Plate luting
P01861188A0000|275 295|ASIF compression plates
P01862027A0212|53 76|Rothmund-Thomson syndrome
P01862455T0000|0 14|Thyroid lymphoma
P01863887A0174|0 15|Space limitations
P01863887A0174|54 68|pharmaceuticals
P01863887A0174|75 91|tissue plasminogen
P01863887A0174|137 149|growth hormone
P01863887A0174|150 163|erythropoietin
P01863887A0174|164 178|clotting factors
P01863887A0174|182 194|blood products
P01864821A0000|23 33|cell disease
P01864821A0000|67 77|globin chain
P01864821A0000|168 179|blood vessels
P01864837A1029|71 85|mouse contrapsin
P01864837A1029|121 147|rat alpha 1-protease inhibitor
P01865010A0000|175 189|representations
P01867069A0000|32 47|% nicotine sulfate
P01869565A1254|25 37|transcription
P01869565A1254|41 57|translation system
P01869565A1254|72 82|ADH promoter
P01869907A2146|3 21|across-fiber pattern
P01869907A2146|47 59|NaCl solutions
P01869968A0000|8 27|radioactivity content
P01869968A0000|47 60|administration
P01869968A0673|6 23|regression analysis
P01869968A0673|127 138|significance
P01870194A0302|5 29|immunodeficiency virus type
P01870428A0677|60 74|LDL particle size
P01870500A0276|0 12|Contributions
P01870500A0276|33 52|target volume elements
P01870500A0276|199 216|reciprocity theorem
P01871033A0434|71 90|laboratory simulation
P01871033A0434|98 111|clearing cement
P01871033A0434|115 127|testing cement
P01871135A0295|22 33|reading frame
P01871135A0295|128 146|rat liver glucokinase
P01871971A0836|57 67|binding site
P01872856A0277|84 96|radioactivity
P01873999A0000|47 57|model system
P01873999A0000|113 126|gene expression
P01873999A0000|133 148|secretion process
P01874195A0139|58 75|sequence similarity
P01874195A0139|96 123|signal transduction mechanisms
P01874195A0139|164 185|tyrosine kinase activity
P01874752A0948|41 58|conditions cdc2/p58
P01875922A0770|0 15|Mutation analysis
P01876836T0000|0 13|Identification
P01876836T0000|45 60|GA binding protein
P01878489A0959|80 99|NADPH oxidase activity
P01878755A0496|40 52|disappearance
P01878755A0496|79 93|blood appearance
P01881595A0476|29 39|NnS neurones
P01881595A0476|111 121|NnS neurones
P01882386A0000|3 15|effectiveness
P01882386A0000|18 36|alpha-mercapto-beta
P01882386A0000|59 94|N-benzyl-N-dithiocarboxy-D-glucamine
P01882386A0000|120 131|mobilization
P01883992A0922|94 106|beta-zein gene
P01883992A0922|119 132|maize endosperm
P01884435A0088|65 80|ptH distributions
P01884435A0088|91 101|tissue sites
P01884435A0088|135 148|microelectrode
P01884435A0088|173 184|measurements
P01884998A1135|42 54|transcription
P01885006A0995|20 34|superactivation
P01885613A1298|87 98|collagen gene
P01885752A0198|0 19|Chlamydia trachomatis
P01885752A0198|23 39|Chlamydia psittaci
P01885752A0198|57 72|methanol fixation
P01885915A0000|43 62|Pasteurella multocida
P01885915A0000|77 88|endocarditis
P01885915A0000|103 115|P. haemolytica
P01886043A0380|142 159|inclusion complexes
P01886368A0000|0 14|PO2 measurements
P01886368A0000|36 60|recess type microelectrodes
P01886774A0000|51 64|Echerichia coli
P01886774A0000|68 83|characterization
P01886774A0000|101 115|octamer sequence
P01888896A0505|1 14|deletion series
P01888896A0505|95 108|initiation site
P01890362A0305|37 52|eye complications
P01890989A1392|54 70|estrogen induction
P01893195A0000|100 113|virus Issyk-Kul
P01893927A0704|32 52|phenylephrine infusion
P01895358A0000|8 21|energy turnover
P01895358A0000|107 123|training programme
P01895358A0000|140 152|energy balance
P01895358A0000|164 177|energy turnover
P01895370A0199|57 88|maximum shifted-frequency envelope
P01895384A0746|3 16|IE0 gene product
P01895384A0746|38 48|IE1 promoter
P01895393A0745|123 135|RNA polymerase
P01896777T0000|0 15|Ivermectin uptake
P01896777T0000|19 30|distribution
P01896777T0000|91 108|Onchocerca volvulus
P01897515A0348|0 22|Bone marrow abnormalities
P01897515A0348|64 76|understanding
P01898113A0265|29 41|clearance rate
P01898113A0265|66 77|SWA killifish
P01898164A0839|114 132|aorta diameter ratios
P01898164A0839|133 143|arch indices
P01898928A0260|0 23|DNA hybridization analysis
P01899209A0883|14 26|perfusate PCO2
P01899209A0883|97 109|contractility
P01899209A0883|113 129|oxygen consumption
P01899409T0000a|0 11|Determinants
P01899409T0000a|35 61|revascularisation procedures
P01899409T0000a|67 78|thrombolysis
P01899409T0000a|94 119|tissue plasminogen activator
P01899846A0862|12 25|rbcL-rbcS locus
P01900194T0000|0 11|Relationship
P01900194T0000|32 55|NADH-ubiquinone reductase
P01901405A0694|10 23|mRNA expression
P01901443A0297|28 47|maintenance valproate
P01901859A0000|16 27|4GlcNAc alpha
P01901859A0000|31 53|3-galactosyltransferase
P01901859A0000|65 83|glycosyltransferase
P01901859A0000|168 182|Old World monkeys
P01901946A0243|10 24|oligonucleotide
P01901946A0243|38 48|SRE sequence
P01901946A0243|56 77|mouse c-fos gene promoter
P01901946A0243|129 146|mobility shift assay
P01901946A0243|150 161|Southwestern
P01901946A0243|212 233|affinity chromatography
P01901950T0000|0 19|Sequence requirements
P01901950T0000|32 50|transcription arrest
P01901950T0000|76 89|mouse c-fos gene
P01903404A0688|15 30|ejection fraction
P01903404A0688|182 197|ejection fraction
P01903404A0688|223 237|perfusion status
P01903841A0125|8 21|lysine residues
P01903841A0125|76 87|modification
P01903841A1449|3 25|plasmid shuffle technique
P01904154A0164|15 28|identification
P01904154A0164|32 47|characterization
P01904154A0164|93 105|understanding
P01904154A0164|111 134|gene rearrangement process
P01904437A0000|0 12|Transcription
P01904437A0000|93 107|metR gene product
P01904437A0000|109 125|DNA binding protein
P01904546A0671|44 55|a/alpha cells
P01904546A0671|92 106|a/alpha diploids
P01905199A0210|24 40|antitumor response
P01905199A0210|166 182|modality treatment
P01905517A1076|53 69|sequence data bases
P01906111A1295|112 126|toxicity profile
P01906166A0119|108 125|drug administration
P01906509A0072|50 60|nidogen gene
P01906692A0321|0 12|INTERVENTIONS
P01907265A0670|47 59|endonucleases
P01907265A0670|70 80|cell extract
P01907265A0670|108 126|DNA cleavage activity
P01907941A0275|12 22|I kappa B beta
P01907941A0275|29 40|I kappa B alpha
P01907941A0275|74 83|kappa B site
P01909027A0922|0 15|Sequence analysis
P01909027A0922|30 45|DNA binding domain
P01909027A0922|90 113|fork head DNA binding domain
P01909027A0922|142 156|protein fork head
P01909621A0119|18 29|hemodialyses
P01909960A0134|52 64|noradrenaline
P01909960A0134|67 78|biosynthesis
P01909960A0134|103 115|concentration
P01909960A0134|118 132|normetanephrine
P01910505A0000|6 21|wuzi yanzong pills
P01910505A0000|50 65|cyclophosphamide
P01911767T0000|28 58|ribulosebisphosphate carboxylase
P01911767T0000|65 78|subunit binding
P01913955A0177|105 119|muscularization
P01913955A0177|122 135|precursor cells
P01913955A0177|304 314|muscle cells
P01913955A0177|323 334|accumulation
P01915580A0889|97 111|airway responses
P01915580A0889|115 135|airway hyperreactivity
P01916168A0969|11 33|correlation coefficients
P01916168A0969|44 59|ISO2 measurements
P01916168A0969|73 83|ulcer margin
P01916405A0242|9 23|mucosa tattooing
P01917943A0621a|0 15|Sequence analysis
P01917943A0621a|101 123|transfection experiments
P01917943A0621a|181 220|chloramphenicol acetyltransferase reporter
P01917943A0621b|0 15|Sequence analysis
P01917943A0621b|101 123|transfection experiments
P01917943A0621b|181 220|chloramphenicol acetyltransferase reporter
P01917962A0152|3 13|cDNA segment
P01917962A0152|28 73|immunoglobulin gene recombination signal sequences
P01917962A0152|83 93|cDNA segment
P01917962A0152|114 124|IL-2R L chain
P01917962A0152|168 179|SV40 promoter
P01918010A0000|0 16|Lipoprotein lipase
P01918010A0000|38 58|lipoprotein metabolism
P01918010A1730|21 39|octanucleotide motif
P01918010A1730|84 94|LPL promoter
P01918010A1730|156 171|3T3-L1 adipocytes
P01918010A1730|175 190|HepG2 hepatocytes
P01918070A0281|30 44|T3 receptor alpha
P01918073A0150|34 61|TnIcardiac amino acid sequences
P01918073A0150|71 82|TnI sequences
P01918073A0150|122 138|extension sequence
P01918073A0150|152 190|protein kinase A phosphorylation target site
P01918073A0150|363 374|site sequence
P01918073A0150|453 469|actin/TnC-binding
P01918073A0150|470 490|actomyosin-inhibitory
P01918073A0150|513 530|sequence divergence
P01918073A0150|544 562|TnIcardiac sequences
P01918073A0150|585 608|protein kinase C target site
P01919831T0000|11 28|management casebook
P01921463T0000|2 17|ASSEMBLER routine
P01921463T0000|79 91|microcomputer
P01922082A0149|15 30|mouse TSH beta gene
P01922739A0336|39 50|fluctuations
P01923167A0000|0 25|Blood flow velocity waveforms
P01923167A0000|46 63|Doppler examination
P01923628T0001|30 42|flow cytometry
P01923766A0485|0 15|Sequence analysis
P01923766A0485|69 79|mRNA species
P01923803A0609|37 57|SsoL12 protein sequence
P01923985A0111|24 41|mastocyte mediators
P01924315A0158|33 44|copper levels
P01924315A0158|75 88|SOD1 expression
P01924920A0115|17 28|Mobiluncus SP
P01924920A0115|53 64|Gram staining
P01924920A0115|80 92|microorganism
P01925092A0000|8 20|investigators
P01925092A0304|85 110|tissue plasminogen activator
P01927421A0181|16 27|examinations
P01928923A0000|0 11|Equine amnion
P01928923A0000|19 37|yeast cell derivative
P01928923A0000|85 99|wound medicament
P01930470A0337|56 74|American Association
P01930660T0000|12 23|growth factor
P01932650A0435|49 61|drainage blood
P01932650A0435|94 106|concentration
P01932695A1155|45 59|expression assay
P01932695A1155|79 94|barley endosperms
P01933614A0406|11 26|salmon calcitonin
P01933614A0406|59 70|osteoporosis
P01934378A1219|8 36|muscle metaboreceptor responses
P01934378A1219|50 61|heart failure
P01934378T0000|8 44|muscle metaboreceptor exercise responses
P01934378T0000|60 71|heart failure
P01936213T0000|37 52|membrane fluidity
P01936348A0155|3 14|examinations
P01936997A0795|0 16|RNA gel retardation
P01936997A0795|20 38|competition analyses
P01936997A0795|51 64|TRP-185 binding
P01936997A0795|89 107|TAR RNA loop sequences
P01938178T0000|0 11|Applications
P01939131A0871|46 56|strain cells
P01939199A0588|39 51|transcription
P01939199A0588|106 118|TFIID fraction
P01939199A0588|160 172|transcription
P01939827A0150|10 21|pretreatment
P01939827A0150|42 58|oxide surface layer
P01939827A0150|62 75|titanium powder
P01939827A0150|96 108|precipitation
P01939827A0150|133 143|mmol/L CaCl2
P01939827A0150|145 156|mmol/L KH2PO4
P01939827A0150|159 169|mmol/L Hepes
P01939827A0150|186 198|precipitation
P01939827A0150|235 245|mmol/L CaCl2
P01939827A0150|249 260|mmol/L KH2PO4
P01939827A0150|263 273|mmol/L Hepes
P01939878A0765|14 27|solidification
P01939899A2043|105 116|perturbation
P01939906A0233|4 17|generalization
P01939906A0233|67 78|cost function
P01939906A0233|95 105|search space
P01939906A0233|157 168|wave equation
P01939906A0233|191 208|optimization method
P01939906A0233|220 237|parameter landscape
P01939906A0233|262 273|cost function
P01942033T0000|0 12|Determination
P01942033T0000|17 28|RNA structure
P01942033T0000|39 56|splicing inhibition
P01943184A1050|38 54|Wisconsin solution
P01945430A0660|103 116|labyrinthotomy
P01945430A0660|127 141|neuroma suspects
P01947449A0191|11 29|diffusion limitation
P01947449A0191|62 81|uptake/O2 requirement
P01947449A1082|1 19|Diffusion limitation
P01947449A1082|59 74|requirement value
P01947449A1082|184 199|cylinder diameter
P01954355A0997|0 17|Monitoring patients
P01954835A0000|0 21|Echinococcus granulosus
P01954835A0000|47 64|aspiration cytology
P01956285A0000|109 137|choline-glycine betaine pathway
P01956491A0095|17 29|amphotericin B
P01956491A0095|77 90|filtration rate
P01956491A0095|123 141|creatinine clearance
P01958368A0556|86 110|vitelliform classification
P01958821T0000|8 29|fluorescence microscopy
P01958821T0000|38 48|cell biology
P01961747A0000|1 29|herpesvirus proteinase activity
P01961747A0000|97 110|substrate genes
P01961747A0000|122 139|transfection assays
P01963419A0501|7 25|silver liquid chamber
P01963419A0501|109 119|13N reaction
P01963419A0501|124 134|fluoride ion
P01963419A0501|143 153|18F reaction
P01963438T0000|13 28|electron transfer
P01963438T0000|31 41|cytochrome c
P01963438T0000|82 96|polypyrrole film
P01963858T0001|21 39|adrenaline secretion
P01963858T0001|57 71|neuroglycopenia
P01963858T0001|83 95|microdialysis
P01964989A0145|0 13|Urine specimens
P01964989A0145|30 42|phencyclidine
P01964989A0145|128 141|sodium chloride
P01964989A0145|155 172|potassium hydroxide
P01967130A0645|12 23|pair EFIA cDNA
P01967130A0645|41 51|acid protein
P01967130A0645|103 120|DNA binding proteins
P01968043A0908|85 96|orientations
P01968156T0000|0 18|Dose standardisation
P01968156T0000|21 34|botulinum toxin
P01968224A0119|3 16|coding sequence
P01968224A0119|35 52|residue polypeptide
P01968224A0119|124 140|amino acid sequence
P01968224A0119|188 203|PCNA polypeptides
P01970560A1024|142 165|beta-Galactosidase assays
P01970560A1024|194 212|aroF-lacZ expression
P01970560A1024|234 246|TyrR repressor
P01970926A0000|56 73|concentration rises
P01970984A0668|18 37|serum estradiol levels
P01971191A1271|39 51|isoproterenol
P01971191A1271|93 103|liver volume
P01971191A1271|126 142|outflow resistance
P01972379T0042|0 10|DNA sequence
P01973384A0206|28 39|binding sites
P01973384A0206|86 98|transcription
P01974550A0362|31 50|hexamethonium bromide
P01974550A0362|59 76|ipratropium bromide
P01974550A0362|80 93|microgram/kg iv
P01974550A0362|94 105|indomethacin
P01974876A1051|15 51|restriction fragment length polymorphism
P01974876A1051|104 114|enzyme BglII
P01975157A0836|10 23|transformation
P01975428A0151|84 94|DNA molecule
P01975428A0151|119 130|cell division
P01977585A0222|134 146|protein kinase
P01978834A0076|7 35|abomasum lambda gt11 cDNA library
P01978834A0076|86 112|rabbit H,K-ATPase beta subunit
P01978857A0504|14 30|laboratory testing
P01978857A0504|52 64|CD4 cell counts
P01982061A0615|50 76|transcription initiation site
P01982061T0000|0 15|Characterization
P01982061T0000|52 65|hamster CAD gene
P01982997A1104|28 56|transcription factor expression
P01983026A0483|84 99|CA concentrations
P01983026A0483|120 130|study period
P01984665T0000|22 37|immunoreactivity
P01984665T0000|66 94|dengue-2 virus envelope proteins
P01984665T0000|130 142|baculoviruses
P01985301T0000|61 71|brain damage
P01985920A0156|19 37|rat liver cDNA library
P01985920A0156|44 63|oligonucleotide probe
P01985920A0156|78 99|rat SCP2 protein sequence
P01985920A0156|118 130|pair cDNA clone
P01985920A0156|151 169|SCP2 protein sequence
P01985920T0000|20 37|nucleotide sequence
P01985920T0000|40 67|rat liver sterol carrier protein
P01985924A0554|108 121|chromatography
P01985924A0554|166 183|initiation activity
P01986225A0250|15 28|identification
P01986225A0250|39 50|fission yeast
P01986241A0117|20 34|ACE1 gene product
P01986241A0117|65 78|promoter region
P01986254A0452|0 21|Gel mobility shift assays
P01986360A0000|19 57|interferon response element binding factors
P01986360A0000|79 114|mouse fibroblast lambda gt11 cDNA library
P01986360A0000|160 212|oligoadenylate synthetase gene interferon response element
P01988041A0281|55 70|BAL cDNA structure
P01989561A0100|80 95|perfusion cannula
P01989999A0000|28 44|L-aspartate ligase
P01989999A0000|79 96|purine biosynthesis
P01990254A0791|0 16|Immunophenotyping
P01990266A0678|11 32|UV cross-linking studies
P01990266A0678|81 93|sodium dodecyl
P01992459A0000|64 88|immunodeficiency virus mRNA
P01992459A0000|95 112|Rev response element
P01992953T0000|0 22|Alanine aminotransferase
P01993181T0000|0 25|Nucleotide sequence analysis
P01993181T0000|48 76|PpG7 salicylate hydroxylase gene
P01995951A0000|34 54|immunodeficiency virus
P01996312A0454|43 62|lambda gt11 cDNA clones
P01997465A0276|58 72|collagen content
P02001033A1907|25 38|concentrations
P02002051T0000|0 11|Isoform C beta
P02002051T0000|69 81|protein kinase
P02002511A0637|7 18|applications
P02002511A0637|21 33|PB-PK modeling
P02004521A0266|27 41|CT abnormalities
P02004705A0686|3 14|cdr1 sequence
P02005547A0121|15 27|understanding
P02005547A0121|115 132|hyperbilirubinemia
P02005547A0121|160 171|practitioner
P02006558A0000|0 21|Displacement thresholds
P02008982A0463|20 31|contribution
P02008982A0463|48 59|tuberculosis
P02008982A0463|75 85|sputum smear
P02010912A0366|72 87|MalT binding sites
P02010912A0366|128 141|pulCp promoters
P02011924A0729|130 141|cell leukemia
P02012097T0000|10 21|fluctuations
P02012097T0000|45 71|Plasmodium falciparum malaria
P02012789A0051|10 22|family history
P02014928T0000|21 39|rhinoconjunctivitis
P02014928T0000|73 90|serum albumin powder
P02015921A0523|21 31|Category pN1
P02016053A0752|0 27|Amino acid sequence comparisons
P02016053A0752|33 43|E74A protein
P02016053A0752|99 115|amino acid residues
P02016053A0752|165 182|DNA binding activity
P02019572A0000|13 24|DNA sequences
P02019572A0000|59 80|rat liver pyruvate kinase
P02019572A0000|119 163|chloramphenicol acetyltransferase reporter genes
P02019572A0000|234 244|gene cap site
P02019572A0000|287 298|introduction
P02019572A0000|303 320|hepatoma HepG2 cells
P02019572A0000|321 334|rat hepatocytes
P02019572A0000|351 363|fibroblast LTK
P02020082A0356|25 35|gas exchange
P02020082A0356|131 142|relationship
P02020082A0356|205 217|plasma colloid
P02020314A1290|12 34|micrograms/kg/day GM-CSF
P02020314A1290|69 84|thrombocytopenia
P02020314A1290|90 129|carboplatin-cyclophosphamide chemotherapy
P02020314A1290|157 168|chemotherapy
P02021630A1104|47 58|interactions
P02021630A1104|91 104|guanine N7 sites
P02021630A1104|142 170|DNA phosphodiester conformation
P02021630A1104|180 193|protein binding
P02022188A0112|159 179|mobility group proteins
P02022188A1463|17 28|gene products
P02022188A1463|81 94|order structure
P02022188A1463|98 109|prerequisite
P02022188A1463|123 136|gene expression
P02022920A0334|3 15|C4BP alpha gene
P02023097A0000|8 32|immunodeficiency virus type
P02023097A0000|105 118|gene expression
P02023097A0000|134 149|virus replication
P02023421A0343|7 19|proliferation
P02023421A0343|36 52|collagen synthesis
P02023421A0343|109 120|wound healing
P02023904A0120|44 64|translation start sites
P02024252A0000|47 64|disability pensions
P02024252A0000|70 81|municipality
P02024488A0506|7 21|Jurkat cell lines
P02024488A0506|51 61|CMV promoter
P02024488A0506|103 120|neomycin resistance
P02024625A0202|24 35|presentation
P02024625A0202|85 96|similarities
P02024791A0582|0 11|MEASUREMENTS
P02024791A0582|15 25|MAIN RESULTS
P02024791A0582|81 96|FEV1 measurements
P02024791A0582|101 111|L atropine/0
P02024791A0582|114 128|L metaproterenol
P02024816A0521|69 85|pneumonia patients
P02026144A0741|17 29|GUS expression
P02026147A0000|34 46|protein kinase
P02028125A0101|51 62|AIDS patients
P02028125A0101|89 102|tumour response
P02028125A0101|112 124|cancer therapy
P02029468A0296|0 21|Serum TNF concentrations
P02029468A0296|75 89|reference limits
P02030910A0000|84 95|organization
P02030910A1070|0 30|Polymerase chain reaction analysis
P02033038A0309|23 36|E3 polypeptides
P02033062A1169|6 21|promotor function
P02033062A1169|68 79|chicken IGF-I
P02033062A1169|106 120|reporter plasmid
P02034655A1224|46 63|transfection assays
P02034655T0000|0 15|Characterization
P02034655T0000|27 46|integrin gene promoter
P02034676A0267|18 30|rhombotin gene
P02035805T0000|0 25|Angina haemorrhagica bullosa
P02036066A0000|57 90|hemoglobin polyoxyethylene conjugate
P02038293A0919|10 21|inlet type VSD
P02038326A0538|3 18|gcd2-503 mutation
P02038326A0538|46 57|accumulation
P02038326A0538|90 101|accumulation
P02038326A0538|139 165|translation initiation factor
P02038326A0538|179 194|43S-48S particles
P02041088A1053|12 27|enhancer activity
P02041088A1053|35 49|reporter plasmid
P02041088A1053|100 143|reporter chloramphenicol acetyltransferase gene
P02041088A1053|177 187|39K promoter
P02044785A0000|15 28|adenocarcinoma
P02044785A0000|39 53|retroperitoneal
P02044950A0258|8 30|polymerase chain reaction
P02044950A0258|44 53|U6 RNA genes
P02044975A0380|85 96|instillation
P02045366A1149|0 21|Hydrophobicity analysis
P02045366A1149|45 60|KlaB polypeptides
P02045366A1149|91 105|KlaC polypeptide
P02045524A0000|15 26|availability
P02045524A0000|68 85|Drug Administration
P02045524A0000|170 181|end-of-phase
P02045524A0000|199 210|drug sponsors
P02045809A0331|24 43|B. sphaericus products
P02046202A0625|23 36|IgA nephropathy
P02047597A0149|47 60|field condition
P02052544A0641|14 26|DNA polymerase
P02052544A0641|98 110|DNA polymerase
P02052592A0000|74 85|bone turnover
P02052592A0000|132 143|osteoporosis
P02052592A0000|167 178|oophorectomy
P02052592A0000|192 210|estrogen replacement
P02052592A0000|257 280|tumor necrosis factor alpha
P02052592A0000|298 315|phytohemagglutinin
P02053289A0701|15 27|nt differences
P02053289A0701|83 95|nt differences
P02055484A0538|9 19|PCR products
P02056553T0000|28 40|translocation
P02060052A0954|78 89|mitochondria
P02061282A0447|16 27|pMxL1 plasmid
P02061282A0447|145 169|recombination junction site
P02061333A1359|5 16|observations
P02061333A1359|52 85|phosphopantetheine-attachment sites
P02061333A1359|98 113|thioesterase site
P02061333A1359|144 159|reaction sequence
P02061333A1359|184 196|ACV tripeptide
P02062116A0688|10 34|monoamine oxidase inhibitor
P02062933A0738|70 85|flutamide females
P02065022A0747|61 80|transforming activity
P02066246A0258|51 77|Massachusetts Cancer Registry
P02068085A1273|87 104|activation sequence
P02069738A0000|22 36|stimulus control
P02069873X0000|26 41|vav protooncogene
P02069873X0000|147 168|differentiation lineage
P02070227T0000|11 21|cell seeding
P02072238T0000|0 15|Menetrier disease
P02072798A0330|16 28|stabilization
P02073222A0269|19 32|amitriptyline n
P02073222A0269|36 47|moclobemide n
P02073222A0269|66 77|week protocol
P02075876A0408|3 19|stimulus threshold
P02076620A0548|11 32|plasma fibrinogen levels
P02076816T0000|28 45|sporulation control
P02076816T0000|82 107|IME1 transcript accumulation
P02077560T0000|35 50|safety assessment
P02078080T0040|39 51|disadvantages
P02079811A0407|107 120|acid production
P02080902A0183|54 70|avoidance response
P02081463A0110|28 43|Spec gene activity
P02081463A0110|82 95|initiation site
P02083199A1175|0 20|Phosphopeptide mapping
P02083199A1175|36 59|autophosphorylation sites
P02083230A0938|34 46|signal peptide
P02083230A0938|75 96|amino acid residue domain
P02083230A0938|102 121|N-glycosylation sites
P02083253A1512|3 23|TCF-1 alpha binding site
P02083253A1512|42 65|TCR alpha enhancer activity
P02083253A1512|166 184|transcription factor
P02083546A0000|137 159|photon emission tomograms
P02083546A0000|277 295|motor neurone disease
P02088781A0653|58 69|density units
P02088781A0653|124 135|compensation
P02089054A0121|26 46|liquid-solid partition
P02092131T0000|40 55|hypersensitivity
P02092131T0000|66 79|transfer factor
P02093033T0001|36 48|plutonium-239
P02093033T0001|49 67|hexachlorobutadiene
P02093033T0001|71 87|tributyl phosphate
P02093033T0001|93 103|thymus gland
P02093741A0211|0 13|Data collection
P02093741A0211|26 38|query language
P02093741A0211|42 53|data analysis
P02093741A0211|146 162|analysis technique
P02094257T0000|17 42|adenosine deaminase activity
P02095150T0000|7 22|strain adaptation
P02095150T0000|33 46|hip replacement
P02095150T0000|77 94|ingrowth components
P02099622A1046|0 19|Immuno-cytochemistry
P02099622A1046|40 58|Campylobacter jejuni
P02099622A1046|176 191|Campylobacter spp
P02102823A0492|0 17|Promoter activities
P02102823A0492|36 53|beta-glucuronidase
P02102823A0492|57 82|neomycin phosphotransferase
P02102823A0492|85 103|reporter gene systems
P02102831A1282|21 37|soybean actin genes
P02103140A1088|144 160|retransplantation
P02103403A0149|28 40|alcohol intake
P02105497A1092|26 43|amino acid sequences
P02105497A1092|48 60|HSP70 proteins
P02106287A0478|0 11|Spore inocula
P02107073A0584|7 20|overexpression
P02107073A0584|37 49|STE18 proteins
P02107073A0584|73 89|pheromone response
P02107073A0584|94 107|overexpression
P02107548A0727|7 23|transcription-PCR
P02109544A0000|30 43|screening tests
P02109544A0000|47 66|Chlamydia trachomatis
P02109544A0000|96 116|decision analysis model
P02109544A0000|131 164|leukocyte esterase urine dipstick test
P02110145T0000|129 156|Bacillus cereus beta-lactamase
P02110148A0423|9 23|HindIII fragment
P02110148A0423|39 57|DNA sequence analysis
P02110148A0423|88 107|B. subtilis IF2 protein
P02111015A0574|82 99|sequence similarity
P02111015A0574|115 132|IFN response factors
P02113174A0064|26 36|zinc fingers
P02113174A0064|56 77|transcription factor Sp1
P02113455A0207|55 67|consideration
P02113455A0207|97 111|threshold levels
P02115111T0000|10 27|nucleotide sequence
P02115111T0000|58 70|reading frames
P02115111T0000|76 88|nif gene region
P02115111T0000|122 134|strain PCC7120
P02115116A1137|22 34|sequence match
P02115116A1137|61 76|promoter elements
P02115118A0565|35 44|smg p25A GDI
P02115118A0565|56 68|sodium dodecyl
P02115118A0565|91 108|gel electrophoresis
P02115118A0565|112 152|sucrose density gradient ultracentrifugation
P02115121A0000|0 11|Yeast mutants
P02115121A0000|25 51|pet complementation group G104
P02115121A0000|86 106|dehydrogenase activity
P02115121A0000|132 160|dihydrolipoyl transsuccinylase
P02115572A1323|17 33|V lambda pseudogene
P02115572A1323|40 49|psi V lambda
P02115572A1323|67 80|U266 lambda gene
P02116071A0000|43 55|stage children
P02116071A0000|92 119|type hypersensitivity reaction
P02116537A1237|32 45|concentrations
P02117799T0000a|6 19|orthoclone OKT3
P02117799T0000a|79 99|kidney transplantation
P02117799T0000b|6 19|orthoclone OKT3
P02117799T0000b|79 99|kidney transplantation
P02118519A0516|31 45|consensus motifs
P02118519A0516|103 127|nerve growth factor receptor
P02118519A0516|140 159|neurofilament protein
P02118525A0737|35 45|CCK promoter
P02118525A0737|96 108|transcription
P02118525A0737|116 156|herpes simplex virus thymidine kinase promoter
P02118612A0629|15 29|supine restraint
P02118612A0629|39 57|DOPAC concentrations
P02119530T0000|11 29|metoprolol treatment
P02119530T0000|60 71|fibrinolysis
P02119946T0000|27 37|care setting
P02119946T0000|40 51|introduction
P02120707A0594|103 129|HLA-DRA X-box oligonucleotide
P02120833A0000|45 57|hepatitis NANB
P02121371T0000|62 77|yeast IRA proteins
P02123029A0478|16 33|Raja immunoglobulin
P02123029A0478|76 92|spleen cDNA library
P02123300T0000|73 84|hemophilia A.
P02123300T0000|96 115|Factor VIII Study Group
P02123820A0000|19 34|monoamine oxidase
P02123820A0000|68 81|MAO-B inhibitor
P02123820A0000|107 118|MAO inhibitor
P02123875A0223|96 118|signal peptidase cleavage
P02123875A0223|143 155|translocation
P02123875A0223|171 192|amino acid substitutions
P02123875A0223|200 211|COOH terminus
P02123875A0223|240 252|substitutions
P02123875A0223|258 268|NH2 terminus
P02123877A1452|151 169|serum response factor
P02123877A1452|213 225|gene induction
P02124433A0235|98 109|chemotherapy
P02124433A0235|151 168|immunochemotherapy
P02124710A0193|38 56|c-jun protooncogenes
P02124710A0193|78 96|proliferation period
P02124710A0193|99 128|osteoblast phenotype development
P02124710A1624|41 54|Fos-Jun complex
P02124710A1624|82 97|collagen promoter
P02125016A0145|35 45|SOS response
P02125153A0410|125 136|streptomycin
P02126417A0408|65 79|control subjects
P02126504A0602|10 22|Rh-antibodies
P02129338A0568|10 26|amino acid sequence
P02129338A0568|61 94|alga Scenedemus obliquus plastocyanin
P02131652A0883|13 37|serum gastrin concentration
P02131652A0883|86 99|gastrin release
P02131666A0483|33 50|examinees class II/2
P02132636A0188|25 38|schizophrenics
P02132636A0188|52 65|DST suppressors
P02132636A0188|70 83|nonsuppressors
P02133731A1572|79 91|control levels
P02135343A0131|67 78|distribution
P02135343A0131|81 92|maloclusions
P02135343A0131|122 133|relationship
P02135343A0131|167 186|ANGLE3 classification
P02135536A0621|20 32|brush abrasion
P02135536A0621|114 128|water absorption
P02135536A0621|133 146|micrograms/mm3
P02135536A0621|157 176|expansion coefficient
P02137704A0000|100 124|blood pressure measurements
P02137704A0000|154 166|blood pressure
P02137704A0000|202 214|blood pressure
P02137704A0000|223 233|office visit
P02137704A0000|241 253|blood pressure
P02137704A0000|264 274|office visit
P02137704A0000|282 294|blood pressure
P02137704A0000|350 366|target organ damage
P02137704A0000|429 441|wall thickness
P02137704A0000|450 462|wall thickness
P02137704A0000|471 483|wall thickness
P02137704A0000|526 543|wall thickness/left
P02137704A0000|564 576|diameter ratio
P02138707A0198|38 64|lambda gt11 expression library
P02138707A0198|71 81|protein mXBP
P02138707A0198|146 184|histocompatibility complex A alpha gene X box
P02138707A0198|195 214|transcription element
P02138992A0911|80 91|modification
P02139473A1603|84 100|Fur concentrations
P02139473A1603|159 180|Shine-Dalgarno sequence
P02139891A0532|52 64|activators EIA
P02139891A0532|172 183|ATF/CREB site
P02141425A0175|15 32|fingertip-to-floor
P02141425A0175|84 95|measurements
P02142240A0506|37 49|response rates
P02142240A0506|64 76|concentration
P02142240A0506|79 95|estrogen receptors
P02142240A0506|108 127|progesteron receptors
P02142921T0000|11 47|hormone-releasing hormone analog therapy
P02142993A0176|81 93|leishmaniasis
P02143023A0729|18 32|octamer elements
P02143023A0729|38 53|adenovirus genome
P02143023A0729|82 94|transcription
P02143023A0729|103 117|octamer elements
P02143023A0729|136 150|repeat sequences
P02143186A0867|118 129|coding region
P02143186A1306|0 19|Northern blot analysis
P02143186A1306|131 141|shoot tissue
P02143768T0000|11 25|gastrostomy tube
P02143961A0400|4 18|antidepressants
P02143961A0400|30 42|pain threshold
P02143961A0400|55 66|pretreatment
P02144558A1022|1 15|needs assessment
P02144610A1306|11 28|beta gene expression
P02144610A1306|119 129|AMP response
P02144610A1306|198 213|TCR alpha enhancer
P02144610A1306|220 233|decamer element
P02144610A1306|271 286|TCR beta promoters
P02145195A0253|84 94|binding site
P02145268A0746|10 27|nucleotide sequence
P02145268A0746|69 80|organization
P02145268A0746|91 103|collagen genes
P02145268A1454|36 49|EDS-IV collagen
P02145268A1454|52 66|cyanogen bromide
P02145268A1454|79 98|collagenase digestion
P02146266A0000|13 33|BamHI-HindIII fragment
P02146266A0000|51 93|Neurospora crassa CuZn superoxide dismutase gene
P02146266A0000|160 185|deoxyoligonucleotide probes
P02146266A0000|213 237|N. crassa amino acid sequence
P02146495A0706|83 101|leucine zipper domain
P02147223A1047|26 38|c-fos promoter
P02147422A0000|49 66|U1-70K snRNP protein
P02148291A0173|25 43|HSE oligonucleotides
P02148291A0173|75 91|HSE binding domains
P02148291A0173|109 141|tomato lambda gt11 expression library
P02148799A0000|47 68|nitrogen control circuit
P02148799A0000|71 86|Neurospora crassa
P02149487A0348|4 35|days dexamethasone suppression test
P02149487A0348|51 62|% suppression
P02149487A0348|65 95|dehydroepiandrosterone-sulphate
P02149487A0348|124 135|testosterone
P02149487A0348|139 159|androstenedione levels
P02149566A0478|49 63|phosphocreatine
P02149570T0000|31 48|protein S deficiency
P02151229A0000|41 72|N-isopropyl-123I-iodoamphetamine
P02151229A0000|158 173|diabetes mellitus
P02151229A0000|205 224|fasting plasma glucose
P02151229A0921|0 15|Mean ROI-A/B ratio
P02153243A0965|75 102|fibroblast growth factor family
P02154467A0709|82 97|furin gene product
P02154474A1504|39 56|cAMP responsiveness
P02154599A0382|17 28|footprinting
P02154599A0382|32 59|gel mobility retardation assays
P02154599A0382|94 110|Zta fusion proteins
P02154599T0000|3 19|zta transactivator
P02154599T0000|46 64|cycle gene expression
P02154599T0000|132 145|target promoter
P02154599T0000|149 163|enhancer regions
P02154602A0092|24 37|mouse Mx protein
P02154602A0092|60 73|influenza virus
P02154686A0185|34 45|repeat region
P02154686A0185|96 122|beta-galactosidase synthesis
P02154686A0185|147 172|polyomavirus enhancer region
P02154885A0153|79 91|loop structure
P02154885A0153|112 131|substrate recognition
P02155017A1106|70 89|hypertriglyceridemia
P02155017A1106|137 153|observation period
P02155017A1106|185 197|complications
P02156828A0164|10 26|amino acid sequence
P02157141A0923|39 51|topoisomerase
P02157764A1115|1 15|rabbit antiserum
P02157764A1115|104 115|cDNA sequence
P02157882T0000|0 11|Conservation
P02157882T0000|73 86|transformation
P02158099A0487|11 30|cotransfection assays
P02158099A0487|36 50|Chang liver cells
P02158099A0487|121 142|pSV2CAT reporter plasmid
P02158927A0000|131 141|chromosome X
P02159470A1432|20 33|protein factors
P02159470A1432|62 72|Mt sequences
P02159470A1432|125 137|transcription
P02159470A1432|204 218|phosphorylation
P02159559A0779|21 32|interference
P02159559A0779|48 63|DNA amplification
P02160502A0471|2 29|recombination signal sequences
P02160502A0471|58 75|recombination point
P02160622A0000|56 69|hot-plate tests
P02160622A0000|76 87|motor effects
P02160622A0000|118 147|benzodiazepine agonist midazolam
P02162049A0291|65 75|DNA sequence
P02162103A0000|55 68|phosphoprotein
P02162103A0000|77 93|parainfluenza type
P02162103A0000|222 234|reading frames
P02162467A0311|10 23|cytR expression
P02162467A0311|51 61|CytR protein
P02162467A0311|88 102|cAMP/CAP complex
P02162754A0339|30 46|amino acid sequence
P02162754A0339|52 81|3T3-L1 adipocyte insulin receptor
P02162754A0801|22 36|phosphoryl group
P02162754A0801|53 64|accumulation
P02162754A0801|93 110|signal transmission
P02162754A0801|131 153|glucose-transport system
P02162835A0989|17 36|sequence similarities
P02162835A0989|60 71|architecture
P02162835A0989|80 95|heme binding sites
P02162835A0989|102 118|copper binding site
P02163347A0472|3 14|cDNA sequence
P02163347A0472|30 41|reading frame
P02163347A0472|59 75|amino acid sequence
P02163347A0472|135 146|ets-1 protein
P02163382A0169|17 28|O7-LPS region
P02163382A0169|43 56|cosmids pJHCV31
P02163382A0169|84 104|transposon mutagenesis
P02163382A0169|204 221|target DNA sequences
P02163394T0000|24 34|sacPA operon
P02163394T0000|37 58|Bacillus subtilis shares
P02163394T0000|92 106|antiterminators
P02164585A0416|3 13|TraD protein
P02164585A0814|3 16|protein product
P02164588A0266|158 171|HN glycoprotein
P02164604A0399|43 63|E2 transactivation gene
P02164604A1574|76 87|BPV-1 mutants
P02164604A1574|104 117|acceptor mutant
P02164604A1574|144 155|E2 expression
P02164637A0515|68 85|nitrogen starvation
P02164637A0515|88 105|sporulation defects
P02164637A0515|142 152|cdc25 mutant
P02165589A0000|80 91|X-chromosome
P02165589A0000|126 151|hormone receptor superfamily
P02165589A0888|45 60|c-jun oncoprotein
P02165589A0888|62 74|leucine zipper
P02165589A0888|112 133|heterodimerization site
P02165589A0888|150 164|fos oncoproteins
P02166040A0385|38 59|PEPCK gene transcription
P02166040A0385|128 148|carboxykinase promoter
P02166040A0385|220 237|phosphotransferase
P02166040A0385|243 274|chloramphenicol acetyltransferase
P02166040A0385|292 304|hepatoma cells
P02166040A0385|380 391|transfection
P02166040A0385|413 425|neo expression
P02166040A0385|450 482|chloroamphenicol acetyltransferase
P02166416A0419|21 32|tuberculosis
P02166825A0198|112 128|promoter mutations
P02166825A0198|198 211|promoter region
P02167321T0000|60 77|activator protein-2
P02167321T0000|99 141|tissue-type plasminogen activator gene promoter
P02167321T0000|189 200|phorbol ester
P02167467T0000|3 16|26S rRNA binding
P02167467T0000|26 42|protein equivalent
P02167784A0109|124 137|CO2 measurement
P02168640A0268|11 22|correlations
P02168640A0268|108 119|disturbances
P02169887A0360|56 67|capstructure
P02170687A0000|3 15|E6/E7 promoter
P02170687A0000|33 48|papillomaviruses
P02170687A0000|85 101|transforming genes
P02173399A0333|63 79|tissue radiographs
P02173405A0270|76 89|calcifications
P02174427A1574|51 63|carbon sources
P02174427A1574|98 140|ubiquinol-cytochrome c oxidoreductase activity
P02174974A0000|0 12|Transcription
P02174974A0000|113 127|xylR gene product
P02175433A0575|31 46|beta A-globin gene
P02175433A0575|63 80|Ylp vector sequences
P02175908A0805|48 61|Ulysses element
P02176021T0000|0 12|Determination
P02176021T0000|44 76|electron spin resonance spectroscopy
P02176152A0896|54 65|reporter gene
P02176152A0896|90 103|AP1 binding site
P02176152A0896|114 126|HSV tk promoter
P02176209A0954|55 76|gel retardation patterns
P02176232T0001|0 10|Risk factors
P02176232T0001|22 41|lymph nodes metastasis
P02176822A0000|15 27|protein kinase
P02176822A0000|152 167|glycogen synthase
P02179052A1044|25 40|sequence families
P02179052A1044|83 102|sequence interactions
P02179188A1223|22 36|motile responses
P02179188A1223|69 81|dinitrophenol
P02179188A1223|84 97|cytochalasin B.
P02179815A0582|49 66|immunofluorescence
P02180935A0535|57 72|precursor protein
P02180935A0535|125 166|chondroitin sulfate proteoglycan intermediate
P02181760A0311|33 49|Doppler ultrasound
P02181760A0311|116 134|cotyledon resistance
P02182240A0355|27 38|anistreplase
P02182323A0121|82 97|growth conditions
P02182618A0168|3 18|promoter activity
P02182618A0168|55 86|chloramphenicol acetyltransferase
P02182618A0168|114 128|deletion mutants
P02183467A0668|146 157|lentiviruses
P02185140A0000|42 65|cytochrome P450 lanosterol
P02185140A0000|68 84|alpha-demethylase
P02185140A0000|173 199|yeast transcription promoters
P02185250A0726|74 90|reticulum membrane
P02185250A0726|94 106|translocation
P02187091A0721|40 55|ejection fraction
P02187091A0721|86 101|relaxation period
P02187871T0000|47 84|protein synthesis initiation factor eIF-4D
P02188096A0955|3 14|contribution
P02188096A0955|30 43|splicing events
P02188096A0955|46 60|c-myb expression
P02188096A0955|70 82|c-myb function
P02188168A0000|54 64|drug addicts
P02188168A0000|99 113|HIV-1 antibodies
P02188168A0000|160 174|lymphadenopathy
P02190122A0633|4 15|emancipation
P02190134A0572|77 106|laser photocoagulation treatment
P02190134A0572|167 179|complications
P02194273A0913|8 27|hyperimmune globulins
P02194273A0913|69 81|Streptococcus
P02194972T0000|67 86|Enterococcus faecalis
P02195715A0143|35 50|purpura fulminans
P02195715T0000|19 36|protein C deficiency
P02196311A1034|64 80|antitumor immunity
P02196450A0870|17 31|deletion mutants
P02196450A0870|48 67|sequence requirements
P02196565A0606|32 68|repressor/activator site binding protein
P02196565A0606|128 145|MAT alpha expression
P02196565A0606|194 206|GRFI/RAP1/TUF
P02196565A0606|226 238|gal11 mutation
P02196565T0000|0 16|Yeast Gal11 protein
P02196565T0000|43 58|activation signal
P02196565T0000|115 172|factor I/repressor/activator site binding protein 1/translation
P02198259A0685|90 101|reading frame
P02199311A0620|7 27|transcription extracts
P02199311A0620|32 42|ret1-1 cells
P02199311A0620|73 103|transcription termination signals
P02199311A0620|141 153|tRNA templates
P02200150A1381|113 127|psychotherapist
P02200150A1381|131 144|plastic surgeon
P02200315A0278|6 24|IgM antibody activity
P02200736A1003|87 99|CACCTGTC motif
P02201770A0188|23 40|genus Anomiopsyllus
P02201770A0188|41 55|Anomiopsyllinae
P02201770A0188|56 69|Anomiopsyllini
P02201901A0229|58 68|SSN6 protein
P02201905A1004|31 41|ABFI protein
P02201905A1004|49 59|RAP1 protein
P02201905A1004|121 134|gene expression
P02203672A1542|22 35|cytocentrifuge
P02204029A0184|0 20|RNase protection assays
P02204029A0184|147 159|transcription
P02204621T0000|52 77|tRNA nucleotidyltransferase
P02204621T0000|105 130|tRNA nucleotidyltransferase
P02204623A0000|3 21|juxtamembrane region
P02204623A0000|27 41|insulin receptor
P02204623A0000|44 55|beta-subunit
P02204623A0000|82 95|tyrosyl residue
P02204623A0000|138 159|tyrosyl phosphorylation
P02206789A0002|40 61|anaesthetic preparation
P02208762A0228|20 32|granddaughter
P02209237A0239|138 151|liver cirrhosis
P02209243A0237|17 28|serum albumin
P02209540A1362|37 49|transcription
P02209605A0510|61 72|reading frame
P02209811T0000|24 41|permeability marker
P02209811T0000|63 75|iliac arteries
P02212540A0473|19 31|wall specimens
P02212540A0473|99 113|light microscopy
P02212540A0473|119 148|transmission electron microscopy
P02213566A0000|12 22|coenzyme Q10
P02213566A0000|58 69|hemodynamics
P02217307T0000|62 77|emptying response
P02217741T0001|3 15|interrelation
P02217741T0001|29 43|glucocorticoids
P02220304A0501|34 51|medium MS risk region
P02220304A0501|127 140|MS distribution
P02223652A0939|4 24|antithrombin unit basis
P02223773A0000|0 34|Chick brain actin depolymerizing factor
P02223773A0000|64 77|actin filaments
P02223773A0000|86 98|actin monomers
P02223928T0069|22 37|serotonin agonist
P02225687A0546|0 16|Comprehensive care
P02225687A0546|115 140|pregnancy management options
P02227438A0492|0 22|Primer extension analysis
P02227438A0492|26 38|RNA sequencing
P02227438A0492|58 80|transcription start point
P02227438A0492|83 92|rat ODC mRNA
P02228615A0974|27 50|distribution coefficients
P02228615A0974|68 88|desorption experiments
P02228615A0974|129 147|metal-oxyhydroxides
P02229068A0156|0 13|Gene constructs
P02229068A0156|96 109|precursor SU-TM
P02229072A1012|4 15|growth arrest
P02229282A0454|22 35|serum TNF levels
P02229282A0454|57 77|serum T3 concentrations
P02231162T0000|43 54|tooth contact
P02231479A0585|66 78|conversations
P02231479A0585|97 108|conversation
P02231479A0585|122 133|task activity
P02233626T0000|63 79|strabismus surgery
P02233680A1115|85 106|HaG3-A helianthinin gene
P02233715A0914|14 30|pseudorabies virus
P02233715A0914|35 47|IL-6 construct
P02233715A0914|61 71|IL-6 TATA box
P02233715A0914|78 89|RNA start site
P02233729A1065|89 103|Dhfr transcripts
P02233729A1065|147 161|Dhfr transcripts
P02234731A0503|55 66|inflammation
P02236002A0958|23 41|nucleotide diversity
P02236002A0958|109 127|chicken TCR beta cDNAs
P02236022A0000|3 20|protooncogene c-myb
P02236022A0000|36 54|transcription factor
P02236022A0000|112 124|transcription
P02236060A1671|0 11|Modification
P02236064A1178|0 17|S6 kinase activation
P02236064A1178|26 37|displacement
P02236064A1178|106 120|phosphorylation
P02237431A0000|20 32|T cell receptor
P02237431A0000|129 145|C alpha gene segment
P02237431A0833|3 18|Ets-1 binding site
P02241892A0681|24 45|polyadenylation signals
P02243093A0000|5 27|T-cell leukemia virus type
P02243093A0000|81 93|transcription
P02246362T0000|3 23|Jenkins Activity Survey
P02246447A0460|28 43|regression slopes
P02246447A0460|70 81|portion sizes
P02246447A0460|133 144|portion sizes
P02247072A0794|3 25|SUP44 suppressor mutation
P02247072A0794|112 123|ram mutations
P02247081A0223|70 81|growth defect
P02247081A0223|152 169|growth temperatures
P02247924A0078|47 59|amphotericin B
P02248732A1113|161 172|DOPAC changes
P02249872A1051|54 66|charge density
P02250919A0404|13 32|illness intrusiveness
P02250919A0404|64 74|muscle cramp
P02250919A0404|78 93|headache symptoms
P02250919A0404|117 135|assessment intervals
P02250919A0404|152 163|muscle cramps
P02251119A0319|121 138|hsc70 heat shock gene
P02252953A0300|107 120|susceptibility
P02252953A0300|173 187|eating behaviour
P02253274A0000|3 14|Mauriceville
P02253274A0000|112 126|characteristics
P02253274A0000|129 140|mtDNA introns
P02253663A0687|91 109|serum concentrations
P02254282T0000|18 29|organization
P02254282T0000|33 59|Zymomonas mobilis gene cluster
P02254282T0000|87 103|glucose metabolism
P02254418A0641|15 27|S. lugdunensis
P02254418A0641|37 50|delta hemolysin
P02254749A0133|38 48|170K protein
P02254749A0133|86 98|ATG start codon
P02256678A1224|21 40|footprinting analysis
P02256678A1224|130 145|protein complexes
P02257251T0000|0 14|Pathophysiology
P02258918A0242|89 104|sampling fraction
P02259795A0570|54 65|calculations
P02262439A0508|0 10|MCh infusion
P02262439A0508|51 66|airway resistance
P02264601A0000|0 19|Taste reactivity tests
P02264601A0000|85 104|alcohol nonpreferring
P02265055A0417|0 19|Plasma concentrations
P02265055A0417|58 71|micrograms ml-1
P02265055A0417|83 96|micrograms ml-1
P02265055A0417|109 124|CSF concentration
P02269281A1276|161 174|control signals
P02269426A0428|26 44|Tat trans-activation
P02269426A0428|144 162|Tat trans-activation
P02269426A0428|201 214|mRNA expression
P02270587A0000|13 25|treatment need
P02272095A0832|58 71|pain modulation
P02272095A0832|94 108|cluster headache
P02274343A0064|6 20|foot pathologies
P02274343A0064|32 44|metatarsalgia
P02274343A0064|73 85|hallux rigidus
P02274343A0064|102 116|nail pathologies
P02274343A0064|129 140|neuropathies
P02274509A0623|0 15|Liver dysfunction
P02274509A0623|101 121|indicator liver enzymes
P02276891T0000|0 10|Coenzyme Q10
P02276891T0000|11 21|blood levels
P02277005A0227|3 19|CT characteristics
P02277319A0211|18 30|preservatives
P02277319A0211|87 102|product sterility
P02277319A0211|105 119|bioburden levels
P02277452A0116|16 29|angina pectoris
P02278217A0372|22 38|management failure
P02278217A0372|86 96|section lead
P02278474A0000|0 29|Serum Fibrin Degradation Products
P02278474A0000|55 68|cancer patients
P02280777T0000|3 21|uteroglobin promoter
P02281118A1191|0 31|Prostaglandin synthesis inhibitors
P02281330A0556|14 32|oxygen concentration
P02281330A0556|49 64|Horowitz quotient
P02281948A0245|10 28|mineral oil emulsions
P02282815T0000|0 11|Significance
P02282815T0000|28 44|basement membranes
P02283148T0000|0 11|Significance
P02283148T0000|14 31|cytokine production
P02283148T0000|35 51|adhesion molecules
P02283148T0000|62 76|immunopathology
P02283378A0385|95 113|ultrafiltration tube
P02283378T0000|15 27|determination
P02283378T0000|33 52|cephalosporin DQ-2556
P02283378T0000|95 108|chromatography
P02283873A0308|63 74|parents smoke
P02283873A0308|96 112|smoking prevention
P02284393A0751|41 52|coping styles
P02284393A0751|74 103|EE/low EE research classification
P02284573A0943|74 92|methenamine staining
P02284573A0943|104 119|brushing material
P02287860T0001|47 61|parenchyma cells
P02287860T0001|81 93|X-ray exposure
P02289102A0114|7 23|audiotape cassette
P02289102A0114|53 66|hallucinations
P02289639A0989|81 92|control group
P02290216T0001|42 57|serum SPan-1 level
P02291144A0493|84 99|reference methods
P02291144A0493|117 129|basophil count
P02291628A0264|40 51|applications
P02291628A0264|148 160|endocrinology
P02292272T0000|0 20|Interlimb coordination
P02293019A0000|0 18|Antileukoproteinase
P02293019A0000|123 141|proteinases elastase
P02293664A0946|36 51|vimentin promoter
P02293664A0946|141 151|mRNA cap site
P02294048A0881|18 47|% amino acid sequence similarities
P02294048A0881|91 108|Bacillus megaterium
P02295521A0922|65 81|trapezius activity
P02295521A0922|137 158|muscle activity patterns
P02296509A0997|18 33|household members
P02296509A0997|46 57|seronegative
P02296509A0997|80 94|serum p24 antigen
P02298741A0809|222 234|alpha antibody
P02300541A0000|86 97|dose inhalers
P02300577A0852|41 58|glycosylation sites
P02300577A0852|62 85|endoglycosidase digestion
P02300759A0000|32 53|Gustave Roussy Institute
P02303158T0000|68 78|trk oncogene
P02303874A1643|14 28|titration period
P02303874A1643|95 110|micrograms/24 hrs
P02303874A1643|118 133|micrograms/24 hrs
P02305014A0226|80 92|guide cannulas
P02306539T0000|5 28|Selenastrum capricornutum
P02306539T0000|51 62|Daphnia pulex
P02307067A1348|40 55|families Tydeidae
P02307067A1348|56 69|Nanorchestidae
P02307067A1348|73 84|Tarsonemidae
P02307067A1348|109 131|concentration treatments
P02307371A0263|43 73|transcription elongation blockage
P02307371A0263|86 102|c-myc deregulation
P02307371A0263|131 151|transcription patterns
P02307371A0263|184 203|lymphoma c-myc alleles
P02307371A0263|222 234|Xenopus oocyte
P02307613A0783|0 37|Erythrocyte protoporphyrin concentration
P02307848A0347|109 122|Eco-R1 fragment
P02307850A0000|6 29|RNK-16 lambda-gt11 library
P02307850A0000|62 82|cDNA rat NK cell protease
P02307850A0000|97 111|characteristics
P02307850A0000|120 134|serine proteases
P02307850A1197|14 29|RNKP-1 expression
P02307850A1197|48 58|spleen cells
P02307850A1197|114 139|killer lymphocyte activities
P02310300A0298|3 15|% lymphography
P02310496X0000|7 23|memory impairments
P02310496X0000|74 87|nucleus basalis
P02310496X0000|103 115|memory defects
P02310496X0000|125 145|nucleus basalis lesions
P02310496X0000|245 258|nucleus basalis
P02310496X0000|314 332|place navigation task
P02310496X0000|342 356|reference memory
P02311544A0086|25 36|relationship
P02312470A0774|3 15|BAL-to-plasma
P02312689A0360|3 18|kappa coefficient
P02312689A0360|40 49|Patho Dx Kit
P02312689A0360|56 69|standard method
P02315472A0583|17 27|imaging time
P02317413A0364|46 65|plasma concentrations
P02317413A0364|68 85|neutrophil elastase
P02317413A0364|188 199|heart disease
P02317554T0000|0 12|Determination
P02317554T0000|32 48|imaging properties
P02317554T0000|57 72|microscope system
P02318208A0817|71 97|transcription initiation site
P02318208A0817|112 123|core sequence
P02318208A0817|137 152|promoter sequence
P02320008A0651|27 49|muscle alpha-tropomyosin
P02320999A0606|42 54|particle board
P02320999A0606|65 75|gypsum board
P02320999A0606|103 121|polyurethane lacquer
P02320999A0606|145 159|emission factors
P02323517A0557|64 87|prostaglandin E2 synthesis
P02323517A0557|112 143|prostaglandin generation technique
P02324102A1157|12 24|transmembrane
P02324102A1157|66 77|proteoglycan
P02324102A1157|91 105|lung fibroblasts
P02324102A1157|132 143|Vanden Berghe
P02324104A0151|39 64|phosphotransferase activity
P02324104A1195|36 51|carboxyl terminus
P02324104A1195|59 79|translation stop signal
P02325895T0000b|19 42|mechanoreceptor discharge
P02325895T0000b|81 92|displacement
P02325895T0000b|119 136|squirrel monkey hand
P02326716A0139|73 97|concave rib-vertebra angles
P02326716A0139|114 129|angle differences
P02326716A0139|159 170|displacement
P02326946T0000|0 40|Plasma lecithin/cholesterol acyltransferase
P02326946T0000|87 104|allograft viability
P02326946T0000|115 134|liver transplantation
P02328328A0419|19 50|tumour progesterone receptor status
P02328328A0419|62 76|tumour detection
P02329840A0383|21 35|microelectrodes
P02330041A0335|18 29|localization
P02330041A0335|40 59|transcription studies
P02330041A0335|140 153|control element
P02330041A0335|166 181|rRNA gene promoter
P02330041A0335|192 204|transcription
P02330110A1085|17 33|laboratory studies
P02330333A0325|0 12|Accumulations
P02331361A0268|29 43|myocyte diameter
P02331361A0268|72 87|autopsy specimens
P02332018A0538|107 122|mean GH increments
P02332798A0725|52 65|EVS stimulation
P02333545A0313|3 14|distribution
P02333545A0313|22 37|fibrinogen levels
P02333545A0313|73 84|distribution
P02333749A0411|19 36|regression analysis
P02333749A0411|68 85|serum IgE antibodies
P02333749A0411|88 99|P. orbiculare
P02334972A0145|102 112|risk factors
P02334972A0145|122 134|complications
P02335521T0000|13 40|vitellogenin activator element
P02335521T0000|49 61|transcription
P02335521T0000|87 119|Xenopus laevis vitellogenin promoter
P02335713A0905|44 55|ALAD activity
P02335713A0905|61 75|stearate workers
P02335815A0530|5 20|carboxyl terminus
P02336338A0931|12 24|mean luminance
P02339005T0000|8 20|hyperglycemia
P02339005T0000|23 35|pain threshold
P02339447A0162|36 51|deuterium content
P02339447A0162|126 141|serum level 19-OHA
P02339447A0162|156 215|gas chromatography/mass spectrometry-mass fragmentography method
P02340595A0124|0 15|Sequence analysis
P02340595A0124|106 122|plant mitochondria
P02341669A0000|94 116|pseudorandom pulse trains
P02341669A0000|117 138|maximum length sequences
P02341669A0000|145 161|Legendre sequences
P02342477A1292|78 89|biosynthesis
P02342477A1292|106 122|P4-responsiveness
P02342477A1292|166 182|recognition marker
P02342477A1292|198 215|sequence similarity
P02343033A0000|15 26|dates infants
P02344529T0000|40 53|erythropoietin
P02347102A0000|3 24|pseudolymphoma syndrome
P02347102A0000|72 86|lymphadenopathy
P02347655A0193|59 70|gas exchanges
P02347655A0193|96 115|blood inlet conditions
P02347655A0193|116 128|blood flow rate
P02347655A0193|184 203|blood tissue perfusion
P02348225A0192|7 18|measurements
P02348225A0192|98 109|distribution
P02349998A0297|0 18|Dopamine SERS spectra
P02351239A0693|25 40|hypergastrinemia
P02351239A0693|130 140|HDC activity
P02351239A0693|141 162|histamine concentration
P02351239A0693|166 179|ECL cell density
P02351239A0693|182 197|hypergastrinemia
P02351239A0693|217 231|gastrin infusion
P02351239A0693|267 283|antisecretagogues
P02351297A0000|20 35|toxicity research
P02351297A0000|63 96|atmosphere metal corrosion inhibitors
P02353453A1249|13 25|helicase motif
P02353453A1249|32 49|nsP3 homology region
P02353453A1249|90 105|alphavirus genome
P02353453A1249|128 140|rearrangement
P02353875A0800|70 83|hypersecretion
P02354381A0207|69 86|fiberglass rollaway
P02355293A0749|52 73|failure characteristics
P02355293A0749|132 146|bath environment
P02355765A0220|24 43|benzathine penicillin
P02355920A0681|1 20|consensus binding site
P02355920A0681|27 48|transcription factor SP1
P02355920A0681|87 120|proenkephalin germ cell cap site region
P02356823A0063|43 55|sets technique
P02356823A0063|96 110|alarm properties
P02358975A0709|91 102|gluten intake
P02358975A0709|118 130|IgA deficiency
P02360336A0574|7 20|personnel costs
P02360336A0574|36 53|batch manufacturing
P02360336A0574|63 76|multidose vials
P02361575T0000|17 31|carcinogenicity
P02361575T0000|66 76|Fischer rats
P02361812A1110|30 43|baseline values
P02362161T0000|47 64|anhydrase inhibitor
P02362803A0608|56 67|U3 snRNA genes
P02368931A0587|2 31|addition serum IgE concentrations
P02370571A0663|30 45|iodine deficiency
P02371273A0144|54 66|kilobase pairs
P02372496A0782|0 16|Co-administration
P02372496A0782|38 49|microspheres
P02372496A0782|78 89|drug exposure
P02372496A0782|158 174|5FU administration
P02372712A0002|65 77|carbon dioxide
P02372712A0002|85 97|plasma lactate
P02373686T0000|29 56|chicken progesterone receptors
P02373686T0000|147 162|receptor isoforms
P02373810A1118|29 39|risk factors
P02374886A0305|3 26|Community Adjustment Scale
P02374886A0305|35 45|outcome data
P02374886A0305|74 85|productivity
P02374886A0305|108 120|relationships
P02374886A0305|124 139|presence/absence
P02374886A0305|142 155|symptomatology
P02378615A0807|3 17|protein sequence
P02378615A0807|48 65|glycosylation sites
P02378615A0807|141 152|carbohydrate
P02383693A0301|83 93|Triton X-100
P02383693A0301|102 113|M KOH solution
P02383693A0301|136 160|chemiluminescence detector
P02383771A0544|114 125|distribution
P02384265A0947|57 69|polyp patients
P02384265A0947|89 106|prophylactic effect
P02386485A0554|3 20|nucleotide sequence
P02386895A0496|18 32|nausea/vomiting
P02386895A0496|87 98|hypertension
P02388685A0577|32 57|oyster shell supplementation
P02388685A0577|76 102|alkaline phosphatase activity
P02388685A0577|103 120|bone mineralization
P02388685A0577|162 173|coefficients
P02388685A0577|221 237|phosphorus content
P02390538A0000|143 154|Olympus PF18 S
P02390633T0000|5 16|encephalitis
P02390989A0745|68 81|point mutations
P02390989A0745|128 139|reading frame
P02391344T0000|31 59|rat NADH-cytochrome b5 reductase
P02392032A0657|46 61|relaxation curves
P02392032A0657|86 98|distance scale
P02392032A0657|107 118|architecture
P02392511T0000|0 28|Serotonin 5-HT2 receptor binding
P02392511T0000|31 44|blood platelets
P02393001A0324|101 112|densitometry
P02393895A0918|83 95|insufficiency
P02393895A0918|164 178|differentiation
P02393895A0918|203 216|regurgitations
P02394707A0789|0 15|Promoter elements
P02394707A0789|73 86|initiation site
P02394707A0789|143 161|nucleotide stretches
P02394718A0130|48 69|hybridization screening
P02394718A0130|79 104|deoxyoligonucleotide probes
P02394718A0130|134 150|amino acid sequence
P02395868A0322|101 112|hydrogen bond
P02396415T0001|66 77|hypertension
P02398897A0000|10 29|transcription factors
P02398897A0000|43 55|RNA polymerase
P02399053A1032|41 54|recoil pressure
P02400457A0469|34 46|supine cycling
P02400457A0469|79 92|LBNP conditions
P02400457A0469|210 221|Experiment I.
P02402678A0463|21 32|formulations
P02402678A0463|41 58|% lambdacyhalothrin
P02402678A0463|96 116|aerosol space-spraying
P02402678A0463|123 137|diesel/kerosene
P02402678A0463|168 183|application rates
P02402678A0463|200 214|mosquito control
P02402678A0463|228 242|housefly control
P02403035A0621|8 19|reading frame
P02403634A0788|0 15|Sequence analysis
P02403634A0788|204 224|binding site homologies
P02403634A0788|247 274|muscle-CAAT consensus sequence
P02403926A0000|3 16|trk-2h oncogene
P02403926A0000|37 65|breast carcinoma cell line MDA-MB
P02403926A0000|78 93|DNA-transfection
P02403926A0000|98 108|NIH3T3 cells
P02403926A0000|122 158|trk proto-oncogene receptor kinase domain
P02403926A0307|43 80|beta gal-trk receptor kinase fusion protein
P02403926A0307|94 109|kd phosphoprotein
P02403926A0307|181 191|NIH3T3 cells
P02404451A1532|15 39|scanning-deletion analysis
P02404451A1532|157 170|Cys-118 residue
P02404451A1532|191 203|glycosylation
P02405393T0000|22 37|characterization
P02405393T0000|65 75|c-ets-2 gene
P02405589A0000|27 42|drug interactions
P02405589A0000|78 94|drug-use decisions
P02405818A0550|0 14|Branch occlusion
P02406570A0466|81 92|test plasmids
P02406570A0898|107 120|DNA replication
P02406992A0192|64 77|amaurosis fugax
P02406992A0192|148 164|laboratory studies
P02406992A0192|179 198|carotid artery studies
P02408248A0414|52 67|enzyme inhibitors
P02409297A0984|33 45|fusion protein
P02409297A0984|85 96|polypeptides
P02409297A0984|101 114|virus particles
P02409297A0984|119 130|polypeptides
P02409297A0984|153 169|HBsAg determinants
P02411513A0667|5 19|characteristics
P02411513A0667|114 129|dorsal negativity
P02417023T0001|6 24|superoxide dismutase
P02417023T0001|67 79|determination
P02417669A0218|2 24|maximum photosensitivity
P02417669A0218|134 151|amino acid aspartate
P02418701A0000|104 118|antigen staining
P02418701A0000|194 207|diverticulitis
P02419327A0998|3 17|priming activity
P02420432A1060|35 47|pregnancy test
P02420432A1060|103 118|serum PAPP-A level
P02423533A1314|135 146|rat PC12 cells
P02423533A1314|161 177|nerve growth factor
P02423850A0292|0 15|Deletion analysis
P02423850A0292|98 110|yeast CYC1 gene
P02427024X0000|11 30|fenfluramine anorexia
P02427024X0000|106 125|fenfluramine anorexia
P02427812A0865|73 86|pressor actions
P02431314A0834|63 76|eosinophiluria
P02436005A0707|107 118|mobilization
P02437625A0197|41 62|histoplasmosis syndrome
P02437625A0197|88 99|degeneration
P02437792T0000|54 69|immunoreactivity
P02437792T0000|91 102|pancreatitis
P02437895A0000|12 30|potentials procedure
P02437895A0000|99 110|language task
P02438637T0000|0 16|Mucolipidosis type
P02442837A0060|50 70|calcium channel blocker
P02442837A0060|105 125|calcium channel blocker
P02442837A0060|174 188|bypass procedure
P02443028A0695|45 66|muscle microvasculature
P02444507A0240|0 15|Lysozyme activity
P02445751A0925|16 27|measurements
P02445751A0925|39 49|state levels
P02445751A0925|70 86|cytochrome oxidase
P02445751A0925|93 103|beta subunit
P02449431A1121|0 18|ATP gamma S inhibition
P02449431A1121|38 51|concentrations
P02451872A0391|21 35|methoxydextrane
P02452313A0114|54 69|blocking activity
P02452313A0114|80 98|guinea pig right atria
P02452313A0114|165 178|concentrations
P02454390T0000|11 26|promoter elements
P02454390T0000|49 72|glucocorticoid repression
P02454390T0000|78 99|alpha 1-fetoprotein gene
P02455821A0099|37 72|AccI-EcoRI restriction fragment mapping
P02455821A0099|119 129|EHV-1 genome
P02457922A0991|0 12|Hybridization
P02457922A0991|106 117|2.8-kilobase
P02458234T0000|38 50|sleep spindles
P02458234T0000|76 88|EEG recordings
P02459309T0000|69 83|caudate-putamen
P02459309T0000|156 169|chromatography
P02461368A0162|66 78|type X collagen
P02462047A0208|47 61|pedicle ligation
P02462047A0208|109 124|flap replantation
P02462305A1071|3 17|size discrepancy
P02462305A1071|28 40|glycosylation
P02462305A1071|43 57|phosphorylation
P02462523A0394|7 23|KpnI-SalI fragment
P02462523A0394|140 162|germ-line transformation
P02463050A0514|3 44|corticosterone synthesis inhibitor metyrapone
P02463050A0514|84 97|corticosterone
P02464097T0000|43 77|prostaglandin endoperoxide antagonist
P02466414A0000|25 39|plasma viscosity
P02466414A0000|72 85|blood viscosity
P02466414A0000|121 139|exchange transfusion
P02466414A0000|188 200|weight dextran
P02468795A1086|14 34|acid phosphatase levels
P02468795A1086|76 87|cancer volume
P02469451A0239|3 15|investigation
P02469451A0239|88 109|MAO-B inhibitor deprenyl
P02470955A0101|47 59|CSF AP activity
P02470955A0101|70 81|meningitides
P02470955A0101|97 108|meningitides
P02473156A0000|22 50|lymphocyte cell surface molecule
P02473156A0000|126 141|adhesion proteins
P02473198A0613|24 38|potassium efflux
P02473619A0202|11 23|sensitization
P02473619A0202|64 77|control animals
P02473619A0202|122 134|sensitization
P02473619A0202|218 230|IgE antibodies
P02473718A0000|3 15|investigation
P02473718A0000|35 46|relationship
P02473718A0000|86 98|catecholamine
P02473718A0000|134 145|T-suppressor
P02473907A1338|62 71|Fc epsilon R
P02473907A1338|144 153|Fc epsilon R
P02473942A1207|99 119|transmembrane segments
P02474093T0000|21 36|enzyme inhibitors
P02474110A1039|37 49|blood pressure
P02474110A1039|83 99|inhibitor ramipril
P02474110A1039|188 203|resonance imaging
P02474110A1039|207 222|echocardiography
P02474204A0105|60 73|immunostaining
P02474204A0105|77 88|chromogranin
P02474356A0559|10 22|radioactivity
P02474356A0559|102 113|microspheres
P02475506A0878|42 73|polymerase chain reaction technique
P02475717A0565|0 13|Tissue necrosis
P02475717A0565|31 58|triphenyltetrazolium staining
P02475717A0565|82 99|baseline predictors
P02475717A0565|102 112|infarct size
P02475717A0565|121 132|risk zone size
P02475717A0565|144 157|collateral flow
P02476030A0000|68 90|laser scanning tomography
P02477373A0930|55 81|transcription initiation site
P02479635A0659|0 13|Cotransfection
P02479823A0727|0 15|Sequence analysis
P02480959A0470|4 15|P-450scc mRNA
P02480959A0470|144 156|gonadotropins
P02481230A1258|22 41|bovine alpha transgene
P02481429T0000|6 22|staining technique
P02481429T0000|26 44|Leishmania parasites
P02481779A0213|86 105|plasma concentrations
P02481779A0213|240 251|microgram/ml
P02482293A1518|15 38|T24 bladder carcinoma cells
P02482293A1518|55 88|EGF-R tyrosine protein kinase activity
P02482293A1518|107 118|phorbol ester
P02482511A0860|4 30|phosphodiesterase inhibitors
P02482511A0860|134 151|withdrawal syndrome
P02483210A0000|65 77|exacerbations
P02483210A0000|87 107|relapsing pancreatitis
P02483438A0498|73 99|phosphodiesterase inhibitors
P02484714T0000|10 21|organization
P02484714T0000|40 60|mouse estrogen receptor
P02484994T0001|11 24|gamma globulins
P02485188A0415|9 24|chondroitinase AC
P02485188A0415|28 39|ABC digestion
P02485188A0415|88 102|dermatan sulfate
P02485188A0415|224 242|chondroitin sulfates
P02486634A0632|61 77|contrast injection
P02486634A0632|128 148|collateral development
P02487898A0315|4 20|NGF administration
P02487898A0315|80 96|NGF administration
P02488148A1156|25 35|RSNA meeting
P02489032A0000|0 13|Immunoglobulin
P02489032A0000|61 73|recombination
P02489032A0000|122 133|gene segments
P02489032A0000|154 168|diversification
P02489753A0581|39 49|EMG activity
P02489895T0001|0 11|Muscle action
P02492111A0670|26 39|bone lead values
P02492111A0868|185 198|U.S. guidelines
P02492111A0868|222 243|blood lead concentration
P02492111A0868|248 260|micrograms/dl
P02493644A0588|76 88|transcription
P02493644A0588|115 132|serum growth factors
P02495745T0000|30 60|tissue-type plasminogen activator
P02496090A0252|13 28|tracheostomy tube
P02496090A0252|56 71|mass spectrometry
P02496090A0252|108 124|sampling technique
P02496100T0000|43 53|aflatoxin B1
P02496100T0000|56 73|cottonseed products
P02496109A0754|50 64|gene disruptions
P02496109A0754|70 80|alpha region
P02496109A0754|111 122|fusion vector
P02496109A0754|229 239|alpha operon
P02496109A0754|295 305|L17 interval
P02497340A0989|20 32|antibody genes
P02497340A0989|61 71|chain probes
P02497340A0989|91 101|chain probes
P02498322A0226|47 66|gel retardation assays
P02498322A0226|100 119|oligonucleotide probe
P02498652A0460|5 16|transfection
P02498652A0460|25 47|TSH beta promoter activity
P02498652A0460|117 128|cell cultures
P02500432A1416|31 43|CAT expression
P02502096A0462|56 73|excretion processes
P02502602A0323|11 22|blood samples
P02502602A0323|53 65|determination
P02502602A0323|68 86|acid-base quantities
P02504603T0000|11 25|Weeksella virosa
P02504603T0000|34 44|CDC group IIf
P02505087A1037|14 36|dimerization specificity
P02505087A1037|65 77|leucine zipper
P02507523A0791|3 13|ORF1 product
P02508306A0528|8 19|infiltration
P02508306A0528|36 46|plasma cells
P02508726A0498|5 15|case reports
P02508726A0498|131 141|brain injury
P02508726A0498|177 189|neurotoxicity
P02509123A0371|36 48|P100 component
P02509123A0371|81 98|baseline conditions
P02510242A0313|53 67|hepatitis B virus
P02511069A0532|131 153|polytene chromosome bands
P02511150T0025|22 33|perspectives
P02511430A0000|54 79|immunoglobulin gene enhancer
P02511898A0000|46 58|Chagas disease
P02512010A0801|3 19|PETCO2 measurement
P02512010A0801|68 81|defibrillation
P02514498A0000|63 75|acid secretion
P02514498A0000|98 116|pCO2/pH measurements
P02514498A0000|159 179|Henderson-Hasselbalch
P02515953A0459|41 53|effectiveness
P02518645T0001|8 20|Chagas disease
P02518645T0001|21 39|laboratory diagnosis
P02518691A0251|12 38|IL2R alpha promoter constructs
P02518691A0251|50 61|transfection
P02518691A0251|65 80|DNA binding assays
P02518691A0251|154 167|kappa B enhancer
P02518691A0251|199 221|IL2R alpha gene expression
P02519679T0000|12 30|phosphine fumigation
P02520622A0200|64 75|transit times
P02520622A0200|112 129|cimetropium bromide
P02520622A0200|190 200|group design
P02521217A1035|55 71|membrane fractions
P02521217A1035|74 85|mitochondria
P02521674T0000|54 81|complementation group F mutants
P02522297A0000|14 26|thromboxane A2
P02522297A0000|30 72|prostaglandin endoperoxide receptor antagonist
P02523800A1178|78 101|TGAAACA consensus sequence
P02523800A1178|149 160|BAR1 promoter
P02525044A1026|3 15|recovery index
P02525044A1026|106 118|suxamethonium
P02526165X0000|9 20|Leser-Trelat
P02526165X0000|50 61|Leser-Trelat
P02527365T0000|0 13|Xenopus homolog
P02527365T0000|19 34|mos protooncogene
P02527365T0000|87 100|Xenopus oocytes
P02527745A0865|0 19|Southern blot analyses
P02527745A0865|71 82|conservation
P02528329A0000|5 19|missense mutants
P02528329A0000|94 117|hydroxylamine mutagenesis
P02528730A1073|84 99|donor splice sites
P02529378A0536|0 17|S1 nuclease analysis
P02529378A0536|36 47|transfection
P02529378A0536|55 67|HIV constructs
P02530413A0195|2 15|supine position
P02530413A0195|16 30|plasma ANP levels
P02530470A0604|46 57|staff members
P02530470A0604|67 77|blood donors
P02532032A0385|0 19|Plasma concentrations
P02532210A0000|3 19|adenovirus E1A gene
P02534067A0316|0 13|Administration
P02534067A0316|16 28|dexamethasone
P02534067A0316|72 90|alpha OH progesterone
P02534067A0316|93 111|beta-desoxycortisol
P02534067A0316|112 123|DHEA sulphate
P02534067A0316|124 138|androstenedione
P02534067A0316|142 153|testosterone
P02534067A0316|193 204|androsterone
P02534067A0316|207 224|beta OH androsterone
P02534067A0316|225 239|etiocholanolone
P02534067A0316|249 259|alpha OH DHEA
P02535460A1443|0 13|RNA transcripts
P02536096A0327|22 34|transcription
P02536096A0327|42 63|herpes simplex virus type
P02536096A0327|65 87|thymidine kinase promoter
P02536096A0327|99 134|chloramphenicol acetyltransferase gene
P02536096A0327|180 202|thymidine kinase promoter
P02536096A0327|220 255|chloramphenicol acetyltransferase gene
P02536160A0518|58 73|sense orientation
P02536160A0518|88 100|CAT expression
P02537441A0231|45 60|varicella-zoster
P02537485A0841|5 16|formalin test
P02537485A0841|42 58|morphine analgesia
P02537485A0841|102 118|morphine analgesia
P02538450A0000|78 99|Na,K-ATPase beta subunit
P02538656A0172|120 139|transforming activity
P02538656A0172|142 155|mouse C127 cells
P02538720A0582|26 43|polyubiquitin genes
P02541251A1327|67 88|transcription factor SP1
P02541251A1327|100 113|CCAAT sequences
P02541882A0251|0 15|Radiation therapy
P02542194A1496|83 94|astrocytomas
P02542270A0000|26 40|chloroplast DNAs
P02542270A0000|100 120|C4 photosynthesis genes
P02542270A0000|126 137|bundle sheath
P02542270A0000|141 154|mesophyll cells
P02542612A0530|0 17|S1 nuclease analysis
P02542612A0530|87 108|NotI repeat promoter-CAT
P02542612A0530|123 138|Z transactivation
P02542612A0530|182 195|RNA transcripts
P02543226A1559|85 106|adipose tissue component
P02543226A1559|122 135|breast biopsies
P02543226A1559|206 219|breast biopsies
P02543621A0788|97 119|translocation breakpoint
P02543679A1291|45 55|P initiators
P02543679A1291|75 95|DnaK heat shock proteins
P02543679A1291|129 145|lambda replication
P02543734A0414|9 24|oligonucleotides
P02543734A0414|42 53|bp repeat unit
P02543734A0414|85 106|IE1/2 enhancer/promoter
P02543734A0414|109 128|cotransfection assays
P02545357A0000|3 29|mustard chloroplast gene rps16
P02545903A0639|35 46|immunization
P02545903A0639|116 135|BTV-10 virus particles
P02547079A0910|11 24|calcium balance
P02547079A0910|29 48|hyperparathyroidemia
P02547079A0910|76 89|administration
P02547706A0928|70 83|classification
P02547706T0001|10 24|immunohistology
P02547706T0001|34 46|hybridization
P02547706T0001|75 98|cytomegalovirus pneumonia
P02547706T0001|147 171|bone marrow transplantation
P02547778A0786|53 67|control elements
P02549036A0000|3 26|Bacillus subtilis phage phi
P02549343A1008|66 80|characteristics
P02549343A1008|140 165|immunoprecipitation pattern
P02549343A1008|285 304|neutralizing activity
P02549417A0000|53 73|acristate mitochondria
P02550118A0610|32 44|infiltrations
P02550682A0411|22 37|type IIc carcinoma
P02551886A0332|0 14|Restriction maps
P02552143A0748|23 35|capsid protein
P02552143A0748|50 85|chloramphenicol acetyltransferase gene
P02552316A0526|99 116|seroconversion rate
P02555177A0488|72 90|COX1 introns aI5 alpha
P02555177A0488|118 135|COX3 gene expression
P02555177A0488|144 159|COX1 mRNA splicing
P02555177A0488|162 176|mRNA translation
P02555519A0798|62 93|complementarity determining region
P02555519A0798|128 139|conservation
P02555519A0798|145 161|D-region structure
P02555519A0798|200 212|hapten binding
P02555703T0000|0 22|Tyrosine kinase oncogenes
P02555703T0000|31 53|interleukin-3 dependence
P02555703T0000|81 97|signaling pathways
P02555703T0000|135 152|c-myc transcription
P02556264A0278|4 16|TC-II enhanson
P02556264A0278|38 48|kappa B motif
P02556264A0278|56 73|kappa chain enhancer
P02556264A0278|164 178|cell specificity
P02556264A0278|184 194|kappa B motif
P02556269A0187|32 44|13mer sequence
P02556269A0187|85 100|hypersensitivity
P02556269A0187|223 240|gel electrophoresis
P02556603A0606|71 87|gallbladder cancer
P02556603A0606|102 115|bile duct cancer
P02557217A0000|0 13|Beta-endorphin
P02557217A0000|21 37|cortisol secretion
P02557217A0000|85 103|spray administration
P02557217A0000|107 124|IU salmon calcitonin
P02557217A0398|80 109|corticotrophin-cortisol release
P02557350A0632|3 14|DNA sequences
P02559630A0270|50 68|thromboplastin times
P02559630A0270|69 84|prothrombin times
P02559630A0270|85 97|thrombin times
P02559630A0270|108 121|platelet counts
P02559630A0270|125 160|fibrin/fibrinogen degradation products
P02560415T0012|46 56|face regions
P02562825A0413|0 13|Responsiveness
P02562825A0413|16 35|beta-2 agonist therapy
P02565405T0000|9 21|trauma victims
P02565807A1198|13 29|neu proto-oncogene
P02565807A1198|40 53|kinase activity
P02565807A1198|108 118|NIH 3T3 cells
P02566613T0000|0 25|Somatostatin gene expression
P02566613T0000|73 90|DNA control elements
P02566680A0820|26 41|agonists fentanyl
P02566680A0820|174 186|response rates
P02567030A0482|30 43|discrimination
P02568930T0000|12 27|characterization
P02568930T0000|93 104|CD2 structure
P02568930T0000|112 123|T lymphocytes
P02569411A0151|66 80|nucleus amygdala
P02571924A0000|14 24|mating type A
P02571924A0000|45 73|yeast Rhodosporidium toruloides
P02571924A0000|82 96|mating pheromone
P02571924A0000|97 110|rhodotorucine A
P02571924A0000|120 132|undecapeptide
P02571924A0000|143 160|S-farnesyl cysteine
P02571924A0000|166 180|carboxy terminus
P02572777T0000|0 19|Tumour necrosis factor
P02572777T0000|39 54|distress syndrome
P02573303A0000|30 41|stroke volume
P02573303A0000|130 145|contractile state
P02573829T0000|12 23|conservation
P02573829T0000|92 108|transcription unit
P02573829T0000|124 139|segmentation gene
P02573836A0244|53 75|drug resistance phenotype
P02573836A0244|103 124|amino acid substitutions
P02573836A0244|130 150|core consensus sequence
P02573836A0244|154 170|nucleotide binding
P02574016A0428|51 62|control value
P02574016A0428|87 99|micrograms/kg
P02574016A0428|110 122|micrograms/kg
P02574052A0910|45 58|Type A behaviour
P02574052A0910|62 86|beta-adrenoceptor blockade
P02574193A0663|34 78|Institute Withdrawal Assessment-Benzodiazepines
P02574193A0663|156 172|withdrawal periods
P02574193A0663|265 281|contingency tables
P02574193A0663|293 310|regression analysis
P02574551T0000|0 13|Antihistamines
P02575174A0229|115 126|hypertension
P02575174A0229|142 158|airflow limitation
P02575490A1021|0 19|Northern blot analysis
P02575490A1021|36 52|oIGF-I transcripts
P02575567T0001|0 22|Materials science studies
P02575959A0643|3 13|latency time
P02575959A0643|20 39|lactate concentration
P02576405A0223|67 80|CBV combination
P02576405A0223|81 107|cyclophosphamide-BCNU-VP-16
P02576405A0223|112 122|EDAP regimen
P02577458A0412|69 84|enzyme inhibitors
P02577458A0412|101 116|receptor blockers
P02577458A0412|120 137|calcium antagonists
P02577867T0000|28 39|oncogene jun.
P02580830A1131|79 89|% similarity
P02580830A1131|121 132|mouse AFP gene
P02582240A1009|4 16|ATP/GTP ratios
P02582240A1009|37 54|RNA primer synthesis
P02582240A1009|77 89|ATP/GTP ratios
P02582918A0000|5 33|hepatitis B vaccine immunization
P02582918A0000|34 54|serum antibody response
P02582918A0000|106 117|S/N Ratio Unit
P02584969A0119|42 56|regression model
P02584969A0119|106 119|protection time
P02585492A1005|13 32|complementation tests
P02585492A1005|85 95|parB mutants
P02585492A1005|131 141|P7 mutations
P02586513A0622|34 45|ama-1 product
P02586513A0622|142 156|zinc finger motif
P02586513A0622|164 176|amino terminus
P02586513A0622|242 256|consensus Tyr Ser
P02590097A0093|34 45|infiltration
P02590097A0093|71 82|lobe bronchus
P02590391A0442|27 39|heart contents
P02590391A0442|60 72|phospholipids
P02590391A0442|73 91|phosphatidylcholine
P02590391A0442|92 115|phosphatidylethanolamine
P02590391A0442|116 137|diphosphatidylglycerol
P02590391A0442|138 150|sphingomyelin
P02590391A0442|159 173|acid composition
P02590391A0442|180 196|phospholipid class
P02590615A0636|98 113|pharmacokinetics
P02590869A0743|82 93|lavage fluids
P02591078A0000|6 19|investigations
P02591078A0000|64 88|contact dermatitis reaction
P02591078A0000|106 120|Langerhans cells
P02591078A0000|133 146|OKT6 antibodies
P02591078A0000|150 167|electron microscopy
P02591969A0961|25 49|glucocorticoid stimulation
P02591969A0961|52 71|ADH gene transcription
P02592543A0106|38 52|characteristics
P02592543A0106|53 78|Kanagawa hemolysin reactions
P02592543A0106|82 96|plasmid profiles
P02592640A0466|26 38|beta-carotene
P02592640A0466|227 239|beta-carotene
P02592961A0327|62 83|psychomotor performance
P02595451A1136|18 29|aniridia gene
P02595451A1136|46 69|T-cell leukemia breakpoint
P02595451A1136|79 92|marker sequence
P02595451T0000|15 25|deletion map
P02595451T0000|33 45|chromosome 11p
P02595451T0000|56 70|J1 series hybrids
P02597484A0624|52 68|surface reactivity
P02597549A0964|52 63|dipyridamole
P02597549A0964|105 118|recovery period
P02597549A0964|169 187|thromboplastin times
P02598034A0000|0 21|Middle-latency auditory
P02598745A0251|24 37|Sylvius fissure
P02599995A1031|13 27|activity studies
P02599995A1031|113 125|staphylococci
P02600306A0140|58 79|envelope phase disparity
P02601707A0986|0 19|Gel retardation assays
P02601707A0986|38 49|footprinting
P02601707A0986|53 84|diethyl pyrocarbonate interference
P02601707A0986|140 152|BC3H1 myocytes
P02602150A0993|62 77|sequence elements
P02602150A0993|87 109|replication origin region
P02602150A0993|120 131|construction
P02602150A0993|160 176|gene amplification
P02602150A0993|200 212|virus replicon
P02603374A0383|37 51|dorsal rhinotomy
P02603374A0383|59 74|patient morbidity
P02603374A0383|96 108|complications
P02603923A0220|18 30|skin incisions
P02603923A0220|109 120|growth factor
P02603923A0220|143 157|lactate solution
P02604420A0234|34 52|reticulin antibodies
P02605160A0000|23 36|59Fe absorption
P02605182A0936|10 24|protein sequence
P02605182A0936|75 87|signal peptide
P02605679A0306|13 25|rate constants
P02605679A0306|42 61|isomerization rate k12
P02605679A0306|96 110|degradation rate
P02605679A0306|147 160|hydrolysis rate
P02607766A0000|41 56|characterization
P02607766A0000|60 81|quality control material
P02607766A0000|104 116|concentration
P02607766A0000|155 167|micrograms/dL
P02607766A0000|214 225|micrograms/L
P02607766A0000|239 250|micrograms/L
P02607766A0000|260 272|micrograms/dL
P02607766A0000|305 321|spiking-solutions
P02609112A0000|0 12|Reagent strips
P02609112A0000|45 62|laboratory medicine
P02609112A0000|93 104|laboratories
P02614668A0971|19 31|concentration
P02615078A0283|38 50|actinomycetes
P02620085A0656|29 40|applications
P02620085A0656|73 91|replacement implants
P02621983T0001|0 11|Significance
P02621983T0001|34 45|acid analysis
P02623038A0632|70 85|saline injections
P02627159A0899|19 30|IgG4 antibody
P02627159A0899|59 71|immunotherapy
P02629109A0000|11 26|fertility decline
P02629109A0000|52 67|Mississippi Delta
P02630543A0210|16 31|staining affinity
P02630543A0210|63 73|tissue cells
P02630543A0210|135 149|cell populations
P02631505A0382|26 39|aminoglycoside
P02631566A0151|0 13|Alkoxymetgyl-3
P02631566A0151|14 40|dimethylpyridinium chlorides
P02631566A0151|66 85|3,4-dimethylpyridine
P02631566A0151|90 112|chloromethyl alkyl ethers
P02631566A0151|197 220|1-ethyloxymethylimidazol
P02631566A0151|225 249|chloromethyl alkyl sulfides
P02631743A0275|38 52|color deficiency
P02634490A0186|80 92|CT examination
P02634490A0186|113 124|ATB treatment
P02634872A0000|34 50|endodontics system
P02636920T0001|28 70|Pharmacopoeia Heparin Sodium Reference Standard
P02637597A0362|28 39|relapse stage
P02638964A0372|3 15|maximum stress
P02641762T0001|8 19|heart disease
P02641762T0001|31 56|exercise stress thallium-201
P02641762T0001|67 78|scintigraphy
P02642466T0000|0 15|Sequence analysis
P02642466T0000|47 63|membrane immunogen
P02642976A1474|9 26|consensus sequences
P02644735A0427|41 55|S. frugiperda DNA
P02644735A0427|130 145|host cell sequence
P02645276T0088|0 11|Construction
P02645276T0088|15 32|RIP1 deletion strain
P02645431A1562|20 33|hypocitraturia
P02646007T0000|74 91|protein C deficiency
P02647403A0000|11 24|hallucinations
P02647403A0000|37 51|psychopathology
P02647918A0423|25 43|somatomedin-C levels
P02647918A0588|108 126|somatomedin-C values
P02647918A0588|150 162|GH suppression
P02647918A0588|235 247|disappearance
P02647918A0588|276 287|TRH/GnRH test
P02648396A0565|2 12|Rat-1a cells
P02648396A1033|91 137|tumor promoter phorbol 12-tetradecanoate 13-acetate
P02648646A0216|0 23|Platelet activating factor
P02648646A0216|46 60|minute intervals
P02648646A0216|64 77|airway response
P02648646A0216|103 116|expiratory flow
P02648646A0932|39 62|baseline PC40 methacholine
P02648646A0932|146 169|platelet activating factor
P02649445A0412|9 25|IRI concentrations
P02649445A0412|54 65|body builders
P02649811T0000|10 22|contraception
P02649811T0000|24 42|family planning study
P02650663A0178|96 108|Alzheimer type
P02651448A0000|102 117|depolymerization
P02651448A0000|146 161|depolymerization
P02651487A0000|25 46|calcium channel blockers
P02651487A0000|125 153|excitation contraction coupling
P02651487A0000|205 219|glucagon release
P02655381A0000|103 126|laboratory investigations
P02655381A0000|131 142|hypogonadism
P02655381A0000|143 160|hyperprolactinemia
P02655381A0000|223 234|incompetence
P02655381A0000|246 257|neuropathies
P02656257A0000|16 36|DNA inversion system Cin
P02656257A0000|49 63|bacteriophage P1
P02656257A0000|97 114|crossing-over sites
P02657388A1011|3 18|terminator region
P02657388A1011|63 76|RNA polymerase I
P02664229A0138|152 164|Arap procedure
P02664229A0138|237 254|hypospadias repairs
P02666034A1520|56 83|vasodilator calcium antagonist
P02666034A1520|108 119|vasodilation
P02666034A1520|171 183|placebo course
P02666404A0220|3 22|galactose transporter
P02666404A0220|79 95|sugar transporters
P02666404A0220|117 133|HepG2-erythrocyte
P02666404A0220|142 166|muscle glucose transporters
P02666404A0220|181 204|liver glucose transporters
P02666404A0220|232 249|arabinose permeases
P02666404A0220|285 305|galactose transporters
P02666568A0000|55 68|protocol TCL821
P02669199A0000|0 18|Tumor necrosis factor
P02669199A0000|40 52|shock syndrome
P02670457T0000|3 20|calcium requirement
P02674141A1202|10 24|cysteine residue
P02674141A1202|49 71|activation peptide region
P02674327A0493|21 34|codon usage bias
P02674327A0493|74 87|polyhedrin gene
P02674671A0601|20 35|DNA transformants
P02674671A0601|74 85|met2 mutation
P02674674A1308|64 74|OBF1 protein
P02674674A1308|96 106|ARS function
P02674679A1237|12 39|S1 nuclease protection analysis
P02674679A1237|42 56|RNA preparations
P02674679A1237|68 79|mouse tissues
P02674679A1237|163 182|start site utilization
P02675492A0806|55 67|Ritchie-Index
P02677002A0205|59 91|equilibrium N-carbamyl-L-aspartate
P02677002A0205|105 121|carbamyl phosphate
P02677002A0205|127 148|equilibrium Pi exchanges
P02677429A0366|0 12|Survival rates
P02677429A0366|27 40|treatment group
P02677429A0366|96 109|treatment group
P02677429A0366|285 298|treatment group
P02677666A0356|30 49|complementation group
P02679804A2000|71 92|orotidine monophosphate
P02680843A0724|63 75|investigation
P02684159A0870|0 20|Hybridization analysis
P02684585T0001|0 23|Agranulocytosis treatment
P02685331A0523|3 24|R. meliloti nifH promoter
P02685331A0523|46 57|nifH promoter
P02685331A0523|81 101|methylation protection
P02685331A0523|104 118|guanine residues
P02686588A0592|76 94|alkaline phosphatase
P02686749A0000|11 28|health significance
P02686749A0000|160 178|beta 2-microglobulin
P02686749A0000|181 201|retinol binding protein
P02686980A0000|40 51|organization
P02686985A0811|1 33|transcription factor exclusion assay
P02686985A0811|54 65|PCF1 mutation
P02686985A0811|92 104|transcription
P02686985A0811|132 147|complex formation
P02689439A0000|12 36|glutathione S-transferases
P02689439A0402|88 97|rat Yb1 gene
P02689439A0402|171 180|rat Yb2 gene
P02691557A0273|19 36|breathing movements
P02691557A0273|103 116|concentrations
P02691811A0355|28 42|plasma potassium
P02691811A0355|78 90|blood acidosis
P02691811A0355|128 140|concentration
P02691998A0672|106 124|bolus administration
P02692881A0354|233 247|sodium excretion
P02692881A0354|269 284|calcium excretion
P02692881A0354|302 316|sodium excretion
P02693208A0166|26 38|recombination
P02693208A0166|87 105|repeat recombination
P02693593A0866|21 34|leader sequence
P02694731A0241|28 39|epidemiology
P02695914T0000|3 19|stereoselectivity
P02700977A0444|69 80|XR bond/Silus
P02702566A0000|26 39|5-fluorouracil
P02702849A0418|0 28|Metformin plasma concentrations
P02702849A0418|116 143|patients plasma concentrations
P02702849A0418|177 188|micrograms/l
P02703121T0000|18 38|sclerosing cholangitis
P02703121T0000|64 91|serum alanine aminotransferase
P02703925A0359|34 45|subgroupings
P02703925A0359|64 88|sedimentation coefficients
P02703925A0359|92 113|polydispersity profiles
P02703925A0359|153 175|proteoglycan aggregation
P02703925A0359|179 193|sedimentability
P02703925A0359|223 248|cartilage matrix degradation
P02703925A0359|266 278|proteoglycans
P02703925A0359|383 398|cartilage samples
P02703925A0359|437 453|matrix degradation
P02703925A0359|528 545|S value distribution
P02703925A0359|552 569|cartilage thickness
P02703925A0359|602 620|proteoglycan content
P02703925A0359|669 682|cartilage layer
P02703925A0359|748 762|sedimentability
P02704579A1078|12 23|relationship
P02704579A1078|77 97|gas exchange parameters
P02704579A1078|131 141|gas exchange
P02704579A1078|161 173|lung mechanics
P02705556A1049|51 61|flow reserve
P02707909A0209|2 18|alternative method
P02707909A0209|72 84|dialysate flow
P02708288A0139|0 19|Liquid chromatography
P02708288A0139|107 120|base hydrolysis
P02708288A0139|123 137|fluazifop-butyl
P02708288A0621|3 17|dichloromethane
P02708288A0621|79 89|PRP-1 liquid
P02708288A0621|245 257|oxidation mode
P02708353A1080|0 25|Primer extension experiments
P02708353A1080|42 68|transcription initiation site
P02708353A1452|16 38|polymerase chain reaction
P02708353A1452|104 120|polysome fractions
P02709081T0000|34 47|profile measure
P02709081T0000|53 73|type A behaviour pattern
P02709819A0495|32 51|ciprofloxacin therapy
P02711145T0000|0 16|HIV infectiousness
P02711167A0818|54 74|serum pepsinogen levels
P02711601A0601|28 50|acid phosphatase activity
P02712246T0042|29 43|characteristics
P02713310T0000|0 12|Fundus changes
P02713310T0000|38 55|glomerulonephritis
P02713520T0000|7 17|dose effects
P02713520T0000|20 34|methyl parathion
P02713520T0000|47 60|cholinesterase
P02713520T0000|64 78|ptilochronology
P02714525A0529|0 11|Kidney weight
P02714525A0529|29 39|weight ratio
P02714852T0000|26 39|HLA-C sequences
P02714852T0000|60 71|HLA-B alleles
P02717133T0001|28 48|development conditions
P02717133T0001|51 74|summary oxygen consumption
P02718683A0142|0 18|Handgrip dynamometry
P02720966A0455|34 46|concentration
P02721169A0171|99 111|relationships
P02723503T0000|11 27|alternative method
P02724227T0000|0 15|Perfusion washout
P02724227T0000|44 56|flap tolerance
P02725495A0929|25 35|U2 RNA region
P02725495A0929|55 84|pre-mRNA branchpoint recognition
P02725495A0929|113 126|metazoan U2 RNAs
P02725495A0929|148 159|trypanosomes
P02725513A0617|25 41|CHO spacer promoter
P02725513A0617|79 99|metazoan RNA polymerase
P02729666A0267|11 31|intergroup differences
P02729666A0267|61 73|dentoskeletal
P02729666A0267|81 102|tissue profile variables
P02731611A0134|144 166|Mental Research Institute
P02731671A0000|21 31|nickel oxide
P02731671A0000|35 58|nickel sulfate hexahydrate
P02731671A0000|70 85|nickel subsulfide
P02731671A0000|131 148|inhalation exposure
P02732341A0000|155 175|chloroacetate esterase
P02733116T0000|7 24|National Institutes
P02733690T0000|19 34|characterisation
P02735364A1330|62 87|progesterone receptor status
P02736482A0550|25 40|radiation therapy
P02736482A0550|41 55|brain metastases
P02739739T0000|0 22|COUP transcription factor
P02739739T0000|37 62|steroid receptor superfamily
P02740196A0704|24 37|classification
P02740196A0704|88 100|target numbers
P02740347A0644|0 11|Cosmid clones
P02740347A0644|26 38|VNTR sequences
P02740347A0644|56 73|restriction mapping
P02740627A0137|3 14|oxygen uptake
P02740627A0137|18 36|carbon dioxide output
P02740627A0137|58 74|minute ventilation
P02740627A0137|106 119|oxygen pressure
P02740627A0137|127 137|VE/VO2 ratio
P02740955A0333|30 42|mortality rate
P02743842A0000|34 47|prostaglandins
P02743842A0000|100 115|stress ulceration
P02743842A0000|155 169|prostaglandin E2
P02743842A0000|203 217|lesion formation
P02743842A0000|239 252|back-diffusion
P02743981A0347|72 95|L1e-L10e-L12e transcripts
P02743981A0347|145 158|NAB transcripts
P02744123A0237|53 64|rhesus monkey
P02744123A0237|172 190|background luminance
P02744490A0894|66 87|primer extension studies
P02744490A0894|143 170|mRNA transcription start points
P02745280A0276|82 101|lactate concentration
P02745280A0276|125 138|concentrations
P02745280A0276|159 173|phosphocreatine
P02745280A0276|203 223|resonance spectroscopy
P02745444A0391|3 29|transcription initiation site
P02745444A0391|45 61|S1 nuclease mapping
P02745666A0000|22 37|plasma oestradiol
P02745666A0000|43 54|progesterone
P02745666A0000|96 119|replacement therapy cycles
P02747653A0910|95 107|metamorphosis
P02748595A0492|17 32|baboon liver class
P02751080A0176|46 59|intensity level
P02752303A0000|0 12|Lithium delays
P02752303A0000|64 83|plasma concentrations
P02752629A0163|45 66|methylene diphosphonate
P02756731T0001|0 13|Prostaglandins
P02757033A0905|91 105|heterochromatin
P02757033A0905|125 138|position effect
P02757033A0905|141 153|transcription
P02757862T0000|22 35|microprocessor
P02757862T0000|58 70|defibrillator
P02758382A0478|115 139|sex hormone binding globulin
P02760922A0000|20 36|ribonucleoprotein
P02760922A0000|42 54|core protein A1
P02761008X0000|0 26|Brain cholinesterase activity
P02761008X0000|75 86|night-herons
P02761008X0000|113 131|brain cholinesterase
P02761008X0000|190 205|organophosphorus
P02761008X0000|208 226|carbamate pesticides
P02761150A0000|11 24|zinc deficiency
P02761150A0000|27 37|trace metals
P02761537A0168|0 11|Heating cells
P02761537A0168|80 91|control level
P02761537A0168|112 122|% inhibition
P02761537A0168|125 148|transcription termination
P02761537A0168|241 257|transcription unit
P02761540A0873|0 15|Deletion analysis
P02761540A0873|44 56|AP-1 sequences
P02761540A0873|80 95|enhancer activity
P02763467A0903|19 35|polyacrylamide gel
P02764797A0182|101 113|sampling times
P02764797A0182|121 137|imaging parameters
P02764797A0182|140 151|rf pulse shape
P02764797A0182|155 171|gradient waveforms
P02765001A0105|185 197|family history
P02766330A0779|88 105|calcium antagonists
P02766508A0421|1 22|correlation coefficient
P02766508A0421|84 95|mean IQRST map
P02766745T0000|25 36|relationship
P02767166A0368|17 33|lipid peroxidation
P02767166A0368|126 137|pathogenesis
P02773507A0750|48 62|sample estimates
P02773507A0750|118 132|sample estimates
P02773930T0000|32 46|hyperfiltration
P02774271A0000|61 71|end products
P02774808A0194|64 79|micrograms/100 ml
P02775136A1151|59 75|breathing patterns
P02775136A1151|180 196|breathing patterns
P02776742A0000|31 43|blood pressure
P02776742A0000|66 80|humidity changes
P02776742A0000|161 171|ml kg-1 min-1
P02776742A0000|179 189|fire fighter
P02776742A0000|262 279|breathing apparatus
P02776823A0000|23 38|pharmacokinetics
P02776823A0000|60 71|hydroxyethyl
P02776823A0000|72 111|carbamoyloxymethyl-2-penem-3-carboxylate
P02777797A0720|0 19|DNA blot hybridization
P02777797A0720|77 97|PtdIns transfer protein
P02778237A0585|84 111|maintenance prednisone therapy
P02778873A0761|44 59|enhancer function
P02779752A0000|44 72|serotonin antagonist properties
P02779752A0000|78 89|5-HT2 subtype
P02779752A0000|134 147|agonist actions
P02779752A0776|0 13|m-Chlorophenyl
P02779752A0776|41 63|m-trifluoromethylphenyl
P02779752A0776|174 185|methysergide
P02780157A0576|34 49|spleen MP function
P02780157A0576|81 96|HBsAg carriership
P02781495T0001|9 31|xanthine oxidase activity
P02781567A0544|60 73|stratum corneum
P02783181A0000|44 60|antacid magaldrate
P02783181A0000|115 129|mucus secretions
P02784507A0000|8 32|immunodeficiency virus type
P02784507A0000|63 74|T lymphocytes
P02787430A0124|11 22|panniculitis
P02787430A0124|36 50|biopsy specimens
P02787430A0124|55 70|cytophagocytosis
P02789062A0000|47 57|model system
P02789062A0000|133 146|gene expression
P02789062A0000|164 179|T-cell activation
P02789062A1420|16 43|NF-4FB enhancer binding protein
P02789062A1420|69 89|lambda gt11 cDNA library
P02789062A1420|108 122|oligonucleotide
P02789062A1420|141 165|NF-4FB recognition sequence
P02789217A1323|6 19|IL6 mRNA species
P02789217A1323|45 59|polyadenylation
P02790009A0375|0 17|Sequencing analysis
P02790009A1052|89 112|serine protease inhibitors
P02792270A1220|13 26|EPSP components
P02792270A1220|91 107|flexor motoneurons
P02792270A1220|148 159|flexion phase
P02792430A0000|97 119|prostaglandins synthesis
P02793216A0876|20 31|conservation
P02793216A0876|37 62|membrane attachment sequence
P02793620A0214|78 89|Red Poll bulls
P02793753A0354|17 28|PA dispersion
P02794828A0214|52 64|microcomputer
P02795923A0000|36 48|CT appearances
P02796216A0063|38 53|jaundice syndrome
P02796216A0063|60 72|enterorrhagia
P02796988A0735|3 24|transcription factor Sp1
P02796988A0735|58 75|footprinting assays
P02796988A0735|79 94|gel shift analysis
P02797877A0475|3 16|combination PIP
P02798953A0307|130 143|days postpartum
P02798953A0307|162 176|administrations
P02800417A0332|72 84|PC20 PGF2 alpha
P02800417A0332|88 102|histamine values
P02805945A0000|30 40|growth rates
P02805945A0000|118 143|Scripsiella trochoidea Stein
P02805945A0000|163 182|laboratory conditions
P02805945A0000|272 285|microEin m-2 s-1
P02806916A0000|24 36|oryzacystatin
P02806916A0000|40 66|cysteine proteinase inhibitor
P02806916A0000|97 119|lambda EMBL3 phage library
P02807780A0143|31 43|methylene blue
P02808232A0681|15 27|micrograms/kg
P02809116A0237|102 113|satisfaction
P02809651A0492|37 49|meta-analysis
P02809651A0492|72 83|policy makers
P02809722A0926|67 77|GH secretion
P02809831A0799|45 57|bone formation
P02810911A0372|34 46|neuroblastoma
P02810911A0372|66 81|131I-MIBG imaging
P02810911A0372|92 103|tumor markers
P02811378A0379|53 63|S100 protein
P02811378A0379|132 143|cell epulides
P02813404T0000|13 23|antigen gene
P02813404T0000|77 91|spermatogenesis
P02814820A0967|106 117|Billroth dogs
P02817724A0075|30 40|T2 sequences
P02818122A0000|72 84|animal species
P02818122A0000|106 117|distribution
P02818122A0000|121 133|relationships
P02820128A1333|9 27|sequence repetitions
P02820128A1333|60 79|hexanucleotide ATTGTT
P02820128A1333|105 116|dyad symmetry
P02820128A1670|3 14|significance
P02820128A1670|129 143|protein sequence
P02821340A0434|76 90|mm Hg X ml-1 X min-1
P02821340A0434|102 116|mm Hg X ml-1 X min-1
P02824334A0972|23 41|G-protein gene family
P02825139A0661|66 78|acid sequences
P02825750A0260|24 35|response rate
P02826127A0709|50 65|SV40 octamer motif
P02826127A0709|93 105|protein oct-B2
P02826729A0790|13 27|14C turnover data
P02828926A1870|126 144|actin gene expression
P02828926A1870|165 185|muscle differentiation
P02829183A0117|0 18|DNA sequence analysis
P02830214A0000|11 23|acetazolamide
P02830214A0000|93 113|microelectrode methods
P02830265A0341|14 29|polypeptide chain
P02830265A0341|67 78|reading frame
P02830282A0155|94 104|V-8 protease
P02830282A0155|117 128|polypeptides
P02831796A0000|6 26|immunodeficiency virus
P02831796A0000|72 83|similarities
P02831796A0000|91 111|immunodeficiency virus
P02831796A0000|139 162|immunodeficiency syndrome
P02832149A1009|161 174|myb transcripts
P02832149A1009|223 238|mouse myb oncogene
P02832744A0403|10 23|mos transcripts
P02832744A0403|72 83|quail ovaries
P02833012A0428|62 73|reading frame
P02833021A1185|24 35|organization
P02833021A1185|158 173|promoter function
P02833049A1041|21 34|state RNA levels
P02833101T0000|22 34|cell disorders
P02833101T0000|35 52|bone marrow necrosis
P02833101T0000|61 79|parvovirus infection
P02834478A0000|12 25|weight heparins
P02834843A0000|31 50|rifamycin derivatives
P02834843A0000|224 236|phase cultures
P02834843A0000|239 263|Mycobacterium tuberculosis
P02836623A1094|50 70|months postinoculation
P02836623A1094|133 153|months postinoculation
P02837575A0979|0 12|Sodium dodecyl
P02837575A0979|49 61|topoisomerase
P02837763A0259|0 16|Amino acid sequence
P02837763A0259|73 95|muscle phosphatase 2A cDNA
P02837763A0259|101 119|% nucleotide identity
P02838246A0225|0 19|Herpes virus infection
P02838246A0225|104 116|proliferation
P02838246A0225|122 136|T8 subpopulation
P02838246A0225|179 193|rejection crises
P02839488A1314|96 114|erythrocyte type-1 Gs
P02839716A0673|85 111|HPV-11 enhancer-SV40 promoter
P02839716A1907|44 59|enhancer activity
P02840034A1266|53 70|lung cancer patients
P02843495A0544|0 11|Introduction
P02843495A0544|44 61|macrophage cell line
P02843495A0544|69 86|factor independence
P02843495A0544|90 103|tumorigenicity
P02843694T0001|7 23|E-B virus infection
P02844767A0191|22 36|cotranscription
P02844767A0191|98 110|apocytochrome
P02844767A0596|3 18|Nostoc petBD genes
P02844767A0596|135 150|chloroplast genes
P02844767A1022|0 20|RNA blot hybridizations
P02844767A1022|51 62|cytochrome b6
P02844797A1225|10 22|muscle isoform
P02844797A1225|66 88|sequence Ala-Ile-Leu-Glu
P02844797A1225|183 194|acid sequence
P02844797A1225|217 235|transmembrane domain
P02844797A1225|247 263|consensus sequence
P02844797A1225|277 293|glycosylation site
P02845654A0510|0 11|Substitution
P02845654A0510|15 30|threonine residue
P02845654A0510|35 48|alanine residue
P02845654A0510|69 80|cleavage site
P02845654A0510|105 116|substitution
P02845654A0510|120 134|tyrosine residue
P02845654A0510|138 157|phenylalanine residue
P02845654A0510|160 176|amino acid position
P02845654A0510|186 197|cleavage site
P02846640A0643|37 54|indoxyl phosphatase
P02846852A1459|40 54|E strand promoter
P02846852A1459|94 108|L strand promoter
P02848842A0643|9 20|RNA molecules
P02848842A0643|31 43|kilobase range
P02849100A0441|114 127|plasma membrane
P02849759A0865|3 14|SV40 enhancer
P02850472A0112|40 53|DNA replication
P02850967T0000|11 40|proto-oncogene fos transcription
P02850967T0000|51 73|adenylate cyclase pathway
P02850967T0000|74 89|characterization
P02850971A0180|7 26|oligodeoxynucleotide
P02850971A0180|54 74|VtHb amino acid sequence
P02850971A0180|85 102|hybridization probe
P02850971A0180|112 123|Vitreoscilla
P02850971A0180|167 184|cosmid vector pVK102
P02852805A0216|33 47|characteristics
P02852894T0000|60 71|Thai villages
P02853799T0001|58 71|transformation
P02856622T0001|5 35|serum thyroglobulin determination
P02859434T0000|0 11|Poor response
P02859434T0000|45 56|serum lithium
P02861067A0000|128 147|bronchodilator effect
P02861067A0000|151 165|beta agonist drug
P02861144A0242|21 31|DNA fragment
P02861144A0242|61 76|encoding proteins
P02862656T0000|9 35|dopamine receptor sensitivity
P02862656T0000|54 66|alcohol intake
P02863492A0544|37 51|treatment groups
P02863747T0000|18 29|histone genes
P02865502T0000|40 70|tissue-type plasminogen activator
P02868446A0184|29 44|RPase beta subunit
P02868446A0184|58 68|dnaG protein
P02868446A0184|223 240|core enzyme subunits
P02868848A0167|101 111|penicillin G
P02868848A0167|151 161|gas gangrene
P02869125A0120|28 42|receptor agonist
P02869125A0120|116 135|locomotor stimulation
P02870249T0000|12 23|chemotherapy
P02870720A0188|33 59|beta-adrenoceptor antagonist
P02870720A0188|89 100|isoprenaline
P02870720A0188|103 116|guinea pig atria
P02870720A0188|120 133|tracheal muscle
P02870851A0349|21 32|parotid gland
P02870851A0349|48 59|fluctuations
P02870851A0349|62 82|parotid saliva flow rate
P02873593A0581|165 182|5-HT uptake blockers
P02874078A0252|13 33|luteal phase deficiency
P02874635T0000|21 36|fungicide dinocap
P02874635T0000|77 87|cleft palate
P02875224A1059|113 125|contractility
P02875967A0377|96 108|fertility rate
P02876899A0568|72 101|bevantolol plasma concentrations
P02876899A0568|107 121|absorption phase
P02877124A0000|58 72|promethazine HCl
P02877124A0000|74 86|phenothiazine
P02877124A0000|91 116|H1 receptor blocking activity
P02877124A0000|117 132|chlorpheniramine
P02877124A0000|146 160|trifluoperazine
P02877124A0000|162 174|phenothiazine
P02877124A0000|181 198|H1 blocking activity
P02877124A0000|206 218|drinking water
P02877124A0000|247 264|bone mineral content
P02877124A0000|314 326|body retention
P02877124A0000|334 355|methylene diphosphonate
P02877124A0000|377 390|bone metabolism
P02878100A0674|62 73|transmission
P02878100A0674|178 189|transmission
P02879906A0000|74 85|relationship
P02879906A0000|93 127|beta adrenoceptor subtype distribution
P02879906A0000|163 178|nerve innervation
P02879951T0000|44 65|rat platelet aggregation
P02880841A0313|102 112|beta subunit
P02880841A0313|130 147|nucleotide sequence
P02880841A0313|240 251|chloroplasts
P02880841A0313|255 266|mitochondria
P02882893A0301|0 14|Body temperature
P02882893A0301|69 81|P. s. campbelli
P02883327A0413|3 22|polyadenylation sites
P02883871A1075|25 37|beta receptors
P02883871A1075|91 110|drug hypersensitivity
P02884860A0329|54 66|adrenoceptors
P02885517T0000|7 17|blood donors
P02889352A0000|20 32|blood pressure
P02889352A0000|87 97|beta blocker
P02889352A0000|108 122|enzyme inhibitor
P02889352A0000|125 141|calcium antagonist
P02889495A0000|37 57|episode schizophrenics
P02889495A0000|77 88|flupenthixol
P02889495A0000|148 161|mg flupenthixol
P02890200T0001|48 61|Recklinghausen
P02890200T0001|63 79|neurofibromatosis
P02892762A0296|17 30|repeat elements
P02892762A0296|67 78|promoter site
P02894689A0000|27 38|DNA fragments
P02894689A0000|51 64|chromatin loops
P02894689A0000|84 102|extraction procedure
P02894689A0000|119 134|diiodosalicylate
P02894741A0000|52 67|muscle relaxation
P02894741A0000|84 99|NLA II anaesthesia
P02894789A0954|10 24|recovery indexes
P02895472A0178|105 119|mRNA translation
P02895566A0187|54 75|pressure pain components
P02895566A0187|90 105|ischemia duration
P02895566A0187|127 147|pressure pain component
P02895754A0000|8 27|percent isoproterenol
P02895754A0000|46 83|phosphodiesterase inhibitor theophylline
P02897651A0000|0 14|Hyperthyroidism
P02898752A0683|71 82|granulocytes
P02898752A0683|86 102|platelets recovery
P02899177A0605|27 47|low-frequency kindling
P02899177A0605|135 146|excitability
P02900760A0073|5 20|sequence elements
P02900760A0073|64 87|transcription termination
P02900760A0073|90 103|RNA polymerase I
P02900760A0073|131 149|transcription system
P02900760A0073|164 175|transfection
P02900760A0073|178 199|rDNA minigene constructs
P02901498A0354|3 14|biosynthesis
P02901498A0354|83 93|erbB protein
P02901498A0354|134 157|chicken embryo fibroblasts
P02901763A0977|12 36|C. reinhardtii mitochondria
P02901763A0977|158 175|C. reinhardtii mtDNA
P02901763A0977|238 253|protein synthesis
P02902615A0000|44 56|polyarteritis
P02902656A0481|75 88|repetition time
P02902656A0481|117 128|hyperintense
P02902656A0481|152 165|TR/TE sequences
P02902844A1219|116 127|bacterium PS3
P02902844A1219|131 143|cyanobacteria
P02902927A0145|37 54|rat GHF-1 cDNA clones
P02903500A0278|139 152|immunoglobulin
P02904322A0002|49 61|model ruminant
P02906027A0553|2 19|sequence comparison
P02906027A0553|123 138|CpG dinucleotides
P02906673T0000|11 25|field evaluation
P02906673T0000|28 48|Bacillus thuringiensis
P02906673T0000|56 67|B. sphaericus
P02906673T0000|75 94|floodwater mosquitoes
P02907308T0001|25 47|Richner-Hanhart syndrome
P02907533A0362|24 40|drug concentration
P02907533A0362|45 60|correction factor
P02907533A0362|94 114|diazepam concentration
P02907533T0000|27 41|blood substitute
P02907533T0000|44 58|diazepam binding
P02909528A1081|7 22|promoter activity
P02910496A0583|1 15|decamer sequence
P02910496A0583|16 28|CGA-CCCCUCC-3
P02910496A0583|84 95|cleavage site
P02910496A0583|114 125|RNA substrate
P02910496A0583|140 151|RNAase MRP RNA
P02910989T0000|17 40|beta-adrenergic-blockade
P02910989T0000|59 71|QT/QS2 changes
P02913368A1037|0 18|Pharmacology studies
P02913368A1037|23 39|potassium chloride
P02913368A1037|43 55|acetylcholine
P02913368A1037|81 97|calcium antagonist
P02914422A0409|0 15|Computer analysis
P02914422A0409|77 90|frequency bands
P02914422A0409|112 125|frequency range
P02914492A0183|42 55|hypomagnesemia
P02914492A0183|102 116|normomagnesemia
P02914492A0183|156 170|hypermagnesemia
P02916764A0253|3 13|risk factors
P02916764A0253|32 43|hypertension
P02916764A0253|44 59|diabetes mellitus
P02916764A0253|60 79|hypercholesterolemia
P02916764A0253|80 95|cigarette smoking
P02916764A0253|118 130|family history
P02918474A0817|83 96|subendocardium
P02918474A0817|122 134|subepicardium
P02919530A0000|84 98|artery occlusion
P02919832A0144|73 95|Doppler echocardiography
P02920591A0251|50 63|administration
P02920591A0251|75 87|micrograms/kg
P02920591A0251|105 121|micrograms/kg/min
P02923687A0218|17 28|relationship
P02923687A0218|93 103|cleft palate
P02925013A1112|85 96|accumulation
P02925013A1112|109 121|citrate ligand
P02925568A0460|16 28|father absence
P02925568A0460|129 143|family stressors
P02925568A0460|154 168|psychopathology
P02926499A0340|31 41|analog model
P02927391A0238|49 69|founder SWR/J-RF/J mice
P02929056T0000|15 38|transureteroureterostomy
P02929056T0000|48 67|ureterosigmoidostomy
P02930623A0404|6 20|flexion whiplash
P02934889A0558|95 107|cent reduction
P02934889A0558|110 126|Ostertagia species
P02934889A0558|139 151|cent reduction
P02935638A0000|63 99|sea urchin Strongylocentrotus purpuratus
P02936163T0000|0 15|Platelet function
P02936163T0000|90 117|platelet lipoxygenase activity
P02936284A0357|97 116|elimination half-life
P02938185A0223|47 61|E1b gene products
P02938185A0223|178 189|architecture
P02939260A1553|17 41|amino acid sequence analysis
P02939260A1553|61 72|42K T antigens
P02939260A1553|123 133|DNA sequence
P02939260A1553|171 181|39K T antigen
P02939260A1553|207 222|Edman degradation
P02941237A0160|31 42|serum calcium
P02941237A0160|46 73|phosphorous ion concentrations
P02941237A0160|82 92|blood supply
P02941237A0160|142 160|alkaline phosphatase
P02941237A0160|164 178|pyrophosphatase
P02943562T0000|0 22|Penicillinase production
P02947866A1416|26 43|thallium-201 uptake
P02949170A0184|46 71|micrograms ethinyl estradiol
P02949170A0184|76 95|mg cyproterone acetate
P02949170A0184|98 110|gonadotropins
P02949170A0184|120 131|testosterone
P02949170A0184|132 156|sex hormone binding globulin
P02949170A0184|161 175|androstenedione
P02949170A0184|193 209|testosterone index
P02950216A0084|31 51|laser Doppler flowmetry
P02950216A0084|66 77|output signal
P02950216A0084|78 90|blood cell flux
P02957125A0601|37 49|haemodialysis
P02957125A0601|72 84|cent reduction
P02957125A0601|87 108|plasma ANP concentration
P02958204A0175|25 36|isotretinoin
P02958204A0175|57 72|HDL phospholipids
P02958204A0175|79 90|apoprotein A1
P02958204A0175|100 116|HDL-C subfractions
P02958204A0175|180 191|isotretinoin
P02958204A0175|224 235|acne vulgaris
P02958233A0123|21 40|laboratory parameters
P02958233A0123|60 80|serum sickness reaction
P02958660A1094|42 57|conversion factor
P02960012A0838|14 24|PPNG strains
P02962859A0276|35 65|beta-galactosidase fusion protein
P02964329A0000|3 14|pathogenesis
P02964329A0000|24 36|Joint Mobility
P02964329A0000|122 136|microangiopathy
P02966671A0151|77 89|treatment size
P02966671A0151|137 149|breathing rate
P02966671A0551|123 137|radiation effect
P02966671A0551|268 279|radiotherapy
P02967496A0182|43 55|reading frames
P02967496A0182|95 107|leader segment
P02967915A0000|15 44|hormone 1,25-dihydroxyvitamin D3
P02967915A0000|76 96|calcium binding protein
P02967915A0000|103 116|calbindin-D28K
P02967915A0000|129 141|target tissues
P02967915A0968|13 34|calbindin-D28K promoter
P02969316A0002|46 65|plasma concentrations
P02969316A0002|115 137|plasma ANP concentrations
P02969819A0814|0 19|Ig D-JH recombinations
P02969819A0814|30 49|TcR gene recombination
P02969819A0814|62 71|T cell lines
P02969819A0814|102 115|Cmu transcripts
P02970061A0271|16 27|reading frame
P02970640A0341|6 32|absorption spectrophotometry
P02970640A0341|62 72|E1A proteins
P02970640A0341|97 107|acid protein
P02970640A0341|142 152|acid protein
P02973304A0000|20 38|Budd-Chiari syndrome
P02973304A0000|107 122|patient suffering
P02973304A0000|142 156|cardiosclerosis
P02975680A0000|8 25|accommodation night
P02975680A0000|26 43|sleep EEG recordings
P02975680A0000|130 144|anxiety disorder
P02975753A1333|0 25|Oligonucleotide mutagenesis
P02975753A1333|33 46|binding domains
P02976332A1277|3 15|concentration
P02979426T0000|0 19|Organ transplantation
P02979834T0000|26 59|maltose tetrapalmitate immunotherapy
P02979834T0000|60 87|cyclophosphamide chemotherapy
P02979834T0000|91 102|radiotherapy
P02979834T0000|105 118|ethyl carbamate
P02981840A0907|9 20|pair sequence
P02983316A0310|46 79|complementarity-determining regions
P02983316A0310|104 117|probe sequences
P02983316A0310|164 174|caiman genes
P02983316A0310|263 274|preservation
P02983316A0310|277 294|nucleotide sequence
P02983331T0000|68 81|immobilization
P02985812A0984|80 91|reading frame
P02985820A1287|9 24|sequence elements
P02985820A1287|106 121|retroviruses CMII
P02986279A0000|2 12|milk samples
P02986279A0000|91 105|cytomegalovirus
P02987220A0472|12 23|DNA fragments
P02987220A0472|70 80|DNA fragment
P02987777A0000|30 42|cell carcinoma
P02988457A0650|42 53|potentiality
P02988457A0650|56 72|Bestatin treatment
P02989637A0671|51 79|zona glomerulosa corticosteroid
P02989637A0671|88 101|renin secretion
P02989637A0671|134 149|cord transections
P02989637A0671|226 250|metoclopramide stimulation
P02989637A0671|267 280|renin secretion
P02989786A0328|14 30|enhancer sequences
P02989786A0328|34 50|adenovirus E1A gene
P02989786A0328|66 80|CATase synthesis
P02991060A0465|5 17|IgG antibodies
P02993630A1190|17 31|nucleotide level
P02993630A1190|88 100|enzyme attacks
P02994253A0482|25 39|mean NTE activity
P02994253A0482|106 118|control values
P02994253A0482|127 140|hr postexposure
P02994253A0482|161 173|cord pathology
P02994253A0482|176 191|days postexposure
P02994336A0864|79 91|bromocriptine
P02995967T0000|15 27|protooncogene
P02995967T0000|69 93|growth factor-receptor gene
P02995967T0000|124 142|gland adenocarcinoma
P02995999A0000|3 18|sequence analysis
P02995999A0000|63 81|recombination events
P02995999A0000|97 109|recombination
P02995999A0000|203 220|recombination event
P02995999A0000|238 254|base-pair deletion
P02995999A0000|266 284|recombination events
P02995999A0000|313 334|base-pair substitutions
P02997622A0916|44 59|SCLC cell line DNAs
P02997622A0916|68 85|SCLC tumour specimen
P02997777A0609|59 71|delta top1 top2
P02997777A0609|121 132|top2 ts strain
P02997777A0609|279 293|delta top1 top2 ts
P02998016A0527|127 139|nonsense codon
P02998016A0527|163 174|reading frame
P02998043A1199|29 49|Punta Toro M gene product
P02998043A1199|120 135|carboxy-proximal
P03000457A1554|6 17|kDa precursor
P03000489A0822|158 173|blood lymphopenia
P03001086A0587|12 28|amino acid sequence
P03001086A0587|85 96|Xenopus hsp70
P03001086A0587|141 155|dnaK gene product
P03001110A0546|4 18|phosphorylation
P03001110A0546|30 46|peptide substrates
P03001110A0546|71 98|receptor self-phosphorylation
P03001110A0546|99 120|tyrosine kinase activity
P03001353A0146|2 13|temperatures
P03001353A0146|27 40|transformation
P03001645A0785|49 63|initiation sites
P03001705T0000|9 22|transformation
P03001705T0000|43 64|herpes simplex virus type
P03001705T0000|90 100|gene product
P03002501A1327|43 71|guinea-pig alpha s1-casein mRNAs
P03003695A0395|32 45|c-sis cDNA clone
P03003695A0395|96 107|kbp DNA region
P03004739A0753|16 28|G transversion
P03004739A0753|51 68|CAT pentanucleotide
P03004739A0753|145 161|CAT binding protein
P03004982A0199|3 20|nucleotide sequence
P03004982A0199|37 49|R. sphaeroides
P03004982A1094|91 106|fbcF reading frame
P03005231A0649|105 117|transcription
P03006066A0653|6 20|P135gag-myb-ets
P03006066A0653|35 52|translation product
P03007281A0905|3 13|Dox-A2 locus
P03007281A0905|39 52|OD15 breakpoint
P03009826A0201|38 55|base-pair dimer unit
P03010281A0220|54 67|gene expression
P03011793A0582|7 19|reading frames
P03011793A0582|65 81|amino acid residues
P03013477A0000|28 39|iron overload
P03013477A0000|103 114|hemodialysis
P03013477A0000|127 141|superoxide anion
P03013477A0000|247 265|serum ferritin levels
P03013477A0000|314 332|serum ferritin levels
P03014515T0000|5 24|alpha-galactosidase A
P03014515T0000|25 42|nucleotide sequence
P03015611A0331|3 19|amino acid sequence
P03015611A0331|60 72|lysine residue
P03015628A1078|21 34|hydroxyproline
P03015628A1078|60 79|hyperphosphatasaemia
P03015628A1078|122 133|bone turnover
P03015628A1078|166 197|serum alkaline phosphatase activity
P03015953T0000|10 23|glucocorticoid
P03015953T0000|36 47|cell variants
P03015953T0000|54 80|mouse glucocorticoid receptor
P03016301A0605|8 18|v-myc codons
P03016506A0611|96 106|B95-8 strain
P03016506A0611|139 151|antigen EBNA-1
P03016506A0611|180 194|BamHI-C fragment
P03016506A0611|235 249|G-418 resistance
P03016506A0611|252 262|animal cells
P03016883A0000|35 56|herpes simplex virus type
P03016883A0000|131 144|virus isolation
P03017225A0706|28 40|leather bottle
P03017225A0706|41 59|linitis plastica type
P03017225A0706|81 90|II c portion
P03017996A0731|9 20|biosynthesis
P03017996A0731|37 48|polypeptides
P03017996A0731|52 64|signal peptide
P03017996A0731|148 159|cleavage site
P03018491A0840|3 16|hexanucleotide
P03018491A0840|48 58|GRE activity
P03018491A0840|172 186|receptor binding
P03020001A0781|16 30|mini-Mu elements
P03020001A0781|40 52|kilobase pairs
P03020001A0781|77 88|DNA fragments
P03020001A0781|99 111|kilobase pairs
P03020001A0781|137 149|kilobase pairs
P03020001A0781|198 210|kilobase pairs
P03020513T0000|22 39|T4 DNA topoisomerase
P03020513T0000|57 68|gyrA-protein
P03021050A0501|32 43|quantitation
P03021088A0135|116 129|reconstruction
P03022129A0842|105 117|accessibility
P03022129A0842|162 178|transcription rate
P03023679A0624|128 139|modification
P03023682A0271|48 79|chloramphenicol acetyltransferase
P03023859A0000|43 58|leukemia patients
P03023859A0000|100 112|Ph1 chromosome
P03023859A0000|150 172|breakpoint cluster region
P03023887A0470|0 19|Nuclease footprinting
P03023887A0470|40 61|glucocorticoid receptor
P03023887A0470|132 144|sequence motif
P03023970A0922|24 40|termination signal
P03024343A0372|33 46|neuroendocrine
P03024703A1036|46 61|polypeptide chain
P03024703A1036|113 125|hsp108 protein
P03025606T0000|15 28|control signals
P03025606T0000|32 53|herpes simplex virus type
P03025655T0000|78 91|kinase function
P03025655T0000|95 114|transforming activity
P03025655T0000|117 147|Fujinami sarcoma virus P130gag-fps
P03025862A0860|111 122|addition site
P03026915A1024|104 120|lacZ fusion vectors
P03027661A0000|31 42|miniF plasmid
P03027779A0000|0 15|SPECT examination
P03027905A0632|0 18|Plasma renin activity
P03027905A0632|29 50|plasma aldosterone level
P03029111A0155|14 27|representative
P03029111A0155|39 61|pet complementation group
P03032143A0218|97 112|sequence elements
P03032143A0218|152 163|conformation
P03032143A0218|181 196|yeast kinetochore
P03033283A0837|91 101|DNA sequence
P03033283A0837|105 139|competition filter binding experiments
P03033283A0837|173 193|consensus binding sites
P03033283A1415|60 73|repeat elements
P03034570A0943|17 28|gene segments
P03034570A0943|52 83|chloramphenicol acetyltransferase
P03034570A0943|158 175|papillomavirus type
P03034956A0666|27 40|androgen levels
P03035056T0000|15 44|kappa antibody gene rearrangement
P03035218T0000|0 13|Identification
P03035218T0000|64 86|T-cell leukemia virus type
P03035658A0355|108 127|plasma concentrations
P03036415T0000|11 35|cyclo-oxygenase inhibition
P03036415T0000|41 67|leukotriene receptor blockade
P03036415T0000|87 120|pressure/cardiac index relationships
P03036817A0213|52 70|NdeI restriction site
P03036933A0774|0 10|ACTH release
P03036933A0774|62 74|ACTH treatment
P03037334A0932|33 47|promoter element
P03037334A0932|53 66|yeast RP39A gene
P03037334A0932|91 104|sequence motifs
P03038643A1374|38 51|alpha-spectrin
P03038891A0935|0 15|Northern analyses
P03038891A0935|26 37|mouse tissues
P03038891A0935|63 75|p11 mRNA levels
P03039177A0503|77 92|IR2 repeat element
P03039177A0503|102 128|restriction site polymorphism
P03039387A0920|30 45|cyclophosphamide
P03039387A0920|136 147|methotrexate
P03039387A0920|158 173|cyclophosphamide
P03040403A0155|59 69|YEp13 vector
P03041046A0127|47 57|Moloney MuLV
P03041802A0975|24 41|platelet aggregates
P03041802A0975|61 75|fibrinopeptide A
P03041802A0975|77 91|cleavage product
P03041802A0975|112 129|platelet activation
P03041802A0975|166 177|pathogenesis
P03045117A0936|81 92|growth factor
P03045725A0872|38 52|prolactin levels
P03045725A0872|76 95|breast cancer patients
P03045725A0872|121 136|tumor sensitivity
P03045725A0872|139 150|chemotherapy
P03046655A0000|9 23|prevalence study
P03046931A0247|80 99|nucleotide difference
P03049570A1242|5 16|similarities
P03050147A0896|49 64|E1a-E1b functions
P03050147A0896|110 126|mRNA transcription
P03050147A1520|36 48|scanning model
P03050147A1520|146 162|initiator AUG codon
P03052327A1474|32 61|pancreas-kidney transplantation
P03053713A0752|0 12|DNA sequencing
P03053713A0752|40 51|reading frame
P03057259A0514|3 14|relationship
P03059171A1232|0 13|Administration
P03059171A1232|16 29|anticoagulants
P03059171A1232|41 55|prostaglandin E1
P03059171A1232|131 143|deterioration
P03060846T0000|23 35|L1 binding site
P03061301A0624|0 20|Prostacyclin formation
P03061301A0624|35 47|excretion rate
P03061301A0624|59 95|metabolite 6-keto-prostaglandin F1 alpha
P03061301A0624|116 131|radioimmunoassay
P03061301A0624|140 153|urine specimens
P03061301A0624|195 206|participants
P03061301A1409|85 98|contraceptives
P03061383A0000|97 111|beta-lactamases
P03061383A0000|172 192|agar dilution technique
P03062370A0384|24 34|GCN3 product
P03062370A0384|75 88|GCN4 expression
P03062370A0384|100 120|amino acid availability
P03064811A0485|3 19|amino acid sequence
P03064811A0485|25 39|S. aureus peptide
P03064811A0485|51 65|phosphoryl group
P03065140A0273|31 41|GAL4 protein
P03065140A0273|45 60|DNA binding domain
P03065140A0273|67 95|transcription activation domain
P03065141A0448|109 132|Tn3411 nucleotide sequence
P03065610A0375|32 42|gene product
P03065610A0375|58 76|Western blot analysis
P03066131A0000|70 87|behaviour disorders
P03066131A0000|143 154|hypothalamus
P03066131A0000|244 257|aggressiveness
P03066208A0310|71 83|cell carcinoma
P03066625A0756|65 77|contributions
P03066625A0756|88 98|risk factors
P03066625A0756|123 133|risk factors
P03067505A0688|4 15|prostacyclin
P03069980T0000|21 32|bond strength
P03069980T0000|40 57|glass polyalkenoate
P03072021A0696|3 20|amino acid sequences
P03072021A0696|56 73|targeting sequences
P03072021A0696|111 122|polypeptides
P03072580A0455|0 9|Van der Ende
P03073091A0338|6 20|insulin infusion
P03073091A0338|23 39|% dextrose solution
P03073091A0449|48 66|hour insulin infusion
P03073091A0449|148 161|spironolactone
P03073091A0449|197 209|indomethacine
P03073192T0000|0 49|Mycobacterium avium-intracellulare complex infections
P03073192T0000|63 86|immunodeficiency syndrome
P03075154T0000|12 28|oxalate deposition
P03075154T0000|53 71|ciclosporin A therapy
P03076124A0496|3 22|bile acid sequestrants
P03076124A0496|23 36|cholestyramine
P03076124A0496|89 118|hydroxymethylglutaryl coenzyme A
P03076124A0496|212 232|hypercholesterolaemia
P03076124A0496|250 269|plasma concentrations
P03076124A0496|280 294|LDL-cholesterol
P03078268A0529|44 56|acidification
P03078268A0529|91 104|acidosis models
P03078268A0529|124 145|amphotericin B treatment
P03078268A0529|213 225|acidification
P03080793T0000|55 70|AIDS transmission
P03083441T0000|0 12|Modifications
P03083441T0000|29 43|postcontraction
P03088643A0000|103 113|control rats
P03090237A0202|30 40|response run
P03090237A0202|89 99|response key
P03090237A0202|137 147|response key
P03090372A0607|11 31|glucose tolerance tests
P03091849A0000|12 25|glutaraldehyde
P03091849A0000|41 54|ultrastructure
P03091849A0000|76 87|rat mesentery
P03097509A0654|14 25|RNA molecules
P03097643A1357|32 43|substitution
P03097643A1357|56 70|octamer sequence
P03098018A0139|68 80|P2-A2 pilosity
P03102289A0786|48 64|hCG administration
P03102289A0786|166 178|serum E2 levels
P03104914T0000|28 40|translocation
P03104982A0690|14 29|hemoglobin levels
P03104982A0690|83 95|sex difference
P03108171A0088|44 59|blocking activity
P03108171A0088|62 72|S2 receptors
P03109147A0000|0 13|Ethylene glycol
P03109147A0000|17 32|diethylene glycol
P03109147T0127|10 23|ethylene glycol
P03109147T0127|27 42|diethylene glycol
P03109954A0945|126 146|artery atherosclerosis
P03109954A0945|192 224|plasma HDL cholesterol concentration
P03109954A0945|282 293|relationship
P03109954A0945|301 312|plasma lipids
P03109954A0945|316 328|atherogenesis
P03110678A0702|50 69|polysulphone membrane
P03110678A0702|73 85|haemodialysis
P03110678A0702|89 103|haemofiltration
P03110678A0702|113 131|beta 2-microglobulin
P03110678A0702|191 204|treatment modes
P03110678A0702|230 242|urea clearance
P03110692A0156|363 373|urine volume
P03110746A0146|36 48|triglycerides
P03110746A0146|66 78|adipose tissue
P03110794A0991|16 27|g fluvoxamine
P03110801A0532|20 42|plasma prolactin response
P03112412A0985|71 88|synthetase mutation
P03112412A0985|104 122|thr operon expression
P03114188A0907|88 103|chest wall sarcoma
P03114829T0000|33 43|panic states
P03114995T0000|39 52|gastrin release
P03115087A0515|16 31|height velocities
P03115787A0633|22 37|cyclophosphamide
P03115787A0633|38 55|hexamethylmelamine
P03117046T0000|12 27|characterization
P03117046T0000|31 42|vinculin cDNA
P03117147A1059|57 71|oesophageal EMGd
P03117147A1059|90 100|surface EMGd
P03117147A1059|137 149|investigation
P03118631A0140|15 29|fixation quality
P03119227A0079|3 13|DNA sequence
P03119227A0079|49 64|sequence homology
P03119227A0079|75 100|c-abl proto-oncogene product
P03119227A0079|115 127|amino terminus
P03119227A0079|181 202|tyrosine kinase activity
P03119485A0476|187 202|distress syndrome
P03123983T0000|9 23|neuroplasticity
P03125422A0202|58 75|activator sequences
P03126531T0000|89 116|dopamine agonist pretreatments
P03127463A1017|47 57|CSF activity
P03127463A1017|79 93|bone marrow cells
P03127463A1017|118 130|proliferation
P03127463A1017|146 159|cord blood cells
P03132498A0730|77 87|asthma score
P03133250A0000|85 96|gonadotropin
P03133250A0000|150 162|fertilization
P03133250A0000|166 179|embryo transfer
P03133360A1215|45 68|transcription attenuation
P03137105A0146|1 21|prostaglandin analogue
P03137105A0146|60 71|gonadotropin
P03137105A0146|162 177|oocyte collection
P03137105A0146|205 216|oocyte donors
P03137105A0146|220 235|embryo recipients
P03137346A0319|3 15|nucleolin gene
P03137346A0319|78 94|amino acid residues
P03137601A0212|8 36|L-threo-dihydroxyphenylserine
P03137601A0212|53 66|norepinephrine
P03137601A0212|178 193|NE neurotoxin DSP4
P03138190A0347|64 75|Kupffer cells
P03138190A0347|79 89|target cells
P03138449A0759|32 53|desaturation activities
P03142875A0366|23 44|6-kilobase cDNA sequence
P03143048A1091|0 14|HDL-cholesterol
P03143048A1091|32 48|apolipoprotein A-I
P03143048A1091|63 76|concentrations
P03143485A0366|19 36|protein gene cluster
P03143485A0366|62 74|protein operon
P03143485A0366|94 109|gene organization
P03143485A0366|173 199|liverwort chloroplast genomes
P03144705A0859|3 14|distribution
P03144705A0859|96 113|sequence divergence
P03144705A0859|205 220|Alu family repeats
P03146017A0983|3 20|nucleotide sequence
P03146017A0983|137 156|amino acid polypeptide
P03146150T0000|0 11|Potentiation
P03146150T0000|60 72|Pro-urokinase
P03146784A0158|91 106|stretch receptors
P03146784A0158|145 160|stretch receptors
P03146784A0158|205 218|chemoreceptors
P03147912A0422|11 26|hyperventilators
P03147912A0422|67 78|fluctuations
P03149774A0173|176 196|bicuculline methiodide
P03149774A0173|198 219|GABA receptor antagonist
P03150296A0594|35 53|creatinine clearance
P03150296A0594|77 90|filtration rate
P03150296A0594|177 191|serum creatinine
P03150296A0594|213 231|creatinine clearance
P03154072A0862|3 17|protein mixtures
P03154072A0862|20 30|sesame flour
P03154072A0862|34 45|soybean flour
P03159903A0352|64 80|amino acid sequence
P03159903A0352|102 118|amino acid sequence
P03166458A1356|1 16|protein footprint
P03166458A1356|38 49|GC box element
P03167060A0000|12 23|growth factor
P03168709A0000|40 51|glaucoma eyes
P03168709A0000|86 107|suprathreshold strategy
P03171221A0531|75 92|elastin transcripts
P03172863T0000|15 28|undernutrition
P03172863T0000|31 44|susceptibility
P03178097A0000|3 19|CHARGE association
P03178161A0000|51 69|blood concentrations
P03178161A0000|72 85|micronutrients
P03178161A0000|189 202|Southern Africa
P03178626A0137|79 90|aircraft type
P03179496T0000|26 52|modified-hemoglobin solution
P03179496T0000|78 99|blood volume replacement
P03180595A1040|7 30|gallbladder visualization
P03180595A1040|45 60|ejection fraction
P03181276A0422|2 14|micrograms PAF
P03181276A0422|72 88|allergen challenge
P03183103A0000|10 23|MR examinations
P03183127A0068|43 59|imaging modalities
P03183127A0068|82 99|CT ventriculography
P03183127A0068|103 123|CT myelocisternography
P03184267A0000|19 33|broiler chickens
P03184267A0000|162 174|food poisoning
P03185322A1305|117 129|class-2 smears
P03185540T0000|25 37|transcription
P03185540T0000|49 61|RNA polymerase
P03185540T0000|64 75|purification
P03185540T0000|97 124|TATA box-promoter interactions
P03186091T0000|8 33|plasma cystyl aminopeptidase
P03186091T0000|102 113|hypertension
P03190481A0292|35 46|quantitation
P03190481A0292|77 96|infiltration area unit
P03190914A0149|12 33|migration differentials
P03190914A0149|60 73|responsiveness
P03192537A0370|89 105|amino acid sequence
P03192724A0000|13 28|style differences
P03192724A0000|34 44|drug abusers
P03192724A0000|90 109|FIRO-B interpretation
P03192799T0000|14 28|American Academy
P03192799T0000|31 46|Implant Dentistry
P03194410A0771|59 75|tissue specificity
P03195167A0104|3 22|platelet adhesion rate
P03195167A0104|73 90|haemocompatibility
P03195167A0104|96 121|basic-polymers polyurethane
P03195167A0104|125 141|polyvinylchloride
P03195167A0104|181 192|test chambers
P03198436T0000|23 38|bladder carcinoma
P03198525A0164|8 19|feedlot trial
P03199043A0248|49 69|boundary value problems
P03199043A0248|100 123|permeability coefficients
P03199043A0248|127 140|transport rates
P03199043A0248|148 168|diffusion coefficients
P03199436A1060|9 20|gene clusters
P03199436A1060|29 52|photosynthesis components
P03199436A1060|62 80|psbB-psbH-petB-petD
P03199436A1060|87 103|psbE-psbF clusters
P03200488A0439|43 54|turnover rate
P03200488A0439|73 87|dopamine neurons
P03200488A0439|101 114|administration
P03200844A1211|36 51|pore glycoprotein
P03200844A1211|161 177|pore glycoproteins
P03207975A0709|21 34|administration
P03207975A0709|46 65|plasma concentrations
P03208493A0849|13 26|filtration rate
P03208493A0849|42 57|lithium clearance
P03209019A0662|14 30|promotion bioassay
P03209019A0662|158 169|test material
P03212551T0001|3 14|pathogenesis
P03212929A0000|2 15|ELISA procedure
P03212929A0000|52 62|IgE response
P03212929A0000|71 97|Dirofilaria immitis infection
P03214709A0559|41 66|plasma corticosterone levels
P03216131A0559|16 34|Aeromonas hydrophila
P03218714A0000|31 54|Dandy-Walker malformation
P03227568T0001|39 53|dermatoglyphics
P03228518A0339|62 83|Personal Responsibility
P03229917A0099|57 72|remnant infection
P03233862T0000|0 18|Neuromyelitis optica
P03234790T0001|29 42|administration
P03234790T0001|45 64|methyl isobutyl ketone
P03235487A0404|0 12|Incorporation
P03235487A0404|23 48|M sodium dihydrogen phosphate
P03235487A0404|54 67|sugar solutions
P03239106A0856|13 29|phosphorus content
P03239106A0856|50 61|reabsorption
P03243027T0000|41 61|protein gene expression
P03243027T0000|81 103|Dictyostelium discoideum
P03243920A0591|20 58|plasma concentration-effect relationships
P03246999A0483|43 58|adaptation period
P03249792A0241|43 56|symptomatology
P03249792A0241|63 77|group activities
P03249792A0241|90 102|group dynamics
P03249792A0241|111 123|stress factors
P03249792A0241|173 186|manifestations
P03249840A0411|0 19|Baseline measurements
P03249840A0411|60 76|airway conductance
P03251210A0981|50 63|calcifications
P03253219T0000|40 66|anthracycline cardiomyopathy
P03256150A1866|32 43|requirements
P03257146A1037|40 55|neutrophil counts
P03257146A1037|93 118|marrow neutrophil precursors
P03258069A0000|96 111|nerve stimulation
P03258069A0000|123 139|acupuncture points
P03258069A0000|154 166|pain threshold
P03259437A0140|13 43|neonates serum alpha-amylase value
P03259437A0140|65 76|starch method
P03261223A0644|35 46|disease group
P03261331A0563|37 55|AIDS dementia complex
P03261331A0563|75 87|understanding
P03263357A0112|29 40|relationship
P03263357A0112|68 82|body temperature
P03263357A0112|102 121|plasma concentrations
P03263357A0112|143 157|leukocyte counts
P03263357A0112|161 177|plasma interleukin
P03264299A0679|89 99|ip injection
P03264886A0000|143 154|months period
P03267732A0788|15 32|Ga-fbg scintigraphy
P03268555T0000|22 37|biocompatibility
P03268555T0000|58 78|millipore filter method
P03270085A0382|0 13|Hypomagnesemia
P03270085A0382|22 37|magnesium wasting
P03274204A0642|0 11|Dentalplaque
P03274204A0642|92 108|cent alkaline fuxin
P03275867A0187|71 88|mating type loci HML E
P03275867A0187|144 156|transcription
P03275867A0187|162 174|MAT alpha genes
P03275873A0379|28 40|RNA polymerase
P03275873A0379|133 144|transfection
P03276246A0037|91 102|appendicitis
P03276924A0090|29 41|rearrangement
P03276924A0090|75 88|MoMuLV provirus
P03280021A1615|89 117|measure alpha log Kobsd/alpha log
P03280807A0000|88 106|frameshift mutations
P03280807A0000|152 171|UAG nonsense mutations
P03280807A1447|13 28|suf12-null/SUF12
P03280807A1447|29 41|heterozygotes
P03280912T0000|0 21|Antituberculosis agents
P03280946A0375|11 25|immunity protein
P03280946A0375|115 132|lac promoter control
P03280946A0375|163 179|expression vectors
P03280946A0375|198 220|bacteriophage T7 promoter
P03282232A0743|21 33|fusion protein
P03282813A0794|29 44|oxygen extraction
P03283881A0216|24 37|hypersecretion
P03283881A0216|62 73|inflammation
P03285764A0675|0 18|Hyperprolactinaemia
P03285764A0675|27 38|hypogonadism
P03285764A0675|52 63|neuropathies
P03285764A0675|162 173|consequences
P03287597T0000|22 34|prostate gland
P03292076A0820|75 86|permeability
P03292076A0820|157 170|refractoriness
P03292076A0820|193 204|hemodynamics
P03292076A0820|208 229|eicosanoid biosynthesis
P03292082A0486|24 37|concentrations
P03292082A0486|114 125|glioblastoma
P03296019T0000|0 15|Time delay effects
P03296019T0000|28 39|bond strength
P03296212A0603|266 279|tumor debulking
P03296254A0556|72 86|prothrombin time
P03297181A0127|63 78|quinidine sulfate
P03297181A0127|97 114|quinidine bisulfate
P03298134A0000|35 51|interferon alfa-2b
P03298134A0000|59 73|Schering-Plough
P03298134A0000|95 106|cell leukemia
P03300118A0392|0 13|Oxygen delivery
P03304866T0001|0 16|Revascularization
P03306340A0537|144 158|pancreaticogram
P03309892A0637|92 110|actin gene transcript
P03309892A0637|148 166|initiation start site
P03311954A0000|34 45|institutions
P03311954A0000|150 167|reflux oesophagitis
P03312033A0501|73 90|combination therapy
P03312514A0756|95 114|preischemia amplitude
P03312514A0756|186 199|control animals
P03317796A0853|5 16|control group
P03317796A0853|48 61|osteoarthritis
P03319621A0707|32 45|beta actin mRNAs
P03319646T0000|0 18|Plasma renin activity
P03319646T0000|62 75|chlorthalidone
P03319912A0000|44 62|prophylactic measure
P03320875A2090|54 72|tissue compatibility
P03322829A0952|35 52|compliance category
P03322829A0952|66 78|digoxin marker
P03322829A0952|201 212|prescription
P03326381A0423|44 61|C-peptide excretion
P03329716A0187|16 34|EGF receptor promoter
P03329716A0187|64 80|receptor RNA levels
P03329716A0187|107 118|phorbol ester
P03330711T0000|33 51|Azadirachta indica A.
P03331525T0001|14 27|dentin adhesion
P03331525T0001|47 63|urethane molecules
P03331933T0048|2 14|Felix Lagrange
P03332022A1094|8 31|cysteine clustering region
P03332022A1094|84 101|nucleotide sequence
P03332022A1094|109 132|cysteine clustering region
P03332022A1094|196 209|protein kinase C
P03332022A1094|229 244|cysteine clusters
P03332848A0000|24 36|Doppler probes
P03332848A0000|91 111|carotid artery stenosis
P03334950A0000|3 15|German Society
P03334950A0000|18 34|Pediatric Oncology
P03334950A0000|53 68|Cooperative Ewing
P03334950A0000|70 81|Sarcoma Study
P03334950A0000|116 127|chemotherapy
P03335398A0568|17 31|immunoglobulin G
P03335398A0568|78 89|immunization
P03335398A0568|90 115|passive transfer experiments
P03335651A0000|30 47|parameter weighting
P03335651A0000|213 229|hydrogen weighting
P03335923A0257|63 74|presentation
P03335923A0257|132 148|reflux gastropathy
P03337024A0000|34 50|pharmaco-dynamics
P03337024A0000|64 75|procainamide
P03338154T0000|4 17|concentrations
P03338154T0000|36 51|trypsin inhibitor
P03340548A1018|5 16|chicken liver
P03340548A1018|25 37|chicken MT mRNA
P03340548A1018|73 87|glucocorticoids
P03340548A1018|91 108|lipopolysaccharide
P03340726A1103|46 63|barrier alterations
P03343730A0486|31 43|family history
P03343730A0486|88 107|calcium stone patients
P03344586T0000|0 14|New technologies
P03344586T0000|29 42|classification
P03344812A0924|38 51|HR measurements
P03346157A0000|55 66|examinations
P03346157A0000|70 85|Adult Health Study
P03346157A0000|171 182|institutions
P03346157A0000|225 236|examinations
P03346210A0000|12 23|growth factor
P03346210A0000|57 85|protein tyrosine kinase activity
P03346210A0000|115 142|self-phosphorylation reaction
P03346210A0000|152 164|EGF activation
P03351478A0371|39 48|% G residues
P03352439T0000|5 31|cord abduction rehabilitation
P03352727T0000|3 15|biotechnology
P03352947T0001|36 47|health worker
P03354295A0157|66 77|micrograms/l
P03354341A0177|13 26|filtration rate
P03354341A0177|79 93|clearance method
P03355122A0238|28 46|plasma glucose levels
P03359860A0000|54 68|characteristics
P03359860A0000|90 104|undercompliance
P03359860A0000|178 201|New York Longitudinal Study
P03360667A0000|179 190|mid-altitude
P03360948A0477|69 80|relationship
P03360948A0477|120 151|Behavioral/Emotional Control scale
P03361653A0459|33 51|contour digitization
P03368701A0113|40 52|arteriography
P03368701A0113|90 106|imaging techniques
P03371806A0000|10 23|data processing
P03371806A0000|27 42|latex immunoassay
P03371806A0000|65 79|acid phosphatase
P03371806A0000|126 144|organ identification
P03371894A0355|0 17|Vimentin positivity
P03372422A0558|3 20|maximum deflections
P03372422A0558|120 142|tracer gas concentrations
P03373755T0001|6 17|developments
P03373755T0001|91 115|gastrin receptor blockaders
P03375184A0000|3 23|spermicide nonoxynol-9
P03375184A0000|54 76|alkylphenol-ethoxylates
P03375184A0000|77 94|polyethoxyethanols
P03375184A0000|104 122|formula C9H19-C6H6-O
P03375184A0000|128 138|n-1 CH2CH2OH
P03377864A0000|80 91|Lorentz force
P03377864A0000|95 107|Maxwell stress
P03377891A0652|43 57|life stress group
P03377891A0652|103 115|severity index
P03377891A0652|121 139|Symptom Checklist-90
P03377891A0652|155 166|somatization
P03377891A0652|230 250|psychoticism subscales
P03378994T0000|7 20|administration
P03378994T0000|23 35|sodium cyanate
P03378994T0000|47 61|extraction ratio
P03379058A0188|0 19|Nucleotide sequencing
P03379058A0188|37 52|E1 alpha cDNA clone
P03379058A0188|88 99|reading frame
P03381039A0364|37 48|distribution
P03382310A0903|8 19|technetium Tc
P03382310A0903|72 86|polyarthralgias
P03382310A0903|132 150|management decisions
P03382772A0319|0 16|Practical interest
P03383897A0189|29 44|radiation therapy
P03383897A0189|85 96|leukopoiesis
P03384033A0155|77 88|otolith input
P03384272A0145|58 70|presentations
P03387665A0000|17 28|distribution
P03387665A0000|130 155|Glossina morsitans centralis
P03390074A0000|0 18|Electroglottography
P03395009A1750|48 62|cord compression
P03395009A1750|77 87|group-1 dogs
P03395009A1750|175 186|cord sections
P03395009A1750|258 269|intervention
P03395164A0000|35 45|compound WEB
P03395249A1044|48 60|proliferation
P03395249A1044|89 101|proliferation
P03396628A0207|9 25|observation period
P03398714A0594|47 59|peroxy radical
P03398714A0594|104 129|propagation transition state
P03398823A0459|24 37|administration
P03398823A0459|43 55|mg/kg p-xylene
P03400694A0245|18 29|Thallium-201
P03400694A0245|40 51|scintigraphy
P03400694A0245|98 109|dipyridamole
P03402183A0171|52 63|contractions
P03402183A0171|81 92|contractions
P03402183A0171|142 153|contractions
P03402183A0171|174 191|voltage stimulation
P03402183A0171|214 225|contractions
P03403313A0298|17 28|control rates
P03403313A0298|49 63|treatment groups
P03403313A0298|133 148|radiation therapy
P03403412A0000|123 134|grain content
P03403480A0299|58 70|configuration
P03403480A0299|76 92|femur middiaphysis
P03403480A0299|188 209|collagen concentrations
P03403826T0000|77 88|measurements
P03403826T0000|91 106|stenosis severity
P03403826T0000|167 179|cineangiogram
P03403826T0000|200 210|flow reserve
P03403826T0000|214 260|exercise/redistribution thallium-201 scintigraphy
P03404334T0000|0 11|Water content
P03404334T0000|15 39|equilibrium water partition
P03404495A0172|0 19|Thyroid function tests
P03406054A0351|9 26|line spread function
P03413681A0659|8 19|heart disease
P03417104A0536|34 49|chlorphentermine
P03417104A0536|77 91|stimulus effects
P03417588T0000|30 42|determination
P03417588T0000|45 57|citreoviridin
P03417668A1233|25 43|autophosphorylation
P03417668A1233|52 63|alpha subunit
P03417668A1233|73 83|beta subunit
P03417668A1233|112 123|CaM-kinase II
P03418727A0992|59 70|chemotherapy
P03420266A0000|28 39|hyperthermia
P03420266A0000|69 81|Dunning R3327G
P03420266A0000|91 104|adenocarcinoma
P03420266A0000|118 128|animal model
P03420324A0178|121 134|h/day beginning
P03420466A0000|14 30|cryptosporidiosis
P03421425A0878|32 45|hypothyroidism
P03421425A0878|70 83|determinations
P03423732A0341|57 69|HCO3 secretion
P03423732A0341|114 125|HCO3 response
P03427474A0853|14 24|control rats
P03427474A0853|70 83|concentrations
P03427474A0853|86 103|saccharin solutions
P03427613A0659|74 84|pineal organ
P03428084A0430|4 17|degrees stimuli
P03428084A0430|35 52|scalp distributions
P03428084A0430|59 77|pattern reversal P100
P03428084A0430|84 97|pattern onset C1
P03428274A0000|73 86|adenovirus type
P03428274A0000|91 104|DNA replication
P03428274A0000|125 142|nucleotide sequence
P03428274A0000|181 195|recognition site
P03429371A1051|14 33|cephalothin clearance
P03436119A0000|51 68|bone mineral content
P03436119A0000|93 107|reproducibility
P03436529A1066|78 98|oligodeoxynucleotides
P03436529A1066|131 141|nt positions
P03436877A0950|70 85|lung mass % delta Kf
P03436877A0950|176 188|relationships
P03436877A0950|209 227|blocker pretreatment
P03439248A0000|30 41|dipyridamole
P03439248A0000|45 64|exercise thallium-201
P03439248A0000|75 90|perfusion imaging
P03439248A0000|118 131|artery stenosis
P03439248A0000|177 189|artery disease
P03440780A0779|45 69|vasoconstrictor properties
P03440780A0779|98 119|calcium entry mechanisms
P03440780A0779|151 172|vasoconstrictor effects
P03441587A0000|112 123|erythrocytes
P03443144A0409|4 26|aspirin esterase activity
P03443566A0675|36 52|gain-to-feed ratio
P03443573A0329|7 19|least-squares
P03443573A0329|45 61|longissimus muscle
P03443609A0000|22 40|fluid chromatography
P03443609A0000|136 152|column methodology
P03446332A0831|0 12|Nitrofurazone
P03449358T0001|22 34|polyarteritis
P03450438A0446|10 24|Yates correction
P03451761A0215|6 18|baseline study
P03451761A0215|19 29|WPW syndrome
P03459736A0184|41 54|generalization
P03465957A1008|0 18|Mean fluorosis scores
P03466730A0210|9 20|dysfunctions
P03473253A0000|28 47|cohort mortality study
P03473253A0000|67 81|chemical workers
P03473253A0000|121 148|chloromethyl ether manufacture
P03473253A0000|157 169|U.S. companies
P03473379A0183|57 67|gland biopsy
P03476002A0148|7 18|blood samples
P03476002A0148|44 65|placebo supplementation
P03478354A0436|28 38|d postpartum
P03478354A0436|44 55|corpus luteum
P03478354A0436|64 83|prostaglandin F2 alpha
P03484075T0001|0 17|Emergency treatment
P03485064A0135|11 23|EVS treatments
P03486405A0341|31 50|precursor polypeptide
P03487348A0000|55 76|afterhyperpolarization
P03488532A0235|53 67|dermatomal signs
P03488532A0235|83 100|acyclovir treatment
P03491190A0233|3 15|detectability
P03491190A0233|73 85|stress studies
P03499608A1054|46 66|heterozygote detection
P03499608A1054|91 116|beta-hydroxylase deficiency
P03499657A0000|11 30|serum bone-Gla protein
P03499657A0000|35 58|serum alkaline phosphatase
P03499657A0000|72 101|hydroxyproline/creatinine ratio
P03499657A0000|102 120|uOH-Prol/creatinine
P03499657A0000|160 178|hyperparathyroidism
P03499657A0000|204 217|hypercalcaemia
P03499822A0182|20 37|regression analysis
P03499822A0182|51 64|seropositivity
P03504971A0000|11 22|Goodyear Tire
P03504971A0000|26 47|Rubber Company tradename
P03504971A0000|52 67|polyolefin rubber
P03504971A0000|97 112|% methylhexadiene
P03504971A0000|148 160|vulcanization
P03507689A0000|8 37|phage-plasmid expression vectors
P03507689A0000|57 72|pUC18/19 plasmids
P03507689A0000|129 143|bacteriophage f1
P03507689A0000|157 179|bacteriophage T7 promoter
P03507689A0000|189 210|beta-galactosidase gene
P03508698A0535|23 35|finger flexors
P03508698A0535|58 72|triceps reflexes
P03513989A0580|44 58|UROD-deficiency
P03513989A1149|69 87|porphyrin metabolism
P03513989A1149|134 145|pathogenesis
P03515840A0000|93 105|histiocytosis
P03515840A0000|155 168|generalization
P03516189A0406|23 35|suxamethonium
P03516189A0406|39 48|mg kg-1 i.v.
P03520729A0381|41 52|plasma levels
P03520729A0381|55 67|renin activity
P03520729A0381|71 94|aldosterone concentration
P03522105A1011|4 31|trough serum TOB concentrations
P03526279T0000|23 33|nursing R.N.
P03528748A0414|3 16|maxicell system
P03531317A0930|56 69|hypergeometric
P03534581A0976|70 83|5-fluorouracil
P03534581A0976|98 113|cyclophosphamide
P03534581A0976|133 144|control group
P03537686A0099|29 45|mutagenesis marker
P03537686A0099|49 70|supF suppressor tRNA gene
P03537686A0099|180 191|transfection
P03537721A0491|24 47|recombination experiments
P03537721A0491|84 96|chromosome XVI
P03537721A0876|10 21|observations
P03537721A0876|52 69|precursor molecules
P03537721A0876|85 105|PEP4 gene self-activate
P03537721A0876|115 126|yeast vacuole
P03540591A0330|64 76|P0 transcripts
P03540591A0330|149 160|reading frame
P03540853A0652|13 29|amino acid sequence
P03540853A0652|38 53|sequence homology
P03540853A0652|58 75|DNA binding proteins
P03542945T0000|0 12|Ciprofloxacin
P03543485A0069|62 79|space flight effects
P03543936A0000|78 94|ras oncogene family
P03544858A0374|101 115|HDL-cholesterol
P03545955A0751|3 14|glucose areas
P03545955A1378|3 22|serum insulin response
P03549045A0878|37 47|sinus arrest
P03550444T0000|14 24|yeast system
P03552363A0568|11 28|serum insulin levels
P03552363A0568|48 59|correlations
P03552363A0568|83 101|blood pressure levels
P03552363A0568|160 171|correlations
P03552363A0568|205 222|blood pressure level
P03553149A0299|81 92|cleavage site
P03553439A0404|42 52|tumor tissue
P03553439A0404|111 121|tumor tissue
P03555318T0000|3 14|pharmacology
P03556834T0000|5 22|inhalation toxicity
P03556834T0000|25 36|T-2 mycotoxin
P03559193A0000|10 22|investigation
P03559193A0000|66 79|Framingham Type
P03561622A0659|79 102|DiaTAP button graft complex
P03561622A0659|163 175|blood cultures
P03561622A0659|185 205|term vancomycin therapy
P03563399A0534|3 17|signal durations
P03563399A0534|47 60|S pi No threshold
P03563604A1075|58 69|parasite rate
P03563604A1075|83 98|drug intervention
P03567017A0000|119 134|drug accumulation
P03568311A0273|49 61|wedge pressure
P03568311A1361|24 45|pericardiocentesis data
P03568311A1361|61 75|stroke work index
P03570455A0433|24 35|hypocalcemia
P03572706A0329|18 32|interpretations
P03572706A0329|118 135|treatment condition
P03572706A0329|177 187|MMPI profile
P03575656A0120|25 36|chemical form
P03577670A0102|59 77|matter hypodensities
P03577670A0236|27 40|leukodystrophy
P03577670A0236|73 86|arylsulfatase A
P03581160A0583|18 36|heart rate reactivity
P03581160A0583|79 107|artery pulse amplitude responses
P03582149T0001|34 45|valve disease
P03582149T0001|84 97|school students
P03582149T0001|100 114|Jiangxi Province
P03582184A0448|61 76|dosage adjustment
P03583001A0111|39 50|gas injection
P03584426A0706|48 60|stool isolates
P03584426A0706|122 133|suckling mice
P03586925T0001|46 63|descriptor language
P03586925T0001|67 98|Roentgenology and Medical Radiology
P03586925T0001|110 124|Medinform system
P03590911T0001|45 60|light sensitivity
P03591464A0840a|36 50|disease activity
P03591464A0840a|67 92|calcium antagonist treatment
P03591464A0840b|36 50|disease activity
P03591464A0840b|67 92|calcium antagonist treatment
P03592297A0138|0 14|Dorsal foot TcpO2
P03592297A0138|61 79|surface temperatures
P03592297A0138|153 165|vasomotor tone
P03592297A0138|220 231|vasodilation
P03592297A0138|257 268|vasodilation
P03592297A0679|17 28|quadriplegia
P03592297A0679|103 119|vasodilation index
P03595418A0688|3 21|nucleotide sequences
P03595418A0688|41 67|ornithine decarboxylase mRNAs
P03597218A0901|11 24|concentrations
P03597218A0901|50 69|alpha 2-macroglobulin
P03597218A0901|73 84|antithrombin
P03597218A0901|133 146|concentrations
P03597218A0901|176 186|plasma water
P03600705T0000|19 33|oocyst excretion
P03600705T0000|41 57|cryptosporidiosis
P03601275A0601|5 20|dopamine infusion
P03601275A0601|81 91|state levels
P03601275A0601|94 107|plasma dopamine
P03601275A0601|108 121|norepinephrine
P03601275A0601|135 157|dopamine/norepinephrine
P03601533T0001|36 57|complement constituents
P03602261A0238|59 70|correlations
P03602261A0238|105 117|blood pressure
P03602261A0238|135 148|norepinephrine
P03602261A0238|197 208|correlations
P03602261A0238|243 256|norepinephrine
P03602261A0238|266 278|growth hormone
P03605895A0888|16 38|carboxyhemoglobin levels
P03605895A0888|69 91|carbon monoxide poisoning
P03607961T0001|27 38|zhuang qi gong
P03607961T0001|56 71|diabetes mellitus
P03608989A0668|50 61|interactions
P03608989A0668|93 109|filament formation
P03610663A0201|54 72|nutrient utilization
P03610674T0000|18 31|zinc deficiency
P03610674T0000|42 57|fiber zinc content
P03610674T0000|63 76|rat hippocampus
P03612648A0085|22 39|lupus anticoagulant
P03612648A0085|67 84|thromboplastin time
P03615550A0000|45 62|antagonist naloxone
P03615550A0000|97 120|fixed-consecutive-number
P03615763A0170|87 98|associations
P03615763A0170|140 154|atherosclerosis
P03615763A0170|186 197|hypertension
P03615763A0170|198 213|serum cholesterol
P03615763A0170|235 247|family history
P03615763A0170|250 261|heart disease
P03615763A0170|262 281|Type A behavior pattern
P03616237T0001|10 26|status epilepticus
P03618039A0126|52 64|noradrenaline
P03618039A0126|103 132|catecholamine biotransformation
P03622423A0000|48 64|Hartley guinea pigs
P03622423A0000|92 105|concentrations
P03622423A0000|136 151|methyl isocyanate
P03622571A0208|0 16|Radionuclide study
P03622571A0208|58 69|degeneration
P03625688A0372|0 13|Immobilization
P03625762A0308|202 223|behaviour problem rating
P03628532A0000|21 35|taste perception
P03628596A0000|70 92|acid alpha 1-glycoprotein
P03628713A0961|33 44|86RbCl uptake
P03628713A0961|47 57|36B-10 cells
P03628713A0961|85 97|Gy irradiation
P03628713A0961|117 129|radiation dose
P03628794A0648|61 81|I-131 MIBG scintigraphy
P03629974A1468|15 31|amino acid sequence
P03629974A1468|37 47|M RNA product
P03629974A1468|50 63|Uukuniemi virus
P03629974A1468|86 107|Rift Valley fever viruses
P03632739T0000|0 20|Cyclosporine treatment
P03632739T0000|35 46|polymyositis
P03637037T0000|13 27|teaching booklet
P03645733T0001|0 14|Hyperthyroidism
P03649340A1119|69 79|splice sites
P03649340A1119|89 101|exon sequences
P03649340A1119|136 150|splicing process
P03651840A0266|6 22|MAO inhibition data
P03651840A0266|102 116|tranylcypromine
P03652083A0720|21 38|vessel pyridinoline
P03653226A0833|21 44|tissue-distribution study
P03658866A0081|8 25|lupus erythematosus
P03659603A0797|77 90|CO2 sensitivity
P03659805A0404|14 25|significance
P03659805A0404|31 46|prognosis factors
P03659805A0404|125 135|IMB computer
P03659994A0150|90 104|signal intensity
P03659994A0150|143 157|signal intensity
P03664038A0000|58 86|Gudjonsson Suggestibility Scale
P03664038A0000|114 126|reliabilities
P03664038A0000|142 155|suggestibility
P03668003T0000|42 52|skin lesions
P03668396A0171|5 24|equilibrium solutions
P03668396A0171|72 87|convex polyhedron
P03668736A0177|25 35|X-ray counts
P03673640A0533|3 13|MAO subjects
P03673640A0533|44 59|KSP Impulsiveness
P03673640A0533|60 73|EPQ Neuroticism
P03673640A0533|97 108|Irritability
P03673640A0533|125 140|KSP Socialization
P03673640A0533|151 169|personality profiles
P03673640A0533|201 217|suicide attempters
P03673640A0533|238 256|platelet MAO activity
P03673881A0000|54 77|pulse repetition frequency
P03673881A0000|121 137|pressure gradients
P03673881A0000|138 156|Doppler examinations
P03673881A0000|217 228|valve disease
P03676054A0865|130 144|injector cannula
P03676174A0730|59 69|milk intakes
P03678269A0633|31 53|plasma cholesterol levels
P03678269A0633|83 94|modification
P03679407A0556|23 40|N-nitroso compounds
P03679407A0556|158 170|bladder cancer
P03679756A0830|10 26|nerve fiber defects
P03679756A0830|53 64|architecture
P03682805A0375|0 10|Serum levels
P03682805A0375|31 56|coagulation protein activity
P03682805A0375|102 116|skin lymph levels
P03685073A0200|22 34|physostigmine
P03685073A0200|37 65|acetylcholinesterase inhibitor
P03685073A0200|103 115|atropine doses
P03687313A0000|6 26|glucosidase inhibitors
P03690262A0428|3 18|maximum amplitude
P03691316A0560|17 30|contact allergy
P03693543A0405|35 52|Rhodococcus species
P03693543A0405|107 118|elution times
P03693543A0405|132 149|Nocardia asteroides
P03693543A0405|150 167|N. otitidiscaviarum
P03693543A0405|171 184|N. brasiliensis
P03694102A0000|70 88|ECG computer programs
P03696899T0001|0 28|Blood serum erythropoietin level
P03697587T0000|2 23|XXXXY chromosome anomaly
P03697798T0001|46 61|stretch receptors
P03697971A0311|3 15|selenium level
P03697971A0311|19 47|glutathione peroxidase activity
P03697971A0311|66 78|stomach mucosa
P03698251T0000|0 13|Oxygen delivery
P03700952A0273|90 106|laboratory setting
P03703493A0654|67 93|RPE-choriocapillaris complex
P03704087A0394|103 133|State-Trait Personality Inventory
P03704087A0394|137 156|Anger Expression Scale
P03704087A0394|163 185|State Anger Reaction Scale
P03709191A0125|93 107|side differences
P03709627A0247|37 53|acetaminophen i.v.
P03709627A0247|57 70|concentrations
P03710973A0817|12 26|skin temperature
P03710973A0817|125 142|Tre-to-Tsk gradient
P03712050T0000|0 25|Indium-111 leukocyte imaging
P03712106A0000|11 37|L-methionine supplementation
P03712106A0000|57 73|soy protein isolate
P03712106A0000|101 122|nitrogen balance studies
P03712153T0000|15 47|Haemophilus influenzae type b disease
P03712153T0000|77 87|risk factors
P03713187A0691|33 45|lamina propria
P03714348A0833|84 96|CIC population
P03714348A0833|135 156|peak expiratory flow rate
P03717475A0208|35 51|immunodiagnostics
P03717475A0208|52 64|immunotherapy
P03717475A0208|68 84|immunoprophylaxis
P03717936A0252|54 67|aminoglycoside
P03720966A1043|16 30|acid N absorption
P03721594A0000|8 19|phagocytosis
P03721594A0000|93 110|exudate neutrophils
P03721594A0000|125 139|fibrinogen level
P03721594A0000|172 199|dilution protamine sulfate test
P03721594A0000|268 287|Shwartzman phenomenon
P03721666A0000|36 52|contact dermatitis
P03722016A0797|43 54|meal interval
P03732252A0556|132 147|m race performance
P03733563A0716|12 33|herd X period interaction
P03733563A0716|54 65|serum dextran
P03733563A0716|78 102|cholesterol concentrations
P03733563A0820|10 32|serum NEFA concentrations
P03734641A0203|100 111|biomechanics
P03736081A0465|15 27|sinus pressure
P03736081A0465|308 318|% saturation
P03738919A0000|0 13|Calcifications
P03744168T0001|76 99|methano-1H-4-benz azonine
P03745833A0258|134 145|arborization
P03746053A0670|123 134|dorsal column
P03746601A0299|25 37|extravasation
P03746896A0890|107 120|susceptibility
P03746896A0890|143 155|Type A behavior
P03746906A0000|44 71|student Jenkins Activity Survey
P03746906A0000|76 95|questionnaire measure
P03746906A0000|98 110|Type A behavior
P03749226A0506|4 16|phencyclidine
P03749226A0506|44 55|response rate
P03750700T0001|0 12|Possibilities
P03750700T0001|36 49|endoprosthesis
P03751308T0001|10 25|energy metabolism
P03751308T0001|31 46|sensomotor cortex
P03751308T0001|68 87|2-deoxyglucose method
P03755623A1233|7 20|investigations
P03758250A0000|106 116|EMG activity
P03759330A0713|100 113|trunk adiposity
P03761122T0000|19 31|type A behavior
P03763836T0001|9 23|electron therapy
P03765552A0582|95 112|Fc receptor blockade
P03765552A0582|141 157|antibody synthesis
P03765731A0918|46 62|angina pectoris und
P03768208A0879|58 75|bone formation rates
P03769224A0000|40 57|Lupus Erythematosus
P03770143A1209|65 78|fibre structure
P03771670T0058|13 32|heparin-antithrombin
P03771703A0000|13 36|trimethylsilylcarbamates
P03771749A0465|26 41|5-fluorocytosine
P03771749A0465|52 63|ketoconazole
P03771749A0465|67 79|amphotericin B
P03771749A0465|110 123|Candida species
P03771749A0465|157 168|agar dilution
P03771749A0465|172 201|microtiter broth dilution systems
P03772471A1054|44 54|tumor biopsy
P03776080A0400|15 36|post-mortem examination
P03776080A0400|110 120|CWE antigens
P03776438A0000|0 13|Glucocorticoid
P03776438A0000|21 32|hypertension
P03776438A0000|83 99|mineralocorticoid
P03776438A0000|107 118|hypertension
P03777398A0156|30 40|therapy unit
P03779182A0370|10 20|drug problem
P03779205A0459|80 91|presentation
P03780371A0792|55 77|cytochrome P-450PBc2 gene
P03780704A0573|16 27|serum ketones
P03783160A0285|17 29|21-O-angeloyl
P03783160A0285|42 54|R1-barrigenol
P03783160A0285|57 68|21-O-tigloyl
P03783160A0285|82 94|R1-barrigenol
P03785212A0091|15 40|hamster S14 protein sequences
P03785212A1128|0 11|RPS14 introns
P03785212A1128|28 39|Alu sequences
P03788231A0802|94 105|implantation
P03789052A0527|13 26|tissue response
P03789052A0527|40 56|cyanoacrylate site
P03789052A0527|117 130|tissue adhesive
P03791645A1124|35 46|relationship
P03791645A1124|57 68|pathogenesis
P03795488A0487|80 91|response rate
P03799323A0501|25 38|flow conditions
P03799323A0501|48 71|oxygen saturation decrease
P03799323A0501|100 110|sickle cells
P03799790A0146|55 68|ophthalmoscopy
P03799790A0146|72 82|point source
P03802195A0481|5 18|fusion proteins
P03802195A0481|33 44|localization
P03802195A0481|78 94|DNA binding domains
P03802195A0481|100 110|ToxR protein
P03805090A0645|75 88|chondrosarcoma
P03805090A0645|171 182|degeneration
P03805090A0645|218 233|Maffucci syndrome
P03806696A0000|50 64|mercury chloride
P03806696A0000|87 99|Japanese quail
P03806696A0000|100 115|Coturnix japonica
P03810361A0576|29 52|plasma cortisol estimation
P03810361A0576|94 117|plasma cortisol estimation
P03810867A0305|82 98|Lederman-Gadeberg
P03810867A0305|99 110|Sisson-Jesse
P03811852A0109|15 27|complications
P03811852A0109|93 108|magnesium sulfate
P03811852A0109|145 166|adrenocortico-steroids
P03814493T0000|0 11|Chlorambucil
P03818467A0180|24 38|supplementation
P03818467A0180|65 80|plasma tocopherol
P03818467A0180|84 99|Se concentrations
P03818467A0180|117 143|plasma glutathione peroxidase
P03818866A0116|0 13|Framingham Type
P03818866A0116|59 71|blood pressure
P03824908A0116|3 15|M reading frame
P03824908A0116|102 130|arginine amino acid substitution
P03824908A0116|138 153|carboxy-terminus
P03824908A0116|182 196|paramyxoviruses
P03828500T0001|0 14|Intensification
P03828500T0001|32 50|contractile activity
P03829848T0001|0 18|Autotransplantation
P03829848T0001|22 32|vein segment
P03829848T0001|74 86|insufficiency
P03830147A0000|3 15|relationships
P03830147A0000|38 52|lactate increase
P03830147A0000|53 68|lactate threshold
P03830147A0000|84 108|blood lactate concentration
P03830147A0000|164 175|exercise test
P03830147A0000|192 203|blood lactate
P03830147A0000|252 276|blood lactate concentration
P03830147A0000|307 330|blood lactate accumulation
P03830147A0000|348 359|blood lactate
P03830147A0000|368 380|concentration
P03830255A0074|55 66|distribution
P03835413A0616|32 43|irradiations
P03835413A0616|51 62|space flights
P03835413A0616|70 81|difficulties
P03835413A0616|128 147|duration space flights
P03836777T0001|0 11|Practical use
P03836777T0001|15 28|interpretation
P03836777T0001|36 52|hepatitis B markers
P03836777T0001|71 83|HBs Ag carriers
P03836777T0001|99 112|hepatitis stage
P03836853A0204|10 26|year survival rates
P03837609T0000|64 76|mononucleosis
P03838797A0903|0 15|Northern blotting
P03838797A0903|33 47|oligonucleotide
P03838797A0903|110 120|cDNA library
P03840480T0000|46 61|peptide sequences
P03841627T0001|0 11|Chemotherapy
P03841627T0001|27 38|breast cancer
P03843496A0919|130 143|extrapolations
P03843496A0919|152 165|risk assessment
P03843676A0381|6 18|extrapolation
P03848527T0020|0 11|Hisako Minowa
P03857577A0413|0 21|Deletion mapping studies
P03857577A0413|45 56|DNA sequences
P03857577A0413|96 113|level transcription
P03857577A0413|149 161|transcription
P03860162A0000|0 12|Incorporation
P03860162A0000|35 47|amphotericin B
P03860162A0000|89 100|drug toxicity
P03861687A0000|168 184|system stimulation
P03862898A0563|11 27|IgE concentrations
P03862898A0563|60 73|tumor E2R status
P03862898A0563|109 126|risk classification
P03863561A0405|18 28|mutans group
P03863561A0405|88 99|mutans/Strep
P03865743A0859|51 63|apo A-I/B ratio
P03865743A0859|67 80|apo A-II/B ratio
P03865743A0859|94 104|risk factors
P03865743A0859|118 129|heart disease
P03866085A0795|26 47|suppository formulation
P03869442A0223|16 27|hypertension
P03869442A0223|57 69|abnormalities
P03869442A0223|82 93|hypertension
P03869442A0223|128 145|vasopressin therapy
P03871298A0217|6 19|photon emission
P03871298A0217|75 88|representation
P03871298A0217|131 142|localization
P03871445T0000|55 79|positron emission tomograms
P03873141A0304|4 19|patients vagotomy
P03873141A0304|95 107|mortality rate
P03874921A0862|0 12|Documentation
P03874921A0862|38 50|fertilization
P03875231A0627|35 47|abnormalities
P03875231A0627|95 109|differentiation
P03875231A0627|185 197|abnormalities
P03877298A0718|59 78|Cremophor formulation
P03877298A0718|119 131|recovery times
P03877298A0718|147 165|emulsion formulation
P03878585A0507|3 24|percentage RFR reduction
P03878585A0507|71 81|CPB duration
P03878585A0507|89 107|oxygen flow rate index
P03878585A0507|129 150|bubble oxygenator/m2 bsa
P03878585A0507|161 178|blood flow rate index
P03878585A0507|233 256|machine/min CPB time/m2 bsa
P03880838T0000|26 38|artery lesions
P03880838T0000|44 66|captopril administration
P03881260A0000|1 16|yeast DNA fragment
P03881260A0000|64 107|arginine pathway carbamoyl-phosphate synthetase
P03882029A0000|60 75|granuloma complex
P03882029A0000|148 160|cat epithelium
P03883052T0001|10 27|Magdelaine Comtesse
P03883541A0200|3 23|H2 receptor antagonists
P03883541A0200|27 40|sucralfate cost
P03887085A0000|49 63|pharmaceuticals
P03887769A0093|19 33|micrograms J/g Cr
P03887769A0093|45 59|micrograms J/g Cr
P03887769A0584|54 69|iodine deficiency
P03887769A0584|88 103|iodine deficiency
P03888621A0185|39 52|protein product
P03890486A0000|19 38|lymph node enlargement
P03890486A0000|72 87|imaging confusion
P03891766A1473|0 11|Interference
P03891766A1473|93 107|latex adsorbents
P03894482A0549|30 47|serum IgE antibodies
P03894482A0549|58 71|soybean extract
P03894482A0549|72 84|binding values
P03894482A0549|124 135|control serum
P03896991T0000|0 12|New techniques
P03896991T0000|19 34|mass spectrometry
P03898382A0000|16 33|subtraction imaging
P03898382A0000|50 60|67Ga citrate
P03898382A0000|137 154|radiogallium survey
P03898382A0000|172 184|sulfur colloid
P03904004A1577|34 56|medium energy collimation
P03904004A1577|83 98|keV 123I photopeak
P03904004A1577|123 141|breakthrough signals
P03904004A1577|157 170|Compton scatter
P03904004A1577|177 189|energy photons
P03904952T0000|0 15|Nursing education
P03904952T0000|19 36|computer obligation
P03908196T0000|0 16|Shear bond strength
P03908196T0000|44 55|glass ionomer
P03908493A0246|53 77|immunoperoxidase technique
P03910310A0666|26 38|understanding
P03911052A0909|43 53|CABG surgery
P03911052A0909|102 112|CABG surgery
P03911702A0530|74 94|microembolism syndrome
P03911965A0513|21 32|significance
P03911965A0513|100 110|Galphimia D6
P03911965A0513|119 135|Galphimia dilution
P03912247A0282|45 65|collateral circulation
P03913522A0000|28 41|function change
P03915540A0863|13 28|gcd1-101 mutation
P03915540A0863|70 82|GCN4-lacZ mRNA
P03920700A0491|46 59|responsiveness
P03920700A0491|93 105|adrenoceptors
P03921727A0523|3 16|concentrations
P03922116A0197|3 14|distribution
P03922116A0197|50 62|gamma-therapy
P03922116A0197|83 95|gamma-therapy
P03922116A0197|105 119|lymphadenectomy
P03922116A0197|143 160|radiation treatment
P03922116A0197|198 216|luc type installation
P03922116A0197|220 239|iliac lymphadenectomy
P03923828A1031|3 14|availability
P03923828A1031|17 31|cryoprecipitate
P03923976T0001|0 15|Thrombophlebitis
P03923976T0001|48 66|factor XII deficiency
P03925712A0229|43 56|enzyme activity
P03925712A0229|59 70|deficiencies
P03925712A0229|73 91|transport mechanisms
P03928357A0340|0 18|Laboratory pyrolyses
P03928357A0340|73 86|chlorobenzenes
P03928442A0463|121 143|modification specificity
P03929486A0309|55 65|sinus rhythm
P03929486A0309|85 100|ejection fraction
P03930549A0209|32 45|centrifugation
P03930549A0209|121 136|gas chromatograph
P03930894T0000|19 40|acetylcholine receptors
P03930894T0000|93 106|administration
P03931293A0437|65 80|thermoresistance
P03933232T0000|61 76|animal morphology
P03933784A0420|26 37|CSF prolactin
P03934667A0124|16 28|crsA mutations
P03934667A0124|68 81|gene conversion
P03934667A0124|91 113|B. subtilis plasmid pRPD11
P03934667A0124|196 218|B. subtilis RNA polymerase
P03935117T0000|34 64|prostaglandin E2 pharmacokinetics
P03935375A0414|70 81|biochemistry
P03935375A0414|191 202|degeneration
P03935797A0183|58 73|sry messenger RNAs
P03936828T0000|33 46|B-cell lymphoma
P03936828T0000|52 63|thyroid gland
P03937294A0404|0 19|Plasma secretin levels
P03937294A0404|41 54|administration
P03937294A0404|57 72|ethanol solutions
P03937294A0404|112 124|acid secretion
P03937481T0001|18 30|microanalysis
P03937481T0001|78 89|preparations
P03939317A0352|76 97|soybean HS-protein genes
P03940426A0618|174 192|genus identification
P03940426A0618|210 220|agar culture
P03940733A0755|113 125|malabsorption
P03944212A0166|0 13|Tissue pressure
P03944212A0166|21 32|water content
P03944212A0166|102 113|MCA territory
P03944239A0780|48 74|plasma thyroid hormone changes
P03944239A0780|89 105|amiodarone therapy
P03946125T0000|7 26|nutrient interactions
P03952387A0336|81 93|oxyhemoglobin
P03953361A0000|79 96|serial measurements
P03953361A0000|109 122|creatine kinase
P03953361A0000|165 178|concentrations
P03956647A1063|20 39|%Ir microelectrode tip
P03956647A1063|52 77|scanning electron microscopy
P03956647A1063|80 94|charge densities
P03956647A1063|105 117|microC/cm2 X ph
P03956647A1063|149 170|iridium microelectrodes
P03956647A1063|224 236|microC/cm2 X ph
P03956695A0617|0 16|Cortisol excretion
P03959045A0000|15 26|relationship
P03959045A0000|51 64|coaching course
P03959045A0000|84 110|Medical College Admission Test
P03965012A0163|97 109|heart diseases
P03965012A0163|143 157|reference cohort
P03965012A0163|160 175|paper mill workers
P03966687A0000|20 34|childhood asthma
P03967144T0001|0 12|Hypersplenism
P03970191A0275|52 69|electrocorticogram
P03972038A0000|16 27|trajectories
P03972038A0000|33 49|commissural fibers
P03972185A0137|38 54|insulin deficiency
P03972185A0137|55 66|plasma levels
P03972185A0137|91 103|hyperglycemia
P03972185A0137|118 136|plasma glucose levels
P03974790A0053|41 52|brain infarct
P03976323A0821|30 48|blood pressure change
P03977577T0000|0 21|Shoulder forearm support
P03977603A0326|68 79|indomethacin
P03978045A0857|94 108|hyperreactivity
P03978132A0108|2 14|MCCP functions
P03978132A0108|20 33|source emission
P03978132A0108|34 50|surface reflection
P03978132A0108|51 74|photoacceptor sensitivity
P03978132A0108|101 118|distribution curves
P03980386A0000|61 72|distribution
P03980386A0000|104 116|perfusion lung
P03981952T0000|39 55|chloride titrators
P03982288T0000|0 13|Doctor Berglund
P03982288T0000|28 40|union pitfalls
P03984683A0000|81 94|stroke patients
P03985849A0221|14 27|rhinosinusitis
P03985849A0221|85 98|rhinosinusitis
P03985849A0221|194 206|IgA deficiency
P03987818A0440|63 74|heart failure
P03987857A0733|28 38|floor region
P03988001A0227|21 44|rat blood chloroform levels
P03989827T0000|14 30|lactase phenotypes
P03989827T0000|33 46|Aymara children
P03992022A0330|83 98|TMO N-demethylase
P03992022A0330|102 127|aniline hydroxylase activity
P03992022A0330|143 154|pretreatment
P03992022A0330|220 235|enzyme activities
P03995513T0000|36 51|cyclophosphamide
P03995513T0000|92 105|leiomyosarcoma
P03997467A0000|20 37|antagonist naloxone
P03998071T0000|0 23|Electrochemical detection
P03998071T0000|65 76|osteoporosis
P03998813A0406|104 118|frequency tuning
P03999219A0463|0 13|Ultrastructure
P03999219A0463|85 98|alum irrigation
P03999219A0463|179 192|alum irrigation
P04001413A0093|92 105|breath-holding
P04001490T0001|3 15|POEMS syndrome
P04001490T0001|16 29|Polyneuropathy
P04001490T0001|30 41|Organomegaly
P04001490T0001|42 55|Endocrinopathy
P04002131A0506|7 22|disease remission
P04002131A0506|43 54|GAG secretion
P04002131A0506|74 89|hyperheparinuria
P04002667A0181|55 68|tumor diameters
P04002667A0181|94 105|localization
P04002667A0181|147 160|lung parenchyma
P04004168A0000|38 71|triosephosphate isomerase deficiency
P04004168A0000|183 204|motor neuron involvement
P04011338A0620|90 101|relationship
P04013576A0981|10 22|investigation
P04013576A0981|41 52|distribution
P04013576A0981|74 96|Leptospira phospholipids
P04013576A0981|113 124|distribution
P04013576A0981|194 204|carbon atoms
P04013576A0981|222 234|phospholipids
P04013604A0412|75 87|patient-years
P04013604A0412|90 110|slow-release tablet use
P04014833A0400|0 13|Hydrocortisone
P04014833A0400|77 92|blood lymphocytes
P04014833A0400|95 112|phytohemagglutinin
P04014833A0400|116 127|concanavalin
P04014861A0000|104 122|superoxide dismutase
P04014861A0000|147 160|oxygen toxicity
P04015988T0000|0 17|Marrow cell necrosis
P04015988T0000|20 34|anorexia nervosa
P04018444A0000|59 79|cholesterol gallstones
P04019066A0000|13 27|field potentials
P04021281T0001|0 13|Ultrastructure
P04021281T0001|19 29|heart muscle
P04021305A0530|15 30|desympathization
P04021305A0530|54 69|hyper-reactivity
P04021305A0530|91 103|noradrenaline
P04021305A0530|186 199|catecholamines
P04021431A0000|51 61|pulse curves
P04021431A0000|74 86|determination
P04021431A0000|89 102|blood pressures
P04021431A0000|160 173|blood pressures
P04021437A0000|71 85|ear dysfunctions
P04025178A0126|95 105|volume index
P04026903A0512|41 54|relaxant effect
P04026903A0512|63 76|guinea pig ileum
P04026903A0512|111 122|contractions
P04026903A0512|132 144|acetylcholine
P04026903A0512|160 178|5-hydroxytryptamine
P04026972T0000|10 32|alcohol reaction profiles
P04027182T0000|10 25|diabetes mellitus
P04028871A0133|3 18|pharmacokinetics
P04028871A0133|25 36|tetracycline
P04028871A0133|60 71|blister fluid
P04028871A0133|105 117|mg lymecycline
P04028871A0133|123 135|mg doxycycline
P04031488A1091|58 74|brain localization
P04032268A0358|84 97|Ag/AgCl/3 M NaCl
P04032349A0000|42 56|graft thromboses
P04032349A0000|140 152|units/kg/hour
P04032349A0000|156 169|Lys Plasminogen
P04032716A0299|3 20|mean transfer ratios
P04032716A0299|56 68|concentration
P04032716A0299|109 121|transfer ratio
P04033402A1112|38 66|HDL-cholesterol concentrations
P04033402A1112|73 99|HDL2-cholesterol subfraction
P04033402A1112|126 151|triglyceride lipase activity
P04034220A0205|81 92|H. influenzae
P04034220A0205|112 128|tolerance Cefaclor
P04034220A0205|165 179|tract infections
P04034666T0000|5 26|extremity weight bearing
P04034666T0000|39 56|standing conditions
P04036838A0918|60 73|pressure ratios
P04036838A0918|123 141|pressure differences
P04037809A0964|23 35|dose schedules
P04038454A0984|21 38|plasma retinol level
P04038454A0984|96 109|micrograms dl-1
P04038454A0984|137 152|cancer recurrence
P04038454A0984|199 212|micrograms dl-1
P04038702A0768|266 287|cortisol concentrations
P04039109A0139|44 54|fluid medium
P04039109A0139|119 130|power density
P04039307A0613|6 17|progesterone
P04039307A0613|74 88|treatment groups
P04039439A0000|45 56|ppm manganese
P04039439A0000|72 85|manganese oxide
P04039439A0842|67 79|Mn3O4 exposure
P04039525A0475|9 36|bladder platinum concentration
P04039525A0475|139 152|blood chemistry
P04039667T0000|13 25|visualisation
P04039667T0000|28 46|Walker carcinoma-256
P04039667T0000|49 66|Sprague-Dawley rats
P04039744A0141|97 113|i.u. vitamin D3/day
P04040339T0001|0 16|Monitoring changes
P04041307A0614|24 40|calcium antagonist
P04048245A0331|13 29|oxyphenylbutazone
P04048245A0331|33 46|hydrocortisone
P04048245A0331|71 84|serum CPN levels
P04050771A0474|18 29|hazards model
P04050821A0531|66 77|oxygen demand
P04051521T0001|36 49|cancer patients
P04052919A0205|19 39|progesterone secretion
P04052919A0205|69 79|luteal phase
P04052919A0205|163 180|progesterone levels
P04052919A0205|262 273|progesterone
P04055593A0523|43 53|flow signals
P04055593A0523|80 91|compensation
P04055593A0523|130 143|gas composition
P04056256A0416|0 18|Histamine reactivity
P04056256A0416|50 66|nifedipine aerosol
P04056256A0416|94 106|concentration
P04056256A0416|131 147|airway conductance
P04058985A0000|83 97|plasma prolactin
P04061342A0512|61 75|min postexercise
P04062128T0028|0 17|National Institutes
P04062128T0028|20 64|Health Consensus Development Conference Statement
P04066194A0163|0 17|Greater attenuation
P04066194A0163|31 50|baseline-P2 amplitude
P04066194A0163|82 94|probe stimulus
P04066194A0163|180 201|stimulation arrangement
P04066274A0265|74 86|parotidectomy
P04067540A0413|48 59|perpetrators
P04067540A0413|192 202|suicide note
P04068663A0452|21 34|mouse CRF-flora
P04068663A0452|106 118|unsuitability
P04068663A0452|121 133|mouse CRF flora
P04068774A1292|7 19|relationships
P04069756T0025|30 48|leukoencephalopathy
P04070725A0442|0 12|Component P100
P04071063A0863|45 58|platelet counts
P04071063A0863|78 93|fibrinogen levels
P04073848T0000|9 29|stapedius reflexometry
P04073848T0000|46 61|myasthenia gravis
P04074214A0000|18 37|semen characteristics
P04075021T0000|2 20|beta-phenethylamine
P04075021T0000|24 35|distribution
P04075021T0000|41 54|administration
P04075021T0000|91 116|monoamine oxidase inhibitors
P04082592T0000|0 15|Blood eosinophils
P04084607A0663|3 13|imino proton
P04084607A0663|102 117|modification site
P04084607A0663|167 178|imino protons
P04084607A0663|181 201|Watson-Crick base pairs
P04084896A0569|3 16|recommendation
P04084896A0569|99 120|intervention strategies
P04085589A0264a|28 41|secretor status
P04085589A0264a|59 80|spirometry measurements
P04085589A0264a|92 110|serum lysozyme levels
P04085589A0264a|131 147|tract colonization
P04085589A0264b|28 41|secretor status
P04085589A0264b|59 80|spirometry measurements
P04085589A0264b|92 110|serum lysozyme levels
P04085589A0264b|131 147|tract colonization
P04086403A1016|32 45|feed conversion
P04086403A1016|108 121|feed conversion
P04088233A0309|3 13|transit time
P04088396A0145|8 26|patients grades 1-2-3
P04088733T0001|10 23|acid hydrolases
P04088733T0001|36 50|blood leukocytes
P04088936T0001|23 34|antithrombin
P04088936T0001|46 73|plasminogen activator activity
P04088936T0001|88 103|thrombophlebitis
P04093211A0560|63 74|orientations
P04113011T0000|3 17|desensitization
P04113011T0000|21 35|ragweed hay fever
P04114211T0000|16 29|sulphadimidine
P04115870T0000|46 63|Urat-I lithotriptor
P04123217T0000|20 33|chlamydospores
P04123217T0000|36 56|Cryptococcus laurentii
P04123662T0000|12 26|thyroid function
P04138224T0095|12 25|tissue emulsion
P04138224T0095|48 61|gamma-globulin
P04138224T0095|67 80|blood clearance
P04139943T0001|0 12|Demonstration
P04139943T0001|33 46|guinea pig organ
P04139943T0001|78 91|silver staining
P04140567T0001|0 18|Histamine metabolism
P04143528A0394|26 37|nomenclature
P04152725T0001|18 28|liver injury
P04164669T0000|24 37|kinin formation
P04172166T0000|0 12|Poliomyelitis
P04176268T0000|0 13|Aluminium resin
P04176268T0000|34 45|hyperkalamia
P04176625T0000|30 43|cardiomyopathy
P04189158T0000|20 34|Rh sensitization
P04194466T0000|0 14|Serotonin levels
P04194466T0000|17 36|infant hypothyroidism
P04196986T0000|13 28|fluid transferrin
P04213917T0001|13 27|D-penicillamine
P04214345T0000|22 42|serum IgG concentration
P04214345T0000|56 71|xylose absorption
P04214345T0000|74 93|Zambian African adults
P04226360T0001|11 26|platelet function
P04239041T0045|11 25|anticonvulsants
P04246054T0028|30 59|rabbit-anti-lymphocyte globulin
P04246054T0028|104 124|incubation temperature
P04247966T0000|25 46|protein maintenance diet
P04262268T0001|32 42|ear ossicles
P04281856T0001|6 17|sex structure
P04281856T0001|42 65|Ornithodoros tatarovski Ol
P04282315T0001|0 12|Sensitization
P04282315T0001|15 29|hyperlactatemia
P04284435T0000|12 28|calcium absorption
P04291759T0048|0 16|Laboratory aspects
P04291759T0048|42 53|chemotherapy
P04308979T0000|20 31|time interval
P04308979T0000|70 82|translocation
P04311951T0001|61 73|instillations
P04321861T0001|8 37|glutathione reductase deficiency
P04321861T0001|51 70|glutathione synthesis
P04323641T0000|9 26|swine enteroviruses
P04325736T0001|0 12|Serodiagnosis
P04325736T0001|27 40|laboratory mice
P04328746T0073|0 15|Ultrasound effect
P04328746T0073|21 45|cytochrome oxidase activity
P04335965T0000|12 25|colon carcinoma
P04350410T0000|34 47|administration
P04364369T0000|0 20|Pre-beta-1 lipoprotein
P04364369T0000|40 50|risk factors
P04364369T0000|62 73|heart disease
P04371279T0000|9 24|action potentials
P04371279T0000|35 46|muscle fibres
P04371279T0000|58 71|botulinum toxin
P04377003A0000|48 67|polyamines putrescine
P04392584T0000|34 50|hemisphere monkeys
P04407649T0000|12 24|arachnoid cyst
P04407649T0000|63 84|99mTc brainscintigraphy
P04418687T0000|20 34|glucocorticoids
P04423347T0001|9 28|ceruloplasmin content
P04428800T0001|42 52|GPT activity
P04428981T0000|10 26|calcium metabolism
P04437406T0000|36 56|reflection coefficient
P04446923T0001|8 22|characteristics
P04446923T0001|26 39|verticillation
P04446923T0001|42 61|Platynothrus peltifer
P04460692T0000|16 39|laboratory animal medicine
P04468264T0053|29 42|anesthesiology
P04482661T0001|17 27|nursing care
P04482661T0001|42 55|decubitus ulcer
P04482661T0001|79 92|buckwheat chaff
P04487920T0001|7 33|Icelandic Red Cross activities
P04488271T0001|23 38|diabetes mellitus
P04495034T0000|12 24|methylbenzene
P04495034T0000|47 65|Ancylostomum caninum
P04506738T0000|31 41|enamel organ
P04510102T0000|0 17|Electrocardiograms
P04511139T0001|12 31|restoration materials
P04515631T0000|19 30|antithrombin
P04515631T0000|49 61|liver function
P04518624T0000|0 20|Glutathione peroxidase
P04524081T0000|53 77|aluminum chloride solutions
P04524081T0000|80 106|tissue displacement materials
P04536964T0000|26 52|H ion permeability coefficient
P04536964T0000|55 71|bullfrog toe muscle
P04544430T0001|67 78|heart defects
P04546974T0000|42 57|bundle recordings
P04547933T0000|13 27|fibril formation
P04548483T0001|0 13|Blood platelets
P04548483T0001|14 31|coagulation factors
P04548483T0001|46 57|organ changes
P04548483T0001|82 94|rhesus monkeys
P04551650T0001|0 12|Cell viability
P04562038T0001|7 19|investigation
P04563045T0000|6 18|2-chloroethyl
P04563045T0000|42 53|nitrosoureas
P04563045T0000|56 70|cancer treatment
P04578686T0000|0 11|Pneumothorax
P04578686T0000|21 31|lung abscess
P04578686T0000|42 58|transplant patient
P04579436T0000|24 36|colour changes
P04579436T0000|39 58|Brevibacterium linens
P04580044T0047|8 20|relationships
P04580044T0047|27 42|development phase
P04598670T0000|5 20|graft irradiation
P04598670T0000|47 63|immunosuppression
P04613073T0001|21 33|manifestation
P04613073T0001|36 52|Shigella virulence
P04615525T0001|42 56|transplantation
P04615828T0001|14 36|colonel prof. e.cerny m.d.
P04621188T0000|12 25|bacteriophages
P04621188T0000|28 44|Klebsiella bacilli
P04622430T0000|43 54|Rhesus monkey
P04624863T0001|11 23|immunogenesis
P04627477T0001|0 16|Resistance pattern
P04627477T0001|19 43|Mycobacterium tuberculosis
P04632967T0000|42 52|patas monkey
P04632967T0000|67 80|administration
P04632967T0000|83 98|aminorex fumarate
P04645078T0001|26 36|cervix uteri
P04653144T0000|0 14|General formulae
P04653144T0000|28 39|heritability
P04656185T0000|0 23|Glucose disappearance rate
P04656185T0000|36 50|plasma nutrients
P04676734T0000|3 14|relationship
P04676734T0000|48 59|plasma levels
P04676734T0000|62 76|corticosteroids
P04679807T0000|8 24|acid concentration
P04679807T0000|39 57|breathalyzer ampules
P04704186T0000|0 12|Range behavior
P04712626T0000|0 19|Chemical constituents
P04712626T0000|25 37|gentianaceae V
P04712626T0000|64 86|Swertia chirata Buch.-Ham
P04718233T0000|0 24|Methyl mercury intoxication
P04727344T0000|0 17|Microdetermination
P04727344T0000|50 62|isotope method
P04730467T0000|49 64|enzyme activities
P04730467T0000|67 85|epiphyseal cartilage
P04733391T0000|0 25|Metal coordination compounds
P04733391T0000|28 40|thiabendazole
P04746559T0053|12 29|renin secretion rate
P04746559T0053|70 84|vein renin levels
P04752455T0000|0 18|Disability insurance
P04757217T0000|9 21|lipoprotein-X
P04757217T0000|48 61|LCAT deficiency
P04758799T0000|0 11|Pneumothorax
P04758799T0000|32 47|steroid treatment
P04759722T0000|0 16|Polycythemia-1973
P04760826T0000|17 32|Vietnam returnees
P04760826T0000|36 49|undergraduates
P04764049T0001|16 31|nephronophthisis
P04766888T0000|5 18|heparin therapy
P04766888T0000|40 54|meningococcemia
P04778129T0000|0 16|9,11-Seco steroids
P04778129T0000|28 49|estradiol 3-methyl ether
P04782788T0001|13 24|examinations
P04782788T0001|46 64|kidney insufficiency
P04784432T0001|0 12|Possibilities
P04784432T0001|25 38|administration
P04787716T0000|0 11|Observations
P04787716T0000|17 32|flight activities
P04787716T0000|35 54|Chrysops caecutiens L.
P04789916T0001|10 23|clearance curve
P04789916T0001|30 41|bengal-I-131
P04796997T0000|6 17|reproduction
P04796997T0000|45 70|medroxyprogesterone acetate
P04810131T0000|6 31|Aryl hydrocarbon hydroxylase
P04813394T0000|12 30|1,10-phenanthroline
P04813394T0000|50 67|acid determinations
P04824747T0000|0 16|Nonteratogenicity
P04837183T0000|0 11|Observations
P04837183T0000|46 57|hypergravity
P04839176T0001|36 57|blood coagulation system
P04843031T0000|11 39|galactosyltransferase activity
P04852635T0000|17 42|appetite stimulant pizotifen
P04852635T0000|65 85|isonicotinylhydrazine
P04863895T0000|0 11|Relationship
P04884060T0000|3 22|Twentieth Anniversary
P04884060T0000|28 51|Pomeranian Medical Academy
P04890336T0001|29 44|Wassermann reagin
P04890336T0001|63 76|appearance time
P04890336T0001|91 103|FTA antibodies
P04909355T0000|15 29|Actinomycetales
P04911925T0001|0 31|Electrocardiographic QRS complexes
P04919613T0001|18 31|autoantibodies
P04919613T0001|34 58|immunofluorescence technic
P04919613T0001|61 76|collagen diseases
P04921762T0000|7 18|preservation
P04941419T0000|0 24|Yusuf Dawood Docrat L.R.C.P.
P04942414T0000|16 27|pharmacology
P04942414T0000|30 43|5-fluorouracil
P04947347T0000|0 11|Spleen weight
P04947347T0000|24 35|tumour growth
P04947347T0000|41 58|homograft rejection
P04948325T0000|69 82|Crocker sarcoma
P04948325T0000|89 104|Ehrlich carcinoma
P04967824T0000|38 53|melanin synthesis
P04970131T0001|4 20|reflexions apropos
P04975676T0000|58 76|allotransplantation
P04976988T0000|0 12|Heterogeneity
P04976988T0000|20 31|serum albumin
P04989251T0000|10 24|corticosteroids
P04990556T0000|0 11|Reactivities
P04992478T0000|0 16|Plasma histaminase
P04992478T0000|70 83|administration
P05000171T0000|27 38|distribution
P05000171T0000|41 61|horseradish peroxidase
P05000171T0000|92 112|toad bladder epithelium
P05005311T0000|0 13|Immunogenicity
P05005311T0000|23 34|mycobacteria
P05005311T0000|62 77|cross-protection
P05012220T0000|31 45|proctocolectomy
P05020660T0000|31 42|phagocytosis
P05020660T0000|45 58|chlorpromazine
P05027295T0034|0 13|Cholinesterase
P05027799T0000|0 16|Sodium restriction
P05028628T0001|23 34|examinations
P05028628T0001|37 52|occlusion disease
P05031074T0001|0 16|Serum lipid changes
P05031074T0001|41 61|calcium administration
P05031659T0000|36 49|transfer factor
P05034373T0000|24 50|function oxidase enzyme system
P05049711T0000|7 19|session report
P05065548T0075|5 16|constituents
P05065548T0075|19 37|Dryopteris polylepis
P05066316T0001|80 95|aluminosilicates
P05068271T0000|24 35|VMA excretion
P05075857T0000|0 28|Oscilloscope triggering circuit
P05075857T0000|61 71|sweep speeds
P05083872T0000|23 38|training programs
P05083872T0000|41 55|speech pathology
P05093030T0001|68 93|medium-tension intophoresis
P05093030T0001|97 119|partition chromatography
P05095988T0001|37 50|system injuries
P05101762T0000|0 12|Spasmus nutans
P05114515T0000|15 27|enzyme release
P05114515T0000|34 46|normalization
P05114515T0000|72 84|polyarthritis
P05120197T0000|12 23|pancreatitis
P05123884T0000|21 42|4-chlorophenoxyacetate
P05124707T0001|10 21|hospital stay
P05124707T0001|30 42|ulcer patients
P05128149T0001|0 16|Surgical treatment
P05132558T0000|24 35|theophylline
P05132558T0000|54 79|monoamine oxidase inhibitors
P05133723T0000|20 34|gluconeogenesis
P05135168T0000|0 11|New alkaloids
P05135168T0000|22 42|Erythrophleum ivorense
P05138738T0001|7 21|M hemoglobinosis
P05145925T0000|73 83|spleen cells
P05152314T0001|10 21|oscillations
P05152314T0001|25 44|gas dilution indicator
P05170106T0034|62 79|enzyme preparations
P05170106T0034|90 101|chymotrypsin
P05172320T0001|62 73|interdigital
P05172970T0001|37 48|tuberculosis
P05177935T0001|11 23|authorization
P05203499T0001|19 31|scintillation
P05203499T0001|67 78|thyroid gland
P05253274T0001|0 11|Osteosarcoma
P05253274T0001|20 34|3,4-benzopyrene
P05274128T0001|26 38|galactosamine
P05276380T0000|11 26|cigarette smoking
P05276380T0000|33 53|blood coagulation tests
P05284310T0000|35 47|plasma calcium
P05285978T0076|26 38|Cancer Society
P05299993T0000|0 11|Modification
P05303700T0066|0 11|SAM-TR-68-54
P05305671T0000|18 34|color deficiencies
P05309471T0000|13 25|determination
P05309471T0000|49 65|influenza vaccines
P05316745T0000|0 11|Aedes aegypti
P05316745T0000|17 31|Aedes albopictus
P05316745T0000|39 51|Singapore City
P05322558T0000|0 16|Homograft response
P05322558T0000|20 42|hemagglutinin production
P05344097T0000|25 56|skin permeability factor production
P05344097T0000|59 72|Vibrio cholerae
P05353667T0000|6 23|cord representation
P05356107T0001|45 56|tritium oxide
P05359464T0000|18 45|chromosome aberration analysis
P05359464T0000|59 76|radiation dosimetry
P05362866T0000|0 13|Renin secretion
P05362866T0000|39 50|hypertension
P05364951T0001|0 13|Histopathology
P05364951T0001|17 28|pathogenesis
P05368978T0000|60 74|amine mechanisms
P05372511T0105|0 16|Diethylene benzene
P05379901T0000|0 11|Midge control
P05379901T0000|14 26|flood channels
P05388567T0000|25 37|aminophylline
P05394352T0000|0 11|Genitography
P05394461T0001|0 12|Tolerance test
P05394461T0001|22 38|animal experiments
P05410590T0000|38 58|bladder tumor formation
P05410641T0000|12 22|Venturi mask
P05410641T0000|36 48|airway disease
P05412122T0000|17 35|8-phenyl derivatives
P05412122T0000|52 64|benzomorphans
P05412687T0000|40 59|collateral inhibition
P05412687T0000|71 83|tract neurones
P05413428T0000|3 14|distribution
P05413428T0000|49 61|resuscitation
P05413428T0000|64 79|combat casualties
P05414186T0001|8 24|Hong Kong influenza
P05421537T0001|0 11|Difficulties
P05421537T0001|30 44|sputum viscosity
P05424220T0001|0 17|Lipid concentration
P05424220T0001|21 34|lipase activity
P05424220T0001|97 109|sodium content
P05425195T0001|10 34|aspartate aminotransferase
P05425195T0001|47 69|alanine aminotransferase
P05425195T0001|111 127|radiation syndrome
P05425195T0001|142 158|body X-irradiation
P05437405T0000|27 41|dilator capacity
P05437405T0000|77 89|salt retention
P05441564T0001|12 24|pathogenicity
P05441564T0001|57 68|suckling mice
P05445187T0000|15 26|heat exchange
P05445187T0000|67 77|heat balance
P05451324T0000|57 68|CO saturation
P05456002T0000|13 26|doctor shortage
P05460466T0001|13 29|gamma-irradiation
P05460466T0001|55 70|drug preparations
P05463837T0023|11 23|configuration
P05466177T0001|20 31|actinomycin D
P05471866T0000|3 34|plasma growth hormone concentration
P05472485T0000|7 28|cochlear response curves
P05474466T0001|4 23|hemagglutination test
P05488121T0000|0 14|CO2 assimilation
P05488121T0000|17 28|chloroplasts
P05488121T0000|42 52|filter paper
P05492285T0000|12 30|Hyostrongylus ruidus
P05496619T0000|17 45|air pollution control activities
P05497793T0000|16 35|metaraminol treatment
P05497793T0000|110 121|environments
P05501347T0001|14 28|dosage radiation
P05529283T0000|0 11|Quantitation
P05532854T0001|16 29|manifestations
P05533214T0001|0 15|Iodine metabolism
P05536803T0001|14 27|rhodanide space
P05552149T0000|6 20|85Sr scintimetry
P05552149T0000|40 52|arthropathies
P05552642T0000|14 30|hormone production
P05556977T0001|0 12|Morphogenesis
P05556977T0001|45 56|regeneration
P05556977T0001|62 86|phasmid Carausius morosus Br
P05567721T0000|0 12|Sensitivities
P05567721T0000|15 29|thromboplastins
P05567721T0000|32 50|factor VII deficiency
P05572662T0000|49 65|electrocardiogram
P05574818T0000|7 24|computer programmes
P05574818T0000|66 91|contractile characteristics
P05594277T0051|3 14|modification
P05594277T0051|33 45|Jensen sarcoma
P05621339T0001|28 43|Cs137 irradiation
P05627251T0000|21 34|skin potentials
P05642051T0000|17 36|department management
P05671267T0000|0 18|Dimethylaminopropyl
P05671267T0000|23 38|dihydro-5H-benzo
P05672903T0001|0 21|Osteogenesis imperfecta
P05683363T0001|0 12|Investigation
P05683363T0001|65 78|analysis method
P05683809T0000|45 72|surface charge characteristics
P05683809T0000|81 92|blood vessels
P05684081T0001|0 11|Measurements
P05684081T0001|44 58|chamber VA-K-254
P05684081T0001|64 77|osimeter VA-J18
P05689427T0052|0 33|N-Alkyl-N-2-chloroethylaminomethyl
P05689427T0052|59 72|hydrochlorides
P05693602T0001|21 37|blood cell counters
P05693605T0001|0 12|Determination
P05693605T0001|15 27|transaminases
P05693605T0001|34 45|autoanalyzer
P05718386T0001|31 42|complication
P05718500T0001|12 23|observations
P05718994T0000|11 25|fibro-elastosis
P05718994T0000|32 43|incompetence
P05719031T0000|20 32|size reduction
P05722341T0000|0 13|Identification
P05722341T0000|29 43|monosaccharides
P05722341T0000|47 59|disaccharides
P05722341T0000|79 92|chromatography
P05727222T0000|43 59|oxygen consumption
P05727222T0000|62 76|Callionymus lyra
P05732641T0001|8 21|sevine activity
P05732641T0001|29 42|mosquito larvae
P05733952T0001|3 14|significance
P05733952T0001|55 72|antibody production
P05734847T0000|24 46|Glossina morsitans colony
P05742879T0000|0 14|Transformations
P05742879T0000|20 33|morphine series
P05749438T0001|23 36|o-chlorophenyl
P05749438T0001|37 62|methyl-amino cyclohexane HCL
P05751819T0000|79 89|Hariana cows
P05758469T0001|0 18|Hemodynamics changes
P05760665T0000|0 15|Caries prevention
P05763347T0000|8 19|applications
P05769307T0000|0 15|Automatic view box
P05774062T0000|20 32|acid secretion
P05774062T0000|35 46|conductivity
P05781385T0000|3 14|significance
P05781385T0000|20 48|phenolphthalein sulphatase test
P05781385T0000|55 69|differentiation
P05781385T0000|73 86|identification
P05781385T0000|89 103|Nocardia species
P05782943T0001|0 11|Relationship
P05782943T0001|25 44|sarcoidosis granuloma
P05787318T0000|39 49|serum lipids
P05789870T0001|0 38|Phosphate glucose dehydrogenase deficiency
P05789870T0001|46 63|hyperbilirubinemia
P05792868T0000|0 33|Evidence forthe electroosmosis theory
P05792911T0000|24 39|receptor blockade
P05792911T0000|42 58|airway conductance
P05794247T0000|20 31|inactivation
P05794247T0000|34 55|serum lipoprotein lipase
P05796272T0000|12 34|chlorpromazine cataracts
P05798063T0000|12 25|family practice
P05799686T0001|25 36|chemotherapy
P05799686T0001|87 99|cytodiagnosis
P05799686T0001|103 115|incorporation
P05805644T0001|30 41|distribution
P05805644T0001|92 104|incorporation
P05805644T0001|107 119|colloidal ThO2
P05806615T0001|22 40|adrenaline solutions
P05806936T0000|12 23|electrolytes
P05807222T0052|0 11|Ion injection
P05810259T0001|0 15|Polyvinyl alcohol
P05810259T0001|19 34|solution mediator
P05822499T0034|14 25|digiprogenin
P05833022T0001|28 41|enzyme activity
P05833022T0001|47 57|brain tissue
P05837169T0001|0 13|Methoxyflurane
P05839844T0000|0 13|Histochemistry
P05839844T0000|17 34|electron microscopy
P05839844T0000|42 53|liver lesions
P05839844T0000|63 73|Aflatoxin B1
P05850652T0001|52 65|I-131-triolein
P05857301T0000|73 86|administration
P05858571T0000|24 36|2-chloroethyl
P05859016T0000|0 24|Hydroxypropyl methacrylate
P05859016T0000|43 57|embedding medium
P05859016T0000|61 78|electron microscopy
P05881833T0001|53 63|Lower Saxony
P05884183T0001|30 52|agglutination properties
P05890093T0000|80 97|hypervitaminosis-A
P05890093T0000|102 114|mother animals
P05890351T0001|5 20|antitetanus serum
P05896996T0001|14 25|aminoketones
P05902458T0001|14 32|paradichlorobenzene
P05909034T0000|17 28|preparations
P05919308T0001|0 11|Interactions
P05919308T0001|30 41|adrenolytics
P05919308T0001|45 70|monoamine oxidase inhibitors
P05930797T0000|25 43|isoprecipitin system
P05930797T0000|44 59|Australia antigen
P05933228T0000|31 44|neurosecretion
P05938720T0000|29 54|employee orientation program
P05947377T0001|56 71|growth deficiency
P05959588T0000|9 22|Coxsackie B Type
P05959588T0000|24 38|virus infections
P05960999T0001|18 40|passive hemagglutination
P05960999T0001|45 59|polysaccharide C
P05960999T0001|100 112|precipitation
P05960999T0001|129 142|slide latex test
P05967610T0000|10 22|nerve function
P05967610T0000|23 40|noradrenaline level
P05967610T0000|44 62|noradrenaline uptake
P05967610T0000|92 109|reserpine treatment
P05982700T0000|23 43|Cysticercus pisiformis
P05985275T0000|36 47|acorn extract
P05992157T0001|3 15|pathogenicity
P05992157T0001|18 38|Achromobacter puntatum
P05994421T0045|0 12|Consanguinity
P05995140T0001|14 25|significance
P05995140T0001|40 51|glucose level
P06027841T0000|25 42|hyperfine structure
P06027841T0000|48 63|emission spectrum
P06035001T0000|7 18|observations
P06051644T0000|31 43|determination
P06054411T0000|0 16|Retention behavior
P06054411T0000|29 45|gas chromatography
P06054411T0000|59 76|combination columns
P06073427T0001|15 30|characteriaztion
P06074093T0001|7 22|folate deficiency
P06074640T0001|26 41|encephalopathies
P06084279A0218|43 54|serum amylase
P06084810A0169|27 41|polysome complex
P06084864T0001|16 32|alpha fetoproteins
P06088722A0171|40 55|myelosuppression
P06090458A0407|3 23|PEPCK promoter fragment
P06090458A0407|68 80|transcription
P06092588T0000|0 14|Hepatitis B virus
P06093354A0000|43 55|leukemia virus
P06093354A0000|66 77|DNA sequences
P06093354A0000|126 139|Balb/c mouse DNA
P06093363A0612|33 43|% identities
P06093363A0612|51 67|amino acid sequence
P06094591A0000|3 23|envelope glycoproteins
P06094591A0000|26 41|Rous sarcoma virus
P06094591A0000|165 179|carboxy terminus
P06095372A0435|55 72|radiation treatment
P06096380A0662|22 53|phosphoenolpyruvate carboxykinase
P06096863T0000|8 22|activation sites
P06097027A0000|32 55|erythroblastosis virus E26
P06097027A0000|103 121|myeloblastosis virus
P06097027A0000|138 149|tumor viruses
P06097285A1077|95 108|motor behaviour
P06098719A0369|28 45|laboratory findings
P06098828A0352|90 102|RNA polymerase
P06099656T0000|0 11|Construction
P06099656T0000|53 83|adenovirus DNA binding protein gene
P06099656T0000|86 101|cotransformation
P06099656T0000|109 119|HSV-1 tk gene
P06108610A0518|32 50|modality shift effect
P06109017A0000|50 65|4-hydroxyphenoxy
P06109017A0000|65 89|isopropylamino-2-propanol
P06109017A0000|138 149|measurements
P06111283T0032|0 13|Trial treatment
P06111283T0032|16 28|schizophrenia
P06111283T0032|33 55|des-Tyr-gamma-endorphin
P06113084T0000|7 19|taurine levels
P06113084T0000|34 55|calcium binding activity
P06113084T0000|78 91|cardiomyopathy
P06113443T0000|28 39|erythrocytes
P06113443T0000|90 108|separation technique
P06119262T0000|3 15|roll-over test
P06120429T0000|3 20|thyroglobulin assay
P06120429T0000|79 91|thyroid cancer
P06121577A0280|41 53|blood pressure
P06121577A0280|163 181|plasma renin activity
P06131038A0000|9 30|erthrocyte lipid profile
P06131038A0000|34 58|lipoprotein lipase activity
P06131038A0000|61 77|postheparin plasma
P06131038A0000|131 145|atherosclerosis
P06131378A0818|86 107|polyadenylation signals
P06136374A0151|6 22|water temperatures
P06136374A0151|57 72|swimming velocity
P06138313A0948|3 19|distribution phase
P06138313A0948|34 49|elimination phase
P06138313A0948|101 112|distribution
P06141764A0339|0 26|Hybrid-selection experiments
P06142279T0000|6 18|HTLV infection
P06142279T0000|31 43|haemodialysis
P06143734T0000|19 30|progesterone
P06150069A0422|49 64|dose modification
P06150069A0422|68 80|neurotoxicity
P06151942A0235|67 79|blood pressure
P06151942A0235|88 98|risk factors
P06151942A0235|108 120|blood pressure
P06151942A0235|137 148|triglyceride
P06152670T0000|0 13|Plasma secretin
P06152670T0000|14 25|pancreozymin
P06152670T0000|67 81|failure patients
P06152844T0000|20 32|growth hormone
P06152844T0000|36 53|prolactin secretion
P06153936A0784|41 57|gland examinations
P06153936A0784|75 86|year interval
P06155967A1132|3 14|radiologists
P06155967A1132|42 58|reporting terminal
P06155967A1132|98 110|abnormalities
P06158844A0000|22 33|CM-Pf complex
P06158844A0000|54 69|gamma irradiation
P06161823A0129|40 55|ethinyl estradiol
P06162419A0118|98 115|lymphadenosis NK/Li
P06163433T0000|8 21|p-chlorophenyl
P06163433T0000|21 36|cyclopropylamine
P06163433T0000|54 66|concentration
P06163433T0000|70 93|monoamine oxidase activity
P06165132A0000|177 188|pseudoplague
P06165551A0793|4 20|inappropriateness
P06165551A0793|31 42|segmentation
P06165551A0793|190 204|autocorrelation
P06165551A0793|227 247|segmentation algorithm
P06167806A0000|25 43|dimethylpropranolol
P06167806A0000|96 111|tachyarrhythmias
P06173032T0000|11 23|echothiophate
P06173860A0000|53 70|segment depressions
P06173860A0000|81 98|contralateral leads
P06173860A0000|128 144|segment elevations
P06175691T0000|0 28|Bacillus cereus cross-infection
P06175691T0000|32 45|maternity-unit
P06181216A0070|52 73|serum IgA concentrations
P06182979A0807|55 76|anthracycline analogues
P06182979A0807|104 132|cisplatinum diammine dichloride
P06184276T0001|15 27|plasmocytosis
P06184487A1485|38 60|HindIII-P/EcoRI-B region
P06184487A1485|102 112|30K proteins
P06184487A1485|141 151|30K proteins
P06184487A1485|182 209|HindIII-A/EcoRI-C/SstI-G cDNA
P06185014A0642|19 37|complement factor C3c
P06185014A0642|56 73|alpha 1-antitrypsin
P06185493A0468|1 16|polypeptide chain
P06185493A0468|41 62|yeast amino acid sequence
P06185493A0468|80 94|peptide sequence
P06185493A0468|100 113|ADP binding site
P06185493A0468|122 141|muscle pyruvate kinase
P06189698A0246|3 15|P165 component
P06189698A0246|109 119|task demands
P06189698A0246|133 144|P3 amplitudes
P06191243T0000|12 22|drawing size
P06191243T0000|47 57|brain damage
P06193351A1010|16 29|administration
P06193351A1010|108 122|artery occlusion
P06198241A0209|61 78|replication origins
P06198532A0982|161 175|thromboembolism
P06200300A0409|32 44|VEP amplitudes
P06200300A0409|56 70|scalp electrodes
P06203843A0757|27 40|transfer factor
P06204120T0001|8 31|immunofluorescence method
P06204120T0001|35 48|identification
P06204120T0001|51 63|enteroviruses
P06204120T0001|66 77|cell cultures
P06208477A0000|3 14|construction
P06209499A0682|18 35|transmitter release
P06209499A0682|72 84|pressor effect
P06212776A0000|52 63|thalassaemia
P06212776A0000|67 80|G6PD deficiency
P06214605A0123|45 57|configuration
P06218005A0948|47 57|A-P diameter
P06223586A0000|0 17|Immunochemotherapy
P06223586A0000|22 34|schizophyllan
P06223586A0000|108 119|mouse systems
P06223586A0460|72 85|administration
P06224974A0833|32 43|beta-hydroxy
P06227570A0523|46 63|suppressor response
P06229542T0045|10 25|characterization
P06229542T0045|69 87|template rescue assay
P06230499A0128|61 73|fractionation
P06230499A0128|113 123|summary dose
P06230499A0128|313 329|dose fractionation
P06233924T0000|40 58|surface hemorheology
P06234786A0606|0 18|Radiogallium imaging
P06237518A0117|12 26|coupling reagent
P06238540A0798|11 25|volume stiffness
P06238540A0798|32 57|mean wall stress relationship
P06238540A0798|96 114|wall muscle stiffness
P06238540A0798|121 146|mean wall stress relationship
P06238704T0001|19 34|acid diethylamide
P06240448A0652|222 238|pretreatment level
P06241900A0000|56 75|chemical cardioplegia
P06241980A0855|0 13|Oxygen profiles
P06242113T0001|0 18|Cultivation technics
P06242113T0001|22 39|Codonopsis pilosula
P06244732T0000|0 15|Radioimmunoassay
P06244732T0000|18 46|serum creatine kinase B isoenzyme
P06245672T0000|9 28|macrophage inhibition
P06246254A0676|0 16|Restriction enzyme
P06246254A0676|20 39|heteroduplex analyses
P06246254A0676|74 85|src sequences
P06246254A0676|144 156|kilobase pairs
P06251469A0830|17 31|library isolates
P06251469A0830|63 78|restriction sites
P06252520T0000|0 13|Catecholamines
P06254403A0000|3 15|antibody titer
P06254403A0000|31 44|SA-11 rotavirus
P06254403A0000|86 98|blocking assay
P06254973A1757|17 29|calf thymus DNA
P06254973A1757|60 74|polynucleotides
P06254973A1757|92 103|accumulation
P06254973A1757|200 210|binding site
P06254973A1757|226 237|accumulation
P06258699T0000|51 69|GU bladder irrigation
P06259220A0000|218 230|shock exposure
P06259220A0464|70 83|administration
P06259389A0000|57 68|mouth disease
P06259389A0000|83 96|Gifu prefecture
P06270347A0740|1 14|22K polypeptide
P06270347A0740|29 46|translation product
P06270347A0740|76 86|DNA fragment
P06272844A0000|198 210|SV40 chromatin
P06278424A0145|21 32|requirements
P06278424A0145|38 49|CH gene switch
P06278424A0145|80 91|gamma 2b genes
P06278424A0145|113 124|mouse myeloma
P06278544T0027|13 27|Physiopathology
P06279309A0000|16 36|erythroblastosis virus
P06281759A1086|15 25|host mutants
P06281759A1086|40 52|sib regulation
P06281759A1086|85 100|endoribonuclease
P06281759A1086|109 120|int mRNA decay
P06281759A1086|132 143|int synthesis
P06281786A1222|49 60|histone genes
P06281891A0399|78 94|complex modulation
P06281891A0399|97 112|pain transmission
P06286443A0498|13 27|serum ACTH levels
P06286549A0000|10 25|aminopropylamino
P06286549A0000|115 126|fibrosarcoma
P06286549A0000|130 141|tumor nodules
P06286549A0000|162 182|gamma-radiation injury
P06287212A1352|16 27|polypeptides
P06287212A1352|128 156|transcription initiation events
P06287231A0914|10 24|TRP1 RI Circle DNA
P06287231A0914|100 117|bulk yeast chromatin
P06287737A0477|152 175|posttransfusion hepatitis
P06287737A0477|255 267|liver diseases
P06287737A0477|313 324|transfusions
P06287737A0477|372 383|type B disease
P06290859A0426|5 22|hepatitis B patients
P06290859A0426|48 70|hepatitis Bs antigenaemia
P06290859A0426|125 137|liver function
P06290899T0000|23 47|egg drop syndrome-1976 virus
P06290899T0000|53 65|chicken flocks
P06291369A0000|23 49|equilibrium ventriculography
P06291369A0000|60 74|catheterization
P06291369A0000|96 106|day interval
P06291369A0000|168 183|ejection fraction
P06295429A0412|102 114|sensitization
P06296833A0000|28 55|cuticle protein gene expression
P06298720A0893|9 20|conservation
P06298720A0893|42 55|repeat sequence
P06298720A0893|73 92|integration mechanism
P06298720A0893|96 107|VL30 elements
P06298720A0893|111 124|MuLV proviruses
P06300662T0000|1 17|cDNA cloning vector
P06300662T0000|41 51|cDNA inserts
P06300836A0285|0 12|Hybridization
P06300836A0285|49 59|RR1 colonies
P06300836A0285|115 137|DNA clones representative
P06300836A0285|151 162|reovirus RNAs
P06300836A0285|175 193|constituent segments
P06300836A0285|199 213|rotavirus genome
P06304771A1284|56 69|polyomaviruses
P06304771A1284|73 84|adenoviruses
P06304771A1284|115 128|DNA replication
P06304771A1284|135 147|transcription
P06304771A1284|163 173|JCV sequence
P06306342A1156|77 89|acid secretion
P06306342A1156|163 177|Heidenhain pouch
P06307099A1005|0 10|Lung density
P06308536T0001|3 25|hepatitis A virus antibody
P06308536T0001|50 62|liver diseases
P06308607A0375|60 78|DNA sequence analysis
P06308607A0375|104 114|p30 sequence
P06308607A0375|141 158|polymerase sequence
P06309020A0473|21 31|mg X kg-1 X h-1
P06309020A0473|65 82|lipopolysaccharide
P06309855T0000|0 18|Gel route preparation
P06309855T0000|36 48|porcelain frit
P06310159A0000|67 79|retrovirus MH2
P06310553T0000|53 67|muscle actin gene
P06310608A0749|24 35|substitution
P06310608A0749|104 114|Ableson MuLV
P06310608A0749|138 149|sarcoma virus
P06314276T0000|99 110|gene promoter
P06314312A0359|14 27|soybean protein
P06314312A0359|183 196|feed efficiency
P06316347A0852|72 97|beta-galactosidase activity
P06316623A0188|98 116|immunodiffusion test
P06318078T0000|12 33|herpes simplex virus beta
P06318078T0000|94 109|alpha gene product
P06318091A0395|3 20|splice acceptor site
P06318322A0350|56 68|recombination
P06318322A0350|189 200|messenger RNA
P06319040A1627|34 47|system activity
P06319040A1627|54 73|carotid chemoreceptor
P06319071A0173|54 73|calcium stone-formers
P06319071A0173|119 130|counterparts
P06319071A0173|197 208|units mumol/g
P06319072A0711|87 104|cell receptor number
P06319072A0711|158 182|beta-adrenoceptor function
P06319421A0937|75 87|amitriptyline
P06319421A0937|91 107|mianserin blockade
P06319421A0937|140 161|alpha 2-adrenoreceptors
P06319740A1331|60 72|amplification
P06319740A1331|85 107|erythroblast hyperplasia
P06319740A1331|147 161|Rauscher disease
P06320380T0001|0 16|Surgical treatment
P06321505A0401|1 16|promoter sequence
P06321505A0401|17 32|Goldberg-Hogness
P06321505A0401|97 109|transcription
P06321505A0401|125 141|S1 nuclease mapping
P06321505A0401|176 188|transcription
P06321505A0401|191 200|rat PTH mRNA
P06321634A0123|40 53|leader sequence
P06321634A0123|134 149|TRs/IRs sequences
P06321770A1353|15 46|chloramphenicol acetyltransferase
P06322183A1070|0 13|NPT II synthesis
P06322183A1070|24 38|agar plate assays
P06322183A1070|41 59|kanamycin resistance
P06322183A1070|65 83|immunoprecipitation
P06322183A1070|89 100|NPT II protein
P06323556A0126|37 50|EOE-13 infusion
P06323556A0126|70 85|perfusion pattern
P06324121A0256|73 84|reading frame
P06327039A0743|44 56|wall thickness
P06327039A0743|60 74|body surface area
P06327039A0743|78 90|blood pressure
P06327039A0743|209 222|catecholamines
P06327292A0846|13 35|Shine-Dalgarno sequences
P06327292A0846|80 90|start codons
P06327638A0155|48 79|chloramphenicol acetyltransferase
P06327638A0155|94 105|1.1-kilobase
P06328002A0000|21 32|sarcoma virus
P06328002A0000|58 76|Moloney sarcoma virus
P06328012A0549|13 23|EBNA protein
P06328012A0549|55 66|transfection
P06328012A0549|81 93|kilobase pairs
P06328012A0549|102 115|I1f subfragment
P06328485A0277|23 40|nucleotide sequence
P06328485A0277|233 252|chicken proto-myc gene
P06328504A0161|36 51|clone lambda PGK-1
P06328504A0161|91 112|phosphoglycerate kinase
P06331684A0607|32 44|tumor antigens
P06331684A0607|77 89|stomach cancer
P06333433A0000|27 41|influenzae type b
P06333433A0000|80 103|H. influenzae type b disease
P06333433A0000|155 172|lipopolysaccharide
P06333878T0000|11 22|acid overdose
P06336045A0261a|73 88|indentation phase
P06336045A0261a|95 116|threshold response phase
P06336045A0261b|73 88|indentation phase
P06336045A0261b|95 116|threshold response phase
P06340643A0598|29 41|possibilities
P06340643A0598|69 79|donor organs
P06340703A0324|25 37|Masson Fontana
P06341139A0213|0 11|Blood glucose
P06341139A0213|15 27|plasma insulin
P06341661T0001|47 61|Blalock-Taussig
P06342141A0226|31 43|understanding
P06342141A0226|46 66|family pathophysiology
P06342141A0226|177 192|family health care
P06342141A0226|321 335|value judgements
P06342141A0226|415 426|consequences
P06342141A0226|433 456|health care delivery system
P06342141A0226|504 519|literature review
P06346427A0000|23 35|insulin levels
P06349364A1051|69 81|serum globulin
P06349364A1051|101 126|group B Streptococcus antigen
P06360426A0501|72 83|colour change
P06360426A0501|89 99|pH indicator
P06361318A0440|11 23|efficacy rates
P06361318A0440|100 115|committee members
P06361318A1127|123 135|incidence rate
P06362143A0565|0 18|Plasma renin activity
P06362143A0565|56 75|isoprenaline infusion
P06362239T0001|0 11|Martin Luther
P06362602T0001|49 64|vaccine additives
P06362602T0001|79 90|immunization
P06364265T0062|7 27|gamma-ray spectroscopy
P06367414A0000|9 25|calcium antagonist
P06367414A0000|109 122|crossover trial
P06369355A0834|127 144|replication protein
P06369954T0000|49 60|hemodynamics
P06370553A0444|7 26|plasma norepinephrine
P06372563T0000|32 43|heart failure
P06372563T0000|86 97|hyponatremia
P06373409A1163|80 91|restorations
P06373855A0000|6 20|biopsy specimens
P06373855A0000|79 99|pityriasis lichenoides
P06373855A0000|146 163|immunofluorescence
P06373855A0000|167 190|immunoperoxidase technics
P06376227A0217|26 36|PP secretion
P06379363A0415|104 119|diabetes mellitus
P06381438A1280|0 25|Lung prostacyclin production
P06382374A0206|25 45|insulin administration
P06382374A0206|63 75|glucose levels
P06382374A0206|197 211|control subjects
P06384983T0000|12 23|hypertension
P06388189T0001|0 14|Transplantation
P06388818A0000|108 127|chemotherapy regimens
P06388818A0000|153 164|chemotherapy
P06388818A0000|208 225|bone marrow infusion
P06391496T0000|29 40|polypeptides
P06391496T0000|46 60|antacid activity
P06394347A1024|0 11|Hydrallazine
P06394347A1024|39 57|plasma renin activity
P06394347A1024|79 91|noradrenaline
P06395804A0382|0 13|Urease activity
P06397009A0204|56 71|conductor Bozzini
P06397009A0204|170 182|possibilities
P06401749T0000|23 36|osmoregulation
P06401749T0000|39 66|arginine vasopressin secretion
P06402480A0373|3 16|susceptibility
P06402480A0373|22 32|PPNG strains
P06402480A0373|77 90|plasmid pattern
P06402480A0373|126 137|surveillance
P06402480A0373|187 201|recommendations
P06402859A0000|0 14|Antithrombin III
P06402859A0000|23 35|plasma protein
P06404842A0127|66 82|depot testosterone
P06407348A0516|167 181|muscle receptors
P06411659A0264|15 26|measurements
P06411659A0793|20 31|energy intake
P06411659A0793|50 66|energy expenditure
P06412385A0356|22 32|lung disease
P06412385A0356|44 57|muscle weakness
P06412385A0356|114 125|lung capacity
P06412385A0356|205 224|carbon dioxide tension
P06414990A0057|118 136|thyrotropin response
P06419251T0000|0 18|Movement programming
P06419251T0000|28 40|understanding
P06419251T0000|53 64|requirements
P06426493A0331|22 37|state anaesthesia
P06426493A0331|49 60|measurements
P06428116T0000|33 46|hypothyroidism
P06429992T0000|0 17|Gonadotropin levels
P06434572A0157|63 74|GH deficiency
P06434572A0157|87 101|hypopituitarism
P06434572A0157|118 134|growth retardation
P06434587A0551|82 93|FSH responses
P06437579A0727|66 76|dose regimen
P06437579A0727|87 103|patient compliance
P06439135A0250|0 10|Regional CBF
P06441624A0263|54 67|bone metabolism
P06443639T0001|53 69|circuit television
P06443714T0001|9 28|Rhodnius prolixus Stal
P06443714T0001|35 50|babassu palm trees
P06444119A0340|109 121|growth factors
P06444119A0340|128 141|toxin formation
P06452461A0930|58 71|post AVR studies
P06452827T0001|28 44|Huntington choreas
P06453290A0000|32 43|organization
P06454625A0000|18 33|animal experiment
P06454625A0000|109 136|Infrared-Contact-Coagulation
P06454625A0000|161 184|magnification angiography
P06454625A0000|185 203|magnification factor
P06459831T0001|0 13|Cardiovascular
P06459831T0001|59 74|tobacco poisoning
P06460889A0111|56 68|blood pressure
P06460889A0512|14 24|.3 mg/kg i.v.
P06460889A0512|55 67|pulse pressure
P06466804A0686|32 44|shear stresses
P06466804A0686|58 70|tape recording
P06466804A0686|86 98|flow waveforms
P06467241A0000|0 18|Modern cancer therapy
P06467241A0000|37 48|radiotherapy
P06467241A0000|49 60|chemotherapy
P06467241A0000|76 88|immunotherapy
P06467241A0000|92 103|hyperthermia
P06467797A0233|32 46|plasma clearance
P06467797A0233|53 68|10-hydroxylation
P06468565A0000|3 20|response properties
P06468565A0000|36 49|canal afferents
P06468565A0000|97 109|time constants
P06468565A0000|116 137|frequency gain constants
P06468565A0000|149 170|frequency gain constants
P06468632A0135|72 84|artery forceps
P06468673A0358|23 38|E2 concentrations
P06468673A0358|54 64|mucus scores
P06468694A0441|16 29|caudate nucleus
P06468694A0441|69 82|administration
P06468694A0441|123 135|deterioration
P06473219T0000|7 23|urine glucose tests
P06473219T0000|47 62|diabetes mellitus
P06473252A1073|53 65|egg production
P06479362A0680|0 13|Hydrocortisone
P06479362A0680|40 61|postdenervation changes
P06479362A0680|67 80|muscle membrane
P06479362A0680|136 149|muscle membrane
P06479976A0386|82 93|survival time
P06482179A0497|0 13|Catch-up growth
P06482318A0117|0 18|Thrombocyte function
P06482318A0117|69 87|platelet shape change
P06482665A0735|26 43|AMPH administration
P06482665A0735|112 125|caudate nucleus
P06482665A0735|128 141|pigtail monkeys
P06483863A0000|42 59|BALB/cfC3HCrgl mice
P06483863A0000|106 119|beta-estradiol
P06486932A0000|59 72|Malumfashi area
P06487290A0000|35 46|progesterone
P06487290A0000|69 94|radioimmunoassay techniques
P06493655A0415|8 23|FHR decelerations
P06493655A0415|26 37|bradycardias
P06493655A0415|57 70|nonstress tests
P06494215A0248|3 15|response chain
P06494215A0248|46 61|food presentation
P06494766A0241|38 56|Hiss bundle fragments
P06495195A0536|54 72|alkaline phosphatase
P06495195A0536|140 150|liver damage
P06497671T0001|9 27|plasma cortisol level
P06501086A0165|118 138|vas deferens granulomas
P06501086A0165|153 164|serum protein
P06501086A0165|201 220|serum electrophoresis
P06501086A0165|233 261|sperm agglutinin antibody titers
P06503329A0588|65 76|control group
P06503885A0342|4 15|machine drift
P06503885A0342|114 126|x-ray tube heat
P06503885A0342|152 165|overestimation
P06503885A0342|201 220|xenon/CT rCBF protocol
P06503885A0342|263 280|interscan intervals
P06505014A1192|5 17|uncertainties
P06506074A0456|0 11|E2 treatments
P06506074A0456|20 30|hen plasma TG
P06507629A0717|109 123|mumol X min-1 X g-1
P06508393T0000|0 12|Serodiagnosis
P06508393T0000|15 29|trypanosomiasis
P06508393T0000|53 76|card agglutination test set
P06508393T0000|77 87|Testryp CATT
P06513456T0001|0 20|Adenyl cyclase activity
P06517816A0388|92 100|g X m-2 X h-1
P06517816A0388|110 126|saline experiments
P06520418A0325|40 55|valve orifice area
P06520418A0325|108 130|LVIT flow velocity pattern
P06521802A0251|0 20|Scientific cooperation
P06521802A0251|23 41|CMEA member countries
P06521802A0251|92 114|Cancer Research Institute
P06521802A0251|115 127|Slovak Academy
P06521802A0251|138 151|Czechoslovakia
P06524202A0167|16 28|EMG-BFB method
P06524202A0167|29 40|multichannel
P06524202A0167|177 193|motor coordination
P06524727A0601|91 106|incubation period
P06524727A0601|119 131|blood dilution
P06524761A0596|56 69|body weight loss
P06524761A0596|105 128|killed-toxoplasma vaccine
P06524761A0596|222 243|live-toxoplasma vaccine
P06527379T0044|11 33|proline/alanine sequence
P06527379T0044|36 48|beta B1 subunit
P06527379T0044|74 84|DNA sequence
P06527872T0000|80 99|substantia gelatinosa
P06527872T0000|151 165|acid phosphatase
P06531286A0382|9 22|lipid fractions
P06531286A0382|25 40|plant extractions
P06539738T0000|28 45|chlorofluorocarbon
P06542372A0159|36 48|discrepancies
P06542372A0159|118 129|potentiation
P06542918A1131|25 38|discrimination
P06542918A1131|114 124|P3 latencies
P06545651A0346|0 19|Ammonia concentration
P06545651A0346|95 120|protein nitrogen degradation
P06546392A0542|22 42|protein concentrations
P06546392A0542|70 97|erythrocyte sedimentation rate
P06546392A0542|118 131|concentrations
P06546392A0542|134 146|antiproteases
P06548953T0001|5 21|thyroid stimulator
P06548953T0001|27 41|thyroid diseases
P06555107A1227|14 27|administration
P06555107A1227|33 58|calcium antagonist Verapamil
P06555107A1227|104 116|beta-mimetics
P06568939A0000|60 77|eye movement studies
P06571587T0000|45 65|body tissue oxygenation
P06579147A0060|76 89|reconstruction
P06579152A1061|61 82|velopharyngeal activity
P06579152A1061|96 111|feed-back control
P06582285A0222|67 78|D&E abortions
P06584416A0157|5 16|radiologists
P06584416A0157|88 99|examinations
P06585277A0000|66 88|acid phosphatase activity
P06585277A0000|119 129|bone lesions
P06585277A0000|132 146|roentgenography
P06588306A0076|17 37|prophylactic treatment
P06588306A0076|53 64|meningopathy
P06588306A0076|71 84|AIEOP protocols
P06591992A0569|2 13|anisotropism
P06593862T0001|0 16|Hepatitis B vaccine
P06594105A0560|49 63|cent haematocrit
P06597709A0596|60 70|lung volumes
P06597709A0596|84 97|transfer factor
P06597709A0596|140 151|measurements
P06599282T0001|28 40|cell carcinoma
P06600533T0000|56 66|lobe bronchi
P06602580A0664|30 42|complications
P06602580A0664|47 57|otitis media
P06602580A0664|104 131|alpha 1-antitrypsin deficiency
P06606043A0598|63 73|phenyl group
P06607427A0000|143 154|hypothalamus
P06607427A0000|180 196|body weight changes
P06607714T0000|0 13|Limb allografts
P06607714T0000|40 52|cyclosporin A.
P06609166A0209|54 65|acetonitrile
P06609166A0209|130 152|C18 reversed-phase column
P06612373A0000|69 80|prescription
P06615053A0202|41 53|resuscitation
P06615403A0718|13 24|LAD occlusion
P06627569T0001|4 27|type oculomotor stimulator
P06629370A0252|26 52|basement membrane nephropathy
P06629370A0252|103 118|basement membrane
P06630319A0244|115 133|halothane anesthesia
P06653755A0192|5 26|clofelin administration
P06653755A0192|30 50|autoregulation borders
P06654047A0694|148 163|rhabdomyosarcoma
P06654686T0001|14 30|Shwachman syndrome
P06654686T0001|42 68|granulocyte function disorder
P06655634A0195|62 79|cesarean deliveries
P06656249T0000|0 20|Nursing home discharges
P06657559A0489|6 20|broiler chickens
P06657559A0489|37 47|control feed
P06657559A0489|137 147|control feed
P06657559A0489|167 180|ppm ochratoxin A
P06657559A0489|196 208|blood pressure
P06658029A0086|3 20|carcinogen bioassay
P06658029A0086|93 108|hazard evaluation
P06658586T0001|0 22|Angionephroscintigraphy
P06659982A0231|30 40|sleep period
P06662623A0124|50 64|SLOWPOKE reactor
P06662623A0124|80 90|neutron flux
P06667015A0832|130 144|serum CK-MB level
P06667868T0001|116 126|BR-1 benzene
P06668316A0178|18 37|reversed-phase column
P06668316A0178|43 57|phosphate buffer
P06668316A0178|58 69|acetonitrile
P06668316A0178|81 98|baseline separation
P06671047A1124|184 196|Prolactinomas
P06671065A0000|0 10|Serum lipids
P06671065A0000|14 25|lipoproteins
P06671385A0856|36 54|plasma renin activity
P06671385A0856|114 130|body sodium content
P06671925T0000|0 21|Amikacin concentrations
P06671925T0000|32 43|blister fluid
P06672094A0390|75 91|oculomotor nucleus
P06674374T0000|0 28|Hepatitis B vaccination strategy
P06674374T0000|32 49|health-care workers
P06674374T0000|74 93|hepatitis B endemicity
P06674516A0350|13 24|drip infusion
P06675047A0000|23 34|interference
P06675047A0000|112 124|determination
P06683876A0244|85 97|daughter cells
P06684624A0736|7 37|N-acetylglucosaminidase activity
P06684624A0736|41 52|mg creatinine
P06685004A0000|3 14|associations
P06685004A0000|41 56|globulin capacity
P06685004A0000|64 76|body mass index
P06685177T0000|0 11|Dipetalonema
P06685177T0000|22 39|hydrochoerus subgen
P06685643A0179|3 16|concentrations
P06686454A0585|77 99|Klebsiella-Enterobacter
P06686454A0585|123 140|Serratia marcescens
P06687953T0000|10 24|defence capacity
P06687953T0000|43 58|leukocyte enzymes
P06691304A0284|10 28|serum concentrations
P06692517T0000|81 105|indium-111 platelet imaging
P06692517T0000|124 139|echocardiography
P06692631A0129|41 63|microstress distribution
P06694778A0000|11 30|hemodialysis patients
P06694778A0000|46 71|redistribution thallium-201
P06694778A0000|112 123|hemodialysis
P06698047A0445|3 17|Prolactin levels
P06700231A0259|12 25|tumor resection
P06700231A0259|49 60|tumor nodules
P06700469T0000|7 27|hospital accreditation
P06702257T0001|0 14|Antithrombin III
P06702643A0000|8 19|infant hearts
P06702643A0000|32 47|arch interruption
P06704467A0539|87 97|pineal gland
P06707357A0180|12 23|observations
P06707357A0180|58 70|regurgitation
P06707357A0180|91 106|valve replacement
P06707357A0180|170 183|volume overload
P06709700A0230|67 89|Hamilton Depression Scale
P06709700A0230|95 110|Melancholia Scale
P06709700A0230|164 177|outcome measure
P06711642A0093|11 28|immunoglobulinuria
P06711642A0093|91 109|creatinine clearance
P06711642A0093|196 210|urine collection
P06712314A0148|50 61|institutions
P06713200A0630|0 19|Epileptiform activity
P06713204A0867|3 14|AD components
P06713204A0867|77 87|V1 component
P06714298X0000|96 116|micrograms X kg-1 X min-1
P06714298X0000|118 138|calcium channel blocker
P06715792A0295|0 15|HBB concentration
P06715792A0295|48 59|accumulation
P06716977A0136|29 48|ethanol concentration
P06718064T0001|0 16|Plasma lactoferrin
P06719057A0181|29 44|vein phlebography
P06719057A0181|85 97|filing defects
P06720371T0000|12 27|blood coagulation
P06720371T0000|30 41|gout patients
P06721188A0200|59 70|contrast test
P06726257A1179|21 39|5-hydroxytryptophan
P06726257A1179|45 56|accumulation
P06726257A1179|101 112|methiothepin
P06726257A1179|113 124|hypothalamus
P06726257A1179|179 208|autoreceptor antagonist activity
P06726257A1179|211 222|methiothepin
P06726257T0000|9 20|methiothepin
P06726257T0000|32 47|acid diethylamide
P06726257T0000|50 65|serotonin release
P06726257T0000|76 93|serotonin synthesis
P06726257T0000|118 146|serotonin autoreceptor function
P06731302A0930|13 27|bradyarrhythmia
P06731302A0930|78 88|branch block
P06732946A0281|43 54|fibrinolysis
P06732946A0281|104 116|magnification
P06732946A0281|124 136|image analyser
P06735247A0803|12 44|plasma enteroglucagon concentration
P06738410T0000|0 12|Blood pressure
P06740373A0891|105 120|drug testing model
P06740697A0318|45 60|guinea pig strains
P06740919A0162|5 20|Amblyomma lepidum
P06744024A0000|79 90|formalin test
P06749072A0116|7 20|urate excretion
P06749072A0116|95 108|water immersion
P06749072A0116|139 152|water immersion
P06754662T0001|7 30|angiolymphoid hyperplasia
P06754662T0001|35 46|eosinophilia
P06755468A0180|26 38|reading frames
P06755468A0180|89 105|amino acid homology
P06755986A0382|48 64|toxico-infections
P06755986A0382|122 139|hospital infections
P06760394T0001|6 21|tooth replacement
P06760394T0001|40 72|International Team fur Implantologie
P06762025A0171|3 35|13,14-dihydro-15-keto-metabolites
P06762321T0000|0 17|Nucleotide sequence
P06762321T0000|20 43|DNA controlling expression
P06762321T0000|54 79|maltosaccharide utilization
P06762321T0000|82 94|Streptococcus
P06763897A0216|3 14|hypertension
P06764669T0001|12 24|determination
P06764669T0001|50 62|deferoxamine B
P06767648A0734|0 11|Measurements
P06772370A0342|8 19|distribution
P06772370A0342|84 97|protein binding
P06772612A0000|69 93|carotid body chemoreceptors
P06775834A0000|8 18|B phenotypes
P06776918T0000|0 15|Trypanosoma cruzi
P06781339A0501|104 118|hypoventilation
P06781728A0690|16 30|differentiation
P06781728A0690|33 52|osteoprogenitor cells
P06781728A0690|77 90|mineralization
P06781728A0690|126 138|bone formation
P06781728A0690|151 170|fluorochrome labeling
P06782612A0142|62 72|urine volume
P06782612A0142|83 98|lithium clearance
P06782869A0263|0 14|Nitrogen balance
P06782869A0263|38 50|complications
P06782869A0263|79 93|serum creatinine
P06782869A0263|94 112|creatinine clearance
P06782869A0263|140 163|serum alkaline phosphatase
P06784123A0286|46 58|recombination
P06784123A0771|27 48|sequence characteristic
P06784123T0000|16 36|immunoglobulin C mu gene
P06786756T0000|9 24|DNA rearrangement
P06786756T0000|39 51|RNA processing
P06786756T0000|69 92|immunoglobulin delta genes
P06790572A0330|54 66|amphotericin B
P06790572A0330|67 85|trimethoprim lactate
P06791500A0622|23 37|fluid delta OD450
P06794666A0208|14 35|neuroeffector influence
P06794666A0208|100 127|neurotransmitter biosynthesis
P06794666A0208|141 168|cardiomyocyte adrenoreceptors
P06795119T0000|0 18|Lens aldose reductase
P06795654A0434|0 11|Fenfluramine
P06795654A0434|39 52|mg/kg/infusion
P06795654A0434|67 93|self-administration behavior
P06795654A0434|106 123|minimum requirement
P06795832A0148|65 78|HBe-antibodies
P06795900A0000|19 58|acid cyclo-oxygenase inhibitor indomethacin
P06795971A0000|26 36|model system
P06796300A0759|18 32|prolactin levels
P06796300A0759|35 46|nursing women
P06796300A0759|73 96|oestradiol administration
P06797063A0000|10 29|procoagulant activity
P06797063A0000|30 49|antigen concentration
P06797063A0000|53 73|von Willebrand activity
P06797063A0000|76 93|ristocetin cofactor
P06798609A0000|74 88|gamma-vinyl GABA
P06801778T0001|0 11|Significance
P06801778T0001|26 44|gas exchange reaction
P06801778T0001|77 89|effectiveness
P06801778T0001|98 111|commissurotomy
P06802500T0001|0 16|Thyreoliberin VUFB
P06802500T0001|19 36|thyroid gammagraphy
P06803634A0810|22 34|relationships
P06803634A0810|89 110|blood gas determinations
P06805537T0001|10 28|hemophilia treatment
P06807149T0000|26 37|preparations
P06807149T0000|40 59|disodium cromoglycate
P06807149T0000|93 104|bronchospasm
P06807192A0312|59 76|glucose utilization
P06807659T0001|0 11|Phagocytosis
P06808287T0001|11 29|hemophilia A carriers
P06808529A0167|14 31|isoniazid solutions
P06808529A0167|68 84|EDTA concentration
P06809474A1156|0 12|Bile bilirubin
P06809474A1156|37 48|haem infusion
P06809474A1156|77 89|investigation
P06809586T0000|0 25|Autoimmune manipulation aids
P06809586T0000|34 51|diabetes management
P06810070A0502|51 63|control spores
P06810694A0328|13 27|HDL-cholesterol
P06810694A0328|42 59|VLDL-triglycerides
P06810694A1000|0 10|Apo A-I level
P06810694A1000|44 61|ethanol consumption
P06816053A0849|29 41|drug reactions
P06816053A0849|80 91|mast cell test
P06816123A0526|24 44|glutathione peroxidase
P06816123A0526|71 84|defense systems
P06816442T0001|17 30|serum myoglobin
P06816609A0639|3 25|% blood pressure reduction
P06817410A0982|47 58|epidemiology
P06817410A0982|158 168|drug addicts
P06818113A0384|102 124|corticosteroid treatment
P06818113A0384|152 171|plasminogen activator
P06818113A0384|175 188|clotting factor
P06821147A0468|0 16|Sulphur amino acids
P06822645T0039|10 37|increase growth hormone release
P06823837A0562|105 116|outflow tract
P06825641A0076|11 28|landfill operations
P06828396A0095|10 22|contamination
P06828396A0095|60 82|biopsy fixation technique
P06829082A0187|74 104|brain tissues glutaminase activity
P06829082A0187|117 138|incubation temperatures
P06830033A0661|7 18|observations
P06830033A0661|41 52|pneumothorax
P06830351A0397|19 32|classification
P06833422T0000|0 12|Determination
P06833422T0000|17 35|alpha-hydroxy-9 beta
P06833422T0000|38 51|alpha-pregna-4
P06833422T0000|80 92|ion monitoring
P06835516A0000|13 26|epidermoid cyst
P06835914A0192|0 15|Copper treatments
P06835914A0192|58 69|copper intake
P06837312A0000|90 101|vitamin D3/kg
P06837312A0000|116 129|months duration
P06837312A0000|147 165|vitamin D3 withdrawal
P06838388A0896|41 51|tissue scars
P06838388A0896|92 106|parenchyma areas
P06838388A0896|116 128|normalization
P06840803A0397|66 78|i.v. challenge
P06842629A0446|11 24|GMBF reductions
P06842629A0446|51 65|treatment groups
P06848729A0000|17 29|neuroblastoma
P06849842T0000|0 30|Penicillin-G degradation products
P06849842T0000|45 58|granulopoiesis
P06851280A0144|0 15|Plasma fibrinogen
P06851327A0000|64 79|Neisseria species
P06853042A0282|13 25|acidification
P06853042A0282|59 81|bicarbonate reabsorption
P06854957T0066|43 58|echocardiography
P06856306T0000|3 18|Tullio phenomenon
P06856306T0000|19 29|fistula test
P06856306T0000|55 66|significance
P06858449A0335|0 11|Disturbances
P06858805A0314|39 54|hypersensitivity
P06858967A0167|0 24|Serum lactate dehydrogenase
P06858967A0167|28 44|haptoglobin levels
P06864837T0000|18 43|spine immobilization methods
P06869215A0347|35 52|hypocomplementemia
P06872800T0000|45 56|HBV infection
P06873504T0000|12 24|relationships
P06873504T0000|55 81|sodium metabolism alterations
P06873504T0000|84 97|liver cirrhosis
P06875478A0542|1 19|microU/l thyrotropin
P06876006A0930|0 14|Echosismography
P06876317T0033|0 12|Relationships
P06876317T0033|34 51|deficiency syndrome
P06880563A0516|117 131|administrations
P06880563A0516|150 163|administration
P06880563A0516|166 179|chlorpropamide
P06880604A0167|1 12|reassessment
P06880604A0167|18 31|prevalence data
P06880604A0167|108 120|prevalence day
P06882578A0464|5 23|ultramarathon runner
P06882578A0464|27 44|testosterone levels
P06882578A0464|75 89|training session
P06882578A0464|193 205|hours training
P06883385A0509|53 71|neopterine excretion
P06886031A0898|64 75|patient group
P06886948A0750|43 55|energy intakes
P06886948A0750|72 83|requirements
P06890622A0067|107 118|hypertension
P06890622A0067|155 167|pre-eclampsia
P06891051A0587|85 97|platelet count
P06891270A0000|49 61|extensibility
P06891270A0000|65 77|contractility
P06895559A0000|38 49|aminophyllin
P06895559A0000|51 76|phosphodiesterase inhibitor
P06895559A0000|113 125|rabbit fetuses
P06895663A0810|83 94|significance
P06897114A0240|49 70|DNA sequence recognition
P06911559T0000|13 25|nurse managers
P06916588A0304|3 15|infection rate
P06916588A0304|49 64|Hickman catheters
P06919347T0001|25 44|Laboratory Assistants
P06919347T0001|77 96|laboratory assistants
P06928974T0000|3 19|electrocardiogram
P06931124A0109|24 39|complex formation
P06935514A0000|99 110|desametazone
P06935514A0000|147 160|dentinogenesis
P06938948T0001|15 34|serum immunoglobulins
P06946314T0000|0 13|Serum IgE levels
P06946314T0000|16 31|Tauranga children
P06946693T0000|5 24|prostaglandin F2 alpha
P06948868A0082|45 62|faculty evaluations
P06950004T0047|7 18|distribution
P06950004T0047|45 57|iontophoresis
P06953957A0503|7 28|creatine kinase activity
P06957125T0000|56 71|stimulating drugs
P06957633T0001|54 69|erythroblastosis
P06959130A0996|3 21|arginyl peptide bonds
P06959130A0996|104 116|Arg145-Ala146
P06959130A0996|120 132|Arg180-Val181
P06962634A0190|49 69|porphyrin binding sites
P06962634A0190|97 114|porphyrin transport
P06963337T0000|54 65|hypertension
P06969638A0180|4 15|examinations
P06969638A0180|40 55|CNS abnormalities
P06969638A0180|79 97|meningeal infections
P06969638A0180|113 124|determinants
P06969638A0180|163 175|complications
P06972443A0375|60 72|abnormalities
P06973664A0000|15 30|cleavage syndrome
P06975206A0279|8 21|administration
P06975206A0279|24 36|betamethasone
P06978566A0197|50 60|lung lesions
P06978566A0197|78 88|maximum dose
P06981991A0756|0 13|Aneurysmectomy
P06981991A0756|101 112|bypass grafts
P06981991A0756|197 209|artery disease
P06984225A0367|33 43|patent graft
P06992600A0405|3 24|extraction measurements
P06992600A0405|55 67|contamination
P06993660A0000|22 35|norepinephrine
P06993660A0000|61 77|relaxant responses
P06993660A0000|80 92|isoproterenol
P06994035T0001|2 16|line calculation
P06994035T0001|19 39|steroid concentrations
P06994035T0001|42 57|radioimmunoassay
P06994049T0001|21 34|hypothyroidism
P06997203A0325|2 16|rubella patients
P06997203A0325|30 41|confirmation
P06997203A0325|122 139|antibody conversion
P07004236A0741|22 36|folate compounds
P07004236A0741|45 63|formate accumulation
P07004236A0741|90 105|formate oxidation
P07004236A0741|186 202|methanol poisoning
P07007181T0000|11 25|sodium saccharin
P07007591A0324|3 18|residue functions
P07007591A0324|33 50|In-113m transferrin
P07007591A0324|223 238|residue functions
P07015018A0395|38 56|migration inhibition
P07015262A0396|9 25|cefadroxil therapy
P07015262A0396|61 74|tract infection
P07015262A0396|109 120|microgram/ml
P07018810A0002|0 23|Plasma renin concentration
P07034479A1050|28 39|placebo group
P07037479T0000|3 15|cracked-tooth
P07038684A1050|7 28|peptide map similarities
P07038684A1050|50 61|sequence data
P07038684A1050|123 140|amino acid sequences
P07038684A1050|162 183|p60 initiator methionine
P07040659A0212|16 27|control group
P07044389T0000|10 31|Economic Recovery Tax Act
P07044389T0000|56 67|pathologists
P07044389T0000|71 82|audiologists
P07044842A2062|3 14|relationship
P07044842A2062|29 41|complications
P07044842A2062|62 76|pathophysiology
P07045156A0204|92 105|immunoglobulin
P07061263A0293|59 70|air inflation
P07061350A0042|93 109|distortion product
P07062036A0072|31 43|sham operation
P07063606T0000|40 57|barrier alterations
P07064662A0222|53 64|target fibres
P07064662A0222|122 132|dorsal roots
P07064923T0000|11 44|phenylalanine hydroxylase deficiency
P07064923T0000|45 59|phenylketonuria
P07065206A0398|4 15|control sheep
P07065206A0398|20 42|plasma TXB2 concentration
P07065206A0398|60 73|ng/ml prebypass
P07068493A0414|92 102|CO2 pressure
P07068493A0636|27 43|oxygen consumption
P07068496A0000|83 99|sucrose indicators
P07068496A0000|123 133|rabbit lungs
P07068887A0000|37 50|dimensionality
P07068887A0000|105 135|Michigan Alcoholism Screening Test
P07068887A0000|169 182|symptomatology
P07072635A0000|48 61|administration
P07072635A0000|64 78|desferrioxamine
P07073520A0153|18 31|hemofiltration
P07073520A0153|37 53|substitution fluid
P07073520A0153|61 73|concentration
P07073520A0153|108 118|fluid volume
P07073520A0153|150 160|fluid volume
P07075438T0000|11 31|serial xeroradiography
P07076222A0543|0 14|Recommendations
P07078263T0000|17 28|deferoxamine
P07078263T0000|41 55|hemochromatosis
P07079595A0848|100 119|diameter measurements
P07079595A0848|162 176|sperm production
P07080496A0097|15 27|investigation
P07080496A0097|30 41|lipoproteins
P07080496A0097|155 166|lipoproteins
P07081327A0546|39 52|concentrations
P07084198T0000|0 13|Selenium status
P07084198T0000|16 28|thoroughbreds
P07084198T0000|34 46|United Kingdom
P07084814T0000|20 38|phospholipid reagent
P07084814T0000|42 58|coagulation assays
P07088195T0019|11 22|consequences
P07090151A0165|31 42|release bolus
P07096587A0267|52 66|training program
P07106534A0160|34 47|growth function
P07107287A1083|62 75|99Mo generators
P07107462A0202|27 43|dissociation curve
P07107462A0202|67 80|training period
P07107773A0000|186 200|amine precursors
P07107773A0000|218 234|gas chromatography
P07107773A0000|239 264|resolution mass spectrometry
P07107773A0000|277 289|ion monitoring
P07107773A0000|297 342|trifluoroethyl-pentafluoropropionyl derivatives
P07109788A0333|56 67|pyloroplasty
P07110999A0160|35 46|tetraparesis
P07110999A0160|47 58|incontinence
P07110999A0160|62 80|oculomotor paralysis
P07112320A0086|0 28|CSF adenosine deaminase activity
P07112471A0639|0 18|Histamine reactivity
P07112654A0388|103 115|hospital staff
P07113365A0737|52 63|surface angle
P07114083A0153|5 15|MOPP therapy
P07114083A0153|66 78|normalization
P07114083A0153|84 106|glucocerebrosidase level
P07114083A0153|110 122|disappearance
P07116298A1079|112 132|Corynebacterium parvum
P07116962A0299|3 18|COP-PAWP gradient
P07124743A1223|16 31|glassware factory
P07124743A1223|32 44|As2O3 exposure
P07124743A1223|93 105|determination
P07124743A1223|147 164|mouth contamination
P07124743A1223|242 262|microgram/g creatinine
P07125064T0000|67 86|Schistosoma japonicum
P07125064T0000|89 106|Schistosoma mansoni
P07125238T0000|32 43|blood vessels
P07126067T0000|12 23|reproduction
P07126413A0000|9 22|delivery system
P07130335A1081|0 13|Administration
P07130335A1081|19 46|dopamine agonist bromocriptine
P07130335A1081|105 122|plasma 18-OHB levels
P07132408A0387|30 50|magnesium cardioplegia
P07134924A0640|20 32|malformations
P07136524A0180|95 106|osteosarcoma
P07136524A0180|117 139|retinoblastoma survivors
P07136569A0000|19 32|school children
P07140493A1045|96 108|acid secretion
P07141130A0615|138 153|cells/100 microns
P07147622T0000|13 26|storage disease
P07154928T0001|0 11|Modification
P07155579T0001|12 26|bacteriospermia
P07160491A0547|89 107|dose reduction factor
P07162146A0000|16 30|ultrafiltration
P07162146A0000|33 49|sample preparation
P07162146A0000|67 80|quantification
P07162146A0000|83 96|ethylene glycol
P07162146A0000|107 123|gas chromatography
P07165767T0000|0 11|Mastocytosis
P07168531T0001|4 20|Onchocerca species
P07172690A0547|19 30|disturbances
P07172690A0547|44 58|energy transport
P07172690A0547|59 75|creatine phosphate
P07172690A0547|76 96|creatine phosphokinase
P07172690A0547|105 115|calcium pump
P07172690A0547|222 233|% restriction
P07173729A0000|7 22|penetration tests
P07174046T0000|0 14|Vibrio fluvialis
P07174046T0000|15 26|group F vibrio
P07174122A0000|0 18|Serum creatine kinase
P07174122A0000|91 106|bicycle ergometry
P07174122A0000|111 121|lifting task
P07180901A0539|62 84|prostaglandin synthetase
P07181985A0107|8 23|mg mitomycin/20 ml
P07182523A0462|59 74|SOA concentration
P07183576A0157|16 28|concentration
P07183576A0157|31 44|flucloxacillin
P07183576A0157|71 83|micrograms/ml
P07183576A0157|108 119|micrograms/g
P07183576A0157|139 150|micrograms/g
P07183576A0157|179 190|micrograms/g
P07184375T0001|30 41|methotrexate
P07184375T0001|45 56|prednisolone
P07184375T0001|59 81|combination chemotherapy
P07184598T0001|19 33|hyperthyroidism
P07184774T0000|0 13|Re-examination
P07184795A0517|10 23|determinations
P07184795A0517|38 53|serum CPK activity
P07190627T0000|15 41|plasminogen activator release
P07191183A0505|74 85|autoxidation
P07191804A0000|34 52|bicycle exercise test
P07192369T0000|65 78|administration
P07192369T0000|81 102|l-alpha-acetylmethadol
P07192722A0682|23 39|parathyroidectomy
P07192722A0682|62 76|serum iPTH levels
P07194905A0332|50 63|tissue necrosis
P07194905A0332|114 128|brain maturation
P07195615A0087|60 75|Cd administration
P07195615A0087|100 111|accumulation
P07202224A0452|90 103|attractiveness
P07203410T0000|0 11|Family visits
P07203410T0000|50 62|state hospital
P07205120T0000|42 53|ECG wave forms
P07208984A0000|72 88|tomography studies
P07214230T0000|12 33|Fusarium moniliforme var
P07214230T0000|40 51|subglutinans
P07214230T0000|72 82|pitch canker
P07214230T0000|88 114|soil bacterium Arthrobacter sp
P07214665A0000|25 56|fluorouracil imidazole carboxamide
P07214665A0000|84 109|bis-chloroethyl nitrosourea
P07214665A0000|161 172|breast cancer
P07217329A0000|36 48|determination
P07217329A0000|52 71|alpha-acetylmethadol
P07217329A0000|100 116|noracetylmethadol
P07217329A0000|117 135|dinoracetylmethadol
P07217329A0000|158 170|dinormethadol
P07217329A0000|206 219|chromatography
P07217523A0364|12 26|recognition task
P07217523A0364|82 93|vowel context
P07218008T0000|6 23|response properties
P07218008T0000|76 91|Aotus trivirgatus
P07219297T0000|21 35|standardization
P07219821T0028|21 34|considerations
P07221179A0156|21 31|GABA content
P07221179A0156|43 54|GABA decrease
P07221179A0156|78 91|administration
P07221354T0000|9 20|applications
P07221354T0000|23 33|pulse dosing
P07225540A0193|31 60|electron capture detection method
P07225540A0193|79 91|plasma samples
P07226440T0000|3 14|hemodynamics
P07228955A0000|34 45|interference
P07228955A0000|48 67|theophylline analysis
P07228955A0000|70 81|paraxanthine
P07228955A0000|82 101|1,7-dimethylxanthine
P07234308A0121|5 16|drug regimens
P07234308A0121|48 61|remission rates
P07234974T0000|23 34|Jat dentition
P07235317T0000|37 52|Phadebas RAST test
P07235355A0462|108 124|density dependence
P07237123T0000|24 36|unit responses
P07237123T0000|48 59|nerve volleys
P07237560A1038|88 99|substitution
P07237560A1038|133 146|Hind III linkers
P07237560A1038|172 184|transcription
P07237817T0000|0 14|Cross reactivity
P07237817T0000|17 34|theophylline RIA kit
P07240343A0000|0 11|Strontium-90
P07240343A0000|48 61|post conception
P07247059A0775|0 14|Catheter transit
P07247059A0775|34 45|step increase
P07247059A0775|48 60|concentration
P07247059A0775|110 120|transit time
P07249497A0688|36 46|estrogen PPI
P07249497A0688|95 105|estrogen use
P07249544A0343|28 52|serum creatine kinase levels
P07249660T0000|0 12|Determination
P07249660T0000|21 34|distensibility
P07249660T0000|61 72|hypertension
P07249895A0177|18 31|prostaglandins
P07249895A0177|73 86|LES hypotension
P07249895A0177|127 138|indomethacin
P07249895A0177|142 154|micrograms/kg
P07249895A0177|186 207|prostaglandin synthesis
P07251564A0569|80 91|ASDC nosology
P07253335T0000|9 31|prostaglandin inhibitors
P07253335T0000|66 77|stroke-prone
P07256543A0814|40 55|inhalation injury
P07256543A0814|92 114|carboxyhemoglobin levels
P07256543A0814|141 151|space injury
P07256543A0814|183 194|airway injury
P07260389A0221|0 11|Methisergide
P07260389A0221|34 51|serotonin receptors
P07260987A0336|3 17|plasma half-life
P07260987A0336|24 47|disposition phase t1/2 beta
P07262625A0000|0 20|Corticosteroid therapy
P07262625A0000|55 69|occult infection
P07262625A0000|95 118|host parasite relationship
P07262625A0000|198 214|protozoal parasite
P07262625A0000|215 226|Giardia muris
P07262625A0000|248 262|corticosteroids
P07263374T0000|6 17|lung function
P07263374T0000|32 44|pneumonectomy
P07263745T0000|9 28|Charnley arthroplasty
P07264787A0351|94 108|hyperthyroidism
P07266969A0246|3 14|relationship
P07266969A0246|56 77|breast cancer management
P07267675A0000|24 36|cephalosporin
P07268828A0000|1 17|fluoroimmunoassay
P07268828A0000|24 36|determination
P07268828A0000|46 57|plasma levels
P07268828A0000|132 151|solid-phase particles
P07270991A0149|4 17|pollen allergen
P07270991A0149|27 38|grass species
P07274042A0249|14 27|concentrations
P07274428A0000|82 94|contrast agent
P07274428A0000|113 128|cholecystography
P07274428A0000|175 186|RCA triombrin
P07274428A0000|204 217|indigo-carmine
P07274482A0000|73 87|afterdischarges
P07277222A1391|159 170|interactions
P07278104T0001|0 22|Leukocyte enzyme activity
P07278104T0001|26 59|blood lymphocyte blast transformation
P07278578T0001|15 26|chemotherapy
P07280654A0000|52 66|averaging method
P07282552A0990|107 119|subepicardium
P07282552A0990|130 143|subendocardium
P07282943A0097|38 54|superfusate oxygen
P07286057A0159|7 25|AUC infinity analyses
P07286057A0159|29 44|pharmacokinetics
P07286057A0159|147 160|administration
P07293100T0001|0 15|Gastrin secretion
P07293100T0001|22 36|food stimulation
P07293100T0001|48 61|system diseases
P07293327T0001|0 22|Fibrinogen determination
P07295417A0092|99 110|phase imaging
P07296303A0418|44 61|lateralis posterior
P07296997A0125|67 93|Tc-99m-PyG cholescintigraphy
P07297576A0454|18 39|drinking water ad libitum
P07297576A0454|76 88|drinking water
P07297978A0570|30 40|case history
P07297978A0570|41 53|smoking habits
P07298209A0291|3 15|determination
P07298209A0291|26 44|performance capacity
P07298209A0291|127 142|bicycle ergometer
P07298259T0000|0 12|Determination
P07298523T0000|8 19|indomethacin
P07298523T0000|23 42|prostaglandin F2 alpha
P07299857A0294|163 176|intrarectally.
P07299857A0294|189 202|administration
P07304905A0336|0 14|Autotransfusion
P07304905A0336|36 48|Heparin-ACD-B
P07304905A0336|60 76|Heparin-ACD-B etc.
P07308849A0817|41 60|sham operation animals
P07309562T0000|36 48|determination
P07310206A0154|3 14|architecture
P07310206A0154|17 32|microvasculature
P07310206A0154|67 92|scanning electron microscopy
P07310206A0154|101 118|resin casting method
P07311881T0000|0 10|MSMS Council
P07311881T0000|25 38|health director
P07320153T0000|105 121|injection analysis
P07320153T0000|124 137|catecholamines
P07323063A0000|149 169|mg/kg dl-isoproterenol
P07323573A0644|26 37|dissociation
P07326596A0061|3 15|IgA deficiency
P07327097A0647|126 137|granule cells
P07328000T0000|0 19|Nutritional cataracts
P07328000T0000|22 33|timber wolves
P07330073T0000|12 31|transfusion reactions
P07337609A0531|43 56|antibody titers
P07337609A0531|160 171|immunization
P07337609A0531|181 192|immunization
P07340196T0001|15 27|determination
P07340196T0001|62 75|infectiousness
P07340196T0001|78 100|hepatitis B virus carriers
P07341346A0174|17 28|shunt vessels
P07345217A0000|10 22|complications
P07347728T0000|0 12|Arachnoid cyst
P07355527A0467|23 34|Lich-Gregoir
P07356273T0022|24 37|cell carcinomas
P07369183T0000|26 43|coagulation testing
P07369458A0606|62 78|muscle temperature
P07369458A0606|117 131|amputation level
P07372433A0000|24 36|relationships
P07372433A0000|39 53|guinea pig ureter
P07372928A0105|28 42|Mossbauer source
P07372928A0105|92 120|signal-transmission properties
P07375864A0431|22 35|nonspecificity
P07375864A0431|41 51|platelet MAO
P07375864A0431|106 118|schizophrenia
P07375864A0431|172 182|platelet MAO
P07377378A0143|0 18|Estrogen replacement
P07377378A0143|29 42|beta-estradiol
P07377378A0143|45 69|beta-estradiol-3-benzoate
P07377378A0143|133 146|heat production
P07377954A0117|111 127|oxygen consumption
P07377954A0117|148 163|health volunteers
P07377954A0117|165 175|emg activity
P07377954A0117|200 219|gastrocnemius muscles
P07377954A0117|258 289|postexercise ankle pressure changes
P07379334A0503|49 62|transfer factor
P07380615A0478|158 171|work efficiency
P07380615A0478|242 254|collar workers
P07385543T0001|26 46|blood sulfhydryl groups
P07385920A0189|27 40|blood lead level
P07385920A0189|64 79|blood haemoglobin
P07385933A0085|9 19|iv injection
P07385933A0085|38 49|kg body weight
P07386500A0174|8 27|clotting factor assays
P07386500A0174|93 106|determinations
P07387242A0236|0 13|Blood variables
P07387242A0236|85 98|plasma proteins
P07387242A0236|130 146|clotting functions
P07393856A0314|28 41|acid ethyl ester
P07393856A0314|58 74|reference standard
P07393976A0000|12 30|sodium phenobarbital
P07393976A0000|41 54|sodium barbital
P07393976A0000|72 84|taste aversion
P07393976A0000|125 138|discrimination
P07393976A0000|144 166|bottle taste aversion task
P07393976A0000|171 194|% sodium saccharin solution
P07394364A0738|25 45|gas exchange parenchyma
P07395750A0294|0 15|Underestimations
P07395750A0294|65 77|methodologies
P07396545A0217|0 11|Chemotherapy
P07397066T0000|0 13|Drug inhibition
P07397066T0000|21 40|blood aspirin esterase
P07405701T0000|32 55|platelet monoamine oxidase
P07406527A0212|33 50|porphyrin excretion
P07406527A0212|57 72|porphyrin content
P07406527A0212|147 157|HCB controls
P07408970A0706|20 33|administration
P07410037A0752|8 20|stone-formers
P07410037A0752|55 73|magnesium metabolism
P07410037A0752|105 116|control group
P07413441T0070|16 27|localisation
P07413441T0070|41 52|distribution
P07413781A0169|44 62|stimulus preexposure
P07413781A0169|131 142|conditioning
P07414817T0001|0 17|Cataract extraction
P07415340A0280|39 52|pneumocytes typ
P07416204A0437|34 45|potentiation
P07416204A0437|64 77|pacing interval
P07416204A0437|97 108|extrasystole
P07416204A0437|149 160|potentiation
P07416204A0437|208 219|potentiation
P07418498A0217|21 33|complications
P07418498A0217|36 50|corticosteroids
P07418498A0217|115 127|amphotericin B
P07418498A0217|152 162|lung abscess
P07418829A0191|0 11|Implications
P07419485A0158|139 152|simplification
P07425838A0182|15 30|pheochromocytoma
P07426101A0124|16 45|lipoprotein lipid concentrations
P07426101A0124|46 83|adipose tissue lipoprotein lipase activity
P07426101A0124|84 101|anthropometric data
P07426101A0124|102 119|alcohol consumption
P07426101A0124|120 132|smoking habits
P07426101A0124|166 181|bicycle ergometer
P07426101A0124|211 224|training period
P07426745A0177|20 49|blood erythrocyte membrane injury
P07426745A0177|91 106|gamma-irradiaton
P07428037A0989|34 47|mouse mt 12S rRNA
P07428037A0989|68 85|bp hairpin structure
P07428037A0989|196 210|mRNA binding site
P07428037A0989|233 252|corn chloroplast rRNAs
P07429009T0121|21 42|cell population dynamics
P07431059A0000|6 18|cadaver brains
P07431059A0000|42 54|magnification
P07431059A0000|98 109|pineal region
P07431059A0000|125 136|relationship
P07431059A0000|183 198|cerebellar artery
P07432288A0218|0 17|Serum antibody titre
P07432288A0218|54 67|recurrence rate
P07434456A0286|95 110|% glycerol content
P07434456A0286|114 125|measurements
P07435185A0074|95 105|drill biopsy
P07436459A0245|95 113|vitamin B6 deficiency
P07436459A0245|151 170|tryptophan metabolism
P07436702A0156|3 16|control persons
P07436794A0148|3 14|control group
P07436794A0148|25 39|carotid arteries
P07438346A0381|14 36|lidocaine concentrations
P07438482A0145|44 55|blood samples
P07438482A0145|72 84|determination
P07440085T0061|0 15|Arm function tests
P07440430A1074|200 223|hemoglobin concentrations
P07445971A0241|61 73|nerve ligation
P07449253A0411|119 129|blood volume
P07450031A0691|6 21|sedative activity
P07450031A0691|67 82|benzothiazepin-6
P07450031A0691|133 148|benzothiazepin-6
P07450388A0406|86 99|pressure sensor
P07450388A0406|106 122|duodenofiberscope
P07453919A0000|44 57|investigations
P07453919A0000|75 88|blood cell count
P07453919A0000|102 115|determinations
P07453919A0000|127 141|acid phosphatase
P07453919A0000|228 243|blood neutrophils
P07455042A0457|69 95|Dynamic Spatial Reconstructor
P07455042A0457|121 137|density resolution
P07455042A0457|163 175|contrast agent
P07455042A0457|244 255|measurements
P07458171A0086|29 42|Platyhelmintha
P07461226A0958|63 79|plasma epinephrine
P07461226A0958|82 101|norepinephrine levels
P07461848A0230|18 31|concentrations
P07461848A0230|52 63|tobacco smoke
P07461848A0230|105 117|micrograms/m3
P07461848A0230|139 151|micrograms/m3
P07462481A0422|10 31|backscatter coefficient
P07463294A1216|12 23|tumor relapse
P07463465A0297|34 45|control women
P07466831A0714|0 16|Pentachlorophenol
P07466831A0714|38 49|HCB porphyria
P07466831A0714|88 105|porphyrin excretion
P07466831A0714|140 155|porphyrin pattern
P07467975A0316|0 13|Family planning
P07467975A0316|88 101|contraceptives
P07467975A0316|193 204|secundiparae
P07467975A0316|243 256|multigravidity
P07467975A0316|290 301|reproduction
P07467975A0316|326 342|behaviour patterns
P07469692A0000|3 23|term osteomesopycnosis
P07469692A0000|48 58|bone disease
P07471210A0384|102 114|messenger RNAs
P07472582A0993|3 16|identification
P07472582A0993|43 59|99mTc-tetrofosmin
P07473169A0133|80 98|superoxide dismutase
P07473169A0133|102 119|catalase activities
P07473742A0187|3 14|protein ELT-1
P07473742A0187|67 96|vertebrate transcription factors
P07474078A0838|45 62|integration studies
P07474078A0838|93 106|CA dinucleotide
P07474078A0838|155 173|integration activity
P07474085A0932|55 68|frameshift site
P07474124A1360|66 88|parainfluenza virus genus
P07474124A1360|145 156|requirements
P07474124A1360|183 195|F glycoprotein
P07474140A1036|65 81|amino acid residues
P07474140A1036|112 124|ICP27 homologs
P07474140A1036|132 144|herpesviruses
P07474451A0000|8 23|resonance imaging
P07474451A0000|91 105|signal intensity
P07474772A0274|3 29|Laser Scanning Ophthalmoscope
P07475733T0000|17 33|HIV-1 transmission
P07476164A1602|40 55|resonance studies
P07476164A1602|142 152|CspB protein
P07476701A0654|24 36|IgE antibodies
P07476701A0654|86 99|correspondence
P07476963A0000|49 66|retinoid X receptors
P07476963A0000|81 96|hormone receptors
P07476971A0381|35 49|SKUT-1B-20 cells
P07476971A0381|57 80|transcription factor Pit-1
P07476975A0492|22 33|somatotropes
P07476975A0492|48 59|gonadotropes
P07476975A0492|165 176|distribution
P07477245A0625|13 25|A. parasiticus
P07477245A0625|41 58|aflatoxins B1 B2 G1 G2
P07477245A0625|99 112|concentrations
P07478523A0551|32 45|amino acid forms
P07478523A0551|123 139|RET protein isoform
P07478525A1177|13 25|MHBst proteins
P07478525A1177|78 89|dimerization
P07479004A0421|17 35|mobility shift assays
P07482069A0606|56 73|vasculitis symptoms
P07483276A0139|39 51|reading frames
P07483276A0139|124 143|herpes simplex virus-1
P07483276A0139|149 165|pseudorabies virus
P07483276A0139|175 187|herpesvirus-1
P07483276A0139|191 211|varicella-zoster virus
P07483285A0322|5 19|HPV16 E6/E7 cDNAs
P07483285A0322|38 58|SV40 enhancer/promoter
P07483285A0322|113 126|transformation
P07483285A0322|149 160|DNA synthesis
P07483285A0322|183 195|E7 gene product
P07483857A0350|0 22|Correlation coefficients
P07483857A0350|33 48|reference methods
P07483857A0350|93 132|connective-tissue-protein frei meat protein
P07483857A0350|147 171|connective-tissue-protein
P07487067A0592|3 21|translation products
P07487067A0592|149 163|transit peptides
P07487067A0592|167 185|plastid localization
P07487363A0447|3 13|serum levels
P07487363A0447|50 62|food allergens
P07487811A0000|72 83|bone turnover
P07487811A0000|111 129|Systems Experiment-1
P07487908A0230|31 43|transcription
P07487908A0230|61 91|chloramphenicol acetyltranferase
P07488247T0000|20 42|aryl hydrocarbon receptor
P07488247T0000|50 73|translocator interactions
P07488247T0000|78 100|aryl hydrocarbon receptor
P07488291A0934|15 26|observations
P07488291A0934|41 52|somatostatin
P07488291A0934|56 77|triamcinolone acetonide
P07488291A0934|133 154|triamcinolone acetonide
P07488959T0000|35 51|lymphocytopoiesis
P07489502A0000|3 26|influenza virus NS1 protein
P07489502A0000|150 165|pre-mRNA splicing
P07490156A0647|13 29|nicotine treatment
P07490278A0799|55 70|mother cell cortex
P07490742A0636|43 61|dsRNA binding domains
P07490766T0000|70 88|c-Myc leucine zippers
P07490766T0000|124 135|interactions
P07490766T0000|166 183|heterodimerization
P07490770A0267|151 165|DNA endonuclease
P07491111A0221|16 26|DMS-79 cells
P07491111A0221|63 76|cell lung cancer
P07491305A0102|27 38|localization
P07491305A0102|43 58|accessory pathway
P07491305A0102|114 124|sinus rhythm
P07491305A0102|152 168|delta wave polarity
P07491791A0263|3 18|promoter mutation
P07491791A0263|42 52|E1A products
P07491791A0263|70 89|helper adenovirus type
P07493627A0882|137 150|EC-1 expression
P07494244A0335|45 57|transcription
P07494244A0335|92 107|ATF/CREB proteins
P07494274A1015|155 170|virion maturation
P07494293A0585|53 83|T-cell signal transduction cascade
P07494303A0000|5 29|immunodeficiency virus type
P07494303A0000|115 135|monocytes/macrophages
P07494306A0240|47 58|interactions
P07494306A0240|208 218|protein VP22
P07494314A1287|37 58|kinase interaction sites
P07494314A1287|62 84|tyrosine phosphorylation
P07494314A1287|90 102|LMP2A homologs
P07494314A1287|138 159|sequences heterogeneity
P07494314A1287|176 188|repeat regions
P07495059T0078|12 39|ECAT Angina Pectoris Study Group
P07495120A0260|98 113|radiation therapy
P07495726A1189|66 91|recombination hotspot region
P07495726A1189|97 115|Bcl-2 proto-oncogene
P07496184T0001|63 84|Vienna University Clinic
P07496400A0525|196 209|inflorescences
P07498727A0724|47 62|T.A transversions
P07498727A0724|68 79|rad18 mutator
P07498727A0724|101 113|substitutions
P07498727A0724|148 162|T.A transversion
P07498791A0680|98 110|protein kinase
P07498791A0680|133 155|osmolarity stress pathway
P07499242A0898|47 61|RAFTK expression
P07499252A0150|2 16|hGM-CSF receptor
P07499252A0150|36 52|consensus sequence
P07499409A0367|103 119|targeting sequence
P07499421A0237|58 79|rat hepatocytes plasmids
P07499421A0237|123 169|chloramphenicol acetyltransferase reporter plasmid
P07499848A0409|78 91|germ-line gamma
P07499848A0409|96 113|epsilon transcripts
P07500386A0870|12 32|GapIII protein activity
P07500950A0000|1 16|tobacco homologue
P07500950A0000|40 72|Agrobacterium rhizogenes Ri-plasmid
P07500950A0000|98 117|Nicotiana tabacum L. cv
P07500953A0305|4 17|ADR1 gene dosage
P07500953A0305|30 42|transcription
P07501016T0000|34 51|galaxy TXFS2226-184
P07501458A0578|15 35|C/EBP family inhibitors
P07501700A0000|23 41|pretreatment regimen
P07501700A0000|46 65|monophosphoryl lipid A
P07501700A0000|71 87|micrograms/kg i.v.
P07501992A0125|26 41|scanning electron
P07501992A0125|69 88|spectroscopy analysis
P07504171A0715|17 36|growth factor receptor
P07504171A0715|43 56|phosphopeptide
P07504171A0715|101 112|Src SH2 domain
P07504171A0715|133 149|PDGF-R binding site
P07504171A1214|16 28|Src SH2 mutants
P07504171A1214|37 53|binding properties
P07504171A1214|100 123|crystal structure solution
P07504171A1214|130 141|Src SH2 domain
P07504712A0843|5 16|observations
P07504712A0843|21 39|actin plaque assembly
P07504712A0843|51 71|cell substrate adhesion
P07505798A0000|32 55|type A influenza A/Japan/57
P07505798A0000|60 72|hemagglutinin
P07505798A0000|107 131|histocompatibility complex
P07505798A0000|160 171|T lymphocytes
P07507187T0000|24 36|DNA expression
P07507187T0000|49 65|cointernalization
P07507207A0991|16 29|IRF binding site
P07507207A0991|47 59|IRF-2 promoter
P07507207A0991|122 136|IRF-1 expression
P07507458A0250|83 97|hepatitis C virus
P07507458A0250|127 137|RIBA methods
P07508140A0448|0 23|Hepatitis B surface antigen
P07508140A0448|58 80|hepatitis C virus antibody
P07508250A0537|53 66|selenium intake
P07508250A0537|70 95|liver selenium concentration
P07508250A0537|134 150|time liver selenium
P07508250A0537|226 238|investigation
P07508441A0487|86 99|56K autoantigen
P07508441A0487|103 117|HeLa cell extract
P07508441A0487|136 149|cDNA sequencing
P07508441A0487|165 177|56K cDNA shares
P07508441A0487|220 236|amino acid sequence
P07508441A0487|353 372|binding protein family
P07508954A0000|16 32|complex peroxidase
P07508954A0000|59 76|Mycobacterium bovis
P07508954A0000|124 136|Ziehl-Neelsen
P07509053A0139|77 89|establishment
P07509449A0000|29 44|sarcoma virus CT10
P07509449A0000|53 65|fusion protein
P07509449A0000|98 109|Gag sequences
P07509449A0000|155 172|Src homology regions
P07509449A0000|184 195|SH3 sequences
P07509450A0705|12 29|methylation pattern
P07509450A0705|36 47|inactivation
P07509450A0705|83 98|cytosine residues
P07509450A0705|108 125|nucleotide sequence
P07509450A0705|154 170|HSV tk gene activity
P07509472A1320|14 27|study documents
P07509472A1320|53 70|neovascularization
P07509472A1320|87 110|alpha interferon treatment
P07509624T0000|22 32|11q23 region
P07509624T0000|43 63|chromosome aberrations
P07509624T0000|91 108|gel electrophoresis
P07509811A1357|10 28|CRE oligonucleotides
P07509811A1357|57 70|protein binding
P07509811A1357|101 114|protein binding
P07509811A1357|140 155|oligonucleotides
P07509811A1357|183 201|CRE oligonucleotides
P07509811A1357|229 247|CRE oligonucleotides
P07509811A1357|364 383|transcription factors
P07509811A1357|402 421|transcription factors
P07509811A1357|424 438|chromaffin cells
P07510461A0731|20 36|test abnormalities
P07510635A0479|84 96|transcription
P07511444A0728|0 11|HCV infection
P07511444T0000|0 23|Hepatitis C virus infection
P07511444T0000|40 51|liver failure
P07511444T0000|82 106|bone marrow transplantation
P07511496A1511|4 23|plasma concentrations
P07511818A0485|30 44|cell populations
P07511818A0485|177 189|control vector
P07511818A0485|204 219|IFN-beta sequence
P07512159A0992|16 34|polypyrimidine tract
P07512159A0992|51 68|splicing efficiency
P07512159A0992|116 134|branchpoint mutation
P07512258A0441|0 19|Liver transplantation
P07512258A0441|49 61|complications
P07513703T0000|29 54|protein tyrosine phosphatase
P07513703T0000|109 134|insulin receptor substrate-1
P07514295A0000|0 22|Tyrosine phosphorylation
P07514295A0000|80 100|T-cell antigen receptor
P07514295A0000|152 169|signaling machinery
P07514301A0000|34 46|protein kinase
P07514301A0000|158 176|tumor suppressor gene
P07516337A1119|61 73|stoichiometry
P07516337A1119|110 120|Jurkat cells
P07516466A1054|119 142|phosphoprotein substrates
P07516466A1054|159 178|phosphorylation state
P07516466A1054|211 221|NIH 3T3 cells
P07516597A1017|67 84|polyprotein segment
P07516597A1017|103 115|proteinase NS3
P07516597A1017|118 134|antigen processing
P07516597A1017|138 149|presentation
P07516597A1017|174 189|T cell determinant
P07516866A0000|12 22|PRL receptor
P07516866A0000|76 97|pigeon crop sac libraries
P07516866A0000|110 122|transcription
P07516866A0000|134 156|polymerase chain reaction
P07517544A0515|89 100|pancreatitis
P07517869A0411|14 30|dephosphorylation
P07517869A0411|143 163|phosphatase inhibitors
P07517869A0411|184 202|sodium orthovanadate
P07518257A0351|28 44|S1 nuclease mapping
P07518426A0000|0 12|Interleukin-8
P07518426A0000|70 84|C-X-C chemokines
P07518561A0496|22 48|p72syk protein tyrosine kinase
P07518561A0496|78 91|TCR/CD3 complex
P07518561A0496|140 157|receptor triggering
P07518578A0000|24 39|Rous sarcoma virus
P07518578A0000|143 154|localization
P07518578A0000|170 183|binding ability
P07519447T0000|0 11|Organization
P07519447T0000|55 67|oxide synthase
P07519463A0000|37 50|work efficiency
P07519463A0000|51 70|segment work/regional
P07519481A1275|26 44|follicle development
P07519481A1275|101 112|KL expression
P07519481A1275|115 127|follicle cells
P07519481A1275|153 164|oocyte growth
P07519606A1269|0 12|Anti-NPROSP-C
P07519606A1269|71 82|proSP-C forms
P07519606A1269|85 98|lamellar bodies
P07521009A0377|109 121|DNA mismatches
P07521285A1109|44 55|nerve lesions
P07521285A1109|109 136|motor conduction abnormalities
P07521285A1109|171 185|F wave parameters
P07521285A1109|198 213|chronodispersion
P07521285A1109|263 276|minimum latency
P07521285A1109|296 307|F wave studies
P07521601A0000|13 25|growth factors
P07521601A0000|63 74|myelopoiesis
P07521601A0000|93 104|chemotherapy
P07521601A0000|107 120|cancer patients
P07521916T0000|36 48|site sequences
P07521916T0000|56 80|immunodeficiency virus type
P07522163T0000|0 11|Presentation
P07522163T0000|15 37|horse cytochrome c peptide
P07522163T0000|63 87|histocompatibility complex
P07522163T0000|132 143|T lymphocytes
P07522163T0000|161 176|MHC anchor residue
P07522163T0000|211 224|CTL recognition
P07523363A0440|30 43|fragment island
P07523363A0440|89 117|USF2 translation initiation site
P07523710T0000|39 51|serum prostate
P07523710T0000|105 119|ultrasonography
P07524265T0000|27 43|stimulating factor
P07524265T0000|78 90|complications
P07525548A1380|30 45|ligand affinities
P07525548A1380|88 106|fibronectin variants
P07525548A1380|127 145|fibronectin variants
P07525596A0584|121 134|PPIase activity
P07525843A0859|17 30|H-2d NP peptides
P07525843A0859|55 67|H-2b NP peptide
P07525843A0859|99 109|target cells
P07525843A0859|184 217|histocompatibility complex molecules
P07526609A0736|53 72|PKR activator sequence
P07527168A0524|0 11|Microvessels
P07527168A0524|61 72|angiogenesis
P07528028A1192|39 63|FGF-1 cell surface receptors
P07528028A1192|105 117|transfectants
P07528028A1192|163 175|transfectants
P07528325A0165|84 102|transcription factor
P07528325A0165|193 204|DNA sequences
P07528325A0165|215 228|gene expression
P07528531A0904|73 87|blood cell counts
P07528667A0834|5 19|initiation sites
P07528746A1049|0 23|Phosphoamino acid analysis
P07528746A1049|38 50|ASGPR subunits
P07528746A1049|123 138|phosphoamino acid
P07528772A0616|28 39|requirements
P07528772A0616|43 59|ZAP-70 interaction
P07528772A0616|82 93|binding assay
P07528772A0616|110 147|glutathione S-transferase fusion proteins
P07528772A0616|270 281|TCR zeta chain
P07528772A0616|282 291|TCR zeta cyt
P07528772A0616|314 332|CD3 epsilon TAM motifs
P07528772A1539|35 45|TAM peptides
P07529124A0119|174 191|amino acid sequences
P07529504A0000|33 47|characteristics
P07529504A0000|71 97|X-ray contrast agent iopromide
P07530502A0974|38 53|SI4-h220 cultures
P07530502A0974|85 99|c-kit expression
P07530502A0974|106 123|protein degradation
P07530502T0000|14 24|Steel factor
P07530502T0000|46 69|tyrosine kinase activation
P07530549A0956|37 49|GRAIL programs
P07531321A0369|23 33|PVC/24 hours
P07531321A0369|49 60|distribution
P07531321A0369|69 80|CI evaluation
P07533527A0128|60 72|hybridization
P07533758A1038|3 20|amino acid sequences
P07533758A1038|42 53|RfbB homologs
P07533858A1503|15 34|alanine substitutions
P07533858A1503|63 75|substitutions
P07533858A1503|89 103|oligomerization
P07533880T0000|3 13|FinO protein
P07533880T0000|16 27|IncF plasmids
P07533880T0000|80 94|duplex formation
P07534285A0155|23 35|ligand binding
P07534285A0155|43 65|tyrosine phosphorylation
P07534285A0155|105 115|Mpl receptor
P07534286A0842|1 19|chicken paxillin cDNA
P07534297A0141|21 42|pair HindIII DNA fragment
P07534297A0141|74 91|AP endonuclease gene
P07534297A0141|100 131|chloramphenicol acetyltransferase
P07534306A0444|27 41|GrsA derivatives
P07534306A0444|93 107|deletion mutants
P07534306A0444|162 180|amino acid activation
P07534306A0444|181 206|carboxyl thioester formation
P07534306A0444|248 260|phenylalanine
P07535593A0714|5 20|T-cell precursors
P07535593A0714|28 40|V delta 2D delta
P07535593A0714|42 55|rearrangements
P07535768A1076|16 32|expression pattern
P07535768A1076|105 125|MAP kinase phosphatases
P07537267A2094|73 86|HPFH-3 deletion
P07537267A2094|185 201|gamma-globin genes
P07537362A1112|24 49|Shb-SH3 domain proteins v-Src
P07537362A1112|70 90|coimmunoprecipitation
P07537736A0453|165 191|cytokine receptor superfamily
P07537851A0000|0 12|Transcription
P07537851A0000|26 45|cell adhesion molecule
P07537851A0000|86 103|lipopolysaccharide
P07537851A0000|122 147|cytokines interleukin-1 beta
P07537851A0000|151 174|tumor necrosis factor alpha
P07538068A1094|29 42|control element
P07538068A1094|79 91|Hox expression
P07538068A1094|107 120|Hoxa-7 enhancer
P07538122A0800|37 47|Fab fragment
P07538173A0307|23 45|DNA-RNA helicase activity
P07538173A0307|54 66|ATP hydrolysis
P07538818A0197|34 57|growth signal transduction
P07538818A0197|91 112|amino acid substitutions
P07538818A0197|205 217|interleukin-3
P07538818A0197|238 250|FDCP cell lines
P07539119A0291|51 67|c-abl kinase domain
P07539119A0291|70 81|NH2-terminus
P07539119A0291|85 97|G128R mutation
P07539119A0291|105 118|transformation
P07539119A0291|153 163|G128R mutant
P07539119A0985|44 55|Abl SH3 domain
P07539119A0985|70 83|target proteins
P07539314T0000|85 96|nifurpirinol
P07540607A0709|66 79|immunoglobulin
P07540866A1069|13 25|insulin effect
P07540866A1069|36 50|ras GTP formation
P07540866A1069|54 70|MAP kinase activity
P07540866A1069|86 97|A/K1018 cells
P07541589A0652|28 39|cancer volume
P07541589A0652|81 95|vesicle invasion
P07541589A0652|99 117|lymph node metastasis
P07541912A0485|0 15|Sequence analysis
P07541912A0485|67 83|G-C content regions
P07542577A0438|3 16|fusion proteins
P07542616A0486|99 121|yeast initiation factor-3
P07542616A0486|195 215|translation initiation
P07542698A0137|43 54|preparations
P07542698A0137|83 93|probe RH-414
P07543592A0624|82 112|receptor tyrosine phosphorylation
P07543592A0624|116 130|down-regulation
P07543684A1027|63 80|CFTR gene expression
P07543868A0414|11 26|restriction sites
P07543868A0414|62 73|cDNA fragment
P07544357A0808|12 23|ALVA-31 cells
P07544357A0808|31 43|tumorigenesis
P07544357A0808|47 58|invasiveness
P07544357A0808|145 155|CD44 variant
P07544357A0808|184 204|prostate tumor behavior
P07545510A0735|3 13|gene product
P07545510A0735|67 80|immunoblotting
P07546293A0968|21 34|protein binding
P07546294A0000|3 15|RAD6/UBC2 gene
P07546794A0100|0 15|Echocardiography
P07547220A0229|10 28|screening programmes
P07547220A0229|32 45|Haemoccult test
P07547500A0066|23 35|fusion protein
P07547500A0066|94 113|chicken l kappa B-alpha
P07547510A0261|56 72|HNF-3 beta promoter
P07547510A0261|170 180|binding site
P07547510A0261|241 263|HNF-3 beta gene expression
P07548425A0000|133 153|tail muscle motoneurons
P07549005A0530|7 26|parallax measurements
P07549005A0530|53 64|Epon sections
P07551787A0917|15 26|optimization
P07551787A0917|57 69|investigation
P07551787A0917|125 145|radiotherapy technique
P07552974A0217|8 19|requirements
P07553942A0810|3 16|pea rps10 intron
P07553942A0810|94 112|Marchantia rps10 gene
P07554541A0587|68 90|electrolyte disturbances
P07555373A0000|0 13|Serum magnesium
P07557091A0314|19 30|serum albumin
P07557276A0526|0 22|Alanine aminotransferase
P07557387A0241|120 137|NIH-3T3 fibroblasts
P07557424A0124|33 43|fusion clone
P07557424A0124|66 78|fusion library
P07557717A0184|20 35|chest wall muscles
P07558263T0000|29 53|guillotine amputation wound
P07558583A0562|84 100|peptide substrates
P07558583A0562|137 158|tyrosine kinase activity
P07559233A0534|0 22|Citrate synthase activity
P07559233A0534|90 109|triceps brachii muscle
P07559347A0000|26 36|operon bglPH
P07559347A0000|39 54|Bacillus subtilis
P07559355A0066|40 53|urease activity
P07559355A0066|98 109|organization
P07559355A0066|147 164|Proteus gene cluster
P07559356T0000|3 16|hypBFCDE operon
P07559356T0000|21 54|Rhizobium leguminosarum biovar viciae
P07559402A0622|58 71|protein kinase C
P07559402A0622|90 103|protein kinase A
P07559488A0440|0 17|Control experiments
P07559488A0440|32 44|fusion protein
P07559488A0440|53 71|affinity binding site
P07559488A0440|75 90|estradiol-17 beta
P07559488A0440|122 133|reporter gene
P07559510A0000|8 38|Micrococcus luteus UV endonuclease
P07559510A0000|103 115|endonuclease V
P07559510A0000|120 134|bacteriophage T4
P07559524A0000|28 40|growth factors
P07559524A0000|48 65|G1 phase progression
P07559524A0741|0 23|Cyclin D1 promoter activity
P07559524A0741|39 52|overexpression
P07559524A0741|72 84|protein kinase
P07559639A0996|13 32|R206S HSF substitution
P07559639A0996|83 94|consensus HSE
P07560137T0000|28 49|MMPI-2 depression scales
P07560662A0496|24 38|saline challenge
P07563072A0773|13 33|rrnB P1-lacZ expression
P07563072A0773|45 55|ppGpp levels
P07563072A0773|105 120|hypersensitivity
P07563076A0766|5 18|intron chimeras
P07563076A0766|73 83|splice sites
P07563076A0766|228 243|splicing proteins
P07563090A0124|43 54|DNA synthesis
P07563090A0124|60 74|yeast Ty1 element
P07563090A0624|0 15|Characterization
P07563090A0624|42 53|DNA fragments
P07563090A0624|176 187|DNA fragments
P07563090A0624|214 230|primer binding site
P07563090A0624|281 303|RNA reverse transcription
P07564004A0292|17 31|Cr2O3 inhalation
P07565031A0454|6 17|food products
P07565031A0454|38 49|V. cholerae O1
P07565031A0454|93 103|cream cheese
P07565031A0454|104 119|apricot marmelade
P07565031A0454|182 192|meat sausage
P07565031A0454|200 213|spinach ravioli
P07565031A0454|223 233|milk dessert
P07565031A0454|247 259|milk confiture
P07565113A0000|29 44|transposon Tn4451
P07565113A0000|87 105|parent plasmid plP401
P07565113A0000|108 129|Clostridium perfringens
P07565685A0420|3 18|peptide sequences
P07565685A0420|79 89|Notch motifs
P07565688A0797|0 27|Immunofluorescence microscopy
P07565688A0797|31 55|cell fractionation analyses
P07565688T0000|66 83|adenosine deaminase
P07565709A0000|0 15|T-cell hybridomas
P07565709A0000|96 109|T-cell receptor
P07565712A0286|136 151|quasipalindromes
P07565713A0634|0 13|Overexpression
P07565713A0634|40 55|HSP60-null allele
P07565713A0634|106 118|Hsp60 activity
P07565720A0256|3 18|DNA binding domain
P07565720A0256|40 52|fusion protein
P07565720A0256|60 83|glutathione S-transferase
P07565720A0256|86 105|Schistosoma japonicum
P07565723A0200|35 49|phosphorylation
P07565723A0200|79 93|differentiation
P07565731A1629|28 42|mRNA degradation
P07565731A1629|96 113|ribonucleoproteins
P07565736A2134|50 76|GM-CSF receptor alpha promoter
P07565775A1265|110 121|EpG formation
P07565775T0000|105 115|GMP transfer
P07565776A0612|60 76|HSP12 inducibility
P07565776A0612|103 116|overproduction
P07565776A0612|189 205|salt concentration
P07565797A0116|10 21|inactivation
P07567079A0014|24 41|Cryptosporidium spp
P07567079A0014|96 110|density gradient
P07567079A0014|188 200|contamination
P07567979A1266|78 91|testis receptor
P07567980T0000|18 31|domain peptides
P07568116A0902|3 16|hydropathy plot
P07568116A0902|86 98|signal peptide
P07568118A1267|44 61|Shc phosphorylation
P07568118A1267|104 119|p21ras activation
P07568118A1267|151 185|growth factor tyrosine kinase receptors
P07568576A0074|22 33|relationship
P07568576A0074|41 53|Type A behavior
P07568576A0074|67 83|emotion dimensions
P07568865A0305|22 34|contamination
P07569075A0585|16 33|lung cancer patients
P07569075A0585|106 121|chest radiography
P07569640A0539|0 21|Protein electrophoresis
P07569640A0539|37 49|albumin levels
P07569770A0298|17 30|non-responders
P07569770A0298|85 96|immunization
P07569770A0298|101 111|booster dose
P07571766A0122|80 94|catheterization
P07571766A0122|137 157|ST-segment depressions
P07571953T0000|27 38|mycobacteria
P07572582A0000|27 43|calcium antagonist
P07572582A0000|52 64|chemical class
P07572582A0000|108 121|calcium channel
P07574064A1416|23 45|concentration anesthesia
P07574064A1416|157 176|response relationship
P07574682T0000|51 69|alkaline phosphatase
P07575416A0000|0 13|Protein kinase C
P07575416A0000|150 167|tissue distribution
P07575416A0000|179 190|localization
P07575416A1970|61 75|oligonucleotide
P07575416A1970|96 106|PKC zeta mRNA
P07576178A0000|0 23|Polypeptide growth factors
P07576179A0781|36 51|CpG dinucleotides
P07576307A0144|68 80|rat enkephalin
P07576307A0144|122 140|enkephalin phenotype
P07576307A1654|115 127|tumor cell line
P07577904A0141|92 103|camera aquosa
P07577904A0141|142 155|microphthalmos
P07579023A0214|9 20|dose-finding
P07579023A0214|119 130|liver enzymes
P07579164A0409|41 56|RNA editing events
P07579328A0653|14 38|CAT reporter gene expression
P07579328A0653|42 57|GAL4 binding sites
P07579328A0653|79 93|cell lines NIH 3T3
P07579328A1345|21 36|DNA binding domain
P07579328A1345|51 72|reporter gene expression
P07579683A0660|10 31|hGMR beta subunit mutants
P07579683A0660|86 98|c-myc promoter
P07579695A0336|96 127|yeast centromere protein genes-CEP1
P07579695A0693|36 46|Mif2 protein
P07579695A0693|90 104|yeast centromere
P07579704A0085|16 26|actin cables
P07580058A0000|12 29|Codonopsis pilosula
P07580058A0000|46 76|tissue-type plasminogen activator
P07580058A0000|84 112|plasminogen activator inhibitor
P07580058A0000|149 160|heart disease
P07580058A0000|165 175|blood stasis
P07580782T0000|0 14|Imaging features
P07580782T0000|24 37|epidermoid cyst
P07582316A0696|63 83|IS6110 banding patterns
P07582592A0545|121 134|administration
P07582592A0545|151 173|botulinum toxin injection
P07583190A0306|104 118|brain potentials
P07583190A0306|157 181|phrase structure violations
P07583562A1826|117 128|hypertension
P07585246T0000|0 16|SL1 trans-splicing
P07585246T0000|66 94|Caenorhabditis elegans pre-mRNA
P07585559A0000|37 52|2-hydroxyethoxyl
P07585559A0000|61 78|methyl-1M-pyrazo lo
P07585559A0000|152 184|muscle alpha-actin promoter activity
P07586403A0765|27 51|risk factor-selection scale
P07588240A0000|3 46|Caenorhabditis elegans death susceptibility gene
P07588240A0000|100 116|interleukin-1 beta
P07588245T0000|12 25|glucocorticoid
P07588245T0000|80 101|thyroid hormone receptor
P07588608A1687|16 35|ERF repressor function
P07588608A1687|84 98|i.e.gag-myb-ets
P07588608A1687|143 159|cell proliferation
P07588628A0318|0 13|Overexpression
P07588633A0362|18 42|c-fos protooncogene product
P07588633A0362|163 173|NIH 3T3 cells
P07588750T0061|65 80|Pyrococcus woesei
P07588750T0061|101 116|characterization
P07588777A1524|5 16|observations
P07588777A1524|96 112|p44mapk MAP kinases
P07589069A1245|146 157|reading frame
P07590264A0373|43 57|polyadenylation
P07590264A0373|172 187|end RNA processing
P07590264A0373|244 257|gene expression
P07590268A0350|79 96|sequence similarity
P07590268A0740|7 22|MAPKAPK-2 message
P07590283A0820|27 40|Pol beta protein
P07590283A0820|79 96|polymerase activity
P07590283A0820|137 155|template utilization
P07590283A0820|165 186|polymerization reaction
P07590525A0811|29 40|revertants/g
P07590657A0624|0 14|Cholangiography
P07590744A0829|17 28|cDNA sequence
P07592072A0217|116 135|prostaglandin F2 alpha
P07592220A0846|25 41|minute ventilation
P07592220A0846|44 60|oxygen consumption
P07592439A0000|42 62|Listeria monocytogenes
P07592467A0000|14 36|peroxisome proliferation
P07592485A0734|15 28|gene expression
P07592485A0734|93 106|NCR sensitivity
P07592485A0734|145 161|ure2 delta mutation
P07592647A0797|18 46|DNA Pur alpha recognition element
P07592647T0000|33 53|retinoblastoma protein
P07592647T0000|92 120|DNA Pur alpha recognition element
P07592658A0309|54 71|p50/p65 heterodimer
P07592676A0466|120 136|repressor activity
P07592706A1465|70 80|lipase ratio
P07592710T0000|23 38|protein kinase PKR
P07592710T0000|78 100|immunoglobulin kappa gene
P07592711T0000|22 33|yeast protein
P07592711T0000|57 86|G protein alpha subunit deficiency
P07592711T0000|107 117|beta subunit
P07592723A0814|0 12|Phorbol esters
P07592723A0814|23 37|phosphorylation
P07592723A0814|40 53|CSK 35H proteins
P07592723A0814|101 118|PKC binding activity
P07592723A0814|133 145|PKC substrates
P07592730A0204|8 20|TSG-14 protein
P07592730A0204|102 119|lipopolysaccharide
P07592730A0204|152 164|phase proteins
P07592730A0204|174 188|TSG-14 synthesis
P07592946A0261|33 44|p44 MAP kinase
P07592946A0261|88 100|determination
P07592946A0261|106 126|intron/exon boundaries
P07592946A0261|133 148|characterization
P07592946A0997|52 67|start sites region
P07592946A0997|149 160|binding sites
P07592946A0997|178 190|binding factor
P07593266A1174|71 87|pair stem structure
P07593896A1053|21 40|measurement technique
P07593896A1053|66 80|P0.1 measurement
P07594047T0000|39 58|afterdepolarizations
P07594592A0755|13 41|NF-IL6 beta leucine zipper domain
P07595221A0733|125 136|transfection
P07595374A1215|201 212|LMP1 promoter
P07595857A0521|3 16|peak velocities
P07595857A0521|75 88|flow velocities
P07595857A0521|277 289|cardioversion
P07595857A0521|327 339|cardioversion
P07595857A0521|382 395|cardiomyopathy
P07596283A0396|41 53|triglycerides
P07596287A0183|3 20|nucleotide sequence
P07596287A0183|58 70|reading frames
P07596287A0183|94 108|protein products
P07596287A0183|158 190|cassette membrane transport proteins
P07596287A0183|237 249|export systems
P07596287A1724|32 43|bp transcript
P07596287A1724|94 108|mutagenesis data
P07596558A0824|26 39|concentrations
P07596697A0971|38 53|motilin responses
P07596697A0971|112 123|control group
P07597030A0260|46 61|characterization
P07597488T0000|22 35|G6PD deficiency
P07597804A1007|67 86|glycoprotein gene EUS4
P07598106A0709|0 16|Mean growth changes
P07598106A0709|100 112|malocclusions
P07598303A1728|57 81|bone marrow transplantation
P07598303A1728|101 115|survival benefit
P07599449A0445|3 16|fracture groups
P07599449A0445|75 87|control groups
P07600111A0000|32 57|immunodeficiency virus types
P07600111A0000|204 217|police officers
P07600111A0000|220 232|Guinea-Bissau
P07600986A0605|9 28|immunoprecipitations
P07600986A0605|32 45|gel shift assays
P07600986A0605|138 155|transcription units
P07601078A1003|18 33|postexposure time
P07601078A1003|38 49|dioxin burden
P07601121A0153|104 116|transcription
P07601445A0207|16 37|BAT1 translation product
P07601445A0207|78 101|WM6 Drosophila gene product
P07601445A0207|126 146|Caenorhabditis elegans
P07601445A0207|166 178|protein family
P07601445A0207|194 205|RNA helicases
P07601827A0778|7 17|lacZ fusions
P07601827A0778|44 55|DNA sequences
P07601828A0095|25 40|characterization
P07601828A0095|58 71|flagellar genes
P07601828A0095|86 99|orfX-fliP locus
P07603726T0000|10 28|adaptation exercises
P07603726T0000|63 78|neuroma resection
P07603956A0115|91 103|incorporation
P07604047A0704|91 113|transcription-PCR method
P07604047A0704|183 195|fusion protein
P07604783A0952|45 59|acid composition
P07604783A0952|84 102|bile acid composition
P07605990A1110|70 91|GM-CSF promoter activity
P07605990A1110|161 173|PEBP2 isoforms
P07605990A1110|200 215|promoter activity
P07606548T0000|19 36|board certification
P07606548T0000|39 53|pharmacotherapy
P07606587A0266|0 22|Piperacillin-tazobactam
P07607197A1048|5 23|plasma renin activity
P07607213A0140|23 52|structure/activity relationship
P07607233A0186|44 54|epilancin K7
P07607233A0186|101 118|nucleotide sequence
P07607342A0703|70 94|aldose reductase inhibitors
P07607537A0954|98 117|VP16 activation domain
P07607607T0000|39 54|fructose infusion
P07607669A1112|43 53|CpG doublets
P07607669A1112|73 84|binding sites
P07608268A0194|32 45|GnRH deficiency
P07608268A0194|70 95|melatonin secretion profiles
P07608649A1429|9 21|blood pressure
P07608649A1429|28 39|CyA treatment
P07608968A0836|66 76|core domains
P07608968A0836|83 96|transactivator
P07608968A0836|132 144|transcription
P07609037A0775|97 112|DNA affinity resin
P07609037A0775|129 141|transcription
P07609037A0775|158 169|MMTV promoter
P07609079A0387|0 14|Transactivation
P07609079A0387|48 62|receptor mutants
P07609079A0387|147 170|transcription factor TFIIB
P07610052A1064|47 58|C35 complexes
P07610052A1064|112 126|EMSA experiments
P07610052A1064|161 172|observations
P07610052A1064|200 213|rat APP promoter
P07610324A0319|122 135|reconstruction
P07610716A0117|16 31|prevalence values
P07610716A0117|57 68|MS-frequency
P07610735A1471|77 87|sinus rhythm
P07614762A0224|15 25|antigen test
P07614762A0224|46 63|latex agglutination
P07615541T0000|51 88|mouse porphobilinogen deaminase gene locus
P07616056A0278|40 57|feedback inhibition
P07616056A0278|65 86|chain gene rearrangement
P07616563A0532|29 46|carAB control region
P07616563A0532|142 153|GATC sequence
P07616569A0168|42 58|cytochrome oxidase
P07616569A0168|66 79|apocytochrome b
P07616569A0168|101 124|NADH dehydrogenase complex
P07616569A0168|140 153|ATPase subunits
P07616802A0315|31 43|platelet count
P07616802A0315|134 149|heparin cessation
P07618280A0550|53 81|density gradient centrifugation
P07618548T0000|3 23|Babcock Surgical Clinic
P07622058A0411|3 20|PEBP2 alpha proteins
P07622058A0411|94 113|segmentation gene runt
P07622060A0967|89 103|thyroid hormones
P07622521A0418|27 49|G beta gamma binding region
P07622521A0418|134 149|carboxyl terminus
P07622521A0418|204 213|G beta gamma
P07622521A0418|217 227|PIP2 binding
P07623807A0162|42 54|Raf-1 proteins
P07623807A0162|95 109|plasma membranes
P07623814A1040|11 24|cotransfection
P07623814A1040|41 57|estrogen receptors
P07623814A1040|152 168|breast cancer cells
P07623821T0000|12 39|Gax homeobox gene transcription
P07623821T0000|96 109|enhancer factor
P07623825T0000|20 40|transactivation domain
P07623825T0000|43 57|heat shock factor
P07623840A0352|143 161|amino acid limitation
P07623844A0639|24 37|E1B 19K proteins
P07623844A0639|86 97|growth arrest
P07623844A0639|122 133|DNA synthesis
P07623844A0639|137 153|cell proliferation
P07624119A0528|27 57|PAX3-FKHR transactivation domains
P07624119A0528|75 87|test fragments
P07624119A0528|148 159|reporter gene
P07624581A0312|40 65|blood pressure determination
P07624581A0312|86 99|thyroid hormone
P07624581A0312|128 148|glutamine transaminase
P07624581A0312|163 187|triglycerides plasma levels
P07624581A0312|210 222|treatment days
P07624581A0312|237 247|days washout
P07624615A0267|15 29|body temperature
P07626378T0000|0 16|Hepatitis B vaccine
P07626469A1341|5 20|promoter activity
P07626469A1341|68 88|mouse Leydig tumor cells
P07626806A1098|30 40|acid protein
P07627317A1502|63 75|concentration
P07627317A1502|99 119|microgram/g creatinine
P07628389A0145|0 24|Tumor necrosis factor-alpha
P07628389A0145|80 101|testosterone production
P07628389A0145|104 119|mouse Leydig cells
P07628438T0000|13 34|insulin receptor homolog
P07628438T0000|82 97|receptor isoforms
P07628438T0000|111 128|signaling potential
P07628451A0114|28 42|phosphorylation
P07628451A0114|88 102|differentiation
P07628456A0000|18 33|RNA binding domain
P07628456A0000|58 71|amino acid motif
P07629103T0000|22 40|protein isoforms beta
P07629103T0000|112 134|beta-casein gene promoter
P07629113A0726|46 61|metalloproteases
P07629113A0726|81 96|N-ethylmaleimide
P07629122A0323|39 58|phosphorylation sites
P07629122A0323|85 98|protein kinases
P07629123A0885|26 39|leucine residue
P07629123A0885|83 100|heterodimerization
P07629150A0155|15 25|CYP11A1 gene
P07629150A0155|53 71|adrenocorticotropin
P07629150A0155|112 124|growth factors
P07629150A0155|199 224|signal transduction pathways
P07629163A0770|19 34|deletion analysis
P07629163A0770|67 104|guanine nucleotide exchange factor domains
P07629163A0770|122 134|zinc butterfly
P07629163A0770|151 164|transformation
P07629196A0274|62 73|alpha 12Q229L
P07629196A0274|83 94|alpha 13Q226L
P07629196A0274|149 161|protein kinase
P07630687A0010|62 74|family history
P07630687A0010|79 97|catheter association
P07630687A0010|170 181|antithrombin
P07630687A0010|196 215|protein S deficiencies
P07630687A0010|219 237|lupus anticoagulants
P07631267T0001|0 11|Radiotherapy
P07633444T0000|10 21|organization
P07633444T0000|38 54|expression pattern
P07633444T0000|60 83|mouse WD-repeat gene DMR-N9
P07633444T0000|116 129|dystrophy locus
P07633756A0690|3 21|ARX2 procedure models
P07633756A0690|65 85|background EEG activity
P07633756A0690|158 172|reference signal
P07633756A0690|244 262|artefact propagation
P07635312A0692|96 108|act1 mutations
P07635572A1153|90 102|re-expression
P07635572A1153|120 143|CIITA mRNA induction levels
P07636187A0585|17 37|protein expression data
P07636187A0585|46 60|gene transcripts
P07636337A0687|70 88|serum estradiol level
P07636408T0000|27 44|Tesla field strength
P07636408T0000|53 68|resonance imaging
P07636408T0000|112 133|intervertebral foramina
P07636648A1229|16 37|DTaP booster vaccination
P07636648A1229|72 98|serum antibody concentrations
P07636648A1229|121 134|concentrations
P07636648A1229|150 166|pertussis antigens
P07636962A1288|65 76|HSV-alpha TIF
P07636962A1883b|30 45|DNA binding domain
P07636962A1883b|81 92|BHV-alpha TIF
P07636962A1883b|113 127|carboxyl termini
P07637718A0218|14 26|messenger RNAs
P07637718A0218|35 50|trans-sialidases
P07637718A0218|86 98|epimastigotes
P07637718A0218|115 129|trypomastigotes
P07638517A0000|51 68|Sao Paulo City Morgue
P07638517A0000|81 102|individuals AIDS victims
P07638517A0000|134 153|police investigations
P07639703A1703|17 30|thyroid hormone
P07639703A1703|141 164|islet cell differentiation
P07640309A0000|13 28|peptide sequences
P07640309A0000|62 74|mobility group
P07640309A0000|77 103|box transcription factor TCF-1
P07640309A0000|130 145|splice mechanisms
P07640422A0649|0 12|Thromboxane B2
P07640422A0649|86 97|hemodialysis
P07640422A0649|108 119|hemodialysis
P07642538A0138|23 35|RSK activation
P07642538A0138|258 280|MAPK phosphorylation site
P07642538A0744|47 60|kinase activity
P07642544A0868|82 98|phenylarsine oxide
P07642544A0868|126 142|NF-kappa B activity
P07642633T0000|28 39|binding sites
P07642633T0000|53 72|transcription factors
P07642633T0000|120 148|transcription enhancer factor-1
P07644127A0000|157 179|rat substantia innominata
P07644127A0000|192 205|microinjection
P07644127A0000|233 252|acetylcholine agonist
P07644466A0578|36 52|NS3-4A polyprotein
P07644466A0578|59 80|serine proteinase domain
P07644466A0578|116 127|NS4A cofactor
P07644466A0578|174 189|trans-processing
P07644503A0729|10 24|over-expression
P07644503A0729|52 66|differentiation
P07644503A0729|115 125|target genes
P07646439A0535|31 47|platelet membranes
P07646439A0535|67 80|chromatography
P07646439A0535|91 118|mAb F11 affinity chromatography
P07647303T0000|3 18|homeobox gene ATK1
P07647303T0000|21 39|Arabidopsis thaliana
P07647303T0000|93 105|inflorescence
P07647570A0713|68 79|Kupffer cells
P07648338A0815|71 86|cytokine profiles
P07648338A0815|102 112|TNF response
P07648338A0815|127 143|SMA occlusion model
P07649098A0676|36 47|observations
P07649098A0676|50 70|transfection construct
P07649098A0676|155 172|reporter expression
P07649098A0676|192 209|reporter expression
P07649098A0676|276 288|IGF-I promoter
P07649098A0676|291 304|cotransfection
P07649098A0676|307 349|IGF-I promoter-luciferase-reporter constructs
P07649098A0676|373 385|alpha-isoform
P07649098A0676|429 441|protein kinase
P07649098A0676|485 497|PGE2 treatment
P07649098A0676|505 518|cotransfection
P07649098A0676|604 621|reporter expression
P07650958A0123|45 60|electromyography
P07650958A0123|76 91|motor improvement
P07651131A1407|25 47|footprinting experiments
P07651131A1407|63 81|kDa repressor isoform
P07651141A0265|16 27|p-gvpF-M mRNA
P07651340A0286|0 15|Retransformation
P07651340A0286|18 30|uvsH77 mutants
P07651340A0286|72 84|transformants
P07651340A0286|117 129|MMS resistance
P07651386A0925|29 40|p53 induction
P07651398A0257|10 20|dShc protein
P07651398A0257|76 102|growth factor receptor homolog
P07651398A0803|10 20|binding site
P07651398A0803|27 39|dShc PTB domain
P07651398T0000|14 24|gene product
P07651398T0000|53 77|DER receptor tyrosine kinase
P07651400A0335|107 123|consensus sequence
P07651424A0743|16 31|SSM1b transcripts
P07651424A0743|59 74|SSM1a transcripts
P07651734A0961|0 19|Northern blot analysis
P07651835A0652|18 32|binding affinity
P07652066A0677|155 166|system repair
P07652575A0435|11 24|microinjection
P07652575A0435|68 92|Rho inhibitor C3 transferase
P07652575A0435|113 124|DNA synthesis
P07652582A0000|0 15|INF-alpha therapy
P07653094A0169|22 36|deletion mutants
P07653094A0169|86 106|cell surface expression
P07653094A0169|190 202|plasmid vector
P07653094A0169|203 218|pcDL-SR alpha-296
P07653812T0000|11 40|acetyl cholinesterase inhibitors
P07653892A0306|16 28|isoflurane MAC
P07654239A0698|54 73|cell cycle progression
P07654712A0774|3 13|yeast enzyme
P07654740A0563|13 28|selection process
P07654740A0563|56 67|alternatives
P07654740A0563|70 84|transplantation
P07654740A0563|104 120|transplant work-up
P07654740A0563|129 145|inclusion criteria
P07654740A0563|192 208|disease etiologies
P07654740A0563|212 225|co-morbidities
P07654740A0563|244 260|contraindications
P07655184A0852|44 63|transmembrane protein
P07655184A0852|79 94|ER leader sequence
P07655505A0527|20 30|GT-2 protein
P07655505A0527|165 190|phytochrome A gene expression
P07655509T0000|21 32|motif signals
P07655509T0000|102 113|Pisum sativum
P07656588A0101|11 29|DNA sequence analysis
P07656588A0101|39 67|Genethon microsatellite D19S596
P07657162A1412|14 36|transcription activation
P07657162A1412|103 124|trans-activation domain
P07657668A0642|0 12|TH-SH3 binding
P07657668A0642|47 68|amino acid substitutions
P07657668A0642|78 88|Btk TH domain
P07657668A0642|94 105|Fyn SH3 domain
P07658262A0944|0 13|Protein S levels
P07658262A0944|131 142|procoagulant
P07658471A0000|3 19|plant hormone auxin
P07658777A0400|45 61|contraindications
P07659085A1520|13 50|transcription factor Oct-1 forms complexes
P07659085A1520|57 68|octamer motif
P07659085A1520|88 103|gel shift analysis
P07659085A1520|116 129|kidney extracts
P07659085A1520|178 195|androgen regulation
P07659515T0000|11 25|retrotransposon
P07659515T0000|84 117|Crithidia fasciculata miniexon arrays
P07659529A0135|6 21|deletion analysis
P07659529A0135|25 42|transfection assays
P07659529A0135|47 68|reporter gene constructs
P07659529A0135|81 108|transcription control elements
P07659746A1464|3 30|CVA16.4 proteolipid transcript
P07659746A1464|56 74|proteolipid messages
P07659746A1464|103 116|d post-anthesis
P07659757A0191|23 36|fusion proteins
P07659757A0191|103 121|autophosphorylation
P07663160A0287|12 22|DNA sequence
P07663160A0287|55 65|base pairing
P07663160A0287|170 186|protein expression
P07663963A1588|10 25|system activation
P07663963A1588|37 65|metanephrine/epinephrine ratio
P07663963A1588|121 132|cohabitation
P07663963A1588|175 188|control animals
P07665172A0000|0 19|Transcription factors
P07665187A0208|0 14|Primer extension
P07665187A0208|18 28|cDNA cloning
P07665187A0824|0 14|Primer extension
P07665187A0824|18 45|S1 nuclease mapping experiments
P07665187A0824|65 91|transcription initiation site
P07665187A0824|147 161|initiation sites
P07665567A0495|0 15|Sequence analysis
P07665567A0495|79 89|TATA element
P07665567A0495|119 145|transcription initiation site
P07665567A0495|164 179|binding sequences
P07665567A0495|192 211|transcription factors
P07665633A0284|44 56|disk diffusion
P07665633A0284|60 81|agar dilution procedures
P07665633A0284|97 113|National Committee
P07665633A0284|125 143|Laboratory Standards
P07665948A0591|78 91|children groups
P07666414A0614|54 67|microinjection
P07666414A0614|71 93|promoter/lacZ fusion gene
P07666414A0614|101 120|immunohistochemistry
P07666414A0614|160 176|anti-tropomyosins
P07666415A0000|3 20|nucleotide sequence
P07666523T0000|0 12|Investigation
P07666523T0000|48 64|mRNA transcription
P07666523T0000|98 111|RNA transcripts
P07666538A0000|33 47|hepatitis C virus
P07666538A0000|76 88|ribosome entry
P07667097A0267|24 40|splicing complexes
P07667097A0267|102 118|immunoprecipitate
P07667097A0267|138 153|splicing products
P07667195A0146|18 28|sulfate salt
P07667195A0146|79 89|dosage forms
P07667621T0001|0 23|Doppler ultrasound studies
P07668009A0172|23 40|hepatitis A diseases
P07669351A1278|23 38|SSB-ssDNA complex
P07670504A0834|41 54|banding pattern
P07670504A0834|117 128|binding assay
P07672821A0763|33 44|factor H genes
P07672821A0763|93 109|complement factor H
P07672822T0000|58 74|receptor alpha gene
P07673128A0989|28 46|cAMP response element
P07673154A0688|55 68|trypsinization
P07673178A0982|30 46|muscle gene E-boxes
P07673178A0982|102 123|MDF/bH-L-H heterodimers
P07673178A0982|131 146|MCK-L type E-boxes
P07674649A0508|36 49|baseline design
P07674649A0508|70 91|treatment effectiveness
P07675445A0463|65 90|sequence length polymorphism
P07675449A0848|5 24|glioblastoma cell line
P07676492A1000|68 87|transplant recipients
P07676587T0000|10 22|certification
P07676587T0000|26 40|livestock export
P07676655A0214|3 20|serum concentration
P07677836A1356|12 23|matter injury
P07677836A1356|90 108|leukoencephalopathy
P07677836A1356|139 150|chemotherapy
P07678006A0472|0 22|RNase protection analyses
P07678006A0472|47 56|CaM PDE mRNA
P07678006A0472|106 119|CaM PDE isoforms
P07678006A0901|68 79|kidney cortex
P07678006A0901|88 99|T-lymphocyte
P07678051A1303|3 14|PDGFR mutants
P07678051A1303|97 114|inositol phosphates
P07678242A0473|43 55|transcription
P07678593A0708|21 32|V. vulnificus
P07678593A0708|60 78|V. cholerae fur mutant
P07678602A0153|22 42|B lymphoblast cell lines
P07678695A0604|29 39|hybrid cells
P07679390A0721|0 14|RNase protection
P07679390A0721|18 38|primer extension assays
P07679390A0721|85 96|DDT1 aFGF mRNA
P07679390A0721|110 131|transcription start site
P07679390A0721|176 189|splice junction
P07679836A0387|61 81|kidney transplantation
P07680035A0221|10 22|phorbol esters
P07680035A0221|49 60|GnRH response
P07680120A1008|146 156|aFGF protein
P07680629T0000|19 34|characterization
P07680629T0000|59 81|cell surface glycoprotein
P07680629T0000|113 135|Dictyostelium discoideum
P07681147A1420|49 63|phosphorylation
P07681513A0000|16 32|phosphodiesterase
P07681513A0000|69 89|vasodilator properties
P07681539A0000|48 62|hospital workers
P07682842A0294|27 43|fMLF-R transcripts
P07682842A0294|74 86|receptor genes
P07682842A0294|105 124|fMLF-R gene expression
P07682842A0294|179 190|organization
P07683131A0885|70 90|exon/intron boundaries
P07683375A0000|28 40|growth factors
P07683375A0000|117 132|estrogen receptor
P07683375A0000|194 207|protein kinases
P07685263A0503|8 30|polymerase chain reaction
P07685263A0503|47 58|DNA fragments
P07685263A0503|91 106|Whipple bacterium
P07685263A0503|107 125|Tropheryma whippelii
P07685823A1234|0 12|RNA polymerase
P07685823A1234|54 70|base-pair sequence
P07685874A0258|24 46|magnesium concentrations
P07685874A0258|75 85|SLE patients
P07685874A0258|98 115|lupus erythematosus
P07685874A0258|140 160|protein concentrations
P07685874A0258|164 178|amylase activity
P07687320A0526|11 23|plasmid pFV100
P07687320A0526|61 86|complement B-band expression
P07687541A0200|43 54|fission yeast
P07687541A0200|118 132|mtr1/prp20/srm1
P07687541A0992|50 63|ras superfamily
P07687745T0000|33 47|amino acid import
P07688112A0274|82 96|acid phosphatase
P07689154A0168|0 21|Protein phosphorylation
P07689154A0168|50 66|uPA gene expression
P07689154A0168|79 91|protein kinase
P07689154A0168|104 116|phorbol esters
P07689154A0168|251 263|uPA mRNA levels
P07691837A1359|27 39|K3 keratin gene
P07691837A1359|151 171|NFkB consensus sequence
P07691885T0000|0 13|Identification
P07691885T0000|49 67|proto-oncogene c-kit
P07691885T0000|76 99|mast cell leukemia cell line
P07691885T0000|137 148|c-kit product
P07692366A0000|64 75|degeneration
P07692366A0000|159 170|pathogenesis
P07692668A0326|136 152|blot hybridization
P07692668A0326|179 199|transcription strategy
P07692754T0000|0 10|Risk factors
P07692754T0000|30 43|seroprevalence
P07692754T0000|46 69|hepatitis C virus infection
P07692754T0000|80 90|blood donors
P07693132A0100|60 73|Zm-ERabp5 genes
P07693372A0115|90 101|cyclosporine
P07693672A0259|6 17|footprinting
P07693699A0831|24 48|nucleotide binding function
P07693708A0000|49 61|transcription
P07693975T0000|7 19|transcriptase
P07693975T0000|23 40|protease activities
P07693975T0000|48 81|leukosis virus Gag-Pol fusion proteins
P07695629A0489|12 23|mck1 mds1 mrk1
P07696183A0567|193 203|colon origin
P07696183A0567|255 267|myristylation
P07696183A0567|271 290|membrane localization
P07696183A0567|332 349|localization signal
P07696183A0567|378 397|fractionation studies
P07696450A0271|156 169|Nestle-Clintec
P07696878A0222|3 16|leader sequence
P07696878A0222|63 75|reading frames
P07696878A0222|89 103|initiation codon
P07696878A0222|120 131|reading frame
P07696878A0222|144 161|homeodomain protein
P07697294A0329|14 24|HSP81-1 mRNA
P07698219A0551|0 11|Cell adhesion
P07698219A0551|15 29|migration assays
P07698219A0551|66 80|laminin receptor
P07698727A0386|64 75|HIV infection
P07699632A0522|13 23|race persons
P07699632A0522|27 40|Chukcha-Eskimo
P07699632A0715|3 16|data complement
P07699845A0537|8 20|studies SY5555
P07699845A0537|124 141|lacunar tonsillitis
P07699845A0537|209 226|impetigo contagiosa
P07699845A0537|244 258|tract infections
P07699845A0537|264 278|balanoposthitis
P07699845A0537|299 311|lymphadenitis
P07700361A0125|20 31|interactions
P07701266A0808|7 17|Closure time
P07701266A0808|51 62|somatostatin
P07702327T0000|12 30|adhesion prophylaxis
P07702327T0000|46 71|tissue plasminogen activator
P07702752A0545|30 47|rat P450c17 promoter
P07702752A0545|90 106|gene transcription
P07702752A0545|107 124|deletion constructs
P07702752A0545|183 196|rat P450c17 gene
P07702752A0545|231 252|reporter gene luciferase
P07702752A0545|274 287|mouse cell lines
P07702752A0545|316 331|Leydig MA-10 cells
P07702808A0427|14 26|BP differences
P07702808A0427|44 59|corn oil treatment
P07704040A0000|27 39|mouse NMO1 cDNA
P07704040A0000|57 79|menadione oxidoreductase
P07704040A0000|92 106|quinone acceptor
P07704040A0000|107 120|oxidoreductase
P07704040A0000|121 136|quinone reductase
P07704040A0000|152 163|DT diaphorase
P07704273A0000|25 50|ampD ampE deletion derivative
P07704273A0000|125 142|beta-lactamase gene
P07704273A0000|145 163|Citrobacter freundii
P07704273A0000|173 185|plasmid pNU305
P07704456A1014|22 33|acceleration
P07704456A1014|125 135|HMS subjects
P07704689T0000|8 20|thyroid nodule
P07704730T0000|4 16|contraception
P07705476A0292|59 70|protein level
P07705476A0292|71 81|water intake
P07705476A0292|85 95|urine volume
P07705627A1107|63 73|dpp pathways
P07706273T0000|38 56|ATPase B2 subunit gene
P07706287A0698|94 110|cell division cycle
P07706291T0000|2 12|E box element
P07706299A0563|0 15|Inhibition assays
P07706299A0563|166 195|oligosaccharide-protein binding
P07706307A0914|3 19|amino acid sequence
P07706307A0914|48 64|specificity pocket
P07706396T0000|24 36|SEC1 homologue
P07706396T0000|77 88|accumulation
P07706396T0000|91 106|membrane vesicles
P07707523A0704|25 42|NF-kappa B inhibitor
P07707523A0704|43 55|I kappa B-alpha
P07707531A0550|51 62|displacement
P07707531A0550|76 86|binding site
P07707531A0550|110 126|gene transcription
P07707544T0000|15 27|transcription
P07707544T0000|35 59|channel catfish virus genome
P07707544T0000|60 75|characterization
P07708058A0178|64 81|activator protein-1
P07708058A0178|97 110|c-jun homodimer
P07708058A0178|114 135|c-jun/c-fos heterodimer
P07708488A0151|55 69|sequence variant
P07708497A0000|27 40|thyroid hormone
P07708497A0000|51 62|interactions
P07708497A0000|88 105|T3 response elements
P07711667A0766|23 33|risk factors
P07711667A0766|102 113|marrow blasts
P07711667A0766|135 159|remission induction courses
P07711667A0766|179 196|maintenance therapy
P07711667A0766|197 216|consolidation therapy
P07711667A0766|217 230|marrow cell dose
P07711667A0766|249 270|GVHD prophylaxis regimen
P07711667A0766|286 300|decontamination
P07711667A0766|310 321|airflow rooms
P07711730A0000|0 28|Carnitine palmitoyltransferase
P07711730A0000|78 92|lipid metabolism
P07713421A1435a|20 42|gain-of-function mutants
P07713421A1435a|86 107|sex determination signal
P07713421A1435b|20 42|gain-of-function mutants
P07713421A1435b|86 107|sex determination signal
P07713936A0393|35 47|transcription
P07713936A0393|61 73|response genes
P07713936A0393|92 104|transcription
P07714608A1252|90 105|brain temperature
P07714608A1252|108 120|glucose levels
P07714758A1193|0 12|Blood pressure
P07715200A0000|0 16|Anesthesiologists
P07715200A0000|60 73|target response
P07715200A0000|88 100|blood pressure
P07715602A1088|17 32|gene cluster codes
P07715602A1088|56 75|cytochrome c haem lyase
P07717823A0328|0 23|Standard reference sources
P07719527T0000|4 16|allergenicity
P07720572A0701|15 26|myoD promoter
P07720572A0701|30 41|myoD enhancer
P07720572A0701|55 66|conservation
P07720572A1584|48 58|10T1/2 cells
P07720572A1584|91 108|chromatin structure
P07720572A1584|125 140|myoD core enhancer
P07720572A1584|158 169|myoD enhancer
P07720572A1584|205 215|10T1/2 cells
P07720709A0755|34 44|model system
P07720709A0755|116 132|cell proliferation
P07720709A0755|163 178|growth inhibition
P07720709A0755|193 210|AP1 transrepression
P07720710A0861|9 20|HMG2 proteins
P07721074A0766|72 94|patient treatment program
P07721074A0766|111 122|multiplicity
P07721074A0766|134 147|trigger factors
P07721422A0241|0 25|Primer extension experiments
P07721422A0241|47 74|transcription initiation sites
P07721422A0241|99 110|receptor gene
P07721878A1163|3 13|beta subunit
P07721878A1163|19 29|Fc epsilon R1
P07721878A1163|39 60|tyrosine phosphoprotein
P07721878A1163|124 143|Fc epsilon R1 beta chain
P07723247A0187|42 62|transmembrane transfer
P07723247A0187|110 121|computerized
P07723247A0187|129 141|dialysis model
P07723247A0187|165 181|pressure recording
P07723247A0187|221 232|outflow ports
P07723247A1161|7 20|hour incubation
P07723247A1161|80 95|radioimmunoassay
P07728201A0660|48 72|sickle-hemoglobin C disease
P07728201A0660|147 167|penicillin prophylaxis
P07729427A0942|0 15|Deletion analysis
P07730273A1309|10 21|NarQ proteins
P07730273A1309|26 47|amino acid substitutions
P07730273A1309|67 83|histidine position
P07730273A1309|115 128|NarL-phosphate
P07730336A0606|35 54|cAMP response elements
P07730337A1439|12 25|PKC-gamma genes
P07730337A1439|38 54|expression pattern
P07730337T0000|57 70|protein kinase C
P07730795A0104|3 20|amino acid sequences
P07731686A0000|51 64|translocations
P07731686A0000|72 85|T-cell leukemia
P07731898A0823|50 64|bicarbonate ions
P07731898A0823|67 80|concentrations
P07731898A0823|109 120|hemodialysis
P07731898A0823|168 193|superoxide anions generation
P07731898A0823|194 209|erythrocyte SOD-1
P07731898A0823|213 230|catalase activities
P07731898A0823|234 269|erythrocyte membrane lipid peroxidation
P07733075A1200|42 55|clarithromycin
P07733075A1200|142 157|% eradication rate
P07733075A1200|179 195|ulcer healing rates
P07735590A0990|3 15|concentration
P07735590A0990|61 71|p milligrams
P07735590A0990|100 110|cat allergen
P07735590A0990|137 160|micrograms Fel d milligrams
P07735590A0990|187 210|micrograms Fel d milligrams
P07735833A1078|27 46|LysU crystal structure
P07737024A1003|5 19|bowel irrigation
P07737118A0317|11 22|reading frame
P07737118A0317|55 65|LexA protein
P07737944A0000|13 25|growth factors
P07737944A0000|58 76|transfusion practice
P07737944A0000|113 133|blood cell transfusions
P07737944A0000|203 216|erythropoietin
P07738839A0173|56 66|CO2 pressure
P07739382A0457|24 41|amino acid sequences
P07739382A0457|52 63|protein types
P07739520A1250|29 46|Surfeit gene cluster
P07739542A1419|63 76|G1/S transition
P07739542A1419|95 123|retinoblastoma protein function
P07739544A0364|12 28|amino acid sequence
P07739544A0364|34 48|SGC1 gene product
P07739566A1076|10 33|Pax-6-BSAP fusion proteins
P07739566A1076|60 75|amino acid stretch
P07740487A0167|46 62|dysfibrinogenemia
P07740487A0167|66 78|thrombophilia
P07740487A0167|152 166|SSC Subcommittee
P07740487A0167|184 203|International Society
P07742024A0121|24 38|imaging features
P07742024A0121|39 55|operation findings
P07742363A0135|119 130|alpha subunit
P07742363A0941|25 39|yeast eIF-2 alpha
P07742363A0941|103 124|casein kinase activities
P07742550A0407|202 220|mantle cell lymphomas
P07742550A0407|244 256|cell lymphomas
P07742917T0001|10 25|beta-thalassemia
P07743472A0181|18 29|breast cancer
P07743472A0181|59 84|Roswell Park Cancer Institute
P07743472A0181|134 156|cigarette smoking history
P07743515A0223|17 34|tissue distribution
P07743515A0223|90 105|cytotrophoblasts
P07743515A0223|129 152|colon adenocarcinoma cells
P07743697A0703|62 81|plasma norepinephrine
P07743697A0703|99 111|treatment arms
P07743697A0703|193 207|enzyme inhibitor
P07743697A0703|219 236|vasodilator therapy
P07743697A0703|241 271|hydralazine/isosorbide dinitrate
P07744763A0514|0 14|Binding activity
P07744763A0514|53 67|orphan receptors
P07744763A0514|80 115|electromobility supershift experiments
P07744776A0617|0 17|Transcript analysis
P07744776A0617|35 53|B block substitutions
P07744776A0617|60 73|U6 RNA synthesis
P07744846A1006|14 34|Bcl-2 homodimerization
P07744846A1006|51 63|binding assays
P07744846A1006|146 166|Bcl-2 homodimerization
P07744954A0418|81 91|COOH termini
P07745008A0892|0 17|Radioligand binding
P07745684T0000|5 22|papillomavirus type
P07745684T0000|30 43|gene expression
P07745684T0000|62 74|protein kinase
P07745684T0000|94 106|RNA processing
P07745685A1442|87 103|accessory proteins
P07745685A1442|117 133|CAT fusion partners
P07745693A0914|32 43|Lb proteinase
P07745696A0932|0 25|Restriction mapping analysis
P07745696A0932|65 78|BamHI G fragment
P07745696A0932|141 154|SalI O fragments
P07745696A0932|190 202|repeat regions
P07745726A0960|3 31|replication reporter constructs
P07745726A0960|77 93|expression vectors
P07745726A0960|155 167|relationships
P07745726A1496|69 97|nucleotide sequence information
P07745726A1496|133 150|E1 recognition motif
P07746397A0233|32 46|anticoagulation
P07746397A0233|164 181|thromboplastin time
P07746794A0000|50 61|Cyclosporin A
P07746794A0000|96 106|Cremophor EL
P07746937A0100|0 16|Lung function tests
P07747462A0332|0 18|Sequence comparisons
P07747462A0332|32 44|RCR initiators
P07747462A0332|98 118|metal coordination site
P07747462A0332|144 156|tyrosine motif
P07747462A0332|197 214|replicator proteins
P07748451A0343|39 50|restorations
P07748451A0343|65 76|restorations
P07748451A0343|112 124|vinyl siloxane
P07748451A0343|128 147|medium-viscosity poly
P07748451A0343|147 159|vinyl siloxane
P07748493A1045|16 29|Aplysia Afurin2
P07748493A1045|33 43|candidate PC
P07748502A0794|67 80|discrimination
P07748848A0263|19 38|papillary haemangioma
P07748952A0462|113 133|translation start sites
P07748952A1329|35 47|hfq expression
P07748952A1329|101 115|cotranscription
P07748952A1329|153 168|promoter strength
P07748952A1329|174 187|RNase E activity
P07749461A0632|44 59|sGTH alpha subunit
P07749461A0632|104 115|sGTH alpha-G1
P07749461A1022|23 46|sGTH alpha subunit promoter
P07749461A1022|61 72|transfection
P07749461A1022|82 94|sGTH alpha/CAT
P07749461A1022|115 126|rainbow trout
P07750217T0000|0 23|Indium-111 OncoScint CR/OV
P07750217T0000|56 75|carcinoma recurrences
P07751848A0222|3 31|carnitine palmitoyltransferase
P07751848A0222|66 83|nmol/min/mg protein
P07751848A0222|131 148|nmol/min/mg protein
P07752223A0960|36 47|interactions
P07752223A0960|62 73|Myc inability
P07752454A0341|46 60|resistance rates
P07752644A1031|17 30|defibrillation
P07752644A1031|70 84|plasma drug level
P07752886A0595|17 30|FecR derivative
P07752886A0595|42 58|amino acid residues
P07753027A0240|3 20|gene pairs psbB-psbT
P07753030A0173|0 19|Hybridization signals
P07753030A0173|51 74|Rhizobium leguminosarum bv
P07753030A0173|96 116|Rhodobacter capsulatus
P07753030A0173|148 170|Xanthomonas campestris pv
P07753796A0625|12 28|amino acid sequence
P07753796A0625|94 116|liver eIF-2B alpha subunit
P07753796A0743|67 77|eIF-2B alpha
P07753796A0743|80 101|SDS/polyacrylamide gels
P07753837A0724|57 70|plakoglobin RNA
P07753837A0724|105 116|accumulation
P07755884A0000|106 125|sensorimotor deficits
P07755884A0000|165 178|dopamine system
P07755914A0000|34 45|introduction
P07755914A0000|48 61|clarithromycin
P07755914A0000|65 76|azithromycin
P07755914A0000|135 159|Mycobacterium avium complex
P07757315A1227|55 69|drug application
P07757315A1227|101 117|observation period
P07758167A1488|0 11|Growth curves
P07758167A1488|25 37|proliferation
P07758459A1277|125 148|core HAP2/3/4 binding motif
P07758459A1277|169 196|ABF1 consensus binding sequence
P07758837A1118|48 61|GH receptor gene
P07758837A1118|131 144|intron boundary
P07759094A0634|12 23|dinucleotide
P07759094A0634|89 111|microsatellite PCR marker
P07759525A0417|53 71|protein kinase domain
P07759525A0417|100 111|casein kinase
P07759529A0288|64 86|gp91-phox gene expression
P07760790A0327|0 13|Serum induction
P07760790A0327|17 32|MEF2 reporter gene
P07760790A0327|56 66|NIH 3T3 cells
P07760790A0327|82 104|MEF2 site binding activity
P07760819A0731|58 83|PDGF beta receptor activation
P07760819A0731|112 128|cell proliferation
P07760819A0731|131 145|differentiation
P07760841A0221|9 19|binding site
P07760841A0221|41 54|regulator Adr1p
P07760841A0647|90 105|promoter elements
P07760841A0647|120 133|gene activation
P07760844A0413|11 24|AP-1 DNA binding
P07760844A0413|51 68|GH trans-activation
P07761091A0294|0 11|Inactivation
P07761216T0000|12 31|amphotericin B therapy
P07761434A1084|32 50|tumor promoter action
P07761434A1084|115 126|antioxidants
P07761467A0666|41 57|protein components
P07762431A0356|53 65|culture medium
P07762504A0648|24 37|administration
P07763727A1035|0 13|Plasmids pAMS12
P07763727A1035|49 64|laboratory strain
P07763727A1035|139 154|wine yeast strains
P07765118A0967|3 18|maximum induction
P07765118A0967|21 42|ACC-oxidase transcripts
P07765118A0967|81 101|maximum enzyme activity
P07766885A0405|11 26|polypeptide chain
P07766885A0405|158 171|junction region
P07767011A0689|33 45|recombination
P07768824A0167|11 27|fla gene expression
P07768824A0167|74 86|RNA polymerase
P07768836A1126|0 25|Primer extension experiments
P07768836A1126|41 67|transcription initiation site
P07768848A1880|0 11|Polypeptides
P07768898A0492|39 54|apobec1 sequences
P07768898A0492|103 115|suhstitutions
P07768953T0039|39 53|membrane protein
P07770033A0978|0 18|Nucleotide sequences
P07770033A0978|69 80|reading frame
P07770033A0978|158 194|Neurospora crassa copper metallothionein
P07771671T0000|44 59|carbon electrodes
P07772036A1000|68 100|transcription factor/nuclear factor
P07774807A0405|87 98|heterodimers
P07774807A0405|134 146|family members
P07774925A0084|6 18|cosmid contigs
P07774925A0084|30 40|BRCA1 region
P07775428A0172|29 47|nucleotide sequences
P07776685A0000|52 64|immunotherapy
P07776685A0000|111 123|interleukin-2
P07776711A0295|91 104|neuropathy type
P07776711A0295|134 147|polyneuropathy
P07776882A0000|27 44|cell volume dynamics
P07776979A0702|52 71|reporter gene activity
P07777518A0483|0 12|DNA sequencing
P07777518A0483|16 35|Southern blot analyses
P07779558T0000|0 19|Muscle GSH-Px activity
P07779558T0000|53 75|selenium supplementation
P07779811A0901|77 92|reporter activity
P07780525A0495|85 96|health inputs
P07780738A0091|100 113|DNA replication
P07782087A0559|19 46|transcription initiation sites
P07782087A0559|120 141|ribonuclease protection
P07782087A0559|142 156|primer extension
P07782087A0559|161 172|RACE analyses
P07782113A0726|3 20|roxithromycin doses
P07782113A0726|72 82|blood levels
P07782302A0479|24 37|DEDDDL sequence
P07782302A0479|96 114|affinity interaction
P07782302A0479|138 149|HTF9A/RanBP1
P07782775A0889|81 95|BBTV coat protein
P07783064A0452|14 25|strength data
P07783064A0452|60 75|creatinine kinase
P07783822A0000|37 48|presentation
P07783822A0000|97 112|district hospital
P07784061A0894|103 114|kb transcript
P07784078A1064|34 47|gene expression
P07784078A1064|98 110|APL cell growth
P07784079A1018|0 11|Transfection
P07784079A1018|25 40|expression vector
P07784079A1018|45 55|NIH3T3 cells
P07784079A1018|118 133|expression vector
P07784197A0827|66 83|mouse fibrosarcomas
P07784197A0827|158 168|cell extract
P07784197A0827|173 197|BALB/c 3T3 mouse fibroblasts
P07784199A0000|21 33|gene promoters
P07784199A0000|120 137|gene regulator Rap1p
P07784870A0119|124 137|investigations
P07784870A0119|154 167|histochemistry
P07784870A0119|178 195|electron microscopy
P07784870A0119|196 215|immunohistochemistry
P07784870A0119|222 233|microbiology
P07784942T0001|11 24|thrombomodulin
P07786820A0284|33 44|i.v. infusion
P07786821A2292|41 77|consecutive-days-every-3 weeks schedule
P07786821A2292|84 100|patient population
P07787179A0312|26 39|PRB-1b promoter
P07787179A0312|95 116|ethylene responsiveness
P07787179A0312|122 133|reporter gene
P07789275A0325|30 42|metamorphosis
P07789275A0325|82 106|loss-of-function mutations
P07789275A0325|121 137|transcription unit
P07789342A1352|59 73|affinity binding
P07789342A1352|96 106|hyt mutation
P07789342A1352|118 136|transmembrane domain
P07789809A1246|8 19|Western blots
P07789809A1246|97 114|household functions
P07789809A1246|129 144|vesicle transport
P07789809A1246|166 180|differentiation
P07789971A0758|26 38|hybridization
P07790271A1185|21 34|Gy/25 fractions
P07790377A0561|64 75|hamster cells
P07790719A0098|56 69|family violence
P07791760A0424|0 12|GnRH treatment
P07791760A0424|34 48|phosphorylation
P07791760A0424|51 66|tyrosine residues
P07791760A0424|86 97|MAPK activity
P07791760A0424|120 137|complex kinase assay
P07791763T0000|29 52|insulin receptor substrate
P07791763T0000|79 106|phosphatidylinositol 3-kinase
P07791763T0000|124 146|Xenopus oocyte maturation
P07791764A0357|26 37|Jurkat T cells
P07791764A0357|79 96|adapter protein Grb2
P07791768A0930|16 34|cell cycle regulators
P07791768A0930|60 76|hmr delta A mutation
P07791768A0930|93 105|clb5 mutations
P07791768A0930|159 171|establishment
P07791769A0826|108 122|ICP4 binding site
P07791776T0000|0 15|Characterization
P07791783A0000|65 82|leucine zipper motif
P07791783A0000|123 151|rainbow trout testis cDNA library
P07793783A0189|80 101|scalp flap transposition
P07794556A0000|168 183|mutation analysis
P07795104T0000|31 54|hepatitis B virus infection
P07795576A0126|91 109|plasma renin activity
P07796935A0284|98 108|c-erbA alpha
P07797476A1001|3 14|RAP74 subunit
P07797583A0222|22 38|base substitutions
P07797583A0222|73 91|nucleotide positions
P07797583A0222|117 143|transcription initiation site
P07797583A0222|270 286|Drosophila Kc cells
P07798134T0000|3 17|hsp70 gene family
P07798134T0000|20 35|Neurospora crassa
P07798134T0000|43 58|sequence analysis
P07798207A0759|10 27|amino acid sequences
P07798207A0759|39 53|W3A1 ETF subunits
P07798207A0759|139 161|Paracoccus denitrificans
P07798217T0000|10 24|phosphorylation
P07798217T0000|80 93|gene expression
P07798217T0095|8 31|glycogen synthase kinase-3
P07798217T0095|46 59|gene expression
P07798271A0330|113 124|Ets-1 protein
P07799437A0656|92 106|control plasmids
P07799925A0526|0 13|Reconstitution
P07799925A0526|44 64|src family kinase p59fyn
P07799925A0526|92 107|complex formation
P07799925A0526|118 140|tyrosine phosphorylation
P07799931A0287|62 75|L7 gene insights
P07799931A0287|121 132|organization
P07799931A1232|50 61|c-Maf actions
P07799939A0628|45 74|serine/threonine phosphoprotein
P07799948A0777|65 75|Raf-1 kinase
P07799950A0282|62 85|somatostatin gene promoter
P07800479A0201|75 87|RNA maturation
P07800505T0000|0 15|Characterization
P07800505T0000|54 72|phospholipase A2 gene
P07801180A0197|54 68|study approaches
P07802355T0000|38 51|blood cell count
P07802355T0000|80 90|Coulter STKS
P07802355T0000|106 117|Technicon H-1
P07802655T0000|0 15|Characterization
P07802655T0000|27 39|Xenopus laevis
P07802655T0000|60 73|protein binding
P07802655T0000|107 118|protein genes
P07803809A1852|52 66|beta-globin mRNA
P07803809A1852|88 119|tyrosine kinase inhibitor genistein
P07803809A1852|126 156|protein kinase C inhibitor Compound
P07806507A0121|34 47|CD3-TCR complex
P07806507A0121|80 91|polypeptides
P07806507A0121|139 154|recognition event
P07806507A0121|196 212|activation cascade
P07806532A0659|0 11|Protein cHMGI
P07806532A0659|48 67|half-saturation value
P07806651A0097|61 77|Mexican-Americans
P07807002A0500|39 53|initiation sites
P07807002A0500|57 74|germline epsilon RNA
P07807002A0500|89 110|luciferase reporter gene
P07807002A0500|132 146|mouse B cell lines
P07809410A0606|32 45|serum TSH levels
P07809410A0606|46 69|serum thyroglobulin values
P07809410A0606|73 83|131I protein
P07811639A0222|0 16|Endo16 transcripts
P07811639A0222|65 76|stage embryos
P07811639A0222|79 91|gastrula stage
P07811964A1252|22 34|repeat element
P07811964A1252|119 130|dimerization
P07813466A0074|132 142|protein gene
P07813786A0641|61 75|XMyoDa TATA motif
P07814321A0850|69 89|sporulation efficiency
P07814323A0313|72 84|export pathway
P07814323A0313|96 112|flagellum assembly
P07814388A0662|8 22|L-cell membranes
P07814388A0662|97 127|pertussis toxin substrate activity
P07814405A1170|36 49|point mutations
P07814405A1170|59 78|plasma membrane family
P07814405A1170|81 104|guanylyl cyclase receptors
P07814717A0669|47 63|AA supplementation
P07814717A0669|78 91|concentrations
P07815811A1487b|8 23|vasoconstriction
P07815811A1487b|32 43|endothelin-1
P07815811A1487b|56 75|ischemia-reperfusion
P07815811A1487b|81 94|norepinephrine
P07815811A1487b|104 117|concentrations
P07816025A0196|22 38|amino acid sequence
P07816025A0196|41 53|gamma-kafirin
P07816025A0196|81 95|gamma-prolamins
P07816049A0686|205 217|transcription
P07816049A1157|0 35|Southern blot hybridization experiments
P07816049A1157|89 101|haploid genome
P07816049A1157|105 124|Northern blot analysis
P07816619A0000|20 48|Arabidopsis thaliana cDNA clones
P07816619A0000|140 160|cAMP phosphodiesterase
P07816619A0872|14 27|identification
P07816619A0872|154 176|transcription initiation
P07816630A1333|52 75|translation terminator TGA
P07816630A1333|81 92|beta-tubulin
P07818416A0895|22 46|haemoglobin concentrations
P07818416A0895|145 155|revision THR
P07819225A1094|3 14|introduction
P07819225A1094|78 92|Asn-285 mutation
P07819225A1094|140 152|Asn-285 mutant
P07819225A1094|166 187|tetracycline resistance
P07820057A0000|0 23|Tumor necrosis factor alpha
P07820057A0000|65 77|growth control
P07820057A0000|85 96|cell leukemia
P07821790A1084|109 122|transactivator
P07821790A1084|142 152|UCR elements
P07821790A1084|163 183|co-transfection assays
P07822161A1172|13 23|monkey opsin
P07822161A1172|77 91|amino acid levels
P07823919A1422|39 53|RXR heterodimers
P07823951A1100|47 69|transactivation function
P07823951A1100|73 88|globin expression
P07823951A1100|168 180|transcription
P07823953A0777|15 33|I kappa B alpha mutants
P07823953A0777|63 82|I kappa B alpha molecule
P07823953A0777|112 123|I kappa B alpha
P07823953A0777|186 203|localization signal
P07824325A0714|39 51|thorax opening
P07824325A0714|122 145|vancomycin concentrations
P07824325A0714|242 253|micrograms/g
P07824464A0169|26 36|tissue flaps
P07824464A0169|80 100|artery wall dissections
P07824464A0169|101 114|plaque ruptures
P07824464A0169|119 130|fissurations
P07824464A0169|145 156|haemorrhages
P07824464A0169|221 234|artery stenosis
P07824657A1456|11 27|cysteine formation
P07824657A1456|31 41|pCSK4F plant
P07824726A0454|93 108|fatty replacement
P07824726A0454|133 148|fatty replacement
P07824726A0454|173 188|fatty replacement
P07825888A0715|21 37|dementia disorders
P07825888A0715|78 91|cortisol levels
P07826412T0112|58 71|gamma-subunits
P07826625X0000|20 41|transcription apparatus
P07826625X0000|42 54|RNA polymerase
P07826625X0000|83 99|activation domains
P07826625X0000|136 148|RNA polymerase
P07826625X0000|160 173|enhancer domain
P07826625X0000|242 256|proline residues
P07826625X0000|284 300|activation domains
P07826625X0000|385 406|polyglutamine stretches
P07828584A0681|53 70|AP1 bearing promoter
P07828600A0095|17 36|stage selector element
P07828600A0095|53 72|gamma-globin promoter
P07828600A0095|117 129|beta-promoter
P07828600A0095|147 166|stage erythroleukemia
P07828811A0556|63 79|thermosensitivity
P07828824A0307|18 43|photoreceptor cell structure
P07829057A1097|3 14|marker orders
P07829057T0000|0 24|Integrated mapping analysis
P07829057T0000|30 49|Werner syndrome region
P07829102T0000|0 15|Haplotype mapping
P07829102T0000|19 34|sequence analysis
P07829102T0000|40 53|mouse Nramp gene
P07829102T0000|61 74|susceptibility
P07829519A1251|27 45|polyadenylation site
P07829519A1251|145 160|immunoglobulin mu
P07829554A0257|50 63|system response
P07829554A0257|98 114|protein conjugates
P07829554A0257|127 138|wear products
P07830112A0532|63 74|stroke volume
P07831310A0000|8 28|complementation system
P07831310A0000|48 63|tobacco etch virus
P07831799T0000|0 17|Nucleotide sequence
P07831799T0000|49 65|DNA polymerase gene
P07831799T0000|85 101|polyhedrosis virus
P07831829A1324|80 92|heterogeneity
P07831829A1324|95 112|genome organization
P07832086A1023|3 17|drug sensitivity
P07832779A0719|0 14|Deglycosylation
P07832779A0719|19 34|endoglycosidase H
P07832779A0719|84 104|oligosaccharide chains
P07834582A0115|136 147|hypertension
P07835088A0238|12 22|HSD3B2 genes
P07835088A0238|46 63|beta-HSD isoenzymes
P07835088A0238|110 122|hybridization
P07835088A0238|128 149|chromosome 1p13.1 region
P07835273A0000|18 33|glucose transport
P07835273A0000|61 75|insulin receptor
P07835273A0411|49 62|EGFR expression
P07835273A0411|146 161|3T3-L1 adipocytes
P07835710T0000|25 38|porcine I kappa B
P07835826A0195|21 31|2-vitamin D3
P07835826A0195|62 72|3-vitamin D3
P07835886A0894|3 17|kallistatin gene
P07835886A0894|38 50|hybridization
P07835886A0894|58 76|chromosome 14q31-q32
P07835886A0894|88 98|serpin genes
P07835886A0894|107 129|alpha 1-antichymotrypsin
P07835886A0894|130 146|protein C inhibitor
P07835886A0894|147 164|alpha 1-antitrypsin
P07835888A0402|63 77|mouse chromosome
P07835888A0402|82 98|haplotype analysis
P07835888A0402|117 129|backcross mice
P07836218A0128|35 55|beta-endorphin release
P07836218A0128|69 82|exertion levels
P07836218A0128|143 156|beta-endorphin
P07836228A1052|13 25|communication
P07836364A0000|47 58|presentation
P07836364A0000|66 90|histocompatibility complex
P07836364A0000|123 144|antigen presenting cells
P07836390A1152|3 17|characteristics
P07836390A1152|43 58|cleavage reaction
P07836390A1152|105 116|IncP plasmids
P07836390A1152|139 160|transfer DNA replication
P07836406A0884|98 111|phosphopeptide
P07836406A0884|163 176|chromatography
P07836471A0375|10 24|protein sequence
P07836471A0375|70 86|osteosarcoma cells
P07838156A0789|7 27|cotransfection studies
P07838156A0789|58 70|transcription
P07838156A0789|79 100|hormone response element
P07838156A0789|112 123|reporter gene
P07838156A0789|168 183|ROR alpha function
P07840643A1006|16 49|Flavobacterium glycosylasparaginase
P07840643A1006|64 83|glycosylasparaginase
P07841230T0000|0 11|Dissociation
P07841230T0000|15 26|complexation
P07841230T0000|47 60|antimicrobials
P07841663A0685|0 18|Superoxide dismutase
P07841663A0845|77 89|oxygen species
P07841663A0845|99 109|SOD activity
P07841663A0845|147 157|sperm motion
P07844142A0640|127 143|GTPase superfamily
P07844155A0327|40 59|tyrosine phosphatases
P07844155A0327|97 107|LAR isoforms
P07844201T0000|0 11|Sex selection
P07844201T0000|15 28|albumin columns
P07844555A0406|64 82|lymphoma development
P07845672A0368|26 37|blk sequences
P07845672A0368|61 78|% amino acid identity
P07846199A0000|25 46|sensorimotor reactivity
P07846199A0000|80 94|startle response
P07846942A0717|0 18|Digitalis glycosides
P07846942A0717|21 44|beta-receptor antagonists
P07846942A0717|88 99|fibrillation
P07846942T0001|6 17|fibrillation
P07847036A0353|42 54|haemophiliacs
P07848358A0254|15 47|aspartate aminotransferase activity
P07851643A1365|64 76|proliferation
P07851643A1365|85 97|germline cells
P07851643A1365|111 131|oocyte differentiation
P07851758A0330|8 23|analysis maps SAL6
P07851758A0330|26 38|chromosome XVI
P07852037A0548|15 29|DCT method yields
P07852361A0868|53 68|cell cycle changes
P07852400A0519|0 26|Rho GDP/GTP exchange inhibitor
P07853448A0601|13 28|sports scientists
P07853448A0601|86 99|sport performer
P07853488T0000|0 12|Encapsidation
P07853488T0000|15 33|poliovirus replicons
P07853488T0000|58 82|immunodeficiency virus type
P07853488T0000|99 119|complementation system
P07853488T0000|136 150|P1 capsid protein
P07853524A1944|79 106|Tax-CREB-21-bp-repeat complex
P07854130A1387|22 36|pilus biogenesis
P07854130A1387|79 98|pilE insertion mutants
P07854130A1387|111 128|twitching-motility
P07854130T0000|3 17|pilE gene product
P07854130T0000|52 66|pilus biogenesis
P07854130T0000|67 97|shares amino acid sequence identity
P07854130T0000|121 136|prepilin proteins
P07854324A0281|22 33|conservation
P07854324A0281|36 59|cell cycle control elements
P07854324A0281|76 89|vertebrate wee1
P07854324A0281|92 102|mik1 homolog
P07854324A0742|69 81|cell phenotype
P07854324A0742|101 116|growth conditions
P07856102A1616|21 35|phosphorylation
P07856102A1616|84 96|virus assembly
P07857086A0949|49 67|Non Insulin Dependent
P07857163A0551|13 30|6-fluoroquinolones
P07857344A0591|75 105|pidotimod administration schedule
P07857762A0611|3 18|MAP kinase cascade
P07858986A0310|30 43|interferometry
P07858986A0310|80 100|Carpentier-Edwards SAV
P07858986A0310|165 187|glutaraldehyde treatment
P07859238A1150|9 19|side effects
P07859301A0325|70 89|leucine-zipper motifs
P07859301A0325|120 144|transcription factor family
P07859371A1246|58 71|mouse fragments
P07859665A0498|19 30|fiber density
P07859665A0498|72 83|microseconds
P07859665A0498|107 118|microseconds
P07859739T0000|6 25|cyclin D-Cdk complexes
P07859739T0000|70 108|p16INK4/MTS1 tumour suppressor gene product
P07859777A0000|16 27|serum albumin
P07859777A0000|50 61|fermentation
P07859777A0000|88 100|microcapsules
P07859777A0000|150 163|technetium-99m
P07860208A0000|26 42|interleukin-1 beta
P07860208A0000|50 75|tumour necrosis factor-alpha
P07860208A0000|128 145|lipopolysaccharide
P07860208A0000|218 235|glomerulonephritis
P07860646A1363|6 17|intervention
P07862092A0302|77 91|mutation pol3-14
P07862092A0302|104 118|mutation pol3-11
P07862092A0302|148 161|haploid strains
P07862092A0302|176 188|pol3-11 sdp5-1
P07862108A0987|0 25|UV cross-linking experiments
P07862129A1391|49 68|HNF-3 alpha expression
P07862141A0317|91 105|differentiation
P07862141A1412|28 46|transcription factor
P07862150A0429|114 136|TGF-beta binding activity
P07862154A0340|9 23|complementation
P07862162A0408|75 87|transcription
P07862162A0408|101 113|UASINO element
P07862165A0184|10 23|monkey COS cells
P07862165A0184|28 43|oligonucleotides
P07862165A0184|163 176|helix formation
P07862168A0000|15 33|receptor alpha-chain
P07862533A0000|8 30|tumour suppressor protein
P07862533A0000|85 95|zinc fingers
P07862533A0000|128 143|sequence homology
P07862533A0000|154 169|growth response-1
P07863047A0229|22 37|serum ACE activity
P07863047A0229|97 109|oxygen therapy
P07863992A0908|90 101|heart disease
P07863992A0908|102 114|mean follow-up
P07864652A0753|149 165|amino acid sequence
P07864652A0753|185 195|E2 component
P07864652A1901|24 39|domain constructs
P07864709A0324|119 135|enzyme immunoassay
P07865129A0293|26 47|TBP/TATA sequence motifs
P07865786A0457|0 13|Gene expression
P07865787A1086|39 51|octamer motifs
P07865787A1086|153 170|wheat histone H3 gene
P07865876A1292|30 44|DP family members
P07865876A1292|73 90|DP/E2F heterodimers
P07865888A1309|106 117|mitochondria
P07865895A0896|34 51|lung clearance assay
P07865895A0896|84 94|LGL/NK cells
P07865895A0896|122 132|LGL/NK cells
P07865917A0191|61 72|cyclosporine
P07865917A0191|76 89|plasmapheresis
P07865917A0191|93 105|ACE inhibitors
P07867604A1777|30 48|inhibin/activin beta
P07867604A1777|91 105|initiation sites
P07867604A1777|223 235|phorbol esters
P07867622X0000|0 13|Promoter region
P07867622X0000|46 61|alpha 1-chimaerin
P07867622X0000|129 144|alpha 1-chimaerin
P07867944A0365|15 37|transcription start point
P07867944A0365|42 59|nucleotide sequence
P07867944A0365|81 102|consensus sequence motif
P07869721A0000|39 50|closing phase
P07869721A0000|88 107|heart valve prosthesis
P07869913A1076|6 19|ISO+AT infusion
P07869913A1076|85 97|control values
P07869937A1142|16 33|kilogram body weight
P07870305A1015|2 17|nucleus ventralis
P07870305A1015|26 72|thalami-nucleus ventralis lateralis thalami neurons
P07870305A1015|98 120|nucleus entopeduncularis
P07870305A1015|181 200|haloperidol influence
P07871718A1132|32 43|CGGAAR motifs
P07871718A1132|51 62|ICP4 promoter
P07871718A1132|72 87|factors GABP alpha
P07871721A0000|12 23|reading frame
P07871721A0000|38 53|scorch carlavirus
P07871721A0392|4 21|sequence alignments
P07871721A0392|116 131|proteinase domain
P07871721A0392|168 180|histidine1075
P07871754A0857|62 78|HPV gene expression
P07871754A0857|142 154|cooperativity
P07871755A0521|63 78|characterization
P07871757A0846|35 49|initiation codon
P07871757A0846|71 86|promotor sequence
P07871891A0227|19 37|translation fidelity
P07872673A0332|22 33|relationship
P07872673A0332|62 78|expression plasmid
P07872673A0332|132 150|SV40 promoter complex
P07872788A1717|15 30|sequence identity
P07872788A1717|126 142|carboxylesterases
P07873631A0114|15 27|tooth fracture
P07873831T0000|32 47|mycosis fungoides
P07874060A0810|50 64|xanthine oxidase
P07874060A0810|80 92|stomach tissue
P07874060A0810|109 122|administration
P07875595A0910|13 26|PITSLRE PK genes
P07875595A0910|80 92|hybridization
P07875595A0910|97 108|localization
P07875595A0910|130 151|chicken microchromosome
P07876134A0348|15 30|characterization
P07876134A0348|113 124|reading frame
P07876192A0443|98 114|ICE autoprocessing
P07876194T0000|43 63|growth factor receptors
P07876194T0000|110 129|tyrosine kinase domain
P07876210A0275|144 159|Barbie box element
P07876210A0751|13 29|P450BM-3 Barbie box
P07876210A0751|123 134|P450BM-3 gene
P07876300A0994|55 67|protein import
P07876562A1646|62 75|responsiveness
P07876562A1646|128 141|HIV-1 infection
P07877619A1284|60 79|zif268 gene expression
P07877619A1284|100 125|base pair nucleotide sequence
P07878029A0721|51 68|CBF-A-CBF-C complex
P07878029A0721|150 167|CBF-A-CBF-C complex
P07878040A0505|45 57|mouse enhancer
P07879204T0000|0 14|OKT3 prophylaxis
P07879204T0000|37 49|graft survival
P07879204T0000|81 92|cyclosporine
P07880442A0236|8 41|PKC beta transcription initiation site
P07880442A0236|57 71|primer extension
P07880442A0236|75 94|S1 nuclease protection
P07880449A0091|24 40|dose X-rays effects
P07880449A0091|128 142|body irradiation
P07880650A0493|26 45|diffraction intensity
P07880650A0493|72 83|electron dose
P07880650A0493|124 142|diffraction patterns
P07880650A0493|172 193|crotoxin complex crystal
P07881077A0195|0 29|Supplementary Phase Contraste RSE
P07883167A0157|57 68|decay pathway
P07883167A0157|96 109|identification
P07883167A0157|113 128|characterization
P07883168A0090|33 45|stabilization
P07883168A0090|68 84|nonsense mutations
P07883193A0000|1 11|DNA fragment
P07883193A0000|117 129|pGEX-KT vector
P07883193A0000|173 196|glutathione S-transferase
P07883754A0993|5 24|gel retardation assays
P07883754A0993|106 116|NRE fragment
P07885999A0000|71 89|mouse tyrosinase gene
P07885999A0000|121 149|methylation interference assays
P07886610A0000|58 68|hemophilia A
P07887226A0858|16 28|serum ferritin
P07887226A0858|32 55|hemoglobin determinations
P07887226A0858|59 87|serum transferrin receptor assay
P07887226A0858|178 191|iron deficiency
P07887859A0998|0 15|TcPO2 measurement
P07887859A0998|70 84|ulcer management
P07888156A0169|12 29|University Hospital
P07888156A0169|96 109|section service
P07888156A0169|125 140|video conferences
P07888156T0000|15 27|telepathology
P07888306A1659|61 71|PDE activity
P07888306A1659|176 189|concentrations
P07888623A0721|0 12|PMEK1 displays
P07888623A0721|47 57|tobacco NTF3
P07888623A0721|61 84|Arabidopsis ATMPK1 kinases
P07888623A0721|119 138|plant MAP kinase MsERK1
P07888629A0344|86 102|Da cell wall protein
P07888629A0344|123 136|signal sequence
P07888629A0344|233 253|lipid transfer proteins
P07888788A1010|18 33|hypersensitivity
P07888788A1010|47 59|aspergillomas
P07888788A1010|175 187|aspergillomas
P07888828A0765|27 40|identification
P07890485A0827|10 21|illumination
P07890485A0827|34 46|photoreceptor
P07890599A0132|17 32|mouse cDNA library
P07890599A0132|37 48|MIN6 cell line
P07890599A0132|137 147|acid protein
P07890599A0132|192 217|Caenorhabditis elegans unc18
P07890680A1193|17 33|core DNA polymerase
P07890680A1193|128 141|primer terminus
P07890740A0997|50 64|Sf-9 insect cells
P07890740A0997|120 130|PSD activity
P07891638T0000|49 64|chest radiographs
P07891685A1051|125 136|CAT8 promoter
P07891708A1192|116 127|HNF-4 delta C.
P07891709A1542|5 16|observations
P07891709A1542|106 118|deadenylation
P07891713T0000|5 15|Maf proteins
P07891713T0000|74 97|NF-E2 transcription factor
P07891720A0818|52 64|concentration
P07891720A0818|67 77|calcium ions
P07892076A0578|63 78|transmission mode
P07892353A0667|34 45|correlations
P07892353A0667|149 160|correlations
P07892353A0667|174 185|brain regions
P07894359T0000|10 21|hemodynamics
P07896088A0720|32 50|telomere maintenance
P07896088A0720|99 109|rap1 alleles
P07896088A0720|145 166|RIF1 interaction domains
P07896088A0720|188 201|telomere length
P07896291A0693|80 95|characterization
P07896291A0693|125 136|WAGR syndrome
P07896615A0554|3 14|contribution
P07896615A0554|46 57|nm absorption
P07896615A0554|110 125|laser flow Doppler
P07896615A0554|129 141|NIR recordings
P07896615A0554|151 164|water immersion
P07896817A0204|82 101|phospholipase C-gamma
P07896817A0204|129 164|SDS-polyacrylamide gel electrophoresis
P07896846T0000|79 94|suppressor region
P07896852T0000|18 42|growth response factor Egr-1
P07896852T0000|45 77|apolipoprotein AI gene transcription
P07897359A0354|64 74|HeLa T4 cells
P07897359A0354|118 135|T7 polymerase system
P07897696A0000|31 45|acid dehydratase
P07897696A0000|58 86|erythrocyte zinc protoporphyrin
P07897696A0000|108 121|coproporphyrin
P07897696A0000|124 136|concentration
P07897696A0000|198 209|lead exposure
P07897696A0000|225 235|blood levels
P07897696A0000|248 260|micrograms/dl
P07898178A0849|43 54|azathioprine
P07898178A0849|93 104|azathioprine
P07898178A0849|117 138|cyclosporin maintenance
P07898178A0849|174 185|patient death
P07898275A0254|14 24|test objects
P07898275A0254|70 87|31P MRS measurements
P07898275A0254|195 205|test objects
P07898275A0254|264 289|volume localization sequence
P07898589T0000|3 14|tobacco issue
P07898840X0000|0 17|Pregnancy screening
P07898840X0000|27 50|artery Doppler velocimetry
P07898840X0000|121 134|Doppler studies
P07898840X0000|234 245|hypertension
P07898840X0000|254 270|growth restriction
P07899581A0000|14 39|Ca entry blocker nitrendipine
P07899581A0000|54 72|superoxide dismutase
P07899581A0000|93 104|nitrendipine
P07899581A0000|108 126|superoxide dismutase
P07899634A0000|78 90|surface effect
P07899634A0000|95 105|alloy Ti Al Va
P07900915A0000|79 89|blood volume
P07900915A0000|93 105|plasma protein
P07900915A0000|167 181|min-1 hemorrhage
P07900915A0000|198 208|blood volume
P07901121T0000|0 22|Cooperative dimerization
P07901121T0000|31 47|class homeo domains
P07901125A0416|32 49|aa sequence homology
P07901125A0416|90 103|ARO3 homologues
P07901125A0416|121 140|yeast Candida albicans
P07902532A0312|42 54|transcription
P07902532A0312|62 76|thymidine kinase
P07902532A1655|0 15|Deletion analyses
P07902532A1655|45 57|transcription
P07902583A0545|10 28|disassociation rates
P07902583A0545|45 65|Grf10-Swi5-DNA complex
P07903099A0918|91 104|splice acceptor
P07903670A1202|20 37|alpha 1-tubulin gene
P07905413A0585|26 45|plasma concentrations
P07905413A0585|108 124|segment depression
P07905453A0281|18 50|transcription-translation analysis
P07905453A0281|54 72|maxicell experiments
P07906265A0897|60 70|fasD mutants
P07907846A0623|14 26|physostigmine
P07907846A0623|53 77|cholinesterase degradation
P07907846A0623|88 112|bupivacaine administration
P07907846A0623|144 168|physostigmine pretreatment
P07908012A0678|27 41|LNNB performance
P07908012A0678|133 144|relationship
P07908012A0678|152 167|medication levels
P07908187T0000|5 17|possibilities
P07908827A1200|36 49|identification
P07909936A0672|10 26|treatment strategy
P07909936A0672|97 113|radiochemotherapy
P07909936A0672|124 147|stem-cell transplantation
P07910716A0359|3 14|study cohorts
P07910716A0359|138 149|rIFN-alpha 2b
P07910716A0359|165 178|U/m2/day thrice
P07910716A0359|227 240|SC rIFN-alpha 2b
P07910716A0359|253 266|U/m2/day thrice
P07910946A0323|16 33|deletion constructs
P07910946A0323|45 62|transfection assays
P07910946A0323|84 95|reporter gene
P07910946A0323|165 180|promoter activity
P07911736A1715|55 70|myelosuppression
P07912123A0711|15 37|lymphocyte proliferation
P07913080A0564|1 30|decanucleotide promoter sequence
P07913891A0174|67 78|interactions
P07913891A0174|88 99|relationship
P07913891A0174|145 164|transcription factors
P07913891A0174|203 219|tissue specificity
P07913926A0878|0 15|Northern analysis
P07913926A0878|99 109|glnA message
P07914192A0211|0 22|HER2 overexpressing cells
P07914192A0211|106 123|ets response element
P07914192A0211|139 154|bases down-stream
P07914192A0211|203 214|HER2 promoter
P07914192A0844|0 14|Gel-shift assays
P07914192A0844|37 60|oligonucleotide sequences
P07914192A0844|80 93|promoter region
P07914192A0844|213 233|GAGGAA response element
P07914507A1029|12 24|cDNA sequences
P07914507A1029|43 53|mRNA species
P07914507A1029|87 99|addition sites
P07914700A0000|26 48|eIF-2 alpha protein kinase
P07915144A0000|0 13|High-frequency
P07916003A0688|81 94|mouse CD79 alpha
P07916003A0688|105 116|octamer motif
P07916326A0000|17 28|organization
P07916327A0250|32 44|goosecoid gene
P07916577A0190|24 37|candidate genes
P07916577A0190|82 95|gene expression
P07916588A0471|41 66|passion fruit woodiness virus
P07916685A0455|23 44|arogenate dehydrogenase
P07916685A0455|53 75|prephenate dehydrogenase
P07916685A0455|118 129|purification
P07916689A0312|37 48|kb RNA species
P07916689A0312|100 111|carbon source
P07916689A1407|3 14|Y. lipolytica
P07916689A1407|104 123|Y. lipolytica LEU2 gene
P07916729T0000|1 19|leucine zipper domain
P07916729T0000|83 98|enhancer function
P07916983A0623|58 73|N1-N3 neck disease
P07916983A0623|109 120|prescription
P07917016A0581|23 53|zinc finger domain protein sequence
P07917540A0000|74 91|interferon-alpha 2b
P07918097T0000|8 31|Notch homologue mouse Notch
P07918097T0000|55 74|growth factor-repeats
P07918097T0000|104 118|neuroepithelium
P07918128A0000|52 68|hydroxytryptamine
P07918128A0000|75 92|receptor antagonist
P07918128A0000|124 135|chemotherapy
P07918494A1163|49 68|thioredoxin reductase
P07919540A0240|53 64|c-myc protein
P07919540A1119|50 61|c-Myc protein
P07919540A1119|72 84|transcription
P07919540A1119|106 122|reporter construct
P07922709T0000|35 47|growth factors
P07925282A0705|58 68|SRP proteins
P07925282A0705|106 125|protein translocation
P07926729A0000|36 63|signal transduction mechanisms
P07926729A0000|137 153|gene transcription
P07926739A0766|3 19|expression pattern
P07926739A0766|47 59|hybridization
P07926739A0766|101 115|progenitor cells
P07926739A0766|141 159|trichome development
P07926748A0383|51 64|overexpression
P07926748A0383|94 106|not2 mutations
P07926749A0471|7 19|site selection
P07926749A0471|114 136|hormone response elements
P07926749A0471|186 201|core motif PuGGTCA
P07926774A0652|3 25|p73pct1/p85cdc10 complex
P07926775A0895|63 73|slp activity
P07926775A0895|113 124|wg expression
P07926775A0895|142 156|wg transcription
P07926789A0960|3 13|DNA sequence
P07926789A0960|67 77|fusion genes
P07927130A0625|0 30|CMV hyperimmunoglobulin treatment
P07927267T0000|63 74|regeneration
P07927838A0000|87 101|prevalence rates
P07928954A0545|0 18|DNA sequence analysis
P07928954A0545|136 159|lipoprotein signal peptide
P07928954A0545|163 199|consensus prolipoprotein processing site
P07929165T0000|0 10|DNA sequence
P07929165T0000|28 38|actVI region
P07929165T0000|44 55|actinorhodin
P07929165T0000|68 78|gene cluster
P07929411A0087|25 43|polypeptide sequence
P07929411A0087|49 65|Drosophila protein
P07929411A0087|202 215|enzyme activity
P07929431A0949|30 48|mouse promoter region
P07929431A0949|60 103|reporter gene chloramphenicol acetyltransferase
P07929560T0000|0 13|Identification
P07929560T0000|68 81|plaque assembly
P07929560T0000|97 113|filament anchorage
P07931490A0237|136 151|granisetron doses
P07931490A0237|161 173|micrograms/kg
P07931490A0237|192 203|chemotherapy
P07932095A0000|115 133|Oroxylum indicum Vent
P07932943A0113|48 64|awareness strategy
P07932943A0113|90 114|Five-Step Approach strategy
P07932943A0113|120 135|control condition
P07933066T0000|33 46|adenovirus E4-6
P07933066T0000|60 84|retinoblastoma gene product
P07933076A0211|64 79|membrane proteins
P07933095A0000|51 65|retrovirus Rev-T
P07933095A0000|136 157|transcription factor Sp1
P07933095A0000|160 183|chicken embryo fibroblasts
P07933101A0131|38 48|TATA element
P07933101A0131|81 99|HIV-1 gene expression
P07933107A0991|16 33|nucleotide sequence
P07933107A0991|66 76|ASFV strains
P07933107A0991|124 134|% similarity
P07933116A0412|46 56|T-cell lines
P07934331T0037|7 18|registration
P07934666A0158|13 25|magnetization
P07935094A0516|67 84|Tl-201 counterparts
P07935094A0516|93 107|liver background
P07935370A0000|41 57|T-cell development
P07935370A0000|81 95|maturation state
P07935375A1197|47 65|TIS10/PGS2 induction
P07935383A0108|22 37|mapping technique
P07935383A0108|140 151|cleavage site
P07935383A0108|177 197|adenovirus L3 pre-mRNAs
P07935395A0094|41 56|zinc finger motifs
P07935415T0000|98 109|localization
P07935418A0447|6 16|v-erbA probe
P07935426A0714|40 55|zinc finger domain
P07935426A0714|87 104|TdT promoter binding
P07935447A0972|71 89|leucine zipper family
P07935447A0972|149 164|protein complexes
P07935447A0972|215 226|alpha-myosin
P07935451T0000|5 27|T-cell leukemia virus type
P07935451T0000|29 41|Tax activation
P07935451T0000|44 56|NF-kappa B/Rel
P07935451T0000|65 79|phosphorylation
P07935451T0000|96 107|I kappa B alpha
P07935468T0000|12 30|c-fos gene expression
P07935468T0000|59 78|growth factor receptor
P07935471A0613|114 127|mapping regions
P07935472A0276|66 81|expression assays
P07935472A0276|93 105|T-cell line EL4
P07935472A0276|172 187|enhancer activity
P07935472A0276|256 271|enhancer activity
P07935472A0790|14 28|binding activity
P07935472A0790|99 117|mobility shift assays
P07935491A0495|5 15|RZR subtypes
P07935491A0495|98 111|gene expression
P07935491A1182|18 33|response elements
P07935491A1182|79 121|acid receptor-retinoid-X receptor heterodimers
P07935577A0305|13 25|amphotericin B
P07935577A0305|90 104|micro-organisms
P07935626A1249|33 46|gene transcript
P07935626A1249|49 60|mitochondria
P07935997A0000|41 60|serum immunoglobulins
P07935997A0000|130 144|cervix carcinoma
P07936640A0900|74 93|footprinting analysis
P07936640A0900|112 127|TGF alpha promoter
P07936650A0656|69 84|activating region
P07937106A0100|3 15|v-ets oncogene
P07937106A0100|26 38|retrovirus E26
P07937106A0100|61 80|progenitor p68c-ets-1
P07937106A0100|86 107|amino acid substitutions
P07937108A0325|52 66|RNA polymerase I.
P07937112A0220|72 83|denaturation
P07937127A0645|52 68|activation domains
P07937127A0645|102 114|herpesviruses
P07937127A0645|121 137|pseudorabies virus
P07937132A0819|51 65|complementarity
P07937147A0205|35 50|pi protein mutants
P07937656A0182|36 57|Kaplan-Meier-estimates
P07937656A0182|61 73|Log-Rank-Test
P07937656A0182|130 141|disease stage
P07937656A0182|149 161|NSE serum level
P07937656A0182|172 183|micrograms/l
P07937656A0182|191 214|serum alkaline phosphatase
P07937656A0182|242 253|serum albumin
P07937656A0182|264 276|activity index
P07937841A0790|108 124|myb oncogene family
P07937965T0000|51 62|DNA synthesis
P07937965T0000|74 95|3T3-L1 mouse fibroblasts
P07941174T0001|0 11|Laser therapy
P07941739A0000|20 30|yeast genome
P07941739A0000|67 79|chromosome XIV
P07941750A0344|54 69|hydantoinase HyuA
P07941750A0344|89 103|hydatoinase HyuB
P07942076A0497|14 36|estradiol concentrations
P07942076A0497|50 66|estradiol valerate
P07942076A0497|80 97|estradiol ingestion
P07942722T0000|0 11|Constipation
P07944542T0000|0 17|Vibrio cholerae O139
P07945134A0079|127 140|head microphone
P07945330A0103|4 18|differentiation
P07945330A0103|37 49|transcription
P07945937A0358|0 15|Sequence analysis
P07945937A0358|21 33|zebrafish egr1
P07945937A0358|141 171|triplet nucleotide repeat sequence
P07945937A0358|195 207|amino terminus
P07945937A0358|213 223|Egr1 protein
P07947930A0499|13 25|serum proteins
P07947930A0499|26 38|sodium heparin
P07948129A0297|72 103|chloramphenicol acetyl transferase
P07948129A0297|107 118|reporter gene
P07948129A0297|159 172|region promoter
P07948129A0297|184 209|neomycin phosphotransferase
P07948921A0051|53 72|stilbene synthase cDNA
P07949137A0532|34 49|cyclophosphamide
P07949137A0532|66 80|body irradiation
P07949164A0799|29 39|kappa B motif
P07949164A0799|88 107|IL-6 promoter activity
P07949205A0286|9 22|testololactone
P07949205A0286|54 70|aminoglutethimide
P07949205A0286|89 103|breast carcinoma
P07949551A0000|44 65|cadaver transplantation
P07949770T0000|39 53|prostaglandin E1
P07949770T0000|63 82|liver transplantation
P07951410A0647|26 38|participation
P07951410A0647|111 123|participation
P07951410A1332|0 16|E1A autoactivation
P07951410A1332|106 116|E1A promoter
P07951874A0320|0 14|Cestode invasion
P07951874A0320|27 38|host organism
P07953785A0648|6 17|heat exposure
P07953785A0648|52 63|% restriction
P07953785A0648|134 161|marble spleen disease infection
P07954475A0714|63 75|A/J x C3H/HeJ F1
P07954475A0714|99 111|C3H/HeJ x A/J F1
P07954475A0714|154 165|inactivation
P07954475A0714|201 219|tumor suppressor gene
P07956578A0851|0 14|Lesion diameters
P07956578A0851|55 68|configurations
P07956869A0000|36 53|breast cancer tissue
P07956869A0000|89 107|Pathology laboratory
P07956869A0000|160 172|flow cytometry
P07956869A0000|188 202|S-phase fraction
P07957106A0471|38 57|GST-POU fusion protein
P07957106A0471|65 88|glutathione-agarose beads
P07957106A0875|49 69|HSV transactivator VP16
P07957106A0875|99 110|VP16 contacts
P07957158A1532|12 25|filtration rate
P07957158A1532|169 182|Starling forces
P07957559A1557|25 37|proliferation
P07957559A1557|40 51|Ba/F3-EpoRgp
P07957559A1557|88 106|p70 S6 kinase activity
P07957632A0000|97 114|glutamate receptors
P07957632A0000|160 178|halothane anesthesia
P07958446A0000|110 123|gene regulators
P07958446A0000|157 176|helix DNA binding motif
P07958865A1152|34 46|abnormalities
P07958865A1152|49 64|heart development
P07958865A1152|135 146|interactions
P07958898A1050|90 109|transcription factors
P07958911A0500|7 26|trithorax binding site
P07958911A0500|64 75|fork head gene
P07958915A1507|104 116|transcription
P07958915A1507|178 191|protein kinases
P07958920A1157|28 38|SNM1 protein
P07958920A1157|57 67|RNase MRP RNA
P07959011A0379a|39 55|rat class-I ADH gene
P07959011A0379b|39 55|rat class-I ADH gene
P07959734A0194|57 73|peptide sequencing
P07959734A0194|100 116|glycoprotein Gp135
P07959760A0763|122 143|Ewing sarcoma breakpoint
P07959760A0763|302 315|microsatellite
P07959952A1446|53 73|mouse mast cell chymases
P07959952A1446|87 122|polymerase chain reaction amplification
P07959952A1446|154 165|mast cell line
P07960796A0154|21 32|implications
P07961545A1314|79 90|constipation
P07961755A0474|41 62|transit peptide sequence
P07961755A0474|65 81|cysteine synthase C
P07961755A0474|113 127|leader sequences
P07961957A1565|93 114|alpha-MHC gene EM element
P07961958T0000|0 24|Rat kidney carboxylesterase
P07963540A0795|11 23|I-kappa B alpha
P07963540A0795|33 50|kappa B motif binding
P07963540A0795|60 73|factor-kappa B1
P07963540A0795|138 150|cross-linking
P07963540A0795|183 203|kappa B oligonucleotide
P07964162A0941|45 60|MAP kinase cascade
P07964162A0941|100 112|specification
P07964458A0179|1 13|candidate gene
P07964458A0179|58 74|macrophage protein
P07964458A0179|136 150|membrane protein
P07964459A0845|53 68|RING finger family
P07964624A0491|89 107|UGA termination codon
P07964770A0172|47 58|arthroplasty
P07964814T0000|16 29|hallucinations
P07965152A0764|23 33|BMIPP uptake
P07965152A0764|123 143|dobutamine stimulation
P07966565A0901|97 112|replication cycle
P07966583A1268|9 21|transfections
P07966583A1268|47 59|RNA transcript
P07966583A1268|120 132|fusion protein
P07966873A0693|26 37|heart disease
P07966873A0693|40 51|heart failure
P07967360A1048|42 56|TGBM nephropathy
P07967360A1048|77 90|IgA nephropathy
P07967360A1048|116 133|glomerulonephritis
P07967725A0262|105 123|ligand binding domain
P07967725A0262|129 144|carboxyl terminus
P07968409A0123|69 85|Outpatient Service
P07968409A0123|124 139|Ospedale Maggiore
P07968409A0123|140 154|General Hospital
P07969115A0000|7 32|organello footprint analysis
P07969115A0000|70 81|mitochondria
P07969115A0000|205 219|promoter regions
P07969116A0196|3 14|Nur77 protein
P07969116A0196|30 51|transcription activator
P07969132A0268|130 141|gcn2 deletion
P07969135A0913|20 33|Cln2 PEST domain
P07969136A0273|15 33|mobility shift assays
P07969136A0273|114 126|NF-kappa B site
P07969152A0721|44 59|activation domain
P07969152A0721|88 104|CUP1 transcription
P07969152A0721|121 135|heat shock stress
P07969152A0721|139 155|glucose starvation
P07969152A0721|191 209|heat shock activation
P07969152A0721|259 269|hsp70 family
P07969954T0000|11 29|motor neuron syndrome
P07969954T0000|90 102|immunotherapy
P07969954T0000|114 127|plasma exchange
P07969954T0000|142 157|cyclophosphamide
P07971282A0000|62 91|pre-mRNA splicing characteristic
P07972012A0956|34 47|rat lung library
P07972012A0956|97 109|amino terminus
P07972012A0956|140 151|ANP-receptor
P07972012A0956|187 202|carboxyl terminus
P07972012A0956|226 242|phosphatase domain
P07972237A0665|16 29|restriction map
P07972237A0665|89 102|subcloning YACs
P07972831A0563|0 10|PAI-1 levels
P07973364A0325|68 89|carcinogenicity studies
P07973397T0001|0 12|Determination
P07973397T0001|15 29|potassium iodide
P07973825A0445|3 15|recovery value
P07973825A0445|67 79|pulse pressure
P07975763A0000|15 29|hepatitis C virus
P07975763A0000|59 70|liver disease
P07975763A0000|92 103|introduction
P07975763A0000|115 130|detection methods
P07975882T0000|5 18|adenovirus type
P07977239A1283|0 17|Outflow obstruction
P07977239A1283|186 197|pancreatitis
P07977648A0880|15 29|TP53 transcripts
P07978229T0000|9 20|complication
P07979810A0340|54 68|penetration test
P07980440A0138|2 22|H4IIE rat hepatoma cells
P07980440A0138|23 37|glucocorticoids
P07980440A0138|66 95|increase PEPCK gene transcription
P07980440A0138|113 125|phorbol esters
P07980669A0373|5 19|plasma AVP levels
P07980669A0373|67 81|plasma NPY levels
P07981143A0633|59 74|IL-4 inducibility
P07981143A0633|84 105|nucleoprotein complexes
P07981246A0112|29 42|pertussis toxin
P07981246A0112|105 119|differentiation
P07981246A0112|122 134|hormones/IBMX
P07981246A0112|148 161|c-fos induction
P07982964A1017|38 87|phosphodiesterase substrate p-nitrophenyl thymidine-5
P07982964A1017|87 99|monophosphate
P07982995A0000|59 70|growth factor
P07982995A0000|75 87|beta-receptor
P07982995A0000|178 189|hamster ovary
P07983011A0617|0 15|Sequence analysis
P07983011A0617|67 89|serine/threonine kinases
P07983011A0617|148 173|protein kinase kinase kinases
P07983011A0617|180 215|fibroblast growth factor receptor family
P07983011A0617|241 259|leucine zipper motifs
P07983011A0617|408 418|src homology
P07983011A0617|423 442|domain binding regions
P07983704A0330|110 128|retrovirus ancestors
P07983704A0330|134 145|HERV-K family
P07983715A0996|0 13|Point mutations
P07983715A0996|139 154|complex formation
P07983715A0996|191 206|expression assays
P07983715A0996|215 236|luciferase reporter gene
P07983716A1082|23 34|blot analysis
P07983716A1082|45 62|transcriptase-PCRs
P07983716A1082|77 88|transfection
P07983744A0920|80 97|punctate structures
P07983744A0920|171 188|punctate structures
P07984088A0592|0 12|Transcription
P07984088A0592|25 35|ivanolysin O
P07984088A0592|66 85|virulence gene cluster
P07984105A1509|10 24|complementation
P07984105A1509|30 41|WA fyuA mutant
P07984105A1509|61 80|yersiniabactin uptake
P07984105A1509|84 97|mouse virulence
P07985305T0001|14 27|hydronephrosis
P07987924A0670|3 14|inflation hub
P07987924A0670|56 78|USCI Tuohy-Borst Y adaptor
P07987924A0670|110 122|probe hypotube
P07988730A0220|8 23|promoter strength
P07988730A0220|92 123|chloramphenicol acetyltransferase
P07988730A0220|142 153|transfection
P07988730A0220|167 179|Jurkat T-cells
P07988730A0220|209 232|transactivator tax protein
P07988731A0002|142 157|promoter activity
P07988731A1301|68 84|GBF protein complex
P07988945T0000|26 44|lupus anticoagulants
P07990136A1124|20 46|selectivity arrest elongation
P07990136A1124|82 106|tRNA gene transcription unit
P07990136A1124|122 135|identification
P07991582A1023b|95 108|enzyme function
P07992027A0485|64 78|transplantation
P07993559A0233|12 29|Fluorosis Risk Index
P07994021A1223|64 78|PECAM-1 isoforms
P07994021A1223|94 108|phosphorylation
P07994021A1223|135 152|affinity modulation
P07997174A0936|27 41|phosphorylation
P07997174A0936|92 107|A. vinelandii NifL
P07999066A0238|29 43|enhancing factor
P07999066A0238|72 92|IL-2 gene transcription
P07999066A0238|149 160|phorbol ester
P07999066A0238|190 200|Jurkat cells
P07999066A0238|244 278|acetyltransferase reporter constructs
P07999363A0000|35 58|transmembrane FGF receptor
P07999363A0000|115 133|juxtamembrane domain
P07999363A0000|153 164|kinase domain
P07999982A0086|9 24|maximum lod scores
P07999982A0086|95 115|recombination fraction
P07999982A0086|133 151|recombination events
P07999995A0000|14 26|protein kinase
P07999995A0000|54 64|Oryza sativa
P08000074A0162|93 105|reading frames
P08000112T0000|48 72|membrane oxygenator support
P08000427A0000|1 13|cDNA clone pCZ1
P08000427A0000|58 79|tobacco cell cDNA library
P08000497A0179|37 63|methacholine provocation test
P08001136T0000|0 11|Relationship
P08001136T0000|37 49|RNA polymerase
P08001136T0000|52 71|CTD kinase TFIIH/TFIIK
P08001792A0284|49 64|adenylate cyclase
P08001792A0284|85 117|adenylate cyclase activation pathway
P08001966A0563|144 164|Caenorhabditis elegans
P08002564A0249|0 18|DNA sequence analysis
P08002564A0249|78 89|alpha subunit
P08002564A0249|99 112|leucine residue
P08002857A1070|50 70|oesophageal surfactant
P08003700T0000|36 48|cDNA libraries
P08003700T0000|108 127|genome rearrangements
P08004442A0265|45 61|locomotor activity
P08004442A0265|162 184|corticosterone secretion
P08004442A0265|197 209|adrenalectomy
P08005230A0222|9 26|reporter gene system
P08005230A0222|75 87|c-fos promoter
P08005230A0222|145 162|luciferase activity
P08005412A0608|21 34|gene expression
P08005412A0608|69 82|protein complex
P08005412A0608|135 146|interactions
P08005438A1185|97 110|suppressor srn1
P08005438A1185|143 156|gene expression
P08006101A1142|0 35|Standard curve correlation coefficients
P08006101A1142|70 90|validation experiments
P08006101A1142|104 115|study samples
P08006772A0000|8 20|pulse oximeter
P08006773A0836|22 41|plasma concentrations
P08006773A0836|82 94|blood pressure
P08006773A0836|99 110|preeclampsia
P08006773A0836|140 151|preeclampsia
P08006773A0836|155 173|plasma concentration
P08007954A0374|0 14|Deletion studies
P08007954A0374|32 46|response element
P08007954A0374|70 85|cytokine response
P08007975A0000|24 57|high-fidelity chromosome segregation
P08011017A0169|8 23|oxygen saturation
P08011017A0169|101 121|repeat polysomnography
P08011166A0207|11 26|gene organization
P08011166A0207|98 113|characterization
P08011166A0207|116 130|polymerase chain
P08012448T0000|38 49|biosynthesis
P08012448T0000|78 96|bud pattern formation
P08012566A0254|3 29|pentafluorobenzyl derivative
P08012566A0254|32 46|clonidine yields
P08012566A0254|56 66|ion fragment
P08012566A0254|122 133|plasma sample
P08013348A0143|25 35|sex steroids
P08013348A0143|59 75|binding properties
P08013457A0342|0 10|Src homology
P08013457A0342|43 54|interactions
P08013457A0342|69 108|tyrosine kinase receptor signal transduction
P08014228A0278|0 14|Sample treatment
P08014228A0278|64 88|labetalol diastereoisomers
P08014228A0278|99 110|racemization
P08014377A1277|22 35|activity levels
P08015672A1282|2 16|control patients
P08015672A1282|17 30|baseline images
P08015850A1076|23 34|dose response
P08015850A1076|48 63|Ga administration
P08015850A1076|88 99|availability
P08016102A1238|47 66|transcription factors
P08016102A1238|212 228|defense mechanisms
P08016102A1238|236 247|tissue injury
P08016189A0741|60 71|intervention
P08017290A1347|25 39|sinus difference
P08017290A1347|75 94|potassium differences
P08018361A0636|29 42|neutron fluency
P08020702A0137|78 89|disturbances
P08020702A0137|108 121|dog experiments
P08020702A0137|144 167|antibodies administration
P08020806A0187|164 174|feeding tube
P08020962A1226|24 33|V beta locus
P08020962A1226|69 79|DNA elements
P08021175A0486|98 115|AMP receptor protein
P08021175A0486|119 139|integration host factor
P08021177A0000|15 29|fes-entF operons
P08021177A0000|35 55|enterobactin synthesis
P08021177A0000|59 73|transport system
P08021177A0000|147 165|Fur repressor protein
P08021225A0000|0 15|Sequence analysis
P08021225A0000|33 46|EcoRI-fragment
P08021225A0000|49 68|Alcaligenes eutrophus
P08021225A0000|103 118|dihydrolipoamide
P08022212A0071|25 37|two-frequency
P08022212A0071|38 49|AC excitation
P08022212A0071|74 92|admittance locus plot
P08022212A0071|101 119|low-frequency region
P08022212A0071|230 248|phase angle alpha pi/2
P08022212A0071|278 288|frequency G0
P08022212A0071|297 316|ion relaxation time tau
P08023662T0000|43 60|thromboplastin time
P08023662T0000|64 78|prothrombin time
P08025074A0000|61 78|laser energy density
P08025074A0000|88 98|suture lysis
P08028671A0687|16 29|microinjection
P08028671A0687|76 88|transcription
P08029001A1020|47 63|activator proteins
P08029001A1020|67 79|RNA polymerase
P08029001A1020|173 194|transcription machinery
P08029334T0000|15 26|plant omega-3
P08029334T0000|32 46|acid desaturases
P08030239A0833|56 72|amino acid residues
P08030239A0833|120 135|activation domain
P08030239A0833|159 173|EHV-1 tk promoter
P08030239A0833|212 226|EHV-1 IE promoter
P08030243A1011|24 38|RNA capture assay
P08030704A1503|61 95|progesterone/17 beta-estradiol ratios
P08030704A1503|116 127|preterm labor
P08031424T0000|24 35|bronchospasm
P08033490A0875|42 63|O-desmethylvenlafaxine
P08033490A0875|104 119|dosage adjustment
P08033490A0875|146 170|creatinine clearance values
P08034318A0724|3 14|availability
P08034318A0724|141 160|transcription factors
P08034486A0579|39 56|HSV-1 antibody ratio
P08034680A0180|88 100|I kappa B kinase
P08034682T0000|27 69|inositol 1,4,5-trisphosphate receptor subunits
P08034682T0000|72 85|3T3 fibroblasts
P08034708A0000|48 64|eosinophil lineage
P08034708A0000|139 153|differentiation
P08034741A0000|11 24|identification
P08034741A0000|28 43|characterization
P08034741A0000|117 130|border myosin I.
P08035498A0833|10 25|computer analysis
P08035498A0833|59 70|A stem element
P08035498A0833|95 112|AAV promoter regions
P08035499A0941|83 98|dissociation rate
P08035499A0941|104 117|A stem substrate
P08035505A0586|18 29|B polyprotein
P08035796A0890|0 11|32Pi labeling
P08035796A0890|68 79|casein kinase
P08035796A0890|102 116|phosphorylation
P08035796A0890|226 241|growth conditions
P08035833A1556|83 97|import machinery
P08036004A0292|99 113|binding activity
P08037338A0000|30 43|erythropoietin
P08037338A0000|70 81|pathogenesis
P08039422A0000|3 27|nerve growth factor beta gene
P08039422A0000|85 99|mouse Chromosome
P08040336A0435|28 42|collagen element
P08040336A0435|77 97|LAP binding cis-element
P08040336A0435|103 117|albumin promoter
P08040391T0000|106 120|tumour behaviour
P08040468A0303|15 35|mast cell degranulation
P08040468A0303|54 65|pathogenesis
P08040468A0303|89 112|fibroblast enzyme activity
P08041362T0000|19 38|cysteine synthase cDNA
P08041362T0000|79 93|complementation
P08043523A0000|16 26|serum levels
P08043523A0000|53 73|acetylcholine receptor
P08044794A0000|3 17|tumor suppressor
P08044800A0550|4 32|DNA containing promoter activity
P08044802A0462|7 18|Southern blot
P08044802A0462|22 38|karyotype analyses
P08044802A0462|91 104|rearrangements
P08045834A0783|3 20|PCr resynthesis rate
P08045834A0783|68 79|ATP synthesis
P08046923A0000|62 73|osteomalacia
P08048582A0821|77 91|ml O2.min-1 times
P08048582A0821|134 148|ml O2.min-1 times
P08048916A0000|7 22|insulin receptors
P08049401A0428|0 15|Immunodepression
P08049401A0428|44 65|glucocorticoid activity
P08049401A0428|108 122|thyroid hormones
P08049444A0351|18 40|peptide sequence analysis
P08049444A0351|122 135|binding protein
P08049521T0000|8 29|protein phosphorylation
P08049885T0000|5 16|pancreatitis
P08049885T0000|18 35|multisystem disease
P08051019A0365|8 19|biosynthesis
P08051059A1000|24 35|rhlA promoter
P08051059A1000|81 92|binding sites
P08051059A1000|99 111|RhlR regulator
P08051074A0000|23 34|footprinting
P08051074A0000|69 89|immunodeficiency virus
P08051102A0532|20 31|rAC-st myosin
P08051102A0532|37 60|chain phosphatase activity
P08051151A0347|96 108|chain reaction
P08053697A0000|63 79|hyperpigmentation
P08054281A0731|3 16|retention index
P08054281A0731|136 147|relationship
P08054281A0731|155 165|201Tl uptake
P08055939A0159|62 72|H1 molecules
P08055939A0159|120 135|hexapeptide motif
P08055939A0159|168 178|H1 molecules
P08055939A0707|72 87|Arabidopsis genes
P08055941A1264|31 42|beta subunits
P08055941A1264|48 62|artifactual beta
P08057356A0531|34 45|substitution
P08057356A0531|69 85|response regulator
P08057356A1824|20 39|operon control regions
P08057356A1824|62 74|NarL heptamers
P08057356A1824|97 108|orientations
P08057421A1583|16 32|competition assays
P08057421A1583|44 64|oligonucleotide probes
P08057421A1583|90 105|CBF1 binding sites
P08057421A1583|148 159|CD23 promoter
P08057421A1583|166 186|EBV LMP-1 promoter sites
P08057762A0878|24 38|reproducibility
P08057762A0878|64 78|reproducibility
P08057833A0573|6 17|ParA proteins
P08057833A0573|55 75|translation initiation
P08057833A0573|90 100|start codons
P08057833A0573|118 129|reading frame
P08058326A0463|57 71|tal-1 expression
P08058326A0463|138 149|counterparts
P08062824A0626|73 89|isomerase activity
P08062833A0000|25 51|transcription initiation site
P08062833A0000|57 71|mouse desmin gene
P08062833A0000|95 105|binding site
P08063766A0595|40 53|envelope lamin B
P08063775T0000|50 63|gene expression
P08063791A1370|57 70|sequence motifs
P08063791A1370|91 103|modifications
P08063791A1370|120 130|Ras proteins
P08063836A0904|28 45|c-myc transcription
P08064351A1020|0 11|Long-latency
P08065310A1144|46 63|heterodimerization
P08065310A1144|165 182|receptor gene family
P08065324A0458|77 88|TATA elements
P08065324A0458|120 132|transcription
P08065327A0000|9 24|DNA rearrangement
P08065327A0000|63 74|macronucleus
P08065327A0000|82 101|germ line micronucleus
P08065331A0279|16 37|site selection procedure
P08065331A0279|56 67|DNA sequences
P08065331A0279|112 126|E2A-HLF proteins
P08065338T0000|37 53|activation domains
P08065338T0000|113 125|transcription
P08065365A0000|23 39|ribonucleoprotein
P08065366A0918|58 78|chromosome segregation
P08065901A0997|85 97|transcription
P08065901A0997|134 145|interactions
P08065901A0997|156 167|KRAB-A domain
P08067013T0001|13 24|significance
P08067013T0001|27 57|creatine phosphokinase antibodies
P08067123A0248|49 70|assay systems ORTHO ELISA
P08067123A0248|74 85|ABBOTT HCV EIA
P08067123A0248|92 104|detection rate
P08067123A0248|107 121|anti-HCV-C100-3
P08067123A0248|134 144|blood donors
P08067123A0248|191 203|HBsAg carriers
P08067123A0248|225 239|anti-HCV-C100-3
P08067546A0000|38 55|vasomotor responses
P08067546A0000|84 99|sodium thiopental
P08067546A0000|172 186|vasodilator tone
P08067546A0000|208 230|vasoconstrictor activity
P08067607A0568|37 57|serum CRP concentration
P08067607A0568|70 83|baseline values
P08067607A0568|106 117|control group
P08069298A0492|16 29|splice variants
P08069298A0492|89 108|leptomeningeal tissue
P08069298A0492|131 149|leptomeningeal cells
P08069427T0000|0 25|Roux-en-Y gastroenterostomy
P08069481A0736|43 53|calf muscles
P08070004A0782|32 46|PCZ plasma levels
P08070004A0782|73 87|plasma half-life
P08070654A0000|88 101|SPB duplication
P08070654A0574|18 31|SPB duplication
P08070654A0574|91 108|caltractin/centrin
P08070654A0574|134 146|Chlamydomonas
P08071356A0232|6 25|transcript elongation
P08071356A0232|39 50|DNA footprint
P08071356A0232|72 90|transcription bubble
P08071356A0232|108 129|transcription complexes
P08071356A0232|147 163|template positions
P08072352A0567|43 60|aspirin sensitivity
P08072352A0567|68 79|eosinophilia
P08072547A0690|29 42|protein kinases
P08072547A0690|67 80|serine residues
P08072547A1009|33 54|JNK phosphorylation site
P08072547A1009|94 109|activation domain
P08072547T0000|55 67|protein kinase
P08073505T0000|16 40|information retrieval tools
P08073505T0000|69 83|ExPASy WWW server
P08075070A1632|69 81|operator sites
P08075070A1632|86 101|repressor domains
P08075070A1632|109 126|sequence homologies
P08076631A0000|12 34|transcription factor AP-1
P08076631A0000|38 53|vitamin D receptor
P08076631A0000|99 112|promoter region
P08076631A0000|132 146|osteocalcin gene
P08076631A0000|223 243|osteosarcoma cell lines
P08076937A0851|40 59|restriction digestion
P08076937A0851|86 99|mismatch primer
P08076937A0851|115 127|point mutation
P08076937A0851|136 155|Tru9I restriction site
P08078416A0581|23 35|disinfectants
P08078416A0581|43 54|biofilm cells
P08078416A0581|102 115|concentrations
P08078416A0581|121 133|disinfectants
P08078473A1107|43 55|ste13 mutation
P08079268T0028|5 25|Medi-Jector EZ dermojet
P08082215A0230|19 32|past-infection
P08082215A0230|35 49|cytomegalovirus
P08082286A0748|0 16|Acupuncture effect
P08082292T0000|89 100|tuberculosis
P08082360A0411|0 13|Smoking history
P08082360A0411|22 37|oxygen saturation
P08083011A0584|71 84|R-L brain weight
P08083011A0584|110 123|R-L brain weight
P08083011A0584|139 150|testosterone
P08083220A0988|17 32|complex formation
P08083220A0988|75 92|c-fos protooncogene
P08083220A0988|160 172|serum response
P08083963A0795|51 64|extract protein
P08083963A0795|102 113|footprinting
P08083963A0795|117 145|methylation interference assays
P08083998A1723a|23 39|leader-mRNA fusion
P08083998A1723a|42 65|coronavirus transcription
P08083998A1723a|86 103|RNA-RNA interaction
P08083998A1723b|23 39|leader-mRNA fusion
P08083998A1723b|42 65|coronavirus transcription
P08083998A1723b|86 103|RNA-RNA interaction
P08083999A0501|51 65|BPV-1 E2 proteins
P08083999A0501|72 86|consensus E2 site
P08083999A0501|153 165|transcription
P08084339A0907|49 60|reading frame
P08084339A0907|145 159|TCR C alpha region
P08084339A0907|184 203|amino acid polypeptide
P08084592A0145|7 27|fibroblast cell hybrids
P08084592A0145|55 68|tumorigenicity
P08085228A0000|11 25|characteristics
P08085228A0000|29 42|risk factor data
P08085228A0000|87 98|distribution
P08085228A0000|119 139|immunodeficiency virus
P08085228A0000|167 183|testing facilities
P08085609A0384|51 63|chimpanzee M1s
P08085609A0384|115 133|crown fissure termini
P08086450A0467|84 99|guanine-cytosine
P08086450A0467|128 140|binding motifs
P08086453T0000|9 24|promoter analysis
P08087887A1067|3 19|polyubiquitin gene
P08087887A1067|47 61|Volvox life cycle
P08087887A1067|121 134|post-inversion
P08088022A1417|55 66|heart disease
P08088513A0419|88 103|DEAH protein Prp16
P08088777A0754|3 20|consensus gene order
P08089184A0825|13 26|megabase region
P08089834A0561|65 80|amino acid residue
P08089887A0742|9 22|OUTCOME MEASURE
P08090746A1288|40 51|region shares
P08090746A1288|75 91|promoter sequences
P08090746A1288|103 124|ethylene responsiveness
P08090746A1288|132 157|tomato fruit-ripening E4 gene
P08090767A0000|21 38|DNA polymerase delta
P08090767A0000|141 158|base excision repair
P08090767A0000|170 189|DNA methylation damage
P08091655A0000|25 36|Disease Virus
P08091655A0000|54 68|EcoRI-B fragment
P08091665T0000|0 10|Cowpox virus
P08091665T0000|80 90|TNF receptor
P08091669A0828|37 47|39k promoter
P08091669A0828|75 86|reading frame
P08091669A0828|116 126|ie1 promoter
P08093450A0688|32 43|ALAS promoter
P08093450A0688|76 117|chloramphenicol acetyltransferase expression
P08093450A0688|142 152|NRF-1 motifs
P08093616A1214|6 25|footprinting analysis
P08093616A1214|72 93|DNA polymerase alpha gene
P08093616T0000|5 22|8-base pair sequence
P08093616T0000|73 85|binding factor
P08093616T0000|129 146|DNA polymerase alpha
P08093642A0600|11 42|microsatellite repeat polymorphism
P08093642A0600|48 61|heterozygosity
P08093642A0600|83 119|restriction fragment length polymorphism
P08093642A0600|125 138|heterozygosity
P08093642A0600|154 164|lambda clone
P08093642A0600|172 182|D10S94 locus
P08093642A0600|225 238|linkage mapping
P08094464A2014|15 30|attenuator region
P08094464A2014|81 93|configuration
P08094464A2014|104 125|base-residue divergence
P08095698T0000|99 119|nephropathia epidemica
P08095872A1672|116 129|LONG/CIRC ratio
P08095872A1672|157 175|contraction efficacy
P08096066A0623|3 14|RFLP patterns
P08096066A0623|134 147|drug resistance
P08097666A1135|21 33|modifications
P08097732A0000|64 79|sea urchin embryos
P08097732A0000|137 151|sequence element
P08097732A0000|172 187|Spec1/Spec2 genes
P08098842A0660|55 76|transcription start site
P08098842A0660|205 218|gene expression
P08098882T0001|12 26|desensitization
P08098914A0400|17 31|Pes-Ves relation
P08099443A0359|37 51|yeast eIF-2 alpha
P08099443A0359|96 106|GCN2 protein
P08099443A0359|118 132|GCN4 translation
P08100765A0361|23 49|transgene expression patterns
P08100765A0361|119 130|compartments
P08100843A0134|0 15|Southern analysis
P08100843A0134|70 81|mouse strains
P08101134A0376|3 16|concentrations
P08101134A0376|63 75|MPTP treatment
P08101171A0924|35 49|Pc group products
P08101839A0000|72 83|mdr1 promoter
P08101839A0000|103 119|cell proliferation
P08101843A0151|3 25|tyrosine hydroxylase gene
P08101843A0151|50 61|consensus CRE
P08101843A0151|95 121|transcription initiation site
P08102364A0000|34 52|Nicotiana tabacum var
P08103379A0577|104 125|amino acid substitutions
P08103935T0000|12 27|characterization
P08103935T0000|30 49|SRF accessory proteins
P08104189A1168|21 35|proSRIF cleavage
P08105727A0099|11 33|dopamine receptor agonist
P08105727A0099|48 64|animal experiments
P08105994T0000|32 61|serum gamma-glutamyl transferase
P08106087A0139|27 37|kDa zein gene
P08106087A0139|133 152|polyadenylation sites
P08106245A0325|9 26|radon concentration
P08106245A0325|142 153|measurements
P08106245A0325|256 267|measurements
P08106313A1492|119 129|sigma factor
P08106325A0000|71 81|tox operator
P08106325A0000|99 116|nucleotide sequence
P08106325A0000|139 157|diphtheria toxin gene
P08106369A0000|104 120|membrane receptors
P08106398A1003|38 50|leader peptide
P08106398A1003|66 80|nisin maturation
P08106512A0522|7 20|promoter region
P08106512A0522|47 58|reporter gene
P08106512A0522|73 86|promoter region
P08106512A0522|115 130|interferon-alpha
P08107167A0222|51 67|parkeri antibodies
P08107167A0222|145 156|serum samples
P08107208A0673|57 68|recombinants
P08108099T0000|12 23|desmopressin
P08108343A0000|135 146|hypogonadism
P08108343A0000|187 199|insufficiency
P08108343A0000|249 268|gonadotropin reserves
P08108413A0964|90 103|PANG expression
P08111035A0098|40 57|bp promoter fragment
P08111035A0098|61 78|B. napus oleosin gene
P08111035A0098|103 120|beta-glucuronidase
P08111035A0098|146 158|tobacco plants
P08111035A0098|171 189|oleosin promoter-GUS
P08111974A1034|62 72|tubulin mRNA
P08111974A1034|152 163|trans-factor
P08112526A0443|26 45|calcium concentration
P08112526A0443|54 74|detrusor contractility
P08112601T0000|10 21|organization
P08112611A0404|26 37|reading frame
P08112870A0484|0 14|Western blotting
P08112870A0484|15 28|immunoblotting
P08113736A0309|3 18|gene organization
P08113736A0309|109 122|dianthoviruses
P08114702A0000|63 82|transcription factors
P08114702A0000|118 131|control regions
P08114710A0137|39 56|HIV-1 transcription
P08114745A0953|44 56|RNA production
P08114745A0953|92 107|termination sites
P08114745A0953|157 178|transcription complexes
P08115744A0462|45 61|laser densitometer
P08115744A0846|99 121|quality assurance program
P08118044A0318|78 88|FDC-P1 cells
P08119149A0000|0 24|Tumor necrosis factor-alpha
P08119907A0000|35 47|p21ras protein
P08119907A0000|72 85|growth factor-I
P08119907A0000|91 107|signaling pathways
P08119958A0273|96 108|signal peptide
P08119995A0814|35 53|T3R-RXR heterodimers
P08119995A0814|56 71|response elements
P08120019A1500|87 99|sequestration
P08120029A0864|18 38|decay reaction mixtures
P08120029A0864|63 80|sense RNA transcript
P08120029A0864|91 103|stabilization
P08122364A0954|0 15|Deletion analyses
P08122364A0954|42 59|promoter constructs
P08122364A0954|110 122|pCD41 sequence
P08122370A0331|15 26|counterparts
P08122370A0331|36 52|herpes simplex type
P08122370A0331|59 75|pseudorabies virus
P08122370A0331|88 102|herpesvirus type
P08123787A0554|11 27|amino acid sequence
P08123787A0554|47 57|HemB protein
P08123787A0554|94 117|metal cofactor requirement
P08123787A0554|163 176|overexpression
P08124785A0445|58 81|circumflex artery stenosis
P08124785A0445|155 165|flow reserve
P08124785A0445|188 210|mean transit time Tmicro-1
P08124912A0456|72 90|beta 2-microglobulin
P08124956T0000|43 54|pancreatitis
P08125258A0142|140 152|perturbations
P08125319A1085|98 110|data libraries
P08125337A0940|0 13|Sterol analysis
P08125337A0940|49 60|accumulation
P08125337A0940|90 103|Erg24p activity
P08125949A1162|43 56|spinach L12 mRNA
P08125949A1162|180 202|L12/chloroplast ribosome
P08126096A0478|175 189|domain antiserum
P08126096A1071|3 16|alpha 7A form RNA
P08126096A1071|79 90|coding region
P08126096A1071|126 138|reading frames
P08127950A0000|112 128|0800h plasma levels
P08127950A0000|151 166|triiodothyronine
P08127950A0000|173 197|thyroid stimulating hormone
P08128629A1164|0 10|CRS function
P08128629A1164|25 43|gene expression assay
P08130942A0051|0 14|Regionalization
P08130942A0051|17 28|drug delivery
P08131545A0158|31 46|community members
P08131545A0158|171 191|Legionella pneumophila
P08131545A0158|192 206|cytomegalovirus
P08131545A0158|217 232|Coxiella burnetii
P08131746A0140|23 43|serine phosphorylation
P08131746A0140|54 69|activator kinases
P08132574A0831|31 46|complement C2 gene
P08132574A0831|99 118|cytochrome CYP1A1 gene
P08132667T0000|22 52|proprotein processing enzyme furin
P08133502T0105|0 26|European Community Huntington
P08133502T0105|28 57|Disease Collaborative Study Group
P08134108A0277|19 42|alpha-actin gene promoters
P08134108A0277|50 64|YY1 binding sites
P08134115A1161|25 37|fusion protein
P08136383A0359|18 29|MR tomography
P08138180A0593|89 100|SPT10 protein
P08139001A1235|33 46|carboxy termini
P08139001A1235|52 69|NS1 protein molecule
P08139001A1235|119 133|tubule formation
P08139004A0278|64 75|UGC sequences
P08139017A1465|66 80|primer extension
P08139017A1465|108 121|Ets-1 cDNA clone
P08139031A1168|83 98|cysteine residues
P08139031A1168|104 118|ORF4 polypeptide
P08139031A1168|151 172|transactivator function
P08139031A1168|192 207|cysteine residues
P08139031A1168|247 258|interactions
P08139031A1168|284 299|acid interactions
P08139031A1168|309 324|ORF4 inducibility
P08139539A0446|2 11|Rat 1a cells
P08139539A0446|12 25|m1R stimulation
P08139539A0446|28 45|phospholipase C beta
P08139539A0446|142 156|protein kinase A.
P08139542T0000|25 37|leader peptide
P08139542T0000|93 111|yeast gene transcript
P08139543A0427|35 50|SLK1-SLT2 pathway
P08139543A0427|67 83|suppression screen
P08139543A1520|49 61|NHP6B function
P08139562A0404|137 149|GCN4 start site
P08139577T0000|21 48|yeast transcription factor IIIB
P08139577T0000|76 88|transcription
P08139914A0554|29 43|dnHLH protein Id1
P08139914A0554|52 66|differentiation
P08139928T0000|8 28|ribonucleoprotein gene
P08140847X0001|181 195|disease patients
P08142875A0877|92 103|intervention
P08143198T0001|33 47|transplantation
P08143198T0001|54 82|composites dorsal pedal skin flap
P08143198T0001|93 116|m. extensor hallucis brevis
P08143236A1055|7 20|ethanol regimen
P08143236A1055|58 70|g ethanol.kg-1
P08143236A1055|72 83|day-1 regimen
P08143667A0222|54 69|closure pressures
P08144470A0711|20 32|asgB480 allele
P08144470A0711|100 111|substitution
P08144470A0711|126 139|protein product
P08144497T0000|24 34|raf-1 kinase
P08144504T0064|32 44|ATP hydrolysis
P08144572A0786|22 39|polypeptide binding
P08144572A0786|101 116|Ssa Hsp70 proteins
P08144615A0533|21 37|endoprotease Asp-N
P08144615A0533|70 86|NF-IL6 bZIP domains
P08144631A0000|11 25|tyrosine kinases
P08144631A0000|40 51|associations
P08144631A0000|71 81|Src homology
P08144631A0000|103 125|tyrosine phosphorylation
P08144668A0802|86 97|reading frame
P08144668A0802|157 173|membrane anchoring
P08144852A0000|17 30|stress hormones
P08144852A0000|39 54|11-deoxycortisol
P08144852A0000|76 88|corticotropin
P08144852A0000|149 166|cortisol deficiency
P08145646T0000|38 48|sigma factor
P08145646T0000|55 75|Rhodobacter capsulatus
P08145646T0000|115 135|nifU2-rpoN superoperon
P08145770A1078|7 18|observations
P08145770A1078|59 74|retinoid pathways
P08145770A1078|132 155|differentiation processes
P08148463A0000|94 107|granulocyte CSF
P08148463A0000|133 145|macrophage CSF
P08148756A0358|11 25|lung destruction
P08148756A0358|81 97|hemoglobin content
P08149484A0151|0 17|Expression plasmids
P08149484A0151|40 51|kinase domain
P08149484A1551|94 106|transcription
P08150970A0434|5 15|cutoff level
P08151787A0355|16 31|oligonucleotides
P08151787A0355|48 77|amino acid motifs 726-GRKRKSP-732
P08151787A0355|90 104|500-VRPRKRR-506
P08151787A0355|260 271|localization
P08151787T0000|22 40|localization domains
P08151787T0000|55 80|colocalization interactions
P08151787T0000|111 132|transactivator proteins
P08151787T0000|135 152|herpes simplex virus
P08151790A0354|3 20|revertant TATA boxes
P08151790A0354|45 58|HIV replication
P08151790A0354|100 110|Sp1 mutation
P08152800A0357|157 173|Molecule PEA3-like
P08152800A0709|0 15|Gel shift analysis
P08152800A0709|81 95|oligonucleotide
P08152800A0709|109 143|consensus nucleotide core sequence GGAA
P08152800A0709|159 169|Ets proteins
P08154182A0955|34 56|lambda AD5 cloning vectors
P08154182A0955|91 119|Neurospora crassa cDNA libraries
P08156332T0000|23 35|sympathectomy
P08157009A0264|0 18|Sequence comparisons
P08157009A0264|55 66|sigma subunit
P08157009A0264|96 106|AP-1 complex
P08157009A0264|139 168|plasma membrane AP-2 sigma subunit
P08157009T0000|80 98|clathrin AP-1 complex
P08157009T0000|148 159|Golgi complex
P08157663A0882|49 60|organization
P08157663A0882|64 77|vertebrate gene
P08157663A0882|96 110|membrane protein
P08157663A0882|158 169|polypeptides
P08157674T0000|11 26|characterization
P08157674T0000|55 84|protein tyrosine kinase substrate
P08159174A0581|41 56|Southern analysis
P08160054A0224|15 28|deterioriation
P08160054A0224|66 77|liver enzymes
P08160054A0224|90 114|alanine aminotransaminases
P08160054A0224|124 135|coagulopathy
P08160905A0217|34 57|hepatitis B surface antigen
P08163183T0000|37 68|Clostridium thermosaccharolyticum
P08163183T0000|100 110|XylA enzymes
P08163498A0789|3 17|phosphopeptides
P08163498A0789|33 46|SGASGLLTSEHHSR
P08163498A0789|52 65|SGASGLLTSEHHSR
P08163498A0789|97 111|phosphorylation
P08163498A0789|115 128|trypsinization
P08163528T0000|13 38|Mas70p signal anchor sequence
P08163546A1230|154 165|intersection
P08163546A1230|195 208|sorting pathway
P08164302A0547|13 24|TPN solutions
P08164302A0547|57 75|nutrient composition
P08164302A0547|100 110|energy level
P08164661A0414|12 22|TFIIIC alpha
P08164661A0414|133 145|RNA polymerase
P08164679A0809|0 20|Transactivation domain
P08164679A0809|59 76|runt homology region
P08164680A1086|17 32|protease activity
P08166402A0631|0 17|Cerebral125 albumin
P08166402A0631|74 88|hyperosmolality
P08167396A0154|65 91|substantia nigra pars compacta
P08167555A0972|46 57|pretreatment
P08169201A0291|47 57|carA product
P08169201A0291|89 106|nucleotide sequence
P08170400T0000|62 80|transcription factor
P08172416A0860|106 121|folliculogenesis
P08172598A0237|43 55|N. patriciarum
P08172598A0237|86 98|kb mRNA species
P08172653A1589|38 48|TnT isoforms
P08172653A1589|80 91|modification
P08172905A0000|25 45|alanine tRNA synthetase
P08172905A0000|59 73|RNA miniduplexes
P08172905A0000|93 103|acceptor end
P08172905A0000|106 116|alanine tRNA
P08172905A0000|133 143|U70 base pair
P08173532A0000|6 17|reaction time
P08173532A0000|122 132|target onset
P08173532A0000|138 149|facilitation
P08173693A0390|76 94|angina pectoris class
P08173814A0132|23 39|host cell machinery
P08173814A0132|60 71|interference
P08173814A0132|127 140|host physiology
P08175188A0685|1 13|concentration
P08175188A0685|46 59|baseline values
P08176742A0190|23 37|assay conditions
P08176742A0190|58 77|transposition pathway
P08177143T0000|5 17|cell carcinoma
P08178446A1160|46 56|ras activity
P08178446A1160|114 130|signaling pathways
P08178490A0879|22 35|signal function
P08178490A0879|43 56|anchor function
P08178572A1118|4 30|concensus poly A addition sites
P08179827T0000|34 45|transmission
P08179827T0000|48 71|hepatitis B virus infection
P08180129A1256|16 32|TPA concentrations
P08181755A0989|0 15|Northern analysis
P08181755A0989|28 42|pcbAB transcript
P08182041A1067|32 43|requirements
P08182041A1067|101 120|CREB activation domain
P08182041A1067|125 141|PEPCK TATA sequence
P08182041A1067|164 176|hepatoma cells
P08182056A0695|15 26|conservation
P08182056A0695|41 60|NQO1 gene organization
P08182056A0695|121 133|NQO gene family
P08182171A0000|14 42|Propionibacterium acnes product
P08182171A0000|57 72|coliform mastitis
P08183552T0000|26 48|tyrosine kinase substrate
P08183915A0000|62 89|transcription factor NF-kappa B
P08183915A0000|102 118|p70 I kappa B protein
P08183915A0000|119 130|I kappa B gamma
P08183915T0000|21 34|RNA transcripts
P08183915T0000|53 69|p105 NF-kappa B gene
P08183915T0000|79 98|I kappa B gamma isoforms
P08185288A0106|77 95|respiration chambers
P08187085A0086|5 18|rearrangements
P08187085A0086|64 83|tyrosine kinase domain
P08187085A0086|102 113|end sequences
P08187088A0530|14 27|heterozygosity
P08187088A0530|70 82|chromosomes 3p
P08187177A0405|7 21|amino acid change
P08187177A0405|38 50|sorting signal
P08188258A0000|26 46|prolyl-tRNA synthetase
P08188290A0544|8 19|sequence data
P08188290A0544|40 56|TCRAC/TCRDC region
P08188290A0544|72 86|polymerase chain
P08188290A0544|143 159|TCRAJ gene segments
P08188606A1034|0 18|Restriction analysis
P08188606A1034|22 42|Southern hybridization
P08188606A1034|162 178|cadmium resistance
P08188978A0822|51 63|MSNA burst peak
P08188978A0822|120 138|pulse-synchronicity
P08189174A0148|76 96|breast cancer screening
P08189498T0000|0 13|Identification
P08189498T0000|48 59|disease virus
P08189498T0000|72 83|repeat region
P08189503A0000|34 61|mouse hepatitis virus strain A59
P08189503A0000|97 115|cassette mutagenesis
P08189503A0000|158 170|mRNA synthesis
P08189533A0203|105 131|baculovirus expression system
P08189533A0203|147 162|vaccinia virus/T7
P08189533A0203|169 184|expression system
P08189533A0919|0 17|Gel electrophoresis
P08189533A0919|28 45|immunoblot analyses
P08190633A0000|3 25|transcription factor AP-2
P08192140A0209|3 14|participants
P08192140A0209|34 56|hepatitis B vaccine trials
P08192140A0209|72 82|New York City
P08192140A0209|91 102|San Francisco
P08192795T0000|43 60|lupus erythematosus
P08193147A0831|17 32|crystal structure
P08193147A0831|35 52|Desulfovibrio gigas
P08194139A0498|11 38|Serum prolactin concentrations
P08194549A0000|55 66|relationship
P08194549A0000|102 125|blood lactate accumulation
P08194970A0000|6 18|opportunities
P08195186A0000|8 19|cDNA sequence
P08195186A0000|36 46|T lymphocyte
P08195186A0000|146 165|amino acid transporter
P08195186A0000|202 214|Tea expression
P08195186A0000|217 228|T lymphocytes
P08195216A1022|85 97|transcription
P08195216A1022|158 172|GCN4p activation
P08195217A0799|45 80|reticulocyte lysate translation product
P08195217A0799|121 133|sodium dodecyl
P08195233A0147|147 159|tumorigenesis
P08196607A0280|0 15|Deletion analysis
P08196607A0280|21 32|ICL1 promoter
P08196607A0280|41 54|identification
P08196607A0280|77 91|sequence element
P08196607A0280|193 204|reporter gene
P08196616A1112|78 93|ZAP-70 SH2 domains
P08196616A1112|106 121|tyrosine residues
P08196616A1112|168 190|phosphotyrosine residues
P08196618A0473|28 52|phosphotyrosine substrates
P08196618A0473|80 94|cysteine residue
P08196624A0593|36 49|T beta R-I signal
P08199204A0746|43 55|PKC activation
P08199204A0746|69 91|tyrosine phosphorylation
P08199204A0746|102 113|P2 production
P08199878T0000|20 39|glucose concentration
P08199878T0000|42 56|brain metabolism
P08199878T0000|74 86|brain ischemia
P08200528A0970|33 44|Tn903 neo gene
P08200528A0970|51 99|Rhodosporidium toruloides phenylalanine ammonia lyase
P08201352A0239|21 38|protein C deficiency
P08201352A0239|39 57|vitamin K antagonists
P08201352A0239|95 106|skin necrosis
P08201932A0355|37 49|polyarthritis
P08202546A1206|26 49|hUBF-promoter interaction
P08204348T0000|47 60|cell lung cancer
P08204403A0000|97 119|radioimmunoscintigraphy
P08204426T0001|49 63|diaphragm pacing
P08204426T0001|78 98|implantation technique
P08204824A0000|118 135|Catharanthus roseus
P08205827A0940|11 23|Translocation
P08205827A0940|105 121|animal experiments
P08205827A0940|129 141|translocation
P08206848A0296|26 37|polypeptides
P08206867A0874|0 23|Southern blotting analysis
P08206991A0466|16 30|palmitate analog
P08206991A0466|83 97|N-myristylation
P08206991A0466|111 123|palmitylation
P08207022T0000|0 17|Subunit composition
P08207022T0000|21 35|domain structure
P08207022T0000|41 75|Spo0A sporulation transcription factor
P08207022T0000|78 93|Bacillus subtilis
P08207232A0503|15 35|mobility shift analysis
P08207232A0503|116 126|NF-IL-6 site
P08207232A0503|132 143|IL-8 promoter
P08207405A0372|3 21|citrus tristeza virus
P08207405A0372|69 87|fleck virus templates
P08207405A0372|97 119|kb amplification products
P08207795A0409|33 51|phosphorylation site
P08207795A0409|83 103|mutagenesis procedures
P08207805A0000|3 31|p53 tumor suppressor gene product
P08208247T0030|31 41|segment 64AB
P08208247T0030|70 90|acid decarboxylase gene
P08208540A0000|0 13|Rearrangements
P08208540A0000|53 64|malignancies
P08208540A0000|81 92|significance
P08208540A0417|180 193|ankyrin repeats
P08208540A0417|210 225|carboxy-terminus
P08208540A0417|245 257|ankyrin repeat
P08208540A1114|9 29|co-transfection assays
P08208540A1114|39 60|NFKB2 expression vectors
P08208540A1114|77 92|reporter plasmids
P08208540A1114|138 155|repressor functions
P08209423T0000|24 41|nucleotide sequence
P08209423T0000|48 70|MDV-1 BamHI-D DNA fragment
P08209423T0000|109 124|glycoprotein gene
P08209772A0167|25 36|reading frame
P08212571A0597|0 14|Co-transfection
P08212571A0597|67 81|tat ORF mutations
P08212571A0597|106 120|virus production
P08212571A0971|19 29|rev proteins
P08212571A0971|201 219|tat expression vector
P08212897A0404|3 23|hydrophobicity profile
P08212897A0404|29 45|methyltransferase
P08212897A0404|86 105|transmembrane domains
P08213747A0000|44 68|immunodeficiency virus type
P08213747A0000|296 322|baseline HIV-1 seroprevalence
P08213747A0000|326 341|HIV-1 risk factors
P08213747A0000|429 440|United States
P08213747A0000|441 460|Baltimore/Washington
P08217862A1336|25 47|rat conditioning paradigm
P08217862A1336|107 119|nerve activity
P08218056A0000|3 16|ultrastructure
P08218230A1505|47 57|binding site
P08218230A1505|76 94|transcription factor
P08218230A1920|50 75|glucocorticoid inducibility
P08218230A1920|120 131|determinants
P08218230A1920|161 193|Xenopus fibrinogen B beta subunit gene
P08218230A1920|211 221|liver tissue
P08219081A0000|68 84|PR-1 protein family
P08220494A0231|65 78|bp cyt-1 element
P08220494A0231|124 139|promotor activity
P08220494A0231|164 176|tobacco plants
P08222384A0455|53 76|surface electrocardiogram
P08222618A0000|8 23|computer programs
P08222618A0000|29 47|logit transformation
P08223425T0000|3 15|yeast SSS1 gene
P08223425T0000|39 58|protein translocation
P08223554A0574|23 38|polypeptide chain
P08223554A0574|67 80|transit peptide
P08223592A0424|65 86|transcription start site
P08223592A0424|169 188|polyadenylation sites
P08223613A0105|85 111|synthase/phosphatase complex
P08223613A0105|146 158|cif1 mutations
P08223613A0519|123 146|trehalose synthase complex
P08223613A0519|155 167|TSL1 homologue
P08223823T0000|0 17|Stroop interference
P08223823T0000|18 29|aging effects
P08223823T0000|45 64|Stroop Color-Word Test
P08223875A0711|14 25|PA production
P08223875A0711|30 45|CD3 cross-linking
P08224260A1248|46 60|ultrasonography
P08224260A1248|97 109|endometriomas
P08224907A0000|7 26|Southern blot analysis
P08224907A0000|36 61|gene encoding enhancer factor
P08224907A0000|86 96|band pattern
P08224907A0000|101 121|cDNA subfragment probes
P08225657A0000|50 59|NYHA Class I
P08225657A0000|63 76|II heart failure
P08226616A0000|28 49|fungus Neurospora crassa
P08226616A0000|117 128|assimilation
P08226777A0936|1 25|Dictyostelium transformant
P08226780A0160|30 48|protein interactions
P08226798A1124|27 45|HIV envelope proteins
P08226798A1124|114 125|cytotoxicity
P08226956A1397|26 42|growth temperature
P08227129T0000|38 49|muscle MyBP-C
P08227129T0000|83 103|immunoglobulin C2 motif
P08228805A0540|26 46|TCR signal transduction
P08228805A0540|52 82|guanine nucleotide binding protein
P08228805A0540|114 134|protein tyrosine kinase
P08228997A0866|33 49|lipid accumulation
P08229102A0768|17 33|QLMI questionnaire
P08230418A0812|97 125|urokinase plasminogen activator
P08230418A0812|133 155|acid phosphatase promoter
P08230445A0000|22 33|reading frame
P08230445A0000|41 65|immunodeficiency virus type
P08230452A0551|43 56|P1 polyproteins
P08230452A0551|83 99|processing defects
P08230452A0551|133 145|vaccinia virus
P08230452A0551|166 186|poliovirus 3CD protease
P08230452A0551|206 220|assembly defects
P08230452A0551|234 254|complementation system
P08230452A0551|286 300|vaccinia viruses
P08230452A0551|308 322|capsid precursor
P08230452A0551|335 350|poliovirus genome
P08230452A0551|379 392|capsid proteins
P08230452A1489|10 23|capsid proteins
P08230452A1489|38 48|P1 precursor
P08230452A1489|54 71|valine substitution
P08230452A1489|77 89|amino terminus
P08230452A1489|118 132|capsid particles
P08231398A0802|50 62|blood cultures
P08231398A0802|111 124|M. tuberculosis
P08231398A0802|140 153|prison patients
P08231398A0802|174 194|immunodeficiency virus
P08231398A0802|215 231|immunosuppression
P08231816A1473|49 77|penicillin producing conditions
P08231816A1473|135 150|promoter fragment
P08232304A1166|72 87|promoter activity
P08232304A1166|129 169|chloramphenicol acetyltransferase construct
P08232412A1342|27 49|expression vector pALTNEO
P08232412A1342|77 87|L. enriettii
P08234166A0425|3 17|bioavailability
P08234166A0425|115 126|RT conditions
P08234276A0556|44 55|IL-8 promoter
P08234276A0556|86 106|NF-kappa B binding sites
P08237171A0000|83 95|hydrocephalus
P08237578A0253|9 23|lipid metabolism
P08237578A0253|45 57|triglycerides
P08237578A0253|69 83|LDL-cholesterol
P08237578A0253|87 101|HDL-cholesterol
P08237578A0253|127 142|Norplant-2 rod use
P08237578A0253|182 197|preinsertion mean
P08238626A0248|16 31|baseline brain pHi
P08239164A0551|98 108|lung disease
P08239164A0551|172 182|lung disease
P08239586T0000|38 51|nephrotoxicity
P08240170A0000|11 23|salmonellosis
P08241656A0189|66 79|cholelithiasis
P08243476A1177|20 37|tryptophan residues
P08243476A1177|112 127|Paracoccus enzyme
P08244034T0000|11 43|Leishmania surface glycoprotein GP63
P08244034T0000|59 85|baculovirus expression system
P08244034T0000|95 111|metalloproteinase
P08245013A0000|46 60|destabilization
P08245013A0000|111 133|receptor down-regulation
P08245013A0000|152 164|understanding
P08245125A0822|31 43|F-actin nuclei
P08245456A0501|67 82|O2-dibutyryl cAMP
P08245456A0501|139 152|IL-5 production
P08245456A0501|168 180|protein levels
P08245461A0700|0 21|Hu-Met-1 mRNA expression
P08245461A0700|43 57|T cell tumor lines
P08246984A0923|46 63|PI 3-kinase isoforms
P08246987A0260|31 42|kinase domain
P08246987A0260|58 68|Src homology
P08247005A0584|17 35|drs2 mutation process
P08247005A0584|39 50|20S precursor
P08247043T0000|13 32|liver transplantation
P08248246A0838|124 139|R1 gene expression
P08248253A1785|13 24|observations
P08248253A1785|59 74|chicken L-CAM gene
P08248688A0726|87 98|NO production
P08249319A0578|26 40|mislocalization
P08249390A0111|13 28|diabetes mellitus
P08251506A0503|146 163|DRE oligonucleotide
P08251622A0000|33 69|Brassica napus 2S storage protein napA gene
P08252067A0917|49 59|COOH termini
P08252067A0917|111 122|conservation
P08252976A0467|83 102|pressure dissipations
P08253386A0800|39 65|fibronectin splicing enhancer
P08253386A0800|127 143|splicing complexes
P08253386A0800|193 211|branch site sequences
P08253387A0801|12 26|enhancer mutants
P08253387A0801|39 54|trans-activation
P08253387A1291|35 44|hLEF HMG box
P08253387A1291|90 105|TCR alpha enhancer
P08253387A1291|122 133|interactions
P08253777A0301|1 19|cAMP response element
P08253777A0301|23 37|consensus signal
P08253958A0000|47 58|Helicobacter
P08253958A0000|74 93|serum immunoglobulin G
P08254738A0428|51 63|baculoviruses
P08254738A0428|153 167|T-antigen kinase
P08255022A0827|11 23|hypoperfusion
P08255022A0827|93 103|blood volume
P08255022A0827|120 134|blood cell counts
P08255341A0554|52 64|metronidazole
P08255341A0554|66 81|tissue amoebicide
P08255758A0000|60 74|retrotransposon
P08255758A0000|127 139|homeoproteins
P08257666A0662|116 134|learning performance
P08257754A0711|58 69|HB antibodies
P08257754A0711|119 130|HB antibodies
P08258025A1131|43 60|treatment variables
P08258025A1131|71 84|Karnofsky index
P08259650A0640|0 25|Nucleotide sequence analysis
P08260635A0926|69 88|transit peptide region
P08261398A0392|17 35|cell lines P388/ADR/3
P08261398A0392|72 90|alpha mRNA transcript
P08261398A0392|148 161|P388/4 cell line
P08261398A0838|11 23|amplification
P08261398A0838|137 151|P388/ADR/7 cells
P08262041A0727|3 14|phi AP3 factor
P08262041A0727|25 38|phosphoprotein
P08262041A0727|53 67|phosphorylation
P08262054A0565|50 66|membrane protein 2A
P08262054A0565|179 197|B cell transformation
P08262067A1608|72 83|cell polarity
P08262067A1608|132 144|establishment
P08262067A1608|147 158|cell polarity
P08262067A1608|162 181|cell wall biosynthesis
P08263933T0000|42 70|cyanobacterium Synechocystis sp
P08264579A1209|62 77|characterization
P08264579A1209|91 110|peptide transport gene
P08264582A0750|107 120|point mutations
P08264582A0750|144 160|amino acid residues
P08264583A0520|136 156|test plasmid substrates
P08264591A1190|40 52|RNA polymerase
P08264591A1190|75 86|determinants
P08264591A1190|89 119|transcription start site selection
P08264617A0000|52 68|NIH 3T3 fibroblasts
P08264617A0000|122 145|ErbB-3 signal transduction
P08264617A0000|150 165|ligand activation
P08264628A0418|0 25|Oligonucleotide competitors
P08264628A0418|47 59|accessibility
P08264631A0746|26 37|ADR1 activity
P08264631A0746|72 85|ADR1 DNA binding
P08264631A0746|97 117|ADH2 promoter sequences
P08264650A0925|28 43|mds1 null mutation
P08264664A0128|42 57|AP-1 binding sites
P08265602T0000|3 14|Ala mutations
P08265602T0000|54 73|transmembrane segment
P08265602T0000|76 94|phage M13 coat protein
P08267658A0391|46 57|lactobionate
P08267658A0391|105 116|preservation
P08267658A0391|119 132|rat hepatocytes
P08267658A0391|143 162|drug transport studies
P08267667A0748|8 21|administration
P08267667A0748|153 171|learning acquisition
P08267667A0748|212 229|h memory acquisition
P08267667A0748|273 288|h memory retention
P08267667A0748|337 352|h memory retrieval
P08268718A0676|5 15|bcl3 protein
P08268833T0000|22 33|cyclosporin A
P08268912A0657|7 28|translation experiments
P08268912A0657|102 122|SDS polyacrylamide gels
P08269424A0339|15 28|administration
P08270257A0551|1 24|sequence homology analysis
P08270257A0551|50 60|homolog gene
P08270580A0155|48 60|amphotericin B
P08270580A0155|64 76|cotrimoxazole
P08270985A0590|0 16|Response durations
P08273122A0708|26 37|QA/QI process
P08273122A0708|50 77|blood administration practices
P08273122A0708|116 140|blood administration policy
P08273122A0708|174 194|component transfusions
P08274774A0958|10 20|REP21 plants
P08274774A0958|59 71|tobamoviruses
P08274774A0958|81 97|tomato mosaic virus
P08274774A0958|114 124|mosaic virus
P08274774A0958|150 160|mosaic virus
P08274774A0958|164 182|ribgrass mosaic virus
P08275618A0457|134 150|concentration area
P08276234A0119|89 101|c-fos promoter
P08276234A0119|128 139|DNA structure
P08276336A0371|41 53|colonoscopies
P08276336A0371|84 95|relationship
P08276732A0799|20 33|DPOAE amplitude
P08276732A0799|82 95|susceptibility
P08276762T0000|14 30|base substitutions
P08276762T0000|33 48|glycine-870 codon
P08276762T0000|51 71|gramicidin S synthetase
P08276762T0000|79 95|proline activation
P08276851A0347|12 24|Pay4p sequence
P08276851A0347|80 92|relationships
P08276851A0347|204 219|protein transport
P08276851A0347|220 235|cell cycle control
P08276854A1894|35 53|decorin gene promoter
P08276854A1894|83 102|proteoglycan promoter
P08276854A1894|139 152|pur/pyr segment
P08276854A1894|180 196|gene transcription
P08276865A1188|3 30|kinase inhibitor staurosporine
P08276865A1188|148 160|protein kinase
P08276865A1188|171 181|LPA receptor
P08276865A1188|184 199|p21ras activation
P08276871A1001|99 111|transmembrane
P08277632A0997|3 14|survival rate
P08277632A0997|65 76|R2b operation
P08278423A0147|27 39|abnormalities
P08278423A0147|103 126|disaccharide intolerances
P08278548A0597|18 29|psaL products
P08278548A0597|92 123|polyacrylamide gel electrophoresis
P08278548A0597|130 140|psaE product
P08278929A0866|10 24|SPF type V embryos
P08278929A0866|114 125|VSD incidence
P08279098T0001|42 55|myopia patients
P08280476A0602|34 55|HIV-1 Z2Z6 core enhancers
P08280476A0602|86 98|point mutation
P08280925A0261|51 61|C57Bl/6 mice
P08281153A0543|32 43|conservation
P08281153A0543|46 60|intron sequences
P08281536A0626|0 12|Interleukin-6
P08281634A1801|17 30|iron metabolism
P08281740A0000|14 39|Plowright Rinderpest vaccine
P08281740A0000|102 114|IgG antibodies
P08282501A0358|33 53|angiography procedures
P08282749A1474|6 21|Hospital solution
P08283292A0779|12 41|liver cholesterol concentrations
P08283292A0779|187 198|control group
P08283531A0700|3 26|Stryker frame modification
P08283531A0700|40 61|Dornier HM3 lithotriptor
P08283531A0700|79 91|visualization
P08283531A0700|101 112|localization
P08284227A0336|46 61|kb mRNA transcript
P08284227A0336|88 103|cell types Id1 mRNA
P08284227A0336|130 141|cycling cells
P08284337A0825|30 40|IHD patients
P08284337A0825|81 93|cardiologists
P08285710A0634|13 26|transcript mRNA
P08285710A0634|51 62|blot analysis
P08285710A0634|125 140|protein synthesis
P08286035A0587|13 31|sequence information
P08286035A0587|106 118|transcription
P08286035A0587|136 158|polymerase chain reaction
P08288240A0304|3 20|sequence similarity
P08288240A1343|87 98|modification
P08288240A1343|124 141|stathmin/Lap18 gene
P08288554A0295|10 26|amino acid sequence
P08288554A0295|32 44|mouse HO-1 gene
P08288554A0295|112 130|mouse BALBc/3T3 cells
P08288596A0663|38 50|transcription
P08288596A0663|183 203|TATA box binding protein
P08288596A0663|226 239|binding protein
P08288606A0240|6 20|polymerase chain
P08288606A0240|60 71|pair fragment
P08288606A0240|97 108|placenta mRNA
P08288606A0240|151 164|coding sequence
P08288606A0240|192 202|cDNA library
P08288622A0725|44 56|heterogeneity
P08288622A0725|102 115|intron sequence
P08288622A0725|138 157|splicing acceptor site
P08288633A0144|32 52|Caenorhabditis elegans
P08288633A0144|82 98|amino acid residues
P08288633A0144|128 145|sequence similarity
P08288633A0144|188 200|protein region
P08288633A0144|249 260|Rho subfamily
P08289342A0931|23 36|resolution site
P08289342A0931|55 68|DNA replication
P08289593A1404|76 86|cocaine dose
P08289783A0000|8 18|gene product
P08289783A0000|47 66|transcription factors
P08289783A0000|103 126|differentiation decisions
P08290278A0374|34 44|Myc function
P08290278A0374|51 79|candidate tumor suppressor genes
P08291233A0000|26 49|chicken embryo cDNA library
P08291233A0000|117 135|Rous sarcoma virus LTR
P08291620A0372|18 34|locomotor behavior
P08291620A0372|51 65|torso morphology
P08291761A0416|40 53|CSF composition
P08291761A0416|57 77|serum IgG concentration
P08293412T0000|50 61|tolerability
P08293412T0000|79 101|5-HT3 receptor antagonist
P08293993A0948|52 84|alpha-factor prepro secretion leader
P08293993A0948|103 125|invertase signal sequence
P08294429A0153|65 96|chloramphenicol acetyltransferase
P08294429A0153|99 113|luciferase genes
P08294429A0153|150 168|hGH promoter activity
P08294459A0446|12 28|amino acid sequence
P08294511A0639|112 129|snRNP core particles
P08294865A0236|89 107|peptide/DR complexes
P08294906A1315|4 15|distribution
P08294906A1315|34 59|neurotransmitters glutamate
P08296434A1141|3 18|Harleco apparatus
P08297376A0236|0 14|Co-transfection
P08297376A0236|17 33|expression vectors
P08297376A0236|37 64|CCAAT/enhancer binding protein
P08297376A0236|105 136|rat uncoupling protein gene promoter
P08298129A0274|84 95|gene promoter
P08298129T0000|12 27|characterization
P08298129T0000|64 75|integrin gene
P08299568A1401|84 99|glucose transport
P08299725A0724|72 85|tumor cell lines
P08299896A0880|0 19|Regression line slopes
P08300463A0581|0 11|Praziquantel
P08300463A0581|60 77|neurocysticercosis
P08300527T0000|12 32|erythromycin synthesis
P08300527T0000|47 84|malonyl-coenzyme A decarboxylase gene eryM
P08300527T0000|87 112|Saccharopolyspora erythraea
P08300601A0745|54 66|E12 homodimers
P08300601A0745|70 89|E12/MyoD heterodimers
P08300605A0432|34 48|deletion mutants
P08300605A0432|124 135|instar larvae
P08300605A0432|224 237|initiation site
P08300611A0341|77 88|TraI proteins
P08300611A0341|155 171|amino acid residues
P08300625A1352|61 75|peptide sequence
P08300625A1352|110 121|slyD function
P08301702A1083|35 55|rat cytochrome P-450 1A1
P08301702A1083|175 188|immunoblotting
P08301841A0000|15 28|enzyme activity
P08301841A0000|80 93|angina pectoris
P08302589A1132|14 25|cell motility
P08302589A1132|77 89|protein kinase
P08302589A1132|102 113|phorbol ester
P08304342A0605|20 42|hemochromatosis families
P08304342A0605|54 79|hemochromatosis chromosomes
P08305058T0000|0 11|Pneumothorax
P08306356A0000|17 29|malformations
P08306959A0278|11 30|IFN gamma inducibility
P08306959A0278|99 120|IFN gamma activation site
P08307338A0227|97 107|cytochrome b
P08308008A0201|63 79|ets sequence motifs
P08308008A0201|145 157|COXIV promoter
P08309726A0000|27 38|pathogenesis
P08309726A0000|60 75|distress syndrome
P08309726A0000|105 117|relationships
P08309726A0000|126 141|activation status
P08309726A0000|186 199|cytokine levels
P08309953A0776|27 53|dopamine receptor stimulation
P08309953A0776|65 80|dopamine agonists
P08309953A0776|120 134|characteristics
P08309953A0776|140 159|reaction time response
P08309957A0000|44 55|jaw movements
P08309957A0000|76 89|administration
P08309957A0000|114 127|agent reserpine
P08309975A0662|24 39|nucleus accumbens
P08312243A0177|86 97|Ca metabolism
P08312243A0177|109 121|Zn-sufficient
P08314163T0000|29 43|agranulocytosis
P08314163T0000|86 108|colony stimulating factor
P08314163T0000|117 130|administration
P08314922A0941|45 60|perfusion changes
P08314922A0941|68 79|brain surface
P08314922A0941|91 102|tissue damage
P08316209A0000|53 68|Neurospora crassa
P08316209A0000|142 157|sulfur catabolism
P08316240A1068|70 83|hexamer element
P08316240A1068|92 110|MluI restriction site
P08316240A1068|175 191|DNA synthesis genes
P08317092A0304|59 71|helicase motif
P08317092A0304|97 114|RNA polymerase motif
P08317092A0304|165 185|RNA replication complex
P08317092A0304|211 222|tobraviruses
P08317094A0778|122 136|initiation codon
P08319396A0448|21 34|intensity areas
P08319396A0448|120 133|intensity areas
P08319396A0448|142 159|cerebellar peduncle
P08319907A0754|8 19|rap1t alleles
P08319907A0754|59 78|telomere tract lengths
P08319907A0754|93 115|telomere position effects
P08320120A0361|10 24|microangiopathy
P08320120A0361|122 138|sodium fluorescein
P08321199T0000|76 88|establishment
P08321203A0840|0 11|NF-kappa B p65
P08321227A0854|33 45|culture medium
P08321741A0396|56 68|myelofibrosis
P08321741A0396|160 176|Metaplasia-AMM-in
P08321741A0396|225 236|increase-CML
P08322117A1019|107 120|Sussett formula
P08322823A0839|58 69|UTS phenotype
P08323294T0000|0 49|Chicken sterol carrier protein 2/sterol carrier protein x
P08323294T0000|50 60|cDNA cloning
P08323294T0000|80 91|conservation
P08324107A0000|12 31|albumin concentration
P08324107A0000|69 81|plasma protein
P08324792T0000|54 64|infarct size
P08324792T0000|76 86|rabbit heart
P08325504A0226|14 30|RD21 mRNA synthesis
P08325639A0129|31 43|20S proteasome
P08325639A0129|120 137|proteinase activity
P08325720A0840|27 38|blood lactate
P08325720A0840|63 82|muscle enzyme activity
P08325720A0840|83 97|citrate synthase
P08325720A0840|98 128|3-hydroxyacyl-CoA-dehydrogenase
P08325720A0840|129 148|lactate dehydrogenase
P08325720A0840|157 173|muscle capillaries
P08325720A0840|184 203|muscle buffer capacity
P08325883A0368|24 34|RBP1 protein
P08325883A0368|56 74|RNA recognition motif
P08325883A0368|78 95|glutamine stretches
P08325883A0368|160 172|alpha-helixes
P08327488A0839|107 118|helper genome
P08331067T0000|8 25|nucleotide sequence
P08331067T0000|31 54|bacteriophage K1F tail gene
P08331067T0000|63 86|endo-N-acylneuraminidase
P08331067T0000|125 141|bacteriophage PK1E
P08331728A0686|23 39|ribonucleoprotein
P08332033T0000|14 27|quantification
P08332033T0000|69 82|micro-infarcts
P08332033T0000|101 117|neurotropin effect
P08332492A0145|63 74|T lymphocytes
P08332492A0145|98 122|immunodeficiency virus type
P08332495A0408|24 34|CAT activity
P08332495A0408|53 70|lung adenocarcinoma
P08332495A0408|117 131|T7 RNA polymerase
P08332495A0408|132 145|pT7-EMC-CAT DNA
P08333643A0000|0 12|Pneumoscrotum
P08334158A0660|40 54|cystein residues
P08334158A0660|80 91|Fe/S proteins
P08334304A0473|68 87|peptide growth factors
P08334304A0473|113 123|p21 rasVal12
P08334989A0070|166 178|transcription
P08334989A0070|182 203|luciferase reporter gene
P08334989A0070|223 239|NIH3T3 fibroblasts
P08336012A0632|55 66|BAL fluid cell
P08336012A0632|85 98|administration
P08336698T0000|38 49|heterodimers
P08336698T0000|83 105|transcription activation
P08336738A1273|44 63|PSTAIRE sequence motif
P08337828A0895|24 35|Western blots
P08337828A0895|38 62|Autographa californica MNPV
P08337828A0895|76 100|Spodoptera frugiperda cells
P08337841A0612|112 128|consensus sequence
P08337841A0612|173 193|polyadenylation signal
P08337841A0612|234 259|GNS protein termination codon
P08342703A0966|71 85|outflow pressure
P08343041A0000|59 78|hospital laboratories
P08343216A0883|12 31|IgG subclass responses
P08343216A0883|52 64|IgG subclasses
P08343961A0000|0 18|Anterior body pattern
P08343961A0000|53 64|distribution
P08345191A1140|3 17|peptide sequence
P08347677A0308|3 27|phosphorylation efficiency
P08347677A0308|71 86|arginine residues
P08347677A0308|101 114|arginyl cluster
P08347677A0308|165 185|4-Ala-Ala-Ser-Val-Ala
P08348919T0000|0 13|Botulinum toxin
P08349104A0000|71 82|availability
P08349104A0450|116 128|tsf6 mutations
P08349104A0450|166 180|hybrid promoters
P08349104A0450|212 228|operator sequences
P08349632A0679|0 17|Sequence comparison
P08349632A0679|100 111|PSG12 psi gene
P08350061A0209|86 108|T cell development program
P08352066A0000|21 34|beta-estradiol
P08352066A0000|54 67|bone resorption
P08352066A0000|85 97|bone formation
P08352268A0000|16 29|erythropoietin
P08355062A0000|48 82|99mTc-hexamethylpropyleneamine oxime
P08355680A0824|30 45|mRNA accumulation
P08355680A0824|91 105|HIV-1 constructs
P08355680A0824|161 191|glucose 6-phosphate dehydrogenase
P08355696A0236|3 13|UV induction
P08355696A0236|36 53|UV response elements
P08355697A0000|0 26|Protein tyrosine phosphatases
P08355697A0000|43 64|protein tyrosine kinases
P08355697A0000|97 110|cell activation
P08355697A0000|120 134|differentiation
P08356792A1275|12 22|p21X protein
P08356792T0000|0 19|HTLV-1 gene expression
P08356944A0589|25 49|sodium lauryl sulfate method
P08356944A0589|62 84|hemoglobin concentration
P08356944A0589|116 138|cyanmethemoglobin method
P08357834A0285|25 42|amino acid sequences
P08357834A0285|56 70|PKC-delta clones
P08357834A0285|84 98|mouse homologues
P08357834A0285|124 141|sequence divergence
P08357834A0285|180 199|sequence conservation
P08357834A0285|222 237|PKC family members
P08357834A0285|255 266|counterparts
P08360180A1041|16 26|barley PSI-K
P08360180A1041|50 62|PSI-K sequence
P08360180A1041|195 208|cyanobacterial
P08361755A0734|20 32|transfections
P08361755A0734|47 58|NF-kappa B p50
P08361755A0734|62 80|serum response factor
P08361755A0734|126 138|NF-kappa B site
P08361761A0174|55 69|reporter plasmid
P08361761A0174|88 102|Sp1 binding sites
P08361761A0174|125 148|chicken embryo fibroblasts
P08361761A0174|269 283|reporter plasmid
P08361761A0174|300 324|immunodeficiency virus type
P08361761A0174|362 379|kappa B binding sites
P08361761A0174|419 433|Sp1 binding sites
P08363332A0365|51 74|surface electrocardiogram
P08363332A0365|152 166|mapping catheter
P08363332A0365|203 220|activation sequence
P08365944A1537|99 112|5-fluorouracil
P08365944A1537|146 157|radiotherapy
P08366034A0637|23 38|cysteine residues
P08366034A0637|39 56|carboxymethylation
P08366034A0637|92 105|disulfide bonds
P08367487A1014|36 46|17S U2 snRNPs
P08367487A1014|55 65|12S U2 snRNPs
P08367487A1014|68 87|HeLa splicing extracts
P08367487A1014|187 207|mRNA-splicing activity
P08369887A0781|23 40|viscosity variables
P08370119A0642|101 112|reading frame
P08370119A0642|149 175|muscle cell AT1a receptor cDNAs
P08370119A1521|21 34|promoter region
P08370119A1521|48 69|transcription start site
P08370119A1521|143 155|transcription
P08370119A1521|161 174|luciferase cDNA
P08371650T0000|13 28|claudication pain
P08371650T0000|41 52|implications
P08371713T0000|43 60|endothelin receptor
P08371936T0000|13 31|Independence Measure
P08371936T0000|63 73|self ratings
P08373274A0546|35 46|week postburn
P08374753A0335|13 26|relaxation time
P08374753A0335|40 59|diffusion coefficient
P08375651T0000|35 50|clathrin function
P08376397A0788|3 20|binding specificity
P08376796A0172|198 213|diabetes mellitus
P08376796A0172|253 264|efficiencies
P08377199A1432|43 54|conformation
P08378082A1031|82 94|cell phenotype
P08380736A0895|77 89|amino terminus
P08380896A0938|40 55|polymerase domain
P08380896A0938|95 112|preinitiation stage
P08381121A0773|8 27|transmembrane regions
P08382303A0507|12 25|transport motif
P08382303A0507|62 77|papillomaviruses
P08382303T0000|3 22|E1 replication protein
P08382303T0000|31 48|papillomavirus type
P08382303T0000|75 92|localization signal
P08382303T0000|106 131|p34cdc2 phosphorylation site
P08382359A0469|64 77|tumor induction
P08382359A0469|116 129|point mutations
P08382359A0469|285 298|tumor induction
P08382769A0924|17 28|conservation
P08382769A0924|105 122|recognition element
P08382769A0924|129 140|SRP54 protein
P08382778A0891|19 31|protein shares
P08382778A0891|113 132|transcription factors
P08383129A0776|15 36|mass polypeptide complex
P08383129A0776|60 78|antigen presentation
P08383129A0776|110 124|protein antigens
P08383129A0776|165 177|T-lymphocytes
P08383129A0776|183 193|cell surface
P08383214A0389|23 37|Trp-595-Tyr-596
P08383214A0389|83 94|RNase H domain
P08383217A0357|69 81|Bel-1 activity
P08383217A0357|127 142|activation domain
P08383287A0611|46 73|thyroid hormone responsiveness
P08383287A0611|101 122|hormone response element
P08383492A1205|149 166|cytochrome oxidases
P08383492A1205|176 192|c-type cytochromes
P08383526A0591|45 59|receptor protein
P08383622T0000|47 73|cytochrome oxidase expression
P08383622T0000|99 116|ETS domain activator
P08383850A0206|17 35|beta-funaltrexamine
P08383850A0206|61 76|nonequilibrium mu
P08384309A0000|21 43|region/helix-loop-helix
P08384309A0000|48 61|dioxin receptor
P08384309A0000|70 87|signal transduction
P08384309A0000|96 130|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08384309A0000|162 178|DNA binding protein
P08384309A0000|202 212|target genes
P08384309A0000|224 245|dioxin response elements
P08385337A0282|1 18|sequence comparison
P08385337A0282|29 56|CCAAT/enhancer binding protein
P08385337A0282|62 79|consensus sequences
P08385337A0282|85 100|DNA binding region
P08385337A0282|104 117|leucine zippers
P08385581A0126|82 98|recombination gene
P08386279A1621|3 25|transactivation function
P08386279A1621|98 111|HIV-1 infection
P08386279A1621|135 157|HIV-1 promoter activation
P08386280T0000|13 29|C/EBP binding sites
P08386280T0000|35 50|Rous sarcoma virus
P08386280T0000|72 83|gag enhancers
P08386317T0000|7 26|protein phosphatase 2A
P08386317T0000|43 55|protein kinase
P08386318A1102|76 89|protein kinase C
P08386319A1229|49 65|threonine residues
P08386319A1229|87 99|phenylalanine
P08386319A1229|138 150|Mpk1p function
P08386592A0089|0 22|Growth factor stimulation
P08386592A0089|123 137|phosphorylation
P08386592A0089|197 207|Elk-1 kinase
P08387507A1015|23 34|MyoD function
P08387507A1015|119 138|peptide growth factors
P08387507A1015|219 241|myoblast differentiation
P08387519A0000|42 57|desmin expression
P08387519A0000|154 167|gene expression
P08387662A0302|12 23|patients self
P08387743A0624|130 151|Mn-superoxide dismutase
P08387994A0980|3 18|orf61 gene product
P08388496A1117|50 68|virus producer status
P08388496A1117|136 153|BamHI-A transcripts
P08388510A0891|10 38|cell surface immunofluorescence
P08388510A0891|93 105|glycoproteins
P08388543A1263|103 116|protein kinase C
P08388543A1263|120 138|calcium mobilization
P08388543A1263|161 172|GDP/GTP state
P08388600A0000|0 16|Estrogen treatment
P08389074A1227|65 89|activation domain functions
P08389365A1344|45 56|repair system
P08389453A0193|0 19|Uracil DNA glycosylase
P08389453A0193|48 60|repair pathway
P08390665A0000|0 20|Lithium phthalocyanine
P08390665A0000|95 106|crystallites
P08390665A0000|166 182|resonance oximetry
P08390747A0586|50 61|hep syn gB gene
P08390831A0143|141 152|risk patients
P08391748A0452|51 62|contractions
P08391748A0452|99 113|QRS prolongation
P08391748A0452|137 150|QT prolongation
P08391748A0452|182 196|QRS prolongation
P08391748A0452|230 243|QT prolongation
P08391748A0452|280 294|QRS prolongation
P08391748A0452|318 331|QT prolongation
P08392221A0449|63 80|estrogen conjugates
P08392221A0449|165 176|matairesinol
P08392221A0449|187 199|enterolactone
P08392221A0449|208 228|O-desmethylangolensin
P08392623A1374|0 18|IE2-IE2 interactions
P08394019A0695|0 12|Precipitation
P08394019A0695|18 34|GST fusion proteins
P08394019A0695|57 70|SH2/SH3 domains
P08394255A0000|16 26|cDNA library
P08394255A0000|40 51|pcDNA1 vector
P08394255A0000|84 106|polymerase chain reaction
P08394255A0000|161 179|hormone receptor cDNA
P08394464A1080|11 21|Rev proteins
P08394862A0565|61 72|CMV hepatitis
P08395004A0141|12 24|spt2 mutations
P08395004A0141|53 64|interference
P08395004A0141|76 111|delta promoter insertion his-4-912 delta
P08395004A0141|147 160|HIS4 mRNA levels
P08395004A0558|7 18|localization
P08395004A0558|22 48|protein sequence similarities
P08395004A0558|65 80|SPT2/SIN1 protein
P08395004A0558|119 129|protein HMG1
P08395010T0000|35 48|thyroid hormone
P08395010T0000|60 72|acid receptors
P08395010T0000|125 142|homodimer formation
P08395014A1364|7 18|interactions
P08395014A1364|38 54|pathway components
P08395014A1364|68 80|BCK2 functions
P08395014A1364|90 102|pathway branch
P08395654T0000|70 85|rat aromatase gene
P08395681A0388|101 113|reading frames
P08395681A0388|169 182|binding ability
P08395681A0388|202 222|retinoblastoma protein
P08395681A0388|233 255|complementation activity
P08395681A0388|272 290|adenovirus E1A mutant
P08396120A0690|3 28|rhaB transcription start site
P08396261A0388|41 56|growth inhibition
P08396261A0388|71 81|PKA subunits
P08396261A0388|160 174|cyclase activity
P08396261A0388|198 210|transformants
P08396261A0388|336 346|cAMP binding
P08396261A0388|429 441|C alpha protein
P08396667T0000|80 96|lymphocyte subsets
P08396713A0305|103 137|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08396713A0305|153 169|Ah receptor protein
P08396713A0305|192 207|heat shock protein
P08396749A1112a|0 13|LDL cholesterol
P08396749A1112b|0 13|LDL cholesterol
P08397123T0000|58 91|corticotropin-releasing hormone gene
P08399970T0000|4 29|bioencapsulation technology
P08400240A0166|8 27|hypersensitivity site
P08400240A0166|39 56|locus control region
P08400240A0166|64 79|gamma-globin gene
P08400240A0166|155 170|gamma-globin mRNA
P08400928A0318|0 12|INTERVENTIONS
P08400928A0318|45 79|levodopa/dopa decarboxylase inhibitor
P08400928A0318|89 130|levodopa/decarboxylase inhibitor/selegiline
P08400928A0318|150 162|bromocriptine
P08401570A0828|23 34|binding sites
P08401570A0828|38 59|transcription factor Sp1
P08401570A0828|146 165|transcription factors
P08401614A0187|133 143|bean tissues
P08403245A1234|0 24|Plasma thromboxane B2 levels
P08403804A0754|24 41|regression analysis
P08403804A0754|83 104|cyclosporin trough level
P08403804A0754|132 146|serum creatinine
P08405433A0000|20 31|growth factor
P08406004A0691|19 36|transfection assays
P08406004A0691|54 71|reporter constructs
P08406004A0691|85 97|JB cis-element
P08406352A0172|0 11|Army veterans
P08406352A0172|23 34|fever vaccine
P08406352A0172|51 65|hepatitis B virus
P08406352A0172|151 174|Veterans Affairs hospitals
P08406419A0155|44 58|hepatitis C virus
P08406419A0155|90 114|Ortho Diagnostic Systems Inc
P08406497A0000|23 43|glycoprotein component
P08406497A0000|78 91|Marfan syndrome
P08407784A0850|29 41|srjA mutations
P08408194T0000|24 44|membrane-cytoskeleton
P08408194T0000|103 121|ATPase distributions
P08408825A0000|8 25|lupus erythematosus
P08408825A0000|51 64|autoantibodies
P08408841A0281|7 19|abnormalities
P08408841A0281|64 76|abnormalities
P08410042T0000|38 52|dura mater grafts
P08410097A0356|5 17|mean intensity
P08410097A0356|49 73|regression coefficient beta
P08410097A0356|102 113|oxygen uptake
P08410097A0356|156 171|plasma fibrinogen
P08411024T0000|47 68|fibrosis carrier testing
P08411276A0302|82 101|Trauma Score variables
P08411276A0302|102 122|Glascow Coma Scale score
P08411276A0302|131 143|blood pressure
P08411276A0302|178 201|Severity Characterization
P08411276A0302|257 271|ASCOT components
P08412620A0688|40 62|transcription start point
P08412662A0333|60 78|transposon insertion
P08412662A0333|113 127|kb EcoRI fragment
P08413186A0077|166 179|reductase genes
P08413186A1199|45 68|N. plumbaginifolia species
P08413205A0733|9 31|transfection experiments
P08413205A0733|44 56|Pax-8 isoforms
P08413205A0733|90 102|transcription
P08413205A0733|151 169|recognition sequence
P08413209A0159|62 80|motif characteristic
P08413215A0327|33 49|NF-kappa B subunits
P08413215A0327|69 81|transcription
P08413215A0327|89 100|IL-8 promoter
P08413223A0847|23 43|IL-1 beta NF-kappa B site
P08413223A0847|118 129|phorbol ester
P08413223A0847|160 173|gene expression
P08413239A0490|77 87|U snRNA genes
P08413239A0490|105 116|end formation
P08413239A0490|119 131|U2 transcripts
P08413274A0452|54 74|X-box oligonucleotides
P08413291A1473|26 45|rat TnI-CAT fusion gene
P08414410A0270|111 122|field defects
P08414410A0270|210 224|nerve fiber layer
P08414502A0244|102 114|transcription
P08415637A0000|3 24|ADP-ribosylation factor
P08415637A0000|61 74|RAS superfamily
P08415712A1153|7 26|Southern blot analysis
P08415712A1153|30 46|chromosome mapping
P08415712A1153|170 191|Huntington disease locus
P08416952A0956|9 23|labeling studies
P08416952A0956|41 53|co-expression
P08416952A0956|73 89|protein substrates
P08416952A0956|137 148|substitution
P08416952A0956|194 210|protein substrates
P08416977A0892|55 68|chromatography
P08417330A0149|28 43|promoter fragment
P08417330A0149|68 88|heat shock inducibility
P08417330A0149|106 126|CYC1-lacZ reporter gene
P08417331A0745|81 92|G beta subunit
P08417349A1633|115 130|mutation fixation
P08418183A0000|45 56|transmission
P08418183A0000|64 94|T cell leukemia/lymphoma virus type
P08418183A0000|132 150|Miyazaki Cohort Study
P08419333A0126|33 47|DNA repair enzyme
P08419376A0357|3 20|nucleotide sequence
P08420230A0544|5 20|echocardiography
P08420230A0544|24 42|thallium-201 imaging
P08421295A0365|4 17|fusion proteins
P08421295A0365|80 101|4ACAG consensus sequence
P08421295A0365|107 119|LexA repressor
P08421687A0397|3 24|selenocysteine residues
P08421823A1041|15 32|protein S deficiency
P08421897A0000|107 129|stringency hybridization
P08421897A0000|171 191|animal retrovirus genes
P08421910A0599|115 134|uv cross-linking assay
P08422975A1205|41 65|kinetoplastid mitochondria
P08425221A0000|27 40|tyrosine kinase
P08425221A0000|50 70|B cell progenitor kinase
P08427501A0221|64 77|enzyme activity
P08427501A0221|92 105|enzyme activity
P08428722A1123|76 97|blood urea nitrogen level
P08428722A1123|98 132|serum aspartate aminotransferase level
P08428750T0000|0 11|Localization
P08428750T0000|72 90|chromosome 10p13-ter
P08428907A0653|11 21|stage larvae
P08428907A0653|25 37|OBP transcript
P08428940A1763|93 105|RNA polymerase
P08428952A0399|131 143|tumorigenesis
P08428952A1957|51 64|plastin isoform
P08428953A1718|53 78|reporter beta-galactosidase
P08428953A1718|375 393|L-plastin expression
P08428965A1868|30 50|CBP/tk binding activity
P08429019A0735|32 45|silencer region
P08429019A0735|139 161|GATA-1 consensus sequence
P08429019A2022|34 53|YY1 consensus sequence
P08429019A2022|65 79|protein B binding
P08429019A2022|115 141|yeast ABF-1 consensus sequence
P08429020A0495|77 88|reading frame
P08429020A0495|92 103|glycoprotein
P08429568A0000|0 16|Rhizobium meliloti
P08429568A0000|22 36|plasmid pRmeGR4b
P08429568A0000|47 79|nodulation competitiveness locus nfe
P08429568A0000|97 116|nodulation efficiency
P08429568A0000|151 162|alfalfa roots
P08430087A0467|40 50|gamma chains
P08430087A0467|89 105|beta gamma activity
P08430087A0467|120 135|membrane extracts
P08430095A0161|22 35|identification
P08430095A0913|56 72|splicing apparatus
P08430095A0913|85 99|snRNA maturation
P08431100A0108|32 47|motor performance
P08431100A0108|112 124|consciousness
P08431100A0108|152 164|children group
P08432137A0000|30 47|adenosine deaminase
P08432137A0000|78 95|PADA/serum ADA ratio
P08432137A0000|140 157|PLYS/serum LYS ratio
P08432137A0000|182 196|interferon gamma
P08432526A0580|36 50|sequencing cDNAs
P08432526A0580|61 96|polymerase chain reaction amplification
P08432526A0580|100 120|fibroblast cDNA library
P08432696A1117|79 93|aminopeptidase N
P08435755A0938|13 35|scopolamine hydrobromide
P08435755A0938|123 136|stage-3 seizure
P08435755A1078|39 50|kindling rate
P08435755A1078|77 93|seizure parameters
P08435885A0787|35 63|pyridinium cross-link excretion
P08435885A0787|67 94|thyroid hormone concentrations
P08437521A0000|108 135|nitrogen metabolite repression
P08437521A0000|196 206|areA product
P08437521A0000|243 253|areA control
P08437737A0100|0 13|Naval personnel
P08438584A0524|4 19|promoter activity
P08438584T0000|16 34|coat protein promoter
P08438584T0000|51 61|mosaic virus
P08438584T0000|83 99|C1-C2 gene products
P08439564A0883|3 28|amino acid sequence alignment
P08439564A0883|50 67|Cbl binding proteins
P08439564A0883|91 105|transcobalamin I
P08439564A0883|109 126|porcine haptocorrin
P08439597A0000|9 21|communication
P08439597A0000|58 74|enzyme immunoassay
P08439597A0000|107 123|fluoroimmunoassay
P08439597A0000|130 142|determination
P08439597A0176|44 54|study design
P08439597A0176|66 77|blood samples
P08439597A0176|87 102|screening centres
P08440238T0000|84 97|phosphoprotein
P08440238T0000|151 164|transformation
P08440238T0000|165 177|tumorigenesis
P08440688A1509|68 79|LLC-PK1 cells
P08440688A1509|92 106|differentiation
P08440688A1509|110 123|hormone signals
P08441379A0912|16 29|proIL-1 beta cap
P08441379A0912|79 89|proIL-1 beta
P08441379A0912|109 124|enhancer elements
P08441379A0912|207 224|IL-1 beta expression
P08441394A1297|30 54|signal transduction pathway
P08441394A1297|64 76|transcription
P08441394A1297|146 158|Ras activation
P08441411A1260|31 45|Gfi-1 expression
P08441423A0145|94 108|GCN4 translation
P08441869A0334|3 17|plateau MO2 value
P08442384A0430|65 76|reading frame
P08442384A0430|122 137|amino acid peptide
P08442384T0000|3 23|SCH9 protein kinase mRNA
P08442384T0000|58 69|reading frame
P08443122A0657|20 49|fibroblasts PILOT gene expression
P08443339A1374|13 24|localization
P08443339A1374|38 53|promoter function
P08443339A1374|56 68|leaf epidermis
P08443340A0522|28 45|expression patterns
P08443340A0522|67 81|promoter regions
P08443340A0522|101 113|glucanase gene
P08443340A0522|119 136|beta-glucuronidase
P08443340A0522|140 151|reporter gene
P08443340A0522|202 214|tobacco plants
P08443341A0384|0 19|Southern blot analysis
P08443341A0384|74 85|MB cDNA clones
P08443341A0384|96 112|MA type myrosinases
P08443341A0384|149 165|MB type myrosinases
P08444344A0000|0 10|Zinc fingers
P08444345A0403|83 94|EFIA/DbpB/YB
P08444345A0403|96 107|family member
P08445299T0000|16 27|insufflation
P08445299T0000|30 41|deferoxamine
P08445299T0000|49 61|ozone toxicity
P08445655A1009|0 11|Localization
P08445655A1009|17 30|insertion locus
P08445655A1009|36 46|yeast genome
P08445655A1009|50 71|complementation studies
P08445729A0657|16 29|spacer sequence
P08446579A0784|9 33|transcription factor Gal-ER
P08446579A0784|118 133|activating domain
P08446579A0784|139 160|herpesvirus protein VP16
P08446579A1210|64 79|estrogen addition
P08447005T0001|24 48|influenzae type b meningitis
P08447005T0001|54 65|introduction
P08449133A0578|0 13|Endosonography
P08449133A0578|32 45|tumor extension
P08449943A0225|88 101|kinase isozymes
P08449943A0225|127 139|leukemia cells
P08449978A0000|10 28|cell cycle regulation
P08449978A0000|99 111|protein kinase
P08450015A0175|80 100|solid-phase extraction
P08450015A0175|127 154|n-propyl carbamate derivatives
P08451187A0267|49 60|ars sequences
P08451331T0000|61 72|hypothalamus
P08453101A0128|0 14|Pokeweed mitogen
P08453101A0128|50 66|c-jun messenger RNA
P08453950A0498|9 24|seizure induction
P08454077A0956|31 47|mg/kg i.v. infusion
P08454077A0956|70 86|revascularisation
P08454077A0956|223 235|muscle salvage
P08454591A0692|87 99|CAAT sequences
P08454591A0692|107 128|transcription start site
P08454591A1322|20 31|inducibility
P08454591A1322|78 89|binding sites
P08454858A0285|157 174|signal transduction
P08455598A0000|55 65|alpha * cells
P08455598A0000|75 95|a/alpha aar1-6 genotype
P08455598A0000|106 123|alpha mating ability
P08455598A0000|132 144|mating ability
P08455611A0000|59 72|globin promoter
P08455611A0000|79 89|alpha globin
P08455611A0154|21 35|expression assay
P08455611A0154|91 112|globin promoter activity
P08455623A0630|30 40|23S pre-rRNA
P08455623A0630|114 125|proteins NOP1
P08456378A0134|52 67|lymphangiography
P08456879A0000|48 61|concentrations
P08456879A0000|64 76|serum cotinine
P08457205A0240|8 24|amino acid sequence
P08457205A0240|74 90|% sequence identity
P08457291A0170|43 57|proto-oncogenes
P08457291A0170|118 130|c-fos oncogene
P08458849A0364|25 41|flaN transcription
P08458849A0364|79 89|ftr elements
P08458849A0364|112 133|transcription start site
P08458906A0827|1 12|micrograms/l
P08459465A0257|39 56|energy expenditures
P08459465A0257|116 132|energy expenditure
P08459465A0257|187 203|energy expenditure
P08459465A0257|220 241|energy expenditure times
P08459465A0257|244 257|activity factor
P08459465A0257|262 273|stress factor
P08460918A0252|135 146|mumol liter-1
P08460918A0252|147 165|alkaline phosphatase
P08460918A0252|178 205|gamma-glutamyltranspeptidase
P08460918A0252|303 320|hyperbilirubinemia
P08460918A0252|325 336|mumol liter-1
P08461946A0386|72 84|split function
P08461981A0882|62 82|regeneration phenomena
P08463284A1531|20 32|p34cdc2 kinase
P08463320A1219|6 38|copper-phenanthroline footprinting
P08463320A1219|51 79|gel shift assembly intermediates
P08463320A1219|125 136|SSB tetramers
P08463320A1219|173 184|SSB tetramers
P08463485T0000|21 37|endotoxin infusion
P08463485T0000|55 69|oxytocin release
P08464056A0000|24 37|finger proteins
P08464056A0000|75 86|C2H2 type ZFPs
P08464056A0000|89 101|Xenopus laevis
P08464056A0510|28 39|organization
P08464056A0510|42 66|FAX-ZFP transcription units
P08464056A0510|79 98|Southern blot analysis
P08464056A0510|113 132|restriction fragments
P08464056A0510|154 176|field gel electrophoresis
P08464056A0510|188 200|hybridization
P08464924A0243|95 106|eIF-5 protein
P08466864A0878|118 138|element binding protein
P08466864A0878|143 153|binding site
P08466864A0878|169 185|PMA responsiveness
P08466864A0878|204 218|Sp1 binding sites
P08466864A0878|227 242|promoter activity
P08468475A1280|17 37|internalization assays
P08468475A1280|69 83|IL-2R alpha chain
P08468475A1280|124 139|IL-2R beta subunit
P08468475A1280|189 209|F42A-IL-2R beta complex
P08468475A1280|223 235|alpha-subunit
P08468475A1280|271 289|F42A binding reaction
P08469831T0001|29 43|prostaglandin E1
P08470021A0195|25 37|IgG antibodies
P08470021A0195|45 60|Trypanosoma cruzi
P08470021A0195|70 80|blood donors
P08470021A0195|86 102|Instituto Nacional
P08470021A0195|116 128|Ignacio Chavez
P08470895A1617|39 51|mRNA start site
P08470895A1617|84 100|enhancer sequences
P08471629A0816|0 14|Pseudosubstrate
P08471629A0816|57 67|PKC isotypes
P08471629A0816|91 102|nPKC activity
P08471629A0816|114 124|Histone IIIS
P08471796A1654|53 66|gene expression
P08471796A1654|69 81|A. caulinodans
P08472750A0999|6 20|oxide inhalation
P08472750A0999|48 59|hypertension
P08472750A0999|62 82|porcine endotoxin shock
P08473731A0149|38 57|alpha/beta components
P08473967T0000|12 28|Jungian type theory
P08473967T0000|35 59|Myers-Briggs Type Indicator
P08474438A0000|17 34|ribonucleoproteins
P08474438A0000|76 88|RNA polymerase
P08474438A0000|144 165|RNA processing reactions
P08474438A0000|175 197|pre-mRNA polyadenylation
P08474438A0000|234 246|mRNA transport
P08474439A0877|74 85|site mutation
P08474439A0877|120 130|muscle types
P08474456A1041|9 28|transfection analysis
P08474456A1041|111 127|LyF-1 binding sites
P08474464A0348|17 28|relationship
P08474464A0348|56 69|TR binding sites
P08475104A0341|22 36|promoter element
P08475104A0341|71 84|G1-S activation
P08475104A0341|95 109|thymidine kinase
P08475104A0341|177 192|p33cdk2 complexes
P08476854A0097|6 17|footprinting
P08476854A0097|106 124|base pair DNA fragment
P08479742A0985|62 78|cell proliferation
P08481004A0321|29 40|endonuclease
P08482539A0913|0 19|Northern blot analysis
P08483412A0000|10 22|nifH promoters
P08483412A0000|127 137|NifA protein
P08483479A1056|37 60|collagen promoter activity
P08483479A1056|113 128|collagen promoter
P08483479A1056|142 160|elements down-stream
P08483479A1056|193 206|cAMP repression
P08483479A1056|209 230|collagen gene expression
P08484514A1536|44 63|baseline vein diameter
P08484891A0000|28 39|conditioning
P08485317A0000|3 18|fission yeast dsk1
P08485317A0000|60 70|dis1 mutants
P08485317A0000|89 101|protein kinase
P08486035T0000|12 33|patent ductus arteriosus
P08486035T0000|55 69|minithoracotomy
P08486276A0419|0 17|Sequence comparison
P08486276A0419|45 59|protein database
P08486276A0419|83 101|% aa sequence homology
P08486276A0419|113 125|transmembrane
P08486276A0419|159 173|chloramphenicol
P08486276A0419|179 190|tetracycline
P08486276A0419|224 237|symport protein
P08486705A0181|113 124|eIF-5 protein
P08488700A0283|84 95|immunization
P08488700A0283|139 154|blood derivatives
P08491124A0517|12 23|construction
P08491124A0517|29 43|mouth protectors
P08491124A0517|71 85|instrumentation
P08491124A0517|138 152|mouth protectors
P08491383A0154|3 15|alpha-subunit
P08491383A1291|17 29|alpha-subunit
P08491383A1291|66 85|transcription factors
P08491383A1291|127 144|interaction domains
P08491683A0651|78 91|adenocarcinoma
P08492164T0000|11 21|burst firing
P08492164T0000|54 68|depth dependence
P08492164T0000|89 107|interaction measures
P08492290A0306|72 89|stability constants
P08495786A0085|0 21|Cryopreservation straws
P08496157A0000|72 84|carboxyl tails
P08496157A0000|107 123|splicing mechanism
P08496184A0772|13 24|reading frame
P08496184A0772|98 112|type counterpart
P08496185A0484|20 45|nucleotide sequence analysis
P08496185A0484|58 76|adenylate kinase gene
P08496475T0000|0 12|Calcification
P08496475T0000|26 38|Streptococcus
P08496475T0000|44 58|Corynebacterium
P08496475T0000|59 70|Bacterionema
P08496599A0310|77 87|mRNA species
P08496601A1153|28 38|muMIP-1 beta
P08496601A1153|42 53|muMIP-1 alpha
P08496601A1153|71 81|CK-1 element
P08496601A1153|94 110|expression studies
P08496601A1153|164 174|muMIP-1 beta
P08496601A1153|180 191|muMIP-1 alpha
P08496601A1153|214 258|growth hormone reporter gene link LPS-inducibility
P08496601A1153|267 282|promoter segments
P08496601A1153|311 331|consensus CK-1 sequence
P08496848A0692|16 34|contrast differences
P08496848A0692|53 64|FSE sequences
P08496848A0692|94 106|SE counterpart
P08497190T0079|0 15|Sequence analysis
P08497190T0079|19 32|identification
P08497248A0000|72 89|c-fms protooncogene
P08497248A0000|155 166|trophoblasts
P08497259A0452|13 32|SUP4A53T61 transcript
P08497259A0452|56 67|tap1-1 mutant
P08497269A0999|4 21|sequence similarity
P08497269A0999|74 86|tRNA molecules
P08497269A0999|169 189|translation elongation
P08497273T0000|32 45|immunoglobulin
P08497273T0000|58 70|alpha enhancer
P08497273T0000|86 106|B-cell differentiation
P08497280A0266|43 62|cell cycle progression
P08497280A0266|112 128|SWI4 transcription
P08497280A1397|55 71|SWI4 transcription
P08497280T0000|47 63|SWI4 transcription
P08498570A1118|21 43|carotid sinus stimulation
P08499376A0000|41 54|predictability
P08499916A0000|25 39|type VII collagen
P08499916A0000|60 72|candidate gene
P08499916A0000|126 145|epidermolysis bullosa
P08500524A0424|86 100|splicing signals
P08500524A0424|119 136|intron organization
P08501030A0456|29 46|.5 operon expression
P08501678A0498|59 84|immunoprophylactic strategy
P08503348A0226|3 27|HMG CoA reductase inhibitors
P08504707A0376|47 60|manifestations
P08504928T0000|16 27|TFIID subunit
P08504928T0000|56 75|cell cycle gene product
P08504932A0123|20 39|GATA factor expression
P08504932A0123|53 64|GATA proteins
P08504932A0123|103 117|site specificity
P08504933A0000|23 37|POU domain factor
P08504933A0000|71 84|cell phenotypes
P08505075A0236|0 12|Maximum number
P08505075A0236|41 58|S. bareilly serotype
P08505340T0000|0 15|Characterization
P08505340T0000|55 90|rat prostaglandin endoperoxide synthase
P08505340T0000|98 111|granulosa cells
P08505605A0461|0 21|Patient characteristics
P08505605A0461|64 83|wound characteristics
P08506317A0000|12 22|C/EBP family
P08506317A0000|25 43|basic-leucine zipper
P08506317A0000|48 67|transcription factors
P08506317A0000|72 83|heterodimers
P08506317A0000|127 140|enhancer motifs
P08506384A0146|16 30|phosphorylation
P08506384A0146|73 93|GDP-GTP exchange factor
P08507921A1021|17 28|observations
P08507921A1021|45 58|stratification
P08507921A1021|78 91|plasma ANF level
P08508774A0242|51 62|DNA fragments
P08508778A0112|0 11|Yeast mutants
P08508861A0294|80 101|lactate extraction ratio
P08508861A0294|108 123|balloon inflation
P08509051A0316|31 43|mortality rate
P08509333A0843|35 50|membrane fraction
P08509333A0843|128 142|membrane protein
P08509335T0000|38 55|1,3-beta-glucanase
P08509419A0785|110 122|TyrRS activity
P08509430A0372|16 30|complementation
P08509430A0372|59 71|Chlamydomonas
P08509430A0372|97 114|frameshift mutation
P08509430A0372|156 168|transformants
P08510320A0000|103 116|concentrations
P08510320A1249|152 163|beta-lactams
P08510647A1347|70 90|utilization properties
P08510647A1347|99 113|barley globulins
P08510924A0490|33 47|transactivation
P08510924A0490|58 70|HSP70 promoter
P08510924A0490|73 83|Myb proteins
P08511994A0000|58 69|ichthiomycin
P08511994A0000|72 85|concentrations
P08511994A0000|99 112|micrograms/dm3
P08512728A0991|120 131|fibrillation
P08512728A0991|151 166|accessory pathway
P08513025A0000|70 83|bilirubin level
P08514757A1100|4 16|immunophilins
P08514757A1100|40 55|receptor assembly
P08514757A1100|123 137|protein function
P08514766A0732|3 16|GTPase activity
P08515619A0184|0 16|Tl-201 uptake ratio
P08515619A0184|187 207|Burrows classification
P08516308A0669|36 48|microcolonies
P08516324A0000|17 29|translocation
P08516324A0000|50 61|Ewing sarcoma
P08517737A0889|79 90|water systems
P08518797T0000|8 24|liver glycogenosis
P08518797T0000|25 36|localization
P08518797T0000|52 64|candidate gene
P08519621A0150|26 37|observations
P08519862T0001|21 33|IgM antibodies
P08520646A0000|0 20|Embryo coculture system
P08521414A1384|197 209|p16INK4A locus
P08522175A0306|52 62|beta subunit
P08522175A0306|163 176|protein sorting
P08522175A0306|180 192|translocation
P08522511A1250|24 36|lyase activity
P08522511A1578|65 86|beta-glucuronidase gene
P08522511A1578|148 175|beta-glucuronidase activities
P08522511A1578|181 193|transformants
P08522530A1342|36 50|primer extension
P08523545T0000|8 25|papillomavirus type
P08523545T0000|48 61|adenovirus type
P08523545T0000|90 104|transactivation
P08523545T0000|107 120|adenovirus type
P08523545T0000|150 172|Oct-1 DNA binding activity
P08523566A1106|22 33|% Nonidet P-40
P08524036A0747|10 21|expectations
P08524036A0747|71 84|enhancer region
P08524036A0747|94 111|point substitutions
P08524036A0747|115 133|insertion/deletions
P08524229T0000|16 32|soybean ribulose-1
P08524229T0000|33 72|bisphosphate carboxylase small-subunit mRNA
P08524260A0835|3 17|domain structure
P08524260A0835|148 164|consensus sequence
P08524260A0835|168 181|calcium binding
P08524267A1022|53 72|prothymosin alpha gene
P08524272T0000|58 72|Jak/Stat pathway
P08524272T0000|98 122|tyrosine phosphatase SHPTP1
P08524284A0309|150 161|HeLa extracts
P08524292A1022|14 27|mechanism study
P08524292A1022|62 76|transactivation
P08524314A0216|7 25|Ty enhancer activator
P08524314A0216|26 37|gene sequence
P08524314A0216|86 96|zinc cluster
P08524314A0216|100 116|dimerization motif
P08525186A0288|102 113|counterparts
P08526620A1344|42 64|SC5b-9 complement complex
P08526620A1344|99 118|complement activation
P08528479A0000|0 17|Videonystagmoscopy
P08528796A1470|9 18|UA PI values
P08529098A0549|8 27|sequence similarities
P08529098A0549|151 163|transmembrane
P08529098A0549|193 214|susceptibility mutation
P08529098A0549|242 255|transport motif
P08529630A0840|26 37|P protein mRNA
P08529654A0589|3 47|B. germanica cyclophilin amino acid sequence shares
P08529654A0589|74 91|cyclophilin isoform
P08529662A0507|54 68|Western blotting
P08530105A0308|27 57|Langer-Giedion syndrome deletions
P08530107A1003|80 101|histidase transcription
P08530149A0689|49 65|consensus sequence
P08530342T0000|8 19|gp39 promoter
P08530345A0880|0 19|Transfection analyses
P08530345A0880|55 66|TGACCT motifs
P08530345A0880|181 203|peroxisome proliferators
P08530369A0099|9 27|autophosphorylation
P08530369A0099|57 88|consensus autophosphorylation site
P08530369A0099|96 119|Src family tyrosine kinases
P08530384A0559|68 78|Oct proteins
P08530384A0559|91 112|resolution footprinting
P08530418A1182|29 45|TR2 orphan receptor
P08530418A1182|52 66|master regulator
P08530418A1182|143 171|acid signal transduction pathway
P08530503A1004|12 30|ARP immunoreactivity
P08530503A1004|44 58|plasma membranes
P08530503A1004|88 98|3T3-L1 cells
P08531373A0470|56 72|skin manifestation
P08531373A0470|86 104|SS-A/SS-B antibodies
P08531669A0950|40 53|Central America
P08531669A0950|57 71|Caribean islands
P08532516A0000|36 49|cdc10-C4 mutant
P08532516A0000|55 66|fission yeast
P08532536A0925|0 13|TIEG expression
P08532536A0925|118 129|growth factor
P08532536A0925|154 176|growth factors/cytokines
P08533472A0777|12 26|protein products
P08533472A0777|53 64|similarities
P08533472A0777|107 151|Candida maltosa cycloheximide-resistance protein
P08533473A0375|79 90|EST sequences
P08533757A0204|14 35|Ashkenazi Jewish descent
P08533757A0204|46 61|185delAG mutation
P08534217A0402|39 52|pollution level
P08534217A0402|93 105|Viskovo region
P08534855A0000|3 21|Arabidopsis FAD7 gene
P08534855A0000|30 47|chloroplast omega-3
P08534855A0000|53 66|acid desaturase
P08534855A0000|83 94|desaturation
P08535138A0857|57 68|cell division
P08535138A0857|84 96|plant hormones
P08535138A0857|97 115|cycMs4 transcription
P08535138A0857|142 153|DNA synthesis
P08535537A0000|66 78|drug treatment
P08535537A0000|90 101|hypertension
P08536694A0000|0 13|Protein kinases
P08537388A0825|161 176|promoter activity
P08537403A0336|3 22|protein kinase domains
P08537403A0336|73 108|sequence motif Asp-Leu-Asn-Ser-His-Asn
P08537403A0336|151 163|subdomains VII
P08538052A0000|40 57|amino acids residues
P08538052A0000|107 117|cDNA library
P08538052A0000|148 164|leukemia HL60 cells
P08538052A0000|178 203|oligodeoxynucleotide probes
P08538052A0000|225 242|amino acid sequences
P08538382A1012|0 12|Erythrocyte AA
P08538483A0207|10 28|consideration weight
P08538483A0207|78 99|body bone mineral content
P08538483A0207|132 143|GnRH agonists
P08538483A0207|157 169|endometriosis
P08538702A0214|45 57|ABA-1 allergen
P08538702A0214|93 104|Brugia malayi
P08538702A0214|105 117|Brugia pahangi
P08538702A0214|159 176|Dirofilaria immitis
P08541499A0306|7 24|transcript patterns
P08541499A0306|27 42|Epifagus plastids
P08541499A0306|78 91|tobacco operons
P08542026A0792|8 21|kD glycoprotein
P08542026A0792|57 72|consensus repeats
P08542026A0792|110 129|complement activation
P08542026A0792|133 143|gene cluster
P08542746T0000|0 11|Diabetes care
P08543173A0314|40 50|start points
P08543173A0314|68 90|primer extension analysis
P08543275A0130|14 26|investigation
P08543275A0130|43 60|pseudoterranovosis
P08543275A0130|139 150|Arctic region
P08543595A1093|57 68|radiotherapy
P08543810A0000|48 59|coelomocytes
P08543810A0000|120 130|cDNA library
P08543810A0000|155 166|sequence tags
P08544820T0000|0 15|Characterization
P08544820T0000|20 47|EcR/USP heterodimer target site
P08544820T0000|60 81|ecdysone responsiveness
P08545502A0914|37 50|activation task
P08546707T0000|30 48|chicken lysozyme gene
P08546707T0000|51 62|NF-kappa Bp65
P08546707T0000|83 94|NF-kappa Bp50
P08547205A1060|36 50|agents alinidine
P08548291A1059|85 103|serum response factor
P08548291A1059|110 129|serum response element
P08548291A1059|156 168|transcription
P08549706T0000|12 35|hepatitis B virus infection
P08549859A1604|42 53|chromosome 3p
P08549859A1604|56 98|Centre d'Etude du Polymorphisme Humain pedigrees
P08550425A1401|75 95|Halobacterium halobium
P08550460A0374|82 97|protein precursor
P08550460A0374|118 150|membrane lipoprotein leader sequence
P08550462A0815|26 37|reading frame
P08550476A0610|43 62|activator protein EpiQ
P08550476A0610|107 121|EpiQ binding site
P08550476A0610|127 138|epiA promoter
P08550564T0000|0 12|CXC chemokines
P08550564T0000|31 53|selectivity determinants
P08550564T0000|130 152|interleukin-8 receptor B.
P08551572A0155|0 20|Oligodeoxynucleotides
P08551572A0155|44 71|translation initiation regions
P08551572A0155|99 111|proliferation
P08551572A0155|142 162|reticuloendotheliosis
P08551577A0000|116 130|envelope protein
P08551577A0000|136 151|Rous sarcoma virus
P08552042A1497|21 39|promoter methylation
P08552042A1497|184 195|reactivation
P08552045A0973|7 24|consensus sequences
P08552045A0973|28 48|phosphatase regulation
P08552045A0973|95 110|binding sequences
P08552045A0973|117 128|Cpflp protein
P08552045A0973|140 152|transcription
P08552045A0973|165 186|methionine biosynthesis
P08552045A0973|193 210|centromere function
P08552082A0480|119 130|protein Abp1p
P08552086A0150|33 55|vitamin D response element
P08552092A1678|12 25|protein binding
P08552092A1678|71 83|transcription
P08552092A1678|91 102|footprinting
P08552092A1678|114 127|promoter region
P08552092A1678|143 155|protein factor
P08552093A0657|0 14|Differentiation
P08552095A0686|29 41|transcription
P08552095A0758|30 45|yeast transcripts
P08552096A0151|15 33|suppression strategy
P08552096A0151|111 126|cell cycle defects
P08552096A0151|141 154|cdc34 mutations
P08552387A0000|9 24|characterization
P08552387A0000|72 82|cell sarcoma
P08552387A0000|97 119|chromosome translocation
P08552387A0000|159 173|factor gene ATF-1
P08552643A0261|105 119|stomatitis virus
P08552643A0261|136 147|IFN treatment
P08552670A0665|55 68|DNA polymer poly
P08552670T0000|0 13|Identification
P08552670T0000|14 25|purification
P08552670T0000|98 109|fission yeast
P08553580A0102|10 21|reading frame
P08553580A0102|57 67|FIV isolates
P08554069A0743|66 78|T transversion
P08554069A0743|88 105|acceptor splice site
P08554069A0743|144 154|RNA splicing
P08554540A1480|26 52|HIT protein similarity regions
P08554723A0187|54 64|acid lesions
P08554723A0187|156 169|sodium appetite
P08554723A0187|179 197|furosemide treatment
P08555076A0333|9 22|Amphotericin-B
P08555289A0207|8 22|storm indicators
P08555446A0000|10 22|tobacco plants
P08555446A0000|67 81|pyrophosphatase
P08555446A0000|91 105|35S CaMV promoter
P08555498A0427|110 128|vertebrate evolution
P08555753A0591|33 45|Wisconsin Card
P08555753A0591|78 91|activation task
P08555753A0591|105 116|neuroimaging
P08556707A1390|48 70|transactivation activity
P08556707A1390|74 84|p53 promoter
P08556707A1390|107 118|temperatures
P08556707A1390|141 151|p53 function
P08556707A1390|182 192|SNU-C5 cells
P08561607A1443|38 52|transplantation
P08561893A0100|57 73|gene transcription
P08561893A0100|77 102|E-box DNA consensus sequences
P08561893A0100|116 129|factor function
P08561893A0100|192 204|family members
P08561897A0604|11 26|supershift assays
P08561897A0604|103 124|competition experiments
P08561897A0604|162 175|CRE/TRE element
P08563483A0094|42 53|gonadotropin
P08564488A1359|4 19|fibrinogen levels
P08564588A1318|0 18|Strontium chloride Sr
P08564588A1318|75 96|management expenditures
P08565548A0196|46 56|silicone gel
P08565548A0196|109 119|silicone gel
P08566747A0756|43 55|transcription
P08566747A0756|78 92|Cln/Cdc28 kinase
P08566747A0756|142 154|transcription
P08566751A0455|37 54|vertebrate Hox genes
P08566754A0783|5 22|splice site sequence
P08566754A0783|45 59|polyadenylation
P08566754A0783|96 113|ribonucleoproteins
P08566754A0783|134 162|splicing factor/splicing factor
P08566756A0752|51 67|SF3a/SF3b subunits
P08566756A0752|68 80|UV cross-links
P08567556A0000|53 63|seal muscles
P08567556A0000|85 95|seal muscles
P08567556A0000|102 122|laboratory simulations
P08567556A0000|159 169|field diving
P08567556A0000|177 188|measurements
P08567556A0000|203 219|lactate production
P08567556A0000|256 269|diving response
P08567683A0401|60 73|acid polypeptic
P08567717T0000|26 59|spindle pole body duplication gene MPS1
P08567847A1005|15 26|SM-CMA system
P08567847A1005|40 51|shortcomings
P08567847A1005|57 70|user-interface
P08567847A1005|121 132|semen samples
P08569680A0636|7 17|areA product
P08569684A0000|0 15|Oligonucleotides
P08569684A0000|53 77|amino acid sequence segments
P08569684A0000|114 127|protein kinase C
P08569684A0000|159 182|polymerase chain reactions
P08569684A0000|210 220|DNA fragment
P08569684A0000|239 261|fungus Trichoderma reesei
P08570615T0000|38 51|point mutations
P08570615T0000|67 78|S-phase entry
P08572616A0000|14 35|differentiation markers
P08573083A0645|50 60|binding site
P08573083A0645|77 95|transcription factor
P08573083A0645|144 158|insulin promoter
P08573637A0434|42 54|determination
P08573637A0434|84 95|formulations
P08574414A1037|63 80|Xanthomonas species
P08575614A0264|0 10|Rad6 mutants
P08575614A0264|100 120|postreplication repair
P08575614A0264|133 150|retrotransposition
P08575618A1138|0 20|RNase protection assays
P08575618A1138|75 88|skin expression
P08575618A1138|93 127|pigmentation/phaeomelanin phenotypes
P08575754T0000|16 32|expression pattern
P08575754T0000|47 58|localization
P08575754T0000|66 77|CDKN2D/INK4d
P08576042A0765|0 13|Overproduction
P08576042A0765|16 26|HrcA protein
P08576042A0765|96 111|delta hrcA strains
P08576042A0765|121 138|heat shock induction
P08576042A0765|151 161|groE operons
P08576042A0765|174 186|transcription
P08576131A0151|40 55|characterization
P08576131A0151|58 69|USF2 isoforms
P08576131A0685|15 32|heterodimerization
P08576131A0685|35 45|USF subunits
P08576131A0685|126 136|USF proteins
P08576179A0126|58 84|translation initiation factor
P08576179A0126|86 97|alpha subunit
P08576179A0126|117 142|polypeptide chain initiation
P08576245A0000|94 108|stress responses
P08576245A0000|168 190|glycoprotein trafficking
P08576262A0160|3 14|IL-8 receptor
P08576262A0160|18 52|seven-transmembrane spanning receptor
P08576546A0975|85 97|dose regiments
P08580083A0259|24 35|significance
P08580083A0259|86 105|Fyn-expression vector
P08580083A0259|119 133|reporter plasmid
P08580083A0259|147 182|chloramphenicol acetyltransferase gene
P08580671A0137|70 81|beta-blocker
P08580671A0137|131 142|hypertension
P08580671A0137|171 182|liver disease
P08581174A0472|43 53|qutA mutants
P08581174A0472|124 134|QUTA protein
P08582143A0614|76 98|cephalosporin substrates
P08582143A0614|143 166|beta-lactamase production
P08582633T0000|98 114|telomere structure
P08583846A0121|32 48|beta-2 transferrin
P08583846A0807|11 38|methodology beta-2 transferrin
P08584035A0740|0 21|Gel mobility shift assays
P08584035A0740|87 103|binding properties
P08584035A0740|131 144|beta I-A element
P08584074A0000|91 102|lobe epilepsy
P08584074A0000|143 162|Bethel Epilepsy Center
P08584530A0545|11 22|correlations
P08584530A0545|141 151|test results
P08585639T0000|22 36|hepatitis B virus
P08585639T0000|45 65|immunodeficiency virus
P08585639T0000|78 89|risk analysis
P08585883A0381|39 50|breeder males
P08585883A0381|100 114|copulation plugs
P08585957A0101|24 42|transcription factor
P08585957A0101|98 108|zinc fingers
P08585957A0101|148 158|gene product
P08585957A0101|194 214|mobility group proteins
P08585994A0567|5 19|reference probes
P08585994A0567|52 71|ost transcription unit
P08585994A0567|101 116|band interval 89A1
P08585994A0567|176 209|segmentation gene expression patterns
P08586643A0951|45 62|phosphoryl transfer
P08586874T0000|23 39|Haplorchis pumilio
P08586874T0000|75 87|redescription
P08587075T0000|10 23|microaneurysms
P08587075T0000|34 48|hepatitis B virus
P08587075T0000|56 74|polyarteritis nodosa
P08588852A0236|102 113|micrognathia
P08589315A1029|16 27|survival rate
P08589315A1029|96 113|tumor lysis syndrome
P08589315A1029|125 142|lupus erythematosus
P08589358A0235|36 49|erythropoietin
P08589358A0841|16 29|erythropoietin
P08589358A0841|76 91|blood transfusion
P08589735A0577|17 29|GUS expression
P08589735A0577|41 55|promoter regions
P08589735A0577|70 100|Arabidopsis alcohol dehydrogenase
P08589735A0577|105 118|maize ubiquitin
P08589735A0577|139 150|CaMV 35S genes
P08590465A0773|3 14|organization
P08590465A0773|50 64|URA1 gene product
P08590465A0773|100 114|URA2 gene product
P08591700A0972|3 19|mean body mass index
P08592590A0822|28 48|haemodialysis patients
P08592590A0822|83 101|interferon treatment
P08595012A0817|2 13|nondiabetics
P08595184A0407|74 85|correlations
P08595184A0407|98 112|field potentials
P08595414A0000|56 67|construction
P08595414A0000|116 127|model genomes
P08595414A0000|144 156|determination
P08595627A1513|68 79|consequences
P08595627A1513|105 115|KATP opening
P08595658A0961|3 14|DNA sequences
P08595658A0961|54 87|plant mitochondrial-processing sites
P08595658A0961|139 151|RNA processing
P08595836T0000|51 62|glass ionomer
P08595878A0201|42 54|PP2A functions
P08595878A0201|85 106|receptor tyrosine kinase
P08595878A0201|110 134|signal transduction pathway
P08595878A0201|148 170|R7 photoreceptor cell fate
P08595878A0201|186 198|Drosophila eye
P08597177T0000|28 43|hydrogen sulphide
P08597596A0135|35 48|ABC transporter
P08597636A0000|64 81|expression patterns
P08597636A0000|120 133|gene regulation
P08598051T0000|25 43|schizosaccharomyces
P08598051T0000|66 86|RNP consensus-sequence
P08598359X0000|9 21|treatment time
P08598359X0000|34 57|treatment energy influence
P08598359X0000|85 98|cell carcinomas
P08598359X0000|258 270|cell carcinoma
P08598449A0784|35 53|surface Ig engagement
P08598449A0784|56 67|B lymphocytes
P08598449A0784|68 79|CD38 ligation
P08598449A0784|100 122|tyrosine phosphorylation
P08598449A0784|136 160|protein tyrosine kinases lyn
P08598449A0784|253 266|concentrations
P08599945T0000|14 27|alpha-amanitin
P08599945T0000|64 81|yeast RNA polymerase
P08599945T0000|98 108|RNA cleavage
P08599946A0999|52 75|ribonucleoprotein complex
P08599946A0999|115 126|interactions
P08599946A0999|169 187|example coiled-coils
P08600028A1129|18 33|trans-activation
P08600028A1129|52 65|intron enhancer
P08600048T0000|16 29|conjunctivitis
P08600048T0000|39 63|bone marrow transplantation
P08601283A0875|21 33|SECIS elements
P08601283A0875|43 55|reading frames
P08601283A0875|71 84|selenoproteins
P08601283A0875|148 159|SECIS element
P08601283A0875|195 207|SECIS function
P08601284A0000|110 124|complementarity
P08601616A0726|4 16|spindle defect
P08601616A0726|19 29|pds1 mutants
P08601616A0726|86 97|G1/S boundary
P08601616A0726|112 126|spindle assembly
P08601806A0875|62 76|differentiation
P08601806A0875|90 102|ganglion cells
P08602169A0484|5 15|point mutant
P08602169A0484|40 51|endonuclease
P08602169A0484|107 118|HML alpha loci
P08602608A1056|30 41|performances
P08602608A1056|120 137|reference procedure
P08603921A1346|16 33|Spc110p truncations
P08603921A1346|44 64|calmodulin binding site
P08604338A0198|16 28|FLI-1 proteins
P08604338A0198|39 58|transcription factors
P08604338A0198|81 92|ets sequences
P08604338A0198|113 128|promoter elements
P08604338A0885|2 27|electromobility shift assays
P08604338A0885|28 43|EWS-FLI-1 binding
P08604338A0885|172 187|complex formation
P08604708A1086|49 66|cellulose dialyzers
P08604708A1086|91 104|blood flow rates
P08605302A1770|0 13|DNA methylation
P08605302A1770|46 60|deoxyadenosines
P08605302A1770|128 139|rice CatA gene
P08605302A1770|169 188|CatA promoter activity
P08605705A0676|12 22|IgM class CIC
P08605705A0676|76 90|disease activity
P08605931A0777|0 13|Epitope mapping
P08605931A0777|70 82|epitope domain
P08606267A0740|67 81|exercise testing
P08606267A0740|118 129|registration
P08606267A0740|158 190|Tc-99m 2-methoxy isobutyl isonitrile
P08608126A0811|37 51|binding affinity
P08608126A0811|104 115|medium-chain
P08608222T0000|71 84|factor receptor
P08608222T0000|109 131|STAT1 homodimer formation
P08608447A0806|27 42|codon recognition
P08608447A0806|49 62|TPI transcripts
P08608448A0353|42 57|dimethylsulphate
P08608448A0353|125 138|structure model
P08610272A0265|16 29|investigations
P08610272A0265|98 120|maintenance chemotherapy
P08610272A0265|149 165|response modifiers
P08610272A0265|169 181|growth factors
P08612852A0553|12 28|plasma IGF-I levels
P08612852A0553|37 49|body mass index
P08614403A0557|26 42|Rev-erbA alpha mRNA
P08614403A0557|53 66|C2C12 myoblasts
P08614403A0989|23 48|GAL4-REV-erbA alpha chimeras
P08614403A0989|97 109|transcription
P08614403A0989|112 131|GAL4 response elements
P08614410A0000|3 19|alpha T3-1 cell line
P08614410A0000|36 54|gonadotroph cell line
P08614410A0000|130 161|glycoprotein hormone alpha-subunit
P08615012A0627|0 13|Cotransfection
P08615025A1214|10 22|glycosylation
P08615025A1214|78 99|glycosylation phenotype
P08615025A1214|143 158|immunoreactivity
P08615025A1214|238 249|cell membrane
P08615025A1214|277 288|membrane gp41
P08615025A1214|304 317|membrane fusion
P08617237A0489|15 26|phosphoforms
P08617237A0489|54 74|DNA binding specificity
P08617237A0489|92 114|tyrosine phosphopeptides
P08617237A0489|139 150|localization
P08617238A0334|0 11|TNF Treatment
P08617238A0334|30 48|p38 MAP kinase pathway
P08617238A0334|70 84|phosphorylation
P08617238A0334|87 98|p38 MAP kinase
P08617238A0334|120 149|substrate protein MAPKAP kinase-2
P08617238A0334|169 183|phosphorylation
P08617238A0334|189 204|heat shock protein
P08617311A0979|15 32|sequence similarity
P08617311A0979|43 55|membrane exons
P08617311A0979|123 133|Xenopus mIgY
P08617800A0150|9 21|transcription
P08617800A0150|63 80|receptor expression
P08617800A0675|6 17|footprinting
P08617800A0675|36 54|mobility shift assays
P08617800A0675|112 140|core recognition sequence TGGGAG
P08617802A0993|41 57|SH2/SH3/SH2 region
P08618433A0000|21 42|growth factor FLT3 ligand
P08618433A0000|73 94|tyrosine kinase receptor
P08618433A1720|47 58|FL expression
P08618433A1720|101 117|leukemia cell lines
P08618433A1720|138 149|cell lineages
P08618882A0343|10 24|RAR alpha mutants
P08618882A0343|27 45|transfection studies
P08618882A0343|60 75|DNA binding domain
P08618882A0343|103 115|BZLF1 activity
P08619866A0000|10 36|serum hepatocyte growth factor
P08619866A0000|79 92|angina pectoris
P08619866A0000|101 113|heart diseases
P08619910A0000|32 44|motor symptoms
P08619910A0000|106 123|dopamine deficiency
P08619910A0000|150 161|observations
P08619910A0000|281 297|nigra zona compacta
P08620003T0000|0 14|Protein splicing
P08620003T0000|28 47|N-O acyl rearrangement
P08620003T0000|69 83|splicing process
P08620856A1172|24 45|western blot experiments
P08620856A1172|107 123|mouse c-kit protein
P08620856A1172|173 184|reading frame
P08620856A1172|247 261|spermatogenesis
P08620889A0771|34 50|aldolase C promoter
P08620889A0771|58 70|transcription
P08621017A1186|24 44|uPA promoter activation
P08621017A1186|117 146|tetradecanoylphorbol 13-acetate
P08621384A0935|11 23|keratinocytes
P08621384A0935|50 69|growth factor receptor
P08621384A0935|97 108|growth factor
P08621384A0935|123 153|PKCdelta tyrosine phosphorylation
P08621420A1166|78 94|NF-kappaB proteins
P08621448A0862|42 64|RL95-2 expression library
P08621453A0815|67 77|cell lysates
P08621542A0535|8 21|protein kinases
P08621542A0535|65 78|protein kinases
P08621542A0535|113 129|CD28 costimulation
P08621628A1233|61 76|hGRalpha activity
P08621661A1035|4 18|P5CDh cDNA clones
P08621661A1035|50 62|Northern blots
P08621664A1430|0 13|Polymerization
P08621664A1430|16 36|neurofilament L protein
P08621664A1430|58 72|phosphorylation
P08621664A1430|75 95|neurofilament L protein
P08621714A0361|31 44|disulfide bonds
P08621719A0000|34 59|c-cbl proto-oncogene product
P08621719A0000|87 109|tyrosine phosphorylation
P08621719A0000|114 137|T cell receptor stimulation
P08621719A0568|91 104|Grb2 SH3 domains
P08621730T0000|2 20|AP-1 binding sequence
P08621730T0000|75 90|promoter activity
P08621730T0000|105 121|growth factor-beta
P08622030A0667|55 77|baseline characteristics
P08622030A0667|87 103|treatment protocol
P08622030A0667|104 120|performance status
P08622030A0667|124 148|serum lactate dehydrogenase
P08622645A1026|56 66|RA induction
P08622668A1155|75 112|phosphorylation-dephosphorylation cycle
P08622668A1155|115 128|C1 hnRNP protein
P08622668A1155|146 160|binding affinity
P08622675A0587|105 115|factor Lef-1
P08622887A1026|15 33|mobility shift assays
P08622887A1026|52 89|glucocorticoid receptor DNA binding domain
P08622887A1026|147 183|oligonucleotide competition experiments
P08622893A0000|19 41|receptor tyrosine kinases
P08622893A0000|101 113|communication
P08622893A0000|163 180|signalling pathways
P08624445A0257|29 46|sequencing analysis
P08624445A0257|52 78|cytosine methylation patterns
P08624445A0257|84 106|transposase binding sites
P08625806A0263|8 21|zinc finger gene
P08625806A0263|115 126|mouse embryos
P08625900T0000|56 80|prolactin promoter activity
P08625900T0000|85 97|protein kinase
P08625924A0411|31 47|aromatase proteins
P08625924A0411|96 121|polyadenylation signal usage
P08625987A1086|8 32|bone marrow cells expression
P08625987A1086|62 73|pro-B/pre-BI
P08625987A1086|111 121|state levels
P08626065A0000|32 47|Bacillus subtilis
P08626065A0000|50 60|DNA fragment
P08626290T0000|0 19|Aeromonas salmonicida
P08626290T0000|68 82|membrane protein
P08626437A0332|73 96|glutathione S-transferase
P08626493A1468|70 94|retinoblastoma gene product
P08626493A1468|129 141|transcription
P08626493A1468|149 161|PEPCK promoter
P08626529A0000|5 18|autoantibodies
P08626529A0000|32 46|syndrome patient
P08626529A0000|91 105|membrane protein
P08626529A0799|88 100|heptad repeats
P08626529A0799|101 114|characteristic
P08626529A0799|117 129|alpha-helices
P08626529A0799|217 234|sequence ESLALEELEL
P08626529A0799|268 279|granin family
P08626529A0799|324 342|neuroendocrine cells
P08626539T0000|0 17|Binding specificity
P08626539T0000|36 57|ApoA-I promoter activity
P08626539T0000|67 78|heterodimers
P08626540A1007|35 48|concentrations
P08626540A1007|93 108|glucosylceramide
P08626540A1007|112 127|lactosylceramide
P08626596A0000|48 60|protein kinase
P08626596A0000|113 124|ATP depletion
P08626610A0931|113 124|COOH terminus
P08626667A1372|0 25|EMSA competition experiments
P08626667A1372|125 143|type oligonucleotide
P08626667A1517|0 12|Transcription
P08626667A1517|116 130|motifs functions
P08626667A1517|146 162|GPT gene expression
P08626698A0989|26 37|ERK3 activity
P08626698A0989|44 62|PKC beta transfectant
P08626698A0989|73 91|immunoprecipitation
P08626698A0989|145 162|complex kinase assay
P08626698A0989|169 182|gel kinase assay
P08626777A0537|0 15|Sequence analysis
P08626777A0537|28 41|Col2a1 enhancer
P08626777A0537|57 70|sequence motifs
P08626777A0537|123 137|link protein gene
P08626777A0537|145 157|cartilage gene
P08626785A0674|33 62|tissue transglutaminase promoter
P08626785A0674|156 191|mouse tissue transglutaminase promoters
P08626785A0674|228 254|pair retinoid response element
P08626785A0674|325 348|hexanucleotide half-sites
P08626785A0674|383 394|DR7/DR5 motif
P08626785A0674|409 423|RXR heterodimers
P08626785A0674|427 439|RXR homodimers
P08626809A0729|72 88|eIF-2alpha peptide
P08626809A0729|93 106|characteristic
P08626809A0729|112 133|eIF-2alpha kinase family
P08627354A0000|86 108|neurotransmitter release
P08627649A0734|15 33|mobility shift assays
P08627649A0734|109 128|transcription factors
P08627667A0132|16 33|AP-1 bZip activators
P08627667A0132|96 108|specificities
P08627719A0784|0 25|UV cross-linking experiments
P08627719A0784|42 53|HSV infection
P08627719A0784|77 90|protein factors
P08627719A0784|120 144|cleavage stimulation factor
P08628254A0665|19 33|Jun/eb1 chimeras
P08628254A0665|43 57|transactivators
P08628255A0932|35 52|luciferase activity
P08628255A0932|79 90|DNA synthesis
P08628255A0932|143 155|H2A.1 promoter
P08628260A0895|18 36|transfection studies
P08628260A0895|87 103|promoter sequences
P08628260A0895|164 179|promoter activity
P08628284A0181|14 32|yeast reporter strain
P08628284A0181|74 85|CYC1 promoter
P08628302A0683|11 29|transcription factor
P08628302A0683|34 45|interactions
P08628302A0683|53 65|RNA polymerase
P08628302A0683|68 89|transcription apparatus
P08628681A0364|48 60|Northern blots
P08628681A0364|80 91|X.laevis cDNA
P08628681A0821|0 19|Sequence conservation
P08628681A0821|99 111|DNA polymerase
P08629348A0237|207 219|hydrocephalus
P08630548A0000|83 95|interleukin-1
P08630548A0000|100 124|tumor necrosis factor-alpha
P08630599A0534|14 40|elastin peptide concentration
P08630599A0534|115 127|micrograms/ml
P08630599A0534|153 165|micrograms/ml
P08630599A0534|189 201|micrograms/ml
P08631667A0851|0 13|Identification
P08631667A0851|68 82|complementation
P08631667A0851|86 100|yeast dTMP kinase
P08631667A0851|140 150|enzyme assay
P08631667A0851|167 180|kinase activity
P08631667A0851|183 194|cell extracts
P08631685A0000|51 66|monoamine oxidase
P08631685A0000|83 98|amine oxidase gene
P08631760A0609|66 79|phosphopeptide
P08631760A0609|93 111|Crk-SH2 binding motif
P08631797A0982|32 46|receptor subunit
P08631797A0982|50 72|tyrosine phosphorylation
P08631817T0000|0 13|Identification
P08631817T0000|42 66|kinase phosphorylation site
P08631817T0000|96 138|deoxyuridine triphosphate nucleotidohydrolase
P08631820A0755|56 70|complementation
P08631820A0755|80 90|yeast strain
P08631820A0755|102 112|FPS activity
P08631822A0677|11 26|plasmin fragments
P08631822A0677|58 71|heparin binding
P08631822A0677|94 106|VEGF receptors
P08631822A0677|137 151|cell mitogenesis
P08631908A0224|63 80|mobility shift assay
P08631934A0000|26 45|transcription factors
P08631944A0663|37 51|C epsilon4 domain
P08631944A0663|102 114|J558L cell line
P08631958T0000|5 19|cytomegalovirus
P08631958T0000|35 51|protein IE2 tethers
P08631958T0000|68 83|repression domain
P08632009A1067|24 41|C/EBP family members
P08632009A1067|61 75|characteristics
P08632009A1067|100 117|expression profiles
P08632009A1067|121 140|DNA binding affinities
P08632009A1067|175 197|DNA binding specificities
P08632015A0879|37 49|transcription
P08632015A0879|52 77|DNA polymerase alpha promoter
P08632015A1226|51 65|DREF polypeptide
P08632015A1226|95 107|division cycle
P08632015A1226|129 140|accumulation
P08632015A1226|228 239|DRE sequences
P08632018A0587|1 11|DNA fragment
P08632018A0587|91 101|MC induction
P08632463A1508|93 115|transcription elongation
P08633855A1064|24 56|E. coli-Streptococcus shuttle vector
P08633855A1064|79 100|lacS deletion derivative
P08633855A1064|103 116|S. thermophilus
P08634290A0000|14 25|retroviruses
P08634357A0527|3 20|extraction recovery
P08634357A0527|23 35|Amphotericin B
P08634420A1784|37 50|UT-7 cell growth
P08634420A1784|120 140|UT-7 cell proliferation
P08634423A0498|14 25|integrations
P08634423A0498|35 47|transcription
P08634423A0498|85 96|integrations
P08634423A0498|125 139|differentiation
P08635771A0000|39 56|EMIT II immunoassays
P08635771A0000|61 96|gas chromatographic/mass spectrometric
P08635771A0000|112 134|methaqualone metabolites
P08636031A1413|16 27|Fur repressor
P08636031A1413|62 73|pvdS promoter
P08636031A1413|100 116|Fur titration assay
P08636031A1413|138 162|gel retardation experiments
P08636031A1413|185 198|Fur preparation
P08636124A0410|80 93|phosphoprotein
P08636149A0220|37 47|cell surface
P08636149A0220|96 114|autophosphorylation
P08636428A1363|62 86|smooth muscle proliferation
P08637006A0000|0 12|Transcription
P08637711A1121|29 43|interferon gamma
P08637711A1121|52 66|response element
P08637711A1121|72 84|IRF-1 promoter
P08637711A1121|168 183|binding complexes
P08637717A0817|44 55|p21-activity
P08637717A0817|111 122|cyclin E/Cdk2
P08637717A1231|57 74|filter binding assay
P08637717A1231|110 128|p21-PCNA interaction
P08638435A0522|25 43|agar diffusion method
P08638435A0522|47 62|Y. enterocolitica
P08638435A0522|70 87|inhibition activity
P08638435A0522|102 113|A. hydrophila
P08639310A0548|20 31|mg tid prn days
P08639521A1032|26 40|protein fragment
P08639561T0000|75 89|tetrahydrobenzo
P08639561T0000|155 169|tetrahydrobenzo
P08639561T0000|176 194|deoxyadenosyl adduct
P08639742T0000|65 87|wheat zinc finger proteins
P08640866A0473|20 30|blood T cells
P08641705A0986|14 25|observations
P08641705A0986|34 47|heterozygosity
P08641705A0986|132 157|beta-globin gene duplication
P08641705A0986|196 206|Hb Costa Rica
P08642285A1548|0 16|DNA-STAT complexes
P08642313A0770|71 85|transactivation
P08642313A0770|97 114|reporter gene assays
P08642313T0000|59 72|Notch homologue
P08642313T0000|129 149|factor-kappa B proteins
P08642693T0000|0 20|Polyprotein processing
P08642693T0000|23 38|Southampton virus
P08642693T0000|39 52|identification
P08642693T0000|62 82|protease cleavage sites
P08643111A0855|44 62|region glycosylation
P08643111A0855|72 89|immunoreactivities
P08643111A0855|242 257|oligosaccharides
P08643111A0855|287 300|antigen binding
P08643382A0752|20 33|transit peptide
P08643382A0752|100 117|chloroplast protein
P08643513A0361|0 15|Deletion analysis
P08643513A0361|45 71|acetyltransferase constructs
P08643513A0361|175 199|osteocalcin gene expression
P08643557A0259|26 36|HOX proteins
P08643557A0259|59 69|target genes
P08643578A0000|156 180|mating pathway reporter FUS1
P08643578A0532|11 31|Rho family protein Cdc42
P08643578A0532|110 123|lacZ expression
P08643633A1187|4 20|immunoprecipitate
P08643646A0479|69 80|biosynthesis
P08643682A0268|11 23|localizations
P08643682A0268|51 76|CBFbeta-SMMHC fusion protein
P08643682A0268|93 110|immunofluorescence
P08643682A0268|113 123|NIH 3T3 cells
P08643682A0268|150 162|fusion protein
P08643759A0338|45 64|personality variables
P08644734A0404|71 90|segment-polarity gene
P08645214A1052|68 90|catalase-peroxidase gene
P08645219A1377|86 96|binding site
P08645219A1377|137 150|binding domains
P08647086A0720|3 23|Cdk2-cyclin-D1 complex
P08647086A0720|159 171|Cdk2-cyclin-E
P08647086A0720|175 187|Cdk2-cyclin-A
P08647086T0000|114 126|Cdk7-cyclin-H
P08647264T0000|34 47|lymphoma B cells
P08647264T0000|52 67|calcium ionophore
P08647264T0000|132 157|cysteine protease CPP32/Yama
P08647264T0000|174 186|substrate PARP
P08647451A0663|0 24|Northern blot hybridization
P08647802A0000|17 32|signaling protein
P08647802A0000|89 106|SH3-SH2-SH3 domains
P08647822T0000|30 50|element binding protein
P08647822T0000|100 112|reductase gene
P08647884A0547|106 116|cell surface
P08648665A0956|8 19|LE6 deletions
P08648665A0956|38 61|transformation efficiency
P08648665A1320|0 12|ORF E8 colinear
P08648665A1320|121 133|pZipNeo vector
P08649372A0501|0 15|Clb2/Cdc28 kinase
P08649372A0755|3 17|carboxy terminus
P08649372A0755|64 78|carboxy terminus
P08649373T0000|23 33|cis elements
P08649386A1032|4 24|UASH consensus sequence
P08649386A1032|73 85|consensus Abf1
P08649389A0000|30 43|CTCF cDNA clones
P08649389A0000|186 203|amino acid sequences
P08649389A0692|34 48|CTCF binding site
P08649389A0692|52 86|transient-cotransfection experiments
P08649393A0000|1 30|chromosome transmission fidelity
P08649393A0000|115 134|readthrough phenotype
P08649393A0000|154 173|kinetochore integrity
P08649403A0963|3 14|growth defect
P08649403A0963|94 106|protein kinase
P08649405T0000|21 33|CD11c promoter
P08649405T0000|96 108|transcription
P08649424A0000|15 42|phenylalanine hydroxylase gene
P08649424A0000|102 116|glucocorticoids
P08649425A0373|83 99|B-cell development
P08649425T0000|25 42|chromatin structure
P08649425T0000|48 71|mouse immunoglobulin kappa
P08649427A0689|15 28|identification
P08649427A0689|97 112|GTPase regulators
P08649428A1227|64 83|c-mos oncogene product
P08649440T0000|3 15|heterogeneity
P08649773A1374|90 101|B lymphocytes
P08649773A1374|116 127|cell lymphoma
P08649841A0956|46 59|Kozak sequences
P08649841A0956|100 114|CAT reporter gene
P08649841A0956|143 162|CAT protein production
P08650818A0000|221 237|Mediterranean area
P08651853A0607|93 108|CA1/prosubiculum
P08651853A0607|134 145|dentate gyrus
P08654200A0274|17 32|resonance imaging
P08654200A0274|51 61|liver volume
P08654200A0274|124 138|model substrates
P08654375A0544|122 140|DNA binding POU domain
P08654390A0000|0 12|Heme oxygenase
P08654390A0000|35 48|heme catabolism
P08654390A0000|87 100|carbon monoxide
P08654435A0540|59 72|Erk2 activation
P08654946A0475|45 61|Xenopus laevis FGF3
P08654946A0986|3 25|transcription start point
P08654946A0986|61 75|mouse promoter P3
P08654972A0000|74 93|cell cycle progression
P08654983A0000|14 38|signal recognition particle
P08654983A0000|41 51|SRP receptor
P08654983A0000|63 78|Bacillus subtilis
P08654983A0000|137 160|SRP receptor alpha-subunit
P08655497A0000|102 116|chloramphenicol
P08655555A0772|51 73|transcription start point
P08655555A0772|94 110|% promoter activity
P08655555A0772|156 171|promoter activity
P08655555A1368|3 13|DNA sequence
P08656672A0678|10 30|ufo mRNA overexpression
P08656672A0678|60 76|leukemia cell lines
P08656672A0678|126 152|cervix carcinoma cell line HeLa
P08657135A1444|84 101|E protein homodimers
P08657150A1049|91 109|promoter specificity
P08657157A0000|166 188|octamer sequence elements
P08657183A0145|30 41|DNA fragments
P08657918A0360|19 37|Coronal 3D GRE imaging
P08657918A0360|69 82|dorsal portions
P08659545A0000|27 39|transcript map
P08659545A0000|65 77|understanding
P08659545A0000|83 97|pathophysiology
P08659545A0000|119 130|exon trapping
P08660748X0000|81 98|population patterns
P08660866A0504|43 55|loss phenotype
P08660892A1044|36 51|co-transfections
P08660892A1044|64 82|SRF expression vector
P08660998A0851|3 16|mMIWC1 promoter
P08660998A0851|57 68|AP-2 elements
P08660998A0851|69 83|primer extension
P08660998A0851|92 119|mMIWC transcription initiation
P08660998A0851|161 174|initiation site
P08661007T0000|40 54|anhydrase family
P08661007T0000|73 98|protein domain relationships
P08661100A0285|14 25|distribution
P08661101A0396|0 18|DNA sequence analysis
P08661104A0687|68 80|cells/tissues
P08661114A0564|30 45|sequence homology
P08661116A0963|0 15|Promoter activity
P08661116A0963|88 107|Northern blot analyses
P08661119A0085|22 44|EP4 receptor gene sequence
P08661119A0085|113 128|blood lymphocytes
P08661613A0691|32 49|management measures
P08661613A0691|137 157|enforcement activities
P08662193A0404|13 32|activation subdomains
P08662617A2051|109 124|uterine epithelia
P08662789A0673|38 54|GenBankTM data base
P08662789A0673|57 73|sequence alignment
P08662852A1297|28 51|GRK5 phosphoacceptor sites
P08662852A1297|64 79|carboxyl terminus
P08662852A1297|126 140|phosphorylation
P08662928A1153|65 76|STAT proteins
P08662928T0000|58 76|signaling mechanisms
P08662928T0000|88 100|transcription
P08662928T0000|108 127|IL-6 response elements
P08662936A0428|22 43|FR-19 amino acid sequence
P08662936A0428|86 98|chicken TEF-1A
P08663000A0000|45 58|gene expression
P08663000A0000|79 91|fibrosarcomas
P08663000A0000|113 130|growth factor-beta1
P08663120T0000|23 33|p70 S6 kinase
P08663127A0697|132 149|glycosylation sites
P08663141T0000|45 71|transcription initiation site
P08663141T0000|120 138|angiotensinogen gene
P08663172A0311|27 39|amino terminus
P08663219A0246|16 27|rat PGS-2 gene
P08663219A0246|57 76|protein consensus site
P08663219A0246|98 116|hormone inducibility
P08663219A0246|151 165|CAT reporter gene
P08663219A0246|183 193|E-box region
P08663310A0157|66 78|response genes
P08663310A0157|168 182|differentiation
P08663326A0000|25 37|DmpR activator
P08663326A0000|47 59|transcription
P08664229T0000|23 38|Allergan Humphrey
P08664229T0000|42 54|autorefractor
P08664229T0000|61 85|Nidek AR-1000 autorefractor
P08664347A0923|13 41|proprotein processing proteases
P08664462A1404|80 91|transmission
P08664462A1404|107 125|muscle contractility
P08664462A1404|162 176|plasma clearance
P08665853A0228|65 76|ErbB proteins
P08665853A0228|84 95|combinations
P08666238T0000|9 29|translation initiation
P08666241A0930|44 55|24p3 promoter
P08666241A0930|70 86|Dex responsiveness
P08666383A1252|30 40|cDNA mapping
P08666383A1252|46 57|fluorescence
P08666383A1252|64 76|hybridization
P08666398T0000|6 18|cosmid contigs
P08666398T0000|30 42|Batten disease
P08666398T0000|55 67|16p12.1-p11.2
P08666404A0311|46 61|brain cDNA library
P08666404A0311|71 104|protein serine-threonine phosphatase
P08666404A0311|110 131|tetratricopeptide motif
P08666913A0000|20 40|transmembrane proteins
P08666913A0000|51 61|gene cluster
P08668124A0744|23 34|TDH3 promoter
P08668142A1048|3 14|introduction
P08668158A1252|51 64|precursor Rpm1r
P08668158A1252|116 132|biogenesis defects
P08668190A1364|8 23|membrane vesicles
P08668190A1364|28 38|hum1 mutants
P08668190A1364|49 64|antiport activity
P08668201A1059|50 65|sequence boundary
P08668201A1059|107 117|MATalpha1 IE
P08668203A1230|52 75|differentiation functions
P08668209A0406|6 25|Cold Spring Harbor Symp
P08668210A0000|86 105|protein kinase pathway
P08668210A0000|129 142|transformation
P08669274T0000|10 26|chain ossification
P08669676A1644|135 149|treatment groups
P08670556A0425|33 61|plasma concentration-time curve
P08670556A0425|76 86|infinity AUC
P08670853A0000|0 15|Cluster formation
P08670853A0000|33 43|cell surface
P08670910A0156|0 13|DNA polymerase E
P08670910A0156|51 71|endonuclease co-purify
P08670910A0156|83 100|polypeptide complex
P08672242A0517|7 28|reporter gene constructs
P08673026T0000|3 17|factor structure
P08673026T0000|43 58|replication study
P08675026A0420|52 63|sequence tags
P08675026A0420|88 108|Caenorhabditis elegans
P08675026A0420|109 119|Oryza sativa
P08675395A0751|59 75|acuity outcome data
P08675608T0000|25 38|hypothyroidism
P08675763A0788|0 11|Mean increase
P08675763A0788|14 29|milk protein yield
P08675763A0788|73 86|protein content
P08675769A0158|94 107|conception rate
P08675769A0158|111 121|calving rate
P08675769A0158|228 239|AI technician
P08676266A0838|15 30|protease activity
P08676266A0838|78 89|control group
P08676383A0518|4 15|half molecule
P08676383A0518|28 44|disulfide linkages
P08676383A0518|52 62|cis peptides
P08676456A0879|9 25|VP16-Tat construct
P08676456A0879|39 54|leucine mutations
P08676456A0879|72 89|AP-1 responsiveness
P08676456A0879|115 134|VP16 activation domain
P08676495A0129|74 87|BPV-1 pre-mRNAs
P08676858A0309|17 32|characterization
P08676858A0309|35 46|S-RNase genes
P08676858A0309|76 90|Malus x domestica
P08676858A0309|106 118|Pyrus serotina
P08676858A1084|31 51|T2/S-RNase superfamily
P08677443A0238|3 22|Hoosier Oncology Group
P08677443A0238|64 75|SCLC patients
P08677443A0238|165 177|survival times
P08677443A0238|204 216|survival rates
P08677678A0258|14 27|administration
P08677678A0258|30 55|immunomodulator neurotropin
P08677678A0258|78 90|consolidation
P08677678A0258|115 131|avoidance behavior
P08678959A0640|0 20|Sestamibi scintigraphy
P08678959A0640|62 76|ultrasonography
P08679131T0000|21 38|hypersensitivities
P08680706A0889|20 32|PO2/FlO2 ratio
P08680706A0889|94 111|Recipient Instilled
P08680706A0889|125 137|Control groups
P08680706A0889|171 186|Donor Aerosol dogs
P08682155A0902|3 25|euglobulin clot lysis time
P08682317A0900|0 13|HS inducibility
P08682317A0900|43 65|HS transcription factor-1
P08682868A0738|11 24|DSK2-1 mutation
P08682868A0738|108 122|Cdc31p stability
P08683108A0965|18 31|interpretation
P08683108A0965|60 86|transcription factor proteins
P08683108A1501|50 79|protein kinase A signaling pathway
P08683108A1501|105 121|junB transcription
P08683983A0785|92 104|leukemia cells
P08683983A1163|20 32|participation
P08683983A1163|180 194|differentiation
P08683983A1163|206 222|cell growth control
P08684522A0415|0 27|Immunofluorescence microscopy
P08684742A0000|18 39|pregnancy complications
P08684742A0000|60 72|amniocentesis
P08684742A0000|106 118|amniocentesis
P08686381A0527|96 122|polyadenylate binding protein
P08686381A0527|183 195|transcription
P08686381A0527|206 216|protein Swi3
P08688190A0000|6 22|flavone glucosides
P08688190A0000|23 52|nevadensin 5-O-beta-D-glucoside
P08688190A0000|56 84|nevadensin 5-O-beta-D-glucosyl
P08688190A0000|85 100|beta-D-glucoside
P08688190A0000|137 157|Lysionotus pauciflorus
P08689520T0000|0 17|Reproductive period
P08689520T0000|25 35|water intake
P08690118A0845|11 28|regression analysis
P08690118A0845|34 45|manual method
P08690118A0845|112 124|fertilization
P08690198A0346|70 84|supplementation
P08690198A0346|94 117|Lactobacillus reuteri R2LC
P08690198A0346|121 145|Lactobacillus plantarum DSM
P08690198A0346|164 175|fermentation
P08691106A0733|29 46|nuclease protection
P08692885A0663|22 40|NF-kappaB activation
P08692885A0663|65 80|zinc finger domain
P08692892A0330|44 60|receptor signaling
P08692892A0330|92 103|maximum level
P08692892A0330|142 153|alpha-factor
P08692924A0328|8 18|DNA sequence
P08692924A0328|147 157|B-cell lines
P08698756A1240|33 45|pre-treatment
P08698756A1240|50 60|coenzyme Q10
P08700531A1420|7 17|chromosome X
P08700531A1420|79 90|hamster cells
P08700531A1420|104 122|chemical carcinogens
P08700531A1420|145 156|localization
P08700531A1420|210 220|cph oncogene
P08700531A1420|278 295|hamster fibroblasts
P08702517A0000|73 90|progenitor cell line
P08702543A0000|78 110|inositol 1,3,4,5-tetrakisphosphate
P08702543A0000|113 126|binding protein
P08702556A0000|24 35|purification
P08702556A0000|58 72|acid phosphatase
P08702556A0000|83 104|porcine thymus membranes
P08702633A0164|57 79|tyrosine phosphorylation
P08702633A0164|85 101|Shc adapter protein
P08702633A0164|104 123|Grb2 complex formation
P08702633A0164|140 181|Ras guanine nucleotide exchange factor activity
P08702644A0499|141 184|glycosylphosphatidylinositol anchor attachment
P08702756A0000|67 87|actin-myosin filaments
P08702756A0000|105 116|cell motility
P08702756A0000|126 142|muscle contraction
P08702807A0964|26 41|signaling pathway
P08702807A0964|108 131|cyclin D1 promoter activity
P08702807A0964|135 159|cyclin D1 protein expression
P08702826A0870|33 52|GSTP1 silencer element
P08702845A0000|86 104|dopamine transporter
P08702845A0000|119 140|dopamine uptake kinetics
P08702845A0000|145 169|CFT binding characteristics
P08702845A0000|223 234|COOH terminus
P08702936A0168|2 18|expression library
P08702936A0168|189 206|virus shuttle vector
P08702936A0984|46 55|T cell lines
P08702936A0984|94 105|granulocytes
P08703005A0645|32 47|promoter activity
P08703005A0645|70 92|transcription factors Sp1
P08703010A0905|65 84|GAP-43 promoter region
P08703959A0659|28 43|proton resonances
P08703959A0659|138 149|sugar protons
P08703959A0659|182 193|adduct duplex
P08704124A0420|65 93|Vigna radiata lambda gt11 library
P08704240A1111|47 65|CREB phosphorylation
P08704240A1111|91 108|PIXY321 stimulation
P08705056T0000|0 16|Workplace violence
P08706368A1024|10 28|LV maximum brightness
P08706368A1024|74 85|correlations
P08706662A1125|35 52|perforin expression
P08706662A1125|148 158|factor NF-P2
P08706731A1303|37 48|similarities
P08706731A1303|64 81|expression patterns
P08706731A1303|97 113|ribonuclease genes
P08706731A1303|145 162|sequence similarity
P08706731A1303|168 186|ginseng ribonuclease
P08706731A1303|210 229|ribonuclease function
P08706731A1303|233 245|PR-10 proteins
P08707424A0709|15 25|ERV3 env mRNA
P08707516A0194|76 91|handicap services
P08707825A0063|31 41|muscle cells
P08707825A0063|44 59|Northern blotting
P08707825A0063|155 171|muscle cDNA library
P08707825A0063|200 210|antibody R4A
P08707840A0753|15 32|electron microscopy
P08707840A0753|92 102|pore complex
P08707846A2308|83 96|ubiquitination
P08707846A2308|111 132|receptor ubiquitination
P08707846A2308|181 196|a-factor receptor
P08707922A0334|0 27|Transcription initiation sites
P08707922A0334|52 68|O beta-globin genes
P08707922A0334|113 138|translation initiation codon
P08707922A0334|154 176|primer extension analysis
P08708984T0000|27 38|indomethacin
P08709224T0000|64 77|SNF-SWI complex
P08709245A1521|43 57|phosphorylation
P08709245A1521|94 118|trans-suppression activity
P08709245A1521|163 174|HDAg particle
P08709251A0000|10 22|recombination
P08709251A0000|33 53|Autographa californica
P08709251A0000|61 77|polyhedrosis virus
P08709251A0000|105 115|DNA fragment
P08709251A0000|138 152|DNA helicase gene
P08709251A0000|172 188|polyhedrosis virus
P08709251A0000|228 238|AcNPV mutant
P08709637A1471|29 44|IL-7R alpha chains
P08709637A1471|136 150|precursor B cells
P08710371A0000|51 64|polyomavirus BK
P08710371A0000|174 191|p53 transactivation
P08710371A0499|49 69|consensus binding sites
P08710371A0499|79 96|base pair mismatches
P08710371A0499|110 125|base pair deletion
P08710377A0577|122 135|BCR stimulation
P08711631A0989|38 53|cyclophosphamide
P08713933A0606|0 19|Laboratory evaluation
P08713933A0606|32 43|neuroimaging
P08716757T0001|0 22|Microcomputer management
P08716757T0001|32 46|hepatitis B virus
P08717391A0466|126 141|particle assembly
P08717391A0466|163 174|antigenicity
P08717391A0466|178 191|immunogenicity
P08719155A0105|62 73|P. falciparum
P08719155A0105|109 120|similarities
P08719155A0105|136 150|surface molecule
P08719155A0105|241 256|circumsporozoite
P08719156A0953|55 66|reading frame
P08719832A0397|25 41|rhinotomy approach
P08720407A1386|52 65|disc herniation
P08720407A1386|93 110|interleukin-1 alpha
P08720407A1386|136 160|prostaglandin E2 production
P08721989A1012|58 74|cytokine receptors
P08721989A1012|91 107|signaling pathways
P08721989A1012|138 154|IL-2R beta function
P08721989A1012|166 181|signal transducer
P08721999A0727|25 41|complementarities
P08722011A0103|25 36|GTPase domain
P08722011A0103|47 57|subunit rRNA
P08722011A0103|72 82|binding site
P08722568A1001|0 18|Chromatin repression
P08722568A1001|26 41|replacement genes
P08722568A1001|101 125|replacement H3 histone genes
P08723352A0084|105 138|retinoblastoma tumour suppressor gene
P08723365T0000|8 19|relationship
P08723365T0000|27 42|hyperinsulinemia
P08723365T0000|69 83|nephrosclerosis
P08723883A0823|0 18|Blood GSH-Px activity
P08723883A0823|35 51|spectrophotometer
P08723883A0823|58 69|modification
P08723883A1684|3 16|concentrations
P08723883A1684|19 36|vitamin A precursors
P08726024A0532|105 116|fluid samples
P08726247A0175|20 39|concentration changes
P08726247A0175|44 55|measurements
P08727192A0000|0 10|STUDY DESIGN
P08728040T0000|74 97|Janus kinase-Stat pathways
P08728040T0000|100 110|oncostatin M
P08728040T0000|119 140|fibroblast growth factor
P08728040T0000|162 173|sarcoma cells
P08730470A0000|30 44|hepatitis C virus
P08730470A0000|97 108|transmission
P08730470A0000|150 165|household contact
P08731155A0499|13 26|reconstruction
P08731222A0000|3 14|distribution
P08731222A0000|18 29|organization
P08731222A0000|77 105|subnucleus reticularis dorsalis
P08731222A0000|127 140|Cuneate nucleus
P08731222A0000|172 186|microinjections
P08731222A0000|189 220|Phaseolus vulgaris leucoagglutinin
P08731511A0625|29 40|antithrombin
P08731511A0625|52 66|heparin cofactor
P08732665A0000|0 12|Amplification
P08732665A0000|16 29|overexpression
P08732665A0000|35 46|c-erbB-2 gene
P08732665A0000|69 88|breast carcinoma cells
P08732665A0000|216 227|growth factor
P08732665A0000|255 266|growth factor
P08732665A0000|270 281|independence
P08733123A0951|20 33|FRG1 transcript
P08733123A0951|102 118|amino acid residues
P08733874A0000|24 36|thyroidectomy
P08733874A0000|40 55|thyroid carcinoma
P08733874A0000|102 115|hypothyroidism
P08733874A0000|141 152|body scanning
P08733881A0343|4 25|thyroid function testing
P08738510A0254|11 25|tumor FDG-uptake
P08739260T0000|24 41|amphetamine effects
P08740416A0239|122 135|signal sequence
P08740416A0919|3 15|SEB1 homologue
P08741206A1551|89 100|vasodilation
P08742135A0000|24 34|hormone ACTH
P08742135A0000|121 134|corticosterone
P08745669A0000|181 197|methyl prednisolon
P08746605A0377|22 34|ACE inhibitors
P08746605A0377|90 101|pancreatitis
P08746981A0154|49 66|mg probiotic/kg food
P08747343A0790|0 11|Protein films
P08748033A0874|57 78|LamB-LacZ hybrid protein
P08749393A0783|3 14|PI3K_68D cDNA
P08749393A0783|76 90|p110 PI 3-kinases
P08749393A0783|93 110|p85 adaptor proteins
P08749394A0874|7 24|interaction studies
P08749394A0874|45 69|glutathione-S-transferase
P08749394A0874|112 123|RAM23 regions
P08749394A0874|126 136|mouse Notch1
P08749394A0874|140 154|Drosophila Notch
P08750173A0000|0 11|AIMS/METHODS
P08750173A0000|31 44|system function
P08750173A0000|108 118|liver injury
P08750173A0000|128 142|D-galactosamine
P08750173A0000|174 193|% liver resection model
P08750190A0000|134 144|CD44 variant
P08750702A0183|0 10|Study groups
P08750702A0183|71 84|blockers WB4101
P08750702A0183|99 118|chloroethylclonidine
P08751635A0135|47 69|hippocampus subfields CA1
P08752714A0000|71 82|malignancies
P08754777A1214|17 29|T3R homodimers
P08754777A1214|37 55|T3R-RXR heterodimers
P08754777A1214|95 112|heterodimer binding
P08754802T0000|63 81|acid oxidation enzyme
P08754802T0000|138 154|adipose expression
P08754834A1097|37 52|response elements
P08754834A1097|71 87|transcription unit
P08754840A0793|8 29|glucan synthase activity
P08754840A0793|81 95|deltabem4 mutant
P08754852A0960|2 21|gel retardation assays
P08754852A0960|111 122|chondrocytes
P08755898A0339|39 55|Bs2 host resistance
P08756332A0000|12 23|Ras subfamily
P08756332A0000|103 119|effector molecules
P08756332A0000|129 146|protein kinase c-Raf
P08756332A0000|165 195|guanine nucleotide exchange factor
P08756433A0282|7 22|characterization
P08756433A0282|28 41|promoter region
P08756556A0406|61 78|acid signal sequence
P08756609A0498|10 26|amino acid sequence
P08756609A0498|86 98|invertebrates
P08756636T0000|26 42|yeast Rad51 protein
P08756636T0000|51 63|relationships
P08756636T0000|71 82|Srs2 helicase
P08756642A0230|55 68|myelodysplasia
P08757943A0876|50 72|thymidine kinase promoter
P08757943A0876|89 100|inducibility
P08759870A1128|14 33|fbpA operator sequence
P08759870A1128|52 71|footprinting analysis
P08759870A1128|99 116|Fur repressor dimers
P08760286A0696|41 72|guanine nucleotide exchange factors
P08760286A0696|121 134|identification
P08760286A0696|264 283|Vav signaling pathways
P08760776A1559|40 60|fluticasone propionate
P08760776A1559|121 132|theophylline
P08760872A0696|128 138|CHR elements
P08760889A0531|22 39|amino acid sequences
P08760889A0531|44 59|protein sequences
P08761480A0331|49 60|splice region
P08761480A0331|74 84|PDE4A splice
P08761480A0331|227 238|splice region
P08761480A0331|326 338|fusion protein
P08761480A0331|362 373|splice region
P08762172A0178|5 21|strain differences
P08762472A0000|11 35|ligustrazine hydrochloride
P08762472A0000|60 77|artery hypertension
P08763207A0402|7 19|oxidation peak
P08763207A0402|101 112|accumulation
P08763311A0189|0 12|Phenylephrine
P08763311A0189|20 47|alpha-1 adrenoreceptor agonist
P08763311A0189|76 91|vasoconstriction
P08763311A0189|105 116|hypertension
P08763925A0588|81 91|Western blot
P08764136A0000|81 94|transformation
P08764136A0000|150 162|hybridization
P08764136A0000|176 187|MEC strain 76N
P08766049A0000|33 50|corneal perforation
P08768374A0765|10 26|P-rr cDNA sequences
P08768377A1387|10 20|hcf109 locus
P08768377A1387|45 56|centimorgans
P08768377A1387|64 79|phytochrome C gene
P08768377A1387|92 107|characterization
P08769132A0000|8 23|MSH-2 gene product
P08769132A0000|101 114|mismatch repair
P08769132A0000|216 228|MSH-2 proteins
P08769132A0000|279 292|base mismatches
P08769132A0000|432 451|tumor suppressor genes
P08769132A0000|466 479|chromosome 2p16
P08769409A0114|70 81|mouse embryos
P08769409A0114|135 147|reading frames
P08769566A0000|33 51|transcription factor
P08769566A0000|69 89|zinc finger homeodomain
P08769566A0000|134 150|zinc finger domains
P08770021T0000|9 23|PTHRP production
P08770021T0000|27 48|tyrosine kinase oncogene
P08770021T0000|65 83|Ras signaling pathway
P08770920A1220|13 24|coexpression
P08770920A1220|169 183|transactivation
P08770920A1220|204 224|TAAT-1 element reporter
P08770981A0328|22 40|von Willebrand factor
P08770981A0328|44 56|fragmentation
P08770981A0328|122 139|weight vWF multimers
P08771781A0103|81 92|reading frame
P08771781A0103|100 112|Brassica napus
P08771781A0103|208 222|leaf cDNA library
P08771781A1103|3 18|ORFII gene product
P08771781A1103|101 112|PMSR activity
P08771787T0000|0 15|Characterization
P08771787T0000|54 65|tomato plants
P08771787T0000|87 98|pathogenesis
P08774732A0271|51 70|gel retardation assays
P08775674A0000|49 63|characteristics
P08775674A0000|100 115|hydatidiform mole
P08776735A0000|53 72|type rat LH/CG receptor
P08776735A0000|242 255|responsiveness
P08776748T0000|6 19|P300 amplitudes
P08776748T0000|30 42|schizophrenia
P08776901A0000|0 17|Chloroplast mutator
P08777374A1471|6 19|concentrations
P08777374A1471|55 68|concentrations
P08777374A1471|135 148|concentrations
P08778265A0422|19 29|test battery
P08778265A0422|53 65|Wisconsin card
P08778265A0422|77 96|Street completion test
P08778265A0422|145 159|recognition test
P08780339A0142|13 24|single-blind
P08780339A0142|28 44|Latin-square study
P08780339A0142|66 81|carryover effects
P08781119A0723|23 40|mouse Met-ase-1 gene
P08781119A0723|107 122|rat Met-ase-1 gene
P08781144A1520|59 71|tumour hypoxia
P08783180A0000|91 111|Carollia perspicillata
P08783666A0957|58 70|amifostine arm
P08784787A0383|11 26|thrombin receptor
P08784787A0383|87 100|ligand sequence
P08784787A0383|114 129|receptor cleavage
P08787110A0981|27 39|investigation
P08787110A0981|120 133|investigations
P08787110A0981|153 170|function laboratory
P08789441A0339|5 16|fluorescence
P08789441A0339|23 35|hybridization
P08789441A0339|102 112|sex reversal
P08789441A0339|147 159|translocation
P08789441A0339|175 187|cosmid markers
P08790288A0068|49 64|Spinacia oleracea
P08790288A0068|74 89|Hordeum vulgare cv
P08790291A1022|61 78|DNA damage tolerance
P08790387A0299|5 16|rat rnu allele
P08790387A0299|31 46|nonsense mutation
P08792217A1407|41 55|TIMP-2 mRNA level
P08792217A1407|84 96|up-regulation
P08792217A1407|202 216|TIMP-2 mRNA level
P08794254A2957|11 21|PTA category
P08794339A1162|171 185|adaptor proteins
P08794339A1162|189 200|CREB function
P08794348A1067|11 30|complementation assay
P08794348A1067|130 140|NIa proteins
P08794363A0259|67 83|jun-fos gene family
P08794547A0648|34 55|laser-doppler fluxmetry
P08794601A0000|32 45|clarithromycin
P08794601A0000|49 65|bismuth subcitrate
P08794601A0000|78 93|ulcer healing rate
P08794601A0000|103 125|H. pylori eradication rate
P08794869A0274|72 93|integrin gene expression
P08795304T0000|0 19|Plasma thrombomodulin
P08795304T0000|43 55|complications
P08795304T0000|58 73|diabetes mellitus
P08798420A0207|3 18|characterization
P08798420A0207|24 37|promoter region
P08798420A0207|99 113|AP-1 binding site
P08798420A0207|120 137|PRDII/kappaB domain
P08798443A0660|52 63|substitution
P08798443A0660|218 233|herpes tk promoter
P08798443A1218|16 40|multimerization activities
P08798443A1218|73 89|S528A substitution
P08798443A1218|104 118|phosphorylation
P08798443A1218|154 189|transcription transactivating activity
P08798443A1218|209 220|interactions
P08798610A0843|24 57|phosphatidylcholine carrier vesicles
P08798610A0843|226 239|Dbl oncoprotein
P08798635A0870|102 115|myristoylation
P08798643T0000|50 67|transforming region
P08798648A1816|63 76|enzyme activity
P08798700A0134|3 15|transcription
P08798700A0134|69 82|heme deficiency
P08798700A0134|169 186|activation sequence
P08798762A1279|60 70|Cut proteins
P08798893A0611|107 123|CCCD heterogeneity
P08801403T0001|28 43|presentation form
P08804012A0662|77 90|home management
P08804389A0893|0 19|Northern blot analysis
P08804389A0893|59 81|Xanthomonas campestris pv
P08805338A1061|53 78|OG glycosylase/lyase protein
P08805824A1155|54 80|exit wavefront reconstruction
P08805824A1155|189 203|lens aberrations
P08806693A0584|37 50|GATA-1 promoter
P08806693A0584|138 163|luciferase expression vector
P08806693A0584|188 203|mouse fibroblasts
P08806817A0244|0 15|Sequence analysis
P08806817A0244|56 71|DNA binding domain
P08806817A0244|78 91|orphan receptor
P08806817A0244|118 128|TR2 receptor
P08806817A0716|7 22|DNA hybridization
P08806817A0716|64 81|S. purpuratus genome
P08807245A0843|5 23|retrospective review
P08807288T0000|12 25|identification
P08807288T0000|57 70|ADH2 expression
P08807408A0524|105 118|AV modification
P08807408A0524|130 154|radiofrequency application
P08808120A0774|34 49|aluminum overload
P08808120A0774|50 64|serum iron levels
P08808120A0774|68 79|micrograms/L
P08808120A0774|90 101|micrograms/L
P08808120A0774|141 165|iron transferrin saturation
P08808120A0774|169 187|serum ferritin levels
P08808120A0774|241 256|aluminum overload
P08808120A0774|257 275|serum aluminum levels
P08808120A0774|279 290|micrograms/L
P08808120A0774|301 312|micrograms/L
P08808275A1193|11 26|RAD23 equivalents
P08808275A1193|119 134|yeast counterpart
P08808707A0631|92 104|protein kinase
P08808707A0631|177 190|gene expression
P08808756A0587|0 15|Sequence analysis
P08808756A0587|191 202|accumulation
P08808924A0326|3 19|hydropathy profile
P08808924A0326|66 78|amino terminus
P08808927A0417|52 62|M. bovis PG45
P08808939A0000|0 25|Carbon catabolite repression
P08808939A0000|42 57|Bacillus subtilis
P08808939A0000|73 100|catabolite control protein CcpA
P08808939A0000|110 130|phosphocarrier protein
P08808939A0000|136 159|phosphotransferase system
P08810040A0955|52 68|target locus marker
P08810278A0682|68 81|CRKL-SH2 domain
P08810278A0682|173 198|BCR/ABL expressing cell lines
P08810278A0682|229 239|ALL patients
P08810323A0735|12 30|polyglutamine motifs
P08812012T0000|45 57|Stroop effects
P08812106T0000|32 42|crescent RNA
P08812490A0000|28 42|gene symbol AQP2L
P08812490A0000|91 107|kidney cDNA library
P08812490A0542|0 23|PCR/Southern blot analysis
P08812490A1509|7 22|sequence homology
P08812490A1509|98 117|MIP family gene cluster
P08812490A1509|120 139|chromosome locus 12q13
P08813766A0605|96 112|consensus sequence
P08813766A0605|116 135|C2H2 zinc finger domain
P08813900A1088|53 66|mineralization
P08813900A1088|129 139|P deficiency
P08814651A0000|56 77|ethanol withdrawal signs
P08814651A0000|104 114|rating scale
P08816052A0238|97 145|Kaufman Short Neuropsychological Assessment Procedure
P08816438A0316|22 37|plasmid loss rates
P08816438A0316|40 54|cdc28-1N strains
P08816438A0316|83 100|replication origins
P08816438A0316|132 145|DNA replication
P08816438A0316|164 183|plasmid loss phenotype
P08816443A1674|49 62|reorganization
P08816443A1674|68 79|cytoskeleton
P08816443A1674|153 164|kinase domain
P08816443A1674|201 212|stress fibers
P08816443A1674|221 237|adhesion complexes
P08816452A0936|31 48|tissue distribution
P08816453A0000|71 81|Raf-1 kinase
P08816459A0090|2 18|interaction screen
P08816459A0090|26 41|repression domain
P08816459A0090|47 66|orphan receptor RevErb
P08816459A0090|99 120|thyroid hormone receptor
P08816459A0090|134 145|acid receptor
P08816460A1769|36 54|Jun kinase activation
P08816460A1769|77 93|Ras transformation
P08816461A0892|89 100|mRNA turnover
P08816461A0892|104 122|nonsense suppression
P08816472T0000|0 13|Identification
P08816472T0000|58 72|response pathway
P08816498A0000|3 29|serine/threonine kinase Raf-1
P08816498A0000|58 82|signal transduction cascade
P08816498A0000|120 133|plasma membrane
P08816504T0000|50 77|phosphatidylinositol 3-kinase
P08816504T0000|91 105|receptor binding
P08816504T0000|151 161|Ras activity
P08816507A1125|11 28|cotransfections E1A
P08816507A1125|56 66|p53 promoter
P08816759A0000|3 23|retinoid Z receptor beta
P08816759A0000|33 46|orphan receptor
P08816759A0000|69 80|acid receptor
P08816759A0000|83 104|thyroid hormone receptor
P08816792A0000|13 25|protein kinase
P08817323A0714|14 29|sequence identity
P08817323A0714|57 68|DXS6673E gene
P08817323A0714|84 95|sequence tags
P08817323A0714|122 133|DXS6673E gene
P08817324A1070|21 46|Xq28 duplication breakpoints
P08817324A1070|100 121|CAGGG pentamer sequences
P08817324A1070|133 150|paralogy boundaries
P08820324A1699|33 44|TOF responses
P08820642A0173|60 88|Hrp secretion pathway components
P08820642A0173|139 150|cosmid pHIR11
P08820648A0123|33 55|ribonucleotide reductase
P08822399A0518|47 60|susceptibility
P08823163T0000|29 52|diphtheria toxin repressor
P08823163T0000|149 162|co-corepressor
P08823187A1020|22 36|porcine proteins
P08823187A1020|81 99|membrane dipeptidase
P08823187A1020|134 147|disulfide bonds
P08823646A1012|0 13|Administration
P08823646A1012|42 55|overestimation
P08823646A1012|74 85|measurements
P08823709A0220|18 29|modification
P08823709A0220|33 57|triglyceride lowering drugs
P08824585A0260|18 30|protein kinase
P08824585A0260|50 65|progenitor kinase
P08824585A0260|133 147|progenitor cells
P08824798A0761|5 20|ESP1/CRP2 protein
P08824800A0808|42 66|agarose gel electrophoresis
P08824805A0832|12 25|exon boundaries
P08824881A0133|0 13|Linkage studies
P08824881A0133|23 40|locus heterogeneity
P08824881A0133|63 76|chromosome 9q34
P08824884A0000|115 125|X chromosome
P08825087A0213|0 18|DNA sequence analysis
P08825087A0213|26 45|bp BamHI-ClaI fragment
P08825087A0213|67 79|reading frames
P08825178A0071|10 28|inpatient experience
P08825178A0071|92 104|participation
P08825554A0000|0 14|Tristetraprolin
P08825554A0000|51 70|transcription factors
P08825554A0000|98 112|CCCH zinc fingers
P08825636T0000|78 88|p50 proteins
P08825636T0000|91 119|transcription factors NF-kappa B
P08825636T0000|123 135|I kappa B-gamma
P08825636T0000|136 147|implications
P08825636T0000|169 186|signal transduction
P08825639A0827|10 25|Alu repeat element
P08828142A0000|6 20|leukemia viruses
P08828142A0000|55 70|oncoretroviruses
P08828142A0000|129 140|environments
P08828152A1238|15 32|amino acid sequences
P08828152A1238|38 53|RPO1 polypeptides
P08828152A1238|150 168|amino acid similarity
P08828152A1238|184 196|relationships
P08828857A2423|136 149|gene expression
P08829393A0083|11 26|dipole estimation
P08829393A0083|38 50|SEP components
P08831364A1252|84 97|conduction time
P08832146A0959|37 59|bone alkaline phosphatase
P08833153A0628|26 43|hCHLR gene sequences
P08833153A0628|235 248|repeat sequence
P08833653A0304|17 45|LIM domain homeobox protein isl-1
P08833653A0304|58 74|rat amylin promoter
P08833653A0304|94 107|islet cell lines
P08833653A0783|37 62|amylin gene promoter elements
P08833653A0783|212 223|G9 islet cells
P08835393A2829|43 66|signal transduction events
P08835393A2829|71 89|calcium mobilization
P08835393A2829|93 116|promoter response elements
P08835895A1292|49 64|immunodeficiency
P08835969A0000|169 179|serum assays
P08835969A0000|185 195|beta subunit
P08835969A0000|212 223|gonadotropin
P08836032T0000|0 14|Bifunctionality
P08836032T0000|36 49|region sequence
P08836032T0000|64 75|ori functions
P08836032T0000|89 108|sequence requirements
P08836172A1382|38 52|over-expression
P08836172A1382|108 119|p21Cip1/Waf1
P08836172A1382|123 135|myogenin mRNAs
P08836172A1382|141 155|serum withdrawal
P08836740A1025|52 65|deletion mutant
P08837503A0392|8 19|repeat motifs
P08837503A0392|137 148|repeat motifs
P08837503A0392|170 183|dicot extensins
P08837746A0951|26 38|BrAAP activity
P08837746A0951|68 88|postglutamate cleavage
P08838144A0107|22 33|significance
P08838144A0107|66 83|signal transduction
P08838144A0107|84 98|deletion mutants
P08838144A0107|101 120|S1 or/and S2 subdomains
P08838148A1218|40 55|mouse TRH receptor
P08838148A1218|72 83|transfection
P08838148A1218|115 130|L channel activity
P08838314A0129|77 91|characteristics
P08838314A0129|92 107|tissue expression
P08838314A0129|119 130|localization
P08838585A0968|38 54|backbone deviation
P08838805T0000|7 18|organization
P08838805T0000|29 44|beta-catenin gene
P08839498A0507|30 41|distribution
P08839498A0507|133 144|distribution
P08839832A0729|16 27|CD30v protein
P08839832A1220|12 26|phosphorylation
P08839832A1220|32 43|CD30v protein
P08842143A0000|0 12|Plasmid pAL618
P08842143A0000|31 42|determinants
P08843411A0801|85 96|dimerization
P08843412A0543|27 44|40-amino acid region
P08843412A0543|71 86|chicken ovalbumin
P08843412A0543|95 121|promoter transcription factor
P08843419A1290|45 56|interactions
P08843419A1290|95 106|interactions
P08844448A0000|47 60|crossover study
P08844448A0000|162 176|lipase inhibitor
P08844448A0000|230 242|weight control
P08844712A0000|121 136|alpha-chloralose
P08845378A0368|0 23|Restriction enzyme mapping
P08845378A0368|27 42|Southern analysis
P08846775A0110|21 37|Swi6 cell viability
P08847138A0609|3 16|detection ratio
P08847723A2351|0 11|IMPLICATIONS
P08847723A2351|46 58|inconsistency
P08847723A2351|132 143|associations
P08847723A2351|144 155|replications
P08848013A1469|58 73|promoter activity
P08848052A0733|35 50|RNA-export factor
P08849569A0615|20 36|assay coefficients
P08849778A0226|15 33|toeprinting analyses
P08849778A0598|26 41|initiator protein
P08849778A0598|63 75|leader peptide
P08849834A0000|28 41|volume flow rate
P08849834A0000|85 114|colour Doppler ultrasound imaging
P08850585A0602|3 18|enzyme activities
P08850585A0602|51 65|pathophysiology
P08850585A0602|103 118|virulence factors
P08851337A1092|0 12|Tonsillectomy
P08851337A1092|82 95|angina patients
P08851434A0383|13 35|fat/water intensity ratio
P08853303A0431|97 114|bolus MMC injections
P08853303A0431|149 159|MMC infusion
P08853893A0158|35 46|E2F complexes
P08854844A0637|21 37|non-visualization
P08854844A0637|48 61|h post injection
P08856077T0000|26 56|tryptophanyl-tRNA synthetase mRNA
P08856132T0000|45 56|kinin release
P08858211A0694|4 14|GAP activity
P08858211A0694|28 49|3T3-L1 adipocyte lysates
P08858463A0853|16 27|AIDS patients
P08858463A0853|32 45|cryptococcosis
P08858463A0853|181 194|nephrotoxicity
P08861955A0927|43 56|amino-terminus
P08861955A0927|73 97|guanine nucleotide exchange
P08861955A0927|128 138|Rab proteins
P08861955A0927|157 174|GTP binding proteins
P08861963A0375b|16 29|RNA polymerases
P08861963A0375b|43 61|mutant alpha subunits
P08861963A0375b|92 114|transcription activation
P08861963A0375b|131 145|rrnBP1 UP element
P08861963T0000|0 36|Transcription factor recognition surface
P08861963T0000|42 66|RNA polymerase alpha subunit
P08861963T0000|93 110|DNA enhancer element
P08862743A0603|11 23|erythrocyte Mn
P08863824A0509|10 25|sequence analyses
P08863824A0509|129 147|transmembrane domain
P08864061A0000|12 30|thymidine kinase gene
P08864219A0178|20 33|concentrations
P08864219A0178|40 51|ketoconazole
P08864219A0178|62 73|itraconazole
P08864219A0178|88 100|amphotericin B
P08864219A0178|133 144|inoculum size
P08866485A0125|23 36|export proteins
P08866485A0125|54 65|interactions
P08867519A0557|72 85|administration
P08868660A0087|15 26|contribution
P08868660A0087|62 72|Rivista dell
P08868660A0087|177 197|hypothesis formulation
P08868954A0648|97 114|calcium antagonists
P08868954A0648|142 157|enzyme inhibitors
P08868954A0648|170 181|hemodynamics
P08869763A0378|130 145|receptor subtypes
P08869825A0000|51 64|monooxygenases
P08870266A0651|18 29|observations
P08870266A0651|83 95|NodO secretion
P08870266A0651|148 166|secretion efficiency
P08871542A1352|132 150|Thbs3 gene expression
P08871567A0000|0 11|MSSP proteins
P08871635A0000|0 19|B cell antigen receptor
P08871635A0000|43 67|WEHI-231 B lymphoma cell line
P08872162A0884|63 74|T cell subsets
P08872671A0573|24 45|blood flow shunt fraction
P08872671A0573|88 109|amplitude perturbations
P08873063A0493|10 26|amino acid sequence
P08873063A0875|0 12|ECM disruption
P08873063A0875|15 31|Lytechinus embryos
P08873063A0875|53 76|USF RNA accumulation levels
P08873063A0875|96 109|control embryos
P08873063A0875|115 139|LpS1 RNA accumulation levels
P08873159A0791|51 62|chemotherapy
P08874399A0277|17 28|intervention
P08874399A0277|93 105|concentration
P08874631A1133|0 13|Discrimination
P08876167A0717|176 189|p107 antibodies
P08876701A0177|25 36|UmuC-homolog
P08877103A0081|22 35|mdr2 expression
P08877818A0184|3 15|amplification
P08877818A0184|59 79|TRH progenitor sequence
P08877818A0184|80 94|Lys/Arg-Arg-Gln
P08877818A0184|94 108|His-Pro-Gly-Lys
P08878037A0000|22 49|catabolite control protein CcpA
P08878044A1390|2 19|InlC deletion mutant
P08878045A0606|7 18|N-Nus complex
P08878045A0606|62 73|alpha subunit
P08878045A0606|76 88|RNA polymerase
P08878045A0606|145 157|transcription
P08878573A1370|0 13|Administration
P08878573A1370|85 96|prolongation
P08879080A0265|68 79|path analysis
P08879237A0744|10 24|initiation sites
P08879237A0744|62 83|consensus promoter motif
P08879237A0744|125 141|rice mitochondrion
P08881542T0000|0 34|Sodium polystyrene sulfonate treatment
P08881542T0000|38 52|lithium toxicity
P08881542T0000|62 89|serum potassium concentrations
P08882492A0000|12 30|homeodomain proteins
P08882710A0000|47 65|transcription factor
P08882710A0000|97 112|interferon-alpha
P08884273A1413|3 17|TYAC/P1 resource
P08884273A1413|35 47|polymorphisms
P08884273A1413|94 110|telomere structure
P08884273A1413|152 165|map integration
P08884757A0653|99 117|Assessment Geriatric
P08884757A0653|185 225|Beurteilungsskala fur geriatrische Patienten
P08884757A0653|264 278|Performance Test
P08884757A0653|279 294|Syndrom-Kurztest
P08886845A1274|28 43|myogenin promoter
P08886845A1274|100 117|expression activity
P08887643A1167|74 95|TC21 controls cell growth
P08887643A1167|132 148|signaling pathways
P08887647T0000|0 15|Fission yeast mal2
P08887647T0000|29 49|chromosome segregation
P08887652A0341|43 53|DNA fragment
P08887652A0341|140 151|reading frame
P08887652A0341|180 208|hygromycin B phosphotransferase
P08887661A1061|10 23|cotransfection
P08887661A1061|43 53|NIH 3T3 cells
P08887661A1061|91 108|promoter activation
P08887667A0992|16 38|Tyr-19 dephosphorylation
P08887667A0992|42 56|spindle assembly
P08887667A0992|93 108|spindle formation
P08887667A0992|161 175|Cdc28/Clb kinase
P08887667A0992|178 190|SPB separation
P08887674A0630|14 37|DMP1 recognition sequences
P08887674A0630|49 68|GGA trinucleotide core
P08887678A0000|55 67|GAL10 promoter
P08891131A0000|0 25|Enterococcus faecium strains
P08891131A0000|43 64|glycopeptide resistance
P08891131A0000|79 95|enrichment culture
P08891337A0614|53 66|weight proteins
P08891337A0614|96 114|coactivator function
P08891337A0614|137 155|cAMP response element
P08891337A0614|158 171|binding protein
P08891341A0724|9 26|transfection assays
P08891341A0724|32 53|reporter gene constructs
P08891341A0724|180 191|reporter gene
P08891345A0684|13 29|UTR characteristic
P08891345A0684|147 161|beta-globin mRNA
P08891346A1217|38 54|isoform expression
P08891346A1217|55 65|NIH3T3 cells
P08891346A1217|96 111|expression vector
P08891474A0667|69 91|depolarization threshold
P08891474A0667|121 131|nerve fibers
P08891474A0667|153 166|depolarization
P08892755A0186|29 44|sequence homology
P08892755A0981|8 18|DNA fragment
P08892755A0981|41 72|chloramphenicol acetyltransferase
P08892755A0981|76 87|reporter gene
P08892755A0981|107 120|carp CF cell line
P08892757T0000|62 79|mouse embryogenesis
P08892757T0000|111 128|repression activity
P08892859A0563|94 105|C-MYB protein
P08892859A0563|117 130|RAV integration
P08892859A0563|140 150|c-myb allele
P08893779A0229|21 52|digitorum longus muscle tendon units
P08893822A0560|0 15|Northern analysis
P08894144A0330|85 98|CsA vehicle p.o.
P08894144A0330|103 113|FB vehicle sc
P08894144A0330|133 143|FB vehicle sc
P08894144A0330|145 158|CsA vehicle p.o.
P08894144A1173|26 37|bone turnover
P08894826A0228|23 35|GUM Department
P08894826A0228|41 54|Royal Infirmary
P08894826A0228|102 113|HIV infection
P08895522T0000|24 43|tyrosine kinase domain
P08895522T0000|54 70|trk proto-oncogene
P08895522T0000|82 101|cell adhesion molecule
P08895579A0583|0 15|Northern blotting
P08896272A0000|3 20|nucleotide sequence
P08896280A0860|118 131|acid metabolism
P08896280A0860|143 156|yvh1 disruption
P08896402A0587|98 109|glycoprotein
P08896795A0166|65 76|oil immersion
P08896804A0000|27 40|dose dependence
P08896804A0000|44 60|time course effects
P08896804A0000|66 79|benzodiazepine
P08896804A0000|155 186|BDZ receptor antagonists flumazenil
P08896804A0000|228 245|alcohol-preferring
P08897663T0000|22 33|nomenclature
P08897721A0000|96 109|polysaccharide
P08898336A0268|0 22|RNase protection analysis
P08898336A0268|28 40|rRNA fragments
P08898365A0274|123 135|pore complexes
P08898866A0458|19 43|serine phosphorylation site
P08898866A0458|76 91|expression system
P08898866A0458|158 170|substitutions
P08898866A0458|182 195|serine residues
P08898893A0202|77 117|phorbol ester phorbol 12-myristate 13-acetate
P08898893A0202|127 146|phosphatase inhibitor
P08898893A0202|164 182|HT-1080 fibrosarcoma
P08899719A0318|37 49|reading frames
P08900190A0430|0 12|Growth factors
P08900190A0430|51 84|gene products MAP kinase phosphatase-1
P08900296A0000|3 15|up-regulation
P08900296A0000|36 52|adhesion molecules
P08901135A1132|3 13|NIT2 protein
P08901135A1132|96 115|nitrogen derepression
P08901135A1132|118 135|nitrogen repression
P08901635A0000|115 129|cell wall polymer
P08901658A0498|40 51|flow increase
P08901658A0498|105 122|glyceryl trinitrate
P08902214A1486|16 29|administration
P08902214A1486|98 108|Stat factors
P08902548A0144|15 28|administration
P08902548A0144|31 51|L-5-hydroxytryptophan
P08902847A1946|128 144|order rate constant
P08902988A0258|0 12|Factor V Leiden
P08903339A0264|14 26|determination
P08905819A0531|30 44|0-III components
P08906056A1290|108 128|health care utilization
P08906139A2935|52 76|alkaline phosphatase values
P08906139A2935|101 114|vitamin D intake
P08910292T0000|32 43|proteins Rac1
P08910292T0000|95 114|protein kinase pathway
P08910373A0315|0 16|Percent identities
P08910373A0315|39 49|mouse Y4/PP1
P08910373A0315|58 68|Y2 receptors
P08910550A0501|100 114|cation chelators
P08910550A0501|149 161|transcription
P08910567A2269|8 19|gene fragment
P08910567A2269|39 65|rat liver glucokinase promoter
P08910567A2269|97 124|hepatocyte transfection system
P08912807A0411|19 30|deer receptor
P08912807A0411|53 67|tyrosine residue
P08912807A0411|138 156|beta-casein promoter
P08913186A0431|114 143|convergence retraction nystagmus
P08914388A1645|96 107|sparfloxacin
P08914388A1645|129 141|ciprofloxacin
P08914388A1645|146 157|levofloxacin
P08914522A0118|21 33|protein kinase
P08914522A0118|45 71|pheromone signal transduction
P08914522A0118|161 173|G beta mutation
P08914532A0598|33 57|endohydrolase isoenzyme X-I
P08915051T0000|8 23|resonance imaging
P08915508A0000|13 25|leukemia virus
P08915508A0000|106 120|trans-activator
P08915508A0000|123 135|transcription
P08915508A0000|160 178|hammerhead ribozymes
P08915508A0000|227 238|group antigen
P08915508A0000|260 272|transcriptase
P08915508A0000|292 304|coding regions
P08915508A0000|312 338|immunodeficiency virus type-1
P08915559A0366|0 18|REM sleep deprivation
P08915559A0366|39 55|platform technique
P08916928A0950|69 90|thymidine incorporation
P08916928A0950|114 131|PDGF beta-receptors
P08916960A0350|16 30|biopsy specimens
P08916960A0350|123 134|reading frame
P08916960A1331|54 71|bcl-2 gene sequences
P08916960A1331|77 92|breakpoint region
P08916960A1331|107 118|conservation
P08916960A1331|147 159|translocation
P08916960A1331|174 187|transformation
P08917435A0481|54 66|transcription
P08917435A0481|128 153|c-fos oligodeoxynucleotides
P08917435A0481|195 208|PAI-1 synthesis
P08917449A0000|31 42|neuropoietin
P08917449A0000|60 74|differentiation
P08917696A0485|23 39|fos/jun activation
P08917696A0485|71 83|mobility shift
P08917696A0485|96 111|expression assays
P08917696A0485|114 135|reporter gene constructs
P08917696A0485|146 161|response elements
P08917696A0485|165 201|12-O-tetradecanoyl-phorbol-13-acetate
P08917696A0485|231 242|hydrocarbons
P08917696A0485|285 298|luciferase gene
P08918464A0225|92 117|mouse erythroleukaemia cells
P08918810A0967|13 24|footprinting
P08918810A0967|97 127|protection pattern characteristic
P08918885A0811|24 37|GST-Dig1 fusion
P08918885A0811|60 71|yeast protein
P08918885A1087|10 22|dig1 dig2 cells
P08918885A1087|61 73|dig1 dig2 ste12
P08918885A1087|161 173|growth pathway
P08918918T0000|24 39|HIV-1 LTR promoter
P08918918T0000|86 101|trans-activation
P08918934A0424|29 46|xFxFG repeat regions
P08919986A1262|56 68|disadvantages
P08920499A0164|0 22|Blood sampling procedures
P08921387A1182|34 46|splicing event
P08921387A1182|131 141|EZH1 protein
P08921667A0294|14 26|input function
P08921667A0294|43 60|distribution volume
P08921667A0294|73 87|rCBF measurement
P08921865A1293|34 48|DNA binding motif
P08921865A1293|69 85|terminase proteins
P08921865A1293|131 142|ssDNA regions
P08922344A1539|53 67|xanthine oxidase
P08922344A1539|98 110|blood pressure
P08922344A1539|176 187|hypertension
P08922384A0466|0 13|Immunoblotting
P08922384A0466|61 71|08L antibody
P08922384A0466|99 109|carboxyl end
P08922385A0622|77 102|beta-galactosidase tetramer
P08922385A0622|108 120|fusion subunit
P08922390A0793|40 50|binding site
P08922390A2076|70 81|interactions
P08922390A2076|134 146|demonstration
P08922390A2076|211 222|localization
P08923258A0353|23 38|Cu concentrations
P08923460A0565|37 47|RUSH-1 alpha
P08923469A1391|57 77|RXR heterodimer binding
P08923469A1391|89 111|hormone response elements
P08923469A1391|136 147|half-element
P08923470A0458|0 18|PPAR gamma mRNA levels
P08923470A0458|39 57|nM TNF alpha treatment
P08924381T0000|0 11|Growth factor
P08924381T0000|58 77|breast cancer patients
P08925545T0001|11 24|erythropoietin
P08927169A0178|96 117|Community Health Service
P08927612T0000|9 20|p53 mutations
P08927612T0000|39 52|adenocarcinoma
P08929563T0000|0 15|Rat liver catalase
P08929563T0000|52 72|tripeptide Ala-Asn-Leu
P08929563T0000|89 104|Ser-Lys-Leu motif
P08931388A0806|3 20|mobility shift assay
P08931991A1026|52 70|transcription factor
P08931991A1026|107 122|myosin expression
P08932363A0807|7 19|E1A N-terminus
P08932363A0807|41 61|squelshing experiments
P08932363A0807|129 145|CBP binding ability
P08932385T0000|5 15|Maf proteins
P08932385T0000|36 70|transcription factor TCF11/Nrf1/LCR-F
P08933487A0325|10 22|occasion water
P08933640A0000|40 64|energy sweetener erythritol
P08934540A0673|9 19|nm23-H2 gene
P08934540A0673|35 47|activity ratio
P08935931A0787|21 42|diazepam administration
P08935991A0844|3 29|nucleotide sequence alignment
P08936128A0611|16 28|cost dimension
P08936128A0611|98 109|disagreement
P08936640A0105|0 10|DATA SOURCES
P08936640A0105|31 45|research studies
P08936640A0105|46 59|review articles
P08936640A0105|63 79|government reports
P08936640A0105|92 103|epidemiology
P08937112A0561|10 24|age distribution
P08937631A1223|36 49|cell involution
P08937981A0840|11 23|co-expression
P08937981A0840|36 46|p54 subunits
P08937981A0840|76 87|distribution
P08938418A0099|7 19|embryo library
P08938420A0862|3 14|accumulation
P08938420A0862|114 124|sugar uptake
P08938420A0862|156 172|3-O-methylglucose
P08938420A0862|187 202|mRNA accumulation
P08939966A0816|11 26|protein synthesis
P08939966A0816|46 58|embryogenesis
P08939966A0816|85 95|mRNA decline
P08940132A1120|24 40|fodrin proteolysis
P08940132A1120|144 155|contribution
P08940132A1120|209 226|DEVD-CHO inhibition
P08940298A0962|67 83|vitamin D3 receptor
P08940298A0962|89 104|estrogen receptor
P08942999T0000|9 26|G-to-A substitution
P08942999T0000|116 136|hamster ovary cell lines
P08943032A0000|18 30|tet-repressor
P08943032A0000|35 48|operator system
P08943032A0000|135 146|interactions
P08943354A0295|57 80|Jak family tyrosine kinases
P08943354A0295|139 158|hyperphosphorylation
P08943354A0295|176 189|motheaten cells
P08943928A1137|0 13|Administration
P08943934A0604|22 33|improvements
P08945479T0000|35 53|lymphocyte kinase Lck
P08945479T0000|58 80|tyrosine phosphorylation
P08946668A0077|33 44|cyclosporin A
P08946668A0077|57 70|organ rejection
P08947028A0992|49 62|reorganization
P08948440A0628|3 22|ERH expression profile
P08948440A0628|62 77|animal hemisphere
P08950144A0172|34 44|CNV paradigm
P08950144A0172|54 69|reaction time task
P08950352A0525|145 156|significance
P08951815A0465|19 32|ASN2 expression
P08951815A0465|48 58|lacZ fusions
P08951815A0465|126 152|transcription activator Gcn4p
P08952483A0207|31 49|polypeptide fragment
P08952483A0207|57 83|hamster lysyl-tRNA synthetase
P08952483A0207|143 164|multisynthetase complex
P08952965A1182|57 69|substitutions
P08952965A1182|107 117|region genes
P08952965A1182|149 164|framework regions
P08952965A1182|192 208|MHC contact regions
P08953340A0000|16 29|vanadyl sulfate
P08953340A0000|49 61|anthropometry
P08953340A0000|62 76|body composition
P08953340A0000|161 185|weight-training volunteers
P08954725A1175|18 31|Tbx6 expression
P08955071T0000|12 32|re-replication control
P08955071T0000|35 48|overexpression
P08955071T0000|62 73|fission yeast
P08955111A0989|39 53|enhancer regions
P08955111A0989|106 121|promoter activity
P08955111A0989|132 154|activin betaA subunit gene
P08955136A0606|51 63|PIP5K activity
P08955136A0606|97 112|PIP5KI antibodies
P08955159A0000|5 18|acid ceramidase
P08955159A0000|21 51|N-acylsphingosine amidohydrolase
P08955189A1198|10 27|NheI/BglII promoter
P08955189A1198|37 51|PMA inducibility
P08955189A1198|118 142|EGR-1 transcription factors
P08955306A0224|11 22|blot analyses
P08955306A0224|79 90|reading frame
P08955402A0288|150 165|HOL1-1 background
P08955402A0288|194 204|Hol1 protein
P08955928A0390|25 37|extravasation
P08958137A0534|0 23|Lipid hydroperoxide levels
P08959062A0372|81 93|immunodeficit
P08959117A0708|146 157|measurements
P08959117A0708|197 210|reference group
P08959778A0292|35 47|graft survival
P08959778A0292|70 82|graft function
P08959778A0292|105 120|transplantations
P08959778A0292|123 140|retransplantations
P08960827A1169|65 77|transcription
P08960827A1169|88 98|insulin gene
P08961873T0000|15 34|coproporphyrin levels
P08961873T0000|55 69|hepatitis C virus
P08961873T0000|88 108|immunodeficiency virus
P08962614A0000|3 15|determination
P08962614A0000|18 32|immunoglobulin E
P08962614A0000|60 74|laboratory tests
P08962614A0000|77 91|skin-prick tests
P08962614A0000|107 125|challenge procedures
P08962614A0000|171 187|outcome predictors
P08964172A0221|9 34|cytocentrifuge preparations
P08967870A0000|20 41|postmortem examinations
P08967870A0000|46 61|Moscow hospitals N
P08967963A1735|3 17|promoter segment
P08967963A1735|50 70|rat glioma cell line C6B4
P08967963A1735|90 104|cell line RSMT-A5
P08967963A1735|124 142|beta cell line RIN-5AH
P08967963A1735|178 191|alpha2c-AR gene
P08969495A0256|35 48|mutation ts-A13
P08969495A0256|63 73|nrdE cistron
P08969777A0771|95 118|serum 25-OHD concentration
P08970951A0823|99 109|Pol proteins
P08970951A0823|124 142|HBV DNA intermediates
P08970979A1246|63 75|transcription
P08970984A0765|3 14|SCMV SNE sites
P08970984A0765|42 69|core recognition binding motifs
P08970984A0765|76 87|Rel/NFkappaB
P08970984A0765|94 121|YY1 class transcription factors
P08970984A0765|153 176|tumor necrosis factor alpha
P08970991A0747|4 18|serum withdrawal
P08971835A1057|122 138|reperfusion period
P08972182A0000|3 13|Fas receptor
P08972182A0000|23 39|signalling cascade
P08972182A0000|92 112|receptor cross-linking
P08972182A0527|27 39|interleukin-1
P08972182A0527|61 75|family proteases
P08972182A0527|116 144|cowpox ICE inhibitor protein CrmA
P08972182A0527|157 188|tetrapeptide ICE inhibitor YVAD-CMK
P08972182A0527|195 229|tripeptide pan-ICE inhibitor Z-VAD-FMK
P08972232A0365|58 77|substrate specificity
P08973185T0061|14 30|arginine mutations
P08973185T0061|42 56|phosphorylation
P08973185T0061|60 72|AAC expression
P08973527A0000|32 42|coat protein
P08973527A0000|69 88|Agropyron mosaic virus
P08973527A0000|96 113|Hordeum mosaic virus
P08973630A0923|25 37|Rac activation
P08973630A0923|47 59|Rho activation
P08973630A0923|77 91|Cdc42 activation
P08973630A0923|99 111|Rac activation
P08973917T0000|61 77|tryptophan protein
P08973917T0000|83 93|gene mapping
P08974103A0451|17 28|combinations
P08974103A0451|48 64|laboratory results
P08974135A0052|95 109|vitamin B1 levels
P08974135A0052|170 181|control group
P08975532T0001|0 12|Liver injuries
P08975713A0454|12 22|cDNA library
P08975713A0454|68 81|p53p2 start site
P08975713A0454|171 183|p53p2 promoter
P08976253A0637|56 70|plasma PSA levels
P08977013A0788|3 14|implications
P08977013A0788|37 49|magnification
P08977013A0788|77 91|specializations
P08977235A0134|59 69|JAK2 kinases
P08977235A0134|76 99|STAT transcription factors
P08977235A0588|17 32|tyrosine residues
P08977235A0588|139 153|STAT1 activation
P08977235A0588|168 198|receptor tyrosine phosphorylation
P08977401A0227|3 13|RI alpha gene
P08977401A0227|171 187|RI alpha pseudogene
P08977401A0227|281 291|RI alpha gene
P08977401A0227|307 317|leader exons
P08977401A0227|348 360|messenger RNAs
P08978690A0262|73 95|DNA structure checkpoints
P08978690A0262|102 118|yeast model systems
P08978817A0620|57 80|endocytosis mutants end4-1
P08978817A0620|107 119|growth defects
P08978817A0620|137 151|DIM gene products
P08978996A0000|3 16|identification
P08978996A0000|22 36|hepatitis C virus
P08978996A0000|54 65|liver disease
P08978996A0000|72 87|dialysis patients
P08978996A0000|93 110|transplant patients
P08978996A0000|135 146|epidemiology
P08978996A0000|187 199|patient groups
P08979089A1197|6 17|transfection
P08979089A1197|23 36|BL cell line Raji
P08979089A1197|61 81|core promoter mutations
P08979089A1197|171 186|Ig kappa enhancers
P08979828A1561|16 27|interactions
P08980413A0500|23 47|phase reversal relationship
P08980533A1160|98 109|testis tissue
P08980536A1196|3 14|conservation
P08980536A1196|48 59|CHS promoters
P08980819A0193|158 169|insemination
P08981371A2049a|10 20|PIP2 content
P08981371A2049a|63 76|CSF-1 treatment
P08981371A2049b|10 20|PIP2 content
P08981371A2049b|63 76|CSF-1 treatment
P08985115A1571|8 21|identification
P08985115A1571|33 45|37LRP/p40 gene
P08985115A1571|132 144|understanding
P08985115A1571|182 194|up-regulation
P08985115A1571|216 228|tumor invasion
P08985122A0501|3 16|promoter region
P08985122A0501|48 75|transcription initiation sites
P08985122A0501|116 127|binding sites
P08985122A0501|134 155|transcription factor SP1
P08985415A1096|3 24|STAT-1 signaling pathway
P08986190A0927|38 54|lactate production
P08986214A0000|63 74|liver disease
P08986214A0000|152 173|hepatocyte growth factor
P08986214A0000|180 196|alpha-fetoprotein
P08986228A0000|107 119|malformations
P08986692A0306|0 11|INTERVENTION
P08986692A0306|22 41|hemostasis parameters
P08986770A0268|31 49|I-POU/tI-POU message
P08986770A0268|127 139|splice variant
P08987009A0400|29 41|prerequisites
P08987009A0400|82 94|psychoanalyst
P08987225A0675|55 69|hepatitis C cases
P08988257A1256|56 72|reporter construct
P08988257A1256|109 122|repeat sequence
P08988913A0821|80 94|folate excretion
P08989025A0359|68 81|concentrations
P08989763A0605|42 54|visualization
P08990168A0688|8 23|p48 gene induction
P08990194A0000|25 38|thyroid hormone
P08990194A0000|73 87|thyroid hormones
P08990194A0000|114 133|thyrotropin secretion
P08990194A0000|155 168|refractoriness
P08990194A0000|171 183|hormone action
P08990397A1437|112 124|RNA processing
P08992115A0199|55 73|blood concentrations
P08992115A0199|76 94|acute-phase proteins
P08992115A0199|95 107|KKS activation
P08992115A0199|137 153|lactic acid content
P08993393A0498|21 32|implications
P08993393A0498|76 87|hPACAP-R gene
P08993393T0000|39 52|gene activation
P08993393T0000|59 72|splice variants
P08993393T0000|119 137|polypeptide receptor
P08993831A0000|14 30|muscle development
P08993831A0000|47 58|muscle fibers
P08993831A0000|92 103|combinations
P08993831A0000|121 132|gene products
P08993836A0699|66 79|HNF-3 alpha gene
P08993836A0699|109 121|embryogenesis
P08994825A0000|73 96|Cdc2/28-cyclin B complexes
P08995054A0618|29 45|zinc knuckle region
P08995054A0618|104 116|retroelements
P08995054A1368|60 79|insertions/deletions
P08995054A1368|99 115|nucleotide changes
P08995410A0000|10 25|initiation factor
P08995410A0000|115 125|mRNA binding
P08995410A0000|208 222|ribosome subunit
P08995614T0000|0 13|Identification
P08995614T0000|50 86|histocompatibility complex gene promoter
P08995652A0812|116 128|UL80.5 protein
P08995652A0812|173 185|UL80.5 protein
P08995652A0812|231 243|UL26.5 protein
P08995652A0812|289 301|UL80.5 protein
P08995652A0812|401 413|UL80.5 protein
P08995652A0812|427 438|RRIFVA ALNKLE
P08995652A0812|441 452|RRIFVAAMMKLE
P08995652A0812|455 470|self-interaction
P08995652A0812|476 491|scaffold proteins
P08995652A0812|527 548|maturation cleavage site
P08995652A0812|564 577|UL80.5 proteins
P08995652A0812|598 615|scaffold structures
P08995659A0563|9 29|region splice junctions
P08995659A0563|89 113|sequencing RNA-PCR products
P08995659A0563|147 158|splice region
P08996730A1146|22 42|vibration measurements
P08996730A1146|46 64|employment durations
P08996730A1146|100 113|tool conditions
P08996730A1146|114 126|grinder wheels
P08996730A1146|141 152|difficulties
P08997490A1127|0 9|C/EBP beta V
P08997490A1127|78 93|oligonucleotides
P08997490A1127|136 166|cholesterol hydroxylase promoters
P08997532A0116|30 47|IgE immunoglobulins
P08997532A0116|117 130|ELISA technique
P08998115A0114|0 20|SUMMARY BACKGROUND DATA
P08998115A0114|21 32|Melanoma care
P08998115A0114|102 121|lymph node dissections
P08999414A0819|33 48|genus Dermacentor
P08999857A0801|125 144|collagen gene promoter
P09000049A1341|58 70|Max activities
P09000049A1341|85 101|cell proliferation
P09000108A0330|3 22|transcription product
P09000108A0330|85 106|polyadenylation signals
P09000108A0330|136 162|translation termination codon
P09000146T0000|72 90|sequence alterations
P09000632A2341|18 33|Cys181 side-chain
P09000632A2341|68 83|Tyr181 side-chain
P09001213A1111|17 34|level transcription
P09001213A1111|70 83|chromosome ends
P09001213A1111|86 97|P. falciparum
P09001213A1111|157 171|expression sites
P09001667A0312|52 70|day post-vaccination
P09002672A0439|72 83|repeat arrays
P09002672A0439|125 143|sequence specificity
P09002672A0439|169 181|TTAGGG repeats
P09002672A0439|185 200|binding substrate
P09002672A0439|214 226|TTGGGG repeats
P09003001A1909|3 15|E-box sequence
P09003001A1909|21 31|SE2 fragment
P09003001A1909|37 55|transferrin promoter
P09003001A1909|94 115|consensus E-box elements
P09003311A0478|7 17|DNA fragment
P09003312A0740|35 51|AT-PHH1 delta C-513
P09003312A0740|96 110|photolyase genes
P09003410A0000|8 18|p100 protein
P09003462A0792|14 26|mutation sites
P09003462A0792|87 99|self-splicing
P09003463A0198|33 48|characterization
P09003463A0198|91 102|RII alpha gene
P09004304A0000|31 45|reproducibility
P09004304A0000|67 82|clearance methods
P09004304A0000|88 113|chromium-51 ethylenediamine
P09004304A0000|170 189|blood sample technique
P09004504A0000|26 38|bp DNA fragment
P09004504A0000|64 83|plasminogen activator
P09004504A0000|123 149|Yersinia pestis plasmid pYP358
P09004987T0001|0 21|Serotonin concentration
P09005273A0322|0 18|MAIN OUTCOME MEASURES
P09005273A0322|19 30|Associations
P09005273A0322|68 78|risk factors
P09005273A0322|82 101|chemical interactions
P09005273A0322|113 133|butyrylcholinesterase
P09005273A0322|137 160|neuropathy target esterase
P09005273A1558|14 28|Gulf War veterans
P09005273A1558|90 101|combinations
P09005273A1558|124 144|butyrylcholinesterase
P09005273A1558|148 171|neuropathy target esterase
P09005609A0299|0 17|Control examination
P09005836A0977|43 55|antibody level
P09005979A0841|9 21|GHBP mRNA ratio
P09005979A0841|59 73|differentiation
P09006007A0997|112 122|SelB protein
P09006007A0997|199 211|compatibility
P09006010A0527|3 25|linker-peptide insertion
P09006010A0527|31 43|RsaA C terminus
P09006010A0527|69 85|S-layer biogenesis
P09006010A0527|168 182|secretion signal
P09006022A0252|17 28|gene products
P09006022A0252|81 103|T7 RNA polymerase promoter
P09006051A1162|20 62|carboxyphosphonoenolpyruvate phosphonomutase
P09006051A1162|110 138|carnation Dianthus caryophyllus
P09006051A1162|182 197|citrate synthases
P09006051A1162|226 249|Bacillus subtilis proteins
P09006051A1162|287 312|acetyl coenzyme A synthetases
P09006555A0738|0 18|MAIN OUTCOME MEASURES
P09006555A0738|39 50|hemodynamics
P09006555A0738|59 79|blood gas determination
P09006555A0738|95 107|lavage protein
P09006555A0738|111 127|neutrophil content
P09006555A0738|128 149|neutrophil oxidant burst
P09006555A0738|150 175|lung myeloperoxidase content
P09006555A0738|179 194|scanning electron
P09006910A0000|63 79|retinoid X receptor
P09006910A0000|83 96|gene expression
P09006910A0000|124 139|RXRgamma2 isoform
P09006914A1127|41 63|JNK/p38 signaling pathway
P09006914A1127|132 155|E-selectin gene expression
P09006935A0590|61 74|consensus GC box
P09006936T0000|0 13|Identification
P09006936T0000|80 98|glycoprotein IBalpha
P09008301A0193|6 16|enzyme forms
P09008301A0193|50 67|autoprocessing site
P09010223A0667|65 76|PU.1 proteins
P09010223A1850|134 156|ETS transcription factors
P09011744A0790|38 64|NMDA receptor channel subunits
P09011744A0790|179 199|backcross mapping panel
P09011745T0000|74 86|acid receptors
P09011745T0000|94 105|conservation
P09012405A0785|22 32|XP-D defects
P09012405A0785|71 89|transcription factor
P09012636A0723|32 45|HDL cholesterol
P09012636A0723|46 58|triglycerides
P09012636A0723|141 155|atherosclerosis
P09013499A0198|62 105|N-methyl-D-aspartate receptor antagonist MK-801
P09013499A0198|153 164|conditioning
P09013760A0000|21 42|cleavage cytochrome P450
P09013760A0000|56 69|gene expression
P09013760A0000|83 95|gonadotropins
P09015757T0000|21 36|characterization
P09015757T0000|86 101|bone sialoprotein
P09015799T0000|0 17|Serotonin receptors
P09015799T0000|20 33|suicide victims
P09017443A0734|14 25|marker screen
P09017443A0734|118 131|stratification
P09018122A1389|14 27|ORF-1 sequences
P09018122A1389|62 73|prerequisite
P09018122A1389|98 113|tumor development
P09018133A0244|53 64|relationship
P09018133A0244|93 111|Varicellovirus genus
P09018133A0244|117 135|alpha-Herpesvirinae
P09019302A0600|62 75|derivatization
P09019302A0600|80 94|sodium bisulfite
P09020138A0833|59 72|tyrosine kinase
P09020138A0833|114 132|adapter molecule CrkL
P09020172A0964|113 135|nM dissociation constants
P09020856A0560|57 67|MCK promoter
P09021684A1418|111 128|repressor functions
P09021684A1418|144 156|NF-kappa B2p52
P09021684A1418|174 196|transactivation activity
P09022040A0263|7 25|L-plastin expression
P09022040A0263|126 139|gene expression
P09022040A0263|214 232|nucleotide sequences
P09022040A0263|252 273|L-plastin gene promoters
P09023197T0000|15 30|Bacillus subtilis
P09023378A0959|49 61|transcription
P09023378A0959|64 76|reporter genes
P09023378A0959|90 101|C-repeat/DRE
P09023378A0959|114 130|activator sequence
P09024097A0000|84 96|complications
P09024793A1325|5 37|electrophoresis mobility shift assay
P09024793A1325|116 129|enhancer region
P09024805A0905b|13 29|promoter construct
P09024805A0905b|55 70|consensus Sp1 site
P09024805A0905b|127 139|BZLF1 promoter
P09024805A0905b|151 168|beta-globin TATA box
P09024805A0905b|178 201|phorbol ester inducibility
P09025549A0000|76 88|practitioners
P09025549A0000|123 155|Vancouver sex therapist Bianca Rucker
P09027346A1957|7 21|antibody binding
P09027346A1957|37 57|hCG-ectodomain complex
P09027506T0000|0 10|cDNA cloning
P09027506T0000|11 28|expression analysis
P09027506T0000|43 54|localization
P09028089A0183|31 42|hypertension
P09028089A0183|92 113|transplantation surgery
P09028308A0590|35 47|mitroxantrone
P09028308A0590|68 88|bone marrow suppression
P09028308A0590|139 151|micrograms/kg
P09028308A0590|199 210|chemotherapy
P09028942A0000|103 120|growth response gene
P09028998A0143|81 92|breast tissue
P09029091A0881|31 53|tyrosine phosphorylation
P09029091A0881|56 74|phospholipase C gamma
P09029091A0881|94 104|Jurkat cells
P09029091A0881|118 130|A2/HCP chimera
P09029159A0000|53 72|Ser/Thr protein kinase
P09029713A1120|64 76|activator SF-1
P09029713A1120|83 98|repressor COUP-TF
P09029713A1120|127 139|transcription
P09029956T0000|41 58|structure formation
P09030581A0990|65 78|selectivity ERK
P09030688A0435|2 12|rlf2 mutants
P09030688A0435|72 88|Rap1p localization
P09030781A0734|61 72|cdc2/cyclin B
P09030781A0734|73 84|cdk2/cyclin A
P09030781A0734|85 96|cdk2/cyclin E
P09030781A0734|213 225|cdk4/cyclin D1
P09030781A0734|229 241|cdk6/cyclin D2
P09031639A0474|28 39|reading frame
P09031639A0474|138 148|U1-C protein
P09032233T0000|24 50|POU-homeodomain protein GHF-1
P09032233T0000|86 99|gene expression
P09032248A0239|39 65|Pcl1,2-Pho85 kinase complexes
P09032248A0239|103 121|Cln1,2-Cdc28 kinases
P09032250A0257|95 117|CCAAT binding protein NF-Y
P09032250A0257|123 137|HeLa cDNA library
P09032254A0724|0 15|Enhancer activity
P09032258A0395|12 28|HLA-DR-B7-1-LFA-3
P09032258A0395|35 47|transfectants
P09032258A0395|74 96|NF-AT DNA binding activity
P09032258A0395|121 137|B7-1 costimulation
P09032259A0150|52 65|transformation
P09032259A0150|68 78|NIH 3T3 cells
P09032259A0150|116 132|Ras transformation
P09032259A0972|11 24|Rac1 activation
P09032259A0972|48 59|lamellipodia
P09032259A0972|95 118|Rac1 transforming activity
P09032267A0850|0 13|Overexpression
P09032267A0850|19 39|bZip interaction domain
P09032275A1133|57 74|AHC deletion mutants
P09032304T0000|0 13|Identification
P09032304T0000|34 54|transactivation domain
P09032304T0000|60 77|herpes simplex virus
P09032304T0000|88 98|protein ICP4
P09032328A0650|0 12|DNA sequencing
P09032328A0650|41 56|gammaherpesvirus
P09032328A0650|142 153|gene products
P09034337A0251|71 85|phosphorylation
P09035307A0000|93 135|99mTc-methoxyisobutylisonitrile scintigraphy
P09035612T0000|7 23|endothelin release
P09035612T0000|27 37|infarct size
P09036529A0343|31 42|microgram/ml
P09036529A0343|118 131|concentrations
P09036529A0343|137 149|Apis mellifera
P09036529A0343|157 167|Vespula spec
P09037032T0000|3 15|proliferation
P09037032T0000|88 115|ribonucleoprotein association
P09037032T0000|167 181|differentiation
P09037064A0183|30 47|canarypox ALVAC/HIV
P09037064A0183|58 74|vaccine immunogens
P09037064A0183|113 124|CTL responses
P09037163A1652|59 76|gpc4 gene expression
P09038202A1951|30 47|repression activity
P09039744T0000|29 50|electro-encephalograms
P09039744T0000|61 72|sinc function
P09040011A1316|32 45|G1/S transition
P09040011A1316|79 91|cell viability
P09040011A1316|95 106|transduction
P09040011A1316|121 137|activation signals
P09040011A1316|165 183|Ras/Raf/MAPK pathway
P09042078A0202|74 84|jaw openings
P09042269A1007|48 59|chemotherapy
P09042683A0492|3 18|FBF questionnaire
P09042683A0492|54 68|symptoms profile
P09042683A0492|137 149|schizophrenia
P09042755T0000|14 30|sigma factor sigmaB
P09042755T0000|90 100|growth phase
P09042911A0626|7 22|promoter elements
P09042911A0626|35 48|glucocorticoid
P09043534A1600|34 47|alkalinization
P09045636A0789|0 15|CD3 cross-linking
P09045636A0789|23 45|tyrosine phosphorylation
P09045805A0945|32 44|acoABCD operon
P09045805A0945|71 81|acoK mutants
P09045805A0945|132 154|transactivating function
P09045805A0945|160 170|gene product
P09045842T0000|40 52|RNA polymerase
P09045919A1250|92 104|c-Rel proteins
P09045919A1250|117 144|transcription factor machinery
P09045919A1250|159 174|enhancer activity
P09045919A1250|211 232|B lymphocyte development
P09046013A0000|63 83|calcium channel blocker
P09046013A0000|208 220|carotid artery
P09046090T0000|19 45|transcription factor yTAFII60
P09046090T0000|49 59|G4p1 protein
P09046090T0000|72 89|glucose transporter
P09046090T0000|109 121|kb DNA fragment
P09046090T0000|159 171|chromosome VII
P09046186A0189|31 42|fall distance
P09046384A0403|0 21|Marinol/marijuana usage
P09046384A0403|68 80|amylase levels
P09046384A0403|90 100|DDI subgroup
P09047344A0000|61 72|muscle myosin
P09047344A0000|78 88|chain kinase
P09048617A0648|23 44|tyrosine kinase receptor
P09049198A0289|46 60|liver cell growth
P09049198A0289|127 143|liver regeneration
P09049198A0289|163 175|liver diseases
P09049270A0488|0 19|Northern blot analysis
P09049270A0488|107 118|tomato plants
P09049270A0488|156 169|characteristic
P09049304A1193|2 23|co-transfection studies
P09049304A1193|38 58|Egr-1 expression vector
P09049304A1193|68 88|VPF/VEGF transcription
P09049304A1193|107 117|AP-2 protein
P09049304A1193|159 180|VPF/VEGF gene expression
P09049313A0116|99 119|initiation factor eIF4G
P09050689A0685|64 77|administration
P09050847A0180|28 43|TBP-TAF complexes
P09050847A0180|89 127|transcription initiation factor TIF-IB/SL1
P09050849A0000|111 125|Sec7 gene product
P09050849A0000|142 157|protein transport
P09050861A0903|16 29|identification
P09050867A0542|22 32|binding site
P09050867A0542|36 47|Krox proteins
P09050867A0542|70 81|octamer motif
P09050867A0542|91 113|POU-homeodomain proteins
P09050867A0542|123 138|TN control element
P09051656A0390|0 12|Tissue samples
P09051656A0390|90 108|day morphine infusion
P09053309A1103|20 40|floor plate development
P09053309A1103|81 100|floor plate inducer shh
P09053494A0612|161 174|reference group
P09053835A0865|9 19|p53 activity
P09053835A0865|61 73|protein levels
P09053973A1252|17 30|administration
P09055221A0288|81 94|signal contrast
P09056761A0000|186 204|splice site selection
P09057325A0177|11 21|plasmid pCM2
P09057325A0177|33 55|pathogenicity locus pat-1
P09057325A0177|67 82|deletion analysis
P09057325A0177|86 107|complementation studies
P09057325A0177|117 137|Bg/II/SmaI DNA fragment
P09057648A0422|9 22|cotransfection
P09057648A0422|34 49|sense orientation
P09057648A0422|88 100|c-fos promoter
P09057648A0422|138 169|chloramphenicol acetyltransferase
P09057648A0422|198 208|CAT activity
P09057648A0422|211 221|Jurkat cells
P09057648A0422|268 298|micrograms/mL phytohemagglutinin
P09057648A0422|306 333|mol/L phorbol myristate acetate
P09057703A1389|0 13|Snail mortality
P09057703A1389|41 59|treatment conditions
P09057840A0946|49 66|2SO4-precipitation
P09057840A0946|70 91|affinity chromatography
P09057840A0946|95 107|AMP-Sepharose
P09057841T0000|0 11|Derepression
P09057841T0000|14 27|gene expression
P09057841T0000|61 79|isocitrate lyase gene
P09057841T0000|82 98|Candida tropicalis
P09058250A0128|7 19|complications
P09058323A1287|25 35|cis elements
P09058323A1287|129 139|CNS patterns
P09058323A1287|162 178|gene transcription
P09058373A0670|0 25|RNase protection experiments
P09058373A0670|51 65|GHR1-279 variant
P09058373A1620|21 32|reporter gene
P09058378A1134|19 41|glucocorticoid receptors
P09058378A1134|55 77|transactivation function
P09058378A1134|88 102|transrepression
P09060045A0576|9 22|review analyses
P09060045A0576|28 39|interactions
P09060045A0576|89 104|endotoxin release
P09060444A0557|4 18|promoter segment
P09060444A0557|42 63|luciferase reporter gene
P09060444A0557|137 154|EGF-responsiveness
P09060622A1679|45 57|alphavirus RNA
P09060676A1634|14 31|virus entry features
P09060676A1634|43 55|coronaviruses
P09061697A0629|46 62|99Tcm-tetrofosmin
P09061697A0629|113 123|day protocol
P09061697A0629|153 172|stress imaging studies
P09061697A0629|217 233|99Tcm-tetrofosmin
P09061697A0629|252 262|day protocol
P09061697T0000|10 20|SPET imaging
P09061697T0000|25 41|99Tcm-tetrofosmin
P09061697T0000|82 99|day imaging protocol
P09061698A0177|0 12|99Tcm-DMP-HSA
P09061698A0177|109 125|reference standard
P09061698A0177|129 143|blood pool agents
P09062130A0116|10 23|autoinhibition
P09062130A0116|81 101|N-SH2 domain engagement
P09062130A0116|113 132|phosphotyrosyl ligand
P09062130A0116|181 192|PTPase domain
P09064659A1055|84 95|nonsense mRNA
P09064868T0001|1 11|miracle cure
P09065463A1012|0 16|DNA strand exchange
P09065463A1012|28 39|Rad51 protein
P09065690A0463|63 76|CAR1 expression
P09065690A0463|115 134|nitrogen availability
P09065768A0862|35 46|kb transcript
P09065768A0862|94 104|lactase mRNA
P09068989T0000|8 24|Azadirachta indica
P09068989T0000|39 49|leaf extract
P09071308A0376|44 55|distribution
P09071407T0000|54 65|cohabitation
P09072361A0357|101 114|magnesium ratio
P09073074T0000|9 21|transcription
P09073074T0000|31 46|FGFR-3 psuedogene
P09073074T0000|58 69|developement
P09073582A0444|35 52|BglII-SmaI fragment
P09073582A0444|58 68|SSO activity
P09075739A0827|6 18|splice pattern
P09076336A0281|0 11|GH deficiency
P09076336A0281|72 84|constellation
P09076336A0281|148 160|GH sufficiency
P09076336A0281|169 179|GH secretion
P09077437T0000|0 20|Recognition mechanisms
P09077437T0000|70 82|RNA polymerase
P09077438A0076|33 44|RNA synthesis
P09079625A0935|18 34|adhesion component
P09079638A0883|3 13|3ASubE cells
P09079638A0883|197 211|ligand challenge
P09079650A0136|45 59|response kinases
P09079650A0136|122 135|protein kinases
P09079689A0472|118 129|reading frame
P09079817A0928|10 21|NO production
P09079817A0928|77 88|NO synthetase
P09079878A0000|14 42|Lactobacillus sake plasmid pCIM1
P09079878A0000|89 101|reading frames
P09079902A0713|47 60|pyruvate kinase
P09079904A0995|9 22|iron regulation
P09079904A0995|23 36|sodA expression
P09079904A0995|59 69|DNA topology
P09079904A0995|79 90|coumermycin A
P09079915T0000|9 24|characterization
P09079915T0000|52 65|motility operon
P09079915T0000|85 108|consensus sigma70 promoter
P09079928A0525|0 11|M. leprae OxyR
P09079928A1319|3 13|binding site
P09079928A1319|119 132|characteristic
P09079928A1319|138 152|LysR superfamily
P09080250A0212|50 70|p15E cDNA gene fragments
P09080250A0212|89 111|polymerase chain reaction
P09080250A0212|154 164|tumour cells
P09081392A0174|31 45|salvage regimens
P09082335A0730|18 31|manifestations
P09083291A1378|68 82|G1 phase cyclin D1
P09083291A1378|110 120|cyclin E-cdk
P09083291A1378|160 174|phosphorylation
P09083291A1378|178 189|inactivation
P09083345A0851|118 136|inter-relationships
P09083345A0851|160 174|characteristics
P09083345A0851|201 212|presentation
P09083345A0851|216 232|treatment efficacy
P09083563A0971|44 55|surface layer
P09083563A0971|59 78|leptomeningeal tissue
P09083563A0971|91 106|arachnoid vessels
P09084174A0667|78 90|dehydrogenase
P09084174A0667|102 141|aspartate-beta-semialdehyde dehydrogenase
P09084174A0667|185 195|Asd proteins
P09084176A0601|36 57|slot-blot hybridization
P09084176A0601|93 109|M. smegmatis clones
P09084227A0833|156 171|muscle relaxation
P09084621A0374|0 11|Movement time
P09084621A0374|24 38|characteristics
P09084621A0374|111 136|brain activity proportionate
P09084621A0374|146 162|movement variables
P09084621A2567|56 66|motor cortex
P09085842A0181|72 98|protein/protein interactions
P09085842A0181|125 137|U1-70K protein
P09085842A1559|81 107|protein/protein interactions
P09085842A1559|126 145|phosphorylation state
P09085842A1559|159 174|pre-mRNA splicing
P09086268A0611|73 85|RNA polymerase
P09088371T0000|0 11|Plasma levels
P09088371T0000|33 44|antithrombin
P09088416A0000|95 111|migraine headaches
P09088416A0000|127 137|hearing loss
P09088416A0000|163 177|artery occlusion
P09088737T0000|20 40|thickness measurements
P09089093A0373|67 82|enhancer elements
P09089653A0615|100 117|luciferase activity
P09089653A0615|154 167|control plasmid
P09089653A1112|22 33|interactions
P09089653A1112|43 61|DNase-I footprinting
P09090050A0419|25 37|sugar carriers
P09090054A0186|78 94|alpha-glucosidase
P09090054A0186|126 146|alpha-glucosidase gene
P09090592A0175|35 53|activation fMR images
P09091125A0161|68 83|acid phosphatases
P09091125A0161|90 103|NBT-test values
P09091403T0001|20 31|DNA sequences
P09091403T0001|93 109|microsatellite DNA
P09092493A0861|42 62|AP-1 signaling pathways
P09092580A1354|38 53|MAP kinase pathway
P09092580A1354|91 104|transmigration
P09092636A0802|42 54|rad54-3 allele
P09092636A0802|68 80|recombination
P09092636A0802|104 125|DYZ3 satellite sequences
P09092675A0283|1 16|P22 R17 derivative
P09093867T0000|12 27|Ac/Ds transposons
P09094671A1192|0 28|Candidate tumor suppressor genes
P09094671A1192|87 106|Southern blot analysis
P09096229T0000|0 13|Excision repair
P09096229T0000|140 153|identification
P09096229T0000|202 217|control sequences
P09096234T0000|56 77|DNA sequence specificity
P09096234T0000|78 103|operator site discrimination
P09096234T0000|106 127|phage lambda cI repressor
P09096958A0000|66 78|platelet talin
P09096958A0000|81 95|Western blotting
P09096958A0000|102 114|precipitation
P09096958A0000|118 135|immunofluorescence
P09096958A0000|148 162|antibodies TA205
P09096958A0000|177 193|actin stress fibers
P09096958A0000|221 232|cell motility
P09098066A0119|75 86|proteins HMW1
P09098899A0000|24 34|acid protein
P09098899A0000|69 88|transcription factors
P09098899A0000|159 174|zinc-finger motif
P09098899A0435|3 22|UV absorption spectrum
P09098899A0435|47 60|characteristic
P09098899A0435|86 111|charge-transfer transitions
P09098899A0435|118 148|difference absorption coefficient
P09098899A0435|154 166|acidification
P09098899A0435|167 178|delta epsilon
P09099683A0000|0 19|Diacylglycerol kinase
P09099683A0000|47 69|messenger diacylglycerol
P09099702A0000|61 82|orphan receptor germ cell
P09099702A0692|103 116|mouse protamine
P09099702A0692|156 170|spermatogenesis
P09099743A0585|15 26|purification
P09099743A0585|110 121|polypeptides
P09099743A0585|143 154|polypeptides
P09099745A1446|145 159|phosphorylation
P09099745A1446|198 209|cyclin E-Cdk2
P09099745A1446|230 252|CDK inhibitor association
P09099745A1446|285 299|phosphorylation
P09100202A0000|15 31|Class II recessions
P09100202A0000|91 110|tissue graft procedure
P09101085A0686|67 80|p27Kip1 protein
P09102113A0739|12 26|failure patients
P09103382T0000|6 19|FIGO definition
P09103382T0000|30 42|cancer stage IA
P09104816A0610|86 98|vaccinia virus
P09105042A1497|36 55|myofibrillar disarray
P09105042A1497|62 72|HCM patients
P09105042A1497|162 173|chain protein
P09105042A1497|285 299|beta MHC function
P09105363A0636|30 49|emission spectroscopy
P09105363A0636|72 96|tissue silicon measurements
P09105530A0000|60 76|cheese preparation
P09106057A0000|25 37|determination
P09106057A0000|58 76|anhydroerythromycin
P09106057A0000|184 197|chromatography
P09106057A0000|206 222|chemiluminescence
P09108029A0399|33 48|activator protein
P09108029A0399|67 81|DNA repair enzyme
P09108029A0399|82 92|redox factor
P09108029A0399|118 132|DNA repair enzyme
P09108029A0399|133 146|AP endonuclease
P09108038A1128|52 69|C. elegans homologue
P09108038A1128|102 116|binding proteins
P09108207A0306|10 22|participation
P09108207A0306|41 63|oropharyngeal irritation
P09108279A0431|73 83|ogg1 strains
P09108279A0431|90 105|34mer DNA fragment
P09108279A0431|123 135|8-OxoG residue
P09108451A0160|22 33|laboratories
P09108451A0160|76 95|G1-phase accumulation
P09108451A0160|110 123|tumor cell lines
P09110176A0890|11 24|RT-PCR analysis
P09110176A0890|27 41|Ube3a expression
P09110176A0890|44 55|mouse tissues
P09111004A0732|53 83|phosphorylation motif Thr-Xaa-Tyr
P09111004A0732|103 137|L12 influence p38 substrate specificity
P09111004A0732|185 203|autophosphorylation
P09111048X0000|21 34|mRNA transcript
P09111048X0000|66 85|nitric-oxide synthase
P09111048X0000|99 111|mRNA diversity
P09111048X0000|143 162|nitric-oxide synthase
P09111048X0000|167 180|gene expression
P09111048X0000|190 202|cells/tissues
P09111309A0674|0 13|Cotransfection
P09111309A0674|54 76|kinase expression vectors
P09111309A0674|96 119|HB-EGF promoter activation
P09111314A0970|49 67|184A1L5R cell lysates
P09111314A1243|133 145|p15 transcript
P09111314A1243|155 169|p15INK4B protein
P09111314A1243|208 230|cyclin D1-cdk association
P09111314A1243|234 249|kinase activation
P09111331A0119|3 13|Rlm1 protein
P09111331A0119|26 38|MADS box family
P09111331A0119|41 60|transcription factors
P09111340A0240|50 63|downregulation
P09111340A0240|156 167|myc sequences
P09111340A0240|187 201|beta-globin gene
P09111340A0240|218 249|chloramphenicol acetyltransferase
P09111367A1098|78 92|tal-1 expression
P09111367A1098|238 257|cell cycle checkpoints
P09111367A1098|403 414|tal-1 effects
P09111367A1098|452 476|heterodimerization domains
P09111367A1098|485 496|N-terminally
P09111367A1098|506 517|tal-1 variant
P09111863A0743|54 68|tumor suppressor
P09111863A0743|117 134|chromosome fragment
P09111863A0743|146 159|tumorigenicity
P09111863A0743|164 175|introduction
P09115242A0934|32 55|promoter deletion analyses
P09115242A0934|95 106|protein-beta
P09115242A0934|117 127|binding site
P09115242A0934|160 172|transcription
P09115242A0934|175 187|collagenase-1
P09115247A2069|0 24|11-Aminoundecanoyl-SK-NH2
P09115247A2069|28 52|11-aminoundecanoyl-SH-NH2
P09115247A2069|73 85|alkyl backbone
P09115247A2069|229 241|beta-hydroxyl
P09115247A2069|247 264|epsilon-amino group
P09115265A1160|87 111|transcription factor GATA-1
P09115279A0345|0 18|Cdc2 co-precipitates
P09115279A0345|36 46|cell lysates
P09115357A0073|36 47|availability
P09115357A0073|80 106|immunoglobulin hypermutation
P09115357A0073|138 151|culture systems
P09115357A0073|155 173|hypermutating B cells
P09115365A0000|20 35|heat shock protein
P09115395A0478|73 94|epithelial-microtubule
P09115395A0478|121 142|Elongation factor 1gamma
P09115395A0478|159 169|protein L18A
P09115395A0478|224 245|epithelial-microtubule
P09115395A0478|295 316|innercentrosome protein
P09115395A0478|327 340|RNA helicase WM6
P09115395A0478|360 379|transcription factors
P09115395A0478|392 406|co-factor 2alpha
P09115989A0993|28 46|psoralen cross-links
P09115989A0993|74 90|initiation process
P09117345A0945|70 82|cell migration
P09117345A0945|110 124|phosphorylation
P09118196A0281|34 46|National Adult
P09118196A0281|78 94|Vocabulary subtest
P09118196A0281|102 139|Wechsler Adult Intelligence Scale-Revised
P09118196A0281|157 168|correlations
P09118664A1734|0 11|L-canavanine
P09118664A1734|51 63|oxide synthase
P09118664A1734|88 102|filling pressure
P09118704A0771|43 54|chemotherapy
P09118704A0771|69 87|% confidence interval
P09118704A0771|139 155|bleomycin toxicity
P09119031A1036|12 35|holoenzyme RNA polymerases
P09119031A1036|92 108|core RNA polymerase
P09119031A1036|109 122|alpha2beta beta
P09119031A1036|204 214|sigma factor
P09119391A0870|91 105|protein sequence
P09121424A0296|32 42|Swi3 homolog
P09121430A0132|34 46|protein kinase
P09121430A1075|10 21|Y239/240F Shc
P09121430A1075|57 68|c-myc message
P09121433A0463|48 60|specificities
P09121433A0463|133 149|consensus sequence
P09121435A1183|42 58|TFIIIB-DNA complex
P09121435A1183|73 91|protein footprinting
P09121452A0538|0 22|Domain switch experiments
P09121452A0538|33 49|C/EBP beta proteins
P09121452A0538|69 81|leucine zipper
P09121452A0538|87 102|activation domain
P09121452A0538|138 148|2D5 promoter
P09121454A1328|140 161|transcription machinery
P09121476T0000|37 57|DEAD-box protein family
P09121774A0611|88 102|MAP kinase family
P09121774T0000|27 38|polyomavirus
P09121774T0000|78 97|serum response element
P09121774T0000|103 120|cell transformation
P09121998A0663|130 140|transit time
P09122168A1427|24 36|demonstration
P09122168A1427|89 101|translocation
P09122168A1427|154 171|isoform specificity
P09122176A0970|103 119|RA response element
P09122198A0478|0 13|Point mutations
P09122198A0478|23 38|tyrosine residues
P09123055T0000|26 37|preservation
P09123055T0000|60 70|HTK solution
P09123787A0486|74 106|orbicularis oculi muscle ipsilateral
P09123787A0486|217 238|orbicularis oculi muscle
P09126622A0466|3 18|pigment intensity
P09126622A0466|58 73|CAL transformants
P09128730A0000|8 22|decarboxylation
P09128730A0000|25 40|Malonomonas rubra
P09128730A0000|71 89|acyl-carrier protein
P09128730A0000|101 119|acyl-carrier protein
P09128730A0000|131 146|carboxyltransfer
P09128730A0000|150 162|biotin protein
P09128730A0000|169 183|decarboxylation
P09129147A0644|3 20|Jem peptide sequence
P09129147A0644|27 40|leucine-zipper
P09129147A0644|89 104|ATF/CREB proteins
P09129147A0644|123 142|phosphorylation sites
P09130595A0478|45 56|enhancer site
P09130700A0676|85 103|SPC97 overexpression
P09130700A0676|123 139|co-overexpression
P09130720A0417|35 50|branch site region
P09130720A0417|86 100|TACTAAC sequence
P09130720A0417|116 132|intron recognition
P09131139T0000|19 33|acetylhydrolase
P09132011A0298|15 25|p50 sequence
P09132011A0298|119 151|Drosophila cell cycle control protein
P09132057A0559|33 44|reading frame
P09132057A0559|48 65|sequence similarity
P09132057A0559|95 116|receptor protein kinases
P09132057A0559|139 155|S-receptor kinases
P09132057A0559|195 209|Brassica species
P09132057A0559|216 229|Pto gene product
P09132061A0828|21 33|cDNA sequences
P09132061A0828|73 86|isoperoxidases
P09133122A0656|69 82|video sequences
P09133122A0656|83 95|x-ray analysis
P09135149A0000|110 128|Mik1 tyrosine kinases
P09135149A0000|151 174|Pyp3 tyrosine phosphatases
P09135928A0912|32 42|BP responses
P09135928A0912|56 69|norepinephrine
P09135928A0912|111 123|glibenclamide
P09136015A0529|89 103|diversification
P09136080A1469|22 35|DNA methylation
P09136080A1469|36 53|chromatin structure
P09136080A1469|57 71|transactivation
P09138076A1099|2 23|gel mobility shift assays
P09138076A1099|97 117|oligonucleotide probes
P09138492A0806|0 13|Laboratory exam
P09138492A0806|47 62|chest radiography
P09138492A0806|82 95|calcifications
P09138492A0806|186 204|epidermoid carcinoma
P09139665A0784|17 29|PhLP complexes
P09139694A0789|72 82|DNA fragment
P09139694A0789|121 132|DNA fragments
P09139721A0183|58 74|tolerance subjects
P09139737A0000|117 129|cell membranes
P09139737A0000|180 192|transcription
P09139892A1150|26 37|vfr promoters
P09139892A1150|123 134|crp promoters
P09139910A0350|0 15|Sequence analysis
P09139910A0350|24 34|PCR products
P09139910A0350|78 89|DNA fragments
P09139910A0350|157 174|clone XbaI fragments
P09139910A1572|13 26|Anabaena strain
P09139910A1572|58 69|nifV mutation
P09140474T0000|2 14|leishmaniasis
P09142146A0887|19 29|PAF blockade
P09142146A0887|64 78|WEB-2086 animals
P09142146A0887|89 102|vehicle animals
P09143328A1002|59 76|dinucleotide primer
P09143328A1002|81 93|RNA polymerase
P09143465A0838|9 21|dual-T1 images
P09143465A0838|46 57|image quality
P09144165A0614|59 73|Rel insert region
P09144165A0614|104 119|hypervariability
P09144165A0614|158 185|Rel transcription factor family
P09144165A1275|54 67|DNA recognition
P09144165A1275|91 120|AP-1 family transcription factors
P09144195A1051|20 31|PS1 fragments
P09144195A1051|61 93|phosphorylation/dephosphorylation
P09144770A0906|77 96|FKBP12 binding surface
P09144958A0047|71 95|chlorophyll a/b protein gene
P09146071T0001|51 67|pontine hemorrhage
P09147420A0623|28 38|HCMV IE1/IE2
P09147420T0000|21 35|transactivation
P09147420T0000|94 115|cytomegalovirus IE1/IE2
P09147788A0458|11 29|chain enzyme activity
P09147832A0174|31 43|socialization
P09148770A0977|35 49|phosphoproteins
P09148770A0977|83 94|Csk SH2 domain
P09148903A1715|48 63|HIV-1 LTR activity
P09148903A1715|88 100|translocation
P09148903A1715|106 133|NF-kappaB transcription factor
P09148903A1715|151 183|IkappaBalpha serine phosphorylation
P09148929A0372|33 48|plasmid subclones
P09148929A0372|89 100|organization
P09148935A0805|13 28|c-Src PTK activity
P09148935A0805|46 62|type FAK expression
P09148935A0805|126 154|c-Src binding site Phe-397 mutant
P09149825A0151|19 32|4-META/MMA-TBB
P09149929A0750|79 90|homesickness
P09150566A0316|43 58|complex molecules
P09150595A0225|55 68|E. chrysanthemi
P09150595A0225|81 91|E. amylovora
P09150595A0225|145 158|signal sequence
P09150595T0000|9 24|characterization
P09150595T0000|43 70|Erwinia carotovora hrpNEcc gene
P09151152A0174|21 36|protein C activity
P09151152A0174|101 112|hemodialysis
P09151152A0174|165 178|heparinization
P09151152A0174|199 214|serum lipoprotein
P09151376A0000|22 45|hyperbetalipoproteinemia
P09151806A1125|55 66|mLAT pre-mRNA
P09151806A1125|78 88|branch point
P09151828A0919|10 26|amino acid residues
P09151828A0919|43 59|9ORF1 polypeptides
P09151837A0723|7 24|protein interaction
P09151837A0723|51 82|coimmunoprecipitation experiments
P09151837A0723|136 148|fusion protein
P09151837A0723|219 249|transcription-translation system
P09151925A0479|46 57|embolization
P09151925A0479|76 88|gelatin sponge
P09151925A0479|104 126|ethanol injection therapy
P09152656A0149|20 47|New York Heart Association class
P09152656A0149|60 71|heart failure
P09153010A0499|151 163|threshold MUPs
P09153010A0499|200 214|reproducibility
P09153010A0499|243 257|reference values
P09153010A0499|277 288|laboratories
P09153319A1332|0 22|Transfection experiments
P09153319A1332|51 65|reporter plasmid
P09153319A1332|79 102|collagen promoter sequence
P09153319A1332|132 144|transcription
P09153319A1332|162 187|control phosphorothioate ODN
P09153348A0647|56 88|mineralocorticoid steroid secretion
P09153348A0647|96 112|cortisol secretion
P09153348A0647|174 186|HIV-infection
P09154283A0307|107 119|acetazolamide
P09154621A1475|30 51|safflower phospholipids
P09154621A1475|95 112|liver triglycerides
P09154621A1475|116 131|serum cholesterol
P09154795A0628|83 99|DNA polymerase beta
P09154795A0628|108 119|gene promoter
P09154797A0777|9 27|spermidine transport
P09154797A0777|33 43|lacZ mutants
P09154819A0501|9 22|overexpression
P09154819A0501|37 56|tenascin-C expression
P09154819A0501|92 109|fibroblast cell line
P09154822T0000|15 25|Raf-1 kinase
P09154822T0000|34 44|AMP agonists
P09154827A0158|33 47|hamster cell line
P09154827A0158|57 69|point mutation
P09155015A0140|17 34|protein kinase MEKK1
P09155015A0140|44 65|reporter gene expression
P09155024A0955|0 13|Overexpression
P09155024A0955|83 94|pseudohyphae
P09156883A0294|37 49|blood pressure
P09156883A0294|91 102|pulsoximetry
P09157337A0545|82 102|Infectology Department
P09157760A0000|67 79|peculiarities
P09159111A0437|59 72|NMR experiments
P09159183A0119|8 31|ocs element binding factors
P09159183A0119|63 87|basic-region leucine zipper
P09159183A0119|92 111|transcription factors
P09160881A0491|18 40|co-precipitation studies
P09160881A0491|93 104|interactions
P09162084A0956|36 48|Src-SH2 domain
P09162084A0956|83 107|GST-Src-SH2 affinity matrix
P09162092A0675|0 22|MKK3 autophosphorylation
P09162092A0675|65 76|coexpression
P09162097A0776|22 36|MAdCAM-1 variant
P09162097A0776|75 85|mucin domain
P09162097A0776|99 115|leukocyte adhesion
P09162097A1258|55 66|MAdCAM-1 cDNA
P09162097A1258|102 114|mouse MAdCAM-1
P09162097A1258|127 141|dissimilarities
P09163332A0275|24 42|mutagenesis approach
P09163332A0275|78 94|amino acid residues
P09164856A0980|38 48|TATA element
P09164856A0980|63 75|transcription
P09164856A0980|81 95|glutaminase gene
P09165004A1700|0 10|SRE activity
P09165004A1700|41 55|phosphorylation
P09165004A1700|66 78|complex factor
P09165004A1700|102 115|complex factors
P09165035A0842|0 31|Serum alkaline phosphatase activity
P09165035A0842|32 51|bone mass measurements
P09165035A0842|56 66|energy x-ray
P09165035A0842|91 104|mineral density
P09165035A0842|118 130|testing values
P09165039A0728|3 15|monkey LHR cDNA
P09165039A0728|37 52|sequence homology
P09165039A1372|12 28|marmoset monkey LHR
P09165118A0311|14 27|VA motor neurons
P09165118A0311|89 99|sister cells
P09165118A0311|103 116|VB motor neurons
P09165118A0311|173 186|movement defect
P09167421A0234|42 58|microSelectron HDR
P09168134A0858|0 17|Sequence comparison
P09168134A0858|27 44|kb promoter sequence
P09168134A0858|77 88|U1 snRNA genes
P09168134A0858|150 164|snRNP components
P09168218A0216|57 72|pain syndrome type
P09168218A0216|150 162|ganglion block
P09168511A0640|28 39|developments
P09168511A0640|74 90|steroid budesonide
P09168511A0640|98 110|dexamethasone
P09168623A0614|39 50|mxbD promoter
P09168879A0219|29 51|transcription initiation
P09168892A1016|71 86|trans-activation
P09169127A0371|25 50|neuropeptide Y receptor genes
P09169127A0371|83 102|gene duplication event
P09169420A0000|12 36|phosphoinositide 3-kinases
P09169420A0000|58 78|delta form heterodimers
P09169420A0000|83 93|Src homology
P09169475A0272|77 104|transcription initiation sites
P09169475A0772|0 11|Localization
P09169475A0772|17 39|cytokine response element
P09169475A0772|42 57|deletion analysis
P09169475A0772|104 114|binding site
P09169475A0772|127 139|STAT complexes
P09169593T0000|0 16|Insulin regulation
P09169593T0000|36 54|protein kinase kinase
P09169593T0000|75 87|protein kinase
P09169593T0000|91 102|casein kinase
P09169593T0000|108 118|cell nucleus
P09169593T0000|149 162|gene expression
P09169852A0235|20 31|pag-3 alleles
P09169852A0235|71 86|nonsense mutation
P09169852A0235|96 106|zinc fingers
P09169852A0235|111 126|missense mutation
P09169853A0000|19 30|homeobox gene
P09170159A0348|56 69|marker proteins
P09170159A0721|105 116|Zip structure
P09171081T0000|10 25|characterization
P09171081T0000|60 72|RNA polymerase
P09171081T0000|86 106|plant Chenopodium album
P09171235A0851|9 22|overexpression
P09171235A0851|35 47|concentration
P09171235A0851|64 78|COUP-TFI delta35
P09171235A0851|92 108|silencing activity
P09171239A1118|78 93|hormone receptors
P09171239A1118|139 161|transactivation function
P09171239A2146|77 88|RXR component
P09171389A0549|29 48|transcription signals
P09171389A0549|54 77|Thermus pyr promoter region
P09171389A0549|87 113|amino acid sequence identities
P09171389A0549|128 138|Thermus PyrR
P09171389A0549|145 167|PyrR attenuation proteins
P09171389A0549|173 183|Bacillus sp.
P09171389A0549|257 273|pyr gene expression
P09171468T0000|49 66|breathing apparatus
P09171969A1165|36 46|oxygen pulse
P09171969A1165|61 76|work rate exercise
P09171969A1165|116 129|training effect
P09172312T0000|0 15|Characterization
P09172312T0000|56 68|chicken genome
P09172414A0000|68 80|determination
P09172414A0000|83 100|cocaine metabolites
P09172414A0000|126 139|liver esterases
P09173733A0404|59 79|Fourier transformation
P09173733A0404|195 208|factor analysis
P09174049A1788|13 42|p34CDC2 histone H1 kinase activity
P09176340A1194|0 12|Transcription
P09176837A0211|0 15|Computer software
P09176837A0211|62 72|P solubility
P09176837A0211|113 127|P administration
P09177857A0000|25 39|titanium dioxide
P09177857A0000|47 77|substrates titanium tetrachloride
P09177857A0000|159 188|chemical vapour deposition method
P09178491A0262|30 53|preS2/S gene transcription
P09178491A0262|59 71|HBV adw subtype
P09178491A0262|102 117|initiator element
P09178494A1123|78 91|loop structures
P09178494A1123|117 128|flaviviruses
P09178494A1123|161 172|preservation
P09178752A0574|25 49|transactivation domain AF-1
P09178752A0574|68 92|transactivation domain AF-2
P09180687A0096|57 68|cell division
P09180687A0096|141 166|alanine substitution mutants
P09181130A1067|36 48|recombination
P09181130A1587a|130 141|segmentation
P09181130A1587a|163 174|consequences
P09181130A1587a|180 191|inactivation
P09182281A0197|30 41|Cyclosporin A
P09182527A0443|23 39|p53 ubiquitination
P09182707A0254|23 45|tyrosine phosphorylation
P09182707A0254|53 66|adhesion kinase
P09182707A0254|83 96|tyrosine kinase
P09182707A0254|157 171|protein paxillin
P09182990A0245|166 187|translation termination
P09183406A0637|19 34|thrombocytopenia
P09183406A0637|51 65|incompatibility
P09185183A0089|67 80|motor abilities
P09185586A0000|35 50|scanning ribosome
P09185645T0000|12 42|Tc-99m sestamibi perfusion imaging
P09185645T0000|46 61|echocardiography
P09185645T0000|69 86|arbutamine infusion
P09185645T0000|112 124|artery disease
P09186056A0514|13 26|overexpression
P09186056A0514|62 74|transcription
P09186056A0514|78 89|CAT-reporter
P09186507A0882|82 93|cDNA sequence
P09186507A0882|184 199|CpG dinucleotides
P09187136A0000|34 56|protein kinase C substrate
P09187277A0118|5 29|position-vestibular-pause
P09187371A0450|15 25|mRNA species
P09187637A1199|0 16|Taurine deficiency
P09188699A1388|11 25|rat SP-A isoforms
P09188699A1388|77 87|SP-A species
P09188699A1388|99 110|SDS-PAGE gels
P09188863A0954|63 79|cell proliferation
P09189783A0000|4 16|investigation
P09189783A0000|90 101|carbohydrate
P09189783A0000|138 149|blood glucose
P09189783A0000|153 168|insulin responses
P09189896A0611|42 56|memory processes
P09189896A0611|97 108|instructions
P09190202A0166|4 14|coat protein
P09190202A0166|33 52|Sec23p protein complex
P09190202A0166|84 103|Sec13p protein complex
P09190940A0127|27 45|germline transcripts
P09190940A0127|66 77|switch region
P09190940A0127|81 93|recombination
P09191052A0850|16 30|Pbx dimer partner
P09191052A0850|54 64|Hox proteins
P09192769T0000|19 34|characterization
P09192769T0000|57 73|chemokine receptor
P09192769T0000|97 116|C-C chemokine receptor
P09192786T0000|0 11|Organization
P09192786T0000|53 74|blood group polymorphism
P09192842A0988|33 44|FISH analysis
P09192842A0988|74 90|chromosome 19q13.2
P09192842A0988|107 120|translocations
P09192842A0988|211 224|carcinogenesis
P09192998A0356|107 122|termination sites
P09193077A0000|90 105|chalcone synthase
P09193077A0000|126 144|Petroselinum crispum
P09193080A0904|0 17|Sequence divergence
P09194250A0708|25 35|World Summit
P09194250A0708|58 72|mortality target
P09194250A0708|127 138|inequalities
P09195923A0125|3 14|immunophilin
P09195923A0125|37 61|cyclosporin A-binding class
P09195923A0125|80 102|tetratricopeptide repeat
P09195923A0125|124 146|receptor heterocomplexes
P09195923A0125|170 181|immunophilin
P09197241A0770|42 61|hyperphosphorylation
P09197241A0770|65 79|hyperactivation
P09197408A0126|147 164|heptad repeat motifs
P09199167A0942|0 13|Overexpression
P09199292A0536|57 68|cyclin E-cdk2
P09199292A0536|71 82|cyclin A-cdk2
P09199318A1147|25 37|actin gelation
P09199318A1147|60 78|muscle alpha-actinin
P09199322T0000|0 11|Denaturation
P09199322T0000|64 83|replication protein A.
P09199327A1250|109 131|transactivation function
P09199348A0156|36 50|U14 interactions
P09199353A1924|65 82|chromatin structure
P09199353A1924|98 112|polymerase alpha
P09199413A0518|11 22|inoculum size
P09199932A1357|0 28|Promoter recognition algorithms
P09199932A1357|48 63|promoter elements
P09199932A1357|107 119|E14/NPAT genes
P09199932A1357|156 166|ATM promoter
P09199970A1101|32 44|transmembrane
P09199970A1101|76 91|cofactor activity
P09199970A1101|94 104|C3b cleavage
P09200029A0211|106 126|bone marrow examination
P09200498T0000|15 32|muscle coactivation
P09200530A0411|45 54|Zorbax RX C8
P09200530A0411|76 90|gradient elution
P09200811T0000|9 20|plasmid pDHL1
P09200811T0000|81 106|pGKL1-plasmid DNA polymerase
P09201946A0000|24 41|helicase activities
P09201946A0000|62 94|transcription termination factor rho
P09201946A0000|127 138|RNA molecules
P09201946A0000|155 172|nucleotide residues
P09201946A0000|215 233|termination sequence
P09201980A0910|3 15|p20-CGGBP gene
P09202669A0614|83 108|herpes virus thymidine kinase
P09202669A0614|131 148|neomycin resistance
P09202669A1530|29 46|gene transfer system
P09202669A1530|53 68|rat preproinsulin
P09202859A0091|3 13|serum levels
P09202859A0091|35 46|gonadotropin
P09202859A0091|62 80|alkaline phosphatase
P09203585A0660|82 103|neo replacement cassette
P09203586A1197|48 59|rRNA promoter
P09203586A1197|93 109|activation process
P09203731A0497|8 30|International Commission
P09203731A0497|37 49|Certification
P09203731A0497|65 88|Poliomyelitis Eradication
P09203731A0497|113 141|Pan American Health Organization
P09203731A0497|165 176|transmission
P09204566T0000|50 62|fixNOQP operon
P09204566T0000|65 96|Rhizobium leguminosarum strain VF39
P09204570A0110|22 32|MADS box gene
P09205113A0587|21 30|ES cell line
P09205113A0587|46 56|mouse genome
P09205113A0587|76 90|selection marker
P09205113A0587|97 108|transmission
P09205113A0587|132 144|mouse germ line
P09205965A1249|60 73|bladder filling
P09205965A1249|114 125|transmission
P09205965A1249|144 169|spinal alpha 1-adrenoceptors
P09206968A0000|13 24|regeneration
P09206968A0000|78 90|tunica propria
P09208214A0572|0 18|Sternocleidomastoid
P09208930T0000|0 13|Identification
P09208930T0000|47 63|interleukin-1beta
P09209031A0350|49 71|serine carboxypeptidases
P09209312A0968|3 14|RNA construct
P09209406A1021|45 76|guanine nucleotide exchange factors
P09210012A0000|29 41|relationships
P09211354A0000|0 12|Stromelysin-1
P09211354A0000|13 37|matrix metalloproteinase-3
P09211354A0000|56 68|endopeptidase
P09211354A0000|105 116|organ tissues
P09211605A0478|24 36|extensibility
P09211675A0392|0 11|Surveillance
P09211675A0392|15 26|preeclampsia
P09211675A0392|102 113|measurements
P09211675A0392|116 128|blood pressure
P09211675A0392|139 154|protein excretion
P09211675A0392|216 227|measurements
P09211675A0392|237 251|hospitalization
P09211675A0392|302 317|outpatient visits
P09211675A0392|324 339|hospitalizations
P09211913A0000|0 22|Aryl hydrocarbon receptor
P09211913A0000|30 41|translocator
P09211913A0000|63 82|transcription factors
P09211913A0000|83 105|aryl hydrocarbon receptor
P09211913A0000|159 169|target genes
P09211913A0000|185 198|erythropoietin
P09211913A0000|229 240|hydrocarbons
P09211913A0000|251 263|concentration
P09211934A0722|6 22|footprint analysis
P09212059A1356|20 51|metal affinity chromatography assay
P09212059A1356|52 67|self-association
P09212059A1356|124 137|hLBD constructs
P09212059A1856|112 125|PR dimerization
P09212059A1856|229 244|homodimerization
P09212063A0425|38 49|cosmid clones
P09214274T0001|66 84|metastasis resection
P09215525A0581|49 63|E2F/DP complexes
P09215525A0581|92 104|C2C12 myocytes
P09215891A0000|109 127|microtubule function
P09216936T0000|52 63|leptin levels
P09218436A0443|78 90|transcription
P09218459A0000|0 18|Serum response factor
P09218459A0000|100 118|transcription factor
P09218520A0075|32 57|candidate signal transducers
P09218775A0000|93 106|overproduction
P09218775A1229|99 113|algD-xylE fusion
P09219526A0383|35 47|cDNA construct
P09219526A0383|82 97|peptide sequences
P09220158A0537|121 147|baculovirus expression vector
P09220177A0564|3 17|CPK-MB isoenzyme
P09220177A0564|26 43|percentage increase
P09220177A0564|131 143|cardioversion
P09222057A0176|18 30|dialysis fluid
P09222115A0545|96 106|binding site
P09222115A0545|136 157|response characteristic
P09222115A0545|201 212|surroundings
P09223042A0000|13 23|blood volume
P09223042A0000|46 58|disease states
P09223122A0774|7 23|matter NAA/mI ratio
P09223475A0898|0 37|Chloramphenicol acetyltransferase assays
P09223475A0898|198 208|IE86 protein
P09223479A1193|26 40|poxvirus serpins
P09223479A1193|111 128|gammaherpesviruses
P09223506T0000|0 30|Transcription factor binding sites
P09223506T0000|51 75|immunodeficiency virus type
P09223506T0000|77 98|transcription start site
P09223506T0000|114 129|virus infectivity
P09223647T0000|0 15|Crystal structure
P09223647T0000|107 118|implications
P09223667A0139|16 27|transfection
P09223667A0139|30 50|NIH3T3 fibroblast cells
P09223667A0139|54 75|gel mobility shift assays
P09223667A0139|89 99|binding site
P09223667A0139|145 166|transcription start site
P09223667A0139|176 188|CTCCC sequence
P09223880A1147|17 30|injection speed
P09224655T0000|38 62|CIC chloride-channel family
P09224811A0000|43 55|transcription
P09224811A0000|65 92|cytochrome P450 oxidoreductase
P09224811A0000|241 254|P450R mRNA level
P09225151T0000|29 51|polytetrafluoroethylene
P09225151T0000|81 95|scarring process
P09225151T0000|107 117|wall defects
P09225506A0462|3 14|control group
P09225506A0462|50 67|coagulation factors
P09225682A0579|30 43|antibody titers
P09225682A0579|63 78|syndrome patients
P09225682A0579|150 165|syndrome patients
P09225686A0683|12 34|radiofrequency lesioning
P09225686A0683|59 74|seizure remission
P09225686A0683|82 94|complications
P09225998A0000|0 32|NF-kappa B/Rel transcription factors
P09225998A0000|90 112|regulation/inflammation
P09225998A0000|131 150|cell surface receptors
P09225998A0000|151 167|adhesion molecules
P09225998A0000|176 188|phase proteins
P09226113A0857|22 38|source water sample
P09227099A0106|31 42|modification
P09227099A0106|46 62|bar superstructure
P09227799A0254|47 58|surveillance
P09227799A0254|111 126|stool examination
P09227799A0254|172 185|precipitin test
P09228042A0109|16 42|dermatan sulfate proteoglycan
P09228042A0109|116 134|epiphyseal cartilage
P09228042A0109|155 166|ion-exchange
P09228042A0109|167 179|gel permeation
P09228092A1779|31 45|dUTPase isoforms
P09228202A0581|12 45|5-HT3 receptor antagonists ramosetron
P09228202A0581|115 139|5-HT4 receptor agonist/5-HT
P09228202A0581|140 158|receptor antagonists
P09228202A0581|159 176|cisapride mosapride
P09229420A0158|0 12|Re-evaluation
P09229420A0158|18 31|biopsy specimen
P09229420A0158|95 108|chondrosarcoma
P09229420A0158|141 154|chondromatosis
P09229595A0618|3 16|corneal buttons
P09230129A0039|44 65|affinity chromatography
P09230129A0039|75 87|DNA-cellulose
P09230129A0039|145 157|contamination
P09230216T0000|16 30|glycosylase maps
P09230216T0000|33 51|chromosome 12q22-q24
P09230216T0000|72 85|heterozygosity
P09230384A0725|28 39|mycobacteria
P09230384A1056|121 132|mycobacteria
P09230986A0000|0 20|Autoimmune neutropenia
P09232593A0946|29 45|expression pattern
P09232593A0946|74 84|repeat units
P09233487A1386|25 39|outcome measures
P09233487A1386|99 110|ear selection
P09233772A0136|166 187|cell cycle regulator RCC1
P09233772A0136|189 219|guanine nucleotide exchange factor
P09233772A0136|294 304|beta subunit
P09233772A0136|343 357|SH3 binding sites
P09233772A0136|367 380|leucine-zipper
P09233772A0136|401 424|HECT domain characteristic
P09233772A0136|427 452|E3 ubiquitin-protein ligases
P09233801A1180|7 17|L45 sequence
P09233801A1180|25 40|kinase subdomains
P09233801A1180|56 77|TGF-beta responsiveness
P09233809A0381|39 51|Hnf3g-lacZ YAC
P09233809A0815|34 46|gene targeting
P09233809A0815|62 75|Hnf3g gene locus
P09233809A0815|159 180|reporter gene expression
P09233811A0072|25 39|HMG-box proteins
P09233811A0072|53 76|Ste11 transcription factor
P09233811A0072|100 113|protein Mat1-Mc
P09234690A0242|148 158|binding site
P09234696A0238|9 29|protein kinase cascades
P09234703A0192|42 53|G proteins Rac
P09234713A0754|117 135|double-strand breaks
P09234717A0000|46 59|protein product
P09234717A0000|65 83|c-cbl proto-oncogene
P09234717A0000|129 143|tyrosine kinases
P09234717A0000|147 160|forms complexes
P09234717A0000|218 235|signal transduction
P09234720A1015|108 119|coexpression
P09234720A1015|163 178|neurite outgrowth
P09234723A0846|39 56|splicing regulation
P09234725A1892|33 47|transactivation
P09234725A1892|52 69|interaction surface
P09234725A1892|93 107|transrepression
P09234725A1892|110 121|AP-1 activity
P09234727A0770|8 20|fusion protein
P09234727A0770|30 42|transcription
P09234727A0770|46 57|reporter gene
P09234727A0770|99 109|DNA elements
P09234736A0999|6 26|hybridization analysis
P09234736A0999|199 209|goblet cells
P09234743A0475|53 64|alpha-globin
P09234743A0475|114 128|binding proteins
P09234743A0475|134 146|alpha-complex
P09235073A0000|51 64|Weaver syndrome
P09235618A0000|23 36|neuroinfection
P09235618A0000|37 47|Lyme disease
P09235618A0000|48 68|Guillain Barre syndrome
P09235618A0000|69 83|demyelinization
P09235618A0000|164 174|IgM subtypes
P09235618A0000|215 226|thrombocytes
P09235618A0000|227 243|sedimentation rate
P09235618A0000|246 257|erythrocytes
P09235995A0339|5 16|Biochemistry
P09235998A0788|9 26|membrane expression
P09235998A0788|37 48|beta subunits
P09235998A0788|76 93|17-ketocholesterol
P09235998A0788|112 127|HMG-CoA reductase
P09236118A1455|157 186|nucleoprotein activation complex
P09236224A0939|21 33|p21 expression
P09236224A0939|105 120|PC12 growth arrest
P09236224A0939|127 141|differentiation
P09236441A0639|66 81|oxygen saturation
P09237695A0000|80 93|virus infection
P09238467A0763|39 50|phentolamine
P09238850A0785|75 86|feedback loop
P09238860A0175|92 128|AMP response element binding proteins CREB
P09238860A0175|159 173|protein kinase A.
P09238860A1974|85 105|cytokine Interleukin-2
P09238860A1974|176 190|protein kinase C.
P09241092A1108|39 53|glucuronidation
P09241092A1108|56 71|carbamazepine-10
P09241092A1108|121 136|carbamazepine-10
P09241092A1108|151 170|trans-diol derivative
P09241232A0653|3 13|Ogg1 protein
P09241232A1154|1 17|consensus sequence
P09241232A1154|43 55|lysine residue
P09241232A1154|62 73|endonuclease
P09242375A1313|35 48|mutations E768D
P09242375A1313|60 84|gain-of-function mutations
P09242375A1313|209 222|MEN2B mutations
P09242506A1033|38 53|E2F family members
P09242551A0653|114 128|EBER1 expression
P09242551A0653|152 164|lymphoma cells
P09243267A0401|57 69|cell carcinoma
P09243267A0401|116 138|Roswell Park Cancer Center
P09243385A1314|14 26|presaturation
P09243385A1314|53 65|motion studies
P09243385A1314|75 88|PC velocity data
P09243505A1194|60 70|MADS domains
P09243587A0000|0 17|PURPOSE/OBJECTIVES
P09243587A0000|96 107|breast cancer
P09243587A0000|118 129|interruption
P09243587A0000|157 189|abortion increases breast cancer risk
P09243840A0663|89 99|autopsy room
P09243840A0663|111 133|DNA Laboratory structures
P09244282A1371|95 108|pec-1 phenotype
P09244350A0000|30 53|cancer susceptibility gene
P09244350A0000|68 82|phosphoproteins
P09244350A0000|97 112|tumor suppressors
P09244350A0000|120 136|breast cancer cells
P09244430A0693|14 24|splice sites
P09244430A0693|39 52|adducin isoform
P09244430A0693|81 93|acceptor sites
P09247645A0000|126 139|plasma membrane
P09248639A0152|4 14|cell strains
P09248639A0152|76 87|blister fluid
P09248639A0152|165 180|collagen lattices
P09249039A0124|79 93|differentiation
P09249710A0331|60 95|plaque reduction neutralization testing
P09250554A0402|22 32|diltiazem CD
P09250554A0402|40 54|placebo once/day
P09252397A0081|23 33|repair rates
P09252397A0081|36 62|cyclobutane pyrimidine dimers
P09252397A0081|65 84|nucleotide resolution
P09252397A0081|169 195|transcription initiation site
P09252406A0511|32 42|binding site
P09252406A0511|56 73|Shc adaptor proteins
P09252406A0511|89 108|phosphatidylinositol
P09252406A0511|115 133|phospholipase Cgamma
P09252879A0470|16 27|HRCT findings
P09252879A0470|72 87|methacholine PC20
P09252879A0470|116 127|significance
P09254678A0106|105 122|proteolipid protein
P09254678A0106|141 156|brain development
P09254678A0106|244 256|point mutation
P09254709T0000|15 40|Bacillus subtilis catabolite
P09254709T0000|51 61|protein CcpA
P09254709T0000|65 78|amyO target site
P09256973A0455|44 58|itraconazole/kg
P09256973A0673|12 46|itraconazole plasma drug concentration
P09256973A0673|85 97|micrograms/ml
P09256973A0673|105 117|residence time
P09257651T0000|31 42|90kD proteins
P09257651T0000|77 101|yeast splicing factors Prp4p
P09257887A0457|33 45|microg/kg/day
P09257887A0457|101 115|neutrophil count
P09258439A1001|7 22|expression system
P09259052A0568|0 15|Supershift assays
P09259052A0568|71 86|protein complexes
P09259052A0568|130 142|c-jun AP-1 site
P09259052A0568|158 173|Jun family members
P09259313A0950|13 28|PI kinase activity
P09259313A0950|60 73|PRL stimulation
P09259315A0809|84 99|silencer activity
P09259315A0809|115 129|GT-IIC enhansons
P09259315A0809|144 174|CSEn enhancer/silencer activities
P09259320A0830|20 33|chromatography
P09259320A0830|64 78|O-glycosylation
P09259328A0440|0 25|Deletion mapping experiments
P09259328A0440|176 193|luciferase activity
P09261155A0833|80 104|insulin receptor substrates
P09261184A0170|16 39|gel mobility shift analysis
P09261184A0170|43 63|supershift experiments
P09261200T0001|20 31|head injuries
P09261200T0001|37 50|FLAIR technique
P09261397A0509|0 23|Gag protein sequence motifs
P09261397A0509|79 97|genome encapsidation
P09263010T0000|11 24|B cell apoptosis
P09263094A0799|0 11|MEASUREMENTS
P09263094A0799|15 25|MAIN RESULTS
P09263094A0799|26 38|Lung elastance
P09263094A0799|74 85|measurements
P09263094A0799|88 101|airway pressure
P09263094A0799|198 215|mean airway pressure
P09263094A0799|239 258|breathing frequencies
P09263856A0563|41 52|EGF-1 modules
P09264466A0947|3 13|Cut9 subunit
P09264466A0947|88 99|interactions
P09264466A0947|103 117|phosphorylation
P09265534A0455|12 32|Gy/20 fractions/5 weeks
P09265642A0668|74 88|internalization
P09265932A0575|70 83|L2-3 interspace
P09267306A0381|81 99|laboratory precision
P09267306A0381|134 145|introduction
P09267306A0381|156 167|laboratories
P09267431A0000|3 19|soybean cDNA clones
P09267431A0000|49 62|protein kinases
P09267439A0000|19 32|ras superfamily
P09267542A0126|45 62|Drug Administration
P09267542A0126|80 96|alcohol dependence
P09268298T0000|0 18|Ent-kaurene synthase
P09268298T0000|26 46|fungus Phaeosphaeria sp
P09268387A0293|99 111|RNA polymerase
P09268387A0293|127 143|elongation complex
P09268578A0225|12 24|cDNA sequences
P09268631A0316|11 34|transcription orientation
P09268638A0332|25 48|chromosome walking studies
P09268652A0116|16 32|zinc finger protein
P09268652A0116|63 79|expression library
P09268661A1405|25 36|retroplasmid
P09268661A1405|44 56|transcriptase
P09268661A1405|84 96|cDNA synthesis
P09268661A1405|112 122|CCA sequence
P09269879A0266|28 42|bioavailability
P09269879A0266|64 82|elimination profiles
P09269900A1035|49 61|transcription
P09271393A1333|37 49|Tax anchors CBP
P09271393A1333|55 68|HTLV-1 promoter
P09271393A1333|192 213|transcription machinery
P09271394A0558|35 46|footprinting
P09271394A0558|49 68|MURA-Mu1 TIR complexes
P09271397A1596|80 99|LDL receptor SREBP site
P09271400A0475|24 39|promoter activity
P09271400A0475|86 99|E2F2 expression
P09271400A0475|107 123|growth stimulation
P09271417A1011|14 36|receptor response element
P09271496T0000|0 14|Mapping features
P09271496T0000|17 30|HIV-1 integrase
P09271496T0000|58 75|target DNA molecules
P09271496T0000|105 123|photo-cross-linking
P09272108A1295a|77 89|CAAT sequences
P09272108A1295b|77 89|CAAT sequences
P09272138A1153|43 54|rhG-CSF group
P09275159T0000|20 38|ribonucleoprotein A1
P09275159T0000|81 102|mouse hepatitis virus RNA
P09275164A0000|3 21|m7GpppN cap structure
P09275164A0000|100 116|RNA triphosphatase
P09275164A0000|117 138|RNA guanylyltransferase
P09275164A0000|153 169|methyltransferase
P09275990A0938|34 45|mutagenicity
P09275990A0938|119 140|mutagenicity prevalence
P09276882A0479|31 43|SW by-products
P09276882A0479|110 131|% carbohydrate treatment
P09276882A0479|163 175|% carbohydrate
P09277629A0268|56 70|ERP negativities
P09278441A1160|21 38|CARP mRNA expression
P09278441A1777|0 13|Overexpression
P09278441A1777|22 35|cardiomyocytes
P09278441A1777|82 100|factor transcription
P09278445T0000|0 19|Substrate specificity
P09278445T0000|25 37|RNase activity
P09278445T0000|40 57|yeast RNA polymerase
P09278450A1338|15 33|mobility shift assays
P09278450A1338|37 58|competition experiments
P09278454A1261|16 31|MMP-2 RE1 sequence
P09278454A1261|52 64|Y-box sequence
P09278454A1261|65 76|CTGCTGGGCAAG
P09278454A1261|125 157|DMS protection footprinting analysis
P09278475A0465|36 46|ts phenotype
P09278475A0465|72 84|Ino-phenotype
P09278494A0762|20 30|ETS proteins
P09278494A0762|58 73|promoter activity
P09278494A0762|79 93|Surf-1 direction
P09278758A1636|10 20|Patients wit
P09278758A1636|39 49|neck disease
P09279379A0310|114 127|H2B histone gene
P09279889A1124|97 109|% Azone systems
P09280747A0195|16 39|hydralazine hydrochloride
P09280747A0195|43 61|isosorbide dinitrate
P09280747A0195|168 180|ACE inhibitors
P09282329A0527|29 40|interactions
P09282329A0527|74 96|cell cycle control element
P09282329A0527|120 131|determinants
P09282329A0527|164 182|G1/S phase transition
P09282329A0527|204 218|progenitor cells
P09282911A0277|39 50|cell cultures
P09282911A0277|62 76|RC3/neurogranin
P09282985A0961|50 64|characteristics
P09285715A1257|51 63|export pathway
P09285789A0712|17 47|guanine nucleotide exchange factor
P09285789A0712|87 104|pleckstrin homology
P09285789A0712|129 139|repeat units
P09287036A0457|0 25|Plasma leptin concentrations
P09287352A0930|23 36|STAT activation
P09287352A0930|44 58|SHP-1 expression
P09287352A0930|114 133|protein kinase pathway
P09287362A0589|64 80|PPPLPERTPESFVLADM
P09288848A0780|14 24|HbO2 changes
P09288916T0000|70 82|acid hydrolase
P09288916T0000|102 113|beta subunits
P09288916T0000|133 143|kidney cells
P09290207A0731|22 33|derepression
P09290207A0731|45 58|mating type loci
P09290571A0799|3 13|cycle length
P09291077T0000|9 23|hyperammonaemia
P09291077T0000|39 49|shepherd dog
P09291098A0452|41 52|kb GGT mRNA V-2
P09291098A0452|131 140|rat GGT gene
P09291098T0000|31 72|gamma-glutamyl transpeptidase gene expression
P09292499A0887|5 18|repressor sites
P09292499A0887|54 86|polypyrimidine tract binding protein
P09292499A0887|125 156|UV crosslinking/competition assays
P09293006A1412|68 80|aphII promoter
P09294139A0729|13 30|core homology region
P09294139A0729|39 51|HS12 enhancers
P09294139A0729|209 228|sequence conservation
P09294161A0650|62 77|activation domain
P09294161A0650|131 143|transcription
P09294262A0885|3 16|promoter region
P09294262A0885|25 40|consensus TATA box
P09294422A1223|6 21|cysteine residues
P09294422A1223|81 95|disulfide bridge
P09294422A1223|113 129|activation process
P09294422A1376|133 143|tac promoter
P09294452A2107|63 82|reporter enzyme levels
P09294453A0949|76 93|T beta L biosynthesis
P09297698A0933|39 49|UbCRBP mRNAs
P09297698A0933|125 135|enolase gene
P09299696A1074|3 14|distribution
P09299696A1074|17 30|cryptosporidia
P09299696A1074|56 69|cryptosporidia
P09299696A1074|126 141|characterization
P09299696A1074|185 201|cryptosporidiosis
P09300323A1182|40 53|blood flow ratio
P09300323A1182|90 104|control stenosis
P09300698A1219|15 28|interpretation
P09301350A0946|3 21|sputum interleukin-8
P09301350A0946|45 69|treatment median difference
P09301350A0946|81 99|% confidence interval
P09301350A0946|146 159|expiratory flow
P09301350A0946|232 247|percentage points
P09301350A0946|261 283|mean treatment difference
P09303437A0875|59 69|CAT activity
P09303437A0875|214 230|CAT gene expression
P09304123A0079|5 17|discoloration
P09304123A0079|57 70|tooth structure
P09305592A0000|16 42|translocation characteristic
P09305592A0000|63 73|bcr/abl gene
P09305592A0000|87 99|fusion protein
P09305631A0770|0 13|Overexpression
P09305755A0540|35 46|binding sites
P09305755A0540|89 110|CAAT-box binding protein
P09305755A0540|156 172|activator proteins
P09305870A0894|3 24|recognition specificity
P09305870A0894|30 41|p55 PDZ domain
P09305870A0894|93 111|lymphocyte homologue
P09305870A0894|137 151|tumor suppressor
P09305870A0894|183 195|glycophorin C.
P09305944A0621|14 27|RanGAP activity
P09305944A0621|61 82|rna1p mutant derivatives
P09305944A0621|143 155|yeast proteins
P09305944A0621|196 208|GTP hydrolysis
P09307065A0553|72 84|enterotoxin C2
P09307065A0553|91 105|association rate
P09307065A0553|128 143|dissociation rate
P09307065A0553|168 187|dissociation constant
P09307312A0172|61 71|nerve fibers
P09307312A0172|80 91|microphonics
P09307312A0172|170 198|membrane vibration measurements
P09308234A0225|2 13|Max complexes
P09308738A1216|5 16|United States
P09308738A1216|125 160|factor VIII/von Willebrand factor levels
P09309457A0680|45 57|triglycerides
P09309457A0680|58 69|endothelin-1
P09310836A1019|40 51|SV40 promoter
P09310836A1019|63 91|phorbol 12-myristate 13-acetate
P09311568A0595|3 20|cleavage dipeptides
P09311568A0595|23 38|C1YVV NIa protease
P09311796A0218|68 79|IEP86 binding
P09311796A0218|89 110|TATA-box binding protein
P09311796A0218|120 138|transcription factor
P09311810A0814|5 16|accumulation
P09311810A0814|19 33|cyclin D3 protein
P09311810A0814|59 78|alpha0 deletion mutant
P09311810A0814|172 186|alpha0 sequences
P09311835A0147|33 48|characterization
P09311835A0147|77 87|SV40 mutants
P09311835A0147|148 163|ATP binding pocket
P09312025A0373|27 39|co-expression
P09312025A0373|80 120|phosphatidylinositol 3-kinase p85alpha-p110
P09312025T0000|0 19|Protein phosphatase 2A
P09312025T0000|42 68|protein kinase C zeta signaling
P09312025T0000|111 129|NF-kappaB activation
P09312028A0975|16 28|RXRalphaF318A
P09312028A0975|64 75|heterodimers
P09312028A0975|129 142|RAR AF-2 domains
P09312032A0165|29 39|snoRNA genes
P09312032A0165|112 124|intron lariats
P09312087A0000|29 41|Src homology-2
P09312087A0000|177 195|platelet aggregation
P09312087A0000|243 257|phosphopeptides
P09312087A0000|314 336|tyrosine residues Tyr-663
P09313755A0816|30 42|risk variables
P09314306A0571|0 14|Supplementation
P09314487T0000|19 43|Mycobacterium tuberculosis
P09314487T0000|46 58|air filtration
P09314487T0000|62 84|polymerase chain reaction
P09314537A1600|52 70|ezrin binding protein
P09314554A0149|81 92|reading frame
P09314554A0149|130 141|presentation
P09314554A0149|174 186|reading frames
P09314554A0149|196 229|influenza A PR/8/34 nucleoprotein gene
P09314570A0153|57 69|gene promoters
P09315632A1137|62 78|FGFR3 kinase domain
P09315632A1137|134 146|dysregulation
P09315633A0333|10 26|amino acid sequence
P09315651T0000|59 69|chick retina
P09315678A0278|71 82|protein NAP57
P09316937A0133|53 65|discrepancies
P09316937A0133|84 110|API 20E identification systems
P09317131A0000|7 25|chain class switching
P09317131A0000|55 67|transcription
P09317131A1332|30 58|NF kappa B2 nucleoprotein complex
P09317131A1332|132 146|IgE germline gene
P09317757T0000|24 63|CHRISTMAS ISLAND RED CRAB GECARCOIDEA NATALIS
P09317830T0000|12 24|SONG FREQUENCY
P09321406T0000|3 26|pheromone response pathway
P09321406T0000|36 48|transcription
P09321406T0000|51 69|Ty5 retrotransposons
P09321657A0439|69 81|cox3 promoters
P09321657A0439|101 111|core element
P09321657A0439|126 145|cox3 promoter activity
P09321657A0439|154 169|element mutations
P09321930A0567|19 38|tumor suppressor genes
P09321930A0567|139 152|heterozygosity
P09321930A0567|186 197|inactivation
P09321930A0567|208 221|binding protein
P09322738A0510|81 92|S. coelicolor
P09322872A0745|89 101|recombination
P09323366A0000|3 20|malate synthase gene
P09323366A0000|91 102|carbon source
P09323366A0000|108 119|growth medium
P09323366A0299|2 17|deletion analysis
P09323366A0299|23 39|MLS1 control region
P09323366A0299|94 105|derepression
P09323612A0374|36 61|sleep electroencephalograms
P09323612A0374|140 158|treatment strategies
P09323612A0374|201 217|language disorders
P09324878A0952|36 56|ultrasound examination
P09324878A0952|114 128|type B dissection
P09324922T0065|0 18|Fermentation process
P09324922T0065|24 38|supplementation
P09324922T0065|61 72|acid bacteria
P09325022A0192|70 80|C57BL/6 mice
P09325135A0737|9 21|fusion protein
P09325273A1240|97 116|poly-ubiquitin chains
P09325273A1240|141 151|S proteasome
P09325273A1240|172 188|protein substrates
P09325273A1240|237 256|poly-ubiquitin chains
P09325273A1240|290 312|ubiquitin fusion proteins
P09325278A0458|1 22|data base homology search
P09325278A0458|47 66|ER1 amino acid sequence
P09325278A0458|194 222|Caenorhabditis elegans sequence
P09325284A0469|34 44|acid protein
P09325284A0469|63 77|progelatinase B.
P09325322A1293|49 61|cooperativity
P09325322A1293|91 109|InsP3 concentrations
P09326163A0942|22 35|mortality ratio
P09326246A0567|0 15|Sequence analysis
P09326246A0567|110 127|luciferase activity
P09326246A0567|136 152|bp reporter plasmid
P09326263A0410|19 35|transcription-PCR
P09326263A0410|42 54|methodologies
P09326317A0372|26 42|mutation screening
P09326317A0372|95 109|linkage analysis
P09326727T0000|3 15|regurgitation
P09327881T0000|0 37|Positron emission tomography radioligands
P09327881T0000|41 60|dopamine transporters
P09328341A1449|18 34|vit A2 consensus ERE
P09328341A1449|77 99|TR alpha DNA binding mutant
P09328341A1449|132 146|transactivation
P09328343A0181|50 63|protein complex
P09328349A1679|37 51|characteristics
P09328349A1679|88 104|alpha-subunit gene
P09328349A1679|107 118|trophoblasts
P09328476A0068|42 58|ribonucleoprotein
P09328476A0374|66 84|splicing factor Prp3p
P09328824A0000|44 57|v-erbA oncogene
P09328824A0000|84 112|chicken thyroid hormone receptor
P09328824A0000|208 220|acid receptors
P09328833A0588|38 53|MCF-7 cDNA library
P09331119A0659|41 56|thrombocytopenia
P09331119A0659|60 71|parasthesias
P09331864A0230|0 18|Serum concentrations
P09331864A0848|0 20|Serum E2 concentrations
P09333018A0000|98 116|transcription factor
P09333026A0397|87 102|PTK family members
P09333026A0851|208 219|growth factor
P09333168A0310|0 19|Anti-hepatitis A virus
P09334264A0540|12 25|calf thymus CstF
P09334330A0252|56 69|TGF-beta signal
P09334330A0252|95 124|Smad signal transduction proteins
P09334330A0252|161 171|Smad protein
P09334330A0252|286 301|dauer development
P09334331A0910|46 64|EGF receptor DER/Egfr
P09334475A0327|56 71|National Registry
P09334475A0327|138 153|segment elevation
P09334475A0327|202 215|T wave inversion
P09334475A0327|262 273|thrombolysis
P09335267A0142|12 26|operon structure
P09335298A0529|24 35|parCBA operon
P09335298A0529|44 68|plasmid partitioning system
P09335298A1227|28 39|ColE1 cer site
P09335298A1227|111 123|MC1061K strain
P09335298A1227|141 166|multimer resolution activity
P09335298A1227|212 232|stabilization activity
P09335298A2129|94 113|transformation assays
P09335298A2129|150 162|sensitivities
P09335298A2129|180 195|ParE toxin protein
P09335608T0000|96 114|chain gene transcript
P09335619A0583|0 25|Nucleotide sequence analysis
P09335619A0583|40 51|similarities
P09335619A0583|104 114|RU cytoplasm
P09336455A0000|40 52|mRNA synthesis
P09337861T0000|15 38|phosphoinositide 3-kinase
P09337861T0000|87 105|inhibitor wortmannin
P09338414A0430|79 90|stroke volume
P09338414A0430|91 104|thermodilution
P09339900A0939|20 35|promoter activity
P09340641T0001|33 45|nCPAP pressure
P09341139A0690|10 24|resensitization
P09341139A0690|50 62|beta2AR mutant
P09341139A0690|96 109|overexpression
P09341139A0690|124 136|beta-arrestin
P09341158A0167|3 14|medium chains
P09341158A0167|104 114|beta2 chains
P09341158A0167|172 185|sorting signals
P09341182A0605|58 70|BTB/POZ domain
P09341182A0605|79 90|PLZF-BTB/POZ
P09341192T0000|22 39|GLUT4 translocation
P09341192T0000|42 56|3T3L1 adipocytes
P09341192T0000|65 85|tyrosine kinase pathway
P09341193A0362|55 74|transcription factors
P09341193A0362|100 116|Tax responsiveness
P09343208A1405|118 129|organization
P09343210A1112|22 37|mutation analyses
P09343210A1112|43 56|VCAM-1 promoter
P09343210A1112|70 111|chloramphenicol acetyltransferase constructs
P09343210A1112|148 161|VCAM-1 promoter
P09343210A1112|168 181|NF-kappaB sites
P09343210A1112|207 224|VCAM-1 gene promoter
P09343210A1112|285 300|adhesion molecule
P09343222A0415|9 34|NIH/Swiss mouse CCR5 proteins
P09343398A1193|0 11|Processivity
P09343398A1193|14 25|DNA synthesis
P09343426A0456|0 27|Alanine substitution mutations
P09343426A0456|33 51|Zta activation domain
P09343432A0209|25 38|homology domain
P09343433A0000|46 58|RNA polymerase
P09343433A0000|87 103|effect variegation
P09343433A0000|119 132|yeast telomeres
P09343982A0890|14 33|detrusor contractions
P09344650A0967|14 32|transmembrane domain
P09345037A0886|47 64|trans-factor GATA-1
P09345037A0886|77 103|progenitor cell proliferation
P09345495A0000|0 19|PET activation studies
P09345495A0000|50 62|brain function
P09346238T0000|65 90|SCF ubiquitin-ligase complex
P09346621A1181|14 35|liver allograft shortage
P09346935A0459|24 51|coimmunoprecipitation studies
P09346935A0459|89 104|zinc finger domain
P09346935A0459|147 159|RNA polymerase
P09346935A0927|4 23|ZNF74 sublocalization
P09346935A0927|50 74|pre-mRNA maturating factors
P09346935A0927|78 95|RNA binding activity
P09346935A0927|158 170|RNA polymerase
P09346935A0927|200 213|mRNA processing
P09346935A0927|244 271|KRAB multifinger protein family
P09346935A0927|274 286|RNA processing
P09346938A1680|0 30|Ki-ras4BVal-12 transfectant cells
P09346938A1680|54 66|protein levels
P09346938A1680|81 106|cysteine protease cathepsin B
P09346938A1680|127 150|cathepsin B mRNA expression
P09346953A0000|30 55|heparan sulfate proteoglycan
P09346953A0000|135 157|HSact conversion activity
P09346953A0000|201 248|heparan sulfate D-glucosaminyl 3-O-sulfotransferase
P09348226A0852|39 61|tyrosine phosphorylation
P09349501A0196|65 75|MLL products
P09349501A0196|179 192|leukemogenesis
P09349967A0653|33 43|blood supply
P09349967A0653|69 80|organisation
P09349967A0653|89 100|lamellar bone
P09351242A0719|11 33|AtP5CS1 mRNA accumulation
P09351242A0719|115 127|ABA signalling
P09351242A0719|148 160|cycloheximide
P09351242A0719|190 204|ABA biosynthesis
P09351242A0719|210 230|aba1 Arabidopsis mutant
P09351823A0414|17 29|MAPK functions
P09352016A1110|4 15|AF G-CSF level
P09352127A0953|27 40|serum myoglobin
P09352127A0953|44 62|CA III concentrations
P09353247A0922|14 38|over-replication phenotype
P09353247A0922|96 113|cyclin/CDK activity
P09353247A0922|131 146|over-replication
P09353255A0159|39 51|pore complexes
P09353255A0159|79 98|FG-nucleoporin family
P09353255A0159|101 112|pore proteins
P09353296A0510|27 40|amino acid level
P09353296A0510|61 75|moaA gene product
P09353296A0510|105 115|moaC product
P09353304A0732|36 55|membrane localization
P09353304A0732|66 81|membrane ruffling
P09353343A0919|0 12|RNA polymerase
P09353343A0919|49 60|AUBP activity
P09353343A0919|108 121|hnRNP A1 binding
P09353343T0000|12 38|AUUUA response element binding
P09353343T0000|61 79|ribonucleoprotein A1
P09353343T0000|87 98|T lymphocytes
P09354349A0338|111 124|Warthin-Starry
P09354349A0338|183 199|H. pylori antiserum
P09354644A0124|5 16|biosynthesis
P09354644A0124|64 89|beta1,6-GlcNAc transferases
P09354676A1714|73 85|translocation
P09354676A1714|166 178|tumorigenesis
P09354684A1158|54 69|promoter activity
P09354757A1444|0 16|Amino acid residues
P09354757A1444|67 78|RNase H domain
P09354757A1444|94 105|primer strand
P09356645A0672|74 89|nerve enlargement
P09358045A0000|7 24|length cDNA sequence
P09358045A0000|45 61|growth factor-beta
P09358045A0000|117 137|nematode Brugia pahangi
P09358055A0590|55 69|promoter element
P09358069T0000|0 16|Codon optimization
P09358069T0000|47 60|erythropoietin
P09358837T0000|24 36|albumin levels
P09358837T0000|62 73|hypertension
P09359844A0674|9 22|HSL transcripts
P09359887A1168|31 43|Rat7p/Nup159p
P09360422A0135|36 49|arteriopathies
P09360422A0135|68 79|plasma levels
P09360422A0135|82 95|thrombomodulin
P09360422A0135|98 116|betathromboglobulin
P09360422A0135|136 165|plasminogen activator-inhibitor
P09360953A1057|142 154|PTH-1 receptor
P09360956A0840|24 38|phosphorylation
P09360956A0840|56 67|CKIalpha site
P09360956A0840|142 159|signal transduction
P09360993T0000|0 20|Mouse mast cell protease
P09360993T0000|59 73|serine proteases
P09361007A0922|56 73|pair enhancer region
P09362105X0422|99 114|vasoconstriction
P09362473A1540|63 78|enhancer elements
P09362473A1540|169 189|repressor binding sites
P09362473A1540|231 243|twist activity
P09362473A1540|268 288|twist expression domain
P09362480A0452|9 23|cysteine triplet
P09362499A0000|35 46|DNA inversion
P09362499A0000|67 79|DNA invertases
P09363759A0000|0 18|Protein phosphatases
P09363759A0000|78 95|signal transduction
P09364211A0319|22 43|transcription factor E2F
P09364440A2206|43 57|FSH receptor gene
P09365201A2018|40 55|characterization
P09365201A2018|82 100|aromatase expression
P09365201A2018|108 119|breast cancer
P09365272T0000|35 46|interactions
P09365272T0000|76 93|Xenopus egg extracts
P09365431A0314|29 43|benzodiazepines
P09365431A0314|50 91|acetylcholinesterase inhibitor physostigmine
P09366456A0234|12 26|muscle paralysis
P09366456A0234|84 96|body mass index
P09366456A0234|135 146|body mas index
P09366517A0835|78 92|phosphorylation
P09366517A1828|73 87|phosphorylation
P09367288A0115|57 70|unit rest length
P09367288A0115|90 103|immobilisation
P09367392A0567|78 96|template recognition
P09367392A0567|113 124|accumulation
P09367426A1354|67 82|compartment cells
P09367426A1354|97 110|interpretation
P09367426A1354|134 145|polarization
P09367676A0275|0 23|Restriction enzyme mapping
P09367676A0275|37 57|DNA sequencing analysis
P09367676A0275|71 81|phage lambda
P09367676A0275|127 137|mouse TS mRNA
P09367676A1115|0 19|Transfection analyses
P09368006A1332|32 48|NF-kappaB activity
P09368014A0740|3 17|lysozyme FEF site
P09368026A0000|69 80|odontoblasts
P09368026A0000|91 104|mineralization
P09368026A0435|32 45|Msx2 expression
P09368026A0435|48 67|OC promoter activation
P09368026A0435|68 85|luciferase reporter
P09368026A0435|111 129|MC3T3-E1 osteoblasts
P09368057A1083|40 50|SRF activity
P09368057A1083|54 70|repressor activity
P09368058A0969|28 51|phosphopeptide comigrates
P09368058A0969|76 89|phosphopeptide
P09368100A1354|3 13|mHIF-1 alpha
P09368190A1053|61 77|DNA binding pattern
P09368419A0000|96 114|protein biosynthesis
P09368419A0000|131 144|gene expression
P09368419A0628|25 41|DNA binding protein
P09368419A0628|55 80|DNA-ligand binding screening
P09368760A0665|26 55|Drosophila protein kinase DSTPK61
P09368760A0665|95 112|sex differentiation
P09368760A0665|125 139|spermatogenesis
P09369450A1358|70 85|promoter activity
P09369450A1358|172 183|interactions
P09369450A1358|194 213|transcription factors
P09369450A1358|238 259|transcription machinery
P09369450A1358|263 288|steroid receptor coactivator
P09369451A0693|79 99|myocyte enhancer factor
P09369451A0693|123 135|TTAAAAATAAAAA
P09369453A0273|27 37|Bcl-2 family
P09369453A0273|62 74|death promoter
P09369453A0273|76 88|death enhancer
P09369453A0273|104 122|transmembrane domain
P09369482A0690|0 19|Electromobility shift
P09369482A0690|23 42|cotransfection assays
P09369482A0690|116 135|G6Pase gene expression
P09370276A0781|6 17|reading frame
P09370276A0781|38 53|amino acid protein
P09370307A0093|94 110|barley gibberellin
P09370307A0093|148 165|DNA binding proteins
P09371431A1172|0 11|Strain CFN037
P09371431A1172|16 27|R. etli mutant
P09371431A1172|44 58|Tn5mob insertion
P09371431A1172|64 77|promoter region
P09371431A1172|83 100|thiCOGE gene cluster
P09371431T0000|67 85|terminal oxidase cbb3
P09371431T0000|88 100|Rhizobium etli
P09371455A0000|40 51|lipase operon
P09371455A0000|89 103|metalloprotease
P09371455A0000|106 121|Vibrio cholerae O1
P09371566A1384|48 59|S100 extracts
P09371566A1384|75 93|protein preparations
P09371596T0000|61 75|hepatitis B virus
P09371596T0000|97 115|receptor superfamily
P09371622A0779|18 28|IE1 peptides
P09371622A0779|50 62|transcription
P09371622A0779|89 108|lac operator sequences
P09371626A1345|12 26|replicase assays
P09371626A1345|174 185|mRNA template
P09371657A0165|24 46|alanine cluster mutations
P09371657A0165|104 126|triphosphatase component
P09371698A1254|0 11|Transfection
P09371698A1254|22 33|SK-N-MC cells
P09371698A1254|119 136|bp promoter fragment
P09371698A1254|150 163|pseudo-TATA box
P09371731A0627|41 57|eIF-2alpha kinases
P09372451T0000|92 103|integrin beta
P09372908A1068|103 116|gene repression
P09372908A1068|138 152|Polycomb protein
P09372924A0758|15 28|rhHR23 proteins
P09372924A0758|118 130|hHR23 proteins
P09372924A0758|136 152|DNA repair reaction
P09372937T0000|14 45|information regulator Sir4p anchors
P09372937T0000|49 66|partitions plasmids
P09372950A1283|100 111|cleavage site
P09372960A0456|0 15|Polysome analyses
P09372960A0456|40 51|fal1-1 mutant
P09372968A0532|0 15|Sequence analysis
P09372968A0996|53 63|kappaB alpha
P09373140A0000|3 17|mouse M-lysozyme
P09373140A0000|83 96|gene regulation
P09373155T0000|0 13|Identification
P09373155T0000|56 66|mouse testis
P09373155T0000|78 89|localization
P09373651A0255|67 84|acetone cyanohydrin
P09373651A0255|88 102|hydrogen cyanide
P09374082A0504|22 33|effect states
P09374082A0504|41 52|2-ethylhexyl
P09374082A0504|76 92|hydrolysis product
P09374082A0504|116 129|prostaglandins
P09374082A0504|165 176|thromboxanes
P09374082A0504|221 232|inflammation
P09374082A0504|253 266|characteristic
P09374541A0277|9 27|protein binding sites
P09374541T0000|24 46|E2F recognition sequences
P09374541T0000|57 79|thymidine kinase promoter
P09374541T0000|86 105|cell cycle progression
P09376325A0167|97 114|transcription units
P09376626A0737|77 89|h postexposure
P09376782A0328|57 71|hepatitis C virus
P09377374A0000|11 26|characterization
P09379301A2036|13 27|A. microcephalum
P09380504A1255|46 66|thyroid cancer cell line
P09380504A1255|97 118|cycloheximide treatment
P09380504A1255|146 158|actinomycin D.
P09380507A0514|0 23|Glutathione S-transferase
P09380507A0514|32 51|GST-DP fusion proteins
P09380507A0514|104 133|DNA polymerase alpha gene promoter
P09380697T0000|47 59|up-regulation
P09380697T0000|62 86|caveolin gene transcription
P09380697T0000|102 119|density lipoprotein
P09382850A0000|10 27|Checkpoint pathways
P09382924A0131|51 66|interferon-gamma
P09382924A0131|147 159|20S proteasome
P09383156A0691|8 28|RNase E cleavage product
P09383156A0691|61 87|polynucleotide phosphorylase
P09383188A0654|45 59|ARG box consensus
P09385169T0000|23 44|productivity indicators
P09386074A0694|29 41|LV dysfunction
P09386074A0694|52 69|LV ejection fraction
P09387999A1053|57 70|hair cell losses
P09388198A1396|30 54|signal transduction pathway
P09388198A1396|77 88|p38 MAP kinase
P09388198A1396|160 173|autoregulation
P09388199A0948|54 65|dimerization
P09388199A0948|69 81|ligand binding
P09388199A0948|90 103|protein fusions
P09388199A0948|114 129|DNA binding domain
P09388200A0639|47 66|transcription factors
P09388200A0639|74 91|MDM2 overexpression
P09388200A0639|141 153|transcription
P09388246A0903|22 58|electron microscopy immunocytochemistry
P09388246A0903|151 163|intermediates
P09388271A1243|3 15|mobility shift
P09388271A1243|138 149|kinase kinase
P09389137A0763|3 14|prescription
P09389198A0363|78 88|A delta units
P09389492A0520|67 79|dexamethasone
P09389666A0538|4 16|Hex expression
P09389666A0538|53 76|anteroposterior asymmetry
P09389666A0538|82 92|mouse embryo
P09389666A0538|214 228|endoderm lineage
P09389669A1009|24 40|dorsal leg cell fate
P09389669A1009|77 88|leg disc cells
P09389982A1383|16 28|INR correction
P09389982A1383|74 88|log reference INR
P09389982A1383|99 113|prothrombin time
P09389982A1383|122 139|regression analysis
P09390183A1027|0 18|Western blot analysis
P09390183A1027|50 67|NMT peptide antibody
P09391173A0811|0 22|Transcription start sites
P09391173A0811|28 45|plastid ACCase genes
P09391173A0811|102 114|amplification
P09392979T0000|24 37|histoplasmosis
P09392979T0000|40 51|San Francisco
P09393717A1517|5 16|observations
P09393717A1517|83 98|mutator phenotype
P09393771A1659|0 16|TNF-alpha exposure
P09393875A0873|23 36|papillomavirus
P09393875A0873|83 93|virus genome
P09393875A0873|199 214|Fos protein levels
P09393875A0873|222 235|papillomavirus
P09393966A0190|28 38|region genes
P09395456A0424|21 31|chain motifs
P09395456A0424|34 53|substrate recognition
P09395456A0424|89 106|proenteropeptidase
P09395456A0424|136 154|transmembrane domain
P09395456A0424|160 172|signal peptide
P09395470A0294|0 11|CKbeta4GT-II
P09395470A0294|38 62|transmembrane glycoprotein
P09395470A0294|95 112|glycosylation sites
P09395525A0395|160 172|IGF-I promoter
P09396402A0264|18 30|Semen analyses
P09396402A0264|93 104|chemotherapy
P09396402A0264|160 171|radiotherapy
P09396402A0264|189 200|chemotherapy
P09396427A1488|24 44|infarct-zone viability
P09396437A0878|29 39|NE spillover
P09396722A0185|37 65|ascorbate peroxidase isoenzymes
P09396722A0185|83 94|organization
P09396796A1173|43 57|E2F family member
P09396796A1173|93 111|cell cycle regulation
P09396823T0000|38 50|DNA polymerase
P09396823T0000|69 89|RNA exonuclease domains
P09397261A0940|0 18|Interleukin-1 levels
P09397723T0001|0 20|Responsibility matters
P09398267A0440|0 19|Southern blot analysis
P09398267A0440|64 85|chick embryo fibroblasts
P09398332A0732|146 160|SH2 binding motif
P09398332A0732|178 192|CTLA-4 signaling
P09398598A0256|35 46|hamster ovary
P09398598A0256|75 85|CD4 fragment
P09398855A0438|4 17|J recombination
P09398855A0438|38 50|T-lymphocytes
P09398855A0438|77 93|gamma-irradiation
P09398855A0438|169 185|DNA repair activity
P09400613A0594|0 11|Coexpression
P09400613A0594|45 56|domain fusion
P09400613A0594|101 111|K296R mutant
P09400613A0594|206 236|PKR-Gal4 activation domain fusions
P09400613A0594|269 281|lacZ reporters
P09400613A1209|5 31|GST-PKR fusion chromatography
P09400613A1209|80 90|PKR homologs
P09400738A1046|62 73|instillation
P09400738A1046|91 104|CB instillation
P09402029A1632|25 35|strain H37Ra
P09402029A1632|46 58|hybridization
P09402029A1632|162 172|copy numbers
P09402029A1632|202 212|strain H37Rv
P09402088A2250|38 50|configuration
P09402088A2250|84 99|AVP gene precursor
P09402139A1121|0 11|Similarities
P09402139A1121|33 57|phosphoenolpyruvate kinase
P09402139A1121|105 118|glucocorticoid
P09402139A1121|233 249|glucose metabolism
P09403059A0209|34 44|DNA elements
P09403059A0209|66 98|medium reiteration frequency repeats
P09404725A0644|19 30|gangliosides
P09405195A0320|63 75|recombination
P09405195A0320|147 160|intron excision
P09405195A0320|212 224|recombination
P09405536A0777|9 29|conditioning procedure
P09405536A0777|157 175|conditioning stimuli
P09405685A0113|20 48|DNA binding transcription factor
P09405685A0113|77 90|consensus motif
P09405685A0113|102 115|GPyPyPyPuPuPuC
P09407026A0426|0 11|TSA treatment
P09407026A0426|40 60|enhancer factor binding
P09407026A0426|102 119|chromatin templates
P09407026A0426|134 151|protein acetylation
P09407026A0426|155 173|chromatin remodeling
P09407031A0557|79 93|phosphorylation
P09407031A0557|131 144|Cdc2 activation
P09407031A0974|16 29|overexpression
P09407031A0974|68 78|crb2 mutants
P09407036T0000|33 51|transcription factor
P09407036T0000|79 92|gene expression
P09407090T0000|12 23|localization
P09407642A0305|15 26|gel technique
P09407642A0305|45 61|antibody detection
P09407642A0305|65 78|identification
P09408516T0000|11 23|pyrimethamine
P09408516T0000|33 49|dosage formulation
P09408796A0648|8 25|regression analyses
P09408796A0648|38 74|WAIS-R factor scores Verbal Comprehension
P09408796A0648|89 103|Distractibility
P09408796A0648|145 155|CVLT indices
P09409416A0111|75 91|Doppler instrument
P09409416A0111|92 101|TC-2 64B EME
P09409774A0214|66 84|rat Rattus norvegicus
P09409774A0214|123 137|polypeptide SMR1
P09409821T0000|123 152|postreplication repair mechanism
P09411459A0729|33 44|deletion task
P09411459A0729|102 114|vowel deletion
P09411459A0729|187 198|CVCC material
P09412079T0001|0 10|Diet therapy
P09412079T0001|15 25|soy proteins
P09412079T0001|36 48|stomach ulcers
P09413375A1486|2 12|ICU patients
P09413375A1486|82 101|plasma concentrations
P09414074A0827|0 17|Resistance training
P09414074A0827|64 75|measurements
P09414074A0827|157 171|performance task
P09414287A0637|0 14|Gel-shift assays
P09414287A0637|28 42|Sp1 binding sites
P09415711A1348|0 15|Gel mobility shift
P09415711A1348|81 93|DDT1MF-2 cells
P09415711A1348|121 134|alpha 1B-AR gene
P09415711A1348|140 156|CRE binding protein
P09416467A0959|46 58|ACE inhibitors
P09416467A0959|87 106|ischemia-reperfusion
P09416467A0959|121 136|scavenging action
P09416898A1798|69 80|ARVD patients
P09417082A0127|10 25|signaling cascade
P09417082A0127|39 55|urokinase receptor
P09417108A0000|9 21|Htf9-a/RanBP1
P09417108A0000|25 35|Htf9-c genes
P09417493A0823|53 72|laboratory indicators
P09417493A0823|75 86|inflammation
P09417493A0823|104 119|alpha 2-globuline
P09417493A0823|120 134|prostaglandin E2
P09417870A0105|39 52|protein kinase C
P09417870A0105|75 95|B16 mouse melanoma cells
P09417870A0105|100 116|phorbol dibutyrate
P09417870A0105|151 163|melanogenesis
P09417928A0980|62 75|reading helices
P09417941A1287|3 19|disulphide bridges
P09417941A1287|42 62|spermadhesin molecules
P09418040T0000|0 11|Mg-chelatase
P09418040T0000|21 34|identification
P09418040T0000|38 53|Chl D cDNA sequence
P09418040T0000|148 161|reconstitution
P09418040T0000|167 180|enzyme activity
P09418040T0000|183 195|co-expression
P09418861A0623|67 80|protein kinase C
P09418861A0623|107 130|pleckstrin homology domain
P09418871A0620|50 81|coimmunoprecipitation experiments
P09418882A0760|102 114|yeast extracts
P09418905A1396|83 95|DAG production
P09418905A1396|127 138|S-phase entry
P09418905A1396|142 155|gene expression
P09419415A0236|25 38|STAT activation
P09419415A0236|55 73|fibroblast cell lines
P09419415A0236|105 116|oncoproteins
P09419680A1112|15 25|animal model
P09419680A1112|37 53|barrier disruption
P09419680A1112|87 101|single-fraction
P09419680A1112|111 127|irradiation injury
P09420219A0284|15 27|investigation
P09420219A0284|116 133|beta-actin minigene
P09420219A0284|178 194|enhancer-promoter
P09420219A0284|253 266|adenovirus type
P09420220A0070|29 40|interactions
P09420234A0654|20 37|sequence similarity
P09420234A0654|84 102|chaperonin-60 family
P09420239A1937|89 106|Nef coding sequences
P09420239A1937|116 129|RNA splice donor
P09420239A1937|133 145|acceptor sites
P09420239A1937|146 157|TATA box sites
P09420239A1937|211 240|consensus neutralization epitope
P09420239A1937|259 276|glycosylation sites
P09420252A0092|182 198|auxiliary proteins
P09420269A0000|24 35|rubella virus
P09420275A0682|16 27|requirements
P09420275A0682|31 41|CBF2 binding
P09420275A0682|64 79|oligonucleotides
P09420275A0682|94 114|transversion mutations
P09420275A0682|139 150|core sequence
P09420275A1111|57 69|CD23 promoters
P09420671A1190|32 45|99mTc sestamibi
P09420671A1190|85 97|artery disease
P09420671A1190|123 134|dipyridamole
P09420671A1190|138 152|adenosine stress
P09421507A0000|5 17|protein family
P09421507A0000|54 69|pre-mRNA splicing
P09421508A0696|105 121|transfection assay
P09421511A0827|57 81|RNA-polymerase specificity
P09421511A0827|84 110|telomerase RNA-gene promoters
P09421511A0827|142 157|template sequence
P09421511A0827|163 175|telomerase RNA
P09421516A1516|0 12|Deadenylation
P09421516A1516|23 37|beta-globin mRNA
P09421516A1516|82 92|NIH 3T3 cells
P09421516A1516|136 150|beta-globin mRNA
P09421516A1516|185 201|deadenylation step
P09421521T0000|0 24|Holliday junction resolvase
P09421521T0000|63 82|endonuclease activity
P09421521T0000|88 104|CCE1 homologue YDC2
P09422351A0000|22 34|protein kinase
P09422351A0000|61 89|serine/threonine protein kinase
P09422351A0000|103 113|ion channels
P09422351A0000|161 180|transcription factors
P09422727A0196|44 59|promoter sequence
P09422727A0196|64 93|protein kinase A signaling pathway
P09422727A0196|139 155|CRE binding protein
P09422727A0196|173 193|transcription factor-2
P09423310A0251|0 18|Histopathologically
P09423310A0251|26 37|lymphangioma
P09423856A1098|0 17|Protease activities
P09423856A1098|182 196|autoproteolysis
P09423856A1098|211 222|peptide bonds
P09424012A1774|10 29|field placement errors
P09424012A1774|56 66|mm distances
P09425036A0649|44 58|Src family member
P09425036A0649|115 126|Csk substrate
P09425676A0000|28 44|stimulus-response
P09425676A0000|48 59|associations
P09425676A0000|62 82|S-R compatibility tasks
P09426068A0826|3 21|c-myc/TGF-alpha HCCs
P09426143A1358|85 101|pectinolysis genes
P09426143A1358|201 213|RNA polymerase
P09426143A1358|253 263|target genes
P09426183A0000|13 31|Rel/NF-kappaB family
P09426183A0000|34 63|vertebrate transcription factors
P09426239A0386|95 112|restriction enzymes
P09426595T0000|32 56|saccharopine dehydrogenase
P09426595T0000|61 79|Arabidopsis thaliana
P09426595T0000|80 97|nucleotide sequence
P09426595T0000|101 116|characterization
P09426907A0391|16 28|investigation
P09426907A0391|59 76|silver sulfadiazine
P09426958A0110|67 84|corneal cDNA library
P09427544A0000|16 26|Amycolata sp
P09427544A0000|44 55|pectate lyase
P09427551A0501|92 106|linkage analysis
P09427627A0802|2 15|Xenopus embryos
P09427627A0802|29 47|PDGF receptor protein
P09427627A0930|47 66|transphosphorylation
P09427627T0000|33 53|PDGF receptor signaling
P09427627T0000|66 83|membrane attachment
P09428389A1805|28 39|bicalutamide
P09428389A1805|108 124|serum testosterone
P09428389A1805|141 152|bicalutamide
P09428787A0138|82 105|p69/71 2-5A synthetase gene
P09428799A0897|85 107|intron/exon organization
P09430461A0742|38 49|BMIPP imaging
P09430461A0742|141 164|contrast ventriculography
P09430461A0742|269 280|BMIPP imaging
P09430461A0742|299 312|quantification
P09430461A0742|341 358|threshold technique
P09430461A0742|387 399|determination
P09430661A0796|9 22|overexpression
P09430661A0796|31 44|EphB1 receptors
P09430661A0796|57 70|Nck recruitment
P09430661A0796|98 110|JNK activation
P09430661A0796|121 143|cell attachment responses
P09430668A0172a|14 28|HMG-CoA synthase
P09431812A0576|51 64|Ci binding sites
P09431828A1472|30 45|cyclosporine DR/C
P09432752A0109|65 86|treatment possibilities
P09434160A0767|54 72|bone marrow stem cells
P09434160A2078|43 57|bone marrow cells
P09434185A0902|3 14|organization
P09434185A0902|50 61|DNA packaging
P09434185A0902|65 85|phage assembly proteins
P09434185A0902|98 109|organization
P09434979A0790|40 52|photon fluence
P09434979A0790|67 79|photon fluence
P09435056A0128|27 37|pediocin AcH
P09435056A0128|142 153|COOH terminus
P09435116A0437|49 85|trofluoroacetyl-biphenylol derivatives
P09435789A0961a|42 56|cell cycle arrest
P09435806T0001|30 43|growth kinetics
P09435806T0001|60 76|cancer recurrences
P09436657A0303|55 68|carcinogenesis
P09436657A0303|106 116|risk factors
P09436706A0168|38 57|sperm injection cycles
P09436706A0168|178 214|gonadotrophin-releasing hormone agonist
P09436706A0168|215 229|leuprolide depot
P09436706A0168|233 246|gonadotrophins
P09436795A0350|0 17|Protein C deficiency
P09436795A0350|20 37|protein S deficiency
P09436989A1011|80 101|cell cycle reset function
P09436989A1011|132 157|spindle pole body duplication
P09437001A0769|10 23|overproduction
P09437001A0769|42 54|sec61-2 strain
P09438165A0405|78 93|VOD manifestation
P09438427A0727|44 58|Hoxa1 expression
P09438427A0727|105 139|Hoxa1 beta-galactosidase reporter gene
P09440166A0857|16 33|cDNA insert sequence
P09441664A0377|41 59|transcription factor
P09441664A0377|83 107|HNF-3 beta promoter activity
P09442024A0708|1 14|hybridoma clone
P09442024A0708|73 92|fibroblasts MRC5 cells
P09442024A0708|142 154|Jacalin lectin
P09442031A0586|111 132|TSHR ectodomain variants
P09442031A0586|133 150|places cleavage Site
P09442072A0716|13 24|footprinting
P09442072A0716|189 200|liver factors
P09442080A0856|11 22|binding assay
P09442080A0856|111 140|glutathione S-transferase fusion
P09442080A0856|168 181|domain residues
P09442172A0908|73 89|gonadotrophin dose
P09442172A0908|127 139|pregnancy rate
P09443948A0000|110 123|trichinellosis
P09443948A0000|138 159|immunofluorescence test
P09443948A0000|196 209|trichinellosis
P09443972A1145|43 61|transcription factor
P09443978A0262|85 97|transcription
P09445056A0215|27 47|chemical cross-linking
P09445056A0215|54 70|sulfosuccinimidyl
P09445056A0215|97 108|architecture
P09445056A0215|114 125|gp41 oligomer
P09445488A0230|23 38|USH1C disease gene
P09445488A0230|132 148|STS content mapping
P09445488A0230|152 171|Alu-PCR hybridization
P09445488A1169|0 17|PowerBLAST analysis
P09445488A1169|50 61|sequence tags
P09445488A1169|160 172|DNA binding/EF
P09446600A0260|1 13|fusion protein
P09446600A0260|24 41|beta-galactosidase
P09446616A0780|0 13|Reconstitution
P09446616A0780|16 28|Raf-1 activity
P09447962A1027|18 31|interpretation
P09447962A1027|219 231|HIS4 mRNA level
P09447963A0223|59 72|splicing factor
P09447973A0168|40 59|myristoylation signal
P09447973A0168|99 109|NIH 3T3 cells
P09447973A0168|126 138|mSos C terminus
P09447973A0168|139 152|MyrSos1-deltaC
P09447979A1430|54 66|sequestration
P09447979A1430|72 102|guanine nucleotide exchange factor
P09447994A0000|118 133|response elements
P09447994A0000|156 173|c-fos transcription
P09448574A0964|147 159|system atrophy
P09449018T0000|0 19|Childhood misbehavior
P09450932A0142|56 78|DNA structure checkpoints
P09450932A0142|109 120|DNA synthesis
P09451003A0894|4 20|Esigma54 promoters
P09451003A0894|58 74|sigma54 activators
P09451003A0894|151 165|CRP-cAMP complex
P09451016A1037|9 39|GlcNAc2-PP-Dolichol biosynthesis
P09451016A1037|155 167|transcription
P09451857T0001|0 12|Demonstration
P09451857T0001|15 27|tissue lesions
P09451857T0001|57 69|determination
P09451857T0001|72 85|creatine kinase
P09452444A0000|0 12|Interleukin-6
P09452444A0000|91 104|phase reactions
P09452444A0000|108 120|hematopoiesis
P09452444A0450|63 78|IL-6 gene promoter
P09452444A0450|89 100|reporter gene
P09452444A0450|133 152|transcription factors
P09453537A0863|81 96|recognition sites
P09453689A0000|44 55|pin sensation
P09453689A0000|62 76|bulbocavernosus
P09453689A0000|136 158|bladder function recovery
P09454719A0181|50 64|LTR R/U5 junction
P09454719A0181|99 125|AAUAAA polyadenylation signal
P09454719A0181|164 193|polyadenylation signal sequences
P09454735A1782|11 29|MEK inhibitor PD98059
P09454735A1782|64 87|MAP kinase phosphorylation
P09454735A1782|116 134|adhesion disassembly
P09454735A1782|138 149|cell motility
P09455695A0762|77 93|vitamin E treatment
P09456312A1064|71 88|localization signal
P09458030A0192|54 74|bone mineral metabolism
P09459685T0001|7 20|configurations
P09459685T0001|35 47|stress factors
P09459835A0297|33 47|mg/kg body weight
P09459835A0297|82 96|mg/kg body weight
P09460171T0000|12 25|thyroid hormone
P09460171T0000|26 37|implications
P09460171T0000|81 104|thyroid hormone disruptors
P09461594A0000|35 52|DT40 lymphoma B cells
P09461594A0000|133 152|phospholipase Cgamma2
P09461594A0000|181 208|inositol phospholipid turnover
P09463380A1050|47 65|mesoderm marker genes
P09463964A0243|38 50|micrograms l-1
P09463964A0243|92 104|micrograms l-1
P09464525T0000|13 28|characterization
P09464525T0000|59 69|Fv fragments
P09465783A0449|0 18|Platelet aggregation
P09465783A0449|33 53|micrograms collagen/ml
P09466267A1192|5 15|himA mutants
P09466267A1192|80 98|dmsA-lacZ expression
P09466931T0000|0 12|Cross-talking
P09466931T0000|60 74|response element
P09466931T0000|87 104|ng-2 intermolt genes
P09467044A0973|14 35|breast tumor relapse rate
P09467044A0973|63 73|MGDET groups
P09467707T0000|0 17|Sibling aggregation
P09467707T0000|38 59|lipoprotein cholesterol
P09467707T0000|63 78|apolipoproteins B
P09467707T0000|117 134|Bogalusa Heart Study
P09467900A0701|3 15|CAPLC1 protein
P09467900A0701|79 95|amino acid residues
P09467900A0701|179 191|binding domain
P09467955A0468|45 60|PEA3 binding sites
P09467955A0468|66 77|PEA3 promoter
P09468386A0594|64 76|transcription
P09468386A0594|88 105|promoter constructs
P09468514A1065|0 15|Northern analysis
P09468515A0621|26 39|promoter region
P09468515A0621|76 90|SF-1 binding site
P09469415A1337|73 91|CTL target structures
P09469415A1337|108 120|possibilities
P09469415A1337|160 171|CTL responses
P09469415A1337|180 194|DNA immunization
P09469820A0151|85 97|reading frames
P09469833A0533|34 48|site specificity
P09469833A0533|55 69|deletion mutants
P09471984A0000|73 89|contact dermatitis
P09472038T0000|12 23|polarization
P09472038T0000|47 60|immunoreceptor
P09472608A0253|41 51|protein YB-1
P09472608A0253|62 74|transcription
P09472608A0253|80 92|HIV-1 promoter
P09472608A0253|173 189|transfection assay
P09473040A1303a|45 71|siderophore system activities
P09473040A1303b|45 71|siderophore system activities
P09473317X2131|13 25|Academic Press
P09473483A0953|127 140|HIV-I infection
P09474648A0298|32 46|frequency domain
P09475378A1449|18 54|transcription-polymerase chain reaction
P09475378A1449|58 69|HPLC analysis
P09475378A1449|118 130|splice variant
P09475724T0000|22 38|signaling pathways
P09475898T0000|13 25|amnioinfusion
P09476399A0141|24 36|tea plantation
P09476520A1326|176 188|heterogeneity
P09477316A0140|38 53|Hox gene induction
P09477316A0140|80 95|Hox gene regulator
P09477316A0140|99 137|leucine zipper transcription factor MafB/Kr
P09478921A0126|49 60|pathogenesis
P09478971A1896|0 17|Reporter constructs
P09478971A1896|128 149|mouse embryo fibroblasts
P09478976A0718|0 18|Transfection studies
P09478976T0000|0 10|Oncostatin M
P09478976T0000|60 70|AP-1 element
P09478976T0000|80 94|tissue inhibitor
P09478976T0000|97 123|metalloproteinase-1 promoter
P09479498A0000|23 37|RING-finger gene
P09480831A0272|42 55|gene expression
P09480843A0848|54 67|triplet repeats
P09480929T0000|105 132|baculovirus/insect cell system
P09481826T0000|14 26|liver syndrome
P09481826T0000|83 95|somatotrophin
P09482107A0551|15 28|focus formation
P09482107A0551|80 92|cell viability
P09482107A0551|144 154|growth rates
P09482107A0551|170 180|NIH3T3 cells
P09482107A0551|203 215|plasmid vector
P09482902A0423|33 44|DBA/2 alleles
P09482902A0423|107 128|CDK4/CDK6 inhibitors p16
P09482902A0942|127 139|cyclin D2/CDK4
P09482902A0942|142 153|kinase assays
P09482902A0942|158 178|retinoblastoma protein
P09482902A0942|249 262|susceptibility
P09482902A0942|278 298|plasmacytoma induction
P09483596A0626|93 110|suxamethonium group
P09483596A0626|136 150|rocuronium group
P09484781A1233|32 55|D3 phosphatidylinositides
P09485790T0000|0 22|Alison Bell Memorial Award
P09486035A0051|8 23|population survey
P09486531A0638|6 18|organogenesis
P09486531A0638|19 33|HFH-8 expression
P09486531A0638|86 96|gut endoderm
P09486531A0638|154 169|gut morphogenesis
P09486890A0234|35 47|inoperability
P09486890A0234|60 74|carcinoma spread
P09486890A0234|109 121|visualization
P09487130A0383|14 27|telomere length
P09487130A0383|89 104|DNA repair mutants
P09487590A0657|3 14|mean duration
P09487841A0132|41 57|sample preparation
P09488441A0615|14 26|transcription
P09488441A0615|34 47|immunoglobulin
P09488441A0615|69 100|P-selectin promoter NF-kappaB sites
P09488441A0615|115 127|p50 homodimers
P09488441A0615|145 162|P-selectin promoter
P09488441A0615|172 186|site competition
P09488466A0695|98 126|precursor-product relationship
P09488486A0000|50 62|transcription
P09488486A0000|90 103|RNA polymerases
P09488486A0906|62 90|yeast U6 snRNA gene transcription
P09488486A0906|124 136|transcription
P09488491A0000|0 10|E2F activity
P09488491A0000|33 52|retinoblastoma family
P09488491A0000|55 77|tumor suppressor proteins
P09488713A0886|35 48|Site-1 cleavage
P09488713A0886|77 90|overexpression
P09488725A0904|58 69|polypeptides
P09488725T0000|9 24|characterization
P09489670A1157|126 142|HST6 transcription
P09489670A1157|245 260|Hst6p transporter
P09490676A0800|37 48|Ets-2 protein
P09490676A0800|108 128|oligodeoxynucleotides
P09490727A1041|4 25|structure interconnects
P09491074A0104|77 90|promoter region
P09492038A0352|91 106|promoter activity
P09492038A0352|157 169|binding assays
P09494078A1362|6 18|5HT5A receptor
P09495283A0000|14 25|reporter gene
P09495283A0000|59 87|heat shock transcription factors
P09495771A0379|9 20|fluorescence
P09495771A0379|63 81|midcell constriction
P09498553A0702|30 43|promoter region
P09498553A0702|176 203|transcription initiation sites
P09498553T0000|79 95|P450 monooxygenase
P09498769A0095|3 19|expression pattern
P09498769A0095|22 35|representative
P09498769A0095|84 99|B cell development
P09498769A0095|174 184|plasma cells
P09499031A0000|17 29|gene junctions
P09499031A0000|41 55|stomatitis virus
P09499031A0000|75 90|sequence elements
P09499031A0000|110 124|polyadenylation
P09499031A0000|128 151|transcription termination
P09499031A0000|180 191|reinitiation
P09499031A0000|194 206|transcription
P09499048A1003|16 27|virus progeny
P09499048A1003|119 134|replication cycle
P09499061A0000|47 71|immunodeficiency virus type
P09499254A1309|82 100|islet-cell carcinoma
P09499254A1309|104 119|patient tolerance
P09499254A1309|164 176|investigation
P09501093A0071|70 82|Ras activation
P09501093A0071|110 130|Ras signal transduction
P09501169A0000|0 23|Histone acetylation levels
P09501169A0000|76 92|histone acetylases
P09501169A0000|96 107|deacetylases
P09501982A1178|91 104|Xenopus embryos
P09501982A1178|118 138|Delta-Notch signalling
P09501982A1178|188 202|progenitor cells
P09501982A1178|325 339|differentiation
P09501982A1178|352 368|XNeuroD expression
P09502627A0705|58 80|wall motion abnormalities
P09502627A0705|102 117|ventriculography
P09502627A0705|125 135|infarct area
P09502627A0705|155 178|peak creatine kinase levels
P09502627A0705|209 224|ejection fraction
P09502627A0705|231 247|hospital discharge
P09502720A0214|0 17|CyIIa transcription
P09502720A0214|61 73|specification
P09502720T0000|26 46|cell type specification
P09502720T0000|79 95|complex expression
P09502720T0000|112 127|sea urchin embryos
P09503017A1021|99 114|chromosome 3p21.3
P09503017A1021|158 179|lung carcinoma cell lines
P09503526A0614|37 50|skin vasculitis
P09503526A0614|62 87|diseases WFAg concentrations
P09504423A0114|128 152|glutathione-S-transferase
P09504423A0114|177 192|gene fusion vector
P09504423A0114|216 227|gene sequence
P09504423A0114|237 248|cleavage site
P09504423A0114|269 282|alpha-thrombin
P09504514T0000|42 67|bone-marrow transplantation
P09504514T0000|79 90|chemotherapy
P09504906A0099|89 103|cysteine residue
P09506439A2179|28 40|keratinocytes
P09506439A2179|62 75|gene expression
P09506959T0000|0 13|Identification
P09506959T0000|17 32|characterization
P09506959T0000|85 102|Myc/Max/Mad network
P09506983A0304|66 77|RACE products
P09506990T0000|5 15|ZFM1 protein
P09506990T0000|63 91|transcription activation domain
P09506990T0000|108 123|activator protein
P09507032A1144|15 30|CSF1R/IRDelta960
P09507032A1144|69 83|CSF-1 protection
P09508119A0498|29 40|presentation
P09508377A0863|33 45|UV sensitivity
P09508377A0863|66 77|phaeomelanin
P09508377A0863|84 98|eumelanin levels
P09508377A0863|112 138|eumelanin/phaeomelanin ratio
P09508377A0863|147 163|chemical parameter
P09508511A0588|65 76|fluorofamide
P09508775A0293|77 99|protein kinase activation
P09508775A0293|178 212|protooncogenes/transcription factors
P09509226A1235|62 73|time patients
P09509226A1235|129 139|nursing time
P09510189A0192|30 41|organization
P09510398A1138|3 13|risk factors
P09510398A1138|45 56|hypouricemia
P09510398A1138|81 98|urate concentration
P09510925A0389|5 28|haemoglobin concentration
P09511724A0483|13 24|accumulation
P09511724A0483|31 46|Dsg protein levels
P09511760A0221|7 31|restriction enzyme analysis
P09511760A0221|32 44|Southern blots
P09511760A0221|45 75|polymerase chain reaction analysis
P09511760A0221|79 91|DNA sequencing
P09512416A0460|28 40|dbEST database
P09512416A0460|52 63|sequence tags
P09512416A0460|76 98|Arabidopsis thaliana gene
P09512416A0460|196 207|7TM receptors
P09512550T0000|12 43|apolipoprotein AI enhancer activity
P09512559T0000|38 77|nerve growth factor-luciferase reporter gene
P09512559T0000|102 117|chromosome vector
P09513759A0716|0 16|Calcitriol therapy
P09513759A0716|45 59|serum iPTH levels
P09514156A1147|45 57|element region
P09514159A0562|13 39|hormone-coding gene promoters
P09514260A1083|40 51|pseudo intein
P09514260A1083|92 103|architecture
P09514260A1083|135 146|relationship
P09514260A1083|154 168|protein families
P09514272A0482|0 11|Purification
P09514272A0482|32 43|polypeptides
P09514962A0841|50 63|T-cell lymphoma
P09515031A1020|79 92|SRF binding site
P09515665T0000|14 30|foscarnet efficacy
P09515665T0000|45 64|CMV polyradiculopathy
P09515858A0000|35 52|neutrophil peptides
P09515858A0000|89 105|azurophil granules
P09515921A1662|30 46|pca gene expression
P09515924A0553|43 66|hybridization experiments
P09515924A0553|70 85|sequence analysis
P09515924A0553|99 109|gene regions
P09516472A0292|85 103|Id4 promoter activity
P09517646A0149|0 11|Azithromycin
P09517646A0149|18 36|generation macrolide
P09517646A0149|70 85|pharmacokinetics
P09517646A0149|161 174|pylori regimens
P09518383A0000|56 69|control program
P09518808T0000|0 20|National certification
P09518808T0000|38 53|quality assurance
P09519757A0482|153 165|heterozygotes
P09519828A0809|9 24|VP16-E2 molecules
P09519828A0809|87 102|BPV-4 LCR promoter
P09519828A0809|118 140|E2 transactivation domain
P09519830A0282|74 87|HSV-1 infection
P09519830A0282|185 228|chloramphenicol acetyltransferase reporter gene
P09519830A0282|248 266|thymidine kinase gene
P09520398A0124|48 64|acetylation levels
P09520398A0124|74 85|core histones
P09521907A0190|69 86|expression patterns
P09521909A0081|0 18|APETALA3 transcripts
P09521909A0081|85 99|stamen primordia
P09522979T0000|48 60|preterm labour
P09523478A0572|48 60|toxoplasmosis
P09523478A0572|84 95|reactivation
P09524222A0769|3 15|COOH-terminus
P09524222A0769|237 250|protein kinase C
P09524222A0769|254 271|calcium/calmodulin
P09524222A0769|327 339|beta 4-adducin
P09524222A0769|370 392|calmodulin binding domain
P09524222A1113|0 10|PCR analysis
P09524222A1113|31 49|beta-adducin isoform
P09524229A0000|23 35|enzyme laccase
P09524229A0000|79 98|chestnut blight fungus
P09524229A0000|99 121|Cryphonectria parasitica
P09524229A0000|286 299|concentrations
P09524229A0000|318 339|inhibitor cycloheximide
P09524229A0000|368 380|cyclosporin A.
P09524259A0301|3 18|hp55 gamma protein
P09524259A0301|85 98|mutant receptor
P09524259A0301|146 160|insulin receptor
P09524267A1023|3 14|plant protein
P09524267A1023|86 103|localization signal
P09524267A1023|124 137|helicase motifs
P09524267A1023|177 201|RNA transcription apparatus
P09524267A1023|210 233|nucleotide excision repair
P09524273A0205|28 39|organization
P09524273A0205|42 52|mouse gC1qBP
P09524273A0205|59 74|characterization
P09524276A0939|0 11|LysR proteins
P09524276A0939|43 61|Klebsiella aerogenes
P09524276A0939|124 142|bacterium protection
P09525105A0298|54 68|Buddleia cordata
P09525105A0298|84 99|glycoside linarin
P09525888A1482|51 67|muscle cDNA library
P09525891T0000|20 48|pbx homeodomain protein families
P09527921A1178|38 55|electron microscopy
P09527921A1178|86 98|WDV Rep protein
P09527921A1178|108 118|core element
P09527921A1178|170 183|initiation site
P09527921A1178|225 237|transcription
P09528758T0000|19 37|transcription factor
P09528758T0000|85 96|Oct-6 binding
P09528758T0000|101 111|octamer site
P09528766A0915|39 54|p38/MAPKAP kinase
P09528766A0915|94 119|CREB Ser-133 phosphorylation
P09528768A0000|17 28|accumulation
P09528768A0000|89 101|transcription
P09528768A0000|131 147|chaperone proteins
P09528770A1379|26 49|protein kinase cAPK pathway
P09528770A1379|61 71|UAS activity
P09528770A1379|109 120|carbon source
P09528770A1379|144 158|activators Msn2p
P09528770A1379|177 187|UAS activity
P09528784A0000|16 27|fission yeast
P09528784A0000|73 87|complementation
P09528792A0000|21 50|fibroblast growth factor receptor
P09528858A0205|84 95|gene activity
P09528950A0716|41 62|luciferase reporter gene
P09528987A1348|0 21|Cotransfection analyses
P09528987A1348|27 58|T/EBP promoter-reporter constructs
P09528987A1348|64 84|T/EBP expression vector
P09528987A1348|139 152|autoregulation
P09528987A1348|194 212|T/EBP gene expression
P09529156A1238|20 30|Ser residues
P09529156A1238|43 58|PKC consensus site
P09529156A1238|64 75|receptor tail
P09529156A1238|89 107|phorbol 12-myristate
P09529156A1238|126 140|desensitization
P09529216A0644|0 11|Flap survival
P09529649A0307|52 65|tract infection
P09529721A0000|40 54|classifications
P09529721A0000|71 82|malnutrition
P09529721A0000|123 138|childhood illness
P09529721A0000|145 156|malnutrition
P09531538A0983|42 57|splicing activity
P09531538A0983|68 82|dU2AF38 RS domain
P09531549A0658|7 20|binding studies
P09531549A0658|26 42|GST fusion proteins
P09531549A0658|46 58|yeast extracts
P09531549A0658|136 149|yAP180 proteins
P09531549A0658|202 215|plasma membrane
P09531559A1153|7 22|affinity analyses
P09533030T0000|0 10|Cytochrome b
P09533030T0000|47 60|oxidoreductase
P09533030T0000|61 71|cDNA cloning
P09533030T0000|89 105|liver mitochondria
P09533030T0000|109 128|chromosome assignment
P09533109A0449|19 30|theophylline
P09533109A0449|40 51|distribution
P09533109A0449|81 94|administration
P09533109A0449|162 173|significance
P09535082A0537|59 72|protein binding
P09535082A0537|86 100|target sequences
P09535082A0537|174 184|DNA fragment
P09535579A1105|73 86|interpretation
P09535579A1105|89 105|energy expenditure
P09535833A0228|12 28|amino acid sequence
P09535833A0228|74 108|selenocysteine tRNA gene transcription
P09535833A0228|127 139|Xenopus laevis
P09535851A0591|21 31|beta isoform
P09535851A0591|66 80|P kinase activity
P09535851A0591|87 98|gamma isoform
P09535892A0000|3 13|beta subunit
P09535892A0000|71 84|plasma membrane
P09535908A0321|26 36|LNX messages
P09536028A0945|13 29|contractile action
P09536028A0945|59 79|cyclooxygenase product
P09536028A0945|95 106|contractions
P09536028A0945|150 177|signal pathway probe inhibitors
P09537295A0951|77 113|transcriptase-polymerase chain reaction
P09537295A0951|134 146|primer walking
P09537295A0951|147 161|primer extension
P09537295A0951|165 175|cDNA cloning
P09537295T0000|66 78|transcription
P09537295T0000|103 113|protein gene
P09537361A0149|3 16|iron dependence
P09537361A0149|19 31|transcription
P09537361A0149|64 90|transporter accessory protein
P09537361A0149|108 130|colicin V immunity protein
P09537375A0198|3 20|gntR deletion mutant
P09537378A1227|57 74|gcv-lacZ expression
P09537651A0366|123 157|phorbol ester phorbol myristate acetate
P09538156A0130|0 11|BRCA1 protein
P09538156A0130|36 50|zinc finger motif
P09538220A0000|62 73|tRNAPro genes
P09538220A0000|137 149|transcription
P09538258A0200|47 59|Ras activation
P09539421A0970|4 14|Sir proteins
P09539421A0970|54 78|telomere length maintenance
P09539721A0599|40 50|beta subunit
P09539721A0599|53 65|RNA polymerase
P09539779A0621|17 29|hybridization
P09539779A0621|37 48|mouse embryos
P09539779A0621|88 101|Arp1 expression
P09540062A0755|148 177|H4 promoter/CAT fusion constructs
P09541280A0404|61 73|FK506 ointment
P09541280A0404|84 97|plasma IgE level
P09541636T0000|0 20|Creatine kinase release
P09541636T0000|33 50|artery embolization
P09541721A0894|16 36|ischemia/angiotension
P09543227A0815|45 55|risk factors
P09543227A0815|79 89|risk factors
P09543227A0815|122 132|risk factors
P09544991A0483|0 10|PRL receptor
P09544991A0483|39 57|tyrosine phosphatase
P09544991A0750|63 85|tyrosine phosphorylation
P09544991A0750|164 179|m-Stat5adelta749
P09544991A0750|191 214|transactivation potential
P09545146A0884|90 101|comedication
P09545146A0884|142 160|regression equations
P09545146A0884|180 193|concentrations
P09545146A0884|205 217|validation set
P09545312A1197|3 14|observations
P09545312A1197|38 48|HMG-I family
P09545312A1197|83 95|transcription
P09545323T0000|51 61|DNA mismatch
P09545323T0000|68 81|yeast MSH2-MSH6
P09545323T0000|85 109|MLH1-PMS1 protein complexes
P09545332A0137|40 62|tyrosine phosphorylation
P09545332A0137|68 91|insulin receptor substrate
P09545332A0137|110 122|proliferation
P09545353A1071|27 40|kappaB elements
P09545353A1071|52 104|activating transcription factor/cAMP response element site
P09545353A1071|136 149|E-selectin gene
P09545638A0330a|30 56|yeast hnRNP methyltransferase
P09545638A0330b|30 56|yeast hnRNP methyltransferase
P09545638A0836|11 24|HRMT1L2 protein
P09545638A0836|63 87|methyltransferase activity
P09545638T0000|0 13|Identification
P09545638T0000|17 32|characterization
P09545638T0000|51 76|arginine methyltransferases
P09546424A1550|25 41|PDGF beta-receptor
P09546424A1550|59 69|Crk proteins
P09547311A1394|11 22|interactions
P09547311A1394|207 218|interactions
P09547349A0000|3 72|ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
P09548481A0000|95 108|IL-5Ralpha gene
P09549179A0774|0 10|Serum levels
P09549179A0774|13 24|testosterone
P09549398A1463|23 58|rest/postnitroglycerin technetium-99m
P09549398A1463|70 80|SPET studies
P09549398A1463|84 102|rest/redistribution
P09549398A1463|105 143|rest/reinjection thallium-201 SPET studies
P09549632A1189|65 78|predictability
P09549660A0782|71 82|data scenario
P09550591A0454|46 59|airway pressure
P09550591A0454|112 124|blood pressure
P09551096A0108|98 114|particle formation
P09551182A0212|7 24|retinoid signalling
P09551182A0212|27 42|zebrafish embryos
P09551182A0212|114 126|fusion protein
P09551182A0212|147 167|transactivation domain
P09551182A0212|179 190|acid receptor
P09551182A0212|207 222|DNA binding domain
P09551938A0318|78 93|CCR5 gene promoter
P09551972A1033|0 11|Fluorescence
P09551972A1033|18 30|hybridization
P09551972A1033|33 48|metaphase spreads
P09551972A1033|72 96|hybrid cell line 706-B6 clone
P09551972A1033|108 119|cosmid c101F1
P09552469A0225|54 72|x-ray diffractometry
P09552469A0225|86 97|spectroscopy
P09553040A0651|0 11|Cell survival
P09553040A0651|52 68|signaling pathways
P09553134A0596|23 38|neurite outgrowth
P09553134A0596|55 89|tyrosine kinase inhibitors herbimycin A
P09553143A0729|8 22|ZAP-70 substrate
P09553143A0729|41 53|Erk activation
P09553143A0729|96 106|Jurkat cells
P09553686A0000|199 217|absorption enhancers
P09553686A0000|241 252|applications
P09555046A1617|43 70|branchpoint consensus sequence
P09556561A0671|8 19|H/ACA snoRNAs
P09556561A0671|121 142|pseudouridine synthesis
P09556566A0174|9 24|vitamin D receptor
P09556566A0174|42 59|acid Xalpha receptor
P09556566A0174|78 94|T cell line MT2 cells
P09556573A1062|33 47|PPARalpha ligand
P09556573A1062|123 141|co-activator RIP-140
P09556861A1018|169 183|tRNA-synthetase
P09556861A1018|205 220|protein synthesis
P09556861A1018|233 249|lipid peroxidation
P09557678A0140|54 71|papillomavirus type
P09557678A0140|107 124|carcinoma cell lines
P09557678A0140|147 159|proliferation
P09557678A0140|179 199|G1/S phase growth arrest
P09557682A0490|58 69|combinations
P09557708A1426|0 20|Specialized actin tails
P09557708A1426|31 42|IEV particles
P09557912A0699|113 125|methohexitone
P09557912A0699|155 174|muscle fasciculations
P09557912A0699|184 196|suxamethonium
P09560221A0282|39 49|CAK mutation
P09560221A0282|86 106|fission yeast CAK mutant
P09560325A1285|18 30|modifications
P09560325A1285|37 49|glycosylation
P09560325A1285|53 67|phosphorylation
P09560325A1285|94 105|explanations
P09560325A1285|112 131|protein heterogeneity
P09560390A0771|21 37|checkpoint control
P09560390A0771|38 51|overexpression
P09560390A0771|75 91|cell cycle response
P09561560A0579|0 13|Rhesus macaques
P09561560A0579|44 68|Mengo virus SIV recombinants
P09561560A0579|84 95|CTL responses
P09561560A0579|106 120|SIV gene products
P09561560A0579|134 152|HIV-Nef recombinants
P09561560A0579|165 175|CTL response
P09561560A0579|194 207|HIV1 Nef peptide
P09561616A0142|0 11|Deltamethrin
P09561616A0142|91 108|culicifacies adults
P09562398A0848|0 16|Trichloroethylene
P09562558T0000|0 16|Solution structure
P09564860A2139|10 34|receptor/G protein coupling
P09564860A2139|67 79|loop 3i domains
P09564860A2315|84 98|protein coupling
P09564860A2315|159 176|signal transduction
P09564860A2315|195 210|Gs protein pathway
P09564917A0900|17 34|alpha2-antiplasmin
P09565576T0000|28 45|DNA topoisomerase I.
P09565584A0770|181 199|mutagenesis analysis
P09566731A0458|57 79|chromosome 16p12.1-p11.2
P09566731A0458|91 105|mouse chromosome
P09566731A0458|119 129|cell hybrids
P09566871A0343|2 12|fus3 mutants
P09566871A0343|30 45|protein synthesis
P09566871A0343|101 111|FUS3 strains
P09566871A0343|157 177|transcriptase proteins
P09566871T0000|29 49|Ty1 retrotransposition
P09566871T0000|69 85|protein kinase Fus3
P09566876A0000|10 31|transcription factor IIA
P09566876A0000|53 70|TATA binding protein
P09566876A0000|77 87|promoter DNA
P09566876A0000|97 119|transcription activation
P09566918A1115|0 11|Substitution
P09566918A1115|17 28|Ser-Thr sites
P09568445T0000|73 91|contractile recovery
P09568445T0000|97 108|thrombolysis
P09568549A0188|27 40|administration
P09568549A0188|103 113|serum levels
P09570030T0000|5 21|growth retardation
P09570107A0355|9 24|PCDFs/PCDDs ratio
P09570133A0474|23 34|interactions
P09570133A0474|50 61|interactions
P09570133A0474|66 80|partner proteins
P09570944T0000|0 11|Localization
P09570944T0000|64 83|resistance gene region
P09570944T0000|91 106|chromosome 7q21.1
P09570952A0000|22 33|organization
P09571563A0000|20 32|image analysis
P09571563A0000|111 123|determination
P09572428A0526|3 27|SD serum VEGF concentrations
P09572491A1044|28 43|missense mutation
P09572965A1235|108 125|virulence phenotype
P09572990A0630|38 50|MHC-I ligation
P09573187T0000|44 56|regulator CatR
P09573187T0000|72 83|binding sites
P09573202A0900|40 51|alpha subunit
P09573202A0900|65 76|substitution
P09573202A0900|100 110|acid residue
P09573244A0523|8 18|mRNA species
P09573244A0523|44 67|polyadenylation site usage
P09573374A0687|5 24|Southern blot analysis
P09573374A0687|28 45|restriction mapping
P09573374A0687|86 97|cosmid clones
P09573378A0761|49 63|complementarity
P09574799A1072|0 14|Echinostomiasis
P09574799A1072|62 73|malnutrition
P09574799A1072|126 139|food inspection
P09574799A1072|173 185|helminthiases
P09575143A1189|3 14|localization
P09575143A1189|73 89|SRC-family kinases
P09575143A1189|132 145|immunoreceptor
P09575143A1189|160 175|activation motifs
P09575187A1558|54 69|ER calcium release
P09575187A1558|165 178|kappaB decoy DNA
P09575217A0000|4 20|cytokine receptors
P09575217A0000|27 53|Janus protein tyrosine kinases
P09575217A0000|61 77|signal transducers
P09575217A0000|93 105|transcription
P09575217A0971|14 26|R618K mutation
P09575217A0971|32 45|Stat5 SH2 domain
P09575217A0971|58 72|phosphorylation
P09575217A0971|111 135|Stat5 hyperphosphorylation
P09576230T0000|17 38|oxide synthase inhibitor
P09576230T0000|41 57|reperfusion injury
P09576915A0269|12 24|recombination
P09577365A0747|2 15|angiodysplasia
P09577365A0747|62 73|collagen type
P09577365A0747|184 200|muscularis mucosae
P09577395A0000|126 138|low-amplitude
P09578042A0363|61 74|seizure outcome
P09578042A0363|130 141|lobe epilepsy
P09578570A0200|46 57|organization
P09578570A0200|100 115|PCR amplification
P09578570A0200|118 129|leukocyte DNA
P09578570A0200|144 154|phage clones
P09579602A1720|5 17|modifications
P09579602A1720|46 60|reproducibility
P09579602A1720|63 80|CD34 determinations
P09579602A1720|100 113|sample handling
P09579789A0974|101 113|odor detection
P09579789A0974|117 135|discrimination tasks
P09579808A0000|9 33|alpha-6-D-mannoside beta-1
P09579808A0000|34 64|N-acetylglucosaminyltransferase
P09580062A0100|41 56|cyclophosphamide
P09580062A0100|99 111|cyclosporine A
P09580563A0331|12 28|amino acid sequence
P09580563A0331|78 93|Neurospora crassa
P09580700A0841|3 22|DNA binding activities
P09580700A0841|33 53|repressor preparations
P09580700A0841|149 160|footprinting
P09581552A1323|34 54|tetramerization domain
P09581552A1323|87 98|interactions
P09581775A0185|57 73|NF-kappaB activity
P09581834A2578|156 171|signaling pathway
P09581872A0000|18 30|cell structure
P09581872A0000|49 66|collagen expression
P09582267A0326|54 71|expression plasmids
P09582267A0326|138 157|GM701 fibroblast cells
P09582267A0326|169 180|growth arrest
P09582306T0000|1 13|point mutation
P09582306T0000|66 90|G protein signaling proteins
P09582308A1165|97 108|heterodimers
P09582327A0295|51 69|rat GnRH receptor cDNA
P09582327A0295|151 163|rat LHbeta gene
P09582327A0295|232 249|luciferase reporter
P09582327A0295|276 286|GnRH agonist
P09582343A0000|30 40|cell line SX9
P09582343A0000|52 72|carcinoma cell line FM3A
P09582350A0165|14 41|type IA maple syrup urine disease
P09582350A0165|45 58|E1alpha subunit
P09582350A0165|108 128|ketoacid dehydrogenase
P09582635A0523|20 35|mean bond strength
P09582635A0523|38 52|H.T.V. specimens
P09582635A0523|87 102|mean bond strength
P09582635A0523|105 119|R.T.V. specimens
P09582953A0000|19 39|coagulation factor VIII
P09582953A0000|56 75|C1-esterase inhibitor
P09582953A0000|103 129|acute-phase reactant proteins
P09582953A0000|133 153|coagulation factors VII
P09582953A0000|169 186|hemostasis proteins
P09582953A0000|206 224|acute-phase response
P09582953A0000|264 286|hemostasis abnormalities
P09582953A1097|44 66|fibrinogen concentration
P09582953A1097|85 102|protein C activities
P09582953A1670|70 88|acute-phase proteins
P09583208A0171|17 30|creatine kinase
P09583208A0171|47 58|serum albumin
P09583208A0171|59 72|immunoglobulin
P09583823A0238|67 81|infarction group
P09583823A0238|123 145|yttrium-aluminium garnet
P09584165T0000|49 59|beta subunit
P09584165T0000|89 106|src tyrosine kinases
P09584165T0000|118 128|NIH 3T3 cells
P09584179A0673|0 15|Peptide sequences
P09584179A0673|21 40|zinc finger protein Ttk
P09584179A0673|47 70|transcription factor Adf-1
P09584180A0701|21 32|reporter gene
P09584180A0701|86 102|NF-kappaB proteins
P09584180A0701|120 139|I.29mu B lymphoma cells
P09584194A0000|50 64|docking proteins
P09584194A0000|116 127|cell adhesion
P09584194A1305|38 53|library screening
P09584194A1305|114 125|protein Dim1p
P09585253A1147|32 45|raf-ERK pathway
P09585253A1147|63 74|TF expression
P09585253A1147|77 96|breast carcinoma cells
P09585253A1147|159 170|TF expression
P09585253A1147|173 187|MDA-MB-231 cells
P09585540A0440|87 110|agent 1,10-phenanthroline
P09586285A0551|22 47|H. influenza type b meningitis
P09587549T0001|37 51|interferon alpha
P09588228A0370|21 35|anticytokeratin
P09590294A0453|38 51|identification
P09590294A0453|76 87|Notch pathway
P09590540A0513|63 76|signal sequence
P09590540A0513|204 221|lac operator control
P09590540A0513|225 236|pQE-30 vector
P09591221A0137|0 14|Control subjects
P09592125A0000|6 26|alpha1,2-mannosidases
P09592168T0000|30 45|DNA binding domain
P09592168T0000|61 94|nucleotide excision repair protein XPA
P09592208A0470|90 101|construction
P09592208A0470|138 150|possibilities
P09592219A0652|20 32|effectiveness
P09592219A0652|49 60|intervention
P09593302A1165|14 25|implications
P09593302A1165|36 53|non-responsiveness
P09595496A0000|29 40|endothelin-1
P09596536A0219|27 44|knee loading changes
P09596536A0219|54 67|ACL transection
P09596536A0219|89 109|cartilage degeneration
P09596542A0542|31 45|cartilage matrix
P09596638T0000|23 42|Brassica S locus region
P09596738T0000|10 24|Candida albicans
P09596738T0000|42 61|protein kinase homolog
P09598205A0430|20 34|monosaccharides
P09598205A0430|41 53|disaccharides
P09598205A0430|58 69|beta-alanine
P09598894A0732|23 35|bone formation
P09599102A1191|11 21|Mac1p mutant
P09599102A1191|68 81|transport genes
P09599102A1191|107 120|CUP1 expression
P09599102A1191|124 140|copper sensitivity
P09599664A0881|3 15|DNA sequencing
P09599724A0193|55 77|phenoxy herbicide workers
P09599724A0193|116 128|PCDF congeners
P09599724A0193|131 141|blood lipids
P09599724A0193|172 183|PCDF exposure
P09599724A0193|243 256|cancer findings
P09599897A0000|14 31|laboratory features
P09599897A0000|48 70|Henoch-Schonlein purpura
P09599897A0000|108 119|associations
P09599897A0000|130 146|laboratory indices
P09599897A0000|241 254|manifestations
P09601007A0223|61 76|CO2 concentration
P09601007A0223|87 101|coral reef waters
P09601007A0223|153 166|photosynthesis
P09601007A0223|178 190|calcification
P09601007A0223|194 209|CaCO3 dissolution
P09601510A0215|22 33|retroviruses
P09601510A0215|37 46|FV pol genes
P09601516A0695|0 11|Substitution
P09601516A0695|77 90|fusion activity
P09601516A0695|133 149|surface expression
P09601921A0000|17 33|breakdown products
P09601921A0000|126 137|United States
P09601921A0000|155 169|British Columbia
P09601940A0280|42 54|binding motifs
P09601940A0280|79 98|transcription factors
P09603345A1257|16 28|closterovirus
P09603345A1257|48 65|genome organization
P09603345A1257|153 170|genus Closterovirus
P09604052A0166|43 54|control group
P09604052A0166|111 123|wrist fracture
P09605137A0677|46 58|transcription
P09605137A0677|61 72|IL-2 promoter
P09605137A0677|89 106|reporter constructs
P09605137A0677|138 148|Jurkat cells
P09605930A1428|32 44|transfections
P09605930A1428|48 66|mobility shift assays
P09605930A1428|89 102|rat hepatocytes
P09605934A0801|4 15|E box sequence
P09605934A0801|38 51|binding element
P09605934A0801|119 138|transcription factors
P09606633A0523|0 20|Interferon beta therapy
P09606924T0000|40 70|all-rac-alpha-tocopheryl acetate
P09606924T0000|74 89|retinyl palmitate
P09606924T0000|102 114|infant formula
P09606924T0000|120 146|matrix solid-phase dispersion
P09609705A0895|29 54|bc1 complex crystal structure
P09610755A1731|3 24|side-to-side difference
P09611229A1664|38 60|nmt1-451Dino2 Delta cells
P09611229A1664|90 108|transcription factor
P09611229A1664|123 141|expression/activity
P09611229A1664|185 208|protein N-myristoy-lation
P09611234A0098|0 17|Rev-erbAalpha/beta
P09611234A0098|26 44|Mad bHLH-zip proteins
P09611234A0098|51 66|oncoproteins PLZF
P09611234A0098|94 110|corepressors N-CoR
P09612775A0726|3 17|ParaSight-F test
P09612775A0726|39 56|serum antigen levels
P09613574A0905|45 58|enzyme activity
P09613574A0905|82 93|methyl groups
P09613574A0905|101 112|substrate DNA
P09613574A0905|118 128|MGMT protein
P09613946A0194|1 25|deproteinization procedure
P09613946A0194|55 68|HPLC separation
P09614106T0000|50 61|pair enhancer
P09617765A0174|25 36|reading frame
P09617807A0929|33 51|transcriptase domain
P09617807A0929|139 150|relationship
P09618150A0127|38 50|growth factor I
P09618150A0127|88 100|dibutyryl cAMP
P09618150A0127|119 143|UCP1 gene transcription rate
P09618150A0127|153 172|UCP1 mRNA accumulation
P09618150A1464|24 45|AP-1 DNA binding activity
P09618150A1464|92 105|MEK-1 inhibitor
P09618164A0709|13 38|methyl oligoribonucleotides
P09618164A0709|78 89|mdx myoblasts
P09618475A0747|41 55|down-regulation
P09618481T0000|20 40|p21/WAF1/Cip1 promoter
P09618481T0000|67 78|interactions
P09618481T0000|92 108|Smad family members
P09619631A0344|18 30|C. elegans cDNA
P09619631A0344|103 113|p120 Ras-GAP
P09619777A1583|7 22|base ketoconazole
P09619777A1583|127 138|% dissolution
P09619777A1583|198 209|% dissolution
P09619777A1583|229 243|state conditions
P09620273A0189|71 87|cell proliferation
P09620273A0189|110 132|E2F transcription factors
P09620873A1710|32 58|luteal HSP-27 phosphorylation
P09620873A1710|130 145|PKC family members
P09620873A1710|158 182|sHSP phosphorylation events
P09620955A0370|53 64|program Mfold
P09621062A0810|99 122|promoter function analysis
P09621062A0810|140 185|chloramphenicol acetyltransferase reporter system
P09621372A0369|7 22|blood examination
P09621372A0369|29 40|leukocytosis
P09621372A0369|41 56|thrombocytopenia
P09621893A0000|59 72|responsiveness
P09621893A0000|83 102|alpha2-adrenoceptors
P09622121A0525|72 97|supershift RNA-PTB complexes
P09622121T0000|23 55|polypyrimidine tract binding protein
P09622121T0000|71 87|protein components
P09622121T0000|145 156|branch points
P09623830A0000|19 32|botulinum toxin
P09625762A0426|8 21|oncoprotein E1A
P09625762A0426|44 58|transactivation
P09625807A0000|32 44|display method
P09625807A0000|115 126|cell cultures
P09625807A0000|148 165|carcinoma cell lines
P09626662A1076|105 121|TR/RXR heterodimer
P09627285A0160|39 59|care infertility center
P09627285A0554|52 62|oocyte yield
P09627598A0384|70 82|preponderance
P09627598A0384|106 127|otolith system imbalance
P09628375A0700|5 18|ePTFE specimens
P09628375A0700|19 32|tissue coverage
P09628419A0812|23 40|Kristofferson model
P09628821A1194|17 30|KG1a EST dataset
P09628821A1194|120 136|lineage commitment
P09628890A0455|54 74|carbohydrate structure
P09629449A0540|18 30|ROS production
P09629449A0540|75 87|concentration
P09629449A0540|90 100|PMN elastase
P09630245A0102|0 11|Yeast U1 snRNP
P09630245A0102|124 137|splicing events
P09630245A0903|0 11|Yeast U1 snRNP
P09630245A0903|62 78|snRNP core proteins
P09630245A0903|151 165|U1 snRNP proteins
P09632217A0477|9 28|antagonist naltrexone
P09632217A0477|69 83|stimulus effects
P09632217A0477|153 167|stimulus effects
P09632637A0361|36 49|cell regulation
P09632637A0361|52 71|M6P/IGFIIR expression
P09632637A0361|84 113|M6P/IGFIIR mRNA transcript levels
P09632637A0361|155 173|carbon tetrachloride
P09632709A0464|143 156|gene expression
P09632734A0081|70 85|sequence homology
P09632734A0081|96 118|GDP/GTP exchange proteins
P09632734A0081|142 159|GTP binding proteins
P09632734A0943|7 19|p82 expression
P09632734A0943|33 46|ERK2 activation
P09632785A0000|3 28|pre-mRNA splicing factor U2AF
P09632785A0000|43 67|ribonucleoprotein particle
P09632785A0000|109 127|splice site selection
P09633171A0321|83 97|room temperature
P09633171A0321|161 174|testing machine
P09633274A0000|0 15|Exercise training
P09633274A0000|62 81|heart failure patients
P09633630A0740|48 61|lettuce extract
P09633879A0246|50 68|serum ferritin levels
P09635276A1608|12 36|myosin phosphatase activity
P09635276A1608|54 72|subunit interactions
P09636670T0000|50 67|kinase inhibitor p18
P09636670T0000|91 102|breast cancer
P09636708A0460|3 13|YccA protein
P09636708A0460|115 131|amino acid residues
P09637689A0150|20 36|activator proteins
P09637689A0150|68 80|RNA polymerase
P09638342T0000|65 92|membrane cytoskeleton assembly
P09638485A0111|44 79|leukocyte alkaline phosphatase activity
P09638485A0111|104 115|car mechanics
P09638485A0111|118 134|road tanker drivers
P09638650A0169|52 64|reading frames
P09638650A0169|116 128|RNA polymerase
P09638650A0169|135 152|kDa movement protein
P09638650A0169|160 177|kDa movement protein
P09638650A0169|185 202|kDa movement protein
P09638650A0169|210 223|kDa coat protein
P09638793A1446|25 36|hemodilution
P09638793A1446|129 150|i.v. perflubron emulsion
P09639074A0707|9 19|Sp3 isoforms
P09639074A0707|52 63|constituents
P09639558A0957|67 78|erythrocytes
P09639565A0225|33 48|enhancer activity
P09639565A0225|88 99|SV40 promoter
P09640162A0242|44 56|growth hormone
P09640162A0242|71 93|growth hormone deficiency
P09640162A0242|111 127|ventricle teratoma
P09640802A0467|34 45|consequences
P09640802A0467|78 90|possibilities
P09641167A1359|49 66|LDLr gene expression
P09641167A1359|123 139|gene transcription
P09642042A0646|0 16|Binding affinities
P09642042A0646|28 41|nucleotide mono
P09642042A0646|47 59|triphosphates
P09642042A0646|101 120|beta-phosphate moiety
P09642042A0646|134 149|substrate binding
P09642200A0956|47 58|proteolipids
P09642200A0956|63 83|M. thermoautotrophicum
P09642200A0956|87 98|M. jannaschii
P09642200A0956|229 243|chemical natures
P09642214A0244|46 61|phosphatase SHP-2
P09642214A0244|106 118|protein kinase
P09642214A0244|139 150|SHP-2 mutants
P09642227A0000|0 11|Osteoadherin
P09642227A0000|32 47|bone proteoglycan
P09642227A0000|58 71|keratan sulfate
P09642238A0532|40 55|enhancer activity
P09642238A1285|10 23|enhancer region
P09642238A1285|64 89|transactivation experiments
P09642276A0881|71 84|suicide program
P09642764A0469|31 41|QCM response
P09642764A0469|52 68|Sauerbrey equation
P09643153T0000|23 38|T2N breast cancers
P09643546A0436|0 22|Transcription initiation
P09643546A0436|126 141|stress conditions
P09643548A0000|69 102|cyanobacterium Synechocystis PCC6803
P09645942A1164|12 35|Dsg-plakoglobin complexes
P09645942A1164|66 78|stoichiometry
P09647233A0336|26 44|HIV-1 gene expression
P09647233A0336|98 109|binding sites
P09647240A0000|37 61|Janus kinase-STAT signaling
P09647240A0000|84 105|hepatoma Hep3B cell lines
P09647240A0000|163 174|Val135 mutant
P09649069A0490|31 49|laryngeal parameters
P09649069A0490|97 108|examinations
P09649265A1575|104 114|office visit
P09649265A1575|139 152|biopsy strategy
P09649315A0943|79 95|MIP-1 beta variants
P09649426A0636|13 23|PKA activity
P09649426A0636|61 73|Msn4p activity
P09649437A1140|26 37|interactions
P09649437A1140|62 77|Ets family members
P09649437A1140|111 140|eosinophil lineage determination
P09649438A0182|14 48|transcription elongation factor P-TEFb
P09649438A0182|141 153|Tat activation
P09649501A0358|36 58|HSF1 trimerization domain
P09649501A0358|79 101|protein interaction assay
P09649501A0358|112 140|heat shock factor binding protein
P09649501A0358|250 266|HSF1 heptad repeats
P09649537A0000|35 59|yeast GCN2 eIF-2alpha kinase
P09650180A1130|10 22|recombination
P09650275T0000|26 42|weapons convention
P09650275T0000|46 57|implications
P09650275T0000|80 100|biotechnology industry
P09650299A0000|18 49|Agrobacterium tumefaciens proteins
P09650403A0868|3 13|DHEAS levels
P09650789A0185|57 71|Overhauser shift
P09650789A0185|86 97|energy levels
P09651321A0000|10 36|cysteine proteinase inhibitor
P09651321A0000|47 63|precursor proteins
P09651321A0000|75 86|cell envelope
P09651321A0000|89 101|keratinocytes
P09651321A0000|136 162|keratinocyte differentiation
P09651367T0000|23 33|Ras effector
P09651375T0000|37 54|binding specificity
P09651383A0967|21 36|HNF-4 binding site
P09651383A0967|39 49|element CIIB
P09651383A0967|65 78|HNF-4 synthesis
P09651383A0967|102 116|HNF-4 constructs
P09651383A0967|129 150|apoCII promoter activity
P09652736A1205|47 57|tumour cells
P09652736A1205|93 104|co-activator
P09652736A1205|111 127|E2F/DP heterodimer
P09652737A1244|44 66|Fos family member proteins
P09652737A1244|135 157|Jun family member proteins
P09652737A1244|188 204|DNA binding complex
P09653182A1298|52 63|primer donors
P09653182A1298|91 103|transcription
P09653648A0445|148 163|zinc finger domain
P09653745A0180|55 66|paper queries
P09653745A0180|98 112|control projects
P09653745A0180|216 227|problem today
P09655248A0000|3 19|gp330/Megalin/LRP
P09655248A0000|51 79|lipoprotein receptor gene family
P09655248A0000|138 149|lipoproteins
P09655916A0415|5 23|DNA recognition helix
P09656485A0351|54 73|restriction digestion
P09657003T0000|12 24|relationships
P09657003T0000|51 64|RNA polymerases
P09657003T0000|111 126|elm disease fungus
P09657003T0000|127 145|Ophiostoma novo-ulmi
P09658104T0000|9 40|transcription start site core region
P09658104T0000|44 65|transcription factor YY1
P09658104T0000|68 83|Rous sarcoma virus
P09658104T0000|96 117|repeat promoter activity
P09658122T0000|0 11|Fowlpox virus
P09658122T0000|97 111|nematode protein
P09658403A1207|41 62|progesterone agonist Org
P09658403A1207|91 101|CAT activity
P09658405A0000|79 97|receptor superfamily
P09658769A0058|28 38|IFN alpha-2b
P09658769A0058|65 75|hepatitis C.
P09660823A0934|7 28|Ser/Thr phosphorylation
P09660823A0934|41 52|molecules Akt
P09660823A0934|56 66|p70 S6 kinase
P09660836A0983|33 45|state kinetics
P09660836A0983|48 60|MEK inhibition
P09660836A0983|134 146|deltaN3-S218E
P09660838A0920|55 75|protein kinase cascades
P09660838A0920|98 112|phosphorylation
P09660838A0920|115 128|serine residues
P09660838A0920|176 192|heat shock response
P09661676T0000|21 33|protein levels
P09662443A0402|39 50|organization
P09662443A0402|82 99|caveolin gene family
P09663062A0175|0 19|Tensile bond strengths
P09663062A0175|82 100|Clearfil Liner Bond II
P09663062A0175|105 127|Scotchbond Multi-Purpose
P09663062A0175|130 143|bonding systems
P09664033A1204|4 15|distribution
P09664033A1204|127 143|processing pathway
P09665361T0000|21 34|thyroid nodules
P09665720A0325|29 43|exonuclease site
P09665720A0325|60 73|polymerase site
P09665720A0325|92 105|primer terminus
P09665720A1145|21 32|binding sites
P09665720A1145|45 58|primer terminus
P09665720A1145|74 88|exonuclease site
P09666103A0496|3 16|missense allele
P09666103A0496|67 81|missense alleles
P09666114A0389|53 65|c-met promoter
P09666114A0389|77 88|CAAT elements
P09666114A0389|131 145|Sp1 binding sites
P09667482A0978|30 41|contribution
P09667482A0978|44 56|stress factors
P09667482A0978|159 189|stress system disorder perspective
P09667795A0000|5 16|pancreatitis
P09668063A0274|27 37|Ets proteins
P09668063A0274|40 56|Ras transformation
P09668063A0274|112 125|Ets2 constructs
P09668098A0868|18 31|FGF-BP promoter
P09668098A0868|47 62|deletion analysis
P09668098A0868|139 160|transcription start site
P09668108A1017|0 11|Manipulation
P09668108A1017|17 36|checkpoint regulators
P09668108A1017|47 61|cell cycle arrest
P09668108A1017|104 116|cancer therapy
P09668119A0496|15 33|mobility shift assays
P09668119A0496|61 74|protein binding
P09668119A0496|91 104|point mutations
P09668119A0496|123 140|binding nucleotides
P09670943T0000|0 19|B cell antigen receptor
P09670943T0000|42 59|SHP-2-pp120 complex
P09670943T0000|78 103|Fc gamma RIIB1-BCR coligation
P09671313A0334|24 34|MT Hartsough
P09671576A0900|50 68|streak morphogenesis
P09671579A1168|46 63|signaling processes
P09671579A1168|100 118|boundary development
P09671791T0000|46 65|growth factor receptor
P09671791T0000|78 89|intermediate
P09673037A0358|91 116|reticulin fiber impregnation
P09673436A0898|24 34|ANP infusion
P09673436A0898|59 73|sodium excretion
P09675154A0690|116 128|point mutation
P09675154A0690|136 161|consensus splicing donor site
P09675154A0690|166 181|missense mutation
P09675896A0959|12 25|carboxyl region
P09676349A0000|59 77|release theophylline
P09676349A0000|99 111|Bronchoretard
P09676349A0000|117 129|investigation
P09676419A0158|89 102|questionnaires
P09676419A0158|115 129|family histories
P09676419A0158|141 154|screening tests
P09676419A0158|194 206|determination
P09676419A0158|214 233|serum immunoglobulin E
P09676419A0158|266 288|solid-phase immunoassays
P09677330A0584|27 41|linker region LR1
P09677405A0856|0 16|Pol32Delta strains
P09677405A0856|24 35|antimutators
P09677410A1059|99 113|HBV core promoter
P09678579A0768|52 63|blot analysis
P09678837A0736|33 46|responsiveness
P09678837A0736|49 66|bronchoprovocation
P09678837A0736|71 82|methacholine
P09678837A0736|131 142|pollen season
P09678837A0736|163 178|blood eosinophils
P09679066A1352|27 39|demonstration
P09679750A0304|27 55|prostate cancer chemoprevention
P09679750A0304|95 119|cyclo-oxygenase inhibitors
P09680994A0169|31 43|P. hybrida gene
P09680994A0169|102 117|sequence homology
P09680994A0169|121 140|intron/exon structure
P09680994A0169|154 172|P. hybrida orthologue
P09680994A0169|178 189|Z. mays r genes
P09681822A0520|9 26|c-erbB3 transcripts
P09682897A0218|46 63|electrocardiograms
P09682897A0218|120 132|injury pattern
P09683576A0542|18 29|cleavage site
P09683576A0542|52 65|protease domain
P09683576A0542|66 80|Gln2526-Asp2527
P09685021A0127|7 39|Millipore ultrafiltration membranes
P09685021A0127|75 97|model lenticule materials
P09685021A0127|124 140|membrane pore sizes
P09685021A0127|177 192|surface roughness
P09685021A0127|362 378|epithelialization
P09685226A0000|51 61|cAMP pathway
P09685226A0000|74 86|transcription
P09685226A0000|162 179|lung cancer cell line
P09685346A0419|31 48|homeodomain protein
P09685346A0419|95 111|prolactin promoter
P09685346A0419|114 131|transfection assays
P09686344T0000|36 70|ornithine transcarbamylase deficiency
P09686603A0124|126 143|germline expression
P09686603A0124|146 164|TCR beta gene segments
P09687498A1173|127 138|conformation
P09687498A1173|157 170|overexpression
P09687511A1091|0 13|Downregulation
P09687511A1091|16 28|FUS expression
P09687511A1091|49 59|32Dcl3 cells
P09687511A1091|114 128|colony formation
P09687511A1091|167 181|differentiation
P09687514A0521|40 58|transcription system
P09688264A1029|46 62|UTR silencer action
P09688264A1029|86 99|rat hepatocytes
P09689047A0253|1 12|prerequisite
P09689047A0253|40 54|glycoconjugates
P09689047A0253|69 92|sugar-nucleotide cytidine
P09689047A0253|93 105|monophosphate
P09689047A0253|164 186|Golgi sialyltransferases
P09689919A1192|67 82|PEDF glycoprotein
P09691031A1050|22 33|Sro7 function
P09691031A1050|63 76|myosin proteins
P09691037A0355|74 90|Neurospora species
P09693035T0000|15 36|serine/threonine kinase
P09693035T0000|46 57|UNC-51 kinase
P09693035T0000|60 80|Caenorhabditis elegans
P09693035T0000|81 91|cDNA cloning
P09693134A0782|154 170|column neuroblasts
P09693134A0782|187 203|column neuroblasts
P09694034A0713|54 67|antipsychotics
P09694514A0000|3 36|complement C3a anaphylatoxin receptor
P09694514A0000|79 101|chemoattractant receptor
P09694514A0000|118 133|C3a peptide ligand
P09694514A0000|176 191|histamine release
P09694514A0000|245 261|muscle contraction
P09694725A0500|71 85|oligonucleotide
P09694725A0500|87 111|gamma interferon activation
P09694725A0500|148 163|IL-1beta promoter
P09694869A0932|65 75|p21 promoter
P09694869A0932|76 89|overexpression
P09694869A0932|111 124|cytokine effect
P09694869A0932|130 140|p21 promoter
P09694869A0932|186 204|STAT response element
P09694869A0932|241 254|cytokine effect
P09694897T0000|23 55|ribonucleoprotein C protein tetramer
P09694897T0000|90 113|affinity RNA binding domain
P09696164A0000|43 61|infant death syndrome
P09696819A0450|64 75|vTF7-3 system
P09698457A0778|30 44|Cux/CDPDeltaCR1
P09698457A0976|79 96|tissue distribution
P09698457A0976|156 170|target sequences
P09698512A0296|54 73|transplant recipients
P09700644T0000|27 44|brain abnormalities
P09701609A0116|51 64|orphan proteins
P09701616A0108|7 43|transcriptase-polymerase chain reaction
P09701616A0108|96 121|sand shrimp Metapenaeus ensis
P09701821A1108|10 22|transcription
P09703021A0000|9 42|arylalkylamine N-acetyltransferases
P09703021A0000|107 120|sclerotization
P09703021A0000|121 132|inactivation
P09703021A0000|142 158|neurotransmitters
P09703021A0000|228 248|melatonin biosynthesis
P09703213A0280|20 34|D1 antagonist SCH
P09703213A0280|96 107|facilitation
P09703276A2346|25 37|hydroquinones
P09703276A2346|44 55|mutagenicity
P09703276A2346|59 73|carcinogenicity
P09703816A0139|89 101|iliac arteries
P09704296T0000|65 79|immunoglobulin E
P09704296T0000|83 94|eosinophilia
P09704569T0000|51 67|TR2 orphan receptor
P09704569T0000|80 105|steroid receptor superfamily
P09704857T0000|13 25|skin disorders
P09704857T0000|30 42|CD4 lymphocyte
P09704927A0479|70 87|heterodimerization
P09705258A0837|3 16|IE13.1 cell line
P09705324A0213|6 17|footprinting
P09705324A0213|36 56|mobility shift analyses
P09705324A0213|162 191|thyroid hormone response elements
P09705324A0213|225 240|promoter sequence
P09705324A1602|18 39|rat Std promoter function
P09705324A1602|82 97|liver specificity
P09705324A1602|103 112|rat Std gene
P09705324A1602|181 193|C/EBP elements
P09705324A1602|296 307|interference
P09705324A1602|347 363|DNA-AR interaction
P09705352A0879|60 98|minichromosome maintenance protein complex
P09705352A0879|111 122|fission yeast
P09705497A0227|3 15|yeast MMS2 gene
P09705497A0227|52 84|methyl methanesulfonate sensitivity
P09705497A0227|90 101|mms2-1 mutant
P09705497A0227|132 156|DNA post-replication repair
P09705564T0000|20 37|papillomavirus type
P09705564T0000|60 71|E5 transcript
P09706565A1072|42 55|immobilization
P09707498A0262|0 19|MK-801 administration
P09707498A0262|49 62|seizure latency
P09707577A1047|13 24|distribution
P09708565A0000|78 90|radionuclides
P09708565A0000|127 144|radioimmunotherapy
P09708565A0000|209 225|multicenter trials
P09708565A0000|229 245|commercialization
P09710131A0374|52 76|image intensifier tube modes
P09710131A0374|80 98|laser printer formats
P09710582A0535|55 74|protein kinase pathway
P09710582A0535|102 113|MEK inhibitor
P09710582A0535|144 155|AP-1 activity
P09710591A0981|36 49|serine residues
P09710591A0981|57 78|phosphorylation targets
P09710591A0981|82 94|growth factors
P09710591A0981|125 139|transactivation
P09710591A0981|143 159|block potentiation
P09710599A0310|45 56|response gene
P09710599A0310|126 137|ets-2 protein
P09710599T0000|39 55|protein kinases p42
P09710599T0000|65 84|ets-2 phosphorylation
P09710614T0000|0 13|Identification
P09710614T0000|125 148|phosphoinositide 3-kinase
P09710615T0000|35 49|syntaxin homolog
P09710615T0000|81 98|protein trafficking
P09710621A0598|61 81|cysteine substitutions
P09710621A0598|87 108|Neu juxtamembrane domain
P09710621A0598|123 134|dimerization
P09710621A0598|149 161|interreceptor
P09710641A0000|67 85|transcription factor
P09710641A0000|97 110|eye development
P09710641A0000|163 182|zeta-crystallin genes
P09712037A0470|0 13|Tctex-1 binding
P09712037A0470|64 77|lysine residues
P09712037A0470|135 149|Fyn interactions
P09712037A0470|157 170|immunoreceptor
P09712037A0470|185 200|activation motifs
P09712037A0470|208 228|lymphocyte Ag receptors
P09712297T0000|3 32|prothrombin gene G20210A mutation
P09712297T0000|72 85|vein thrombosis
P09712859A1110|109 120|blood T-cells
P09712898A0911|25 37|p38 activation
P09712898A0911|58 71|protein kinases
P09712898T0000|0 27|Tumor necrosis factor signaling
P09712898T0000|46 58|protein kinase
P09712915A0672|87 109|transcription factors Sp1
P09712919A0307|54 69|signaling pathway
P09712919A0307|91 104|CREB activation
P09713584A1193|24 37|spouse/partner
P09713990T0000|17 30|TP53 target gene
P09713990T0000|36 54|colon cancer cell line
P09713990T0000|88 107|TP53 expression system
P09713996A0262|0 13|Overexpression
P09713996A0262|58 70|patient tumors
P09713996T0000|23 38|characterization
P09713996T0000|58 71|rearrangements
P09713996T0000|85 102|drug resistance gene
P09713996T0000|103 121|MDR1/P-glycoprotein
P09714109A0000|51 63|blood pressure
P09714109A0000|92 104|nerve activity
P09714109A0785|7 27|blood pressure increase
P09714835A0345|15 31|carboxypeptidase D
P09714835A0345|101 117|carboxypeptidase E
P09714835A0345|138 152|characteristics
P09715278A1079|0 11|RA-treatment
P09715278A1079|19 31|transfectants
P09715278A1079|109 125|G1 cell cycle arrest
P09715278A1079|152 162|NT2/D1 cells
P09715278A1526|3 16|histopathology
P09715278A1526|20 37|neovascularization
P09715278A1526|68 82|xenograft tumors
P09715278A1526|94 112|FGF4 over-expressing
P09715278A1526|119 138|control transfectants
P09716095T0000|0 13|Pressure ulcers
P09716179A0974|0 18|RXR-gamma expression
P09716179A0974|103 130|kinase inhibitors p21Cip1/WAF1
P09716179A0974|168 185|cdk2 kinase activity
P09716179A0974|189 205|RB phosphorylation
P09716183A1036|90 109|phosphorylation sites
P09716183A1036|122 144|ERK kinase consensus sites
P09716435A1004|96 112|cortisol elevation
P09717246A0526|48 59|exposure time
P09717246A0526|64 76|rate constants
P09717246A0526|109 119|lipid weight
P09717835A0941|5 20|sequence analyses
P09717835A0941|77 90|Xenopus homolog
P09717887A0239|77 92|occlusive disease
P09717887A0239|121 132|claudication
P09718372T0000|71 88|Sty1/Spc1 MAP kinase
P09718372T0000|91 102|fission yeast
P09718671A0000|14 24|Injury Scale
P09718671A0000|28 46|Injury Severity Scale
P09718671A0000|50 65|TRISS methodology
P09719636A1134|61 74|histidine pairs
P09719636A1134|78 93|H382-X2-H385 pair
P09719636A1134|97 112|H411-X2-H414 pair
P09719636A1134|119 134|H430-X5-H436 pair
P09721207A0637|102 114|vacillans gene
P09721798A1734|60 71|HCV hepatitis
P09721798A1734|109 120|liver failure
P09722161A3065|62 73|Igf2/Mpr gene
P09722508A0953|29 41|Galpha11 Q209L
P09722508A0953|52 74|Src family kinase activity
P09722508A0953|85 107|tyrosine phosphorylation
P09722508A0953|127 138|HEK-293 cells
P09722766A0706|3 21|micturition pressure
P09723896A0000|53 65|transcription
P09723896A0000|135 152|heterodimerization
P09723896A0000|173 184|acid receptor
P09724763T0000|13 24|substitution
P09724763T0000|27 56|abalone sperm fertilization genes
P09724763T0000|64 75|substitution
P09724772A0840|0 19|Gel retardation assays
P09724772A0840|65 84|zia operator-promoter
P09724772A0840|88 102|ZiaR-DNA binding
P09724772A0840|130 143|metal-chelator
P09725651A0077|35 50|Microsoft Windows
P09725651A0077|111 127|Pentium processors
P09725854A1060|101 116|IS1112C Rf3 allele
P09725854A1060|139 153|maintainer lines
P09725854A1060|192 217|urf209 processing activities
P09726201T0000|12 25|interpretation
P09726979T0000|29 44|characterization
P09726979T0000|53 69|sphingosine kinase
P09726987T0000|6 40|SPT3-TAFII31-GCN5-L acetylase complex
P09726987T0000|53 74|transcription factor IID
P09726988A0275|33 42|M-CPT I mRNA
P09726991T0000|12 27|DNA binding domain
P09726991T0000|50 72|transcription factor Mac1
P09727045A0817|132 142|AR N terminus
P09727045A0817|146 164|ligand binding domain
P09727046A0000|122 150|beta-globin locus control region
P09729481A0000|3 43|rat branched-chain-2-oxo-acid dehydrogenase
P09729481A0000|130 144|Sp1 binding sites
P09729481A0000|152 173|transcription start site
P09729481A1177|0 14|Co-transfection
P09729481A1177|20 39|Sp1 expression plasmid
P09729481A1177|49 65|promoter construct
P09729481A1177|80 93|Schneider cells
P09729481A1177|136 151|promoter activity
P09730413A0642|9 22|investigations
P09730413A0642|123 137|treatment option
P09731354A0963|32 45|surface density
P09731513A1090|52 80|transcription factors NF-kappaB
P09731513A1090|102 116|transactivation
P09731704A0000|46 67|estrogen receptor-alpha
P09731704A0000|101 114|gene activation
P09731704A0000|117 138|U2-OS osteosarcoma cells
P09731704A1472|0 11|Transfection
P09731704A1472|33 61|delta5ERalpha expression vector
P09731704A1472|89 100|potentiation
P09731704A1472|116 129|ERELuc activity
P09733493A0493|76 91|hydroxyl radicals
P09733647A1960|12 46|Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-Phe
P09733647A1960|133 146|archeabacteria
P09733815T0000|19 35|membrane protein 2A
P09733815T0000|50 77|protein tyrosine kinase loading
P09733815T0000|105 116|virus latency
P09734808A0000|9 22|test efficiency
P09734808A0000|56 77|contrast/color card test
P09734808A0000|99 110|test stimulus
P09735286A0599|66 75|Mu B protein
P09735366A1180|5 29|homology cloning techniques
P09735366A1180|43 56|mouse homologue
P09735366A1180|72 83|yeast protein
P09735366A1180|127 147|Caenorhabditis elegans
P09735368A0636|39 50|accumulation
P09735368A0636|107 119|K box sequences
P09735371A0227|34 51|homeodomain protein
P09735371A0227|115 132|homeodomain protein
P09735371A0227|145 159|differentiation
P09736239A0436|11 29|resuscitation period
P09736239A0436|55 77|glutamate concentrations
P09736239A0436|125 137|resuscitation
P09736239A0436|177 189|resuscitation
P09736239A0436|229 240|accumulation
P09736239A0436|249 260|excitotoxins
P09736239A0436|277 289|resuscitation
P09736697A0783|64 77|overexpression
P09736697A0783|103 117|Stat3 activation
P09736697A1107|20 33|IL-6 activation
P09736697A1107|86 106|serine phosphorylation
P09736697A1107|154 169|Janus kinases Jak1
P09736715A0729|11 30|phosphatidylinositol
P09736715A0729|34 46|trisphosphate
P09736770A0351|0 11|Transfection
P09736770A0351|22 35|binding studies
P09737453A0557|51 63|IgG antibodies
P09737921T0000|0 15|Genome plasticity
P09737921T0000|27 40|tail fiber locus
P09737921T0000|52 64|bacteriophage
P09737921T0000|65 77|recombination
P09737921T0000|94 104|motifs swaps
P09738010A0305|3 13|FAS promoter
P09738010A0305|56 78|insulin response sequence
P09738010A0305|108 123|base pair position
P09738087A0583|56 73|Cox regression model
P09738693T0000|18 36|neutrophil functions
P09739401A0000|42 59|balance instruments
P09739401A0000|115 129|home environment
P09741783A0000|21 38|aromatase inhibitor
P09741783A0000|57 73|survival advantage
P09741783A0000|128 139|breast cancer
P09743233A0526|28 39|ets component
P09743233A0526|63 78|promoter activity
P09744095A1016|30 42|shy2-1D mutant
P09744095A1016|179 195|inflorescence stem
P09744095A1016|205 219|level expression
P09745797A0943|21 36|underpredictions
P09747651A0000|0 12|Laser ablation
P09747873T0000|17 35|adapter protein GRB10
P09748261A0000|40 58|acyl-CoA synthetases
P09748261A0000|64 85|acid activation proteins
P09748286A0000|72 85|factor receptor
P09748286A0000|112 127|characterization
P09748286A0000|141 152|pair enhancer
P09748513X1360|13 31|Elsevier Science B.V.
P09749533A0764|64 76|flowering time
P09749988A0000|198 210|repulsion zone
P09750325A0000|16 38|intensity light emissions
P09750325A0000|61 86|power energization technique
P09750325A0000|176 196|Listeria monocytogenes
P09750540A0000|8 26|chemical sensitivity
P09750540A0000|92 107|chemical exposure
P09751061A0000|0 17|POU-domain proteins
P09751061A0000|45 55|factor Pit-1
P09751061A0000|71 87|homeodomain family
P09751061A0000|176 202|signal-transduction pathways
P09751114A1987|68 79|MyoD function
P09751166A1460|75 89|TH transcription
P09751458A0845|0 19|desmethyltrimebutine
P09753241A0524|10 21|examinations
P09753241A0524|66 88|myeloperoxidase activity
P09753241A0524|107 117|colon mucosa
P09753730A0881|0 14|T7 transcription
P09753730A0881|96 112|promoter mutations
P09753769A0362|30 45|oligonucleotides
P09753769A0362|62 79|amino acid sequences
P09753769A0362|85 97|PBAN precursor
P09753774A1642|56 77|oligofructans 1-kestose
P09753774A1642|98 119|1,1,1-fructosylnystose
P09753774A2246|34 51|amino acid sequences
P09753774A2246|83 112|plant fructosyl transferase genes
P09753774A2246|132 148|plant fructan genes
P09753774A2246|164 182|plant invertase genes
P09753775A0734|38 50|ICK1 induction
P09753775A0734|79 101|histone H1 kinase activity
P09754571A0169|42 59|display amplicon 3G1
P09754571A0169|91 108|RAG1 mRNA expression
P09755191A0553|101 118|frameshift mutation
P09755191A0553|143 154|reading frame
P09755199A0373|80 91|requirements
P09755199A0559|28 39|Scm mutations
P09755199A0559|77 88|PcG mutations
P09755478A0366|0 15|Northern analysis
P09755478A0366|117 131|trace expression
P09756687A0981|10 25|characterization
P09756687A0981|68 80|rate constants
P09757012A0942|117 141|signal transduction pathway
P09759180A0000|10 25|Fluoroquinolones
P09759180A0000|74 88|cartilage damage
P09759691A1051|56 71|microalbuminuria
P09759691A1051|79 94|albumin excretion
P09759691A1051|177 189|blood pressure
P09759691A1051|238 259|plasma cholesterol level
P09759691A1051|347 359|body mass index
P09759865A0673|62 75|Rel proteins p50
P09759865A0673|86 118|NF-kappaB consensus oligonucleotide
P09759865A0673|121 134|gel shift assays
P09759865A0673|177 191|NF-kappaB-alpha
P09759865A0673|192 204|IkappaB-alpha
P09759865A0673|221 234|myofibroblasts
P09760243A0970|0 14|Cotransfections
P09760243A0970|27 49|HNF-4 expression plasmids
P09760243A0970|68 82|transactivation
P09760243A0970|88 102|apoCIII promoter
P09760341T0000|0 24|Phosphocreatine hydrolysis
P09761711A0000|0 18|Pseudocontact shifts
P09761711A0000|137 160|susceptibility anisotropy
P09761791A0489|29 39|SRZ proteins
P09761791A0489|71 86|blot overlay assay
P09763421A1199|31 53|Fab1p kinase inactivation
P09763421A1199|96 115|acidification defects
P09763446A0000|17 29|Ypt/Rab family
P09763446A1234|9 21|GAP activities
P09763470A0000|0 23|Dopamine beta-hydroxylase
P09763470A0000|61 73|noradrenaline
P09763470A0000|137 155|neuroendocrine cells
P09763470A1756|91 110|transcription factors
P09763607A0521|35 49|phosphorylation
P09764741A0092|47 67|cell division machinery
P09765261A0000|25 38|retrovirus type
P09765261A0000|46 60|trans-activator
P09765261A0000|92 118|basic-domain/leucine-zipper
P09765261A0000|130 162|cAMP response element binding protein
P09765261A0000|236 246|pair repeats
P09765261A0000|256 278|cAMP response element core
P09765271A1108|30 52|insulin response sequence
P09765271A1108|138 169|phosphoenolpyruvate carboxykinase
P09765271A1108|170 193|tyrosine aminotransferase
P09765277A0000|21 45|glucose transporter isoform
P09765277A0000|117 128|trophoblasts
P09765285A0998|32 54|consensus sequence AGGTCA
P09765285A0998|166 188|spacer length requirement
P09765285A1763|11 25|transactivation
P09765285A1763|56 72|binding affinities
P09765285A1763|78 93|response elements
P09765372A0669|62 73|distribution
P09765372A0669|92 104|dorsal surface
P09765388T0000|0 11|Inactivation
P09765388T0000|28 41|adenovirus type
P09765388T0000|77 88|oncoproteins
P09765394A0000|15 36|virus transactivator Zta
P09765394A0000|50 63|gene expression
P09765394A1590|0 13|Cotransfection
P09765394A1590|76 91|activation domain
P09765394A1590|110 124|superactivation
P09765394A1590|127 139|CAT expression
P09765411A0991|0 18|Sequence comparisons
P09765411A0991|137 149|hybrid protein
P09765411A0991|157 188|structure NH2-ubiquitin-S27a-COOH
P09767504A1371|45 57|concentration
P09767504A1371|68 81|administration
P09767575A0657|65 79|ribosome binding
P09767687T0000|45 61|Chlamydophyceaeas
P09767687T0000|92 104|rbcL sequences
P09769209A0100|72 91|nasF operon expression
P09769209A0100|122 145|antitermination mechanism
P09770241A0000|46 56|brain cortex
P09770415A0139|41 55|KRxxxxxxxxxKTKK
P09770415A0139|58 75|amino acid positions
P09770415A0139|123 140|localization signal
P09770493A0499|46 64|cell cycle regulation
P09770493A0499|68 88|cell fate determination
P09770493A0499|146 161|postimplantation
P09770686A0484|40 51|hypertension
P09771555A0499|22 44|anthraquinone sennoside B
P09771967A1052|26 40|chromosome 13q14
P09771985A0238|29 48|ethylmercury chloride
P09773975A1873|9 21|AT1A receptors
P09773975A1873|40 56|hamster ovary cells
P09773975A1873|81 96|Ang II stimulation
P09773975A1873|121 135|internalization
P09773975A1873|184 196|substitutions
P09773981A0415b|12 33|glucocorticoid receptor
P09774444A0351|46 56|zinc fingers
P09774444A0351|62 74|Cys2-His2 type
P09774444A0351|110 128|beta-globin promoter
P09774444A0351|137 158|Sp1 recognition sequence
P09774450A0000|25 35|mouse enzyme
P09774450A0000|42 68|gamma-glutamyl leukotrienase
P09774450A0000|84 96|leukotriene C4
P09774450A0000|103 115|leukotriene D4
P09774484T0000|0 15|UGA codon position
P09774484T0000|38 64|selenocysteine incorporation
P09774484T0000|69 91|glutathione peroxidase-1
P09774641A0824|72 86|phosphorylation
P09774641A0824|92 116|retinoblastoma gene product
P09774662A0958|3 13|ARF promoter
P09774662A0958|48 61|E2F1 expression
P09776360A0620|19 33|binding activity
P09776360A0620|36 58|transcription factor AP-1
P09777477A0000|13 23|brain injury
P09777477A0000|27 45|control participants
P09777477A0000|56 68|vigilance task
P09777600A0000|59 72|chromatography
P09777999A0796|53 63|PaCO2 levels
P09778006A0718|14 25|baseline Vmca
P09778006A0718|46 58|carbon dioxide
P09778006A0718|100 111|measurements
P09778006A0718|151 173|carbon dioxide reactivity
P09778006A0718|223 239|baseline Vmca/mmHg
P09778068A1129|12 30|Cox survival analysis
P09778068A1129|84 96|regurgitation
P09778191A0000|73 87|reserve capacity
P09778191A0000|134 149|resonance imaging
P09778197A0415|0 25|Cost-effectiveness analysis
P09778197A0415|67 85|health care resources
P09778197A0415|165 200|beta-hydroxy-beta-methylglutaryl-CoA
P09778197A0415|210 228|reductase inhibitors
P09778197A0415|250 264|atherosclerosis
P09780002A0996|22 42|transactivation domain
P09780002A0996|72 84|transcription
P09780228A0122|33 48|FK506 gene cluster
P09780228A0613|12 27|domain structures
P09780228A0613|78 96|fatty-acid-synthase
P09780336A0771|10 27|Msy2 mRNA expression
P09780336A0771|49 59|mouse testes
P09780336A0771|132 146|round spermatids
P09780336A0771|183 209|messenger ribonucleoproteins
P09781761A0384|3 15|Ho Chi Minh City
P09781761A0384|38 55|latex agglutination
P09781871A0404|0 16|Glycogen synthesis
P09781871A0404|30 44|gluconeogenesis
P09781871A0404|63 83|cell surface properties
P09781871A0404|166 181|virulence factors
P09781871A0404|204 223|response elicitor HrpN
P09781871A0404|285 301|Erwinia carotovora
P09781874A1061|3 16|cwg2-1 mutation
P09781874A1061|42 60|adenine substitution
P09781874A1061|107 117|change A202T
P09784063A0621|0 15|Deletion analysis
P09784063A0621|69 97|ORF5/deltaX transcript promoter
P09784192A1027|46 68|surface plasmon resonance
P09784245T0000|35 48|identification
P09784245T0000|51 64|protein kinase A
P09784245T0000|68 101|protein kinase C phosphorylation sites
P09786197A0322|21 31|DNA sequence
P09786197A0322|58 76|transposon insertion
P09786197A0322|94 106|reading frames
P09786197A0322|142 159|sequence similarity
P09786404A0541|6 18|aggregates/ml
P09786926A0095|34 59|fatty-acid synthase promoter
P09786926A0095|97 110|overexpression
P09786926A0095|116 133|fatty-acid synthase
P09786926A1372|19 32|binding studies
P09786926A1372|68 85|ADD1/SREBP1 binding
P09786932A1042|178 195|IFNA gene expression
P09787323A0000|10 26|role interleukin-6
P09787323A0000|57 73|thrombocytopenias
P09788739A1096|22 33|serine kinase
P09788739A1096|75 90|signaling cascade
P09788739A1096|132 154|MDA231 breast cancer cells
P09789795A0607|41 53|noradrenaline
P09789795A0607|56 69|concentrations
P09790499A0545|0 19|Northern blot analyses
P09790499A0545|31 44|hBub1 mRNA level
P09790767A0372|31 47|sequence tag clones
P09790768A0621|69 79|liver testis
P09790771A0956|0 16|Gng3lg transcripts
P09790771A1032|20 33|backcross panel
P09790986A0689|41 77|glutathione S-transferase fusion protein
P09792439T0000|15 40|apolipoprotein B mRNA editing
P09792439T0000|57 70|hnRNP C1 protein
P09792439T0000|74 90|40S hnRNP complexes
P09792630A1127|32 57|transcription start site CTCA
P09792630A1127|77 89|consensus CTCA
P09792630A1127|115 130|initiator element
P09792630A1127|146 172|deoxynucleotidyltransferase
P09792702A0754|82 95|JNK1 activation
P09792702A0754|104 122|HSP70 gene expression
P09792714A1408|59 71|transcription
P09792714A1408|118 131|gene expression
P09794414T0000|9 31|protein kinase C signaling
P09794414T0000|43 58|DRA transcription
P09794795A0183|0 12|Ligand binding
P09794795A0183|18 32|receptor complex
P09794795A0183|40 62|tyrosine phosphorylation
P09794795A0183|78 89|Janus kinases
P09794795A0183|93 107|phosphorylation
P09794795A0183|113 141|signal transducing subunit gp130
P09794795A0183|166 180|phosphorylation
P09794795A0183|186 201|signal transducer
P09794795A0183|216 240|transcription factors STAT3
P09794795A0183|255 271|src homology domain
P09794795A0183|284 309|protein tyrosine phosphatase
P09795130A0742|68 88|translation efficiency
P09795170A0774|13 31|polyadenylation site
P09795170A0774|83 98|kb transcript size
P09795213A0129|0 11|RBP56 protein
P09795213A0129|95 108|sub-population
P09795213A0129|111 124|TFIID complexes
P09795213A0129|125 136|Bertolotti A.
P09795213A0129|273 297|proto-oncoproteins TLS/FUS
P09795213A0129|332 344|RNA polymerase
P09795341A0806|17 34|mobility shift assay
P09795341A0806|64 78|binding property
P09797189A0559|12 24|shift analysis
P09797456A0000|13 31|c-myc proto-oncogene
P09797456A0000|64 80|cell proliferation
P09797456A0000|81 95|differentiation
P09797456A0000|96 109|transformation
P09797456A0883|96 110|c-myc expression
P09798068A0290|45 56|reading frame
P09798100A0705|31 52|micrograms cloprostenol
P09798263T0000|35 58|serotonin receptor ligands
P09798263T0000|62 86|calcium channel antagonists
P09798263T0000|108 119|swimming test
P09799086A0725|16 30|hotspot mutation
P09799086A0725|68 87|G nucleotide insertion
P09799237A0624|35 52|gastrulation defect
P09799362A0507|56 71|abbreviation AZF1
P09799362A0507|87 103|Zinc Finger protein
P09799362A1463|0 14|Over-expression
P09799362A1463|55 69|expression level
P09799362A1463|88 111|transcription factor Mtf1p
P09799362A1463|186 204|RNA polymerase mutant
P09799634A0161|16 28|computer model
P09799634A0161|77 92|crystal structure
P09799793T0000|40 53|chromosome 7q22
P09800187A0100|15 26|mouse homolog
P09800187A0100|129 145|DNA damaging agents
P09800187A0100|172 189|mouse lymphoma cells
P09801156A0220|34 58|amino acid sequence homology
P09801333A0174|32 43|reading frame
P09802206A1058|7 22|sequence homology
P09802206A1058|58 91|translation elongation factor-1 alpha
P09802902A0225|43 56|plasma membrane
P09802902A0225|86 107|ARF6 nucleotide exchange
P09803081T0000|35 46|childhood SLE
P09804779A0000|0 19|Transcription factors
P09804779A0000|50 63|protein kinases
P09804779A1163|32 57|Stat5 serine phosphorylation
P09804836A0000|86 109|mouse BAC1.2F5 macrophages
P09804836A0000|110 134|colony stimulating factor-1
P09804836A0000|214 235|affinity chromatography
P09804836A0000|236 262|size exclusion chromatography
P09804836A0000|298 311|chromatography
P09805052A0119|72 85|immunogenicity
P09805977A0143|151 163|xenoestrogens
P09806546A1270|68 82|MHC-II promoters
P09806826A1773|24 35|localization
P09806826A1773|43 53|disease loci
P09806826A1773|137 150|susceptibility
P09806830X1174|13 25|Academic Press
P09806857A0854|6 17|reading frame
P09806857A0854|124 138|Pac25I R-M operon
P09806858T0000|0 13|Identification
P09806858T0000|42 52|plasmid pLS1
P09806919A0447|30 41|instar larvae
P09806919A0447|101 113|ecdysone pulse
P09806919A0447|126 142|puparium formation
P09808155A0813|15 37|protein binding complexes
P09808155A0813|138 148|DNA fragment
P09808216A0000|75 86|manipulation
P09808366A0828|87 102|KA microinjection
P09808441A0320|139 151|lymphotropism
P09808441A0320|187 199|cell carcinoma
P09810087A0379|17 30|seroconversion
P09810087A0379|60 77|herpes simplex virus
P09811695A1146|24 40|HIV-1 Gag sequences
P09811695A1146|87 105|MuLV TM Env protein p15
P09811730A1396|0 14|Competition EMSA
P09811730A1396|97 121|KCS protein binding activity
P09811730A1396|136 151|promoter activity
P09811730A1396|166 190|transfection reporter assay
P09811730T0000|11 26|interferon action
P09811730T0000|27 40|identification
P09811730T0000|151 170|protein kinase pkr gene
P09813041A1122|19 33|phosphorylation
P09813063T0000|24 44|phospholipase D homolog
P09813110A0982|10 26|amino acid sequence
P09813203T0000|22 40|serine substitutions
P09813203T0000|54 71|HIV-1 gp120 IIIB/LAI
P09813203T0000|77 90|immunogenicity
P09813203T0000|96 110|envelope protein
P09813207A0434|0 28|Transcription start site mapping
P09813254A0000|9 22|oligoadenylate
P09813254A0000|51 66|family interferon
P09814637A1214|3 15|PbrO2 readings
P09814637A1214|43 58|microhemorrhages
P09814905A0598|3 14|consequences
P09814905A0598|26 40|swine production
P09815578A1245|71 83|abnormalities
P09815578A1245|86 99|prostate cancer
P09815578A1245|118 139|prostate carcinogenesis
P09815948A1065|89 103|peak plasma level
P09817131A0296|10 24|SF-36 survey form
P09817131A0296|50 67|translation process
P09817190A0074|15 26|cyclosporin A
P09817190A0074|66 77|hypertension
P09817190A0074|80 105|kidney transplant recipients
P09817373A0000|30 49|hypercholesterolemia
P09817373A0000|101 113|insufficiency
P09817373A0000|148 160|oxide synthase
P09817373A0000|185 199|tissue synthesis
P09817373A0000|202 223|constrictor eicosanoids
P09817601T0000|0 15|Characterization
P09819038A0448|30 41|infusion pump
P09819038A0448|58 72|room temperature
P09819038A0448|84 98|body temperature
P09819110A0703|0 12|CD4 lymphocyte
P09819216A0220|4 15|Biochemistry
P09819377A1209|31 47|underaccumulation
P09819377A1209|96 107|accumulation
P09819391A1123|36 50|tyrosine kinases
P09819391A1123|96 107|organization
P09819391A1123|128 151|membrane remodeling events
P09819411A0897|8 24|footprint analysis
P09819411A0897|85 96|CTTCCCTGGAAG
P09819414A1103|55 68|leptin receptor
P09819414A1103|90 103|medium isoforms
P09819421A0000|0 11|Cyclophilins
P09819421A0000|97 108|cyclosporin A
P09819422A0768|7 33|protein retention experiments
P09819422A0768|41 60|Hsp90 heterocomplexes
P09819422A0768|87 101|coprecipitation
P09819440A0000|10 22|transcription
P09819440A0000|60 79|transcription factors
P09819440A0000|86 99|RNA polymerases
P09819440A0783|69 81|RNA polymerase
P09819507A0000|46 58|wound reaction
P09819507A0000|115 135|trabeculectomy surgery
P09820163A0565|26 41|Southern blotting
P09820163A0565|45 63|restriction analysis
P09820205A0000|3 15|zona pellucida
P09820205A0000|96 112|gamete interaction
P09820611T0000|64 77|erythropoietin
P09820621A0067|20 34|thyroid function
P09820621A0067|55 71|energy expenditure
P09820621A0067|75 89|body composition
P09820621A0067|112 123|leptin levels
P09822602A0237|133 144|derepression
P09822602A0237|150 170|transactivation domain
P09822602A0237|219 233|p300 coactivator
P09822602A1172|37 51|transactivation
P09822602A1172|132 149|signal transduction
P09822647A0000|3 18|rat aldolase C gene
P09822652A1118|20 38|HCK promoter activity
P09822652A1118|56 69|concentrations
P09822661T0073|24 40|amino acid residues
P09822661T0073|51 64|quinone binding
P09822685A0596|40 56|Lu-ECAM-1 peptides
P09822685A0596|102 113|reading frame
P09822685A0596|138 149|size proteins
P09822690A0000|9 21|sperm motility
P09822690A0000|59 86|protein phosphorylation events
P09822690A0000|97 111|protein kinase A.
P09823014T0000|45 56|carbohydrate
P09823014T0000|74 85|carbohydrate
P09823014T0000|89 103|lipid metabolism
P09823561T0001|16 27|MALT lymphoma
P09823561T0001|31 52|helicobacter heilmannii
P09823561T0001|53 74|Gastrospirillum hominis
P09823775A1122|58 78|HLA-DRA gene activation
P09824158A1336|10 32|BCL-6 POZ domain mutations
P09824158A1336|89 101|transcription
P09826434T0000|7 22|characterization
P09826434T0000|43 71|platelet cAMP phosphodiesterase
P09826658A0691|4 15|core sequence
P09826658A0691|134 147|BPV-1 pre-mRNAs
P09826778A0943|0 14|Over-expression
P09826778A0943|20 31|cofactor p300
P09826778A0943|75 87|transcription
P09827446T0001|30 41|C4 deficiency
P09827878A0091|5 25|glutathione peroxidase
P09827878A0091|32 50|superoxide dismutase
P09827993A0000|10 29|nucleocapsid proteins
P09827993A0000|46 63|zinc finger proteins
P09827993A0000|75 100|virion RNA binding activities
P09827993A0000|115 132|retrovirus assembly
P09827993A0000|143 158|RNA encapsidation
P09828137A0000|31 60|cell cycle checkpoint control gene
P09828137A0000|132 145|DNA replication
P09829836A0000|80 91|oscillations
P09829836A0815|40 57|cyclin/CDK function
P09829836A0815|95 108|yeast LEU2 genes
P09829843A0119|149 161|complications
P09829843A0819|100 117|neutrophil recovery
P09829843A0819|259 273|neutrophil count
P09829843A0819|277 294|neutrophil function
P09829843A0819|318 340|chemiluminescence system
P09832099A0000|115 133|color kinesis imaging
P09832436A0738|0 13|RT-PCR analysis
P09832436A0738|99 110|PLP diversity
P09832436T0000|19 34|characterization
P09832504A0596|85 100|cysteine residues
P09832505A0903|22 37|activation target
P09832505A0903|81 100|transcription complex
P09832511A0269|11 22|neurogenesis
P09832511A0269|54 72|column neuroectoderm
P09832518A0615|3 18|repression domain
P09832518A0615|37 48|Cdc68 protein
P09832518A0615|149 164|database searches
P09833610A0626|27 41|affinity hormone
P09833740A1112|0 25|Pyrrolidine dithiocarbamate
P09833740A1112|82 98|cytokine responses
P09833740A1112|223 237|provirus latency
P09834070A0793|115 136|protein kinase C activity
P09834070A0793|186 198|B cell function
P09834521A0000|15 25|hydatid cyst
P09835615A0574|78 93|repressor domains
P09836881A0441|37 52|motor performance
P09836881A0441|58 80|Bruininks-Oseretsky Test
P09836881A0441|83 98|Motor Proficiency
P09837714A1068|60 72|modifications
P09837714A1068|107 123|cell proliferation
P09837714A1068|133 147|differentiation
P09837714A1068|150 162|Dictyostelium
P09837715A0581|60 91|chloramphenicol acetyltransferase
P09837715A0581|156 168|leukemia virus
P09837715A0581|172 200|SL3-3 LTR-CAT reporter construct
P09837824A0419|12 26|telSMN mutations
P09837824A0419|108 126|frameshift mutations
P09837824A0419|154 170|missense mutations
P09837907A0857|13 24|TNF receptors
P09837907A0857|47 61|down-regulation
P09837907A0857|94 105|cytotoxicity
P09837907A0857|106 124|caspase-3 activation
P09837907A0857|137 150|AP-1 activation
P09837907A0857|169 183|kinase induction
P09837913A0000|29 40|deiodination
P09837913A0000|62 77|triiodothyronine
P09837913A0419|39 55|sequence tag clones
P09837920A0222|35 46|requirements
P09837920A0222|50 61|consequences
P09837920A0222|74 88|phosphorylation
P09837933T0000|56 70|peptidylglycine
P09837933T0000|86 98|monooxygenase
P09837945A0820|0 17|Immunolocalization
P09837945A0820|45 56|distribution
P09837945A0820|60 83|cell fractionation studies
P09837978T0093|59 71|protein kinase
P09838122A0489|26 43|coding cDNA sequence
P09838122A0489|49 62|mouse homologue
P09840822A0462|68 95|magnetization transfer effects
P09840928A0884|43 56|core histones H3
P09840928A0884|110 121|kinase assays
P09840932A0365|68 79|cyclin A/Cdk2
P09840934A0435|21 32|Ha-RasV12S35
P09840934A0435|50 69|Rafl signaling pathway
P09840934A0435|86 97|Ha-RasV12G37
P09840934A0435|116 128|RalGDS pathway
P09843378A0187|3 20|dopamine D4 receptor
P09843378A0187|86 102|SH3 binding domains
P09843572A0944|44 57|Cdr2 associates
P09843572A0944|99 109|cell lysates
P09843577A0000|67 85|G2/M cell size control
P09843944A0976|128 144|UP element function
P09844106A0835|4 18|phosphorylation
P09844921A0000|9 37|serine-threonine protein kinase
P09844921A0000|60 71|transmission
P09844921A0000|97 119|differentiation messages
P09845043A0000|3 21|US National Institute
P09845043A0000|24 35|Alcohol Abuse
P09845043A0000|100 111|alcohol abuse
P09845043A0000|134 150|alcohol dependence
P09845662A0085|80 92|sodium dodecyl
P09845662A0085|115 132|gel electrophoresis
P09845856A0560|53 65|ulcer diseases
P09846033A0488|29 40|pretreatment
P09846033A0488|43 55|posttreatment
P09846482A0441|75 87|protein kinase
P09846482A0441|103 121|actin polymerization
P09846927A0227|49 59|stomach wall
P09847371A0000|0 19|Jembrana disease virus
P09847371A0000|88 108|immunodeficiency virus
P09847397A0935|92 107|response elements
P09847397A0935|111 125|glucocorticoids
P09849421A0332|87 98|Organization
P09849421A0332|124 140|Cancer Core Quality
P09849421A0332|143 159|Life Questionnaire
P09849421A0332|160 171|EORTC QLQ-C30
P09849722A0797|6 17|presentation
P09849722A0797|53 66|signal increase
P09849722A0797|97 110|cingulate gyrus
P09849722A0797|129 141|cingulate gyri
P09849722A0797|187 198|brain regions
P09849722A0797|236 257|emotion processing tasks
P09849961A0387|0 14|Down-regulation
P09849961A0387|35 55|serine phosphorylation
P09849961A0387|67 84|PI 3-kinase activity
P09849961A0387|106 120|differentiation
P09849961A0387|193 208|myoblast cell line
P09849965A0000|74 85|dimerization
P09849965A0000|93 112|progesterone receptor
P09851614A0109|112 124|cap structures
P09851700A0000|20 50|tissue-type plasminogen activator
P09851988A0085|28 39|anaerobiosis
P09852005A1287|24 50|MADS box consensus binding site
P09852005A1287|136 162|MADS box consensus binding site
P09852005A1287|166 184|serum response factor
P09852005A1287|245 255|OP4 sequence
P09852068A0150b|47 58|footprinting
P09852068A0150b|75 86|significance
P09852068A0150b|157 180|HepG2 hepatoblastoma cells
P09852109A1475|35 49|profile analysis
P09852109A1475|63 74|transcripts C
P09852109A1475|117 128|efficiencies
P09852109A1475|166 176|transcript D
P09852136A0174|84 100|guanine nucleotide
P09852136A0174|117 129|hemagglutinin
P09852136A0507|0 14|Wild type HA-p190
P09852136A0507|91 101|Rho function
P09852136A0507|115 130|ADP-ribosylation
P09852752A0950|58 69|complication
P09854034A0536|92 102|mRNA species
P09855111A0905|23 36|overexpression
P09855111A0905|107 121|SREBP processing
P09856397A0099|0 14|Dry matter intake
P09856397A0099|23 45|nutrient digestibilities
P09856397A0099|46 67|serum chemistry profiles
P09856397A0099|68 93|sphingolipid concentrations
P09857197A0289|64 77|export sequence
P09857265A0669|76 88|contributions
P09857265A0669|119 131|dairy products
P09858531A1017|11 29|RING1 overexpression
P09858531A1017|62 81|proto-oncogenes c-jun
P09858571T0000|3 15|yeast RER2 gene
P09858571T0000|39 75|reticulum protein localization mutations
P09858571T0000|83 103|cis-prenyltransferase
P09858571T0000|116 132|dolichol synthesis
P09858572A0000|3 25|yeast retrotransposon Ty5
P09858577A1186|31 44|ENA1 expression
P09858577A1186|90 106|stress sensitivity
P09858581A0183|89 103|splicing defects
P09858593A0334|16 33|amino acid sequences
P09858593A0334|48 67|Xenopus NeuroD1/BETA2
P09858593A0334|87 107|insulin gene expression
P09858593A0334|118 129|neurogenesis
P09858599A0392|4 22|NUP98-HOXA9 chimeras
P09858599A0392|34 50|NIH 3T3 fibroblasts
P09858599A0392|58 71|transformation
P09858599A0392|83 94|HOXA9 domains
P09858599A0392|111 124|PBX interaction
P09858619A0356|56 69|ZAP-70 function
P09858713A1174|96 107|transduction
P09858713A1174|175 198|gain-of-function activity
P09858714A1171|38 61|shares sequence similarity
P09858745A1350|49 61|cooperativity
P09858745A1350|72 90|footprinting studies
P09858745A1350|174 185|binding sites
P09858745A2033|7 25|transcription assays
P09858745A2033|53 64|intermediate
P09858745A2033|121 134|clcA transcript
P09858883A1106|0 14|BIAcore analysis
P09860979A0521|27 40|binding protein
P09860979A0521|47 59|Crk SH2-domain
P09860979A0521|71 83|JNK activation
P09861099A1011|8 19|correlations
P09861099A1011|38 49|measurements
P09861099A1011|53 65|protein intake
P09861099A1011|76 87|energy intake
P09862343A0225|13 29|gp200-MR6 ligation
P09862343A0225|126 138|up-regulation
P09862343A0225|166 177|B lymphocytes
P09862481A0000|3 15|Mig1 repressor
P09862481A0000|19 35|zinc finger protein
P09862481A0000|48 64|glucose repression
P09862496A0187|20 35|endosperm rupture
P09862496A0187|49 66|betaGLU I expression
P09862496A0187|115 132|betaGLU I expression
P09863624A2301|15 37|receptor internalization
P09863720T0000|49 66|protein S deficiency
P09864141A0528|54 68|phosphopeptides
P09864141A0528|115 130|peptide analogues
P09864141A0528|135 149|phosphopeptides
P09864335A1226|75 88|drug resistance
P09864335A1226|134 146|FCZ resistance
P09864335A1226|163 174|inactivation
P09864689A1408|49 59|washout rate
P09864689A1408|90 101|heart failure
P09866068A1058|11 22|Pretreatment
P09866068A1058|98 110|cyst formation
P09866068A1058|169 182|pregnancy rates
P09867159A1444|22 36|threshold values
P09867253A0229|4 16|c-Jun activity
P09867253A0229|42 57|protooncoprotein
P09867253A0229|91 113|transcription factor AP-1
P09867855T0000|0 16|Dorsal root ganglia
P09867855T0000|32 47|promoter activity
P09867855T0000|53 105|rabbit beta-galactoside alpha1,2-fucosyltransferase gene
P09868412A1628|153 168|swimming exercise
P09868412A1628|272 289|grip muscle strength
P09869297A1807|33 43|CE2 elements
P09869297A1807|56 74|Hoxb1 gene expression
P09869400A0203|71 95|Arabidopsis GLP subfamilies
P09869400A0203|109 119|wheat germin
P09871353A0174|35 57|A. salmonicida infections
P09871353A0174|70 81|furunculosis
P09872326A0566|85 100|heat shock protein
P09872337A0000|141 165|clindamycin phosphate ester
P09872337A0000|169 182|clindamycin HCl
P09872337A0000|206 231|clindamycin phosphate lotion
P09872337A0000|232 243|% clindamycin
P09872832A1262|3 19|BAL concentrations
P09872832A1262|89 101|interleukin-6
P09872832A1262|115 139|tumor necrosis factor-alpha
P09872832A1262|152 166|interferon gamma
P09873060A0901|0 22|Phosphorylation analyses
P09873060A0901|82 96|phosphorylation
P09873291A0620|59 72|knowledge score
P09873291A0620|86 98|patient groups
P09874803A0000|18 45|bacterium group A Streptococcus
P09874803A0000|69 84|cysteine protease
P09874803A0000|135 149|virulence factor
P09874803A0000|161 175|disease episodes
P09875541A0210|3 15|orbitofrontal
P09875541A0210|49 67|dorsal premotor areas
P09875541A0210|114 129|hand movement task
P09876794T0000|12 23|evidence base
P09877417A0704|0 14|Plasma CCK levels
P09878256A0000|3 31|peroxisome biogenesis disorders
P09878256A0000|101 112|deficiencies
P09878256A0000|124 136|abnormalities
P09878437A0967|49 63|phosphorylation
P09878542A1151|98 112|osteopontin VDRE
P09880029A0703|11 27|MDV genome products
P09880029A0703|81 97|amino acid identity
P09880029A0703|119 131|FBNYV proteins
P09880029A0703|147 157|Rep proteins
P09880103A0387|39 51|self-labeling
P09880103A0387|70 86|M hydrogen peroxide
P09880544A0693|13 32|DT-40 lymphoma B-cells
P09880544A0693|103 123|recombination knockout
P09880544A0693|147 157|Fas ligation
P09881692A0094|97 112|Ckappa1 gene locus
P09881692A1109|64 79|oligonucleotides
P09881692A1109|146 161|Southern blotting
P09882303A1413|75 93|deletion TRAF2 mutant
P09882303A1413|132 144|JNK activation
P09882303A1984|45 57|JNK activation
P09882303A1984|84 103|signalling mechanisms
P09882303A1984|113 134|TNF receptor/CD40 family
P09882303T0000|31 45|membrane protein
P09882321A0948|79 101|EBNA-3 protein expression
P09882334A0822|95 106|transfection
P09882334A0822|136 150|tyrosine residue
P09882337A0000|0 20|Varicella-zoster virus
P09882337A0000|24 37|glycoprotein gI
P09882337A0000|46 70|transmembrane glycoprotein
P09882337A0000|109 127|gI Fc receptor complex
P09882348A0611|22 42|phosphorylation status
P09882348A0611|55 77|tyrosine kinase substrate
P09882348A0611|93 109|Shc adapter protein
P09882451A0195|75 92|ferrochelatase gene
P09882451A0195|133 145|transformants
P09882489A0451|64 77|mef2 expression
P09882499A0231|26 40|mouse technology
P09882593A0996|28 40|nickel isotope
P09882593A0996|55 67|drinking water
P09882593A0996|158 170|pompholyx type
P09882638A0235|22 35|collagen fibers
P09882638A0235|41 55|tunica albuginea
P09883639A0000|42 53|mycobacteria
P09884232A0286|54 66|junctions attL
P09884232A0286|91 102|core sequence
P09884232A0286|108 120|recombination
P09884232A0286|147 159|integrase gene
P09884275T0000|0 24|Interferon-alpha treatment
P09884275T0000|87 102|organ transplants
P09884747A0477|37 50|brewery workers
P09884747A0477|58 74|control volunteers
P09884747A0477|80 95|skin prick testing
P09884747A0477|113 125|yeast antigens
P09884747A0477|184 197|serum IgE levels
P09885431A0000|55 72|bridge restorations
P09885431A0000|117 135|impression materials
P09886602A0000|30 41|pretreatment
P09886602A0000|86 97|measurements
P09886602A0000|146 158|radiation dose
P09886602A0000|183 196|prostate cancer
P09886602A0000|214 233|beam radiation therapy
P09886602A0000|245 256|introduction
P09886602A0000|265 275|tumor marker
P09886843A0339|44 57|thyroid hormone
P09886850A0145|60 72|ligand binding
P09886850A0145|97 111|phosphorylation
P09886850A0145|125 147|MEK/ERK signaling pathway
P09887544A0000|26 44|benzodiazepine group
P09887544A0000|47 59|tranquilizers
P09888711A0781|0 20|Bioplastique granuloma
P09888711A0781|137 153|Artecoll granuloma
P09888711A0781|167 179|round vacuoles
P09888994A0858|53 69|mesoderm formation
P09888994A0858|73 85|somitogenesis
P09889202T0000|44 55|domain Zalpha
P09889202T0000|58 84|dsRNA adenosine deaminase type
P09889306A0321|25 44|Glvr-1 gene expression
P09889306A0321|61 72|applications
P09889306A0321|75 85|gene therapy
P09889306A0321|122 153|ape leukemia virus envelope proteins
P09889306A0321|164 175|gene delivery
P09890778T0000|0 12|Carbohydrates
P09890778T0000|16 30|glycoconjugates
P09891009T0000|18 38|mouse glycolate oxidase
P09891046A0269|87 98|PKR signaling
P09891049A0761|68 81|rRNA processing
P09891061A0373|56 67|SpHE promoter
P09891061A1240|61 80|SpEts4 gene expression
P09891061A1240|131 147|sea urchin blastula
P09891065A1493|24 36|SRE activation
P09891085A0815|88 100|27S precursors
P09891092A1000|74 85|end formation
P09891707A0000|23 41|spondyloarthropathy
P09892017A2151|71 89|receptor functioning
P09892021A0712|0 13|Overexpression
P09892021A0712|33 43|NIH 3T3 cells
P09892021A0712|87 108|fibroblast growth factor
P09892422A1096|27 38|tissue sheath
P09892422A1096|143 154|transmission
P09892422A1096|192 204|purkinje fibre
P09892642A0172|3 13|DNA helicase
P09892642A0172|33 44|HPV E2 protein
P09892662A0334|15 32|mutant alpha subunit
P09892736A0343|60 70|% similarity
P09892736A0343|97 114|signal transduction
P09892736A0343|118 132|cell replication
P09893060A0767|0 19|Northern blot analysis
P09893262A1272|83 99|TGF-beta responses
P09893913A0656|46 58|micrograms/kg
P09894962T0000|42 54|malformations
P09894962T0000|85 97|malformations
P09897032T0000|26 37|self-pulsing
P09900679T0000|0 14|Wave cybernetics
P09903722T0000|0 18|Autoionization rates
P09903722T0000|22 33|energy levels
P09903722T0000|46 58|Rydberg states
P09913308T0000|71 81|laser pulses
P09914156A1496|61 88|tenascin-C promoter constructs
P09914156A1496|143 158|promoter activity
P09914156A1496|181 191|pair element
P09914156A1496|223 234|RNA start site
P09914500A0000|7 18|factor kappa B
P09914500A0000|41 59|transcription factor
P09914500A0000|128 149|cytokines interleukin-1
P09914500A0000|153 171|tumor necrosis factor
P09914518A1217|83 109|AF-1 transactivation function
P09914518A1217|149 166|4-hydroxytamoxifen
P09915118T0000|10 23|naris occlusion
P09915118T0000|30 41|rat accessory
P09915798A1077|40 56|chaperone activity
P09915798A1077|68 90|hsp90 dimerization domain
P09915798A1077|132 157|steroid receptor interaction
P09915860A0000|16 32|rat pgp2/mdr1b gene
P09915860A0000|100 115|consensus Sp1 site
P09915860A0119|10 24|transactivation
P09915860A0119|30 47|pgp2/mdr1b promoter
P09915860A0119|69 82|Schneider cells
P09916786A0811|0 11|Measurements
P09916786A0811|20 37|bone mineral density
P09916786A0811|83 101|X-ray absorptiometry
P09916786A0811|125 138|bone remodeling
P09916786A0811|157 175|alkaline phosphatase
P09916786A0811|192 213|urine deoxypyridinoline
P09916786A0811|235 248|chromatography
P09916809A0405|96 121|transmembrane signal peptide
P09917064T0000|17 31|clam CPEB homolog
P09917064T0000|45 59|polyadenylation
P09917387T0000|3 15|RNA polymerase
P09917387T0000|30 41|factor TFIIIB
P09917389A1239|12 26|RNase E digestion
P09917391A0380|0 23|Transcription readthrough
P09917555T0001|23 47|growth factor prescriptions
P09917555T0001|58 70|cancer centers
P09918715A0304|14 24|DNA sequence
P09918715A1158|60 77|TATA binding protein
P09918715A1158|124 136|transcription
P09918715A1158|144 164|core promoter sequences
P09918720A0998|3 14|S229A variant
P09918842A0184|7 18|conservation
P09918842A0184|109 122|RNA replication
P09920539A0272|3 14|stimulations
P09920539A0272|80 102|gonadotropin stimulation
P09920775A0075|34 55|transcription start site
P09920775A0075|78 99|reporter gene expression
P09920775A0075|124 138|differentiation
P09920896A1230|52 63|type peptides
P09920896A1230|94 105|substitution
P09920903A1045|50 66|p53 gene regulation
P09920930A0521|26 37|RhoA function
P09920930A0521|58 68|Luc activity
P09920930A0521|99 113|c-Fos expression
P09920930A0959|38 50|growth factors
P09920930A0959|69 79|Luc activity
P09920930A0959|154 167|co-stimulation
P09920930A0959|172 184|growth factors
P09920982A0253|51 64|susceptibility
P09920982A0253|133 143|acne lesions
P09920982A0253|163 177|Rap ID ANA II panel
P09921179T0001|23 38|echocardiography
P09922230A1482|85 98|stress response
P09922856A0459|58 75|absorption promoter
P09922856A0459|89 102|dose-strengths
P09922856A0459|123 144|Laboratoires Synthelabo
P09923245A0482|19 39|interrater reliability
P09924675A0412|21 33|consideration
P09924675A0412|126 139|rehabilitation
P09924675A0412|172 186|characteristics
P09924675A0412|227 238|intervention
P09924987A0000|31 49|Phytolacca americana
P09924987A0000|67 79|N-glycosidase
P09924987A0000|88 102|adenine residues
P09925120A0074|13 25|meta-analysis
P09925372A0458|61 76|sequence homology
P09925777A1195|11 25|affinity hnRNP A1
P09925777A1195|55 73|beta-globin reporter
P09927449A0421|0 13|Overexpression
P09927570A0507|13 25|RNU2 fragility
P09927570A0507|40 51|transfection
P09927570A0507|58 73|expression vector
P09927570A0507|139 149|E1A proteins
P09927570A0507|174 184|kDa proteins
P09927585A0796|0 30|Competitionsupershift EMSA assays
P09927585A0796|73 97|bandshift complex formation
P09927589T0000|52 77|Caenorhabditis elegans MAB-3
P09927589T0000|114 125|conservation
P09929088A0000|38 49|technologies
P09929088A0000|93 107|cancer screening
P09931191A0434|48 58|Ecc arm curls
P09931191A0434|90 103|muscle ischemia
P09931252A1055|19 40|amino acid substitutions
P09931252A1055|51 61|coat protein
P09931252A1055|114 131|scaffolding protein
P09931391A0944|18 30|liver function
P09932288A0378|101 111|cDNA library
P09933641A0241|39 51|amplification
P09933641A0241|137 149|amplification
P09933848A1008|4 17|alloantibodies
P09933848A1008|72 85|autoantibodies
P09936001T0000|53 64|Sc impurities
P09938097T0000|24 57|photoluminescence undulation spectra
P09940132T0000|38 58|charge-transfer solids
P09945838T0000|17 34|matching conditions
P09945838T0000|45 59|heterojunctions
P09947191T0000|0 28|Neutron scattering measurements
P09947191T0000|65 79|antiferromagnet
P09949160A0600|10 21|32D Epo1 cells
P09949160A0600|96 109|eta PKC isoforms
P09949160A0600|132 143|upregulation
P09949178A0264|33 45|interleukin-6
P09950213A1660|32 42|goblet cells
P09950213A1660|115 127|participation
P09950394A0336|23 45|carboxyhemoglobin levels
P09952378A0529|26 44|% confidence interval
P09952378A0529|87 99|IgG antibodies
P09961326T0000|9 20|fluctuations
P09961682T0000|31 46|stick-slip motion
P09964770T0000|0 13|Microstructure
P09964770T0000|17 28|conductivity
P09964770T0000|43 60|laminate composites
P09965234T0000|11 23|heat transport
P09965234T0000|29 46|octylcyanobiphenyl
P09965234T0000|50 62|liquid crystal
P09965909T0000|26 45|soliton perturbations
P09971776A0838|22 34|CD4 regulation
P09971776A0838|144 157|dileucine motif
P09971790A0856|28 39|endonuclease
P09971790A0856|43 60|helicase activities
P09971790A0856|75 102|amino-terminal-charge cluster
P09971790A0856|116 129|D40A-D42A-D44A
P09971790A0856|144 171|AAV hairpin DNA binding activity
P09971806A1585|54 65|KSHV/Rta gene
P09971806A1585|89 105|tumor pathogenesis
P09971815A2094|38 58|candidate latency genes
P09971815A2094|161 175|latency programs
P09971815A2094|241 251|v-bcl-2 gene
P09971815A2094|324 341|gammaherpesviruses
P09971822A1542|51 68|splicing inhibition
P09973351A1522|19 33|DcuS-DcuR system
P09973607A0254|17 30|identification
P09973607A0254|34 49|characterization
P09973607A0254|59 69|Sp100 splice
P09976626T0000|16 31|precursor effects
P09976626T0000|51 64|transformation
P09980944T0000|0 17|Interplane coupling
P09980944T0000|23 47|superconductor Y2Ba4Cu7O15
P09980944T0000|60 71|NQR spin-echo
P09983871T0000|0 17|Raman investigation
P09983871T0000|20 41|YBa2-xLaxCu3O7 ceramics
P09984526T0000|9 20|point defects
P09984526T0000|23 39|lattice parameters
P09984526T0000|42 55|semiconductors
P09985302T0000|7 22|electron dynamics
P09987961A0093|34 45|angiomatosis
P09987961A0093|46 57|vasculopathy
P09987961A0093|61 73|proliferation
P09987961A0093|76 87|synoviocytes
P09988682T0033|41 79|beta1,6-N-acetylglucosaminyltransferase
P09988767A1496|13 35|mouse back-cross analysis
P09988767A1496|56 69|mouse 3Ost genes
P09988767A1496|137 150|identification
P09988767A1496|174 184|site markers
P09988850A0000|93 117|dementia rating instruments
P09988850A0000|178 198|schizophrenia patients
P09988850A0000|276 288|schizophrenia
P09988850A0000|313 328|autopsy materials
P09989334A0964|24 40|processing signals
P09989334A0964|64 79|donor splice sites
P09989334A0964|86 104|polyadenylation site
P09989339A0968|32 42|brain weight
P09990057T0000|0 12|Recombination
P09990057T0000|16 28|transcription
P09990057T0000|96 113|enhancer core region
P09990057T0000|131 153|matrix attachment regions
P09990060A0803|53 71|dyad symmetry element
P09990060A0803|103 114|IL-2 enhancer
P09990060A0803|121 132|CD18 promoter
P09990060A0937|16 49|coactivator CREB binding protein/p300
P09990060A0937|110 128|dyad symmetry element
P09990060A0937|151 163|IL-16 promoter
P09990315A0205|36 49|protein kinase C
P09990315A0205|153 165|phorbol esters
P09990315A0205|185 197|PKC activation
P09990507A0000|34 51|proteolysis pathway
P09990507A0000|53 67|ubiquitin ligase
P09990507A0763|11 25|Fission yeast SCF
P09990507A0763|97 119|F-box/WD-repeat proteins
P09994942T0000|31 46|antiferromagnets
P09995847T0000|0 24|Optical-absorption spectra
P09995847T0000|38 49|energy levels
P09995847T0000|53 75|transition line strengths
P09995897T0000|20 31|interactions
P09995897T0000|57 72|Si/SiO2 interface
P09999256T0000|37 54|transport phenomena
P09999742T0000|6 18|NO interaction
P10000253T0000|0 14|Chirality-glass
P10000253T0000|18 39|spin-glass correlations
P10001333T0038|0 13|Echo modulation
P10002245T0000|19 30|conductivity
P10002245T0000|70 81|delta crystal
P10006319T0000|0 15|Surface spin waves
P10006319T0000|19 39|Heisenberg ferrimagnet
P10008261T0000|0 20|Temperature dependence
P10008261T0000|47 59|magnetization
P10009565T0000|0 19|GW Gamma approximation
P10009565T0000|23 43|electron self-energies
P10009565T0000|46 59|semiconductors
P10013227T0000|0 19|Precision measurement
P10013227T0000|25 45|pion mass difference m pi
P10021350A0093|45 66|Armadillo/beta-catenin
P10021350A0093|103 123|TCF/LEF family proteins
P10021350A0093|140 159|transcription factors
P10021350A0093|173 185|transcription
P10021350A0093|188 199|Wingless/Wnt
P10022032A0000|40 60|vasodilator nicorandil
P10022032A0000|97 126|receptor antagonists propranolol
P10022032A0000|154 183|calcium channel blocker diltiazem
P10022032A0000|235 246|interactions
P10022210A0620|18 33|direct-immersion
P10022210A0620|35 45|SPME process
P10022850A0929|73 84|coactivation
P10022850A0929|87 102|Zta transcription
P10022850A0929|111 130|reactivation function
P10022858A0985|17 40|splicing enhancer sequence
P10022867A1069a|19 29|apn1 strains
P10022867A1069a|54 66|mutation rates
P10022867A1069a|132 148|lysine prototrophy
P10022867A1069b|19 29|apn1 strains
P10022867A1069b|54 66|mutation rates
P10022867A1069b|132 148|lysine prototrophy
P10022875A1265|25 36|Ras effectors
P10022880A0000|9 35|Ras GTPase-activating protein
P10022880A0000|39 49|p120 Ras-GAP
P10022880A0000|74 86|downregulator
P10022880A0000|100 110|Ras proteins
P10022880A0000|142 167|signal transduction pathways
P10022905A0446|5 16|mog-1 alleles
P10022905A0446|79 94|missense mutation
P10022921A0608|67 79|cell viability
P10022925A0870|3 21|Nmd3 protein sequence
P10022978A1261|3 14|distribution
P10022978A1261|45 56|organization
P10022978A1261|119 132|chromosome arms
P10024383T0000|47 58|hyperostosis
P10024882A0541|96 110|promoter opening
P10025050A1052|89 100|lansoprazole
P10025506A0079|28 42|plastin isoforms
P10025506A1078|8 18|Inr sequence
P10026146A0680|18 31|RIalpha subunit
P10026146A0680|63 76|concentrations
P10026146A0680|142 154|protein kinase
P10026146A0680|177 194|cAMP concentrations
P10026146A0680|219 231|Calpha subunit
P10026146A0680|248 260|protein kinase
P10026211A0543|19 32|pDeltaCREC/EBP
P10026211A0543|92 113|glucocorticoid response
P10026211A0543|144 164|H4IIE rat hepatoma cells
P10026275A0549|16 32|structure elements
P10026784A0331|56 75|transcription factors
P10026784A0331|94 111|POU DNA binding motif
P10026784A0929|38 66|POU domain transcription factors
P10026784A0929|100 114|POU-homeodomain
P10026784A2166|5 16|Oct-1 crystal
P10026784A2166|49 61|GCAT half-site
P10026824A0309|30 50|V1a/V2 hybrid receptors
P10026824A0309|92 102|V1a receptor
P10027498A0536|73 83|U.S. program
P10029337A0406|3 17|fatigue exercise
P10029337A0406|38 62|blood lactate concentration
P10029337A0406|94 112|serum creatine kinase
P10029917A0366|36 49|myofibroblasts
P10029917A0366|109 128|muscle cell dispersion
P10029917A0366|167 184|portal vein branches
P10031854T0000|0 19|New Langevin equations
P10032581T0000|16 43|grazing-incidence diffraction
P10033973T0000|48 62|Bose condensates
P10034615T0000|0 21|Structure determination
P10034615T0000|53 66|reconstruction
P10036181A0603|0 11|Northern blot
P10036181A0603|21 41|hybridization analyses
P10036181A0603|50 69|GPR34 mRNA transcripts
P10036181A0603|87 101|rat brain regions
P10036191A0000|3 20|microphthalmia-TFE
P10036191A0000|56 68|leucine zipper
P10036191A0000|77 96|transcription factors
P10036191A0000|174 187|gene expression
P10036191A0000|197 208|cell lineages
P10037378A0176|3 14|dorsal nerves
P10037460A0221|44 57|memory function
P10037460A0221|80 98|ligand acetylcholine
P10037576T0000|41 58|plaque radiotherapy
P10037774A0366|28 53|signal transduction pathways
P10037774A0366|81 97|LDLR transcription
P10041728T0000|0 18|Vacuum Rabi splitting
P10041728T0000|31 53|linear-dispersion theory
P10041728T0000|77 88|observations
P10043466T0000|62 81|polydiacetylene 4BCMU
P10046849T0000|20 40|structure calculations
P10047970T0013|7 21|world literature
P10049357A0608|40 50|HDAC complex
P10049359A1073|87 100|rhinovirus IRES
P10049742T0000|13 36|consensus binding sequence
P10049775T0000|34 53|Anion Channel isoforms
P10049912T0000|0 13|Identification
P10049912T0000|49 61|UV sensitivity
P10049912T0000|89 112|DNA exonuclease deficiency
P10050883A0967|12 39|phosphatidylinositol-3 kinase
P10050883A0967|70 84|p53 conformation
P10051030A1080|33 47|semen production
P10051400A0000|66 84|cranio-rachischisis
P10051488A1293|17 40|AP-1 DNA binding activities
P10051488A1293|95 115|mobility AP-1 complexes
P10051488A1610|27 40|TIMP-1 promoter
P10052371A0171|0 10|STUDY DESIGN
P10052371A0171|19 39|immunoglobulin A levels
P10052878A0135|13 26|set-up accuracy
P10052878A0135|30 44|reproducibility
P10053852T0000|33 61|Gerasimov-Drell-Hearn sum rules
P10054976T0000|0 11|Spectroscopy
P10054976T0000|59 77|Raman coupling regime
P10055173T0000|0 19|Band structure effects
P10055173T0000|22 40|transport properties
P10055173T0000|54 66|quasicrystals
P10059496T0000|8 26|transmission spectra
P10059496T0000|32 45|Penrose lattice
P10063122T0000|0 22|Two-Channel Kondo Lattice
P10063739A0601|23 49|esophageal sphincter pressure
P10065176A0657|25 45|hormone receptor status
P10065176A0657|68 86|lymph node metastases
P10065176A0657|94 112|lymph node metastases
P10065176A0657|126 140|macrometastases
P10065684A0916|26 36|air trapping
P10065684A0916|57 68|lung capacity
P10066790A0497|0 12|Gel filtration
P10066790A0497|13 33|sedimentation velocity
P10066790A0497|37 66|immunoprecipitation experiments
P10066790A0497|141 157|sigma4 polypeptide
P10066790A0497|174 195|adaptor subunit homologs
P10066798A0391|19 32|kinase activity
P10066798A0391|36 48|protein levels
P10066798A0391|94 108|tumor virus-pp60
P10066815T0000|69 92|phosphoinositide 3-kinase
P10066815T0000|132 153|B cell receptor signaling
P10068040A0136|13 23|mouse genome
P10068418A1194|12 29|bone mineral density
P10068418A1194|131 148|alendronate therapy
P10068446A0124|39 49|thiol agents
P10068446A0124|55 69|PKC preparations
P10068446A0124|111 126|cysteine residues
P10070158A0573|11 24|splicing events
P10070158A0573|56 68|cassette exons
P10070158A0573|109 127|transmembrane domain
P10071212A0399|18 32|O. australiensis
P10071761A2374|22 35|promoter region
P10071761A2374|42 55|identification
P10071761A2374|144 157|UCP2 expression
P10071806A0377|9 21|resectability
P10072205A0167|30 41|distribution
P10072205A0167|49 60|MAP estimates
P10072205A0167|90 107|point approximation
P10072205A0167|110 122|density values
P10072205A0167|139 150|distribution
P10072774A0537|51 72|oligonucleotide primers
P10072774A0537|78 96|ligand binding domain
P10072774A0537|107 126|beta integrin subunits
P10073899A0740|9 26|culture failure rate
P10074282A0236|51 71|NO-synthesis inhibitor
P10074282A0236|74 86|methylene blue
P10074282A0236|94 109|cGMPase inhibitor
P10074425A0729|12 23|inactivation
P10074425A0729|29 47|cyclin E-Cdk2 complex
P10074425A0729|60 76|mitogen starvation
P10074520T0000|0 13|Identification
P10074520T0000|17 32|characterization
P10074520T0000|92 112|Mycobacterium ulcerans
P10074903A0915|60 70|p202 protein
P10074903A0915|87 115|cell growth retardation activity
P10074903A0915|150 165|p21 protein levels
P10074921A1169|35 61|HepG2 hepatoblastoma cell line
P10075415A1178|88 99|UV resistance
P10075415A1178|104 115|plasmid pPSR1
P10076007A0656|28 39|casein kinase
P10077188A1172|52 63|biosynthesis
P10077533A0976|44 57|identification
P10078734A0480|11 23|recovery curve
P10078734A0480|96 114|flexor carpi radialis
P10078876A0000|95 116|rat somatosensory cortex
P10078876A0000|135 156|microspectrophotometry
P10078876A0000|206 228|hemoglobin concentration
P10079173A0000|50 69|RNA recognition motifs
P10080436T0000|31 42|fibrillation
P10080436T0000|56 67|artery bypass
P10080875A0772|12 29|supershift analysis
P10080875A0772|60 79|transcription factors
P10080875A0772|125 146|NF-kappaB components p50
P10080875A0772|174 190|NF-kappaB proteins
P10080875A0772|203 214|AP-1 proteins
P10082137A0262|47 58|accumulation
P10082137A0262|147 171|procollagen mRNA expression
P10082137A0262|174 188|skin fibroblasts
P10082554T0000|19 45|c-myc promoter binding protein
P10082554T0000|85 104|cell growth regulation
P10082573A1015|97 119|globin gene transcription
P10082573A1015|255 277|globin gene transcription
P10082585A0512|44 56|rDNA silencing
P10082585A0512|133 145|reporter genes
P10084294A0219|86 98|serum ferritin
P10084294A0219|102 128|transferrin saturation levels
P10084294A0219|154 165|microg/liter
P10085088A0918|68 82|initiation phase
P10085088A0918|85 100|protein synthesis
P10085120A0000|22 38|signaling pathways
P10085140A1004|48 64|TGF-beta signaling
P10085140A1004|108 119|TAK1 pathways
P10085383A1367|17 30|Lake Okeechobee
P10085383A1367|31 42|Littoral zone
P10085383A1367|53 70|Regulation schedule
P10085605A0239|23 39|alpha-fetoprotein
P10085697T0000|0 39|FASEB Federal Funding Consensus Conference FY
P10086544A0504|104 116|blood pressure
P10086544A0504|153 173|temperature difference
P10086544A0504|196 221|oxygen saturation difference
P10086544A0504|222 232|urine output
P10086544A0504|233 247|serum creatinine
P10086544A0504|258 281|neutrophil elastase levels
P10086544A0504|371 382|ejection time
P10086544A0504|403 416|catecholamines
P10086725A0000|66 87|transcription activator
P10087213A0878|13 28|protein sequences
P10087213A0878|84 117|H. pylori plasmid replication proteins
P10087213A0878|156 178|H. pylori plasmid proteins
P10087549A0720|139 150|control group
P10087993A0782|43 55|delta promoter
P10087993A1352|44 63|repressor proteins BP1
P10087993A1352|95 108|beta globin gene
P10087993A1352|146 161|promoter activity
P10090125A0750|14 37|alpha1 antagonist prazosin
P10090146T0000|59 69|chick retina
P10090146T0000|82 103|R-FABP promoter activity
P10090943A1976|99 113|activation stage
P10091594A0284|39 58|structure predictions
P10091594A0284|64 78|NMR spectroscopy
P10091594A0284|91 101|ELISA assays
P10091594A0284|152 165|helix formation
P10091619A0104|9 24|England ADL scores
P10092132A0285|31 48|gene amplifications
P10092847A0455|16 27|distribution
P10092847A0455|47 60|promoter region
P10092847A0455|64 74|hMT-IIA gene
P10092847A0455|100 125|mouse metallothionein-I gene
P10092847A0455|140 153|MRE arrangement
P10092847A0455|179 193|metal regulation
P10092856A0798|75 100|phosphate isomerase promoter
P10094314A0935|16 27|RNA sequences
P10094314A0935|48 68|zinc knuckle 9G8 variant
P10094396A0000|0 14|Topoisomerase II
P10094396A0000|34 58|protein kinase casein kinase
P10094701A0000|54 66|acetate kinase
P10094701A0000|73 93|Sinorhizobium meliloti
P10094701A0000|120 138|phosphate limitation
P10095059A1003|17 35|nucleotide positions
P10095059A1003|50 64|HIV-1 transcript
P10095061A0592|0 15|Sequence analysis
P10095061A0592|31 41|MEMA protein
P10095062A0558|42 65|topoisomerase IIalpha gene
P10096573A0207|71 92|kappaB consensus element
P10096573A0207|129 146|MGSA/GRO-alpha gene
P10097932A0915|72 87|microalbuminuria
P10098601A1320|103 114|SF-1 sequence
P10098744A0630|101 117|proliferation rate
P10098744A0630|129 144|serum-dependence
P10098744A0630|148 160|proliferation
P10098744A0630|171 184|tumorigenicity
P10098744A0630|220 241|differentiation markers
P10099247A1051|27 39|retention time
P10099247A1051|75 87|SRB population
P10100605A0392|68 81|transformation
P10100605A0392|84 99|dihydrorhodamine
P10100605A0392|137 149|flow cytometry
P10101159A0742|77 89|cbp1 ts alleles
P10101198A0632|1 24|deletion mutation analysis
P10101198A0632|88 101|leucine zippers
P10101198A0946|1 14|database search
P10101198A0946|87 116|transcription termination factor
P10101198A0946|172 185|leucine zippers
P10101198A0946|207 218|interactions
P10101744A0917|11 26|antigen challenge
P10102000A1206|30 40|ERA-II group
P10102000A1206|50 61|ERA-III group
P10102000A1206|71 83|mortality rate
P10102627A0217|11 28|DNA binding activity
P10102627A0217|29 48|AP-1 reporter activity
P10103002A0705|7 25|N-glycosylation site
P10103002A0705|35 45|chicken gp42
P10103002A0705|84 103|carbohydrate analysis
P10103002A0705|139 153|type glycan chain
P10103057A0251|17 28|optimization
P10103057A0251|32 47|characterization
P10119827T0000|0 11|Judge OKs docs
P10119827T0000|18 32|Chicago hospital
P10120952T0000|27 47|gall bladder guidelines
P10125354T0000|0 11|Groups dicker
P10125354T0000|15 25|price breaks
P10132730T0000|38 49|teacher union
P10146207A0223|0 14|Ultrasonography
P10153759A0360|16 27|organization
P10153759A0360|46 65|NHBC organ procurement
P10171173A0955|85 102|deficiency syndrome
P10171173A0955|147 160|research effort
P10181397A0641|29 48|life expectancy ratios
P10181397A0641|52 68|gender differences
P10181397A0641|115 126|United States
P10187317T0000|20 34|AHERF physicians
P10187798A1098|0 13|Overexpression
P10187798A1098|66 87|L929 fibroblast cell line
P10187798A1098|109 128|osteosarcoma cell line
P10190324A0000|17 27|elastin gene
P10192134A1088|66 82|micrograms/kg feed
P10192134A1088|107 119|turkey rations
P10192432A0214|65 78|Consensus Panel
P10192638T0000|0 22|Methanesulfonyl fluoride
P10192638T0000|116 128|Alzheimer type
P10193950A0478|72 88|prostate carcinoma
P10193950A0478|124 143|lymph node involvement
P10193950A0478|188 209|staging lymphadenectomy
P10194225A1132|66 77|pyruvate Gneo
P10194230A0817|23 35|dialysate PGE2
P10194230A0817|39 61|adenosine concentrations
P10194451A0000|26 37|relationship
P10194451A0000|67 95|protein tyrosine kinase activity
P10194451A0000|99 112|manifestations
P10194451A0000|201 214|p210 substrates
P10194451A0000|224 239|chronic-phase CML
P10194451A0000|253 267|progenitor cells
P10194762A0648|7 19|precipitation
P10194762A0648|25 63|glutathione-S-transferase-fusion protein
P10194762A0648|87 107|transactivation domain
P10194762A0648|160 172|fusion protein
P10194769A0146|51 71|cDNA expression library
P10194769A0146|78 99|417-amino acid WD protein
P10194769A0146|127 140|element binding
P10195425T0000|0 15|Characterization
P10195425T0000|21 44|transcription factor MTF-1
P10195425T0000|70 81|Fugu rubripes
P10195425T0000|101 112|conservation
P10195425T0000|120 138|metal stress response
P10195690A0000|71 96|hormone receptor superfamily
P10195697A0456|7 19|F-SRC-1 mutant
P10195697A0456|62 78|enhancing activity
P10196127A1059|82 100|pyroglutamyl residue
P10196266A0000|8 24|mouse Mus castaneus
P10196266A0000|62 83|mink cell focus-inducing
P10196266A0000|103 117|leukemia viruses
P10196316A0715|31 41|virus growth
P10196316A0715|51 67|gK deletion mutants
P10196318T0000|0 23|CCAAT displacement protein
P10196318T0000|58 75|papillomavirus type
P10196318T0000|84 94|E1 promoters
P10196597A0510|68 82|characteristics
P10196597A0510|85 96|drink drivers
P10197763A0580|47 64|AMP response element
P10197763A0580|79 101|nerve growth factor effect
P10197985A0145|7 27|RNase H protection assay
P10197985A0145|47 62|oligonucleotides
P10197985A0145|106 124|branchpoint sequence
P10197985A0145|179 191|cooperativity
P10197985A0145|215 231|pre-mRNA substrate
P10197985A0145|244 259|complex formation
P10198056A0000|14 32|cell surface proteins
P10198056A0000|49 60|lipid bilayer
P10198056A0000|68 95|glycosylphosphatidylinositol
P10198061A0339|14 24|import assay
P10198061A0339|25 36|beta-catenin
P10199539A1353|63 78|a3 oxidation level
P10201468A0297|0 12|Plasma glucose
P10201468A0297|57 67|GLP-1 levels
P10202006A0546|26 38|fusion protein
P10202006A1266|0 13|Polypyrimidine
P10202006A1266|17 28|ssDNA binding
P10202006A1266|113 126|autoantibodies
P10202006A1266|180 194|polypyrimidines
P10202006A1266|209 222|B cell selection
P10202006A1266|229 240|immunization
P10203611T0000|0 52|Technetium-99m methylene diphosphonate scintimammography
P10203611T0000|76 87|breast masses
P10205099A0377|0 12|INTERVENTIONS
P10205099A0377|13 25|Study patients
P10205099A0377|133 144|itraconazole
P10205176A0000|47 61|transregulators
P10205176A0704|59 71|transcription
P10205588A0000|87 98|streptococci
P10205588A0000|101 116|Lancefield group A
P10205588A0000|146 160|characteristics
P10205933A0699|21 33|labyrinthitis
P10205933A0699|71 88|Treponemas Pallidum
P10205933A0699|164 174|Lyme Disease
P10206152A1024|106 117|messenger RNA
P10207041A0065|51 63|transcription
P10207041A0065|66 76|cyclin genes
P10207041A0065|82 96|protein products
P10207049A0693|47 87|serine/threonine phosphoprotein phosphatase
P10207049A1001|28 42|Glc7 phosphatase
P10207049A1001|63 73|subunit play
P10207049A1001|89 101|HSF activation
P10207049A1001|104 120|CUP1 transcription
P10207087A0956|54 82|promoter reporter gene construct
P10207087A0956|89 106|activating activity
P10207092A0924|4 18|phosphorylation
P10207092A0924|75 95|protein kinase activity
P10207092A0924|103 118|sea urchin nucleus
P10208865A1246|22 39|osteoclast cultures
P10208865A1246|79 92|resorption pits
P10208865A1246|95 107|dentine slices
P10208893A0839|59 75|WAD goat population
P10209021A0212|52 70|interaction function
P10209031A0832|3 16|Fyn NH2 terminus
P10209031A0832|117 131|phosphorylation
P10209031A0832|134 150|zeta ITAM tyrosines
P10209031A0832|163 186|zeta ITAM phosphotyrosines
P10209119A0076|17 28|protein Skp1p
P10209119A0076|45 56|member Cdc53p
P10209119A0076|63 89|F-box/WD-repeat protein Cdc4p
P10209119A0076|97 126|SCFCdc4p ubiquitin ligase complex
P10209119A0076|167 180|inhibitor Sic1p
P10209119A0594|49 60|similarities
P10209119A0594|106 123|deletion phenotypes
P10209759T0000|0 14|Antithrombin III
P10209759T0000|42 66|ischemia reperfusion injury
P10211329A0457|5 16|observations
P10211329A0457|27 37|serum lipase
P10211422T0000|5 16|pancreatitis
P10211422T0000|20 31|complication
P10211422T0000|34 52|polyarteritis nodosa
P10211919A0846|42 56|sertraline group
P10211919A0846|108 126|CGI Improvement scale
P10211919A0846|174 189|CGI Severity scale
P10212278A0387|16 29|protein kinases
P10212278A0387|49 63|c-jun expression
P10212278A0387|87 105|protein kinase/c-Jun
P10212278A0387|116 128|protein kinase
P10212278A0387|172 184|protein kinase
P10212284A0000|12 23|growth factor
P10212284A0000|51 66|matrix deposition
P10212284A0000|70 82|proliferation
P10212332T0000|0 17|Chronotherapeutics
P10212426A1067|42 52|hearing loss
P10212969A0470|0 11|Uroflowmetry
P10215485A0837|11 22|correlations
P10215485A0837|68 83|State Examination
P10215594A1728|19 29|LUC activity
P10215594A1728|97 115|2SV40-LUC constructs
P10215608A0161|34 49|characterization
P10215608A0161|76 86|subunit gene
P10215803T0000|45 60|calcium gluconate
P10215850A0754|29 40|organization
P10215850A0754|116 127|localization
P10215850A0754|130 144|position 22q11.2
P10216052A0105|105 120|glaucoma patients
P10216052A0105|133 145|interrelation
P10216052A0105|153 164|disabilities
P10216052A0105|170 183|factor analysis
P10216161A1530|0 17|Sequence comparison
P10216161A1530|20 32|cytochromes bd
P10216161A1530|207 232|B. stearothermophilus enzyme
P10217683A0509|0 20|Canalith repositioning
P10218109T0000|0 16|Solution structure
P10218109T0000|34 57|MutT pyrophosphohydrolase
P10218200A0534|60 85|tissue plasminogen activator
P10218357A0486|85 97|cuff-pressure
P10220275A0694|47 59|preincubation
P10221467T0000|12 23|pericarditis
P10221467T0000|62 83|dopamine agonist therapy
P10223338A1601|47 59|fusion protein
P10223338A2186|95 109|HIV/AIDS vaccine
P10223498A0479|113 137|15-item International Index
P10223498A0479|140 155|Erectile Function
P10224244T0000|30 49|Glc7-Reg1 phosphatase
P10224244T0000|56 70|Snf1-Snf4 kinase
P10224244T0000|88 104|INO1 transcription
P10224289T0000|11 29|Fas ligand expression
P10224289T0000|69 90|T cell receptor zeta chain
P10224293A0000|0 34|Receptor protein tyrosine phosphatases
P10224293A0000|89 106|phosphatase domains
P10224293A2021|23 34|brain regions
P10224293A2021|69 86|RPTP-kappa function
P10224513A0240|41 51|speech tasks
P10224513A0240|65 80|videogame playing
P10224758A0202|3 14|control group
P10224758A0202|24 40|afterbirth samples
P10225279A0450|92 106|herpesvirus type
P10225279A0450|140 156|pseudorabies virus
P10225945A0436|19 30|MAD2 staining
P10225945A0436|67 87|microtubule attachment
P10225945A0436|161 172|kinetochores
P10226074A0637|64 83|translation start site
P10228009A0600|14 25|CINC promoter
P10228155A1293|23 38|tumor development
P10228155A1293|72 99|beta-catenin protein stability
P10228157T0000|16 39|spindle checkpoint pathway
P10228157T0000|52 62|Dbf2p kinase
P10228561A0539|20 31|organization
P10228561A0539|34 50|DNA polymerase beta
P10228561A0539|88 100|DNA phosphates
P10228795A0842|65 78|nerve responses
P10229084A0000|15 32|gel electrophoresis
P10229084A0000|46 63|immunoprecipitates
P10229084A0000|103 114|T lymphocytes
P10229084A0000|128 141|identification
P10229084A0000|156 169|protein complex
P10229084A0000|227 241|phosphoproteins
P10229084A0000|257 281|protein tyrosine kinase Pyk2
P10229084A0000|310 324|adaptor proteins
P10229668A0190|15 26|cdc33 mutants
P10229668A0560|1 13|cdc33-1 strain
P10229682A1151|19 32|gene expression
P10229682A1151|153 163|NF-IL-6 site
P10231026A0253|3 15|gene structure
P10231454A0731|5 16|serum calcium
P10231454A0731|93 111|alkaline phosphatase
P10231485A0342|0 15|Sequence analysis
P10231485A0342|41 80|molybdopterin guanine dinucleotide cofactor
P10231485A0342|152 166|membrane protein
P10231485A0342|178 196|quinol oxidation site
P10231513T0000|26 51|granulation tissue formation
P10231581A1125|105 120|promoter activity
P10231862A1117|109 120|contribution
P10232078A0552|51 66|6-keto-PGF1 alpha
P10232600T0000|72 92|sodium iodide symporter
P10232600T0000|95 117|prostate cancer cell lines
P10233147A0218|54 70|signaling pathways
P10233147A0218|74 90|filamentation MAPK
P10233147A0218|91 108|Cdc42p/Ste20p/MAPK
P10233147A0218|135 147|protein kinase
P10233147A0218|148 161|Cyr1p/cAMP/PKA
P10233885A0899|28 40|transfections
P10233885A0899|61 74|cell line Jurkat
P10233885A0899|111 123|mim-1 promoter
P10233885A0899|135 145|p30 isoforms
P10233946A0000|24 42|spleen necrosis virus
P10233946A0000|141 156|leukemia virus RNA
P10234698A0728|38 51|CNS development
P10234698A0728|61 73|animal studies
P10234698A0728|87 98|pretreatment
P10234698A0728|103 117|corticosteroids
P10235265A0197|84 103|proteolysis machinery
P10235265A0197|125 137|cyclin subunit
P10236651T0000|21 34|pharmacy school
P10236651T0000|47 63|admission criteria
P10240361T0000|31 45|dissatisfaction
P10243927A0000|32 44|investigators
P10243927A0000|50 69|IIT Research Institute
P10243927A0000|96 106|door control
P10271171A0458|31 44|identification
P10271171A0458|88 101|resource center
P10304090T0000|0 18|Medicare SNF benefits
P10308312A0203|32 44|understanding
P10308312A0203|50 70|interaction mechanisms
P10318806A0000|38 49|kinase family
P10318806A0000|101 115|protein kinase-1
P10318806A0000|195 207|growth factors
P10318806A0918|33 45|PDGF receptors
P10318806A0918|54 64|Src homology
P10318806A0918|100 115|Src family kinases
P10318806A0918|116 143|phosphatidylinositol 3-kinase
P10318806A0918|179 189|Src homology
P10318806A0918|208 223|phosphatase SHP-2
P10318806A0918|224 243|phospholipase C-gamma
P10318859A0535|31 50|tyrosine phosphatases
P10318859A0535|60 82|tyrosine phosphorylation
P10318900A0637|39 60|electron cryomicroscopy
P10318900A0637|111 122|conformation
P10318900A0637|152 165|mRNA production
P10318918A0824|105 116|HCV genotypes
P10319320A1022|64 76|Ras activation
P10319320A1022|154 165|angiogenesis
P10319327A1237|10 49|SRE oligonucleotide gel mobility shift assays
P10319327A1237|151 164|protein E12/E47
P10319955A0941|29 42|occlusion rates
P10320177A0487|0 27|Baseline electrocorticography
P10320177A0487|62 85|depth electrode recordings
P10320177A0487|168 185|i.v. administration
P10320480A0451|82 92|beta subunit
P10320480A0451|101 113|RNA polymerase
P10320579A1831|45 63|flagellar chaperones
P10320579A1831|75 89|oligomerization
P10321158T0000|7 21|core fabrication
P10322022A0263|83 101|replication proteins
P10322022A0263|106 121|plasmids pAMbeta1
P10322022A0263|156 168|pAW63 replicon
P10322022A0263|181 194|pAMbeta1 family
P10322629A0198|25 40|characterization
P10322629A0198|43 54|Xenopus Pax-5
P10323225A0244|19 32|2-oxoglutarate
P10323463T0000a|0 15|Interferon-alpha
P10323463T0000a|61 74|manifestations
P10323463T0000b|0 15|Interferon-alpha
P10323463T0000b|61 74|manifestations
P10323863A0852|86 109|rabbit reticulocyte lysate
P10323863A0852|122 146|ribonucleoprotein assembly
P10325413A1211|27 63|DNA containing 5-methylcytosine residues
P10326654A0351|11 26|pilot experiments
P10326654A0351|179 190|fibrillation
P10326856T0000|12 33|pancreaticojejunostomy
P10326856T0000|50 67|purse-string device
P10327051A0688|27 57|Stress-Activated-Protein-Kinase
P10327051A0688|62 72|target sites
P10327051A0688|126 137|p300/CBP-ATF
P10328351A0443|0 11|Blood samples
P10328351A0443|39 59|supplementation period
P10329135A1326|36 47|presequences
P10329135A1326|97 109|protein import
P10329566A0610|74 88|valine anticodon
P10329566A0610|131 143|aminoacyl stem
P10329566A0610|172 183|tetraviruses
P10329574A1733|91 102|OnuMV4-Ld RNA
P10329586A0414|55 66|LNCaP-r cells
P10329586A0414|99 112|overexpression
P10329586A0414|119 132|prostate cancer
P10329625A0715|18 31|cell surface CD4
P10329736A0681|79 106|phosphatidylinositol 3-kinase
P10329736A1106|0 17|Insulin stimulation
P10330134A0765|3 16|mRNA expression
P10330134A0765|62 89|transient-transfection assays
P10330134A0765|102 116|RFX binding sites
P10330146A0730|44 63|luciferase expression
P10330146A0730|107 126|luciferase expression
P10330159A1258|67 83|promoter/enhancer
P10330168A0135|108 118|factor Dbf4p
P10330168A0135|148 161|DNA replication
P10330396A0387|3 22|RanQ69L preincubation
P10330396A0387|30 41|accumulation
P10330396A0387|85 95|pore complex
P10331646A0595|20 36|amino acid sequence
P10331646A0595|58 69|transferases
P10331646A0595|86 98|lymphoma cells
P10331646A0595|154 166|amino terminus
P10331646A0595|182 195|signal sequence
P10331646A0595|216 229|signal sequence
P10331646A0595|235 250|carboxyl terminus
P10331730A0504|97 107|study period
P10331875A0523|4 17|dimer interface
P10331875A0523|127 139|cooperativity
P10332733A0000|3 21|paramyxovirus fusion
P10332733A0000|38 51|membrane fusion
P10333481A1102|12 27|deletion analysis
P10333481A1102|102 117|promoter activity
P10333481A1102|195 208|promoter region
P10333529A0277|4 14|betaAPP mRNA
P10333529A0277|18 28|Abeta levels
P10334888A0960|2 13|reperfusion B
P10334888A0960|68 85|IL-8 concentrations
P10334888A0960|107 118|nondiabetics
P10339566A0602|49 61|SPB subcomplex
P10339566A0602|72 83|Spc94p/Nud1p
P10340447A0424|10 21|coefficients
P10341219A0481|11 31|heparin lyase treatment
P10341219A0481|70 85|YD-repeat protein
P10341219A0481|122 135|mass aggregates
P10342511A0909|16 28|determination
P10342536A0954|5 17|determination
P10342536A0954|23 36|protein content
P10342536A0954|72 90|RAST/EAST inhibition
P10342536A0954|144 154|whey formula
P10342536A0954|174 191|whey/casein formula
P10342536A0954|192 214|soy/pork collagen formula
P10342536A0954|221 236|amino acid formula
P10342829A0236|149 160|reproduction
P10342829A1370|11 29|mobility shift assays
P10342829A1370|77 87|SF-1 protein
P10344736A0796|0 19|CDK4 kinase activities
P10344736A0796|54 72|CDK inhibitor p21Cip1
P10344736A0796|82 103|cyclin E immunocomplexes
P10347144A0516|43 59|baculovirus system
P10347197A0502|14 30|urokinase promoter
P10347197A0502|45 55|Met receptor
P10347197A0502|68 80|co-expression
P10347197A0502|108 130|Sos1 expression construct
P10347203A0832|0 20|Serine phosphorylation
P10347203A0832|48 68|somatostatin treatment
P10347203A0832|86 99|pertussis toxin
P10347203A0832|145 157|proliferation
P10347220A1477|89 102|triphosphatase
P10347220A1477|108 129|RNA guanylyltransferase
P10347220A1477|225 263|triphosphatase-guanylyltransferase Mce1p
P10347220A1477|270 290|methyltransferase Hcm1
P10348859A0292|25 36|binding sites
P10348859A0292|48 60|MerR homodimer
P10349084T0000|26 44|virus seropositivity
P10350454A0000|67 78|8-oxoguanine
P10350484A0346|13 26|kinase activity
P10350638A0000|8 33|carboxypeptidase A inhibitor
P10353073A0118|0 17|Regression analyses
P10355085A1119|96 108|injury pattern
P10355085A1119|127 138|nonsurvivors
P10358031A0303|123 136|cell separation
P10358075A0984|29 44|signaling pathway
P10358075A0984|131 144|PtdIns 3-kinase
P10358079A0391|7 24|neu differentiation
P10358079A0391|39 50|heterodimers
P10358080A1114|8 20|linker regions
P10358080A1114|23 42|transcription factors
P10358080A1114|61 81|DNA binding specificity
P10358080A1114|145 166|HSF1 binding preferences
P10358080A1114|213 241|HSF1 monomer-trimer equilibrium
P10358080T0000|17 44|heat shock factor trimerization
P10358080T0000|50 61|linker domain
P10358083A0263|67 82|characterization
P10358083A0263|129 148|sequence motifs GTGACT
P10358083A0263|169 187|transcription factor
P10358138A0672|101 120|cell surface molecules
P10358138A0672|138 160|signaling adaptor protein
P10359014A1077|18 42|Fra-2 phosphorylation sites
P10359014A1077|73 86|serine residues
P10359014A1077|160 176|threonine residues
P10359603A0430|22 41|Sec1p homologue Vps45p
P10359663A0425|173 186|enhancer region
P10359663A0425|198 228|oIFNtau-SV40-CAT transactivation
P10359663A1280|2 23|co-transfection studies
P10359663A1280|64 78|transactivation
P10359664A0579|60 76|lysyl endoprotease
P10359664A0579|90 104|electrospray MS.
P10359673A0000|3 15|yeast LPD1 gene
P10359673A0000|24 45|lipoamide dehydrogenase
P10359673A0000|76 96|amino acid biosynthesis
P10359673A0000|110 132|GCN4 transcription factor
P10359792A0610|34 44|Rpd3 mutants
P10359792A0610|87 110|dCtBP corepressor proteins
P10359792A0610|153 171|histone deacetylases
P10360454A0916|10 32|serum TNF-a concentration
P10360454A0916|74 87|pentoxifylline
P10360454A0916|140 151|control group
P10360839A1338|68 86|KRAB zinc finger genes
P10360839A1338|122 133|cell lineages
P10360947A1113|9 32|fluorescence spectroscopy
P10361038A0281|68 79|protein genes
P10362652A0350|39 51|Ras activation
P10362652A1456|31 50|carbachol stimulation
P10362897A0545|91 103|Doppler signal
P10363517A0401|47 61|ultrasonography
P10364076A0429|51 62|repeat motifs
P10364159A0813|35 50|FRAP/mTOR protein
P10364159A0813|55 80|FRAP/mTOR immunoprecipitate
P10364159A0813|102 113|kinase assays
P10364163A0092|17 32|zinc finger domain
P10364163A0092|55 74|phosphatidylinositol
P10364202A0646|3 14|coexpression
P10364202A0646|28 47|expression constructs
P10364202A0646|68 81|leukemia factor
P10364202A0646|134 155|GAL4-DBP fusion proteins
P10364319A0109|30 47|EBNA mRNA initiation
P10364319A0109|105 115|control loop
P10364523A0826|4 15|exon trapping
P10364523T0000|10 42|dysplasia translocation breakpoints
P10364523T0000|97 109|control region
P10365883A1355|13 27|characteristics
P10365883A1355|30 40|VRE patients
P10365883A1355|56 68|vancomycin use
P10366446A0893|69 84|interaction motif
P10366503A0812|0 16|Binding affinities
P10366503A0812|116 137|co-immunoprecipitation
P10366503A0812|206 230|terminase interaction sites
P10366503A1506|210 225|terminase regions
P10366503A1506|246 261|packasome complex
P10366559A0605|3 15|hybrid viruses
P10366722T0000|17 28|organization
P10366722T0000|49 73|mouse DNA polymerase epsilon
P10367240A1354|12 27|cryopreservation
P10367240A1354|114 127|cryoprotection
P10367240A1354|159 181|fertilization procedures
P10367240A1354|211 224|sperm injection
P10367385A0000|52 64|beta-carotene
P10367460A0191|3 16|FCMS conditions
P10367460A0191|50 65|power consumption
P10367460A0191|69 92|V maximum capacitor voltage
P10367460A0191|96 107|microseconds
P10367460A0191|121 132|microseconds
P10367460A0191|148 158|Hz frequency
P10367646A0569|122 144|alanine aminotransferase
P10367646A0569|155 168|serum globulins
P10369418A0644|87 104|NF-kappaB complexes
P10369418A0644|129 142|NF-kappaB sites
P10369757A0000|8 27|transcription factors
P10369757A0000|39 56|arginine metabolism
P10369757A0000|77 92|Bacillus subtilis
P10369757A0000|213 225|transcription
P10369757A0000|262 274|transcription
P10369757A0000|313 334|plasmid dimer resolution
P10369775A0178|10 25|protein fragments
P10369775A0178|35 55|residues Arg183-His267
P10369775A0178|71 91|residues Lys438-Gln520
P10369926A0251|6 20|intron structure
P10369926A0251|113 129|CXC chemokine genes
P10369965A0000|3 13|Aa-Pri2 gene
P10369965A0000|41 66|basidiocarp differentiation
P10369965A0000|72 95|mushroom Agrocybe aegerita
P10370675A0649|15 26|liver disease
P10370675A0649|51 65|hepatitis C virus
P10370675A0649|71 82|alcohol abuse
P10370675A0649|110 121|alcohol abuse
P10370778A0000|8 26|aromatase inhibitors
P10370778A0000|89 100|breast cancer
P10370778A0000|155 170|tamoxifen therapy
P10371097A0963|70 83|identification
P10371097A0963|112 130|inhalation technique
P10373029A0204|36 55|gastrocnemius muscles
P10373507A0680|155 194|SRF promoter-luciferase reporter activities
P10374632A0897|10 25|NBP pre-treatment
P10375107A1138|26 37|chemotherapy
P10375638A0859|32 46|NRF-1 expression
P10375638A0859|123 139|translation system
P10375640A0153|18 35|nucleotide sequence
P10375640A0153|64 75|reading frame
P10375718A0000|5 26|fibroblast growth factor
P10375718A0000|51 62|angiogenesis
P10375718A0000|72 83|animal models
P10375718A0000|99 112|administration
P10376065A0881|90 101|spring filter
P10376874A0759|33 52|eRF1-eRF3 interaction
P10376874A0759|85 96|protein eRF3C
P10376874A0759|118 129|eRF1 proteins
P10377345A0740|40 54|UNC-49C subunits
P10377345A0740|71 81|muscle cells
P10378989A0000|72 84|drug reactions
P10379899A0446|108 128|theca cell layer markers
P10379942A0956|87 101|MDV2 UL10 protein
P10379942T0000|0 13|Identification
P10379942T0000|37 56|disease virus serotype
P10379942T0000|58 74|glycoprotein M gene
P10379942T0000|89 106|glycoprotein M genes
P10379942T0000|109 127|Herpesviridae family
P10380232A0000|19 44|cost-effectiveness analysis
P10380232A0000|74 95|regimen-chlorpromazine
P10380232A0000|97 109|dexamethasone
P10380232A0000|121 155|5-HT3 receptor antagonist-tropisetron
P10380232A0000|210 221|chemotherapy
P10380232A0000|254 265|perspectives
P10380659A0545|0 11|Baseline data
P10380800A0194|36 53|amino acid sequences
P10380800A0194|59 69|core regions
P10380800A0194|88 107|RNA polymerase domains
P10380878A0542|72 89|repression function
P10380878A0542|113 130|histone deacetylase
P10381257A0000|54 76|preprotein import complex
P10381257A0000|109 121|mitochondrion
P10381377T0000|35 53|inositol phosphatase
P10381377T0000|87 102|insulin signaling
P10381570A1355|13 25|transcription
P10381570A1355|33 43|binding site
P10381570A1355|109 126|interstripe regions
P10381570A1355|145 157|embryogenesis
P10383764A1809|44 54|VirB4 dimers
P10383764A1809|57 69|homomultimers
P10383764A1809|118 137|transenvelope channel
P10383764A1809|163 173|DNA transfer
P10383764A1809|251 263|export machine
P10383966A0000|3 27|penicillin binding proteins
P10383966A0000|52 64|peptidoglycan
P10385384A0654|53 75|pentose phosphate pathway
P10385395A0000|7 24|density lipoprotein
P10385395A0000|69 85|cholesteryl esters
P10385395A0000|99 113|steroidogenesis
P10385395A0000|120 130|HDL particle
P10388670A1976|37 47|storage time
P10390158A1150|0 13|Point mutations
P10390158A1150|37 48|Pit-1 binding
P10390158A1150|68 87|tiGH promoter activity
P10390538T0000|20 37|zinc-finger protein
P10391075A0000|16 26|autopsy case
P10391075A0000|108 118|MRI findings
P10391246A0756|58 73|kinase activities
P10391277A0000|79 90|fibrillation
P10391903T0000|8 25|pleckstrin homology
P10391903T0000|43 56|adapter protein
P10392266A0111|41 56|serum lipid levels
P10392266A0111|109 122|immunoglobulin
P10392669A0935|116 147|prostaglandin analogue misoprostol
P10392669A0935|303 315|complications
P10392669A0935|318 347|histamine H2 receptor antagonists
P10392669A0935|348 360|H2 antagonists
P10392669A0935|466 478|term treatment
P10392669A0935|531 550|proton pump inhibitors
P10392669A0935|567 578|pantoprazole
P10392669A0935|658 670|barrier agents
P10392669A0935|710 727|prophylactic agents
P10392710A1000|0 13|Lung mesenchyme
P10392710A1000|40 56|lung morphogenesis
P10392710A1000|75 94|peptide growth factors
P10392900A1020|18 28|HIV promoter
P10392900A1020|47 58|localization
P10392900A1020|99 121|tyrosine phosphorylation
P10392900A1020|124 136|RNA polymerase
P10392903A0000|9 31|papillomavirus E2 protein
P10392903A0000|45 57|proliferation
P10392903A0000|90 106|carcinoma cell line
P10392903A0000|132 149|papillomavirus type
P10392903A0889|0 13|E2 point mutants
P10392903A0889|61 76|cdc25B expression
P10392903A0889|86 115|cell cycle inhibitors hydroxyurea
P10392914A0000|0 17|BACKGROUND/PURPOSE
P10392914A0000|149 163|tract malignancy
P10393192A0792|0 21|Neurospora crassa CYT-18
P10393192A0792|47 59|intron mutants
P10393197A0543|19 33|heterochromatin
P10393197A0543|36 51|interphase nuclei
P10393201A0654|21 35|DNA repair system
P10393201A0654|46 62|DNA polymerase beta
P10393201A0654|66 83|DNA ligase III-XRCC1
P10393201A0654|115 125|base residue
P10393251A0283|56 74|restriction analysis
P10393251T0000|34 46|HOX11 oncogene
P10393251T0000|78 90|T-ALL cell line
P10393910A0705|105 116|endonuclease
P10393969A0000|11 24|cell protein no.
P10393969A0000|32 49|herpes simplex virus
P10393969A0000|65 78|transactivator
P10393969A0000|146 157|transfection
P10394116T0000|0 15|Wrist measurement
P10394116T0000|18 30|blood pressure
P10394116T0000|52 63|oscillometry
P10394900A1166|55 68|enhancer region
P10394900A1166|76 97|cauliflower mosaic virus
P10394900A1166|102 112|35S promoter
P10395199A0792|157 171|tumor regression
P10395199A0792|219 230|Virone-Oddos
P10395199A0792|254 266|Schweighoffer
P10395283A0960|46 57|availability
P10395283A0960|82 94|concentration
P10395283A0960|107 122|signal transducer
P10395378A1198|53 74|HA envelope glycoprotein
P10395378A1198|131 144|fusion activity
P10395827A1297|17 38|parallel beta helix model
P10395827A1297|75 85|beta strands
P10395827A1297|96 112|parallel beta sheet
P10395908A0236|88 115|amino acid motif characteristic
P10395911A0288|0 15|Characterisation
P10395911A0288|21 48|chicken apolipoprotein A-I gene
P10396343A0754|25 36|blood samples
P10396343A0754|128 140|T. b. gambiense
P10396343A0754|151 165|T. b. rhodesiense
P10396343T0000|40 56|agglutination test
P10396343T0000|60 74|trypanosomiasis
P10396343T0000|75 87|TrypTect CIATT
P10396793A0815|56 73|dependence criteria
P10396793A0815|132 148|alcohol dependence
P10397257A1142|16 30|CDE/CHR elements
P10397257A1142|151 170|cell cycle periodicity
P10398286A0678|26 37|illustration
P10398286A0678|63 79|sample size methods
P10398682A0365|3 18|crystal structure
P10399136A0389|59 72|pentoxifylline
P10400593A1084|17 38|Plac promoter constructs
P10400712A0000|6 23|parainfluenza virus
P10400712A0000|45 65|Paramyxoviridae family
P10400712A0577|34 44|GS sequences
P10400712A0577|47 59|transcription
P10400712A0577|131 151|gene junction sequences
P10400712A0577|159 169|GS sequences
P10400712A0577|187 213|hemagglutinin-neuraminidase
P10400712A0577|257 276|counterpart sequences
P10400712A0577|286 298|gene junctions
P10400757A0000|8 24|chemokine receptor
P10400757A0000|85 109|immunodeficiency virus type
P10400757A1498|51 62|requirements
P10400757A1498|83 94|HIV-1 strains
P10400757A1498|115 132|mutagenesis efforts
P10400757A1498|201 213|fusion process
P10400760A0663|59 84|amino acid residues E960-A961
P10400760A0663|131 148|cleavage efficiency
P10400785A0912|61 73|export pathway
P10400785A0912|106 126|nucleoporin CAN/Nup214
P10400794T0000|0 13|Identification
P10400794T0000|88 99|similarities
P10400794T0000|108 123|membrane proteins
P10402467T0000|11 21|chain kinase
P10403575A1401|15 35|StAR gene transcription
P10403575A1401|68 80|transcription
P10403575A1401|86 98|control levels
P10403690A0000|61 74|cell lung cancer
P10403690A0000|97 117|ECOG performance status
P10403690A0000|202 224|combination chemotherapy
P10403690A0000|257 274|mesna uroprotection
P10403839A0140|5 23|sequence information
P10403839A0140|130 143|splice variants
P10403839A1459|17 35|bHLH/PAS family genes
P10403839A1459|51 74|intron/exon splice pattern
P10405635A0374|71 88|deletion constructs
P10406047A1244|280 291|lung function
P10406122T0000|32 42|LTR promoter
P10406122T0000|48 73|tobacco retrotransposon Tto1
P10406122T0000|86 99|responsiveness
P10406122T0000|102 114|tissue culture
P10406122T0000|123 137|methyl jasmonate
P10406459A0000|41 52|growth factor
P10406459A0000|57 90|12-O-tetradecanoyl-phorbol-acetate
P10406459A0000|154 175|Ser-133 phosphorylation
P10406459A0000|212 222|NIH 3T3 cells
P10406462A1127|79 90|OR1/RXRalpha
P10406464A0687|10 31|mTRAP100 coprecipitates
P10406464A0687|63 73|TRAP complex
P10406464A0687|110 125|vitamin D receptor
P10406465A0589|29 50|vitamin D responsiveness
P10406466A0000|45 66|thyroid hormone receptor
P10406466A0000|75 86|acid receptor
P10406843A1265|12 24|GlcNAc-TI mRNA
P10406954A0715|0 21|Chemical stability tests
P10406954A0715|59 72|amino acids H219
P10407184A0149|2 15|overexpression
P10407184A0149|21 31|betaAPP gene
P10407184A0149|100 113|neuropathology
P10407184A0520|23 37|promoter regions
P10407184A0520|61 72|reporter gene
P10407184A0520|73 104|chloramphenicol acetyl transferase
P10407184A0520|150 163|promoter region
P10407184A0520|236 249|promoter region
P10407184A0520|288 303|hbetaAPP promoter
P10407269A0000a|36 47|markers cdc18
P10407269A0000a|71 92|fission yeast chromosome
P10407269A0000a|122 134|European Union
P10407269A0000a|159 181|genome sequencing project
P10407269A0000b|36 47|markers cdc18
P10407269A0000b|71 92|fission yeast chromosome
P10407269A0000b|122 134|European Union
P10407269A0000b|159 181|genome sequencing project
P10407985A0574|60 73|micrograms s.c.
P10409656A1016|0 13|Overexpression
P10409656A1016|37 54|macrophage cell line
P10409656A1016|138 149|cell response
P10409699A0292|14 30|sequence tag clones
P10409699A0292|47 64|sequence similarity
P10409699A0292|110 121|mannosidases
P10409699A0292|139 150|coding region
P10409699A0292|164 181|mannosidase homolog
P10409699A0292|214 226|amplification
P10409699A0292|246 268|polymerase chain reaction
P10409724A1021|63 75|response genes
P10409730A0597|3 15|transcription
P10409730A0597|45 61|Rap1p binding sites
P10409730A0597|99 111|transcription
P10409741A0382|85 98|division defect
P10409741A0382|101 112|cdc20-1 cells
P10409749T0000|26 39|discrimination
P10409755A1846|31 42|NO production
P10409755A1846|77 87|JT/Neo cells
P10411139A0887|0 11|Accumulation
P10411139A0887|17 27|U4/U6 duplex
P10411139A0887|41 54|overexpression
P10411140A0499|42 55|RNase E cleavage
P10411160T0000|48 66|skin cancer incidence
P10413604A0063|136 147|DNA synthesis
P10413607A0085|55 69|matrix molecules
P10413607A0085|113 124|DNA synthesis
P10413607A0085|194 211|signal transduction
P10413662A0193|34 56|pMJ101 replication region
P10413662A0193|106 126|iron acquisition system
P10413662A0193|152 164|V. anguillarum
P10413676A0000|21 59|transmembrane integrin receptor clustering
P10413676A0000|87 101|signaling events
P10413676A0595|52 68|FAK kinase activity
P10413676A0595|121 136|SH3 binding region
P10413676A0595|211 223|cell migration
P10413676A0595|241 255|paxillin binding
P10413676A1193|47 59|point mutation
P10413676A1193|87 102|FRNK localization
P10413676A1193|110 121|contact sites
P10414451A0093|115 132|lupus anticoagulant
P10414451A0093|163 174|deficiencies
P10414451A0093|193 207|ATIII activities
P10416429A0221|57 70|NSW PKU database
P10416429A0221|114 127|population data
P10416558A0000|87 101|exercise program
P10416558A0000|127 138|CD4 cell count
P10416558A0000|160 171|health status
P10416558A0000|276 290|exercise relapse
P10417703A1326|52 64|20S proteasome
P10417703A1326|136 151|plant RPT subunits
P10417703A1326|161 177|yeast counterparts
P10419006A0378|34 59|estrogen replacement therapy
P10419006A0378|83 98|breast cancer risk
P10419521A0136|15 32|elongation activity
P10419521A0136|56 68|RNA polymerase
P10419521A0136|71 87|interaction domain
P10419521A0136|113 130|polymerase activity
P10419521A0136|150 162|transcription
P10422342A0535|3 17|radiation burden
P10422342A0535|45 56|examinations
P10422342A0535|120 134|radiation burden
P10422342A0535|152 163|examinations
P10422342A0535|173 186|administration
P10422342A0535|189 200|preparations
P10422468A0524|17 28|malformation
P10422468A0524|105 117|abnormalities
P10422468A0524|144 156|sex chromosome
P10422468A0524|159 172|microdeletions
P10422468A0524|178 188|Y chromosome
P10422468A0524|232 243|fibrosis gene
P10423156A0265|0 11|TaV particles
P10423156A0265|64 77|capsid proteins
P10423292A0782|70 88|transcription factor
P10425445T0000|27 84|mouse growth hormone receptor/growth hormone binding protein gene
P10426450A1458|28 39|liver/spleen
P10426450A1458|59 71|contact poults
P10426450A1458|81 93|contact chicks
P10426450A1458|155 167|contact poults
P10426878A0367|15 25|ISIS-2 trial
P10426878A0367|64 76|Collaboration
P10427654A0000|107 120|adenocarcinoma
P10428294A0227|0 21|Preheparin LPL mass level
P10428759A0743|26 47|receptor kinase activity
P10428811A0628|39 52|binding partner
P10428811A0628|74 87|receptor kinase
P10428811A1067|0 10|Cat proteins
P10428811A1067|72 88|adhesion kinase Fak
P10428862A0834|0 29|Immunoprecipitation experiments
P10429184A0000|69 82|plant cell walls
P10429740A0000|75 87|bowel syndrome
P10429946A0473|30 41|collagen gene
P10429946A0988|21 65|B-Myb-glutathionine S-transferase fusion protein
P10429946A0988|75 90|complex formation
P10430421T0000|0 17|APOE-epsilon4 count
P10430421T0000|45 55|AD increases
P10430421T0000|71 86|Cache County Study
P10430580A0000|8 26|double-strand breaks
P10430583A0000|4 16|DNA repair gene
P10430883A0000|252 277|sodium borohydride reduction
P10430883A0000|285 313|horseradish peroxidase reaction
P10430886A0838|73 87|heteromultimers
P10430890A1059|75 88|rearrangements
P10430890A1059|114 128|partner proteins
P10430944A1298|16 32|JAK/STAT signaling
P10430944A1298|57 68|malignancies
P10433970A0279|28 39|reading frame
P10433970A0279|55 70|DNA binding domain
P10433970A0279|78 95|localization signal
P10433970A0279|99 119|transactivation domain
P10435595A0203|35 50|trans-activation
P10436016A0337|0 12|Gel filtration
P10436016A0337|16 45|co-immunoprecipitation analyses
P10436016A0337|89 114|spindle checkpoint component
P10438540A1185|31 43|domain mutants
P10438540A1185|82 98|transport activity
P10438593A0000|8 34|immunodeficiency virus type-1
P10438593A0000|59 71|transcription
P10438593A0000|85 109|RNA polymerase processivity
P10438607A0330|55 66|gene fork head
P10438627A0885|0 15|Identity elements
P10438627A0885|103 115|T7 transcripts
P10438924A1009|59 104|serine/threonine kinase glycogen synthase kinase-3
P10438924T0000|3 22|B cell antigen receptor
P10438924T0000|38 51|protein kinase B
P10438924T0000|51 90|glycogen synthase kinase-3 signaling pathway
P10438924T0000|94 121|phosphatidylinositol 3-kinase
P10438941A1197|5 23|recombination events
P10438941A1197|54 63|T cell lines
P10438941A1197|80 98|switch recombination
P10438950A0580|7 39|TNF increase AND-34 transcript levels
P10438950A0580|79 97|fibroblast cell lines
P10439040A0658|35 49|c-myc expression
P10439040A0658|98 109|CAT reporters
P10440923A0684|10 26|cell cycle proteins
P10440923A0684|42 60|lovastatin treatment
P10440923A0684|66 77|control cells
P10440923A0684|127 144|kinase inhibitor p27
P10440923A0684|191 204|kinase activity
P10440923A0684|244 264|retinoblastoma protein
P10441243A0443|18 37|leptin concentrations
P10441449X1212|13 25|Academic Press
P10441483A0454|0 20|Oligonucleotide probes
P10441483A0454|54 66|EpRE sequences
P10441506A0098|14 29|sequence homology
P10441506A0098|118 131|leucine-zipper
P10441506A0098|145 156|CZ region/HR1
P10441506A0098|215 230|amino acid stretch
P10441506A0098|231 241|D region/HR2
P10441506A0098|256 267|CZ region/HR1
P10442493A0815|10 20|serum levels
P10442493A0815|98 121|plasma cyclosporine levels
P10443990A0000|17 34|alcohol consumption
P10444813A0448|49 70|metastases interferon-a
P10444813A0448|74 94|somatostatin analogues
P10445161A1565|120 137|organ weight changes
P10445945T0000|0 16|John leonard dawson
P10446131A0132|0 16|PDGF A-chain levels
P10446131A0132|43 59|smooth muscle cells
P10446149A0809|56 67|Ras effectors
P10446149A0809|94 121|phosphoinositol-3 kinase delta
P10446206A0000|0 14|Deletion mapping
P10446206A0000|25 36|presenilin-1
P10446206A0000|108 129|transcription start site
P10446206A0000|158 177|neuroblastoma SK-N-SH
P10446206A0000|181 198|hepatoma HepG2 cells
P10446910A0147|13 28|E2F1 gene promoter
P10446910A0147|71 87|E2-responsiveness
P10446910A0147|99 116|transfection assays
P10446910A0147|130 154|deletion/mutation analysis
P10446910A0147|236 250|transactivation
P10446912A0883|64 83|CYP11A1 transcription
P10446998A0375|13 27|differentiation
P10446998A0375|83 96|responsiveness
P10446998A0375|105 121|c-fos inducibility
P10446998A0955|0 23|Adipocyte differentiation
P10446998A0955|136 148|mobility shift
P10446998A0955|152 170|gel supershift assays
P10446998A0955|190 214|DNA binding characteristics
P10446998A0955|227 237|protein SP-1
P10446998T0000|0 13|Transformation
P10446998T0000|55 85|serum response factor interactions
P10446998T0000|90 110|serum response elements
P10447593A0144|34 49|bacteriophages T3
P10447593A0144|68 84|specificity factor
P10447593A0144|90 101|similarities
P10447593A0144|115 126|sigma factors
P10447597A1004|3 14|Cr.psbA-4 ORF
P10447597A1004|47 58|GIY-YIG motif
P10448036A0748|74 96|competitor concentration
P10448036A0748|113 127|S RNA interaction
P10448036A0748|204 217|RNA interaction
P10448095A0865|3 25|STAT protein accumulation
P10448095A0865|39 53|C/EBP expression
P10448095A0865|139 155|expression profile
P10448285A1035|32 43|survival time
P10448440T0020|31 51|understanding patients
P10448440T0020|63 75|schizophrenia
P10448440T0020|84 102|personality disorder
P10448902A0921|36 56|glutathione peroxidase
P10448902A0921|60 78|superoxide dismutase
P10449899A0881|61 75|integration site
P10450815A0180|10 22|investigation
P10450815A0180|123 134|relationship
P10450815A0180|142 155|tobacco smoking
P10450815A0180|260 271|inflammation
P10451209A0000|27 40|administration
P10451209A0000|114 146|methylprednisolone sodium succinate
P10452306A0502|51 77|norepinephrine concentration
P10452306A0502|165 194|heart catheterization parameters
P10452951A0000|7 22|hormone receptors
P10452951A0000|45 64|transcription factors
P10452991A0331|27 49|influenza virus particles
P10452991A0331|70 80|T cell clones
P10453006A0000|92 105|clone fragments
P10453006A0000|132 145|identification
P10453006A0000|168 179|beta subunits
P10453371A0640|9 22|height z-scores
P10453371A0640|54 64|BMD z-scores
P10453721A0445|8 23|sampling strategy
P10453721A0445|47 74|parameter estimation algorithm
P10453721A0445|90 111|ADAPT II software package
P10454533A0859|42 55|transformation
P10454533A0859|66 80|Hsc70 antagonist
P10454533A0859|139 150|conformation
P10454540A0392|3 23|amino acid changes D206A
P10454540A0392|63 81|exonuclease activity
P10454550A0960|91 107|Snf1 kinase complex
P10454557A0000|193 204|HML locus show
P10454557A0000|207 231|replication origin activity
P10454557A0975|29 41|HML ARS cluster
P10454561A0594|46 60|TD-IkappaBalpha
P10454561A0594|68 109|phorbol myristate acetate-phytohemagglutinin
P10454561A0594|112 130|tumor necrosis factor
P10454561A0594|144 172|IkappaBalpha gene transcription
P10454561A0594|185 211|NF-kappaB DNA binding activity
P10454561A0594|240 252|sequestration
P10454561A0594|263 277|TD-IkappaBalpha
P10454568A0815|9 23|Grb10 expression
P10454568A0815|65 80|expression system
P10454568A0815|128 139|growth factor
P10454568A0815|149 160|DNA synthesis
P10454570A0846|41 61|protein kinase pathways
P10454570A0846|87 103|protein kinase-Jun
P10454570A0846|114 129|kinase activation
P10454570A0846|144 158|phosphorylation
P10454570A0846|290 304|ERK-2 activation
P10454570A0846|364 374|uPA enhancer
P10455087A1400|36 57|body insulin sensitivity
P10455143T0000|0 19|Interdomain signaling
P10455143T0000|51 72|glucocorticoid receptor
P10455183A0530|49 63|Staf zinc fingers
P10455183A0930|60 73|Staf zinc finger
P10455183A0930|128 146|activation mechanism
P10455183A0930|153 163|Xenopus tRNA
P10455183A0930|174 185|U6 snRNA genes
P10455189A0104|79 94|integrin ligation
P10455189A0427|21 43|tyrosine phosphorylation
P10457075A1198|0 36|Independent protrudor muscle stimulation
P10457075A1198|102 113|peak decrease
P10458905A0000|11 22|construction
P10458905A0000|60 77|YAC/BAC clone contig
P10458907A0543|17 42|mouse Rad30b mRNA transcripts
P10458907A0543|51 64|repair proteins
P10458914A0674|13 25|mouse STAP gene
P10459809A1262|8 25|matrix distribution
P10459809A1262|37 47|cell density
P10460015A0465|96 113|bone mineral density
P10460171A0842|0 19|Viscosity experiments
P10460171A0842|34 55|fragment kinase reaction
P10460171A0842|83 100|phosphoryl transfer
P10460172A0823|0 20|Velocity sedimentation
P10460172A0823|21 33|cross-linking
P10460172A0823|37 63|immunoprecipitation analyses
P10460172A0823|117 131|kDa polypeptides
P10460172A0823|144 158|heterotetramers
P10463057A0534|7 22|expression levels
P10464185T0000|9 24|characterization
P10464185T0000|48 78|polysaccharide biosynthesis genes
P10464185T0000|81 109|Streptococcus agalactiae type Ia
P10464291A0597|74 85|protein delta
P10464302A1109b|74 88|pathway proteins
P10464302A1109b|117 131|interaction site
P10464302A1109b|207 218|transmission
P10464302A1109b|221 238|growth factor signal
P10464302A1109b|244 255|cytoskeleton
P10464310A0218|9 31|tyrosine phosphorylation
P10464310A0218|39 54|fibroblast growth
P10464310A0218|107 134|juxtamembrane tyrosine residue
P10464310A0218|150 161|Crk SH2 domain
P10464310A0218|220 235|complex formation
P10466306A0000|19 46|Technetium-99m sestamibi SPECT
P10466825T0000|30 47|baculovirus p10 mRNA
P10467004A0116|94 107|sequence motifs
P10467004A0683|68 90|EBS2/IBS2 sequence motifs
P10467403A0000|3 31|Trk/Nerve Growth Factor receptor
P10467403A0000|82 98|signaling proteins
P10467403A0000|108 135|phosphatidylinositol 3-kinase
P10467465T0000|16 34|significance testing
P10467465T0000|35 48|misconceptions
P10467465T0000|52 63|alternatives
P10468033T0000|0 13|Chemical uptake
P10468033T0000|23 36|stratum corneum
P10468585A0980|76 92|amino acid residues
P10468585A0980|153 168|hsp70 interaction
P10469140A0336|92 105|responsiveness
P10469140A0336|121 172|chloramphenicol acetyl transferase reporter gene deletion
P10469140A0336|176 191|mutation analyses
P10469174A0678|10 25|sequence analysis
P10469174A0678|29 43|NMR measurements
P10469656T0000|51 63|gene induction
P10469656T0000|88 104|MAP kinase cascades
P10469656T0000|121 133|histone H3/HMG
P10470220A1011|21 33|cutoff-levels
P10470220A1011|78 88|Protein S100
P10471587A0239|16 28|C. trachomatis
P10471587A0239|31 46|triplicate assays
P10471587A0239|57 68|RT-PCR method
P10471587A0239|133 146|antimicrobials
P10471587A0239|213 224|erythromycin
P10471696A0734|44 59|Abf1p binding site
P10471696A0734|65 77|HMR-E silencer
P10471696A0734|101 116|Rap1p binding site
P10471721A0141|121 131|pollen S gene
P10471743A0000|31 41|DNA helicase
P10471743A0000|61 92|Arabidopsis thaliana cDNA libraries
P10471746A1102|22 36|tryptophan motif
P10471746A1102|44 62|chromatin remodeling
P10471746A1102|68 83|Myogenin promoter
P10471746A1102|97 117|Myogenin transcription
P10473589A0189|48 62|integrase domain
P10473598A0691|46 67|transactivation ability
P10473598A0691|116 130|transactivation
P10473598A0691|147 163|competition assays
P10473623A0081|7 20|Xenopus embryos
P10473623A0081|36 65|growth factor-beta member activin
P10474898A0629|62 76|CMT1A-REP repeat
P10474898A0629|94 106|hybridization
P10476970A0542|94 107|alpha-subunits
P10477545T0000|15 28|pertussis toxin
P10477545T0000|40 58|CC chemokine receptor
P10477545T0000|84 95|HIV-1 strains
P10477583A0000a|16 30|B cell Ag receptor
P10477583A0000a|43 53|Fc receptors
P10477583A0000b|16 30|B cell Ag receptor
P10477583A0000b|43 53|Fc receptors
P10477597A0126|32 53|serine/threonine kinase
P10477597A0126|68 79|center kinase
P10477597A0126|138 148|SAPK pathway
P10477599T0000|45 64|lymphotactin promoter
P10477599T0000|109 120|interactions
P10477620A0580|16 42|NF-kappa B DNA binding activity
P10477620A0580|54 66|translocation
P10477620A0580|67 89|I kappa B alpha degradation
P10477620A0580|90 102|I kappa B serine
P10477620A0580|105 119|phosphorylation
P10477620A0580|123 135|I kappa B kinase
P10477620A0580|160 176|curcumin treatment
P10478844A1604|0 13|Cotransfection
P10478844A1604|203 214|coactivators
P10479025A0528|38 54|TF-MUSIC algorithm
P10479025A0528|68 79|target region
P10479382A1098|88 106|development patterns
P10479492A0000|13 24|Surveillance
P10479492A0000|25 36|Epidemiology
P10479492A0000|78 89|survival rate
P10479492A0000|93 126|corpus uteri adenocarcinoma FIGO stage
P10480937A0000|6 35|Drosophila A kinase anchor protein
P10480937A0000|46 65|A kinase anchor protein
P10480937A0000|157 170|diacylglycerol
P10482516A1158|7 26|transcription results
P10482516A1158|44 61|structure functions
P10482516A1158|67 86|attenuation mechanism
P10482516A1158|132 155|transcription readthrough
P10482516T0000|2 13|RNA stem-loop
P10482516T0000|31 63|transcription attenuation mechanism
P10482516T0000|91 121|Bacillus subtilis trpEDCFBA operon
P10482620A1009|28 40|transcription
P10482620A1009|91 109|transcription factor
P10482620A1009|151 163|transcription
P10483124T0000|50 68|CIC5F11/CIC2B9 locus
P10483124T0000|71 99|Arabidopsis thaliana chromosome
P10483124T0000|109 123|Ac/Ds transposon
P10483124T0000|144 161|cDNA scanning method
P10483945A0641|7 20|CK-MB elevation
P10484695A0791|4 20|NART-R performance
P10484695A0791|102 119|language impairment
P10484818A0292|41 65|cross-correlation analysis
P10485353T0000|7 32|Haemophilus influenzae type b
P10485353T0000|41 64|polysaccharide antibodies
P10485353T0000|102 113|Burkina-Faso
P10485470A0242|71 91|p21/WAF1/Cip1 promoter
P10485470A0242|125 143|mobility shift assays
P10485470A0242|157 168|TSA treatment
P10485470A0242|186 202|binding activities
P10485585A0175|58 70|neurohormones
P10486210A0126|43 63|aldehyde reductase gene
P10487040A0453|39 51|p53 antibodies
P10487307A0768|17 31|surgery patients
P10487307A0768|57 70|hydrocortisone
P10487744T0000|15 27|sorting signal
P10487744T0000|33 45|beta2 integrin
P10487744T0000|88 101|plasma membrane
P10487753A0788|14 25|XDRP1 protein
P10487753A0788|40 50|Xenopus eggs
P10487753A0788|67 78|cell division
P10487759A0630|15 28|Xenopus embryos
P10487759A0630|138 149|reporter gene
P10487760A0336|75 86|Xenopus MEF2D
P10487921A0132|0 16|ATF1 transcription
P10487953A0765|37 52|S-phase fractions
P10488087A0340|120 146|acetyltransferase constructs
P10488087A0340|157 173|SP-A gene sequences
P10488088T0000|12 25|growth factor-I
P10488088T0000|33 45|bcl-2 promoter
P10488088T0000|56 74|transcription factor
P10488129T0058|51 62|E2F complexes
P10488147A1176|0 13|Identification
P10488147A1176|46 58|understanding
P10488147A1176|73 93|eosinophil trafficking
P10488148A0111|41 59|HIV-1 gene expression
P10488148A0111|92 117|signal transduction pathways
P10488148T0000|0 31|ERK MAP kinase links cytokine signals
P10488148T0000|52 65|HIV-1 infection
P10488337T0000|45 56|dimerization
P10488337T0000|95 106|bZIP proteins
P10488875A0000|8 22|differentiation
P10489680A0927|62 77|grain dust-asthma
P10489822T0000|36 47|inflammation
P10490604A0601|63 76|ZAP-70 block 70Z
P10490604A0601|89 102|NFAT activation
P10490609A0413|0 12|Substitutions
P10490609A0413|137 148|interruption
P10490609A0413|185 195|ARS activity
P10490639A0000|54 66|protein kinase
P10490639A0000|159 172|cyclin partners
P10490662A0431|15 25|lace alleles
P10490662A0431|64 75|morphologies
P10490662A0431|91 101|compound eye
P10490662A0819|6 16|SPT activity
P10490816A0000|30 51|receptor tyrosine kinase
P10490816A0000|86 105|cancer syndromes MEN 2A
P10490826T0000|5 40|tyrosine kinase signal transduction gene
P10490826T0000|104 122|oncoprotein E2a-Pbx1
P10490835T0000|0 20|Protein kinase A-Ialpha
P10490835T0000|65 80|cancer cell growth
P10490835T0000|94 123|tyrosine kinase signaling pathway
P10490843A0159|12 30|POZ/Zn finger protein
P10490955T0000|50 70|T lymphoma cell adhesion
P10490955T0000|91 112|protein kinase signaling
P10490955T0000|115 130|thrombospondin-1
P10490955T0000|134 157|thrombospondin-1 peptides
P10491133A0365|23 38|activity analyses
P10491187T0000|3 26|phosphotransferase system
P10491187T0000|54 67|identification
P10491187T0000|93 125|histidine phosphocarrier protein HPr
P10491213A0263|0 18|Serum concentrations
P10491213A0263|33 51|alkaline phosphatase
P10491213A0263|70 83|bone Gla protein
P10491213A0263|102 113|pyridinoline
P10491213A0263|120 136|deoxypyridinoline
P10491213A0263|164 175|measurements
P10491213A0263|293 307|material density
P10492127A0914|25 38|administration
P10492127A0914|60 94|cholecystokinin-A receptor antagonist
P10492127A0914|146 157|saline intake
P10492169A0939|80 94|plasma protein-A
P10493203T0000|18 39|treadmill exercise score
P10493203T0000|80 92|abnormalities
P10493580A1126|35 46|oxyanion hole
P10493580A1126|60 72|stabilization
P10493580A1126|78 92|transition state
P10493580A1126|116 136|esterase/lipase family
P10493876A0000|3 19|solution structure
P10493876A0000|65 75|fjord region
P10493876A0000|88 99|stereoisomer
P10493876A0000|111 122|dihydroxy-13
P10493876A0000|259 276|thymine residue dT17
P10493876A0000|282 300|DNA sequence context d
P10493876A0000|300 313|C1-T2-C3-T4-C5
P10493876A0000|313 331|A6-C7-T8-T9-C10-C11
P10493876A0000|447 481|G12-G13-A14-A15-G16-T17-G18-A19-G20
P10493876A0000|629 640|calculations
P10496161A0503|0 14|Serum antibodies
P10496284A0115|45 59|immunoglobulin G
P10496284A0115|109 124|IgG synthesis rate
P10496303A1968|44 57|valganciclovir
P10496388A1956a|9 20|nonperfusion
P10496388A1956b|9 20|nonperfusion
P10496553A1004|3 13|healing rate
P10496553A1004|131 154|immunodeficiency syndrome
P10497199A0559|64 76|factor binding
P10497199A0559|93 108|chicken ovalbumin
P10497262A0000|67 105|trypanosomatid species Leptomonas seymouri
P10497262A0000|111 132|U5 RNA affinity selection
P10497262A0000|136 146|cDNA cloning
P10497874A0925|14 33|phosphatidyl inositol
P10497874A0925|37 48|bisphosphate
P10497874A0925|77 91|phosphorylation
P10497874A0925|94 108|tyrosine residue
P10497874A0925|114 130|PLC-gamma1 isozyme
P10498616A0157|61 73|interleukin-3
P10498616A0157|86 115|mast cell/megakaryocyte cell line
P10498616A0157|191 206|expression levels
P10498616A1280|18 38|Caenorhabditis elegans
P10498616A1280|132 145|signaling paths
P10498706A1219|52 65|pelE expression
P10498717A1048|5 16|observations
P10498717A1048|53 69|rsmB transcription
P10498717A1048|90 103|RsmA production
P10499121A0542|18 32|hearing aid users
P10499121A0542|46 62|Class D instruments
P10499121A0542|67 82|input compression
P10499357A0439|0 10|SCOB testing
P10499357A0439|201 213|neurotoxicity
P10501034A0839|0 27|Ribonuclease protection assays
P10501034A0839|129 141|morphogenesis
P10501034A0839|175 187|pigment glands
P10501656A1415|36 55|Northern blot analysis
P10501656A1415|82 95|tumor cell lines
P10501936T0000|0 11|Inactivation
P10501936T0000|17 32|Neurospora crassa
P10501936T0000|51 70|membrane protein TOM70
P10501936T0000|87 99|point mutation
P10501936T0000|131 143|protein import
P10501969A1329|119 131|cardiogenesis
P10502216A0289|55 67|streptokinase
P10502216A0289|96 121|tissue plasminogen activator
P10502402A0129|69 85|mouse T lymphocytes
P10502402A0129|147 158|cytotoxicity
P10502402A0533|54 79|signal transduction pathways
P10502402A0533|90 107|TRAIL gene induction
P10502402A0533|117 137|T lymphocyte activation
P10502434A0367|114 131|vault brachytherapy
P10502434A0604|50 60|ICG3 disease
P10502522A0000|9 23|provirus genomes
P10502522A0000|31 53|T-cell leukemia virus type
P10503540A0602|11 21|primer pairs
P10503540A0602|39 53|banding patterns
P10503540A0602|99 116|polyacrylamide gels
P10503812A1450|46 68|organ transplant patients
P10503812A1450|85 103|allograft recipients
P10503812A1450|161 187|cyclosporin pharmacokinetics
P10504332A0701|0 20|Immunofluoresence data
P10504332A0701|172 186|RAP fluorescence
P10505694A0000|0 13|Interleukin-12
P10505694A0000|85 100|interferon-gamma
P10505694A0000|149 160|cytotoxicity
P10505694A0739|0 14|IL-12 production
P10505694A0739|32 47|C3a concentration
P10505694A0739|69 80|hemodialyzer
P10506143A0610|14 36|JNKK2-JNK1 fusion protein
P10506143A0610|54 64|JNK activity
P10506143A0610|163 175|UV irradiation
P10506143A0610|189 210|GTP binding proteins Rac1
P10508522A1598|19 29|TGF-beta RII
P10509768A1118|28 38|acids intake
P10509768A1118|101 121|serum cholesterol level
P10510295A0606|10 40|ethanol repression autoregulation
P10510295A0606|65 80|repressor element
P10510295A0606|103 116|promoter region
P10510379A0105|8 26|transcription factor
P10510379A0105|82 99|cytokine activation
P10511554T0000|35 49|polymorphism map
P10511554T0000|56 86|clone Caenorhabditis elegans cdf-1
P10512699A0364|40 51|SECIS element
P10512699A0364|92 114|selenocysteine insertion
P10512699T0000|64 86|rat thioredoxin reductase
P10512699T0000|96 106|gene fusions
P10512699T0000|135 147|SECIS elements
P10512699T0000|151 163|co-expression
P10512857A0000|2 13|Wnt signaling
P10512857A0000|14 25|beta-catenin
P10512857A0000|75 86|interactions
P10512857A0000|99 118|transcription factors
P10512882A0137|73 84|localization
P10513756A0584|44 59|8-predictor model
P10513756A0584|89 106|selection criterion
P10514493A0199|19 33|differentiation
P10514493A0199|36 60|N1E-115 neuroblastoma cells
P10514493A0199|114 126|reporter genes
P10514493A0199|135 156|NTR-1 promoter sequences
P10514808T0000|29 43|epileptogenesis
P10516011A0471|27 40|peptide mapping
P10516011A0471|41 56|mass spectrometry
P10516011A0471|103 125|pAP phosphorylation sites
P10516738A0925|43 57|irbesartan/HCTZ
P10516878T0000|0 11|Modification
P10516878T0000|14 39|dopamine D2 receptor activity
P10517666A1069|13 24|binding sites
P10517666A1069|37 54|AP-1 nucleoproteins
P10517672A1417|32 65|alpha1-globin promoter-CAT construct
P10517672A1417|86 109|CCAAT transcription factor
P10517672A1417|121 153|Drosophila Schneider SL2 insect cells
P10517672A1417|179 194|trans-activation
P10517672A1417|197 207|CAT activity
P10517675A0809|0 18|Western blot analysis
P10517675A0809|54 72|p21WAF1/CIP1 protein
P10517675A0809|80 92|protein levels
P10517675A0809|129 149|kinase inhibitor family
P10518496A0952|132 156|periimplantation lethality
P10518496A0952|194 206|organogenesis
P10518502T0000|63 81|germ cell development
P10518502T0000|95 115|Caenorhabditis elegans
P10518561A0261|28 43|Tec family kinases
P10518561A0885|9 23|phosphorylation
P10518561A0885|73 84|kinase domain
P10518822A1037|119 142|CCR3 receptor ligand system
P10518937A0572|3 20|expression analysis
P10518937A0572|41 59|phosphate starvation
P10518937A0572|66 78|adenine supply
P10518956A0137|5 25|thyroid hormone changes
P10518956A0137|105 116|hypothalamus
P10518956A0137|137 148|thyroid gland
P10518956A0137|162 177|deiodinase system
P10520800A0307|101 116|echocardiography
P10520800A0307|120 136|electrocardiogram
P10521345A0202|28 40|Laurentian Fan
P10521345A0202|56 76|sea surface temperature
P10521345A0202|87 109|surface slope waters north
P10521443A0486|19 30|IR activation
P10521443A0486|89 107|NF-kappaB activation
P10521443A0486|129 142|overexpression
P10521443A0486|162 174|IkappaB-alpha
P10521443A0486|193 206|overexpression
P10521443A0486|212 232|NF-kappaB c-Rel subunit
P10521447A0606|47 60|sequence TGTGGT
P10521447A0606|95 131|AML/CBFalpha transcription factor family
P10521447A1190|11 24|overexpression
P10521447A1190|27 40|AML3/CBFalpha1
P10521447A1190|55 72|AML1-ETO repression
P10521450A0437|10 22|Akt activation
P10521509A0000|12 28|G protein signaling
P10521509A0000|86 98|G protein gamma
P10521509A0000|156 170|RGS proteins RGS6
P10521544T0000|36 55|alpha 1,2-mannosidase
P10521544T0000|78 95|Man8GlcNAc2 isomer B
P10521544T0000|110 121|biosynthesis
P10521796A0872|56 72|baseline diagnoses
P10521796A0872|177 191|neck hyperplasia
P10523520A0986|7 19|nematode genes
P10523520A0986|40 50|Hh molecules
P10523634A1404|23 39|Psi synthase domain
P10523634A1404|70 82|Cbf5p proteins
P10523634A1404|95 109|box H/ACA snoRNAs
P10523640A0367|11 27|Src tyrosine kinase
P10523640A0367|47 66|Stat3 phosphorylation
P10523640A0367|103 116|gene regulation
P10523640A0367|140 160|serine phosphorylation
P10523647A0000|3 25|transcription factor CHOP
P10523647A0000|53 63|bZIP protein
P10523647A0000|107 121|stress responses
P10523647A1001|48 63|C/EBP target genes
P10523647A1001|85 95|AP-1 factors
P10523647A1001|107 121|AP-1 target genes
P10523663A0404|39 61|homeobox activator DEAF-1
P10523674A0000|11 43|ribonucleoprotein endoribonuclease
P10523674A0000|90 103|DNA replication
P10523674A0000|116 130|S rRNA processing
P10524258A0286|72 90|immunocytochemistry
P10524258A0286|94 113|Northern blot analysis
P10524258T0000|17 46|fibroblast growth factor receptor
P10524258T0000|54 67|gene expression
P10524258T0000|82 102|muscle differentiation
P10525413A1408|3 18|backbone dynamics
P10525413A1408|102 117|N NMR spectroscopy
P10526670A0236|20 33|actin filaments
P10526670A0236|62 81|phosphatidylinositol
P10526670A0236|85 96|bisphosphate
P10526670A0236|121 136|membrane ruffling
P10526670A1828|151 167|Ras transformation
P10527106A0384|20 32|preponderance
P10527158T0000|17 42|generation staging container
P10527158T0000|46 58|plutonium pits
P10527158T0000|64 79|USDOE Pantex Plant
P10527180A0869|59 74|treatment failure
P10527180A0869|147 165|% confidence interval
P10527180A0869|176 200|Karnofsky performance score
P10527180A0869|236 251|hormone receptors
P10527180A0869|286 297|chemotherapy
P10527180A0869|333 348|survival interval
P10527180A0869|481 502|approaches significance
P10527180A0869|626 637|chemotherapy
P10527426A0521|12 29|SBEI gene transcript
P10527426A0521|60 82|exon I+II+III combination
P10528035A1102|26 38|normalization
P10528035A1102|41 74|serum alanine aminotransferase levels
P10529198A0068|60 73|homologues p140
P10529354A0375|83 94|P28 complexes
P10529354A0375|115 126|26S particles
P10531334A0525|92 104|protein kinase
P10531342A0348|58 73|amino acid repeats
P10531342A0348|96 127|promastigote surface glycoproteins
P10531342A0348|133 148|psa2/gp46 complex
P10531342A1111|35 54|proteophosphoglycans
P10531342A1111|58 72|ppg1 gene product
P10531342A1111|128 150|promastigote cell surface
P10531446A0203|62 84|receptor tyrosine kinases
P10532354A1374|31 44|yeast homologue
P10532354A1374|79 90|accumulation
P10532354A1374|133 155|protein transport pathway
P10532805A0792|11 27|nerve growth factor
P10532805A0792|43 57|differentiation
P10532805A1084|3 16|PC12 cell mutant
P10532805A1084|34 55|protein kinase A activity
P10533066A0758|0 12|TSC1 mutations
P10533066A0758|62 76|splice mutations
P10533066A1197|21 33|abnormalities
P10533066A1197|60 76|missense mutations
P10534048A0297|40 58|projection algorithm
P10534048A0297|88 115|attenuation correction factors
P10534048A0297|151 162|transmission
P10534048A0297|196 209|attenuation map
P10534402A0126|73 90|sequence similarity
P10534402A0126|129 140|Spo11p family
P10534402A0659|15 35|hybridization analyses
P10534402A0659|59 75|testis development
P10534402A0659|88 102|Spo11 expression
P10534402A0659|142 155|pachytene stage
P10534402A0659|170 181|accumulation
P10534402A0659|198 211|pachytene stage
P10536125A0093|95 122|influenzavirus neuraminidases
P10536369A0662|2 23|gel mobility shift assays
P10536369A0662|44 71|VDR-TR heterodimer interaction
P10536788A0931|83 95|control livers
P10540015A0664|0 11|C-SP duration
P10540015A0664|37 47|ALS patients
P10540015A0664|71 90|stimulation intensity
P10540015A0664|108 119|MEP threshold
P10540292A1179|20 36|spv virulence genes
P10540292A1179|108 120|spv expression
P10540553A0980|137 149|proliferation
P10540915A0697|8 19|transsection
P10541432A0185|16 27|erbB proteins
P10541432A0185|44 55|growth factor
P10541432A0185|65 87|tyrosine phosphorylation
P10541432A0185|100 110|Shc proteins
P10541432A0185|157 173|ERK MAPK activities
P10541432A0185|181 197|glioblastoma cells
P10541432A0185|211 227|ERK MAPK activities
P10541550A0487|5 22|immunolocalization
P10541550A0487|47 60|chorion element
P10541550A0487|101 113|amplification
P10541550A0487|121 137|DmORC localization
P10541550A0487|140 152|follicle cells
P10541865A1301|19 30|co-deletions
P10542237A0357|113 130|lipopolysaccharide
P10542237A0357|159 171|IL-6 secretion
P10542249A0415|0 16|Albumin expression
P10542249A0415|69 88|transcription factors
P10542269A0000|0 18|Amyloid beta-protein
P10542269A0000|46 59|amyloid fibrils
P10542269A0000|151 178|beta-amyloid precursor protein
P10542274A1376|26 39|protein kinase A
P10542274A1376|79 105|caveolin-1 protein expression
P10542274A1376|109 124|promoter activity
P10542277A0000|3 15|importin alpha
P10542277A0000|19 33|beta heterodimer
P10542277A0000|91 109|localization signals
P10542281A0382|41 51|link protein
P10542281A0382|96 107|proteoglycan
P10542281A0382|114 124|repeat loops
P10542281A2021|48 61|keratan sulfate
P10543270A1054|7 24|i.v. steroid therapy
P10543727A0282|32 51|transcription factors
P10543727A0282|82 92|binding site
P10543727A0282|96 128|rel/NF-kappaB transcription factors
P10543727A0282|147 160|kappaB1 element
P10543727A0282|183 196|kappaB2 element
P10543727A0282|236 247|H2TF1 element
P10543727A0282|308 329|ATF recognition sequence
P10543728A0358|18 29|cHa-ras cells
P10543728A0358|67 86|DNA binding activities
P10543730A0000|14 31|cyclin Ume3p/Srb11p
P10543730A0000|119 132|stress response
P10543949A0686|17 31|specificity site
P10544037A0617|40 56|amino acid identity
P10544088A0308|22 38|reporter construct
P10544088A0308|62 74|transcription
P10544089A1208|3 16|RNA transcripts
P10544089A1208|77 92|hairpin structure
P10544113A0293|0 25|EIAV LTR sequence variability
P10545192T0000|0 38|Phosphatidylinositol 3-kinase requirement
P10545192T0000|80 95|signaling cascade
P10545192T0000|116 134|agent vanadyl sulfate
P10545248A0567|55 66|binding sites
P10545248A0567|73 96|homeodomain protein Tinman
P10545248A0567|146 159|muscle lineages
P10545281A0836|10 21|introduction
P10545281A0836|38 61|purification tag sequences
P10545281A0836|79 90|coding region
P10545281A0836|113 123|bop gene mRNA
P10545281A0836|127 145|protein accumulation
P10548434A1549|82 96|differentiation
P10548434A1549|131 142|p38 signaling
P10548622A0906|75 96|i.v. sedation/analgesia
P10548622A0906|103 115|egg collection
P10548622A0906|157 174|ultrasound guidance
P10548722A0099|19 30|organization
P10548722A0099|57 69|TcP2beta genes
P10549354A1782|25 39|colon carcinomas
P10549354A1782|87 107|beta-catenin complexes
P10549354A1782|152 163|beta-catenin
P10549354A1782|189 202|downregulation
P10549354A1782|219 232|Axin/Conductin
P10549354A2371|26 37|deregulation
P10549354A2371|40 60|Tcf target gene activity
P10549912A0136|140 155|segment elevation
P10550139A0191|42 54|prostatectomy
P10550139A0191|55 73|bone marrow aspirates
P10550571A0000|62 73|plasma levels
P10550574A1038|64 87|serum alkaline phosphatase
P10551788A0229|28 43|gonadotrope cells
P10551788A0229|75 90|trophoblast cells
P10551796T0000|12 29|HIV-1 transcription
P10551848A0000|24 35|Kurzydlowski
P10551867A0350|16 32|amino acid residues
P10551867A0350|43 60|9-kilobase pair mRNA
P10551867A0350|68 81|splice variants
P10551867A0350|108 123|rat cDNA libraries
P10551879T0000|19 38|protein kinase binding
P10551879T0000|41 65|A-kinase anchoring proteins
P10551879T0000|68 78|living cells
P10551879T0000|81 115|fluorescence resonance energy transfer
P10551879T0000|134 154|protein fusion proteins
P10552357A1936|63 74|microspheres
P10552357A1936|87 98|microspheres
P10552357A1936|102 116|LV opacification
P10552357A1936|214 225|echogenicity
P10553551A0000|0 17|Factor XI deficiency
P10553959A0812|3 16|Ishasha samples
P10554946A0082|23 39|clomiphene citrate
P10555285A1065|4 15|organization
P10555285A1065|28 44|duplication events
P10555285A1065|72 92|FUT3-FUT5-FUT6 cluster
P10555285A1065|204 216|globin cluster
P10556028A0292|32 53|plasmid incompatibility
P10556028A0292|91 102|repA promoter
P10556028A0292|126 141|RepA binding sites
P10556029A0852|0 11|WA constructs
P10556029A0852|52 70|cyclization kinetics
P10556029A0852|84 98|interconversion
P10556033A0000|3 18|RFX protein family
P10556044A0913|26 51|alpha-dystroglycan receptor
P10556046A0328|53 68|signaling pathway
P10556046A0328|96 108|Xenopus embryo
P10556063A0092|45 56|Trk subfamily
P10556089A0901|38 54|muscle development
P10556089A0901|125 139|muscle component
P10556089A0901|166 177|conservation
P10556089A0901|180 191|gene function
P10556145A1034|51 66|sputum Psa density
P10556595A0391|52 63|transversion
P10556751A0758|32 48|transmission rates
P10556751A0758|75 86|immunization
P10557072A0418|26 40|domain structure
P10557072A0418|59 70|kinase domain
P10557072A0418|79 92|proline/serine
P10557072A1218|65 80|signaling pathway
P10557308A0000|0 16|Connector enhancer
P10557308A0000|57 68|RAS signaling
P10559207A0207|21 34|ATP sulfurylase
P10559207A0207|38 55|APS kinase reactions
P10559303A0000|26 40|membrane protein
P10559303A0000|72 85|transformation
P10559303A0000|95 106|B lymphocytes
P10559320A0080|67 77|protein nsP1
P10559324A0716|32 42|Ad5 E4orf6/7
P10559364A0846|69 94|DNA replication compartments
P10559364A0846|108 135|polymerase processivity factor
P10559364A0846|158 174|DNA binding protein
P10559364A0846|185 209|UL112-113 accessory protein
P10559364A0846|230 246|bromodeoxyuridine
P10560014A0000|23 42|heart vascularization
P10560014A0000|63 79|angioarchitecture
P10561095A2141|68 83|calcitonin levels
P10561095A2141|128 145|hypoparathyroidism
P10561251A0000|141 152|breast cancer
P10561251A0000|175 189|modality therapy
P10561251A0000|205 216|chemotherapy
P10561251A0000|235 258|stem-cell transplantation
P10561460A0615|3 17|GPI anchor moiety
P10561460A0615|112 124|signal peptide
P10561460A0615|128 145|GPI signal sequences
P10561546A0000|117 134|localization signal
P10561546A0000|137 155|NF-kappaB p65 subunit
P10562456T0000|49 65|growth hormone gene
P10562456T0000|68 79|rainbow trout
P10562456T0000|80 91|Oncorhynchus
P10562495A0188|46 61|Chordopoxvirinae
P10563212A0514|21 38|SF-36 questionnaire
P10563605A0773|69 82|fiber densities
P10563789A1951|25 41|F beta alpha/CG beta
P10563789A1951|82 93|FSH receptors
P10563836A1234|10 28|AP-2 binding activity
P10563836A1234|66 77|Western blots
P10563836A1234|96 112|AP-2 protein levels
P10564280A0140|111 144|component scaffold attachment factor B
P10564280A0140|157 168|Src substrate
P10564474T0000|65 89|outer-membrane protein OprH
P10564474T0000|93 112|polymyxin B resistance
P10564484A0859|27 37|binding site
P10564484A0859|106 117|requirements
P10564495A0444|18 28|Opa proteins
P10564593A0428|51 64|rearrangements
P10564593A0428|87 99|MCF-7 AdVp3000
P10564593A0428|153 165|translocation
P10564593A1618|18 33|half-transporter
P10564593A1618|70 84|coamplification
P10564593A1618|153 171|MXR half-transporter
P10564593A1618|194 206|drug transport
P10566630A0371|17 29|growth factor I
P10566862A0000|23 34|stereoacuity
P10566862A0000|70 91|depth stereoacuity tests
P10567430A0785|35 45|brain Galpha
P10567524T0000|3 21|elm1 kinase functions
P10567524T0000|32 47|signaling network
P10567533A0818|7 19|transcription
P10567533A0818|21 31|PCR products
P10567533A0818|109 123|tyrosine kinases
P10567538A1028|13 37|acetyltransferase activity
P10567538A1028|90 107|activation function
P10567581A0119|29 54|fork head homolog-11B protein
P10567581A0119|89 100|family member
P10567581A0119|122 145|head transcription factors
P10567581A0119|201 215|hepatocyte entry
P10567581A0119|220 233|DNA replication
P10567582A1334|74 86|embryogenesis
P10567589A1268|87 102|Pmt3p conjugation
P10568275A0679|47 57|Arctic Ocean
P10568455A0000|37 64|slow-release estradiol-17beta
P10568455A0000|80 94|pseudopregnancy
P10568455A0000|136 147|corpora lutea
P10568455A0000|152 166|pseudopregnancy
P10568728A1445|10 28|serum creatine kinase
P10568744A0728|144 162|mating type switching
P10570262A0000|74 90|signaling cascades
P10570996A1213|75 86|scavenger RTK
P10571047A1009|88 103|HindIII fragments
P10572087A0326|15 28|binding partner
P10572087A0326|42 60|anemia group C protein
P10572130A1623|27 49|transcription activators
P10572130A1623|91 103|RNA polymerase
P10572130A1623|140 150|DNA geometry
P10572131A0000|0 16|Klebsiella oxytoca
P10572131A0000|73 87|nasFEDCBA operon
P10572866A0481|37 48|plasma values
P10572866A0481|85 109|aspartate aminotransferase
P10574913A1108|34 56|receptor phosphorylation
P10574913A1108|94 107|Src recruitment
P10574913A1108|128 142|internalization
P10574913A1108|175 187|ERK activation
P10574913A1108|220 232|ERK activation
P10574929A0583|18 30|fractionation
P10574929A0583|40 52|P-CIP2 protein
P10574982A1075|0 14|Supershift EMSAs
P10574992A0901|55 72|PARP enzyme activity
P10574992A0901|90 112|cell death susceptibility
P10574992A0901|161 197|PARP chemical inhibitor 3-aminobenzamide
P10575642T0000|0 12|Skin pH changes
P10575642T0000|27 39|iontophoresis
P10576545A0926|3 14|availability
P10576545A0926|33 44|DNA cassettes
P10576545A0926|63 77|D1A gene promoter
P10578528A0730|73 85|manifestation
P10578528A0730|119 132|symptomatology
P10579331A1225|42 68|rat HDL receptor SR-BI promoter
P10579331A1225|80 101|sterol response elements
P10579331A1225|151 163|transcription
P10579722T0000|0 14|Phosphorylation
P10579722T0000|43 59|myosin phosphatase
P10580071A0436|48 62|transplantation
P10580438A0508|17 34|mobility shift assay
P10580438A0508|43 63|GLUT4 repressor element
P10580438A0508|113 125|preadipocytes
P10582831T0000|22 35|redistribution
P10582831T0000|48 60|complications
P10584138T0001|0 13|Cytoprotection
P10584138T0001|30 41|radiotherapy
P10584138T0001|44 61|radio-chemotherapy
P10585311A1542|15 27|abnormalities
P10585417A1412|38 53|tissue expression
P10585440A0204|37 48|FAK homologue
P10585453A1029|25 41|hGH-N gene promoter
P10585453A1029|64 77|gene activation
P10585463A0859|11 29|prenylcysteine lyase
P10585463A0859|44 74|baculovirus-Sf9 expression system
P10585480A0157|42 72|guanine nucleotide exchange factor
P10585480A0265|0 13|Point mutations
P10585491A0945|2 23|gel mobility shift assays
P10585491A0945|27 41|binding activity
P10585491A0945|61 80|AtpC promoter sequence
P10585491A0945|128 147|AtpC expression levels
P10585491A0945|209 223|binding activity
P10585491A0945|268 287|AtpC expression levels
P10585808A0000|0 26|Mycoplasma hominis infections
P10586074A0129|29 45|plasmid constructs
P10586074A0129|73 93|envelope glycoprotein E
P10586074A0129|119 135|encephalitis virus
P10586107A0160|41 60|transduction pathways
P10586107A0160|73 92|cell surface receptors
P10587460A0302|18 34|VDRE binding domain
P10587460A0302|80 90|hVDR mutants
P10587461A0341|77 91|transition state
P10587576A0596|84 98|SH3GL pseudogene
P10589562A1208|55 65|BB resonator
P10589562A1208|81 99|RF power requirements
P10589711A1228|10 23|narZ expression
P10589711A1228|134 144|salts medium
P10590092A0124|27 45|HIV-1 gene expression
P10590368X0000|9 21|trachelectomy
P10590368X0000|47 58|hysterectomy
P10590368X0000|74 91|stage IA-B carcinoma
P10590368X0000|180 193|stage carcinoma
P10590368X0000|226 238|survival rates
P10591633A0138|52 65|target membrane
P10591633A0138|101 124|SNARE protein interactions
P10591633A0138|179 192|membrane fusion
P10591933A0798|18 30|configuration
P10591976A0317|0 11|Measurements
P10592791A0370|83 96|RIDASCREEN kits
P10592791A0370|126 138|investigation
P10592791A0370|212 222|SET-RPLA kit
P10592791A0370|249 261|RIDASCREEN kit
P10592791A0370|305 318|test procedures
P10592791A0370|356 367|practicality
P10592791A0370|409 424|research purposes
P10592791T0001|12 26|immunoassay kits
P10592791T0001|55 66|enterotoxins
P10592824A1157|63 73|JEV antibody
P10593939A0747|42 63|interaction experiments
P10593939A0747|77 87|SR33 protein
P10593939A0747|114 124|SR45 protein
P10593950A1113|30 43|chromatography
P10593950A1113|86 96|protein p116
P10594903A0000|29 41|nanoparticles
P10594903A0000|112 126|warfare agents GA
P10596955A1032|18 32|failure patients
P10596955A1032|65 75|Axsym method
P10597222A1371|53 65|HMBA signaling
P10597223A0339|19 32|Ras-expression
P10597223A0339|96 106|p21 promoter
P10597223A0339|127 153|transcription initiation site
P10597223A0339|164 175|binding sites
P10597223A0339|189 208|transcription factors
P10597232A0000|3 23|RET/PTC3 rearrangement
P10597232A0000|122 138|thyroid carcinomas
P10597317A1156|41 55|co-transfection
P10597317A1156|94 104|HD-MyZ cells
P10598101A0000|15 32|bZIP protein Opaque2
P10598101A0000|48 61|maize endosperm
P10598101A0000|102 121|kDa zein gene promoters
P10598101A0754|3 16|mEmBP-1 protein
P10598101A0754|28 40|transcription
P10598101A0754|132 144|transcription
P10598101A0754|150 164|kDa zein promoter
P10598101A0754|177 191|expression assay
P10598101A0754|205 223|maize endosperm cells
P10599727A1567|13 36|estrogen treatment regimen
P10600171A1066|23 36|responsiveness
P10600171A1066|91 107|CYP3A2 DexRE-1 site
P10600171A1432|92 128|bHLH/leucine zipper transcription factor
P10601280A0674|59 77|ST3 promoter activity
P10601290A0742|35 54|cell surface stability
P10601290A0742|114 129|T cell recognition
P10601290A0742|161 182|x-ray crystal structures
P10601290A0742|197 216|MHC-peptide complexes
P10601335A0892|0 13|Redistribution
P10601344A1653|26 39|activity assays
P10601410A0977|48 60|remyelination
P10601410A0977|77 92|sclerosis lesions
P10601410A0977|112 125|conduction time
P10601606A0152|3 21|rhabdomyosarcoma R1H
P10601606A0152|50 60|WAG/Rij rats
P10601747A0482|18 29|control words
P10602502A0422|30 49|cell cycle progression
P10602507A0652|96 108|cyclin D1/cdk4
P10602507A0652|154 167|CSF-1 induction
P10602507A0652|205 217|p53 expression
P10603349A1667|3 25|signalling molecules Wnt1
P10603349A1667|83 97|progenitor cells
P10603349A1667|143 162|Myf5 expression domain
P10603349A1667|168 180|mesencephalon
P10604246A0523|0 10|STUDY DESIGN
P10604246A0523|109 125|AutoPBSC tubing set
P10604246A0523|179 191|cell tubing set
P10604583T0000|0 14|Albumin dialysis
P10604583T0000|62 74|Wilson disease
P10604583T0000|98 117|liver transplantation
P10604945A0731|14 31|promoter constructs
P10604945A0731|120 131|organization
P10604945A0731|145 158|promoter region
P10604945A0731|195 209|ethanol response
P10606245A0906|0 13|Overexpression
P10606245A0906|33 49|osteosarcoma cells
P10606245A0906|71 88|OC promoter activity
P10606515A0389|62 80|acid receptor element
P10606664A0000|0 18|Snail family proteins
P10606664A0000|108 128|cell fate determination
P10607566A0880|25 36|beta-catenin
P10607566A0880|115 131|retinoid X receptor
P10607566A0880|159 177|beta-catenin binding
P10607899A0605|0 15|Sequence analysis
P10607899A0605|21 34|promoter region
P10607899A0605|63 84|consensus binding motifs
P10607899A0605|112 138|estrogen receptor binding site
P10607900T0000|0 21|Sak kinase gene structure
P10608053A0923|0 11|Thrombolysis
P10608053A0923|43 58|platelet activity
P10608053A0923|148 164|001versus baseline
P10610716A1127|15 31|missense mutations
P10611235A1927|90 103|relocalization
P10611235A1927|109 125|Ste5p-MAPK cascade
P10611235A1927|131 144|plasma membrane
P10611242A0541|61 72|HIS3 promoter
P10611320A0816|103 114|Cak1p protein
P10611353A0458|0 11|Northern blot
P10611353A0458|22 46|transcription-PCR analyses
P10611353A0458|54 64|mRNA samples
P10611353A0458|192 211|Northern blot analysis
P10612044A1180|26 37|conservation
P10612044A1180|42 56|AP-4 binding site
P10612044A1180|90 116|transcription initiation site
P10612044A1180|135 147|Aal-rpL8 genes
P10612505A1317|71 86|group differences
P10612505A1317|89 103|treatment effect
P10612773A1210|11 21|Serum levels
P10613816X0000|212 223|bone diseases
P10613816X0000|230 241|osteoporosis
P10613843A0107|31 47|duplication events
P10613843A0107|108 118|ion channels
P10613863T0000|3 23|VirR response regulator
P10613863T0000|28 49|Clostridium perfringens
P10613863T0000|115 126|pfoA promoter
P10613874A0663|150 161|GlnA proteins
P10614676A0000|137 147|mg estradiol
P10614676A0000|152 174|mg norethisterone acetate
P10614676A0000|188 212|hormone replacement therapy
P10614857A0584|0 16|Leukocyte cultures
P10616948A0998|5 14|BF ECT group
P10616948A0998|74 94|seizure threshold level
P10617126A1005|129 140|dentate gyrus
P10617144A0386|12 26|phosphorylation
P10617232A0393|0 11|Serum HBV-DNA
P10617232A0393|28 39|liver enzymes
P10617232A0393|64 77|liver histology
P10618645A0750|0 15|Maximum induction
P10618645A0750|35 47|concentration
P10619062T0000|0 23|Haycocknema perplexum n. g.
P10619254A1055|0 12|Animal studies
P10619254A1055|23 38|beam equalization
P10619254A1055|87 98|image quality
P10619353T0000|6 27|estrogen receptor ligand
P10619353T0000|31 61|estrogen response element sequence
P10619353T0000|79 94|chicken ovalbumin
P10619353T0000|103 129|promoter transcription factor
P10620010A1155|49 71|tyrosine phosphorylation
P10620010A1155|117 131|phosphorylation
P10622574A0000|15 29|hepatitis C virus
P10622574A0000|80 94|prevalence rates
P10622576A0552|134 144|drug abusers
P10623758A0947|72 89|beta-galactosidase
P10623804A0808|112 124|decoy proteins
P10623804A0808|127 147|Fc gamma RIIB1 signaling
P10624787A0432|94 107|blood pressures
P10624787A0432|156 168|body mass index
P10624787A0432|180 193|waist-hip ratio
P10625438A1429|57 67|bp insertion
P10625438A1429|195 208|control samples
P10625494A1059|61 72|MDR1 promoter
P10625494A1059|75 87|HL60/VCR cells
P10625683A0091|20 41|protein tyrosine kinases
P10625683A0091|52 66|phosphorylation
P10627518A0544|81 93|contributions
P10627532A0739|105 119|phosphorylation
P10627532A0739|146 168|transcription factor ATF2
P10627834A0178|92 111|New Zealand selections
P10628748A0344|22 32|cAMP pathway
P10628748A0344|55 76|inhibin alpha expression
P10628748A0746|108 127|cAMP-response element
P10628750A0298|40 64|tumor necrosis factor-alpha
P10628750A0298|122 134|factor-kappaB
P10628750A0298|155 165|x NF-kappaB1
P10628750T0000|34 48|kappaB1 isoforms
P10628750T0000|58 102|angiotensinogen gene acute-phase response element
P10628750T0000|131 149|NF-kappaB activation
P10628755A0000|72 82|GH secretion
P10628755A0000|103 131|orphan GH-secretagogue receptor
P10628971A0824|107 125|protein sorting genes
P10628971A0824|141 163|dynamin family member VPS1
P10628971A1165|138 155|ribosome biogenesis
P10628971A1165|207 229|microtubule organization
P10628971A1165|264 297|inositol polyphosphate 5-phosphatase
P10629035A0827|9 20|strandedness
P10629035A0827|127 143|cdc17/pol1 mutants
P10629938A1352|18 29|distribution
P10629938A1352|35 49|GFP-POLO protein
P10629938A1352|55 66|compartments
P10630471T0000|26 38|depth analysis
P10630471T0000|77 88|cell behavior
P10630630A0614|7 17|calphostin C
P10630630A0614|74 86|CFI mRNA levels
P10633075A1111|21 32|Fab fragments
P10633075A1111|63 81|N-acetylglucosamine
P10633499A1306|0 22|Arhythmacanthus Yamaguti
P10634007A0202|17 37|acetaminophen overdose
P10634007A0202|60 71|hemodialysis
P10634007A0202|91 102|intoxication
P10634007A0202|110 122|drug clearance
P10635209A0419|9 20|conditioning
P10637149A0806|15 28|G-A anastomosis
P10637230A0332|49 61|proliferation
P10637238A0291|0 40|Eastern Cooperative Oncology Group trial E3186
P10638607A0000|142 154|cell carcinoma
P10638607A0000|170 183|adenocarcinoma
P10639585A0157|9 25|MPO gene regulation
P10639585A0157|82 96|differentiation
P10640683A0204|0 11|NDRF/NeuroD2
P10640683A0204|81 100|expression constructs
P10640683A0204|104 115|NDRF/NeuroD2
P10640683A0670|9 26|transfection assays
P10640683A0670|64 75|NDRF/NeuroD2
P10640683A0670|88 102|transactivation
P10640683A0670|108 132|rat insulin promoter element
P10640683A0670|178 190|co-expression
P10640683A0670|311 323|transcription
P10640734A0190|4 26|tyrosine phosphorylation
P10640734A0190|78 89|phosphatases
P10640734A0190|110 130|tyrosine phosphatase-1
P10640734A0190|152 163|cell activity
P10641688A0341|36 48|abnormalities
P10641688A0341|52 62|disc changes
P10642524A0156|94 116|tetratricopeptide repeat
P10642531A2322|0 21|Competition experiments
P10642531A2322|52 63|relationship
P10642531A2322|76 94|RGD recognition sites
P10642889A0393|0 15|Sequence analysis
P10643313A0345|5 22|i.v. administration
P10643313A0345|28 42|mg acetazolamide
P10643313A0345|46 57|disinfection
P10643313A0345|76 90|micrograms rt-PA
P10644414T0000|37 54|20-hydroxyecdysone
P10644414T0000|57 85|mosquito ultraspiracle isoforms
P10644753A0725|37 58|antibody affinity column
P10644753A0725|79 92|heparan sulfate
P10644753A0725|116 133|glycosaminoglycans
P10644760A0000|3 17|differentiation
P10644760A0000|35 59|neurotransmitter phenotype
P10644760A0956|52 67|activation domain
P10644760A0956|82 97|repression domain
P10645921A0000|72 83|morphologies
P10645921A1320|80 95|ejection fraction
P10645921A1320|136 152|circumflex disease
P10646820T0000|23 37|lymphadenectomy
P10646820T0000|81 92|hysterectomy
P10646863A0838|0 13|Overexpression
P10646863A0838|85 104|topoisomerase IIalpha
P10647817T0000|33 46|monkey platelet
P10647817T0000|50 71|T cell activation antigen
P10647859A0000|66 84|pressure ventilation
P10648020A0151|7 25|Von Willebrand factor
P10648020A0151|47 79|factors tissue plasminogen activator
P10648020A0151|93 103|tPA capacity
P10648020A0151|107 135|plasminogen activator inhibitor
P10648211A0000|8 26|signaling properties
P10648211A0000|76 86|ion channels
P10648489A1117|64 80|segment depression
P10648489A1117|96 113|peak concentrations
P10648619A0000|21 32|contribution
P10648619A0000|64 79|TATA interactions
P10648619A0000|85 100|promoter activity
P10648619A0000|127 138|silkworm tRNA
P10648619A0000|184 203|interactions accounts
P10648619A0000|213 228|promoter activity
P10649449A0413|41 61|squalene synthase genes
P10649449A0413|109 129|amino acid conservation
P10649456A1061|63 73|stock centre
P10649738A0953|70 83|patient-months
P10650104X0284|16 27|Royal College
P10650104X0284|30 41|Radiologists
P10650938T0000|3 18|estrogen receptor
P10650938T0000|42 61|estrogen dependencies
P10650938T0000|81 91|trout ER gene
P10650939A0789|22 33|coexpression
P10650939A1542|32 51|progesterone receptor
P10650958A1315|41 61|consensus c-myb element
P10650958A1315|138 155|mobility shift assay
P10651805A1600|6 17|transfection
P10651805A1600|45 55|carrier cDNA
P10651805A1600|60 82|mouse L1210 leukemia cells
P10651805A1600|92 109|folate accumulation
P10651805A1600|142 163|acid growth requirements
P10651805A1600|194 205|methotrexate
P10651805T0000|0 15|Characterization
P10651805T0000|83 100|folate accumulation
P10651805T0000|111 123|leukemia cells
P10652093A0139|137 148|DNA molecules
P10652102A0620|72 87|Ty1 transposition
P10652324A0177|10 22|participation
P10652324A0177|25 39|collagen binding
P10652362A0933|31 46|carboxyl terminus
P10652362A0933|76 96|internalization signal
P10652362A0933|126 143|adaptor complex AP-2
P10652800A0984|3 23|insulin therapy regimen
P10652800A0984|77 88|relationship
P10652800A0984|143 155|insulin dosage
P10653400A0000|3 15|applicability
P10653400A0000|30 45|donor nephrectomy
P10653550A1120|0 18|Hyaluronan treatment
P10653550A1120|29 46|collagen remodeling
P10653693A0429|65 85|KAP-1-RBCC interaction
P10653693A0903|52 66|oligomerization
P10653693A0903|82 92|KRAB binding
P10654032A1133|18 33|compression ratio
P10655164A0546|35 47|uncertainties
P10655164A0546|73 83|Li abundance
P10655230A0685|9 24|yeast counterpart
P10655230A0685|28 44|mouse GCN2 isoforms
P10656802A1724|25 51|cathepsin X amino acid sequence
P10657238A0541|0 22|Transfection experiments
P10657238A0541|86 98|transcription
P10657238A0541|101 115|mouse NMuMG cells
P10657658A0165|41 51|HA fragments
P10657658A0165|63 89|I kappa B alpha phosphorylation
P10657658A0165|117 138|reporter gene expression
P10657658A0165|142 163|ICAM-1 promoter activity
P10657899A0685|0 11|Pretreatment
P10657899A0685|43 58|oligonucleotides
P10658445A0208|69 91|PGE1 alpha-ciclodestrina
P10658445A0208|102 116|treatment cycles
P10658445A0208|152 165|reference group
P10658445A0208|180 193|prostaglandins
P10658588A0304|0 26|Desmethylferrochloroquine 1a
P10658588A0304|30 56|didesmethylferrochloroquine
P10658588A0304|82 95|schizontocides
P10658588A0304|137 156|Plasmodium falciparum
P10660069A0819|3 19|rrd1,2delta mutant
P10660069A0819|39 50|inactivation
P10660069A0819|110 139|Hog1p signal transduction pathway
P10660304A0522|12 24|JAK/Tyk family
P10660304A0522|27 41|tyrosine kinases
P10660304A0522|49 63|phosphorylation
P10660304A0522|85 97|CNTF signaling
P10660304A0522|128 142|phosphorylation
P10660304A0522|145 155|STAT3 Tyr727
P10660604A0748|6 21|CARbeta/RXRalpha
P10660604A0748|31 43|transcription
P10660604A0748|50 83|HD-PPRE luciferase reporter construct
P10660676A0000|0 15|Zebrafish cyclops
P10660676A0000|39 54|Growth Factor beta
P10660676A0000|62 76|signaling factor
P10662550A0679|15 27|candidate gene
P10662550A0679|51 70|retardation phenotype
P10662550A0679|77 90|ATR-16 patients
P10662614A0000|3 20|genome organization
P10662614A0000|42 63|wheat streak mosaic virus
P10662614A0000|158 181|amino acid dissimilarities
P10662614A0000|200 211|polyproteins
P10662614A0972|91 102|interactions
P10663558T0000|17 27|light chains
P10663558T0000|40 65|basement membrane reactivity
P10664876A0000|28 41|corticosteroid
P10664876A0000|74 93|corticosteroid series
P10664876A0000|113 126|classification
P10664876A0000|129 151|corticosteroid molecules
P10664876A0000|199 216|hydrocortisone type
P10664876A0000|239 259|betamethasone type-non
P10665308T0001|12 24|tachyphylaxis
P10665798A0598|22 33|serum enzymes
P10665798A0598|40 60|aspartate transaminase
P10665798A0598|61 79|alkaline phosphatase
P10665798A0598|80 100|creatine phosphokinase
P10665798A0598|101 120|lactate dehydrogenase
P10665798A0598|126 149|D. russelli venom injection
P10665798A0598|182 193|tissue damage
P10666222A0330|30 47|survivin cDNA clones
P10666222A0330|93 108|survivin proteins
P10666238A1322|33 45|E2F-1 promoter
P10666238A1322|91 105|transactivation
P10666238A1322|108 128|E2F-1 promoter activity
P10666253A1291|10 22|stabilization
P10666509A0494|69 85|propranolol groups
P10667597A0668|29 42|splice variants
P10668701A1311|20 31|APOE epsilon4
P10668701A1311|96 107|dyslipidemia
P10668701A1311|111 123|atherogenesis
P10669594A0000|65 77|fimbriae SEF17
P10669594A0000|152 186|16-amino acid Leishmania T-cell epitope
P10669594A0000|201 219|metalloprotease gp63
P10669594A0969|39 50|SefA proteins
P10669596A0430|138 153|nuclease activity
P10669596A0430|208 229|RecBCD nuclease activity
P10669751T0000|25 54|protein kinase signaling pathways
P10669751T0000|65 78|cot oncoprotein
P10669751T0000|84 96|c-jun promoter
P10669751T0000|110 123|transformation
P10671224A0254|60 74|CD95L expression
P10671519A0641|0 22|Protein sequence analysis
P10671519A0641|134 149|membrane proteins
P10671520T0000|87 109|T-cell leukemia virus type
P10671520T0000|114 128|HIV-1 expression
P10671554A0492|10 27|amino acid sequences
P10671554A0492|53 64|porcine cDNAs
P10671554A0492|93 109|amino acid residues
P10671554A0492|164 179|Edman degradation
P10671606A0884|4 23|chemical shift imaging
P10671606A0884|27 41|signal intensity
P10673335X0782|13 25|Academic Press
P10673426A0168|92 104|translocation
P10673426A0168|192 203|cytotoxicity
P10674395A0262|69 80|neuropeptide
P10674395A0262|127 151|signal transduction pathway
P10674395A0262|173 185|protein kinase
P10674395A0262|225 237|cell line GT1-7
P10675154T0000|16 29|botulinum toxin
P10675331A0600|26 38|isoproterenol
P10675331A0600|44 66|tyrosine phosphorylation
P10675331A0600|85 97|Erk activation
P10675331A0600|104 126|tyrosine phosphorylation
P10675610A0279|26 39|DNA replication
P10675610A0279|40 52|transcription
P10675610A0279|66 85|cell cycle progression
P10675610A0279|106 117|C-MYC protein
P10677214A1045|28 38|E44D mutants
P10677214A1045|243 254|acid catalyst
P10677214A2842|65 76|N HSQC spectra
P10677214A2842|100 110|loop I-helix
P10677297A0933|61 77|missense mutations
P10678968A1096|28 39|I. scapularis
P10678968A1096|99 113|mouse population
P10678968A1096|129 144|E. phagocytophila
P10679065A0711|0 15|BCR cross-linking
P10679065A0711|48 70|protein kinase-2 activity
P10679065A0711|133 147|protein kinase-2
P10679065A0711|178 193|peptide substrate
P10679065A0711|220 239|phosphoacceptor motif
P10679065A1217|26 70|junB promoter/chloramphenicol acetyltransferase
P10679065A1217|74 85|reporter gene
P10679190A0693|36 47|reading frame
P10679190A0693|99 110|reading frame
P10679649A0311|7 21|TBN measurements
P10679649A0311|60 74|breast carcinoma
P10679649A0311|100 115|cyclophosphamide
P10679649A0311|116 127|methotrexate
P10679649A0311|131 144|5-fluorouracil
P10679649A0311|152 163|chemotherapy
P10679781A1183|4 31|bp Glucocorticoid Response Unit
P10679781A1183|53 75|glucocorticoid induction
P10679781A1183|89 102|dibutyryl-cAMP
P10679781A1183|115 127|phorbol esters
P10679922A1110|68 92|tumor suppressor gene target
P10681520A0525|83 93|GEF activity
P10681562A0263|12 31|PPARgamma antagonists
P10681562A0263|92 105|mutant receptor
P10681562A0263|124 138|PPARgamma action
P10681588A0899a|96 114|transcription factor
P10681588A0899a|143 153|protein beta
P10681588A0899b|96 114|transcription factor
P10681588A0899b|143 153|protein beta
P10683072T0000|73 97|bolus interleukin-2 therapy
P10683072T0000|116 128|cell carcinoma
P10683244A0939|27 37|NBF2 protein
P10683244A0939|107 124|sieve chomatography
P10683244A1860|222 236|phosphorylation
P10683244X2359|13 25|Academic Press
P10683259A0774|0 18|Sulfhydryl titration
P10683259A0774|23 35|iodoacetamide
P10683259A0774|94 112|maleimide derivative
P10683259A0774|191 205|splice junctions
P10683989A0251|11 25|oxide inhalation
P10683989A0251|103 114|Qs/Q tau ratio
P10684069A0508|41 57|minute ventilation
P10684069A0508|91 104|administration
P10684069A0508|107 122|methylphenidatum
P10684069A0508|126 138|aminophylline
P10684097A0175|66 78|sham operation
P10684097A0175|127 142|ethinyl estradiol
P10684111A1411|87 103|MAPK family members
P10684265T0000|8 19|modification
P10684265T0000|25 52|transactivator protein IE2-p86
P10684265T0000|60 74|cytomegalovirus
P10684265T0000|113 126|proteins SUMO-1
P10684534A0634|12 23|heparin doses
P10684534A0634|84 96|clotting times
P10684660A1266|32 47|processing enzyme
P10684941A0722|17 31|complementarity
P10684941A0722|36 51|ligation reaction
P10684941A0722|78 89|nt insertions
P10684967A0000|52 71|transcription factors
P10684967A0000|123 135|thyroid tissue
P10684967A0000|156 168|lung phenotype
P10687366A0000|0 19|National abortion laws
P10687855A1197|133 147|differentiation
P10687855T0000|0 41|Mouse growth hormone transcription factor Zn-16
P10687855T0000|92 108|zinc finger domains
P10687862A1980|3 26|CCAAT core sequence mutants
P10687862A1980|80 95|promoter activity
P10688639A1310|31 49|PU.1 transactivation
P10688639A1310|51 61|PEST domains
P10688639A1310|82 95|p300 expression
P10688646A0535|55 69|HS-40 mutants cis
P10688646A0535|84 95|alpha-globin
P10688646A0535|111 127|hormone hybrid gene
P10688646A0535|149 160|footprinting
P10688646A0535|164 181|expression analysis
P10688660A0992|83 94|progesterone
P10688660A0992|110 122|transcription
P10688660A0992|143 169|progesterone response element
P10688660A0992|178 196|reporter DNA template
P10688661A0237|10 23|binding protein
P10688661A0237|46 64|transcription factor
P10688663A0207|12 33|core histone tail domains
P10688663A0207|43 60|trypsin proteolysis
P10688663A0207|79 94|core histone tails
P10688666A1010|21 34|ASK1 activation
P10688666A1010|49 68|homo-oligomerization
P10690702A0065|7 37|Acetylcholine receptor antibodies
P10690702A0065|53 66|electromyogram
P10690702A0065|93 108|myasthenia gravis
P10690866A0783|41 64|TSH frequency distribution
P10691972T0000|0 15|Characterization
P10691972T0000|54 70|resistance protein
P10691972T0000|98 114|comparison withthe
P10691972T0000|124 140|resistance protein
P10692167A0364|48 59|observations
P10692374A1873|26 37|M. jannaschii
P10692374A1873|61 74|20S proteasomes
P10692374A1873|83 101|nucleotidase complex
P10692374A1873|197 213|amino acid residues
P10692433A0000|3 24|transcription factor E2F
P10692433A0000|50 65|S phase transition
P10693246A0252|132 151|laryngeal nerve chains
P10693314A0521|23 34|CK-MB results
P10694189A0469|56 68|noradrenaline
P10694210A0385|72 88|cingulate cortices
P10694210A0385|106 119|administration
P10694210A0385|122 139|d-chlorpheniramine
P10694511A0570|112 125|uptake activity
P10694605A1327|17 30|infection rates
P10694605A1327|31 52|events/100 patient-days
P10694609A0309|103 118|operating theater
P10695685T0000|48 59|implications
P10695685T0000|71 82|consequences
P10696007A1325|27 45|C2-C3 disk morphology
P10698516T0000|68 82|SAPK/JNK pathway
P10698937T0000|19 32|kinase activity
P10698937T0000|44 56|up-regulation
P10699354A0557|0 11|Reaction time
P10700262A0000|66 79|control systems
P10700262A0000|90 104|brain structures
P10701534A0164|32 50|low-frequency tremor
P10701534A0164|54 65|hemidystonia
P10702253A0357|25 61|transcriptase-polymerase chain reaction
P10702253A0357|72 88|HIF-1alpha subunit
P10702253A0357|155 168|HIF-1alpha gene
P10702285A0855|11 22|relationship
P10702285A0855|47 74|phosphatidylinositol 3-kinase
P10702285A0855|152 170|wortmannin treatment
P10702285A0855|220 242|GLUT4-EGFP translocation
P10702389A1148|14 25|RB2/p130 gene
P10702794A1495|119 130|ERK2 activity
P10702794A1495|140 156|feedback mechanism
P10702926T0089|0 13|Cross-reaction
P10702926T0089|46 68|alpha beta T cell receptors
P10703633A0747|0 15|Strontium nitrate
P10703633A0747|107 125|irritation sensation
P10703633A0747|193 205|mean magnitude
P10703633A0747|211 229|irritation sensation
P10704196A1051|17 32|sulfhydryl groups
P10704196A1051|78 91|plasma membrane
P10704283A0649a|70 87|chromosome 5q31-q33
P10704283A0649a|100 113|gene candidates
P10704283A0649a|149 171|IL-4 cytokine gene cluster
P10704285A0536|25 42|reporter expression
P10704285A0536|70 86|AP-2alpha promoter
P10704285A0536|103 115|AP-2alpha gene
P10704338A0354|120 134|proline residues
P10704338A0354|168 180|alpha-helices
P10704338A0354|225 238|leucine residue
P10704338A0354|239 250|P-position-L
P10704410T0000|0 15|Clb/Cdc28 kinases
P10704410T0000|41 74|replication initiator proteins Mcm2-7
P10704499A0682|13 24|PC12-E2 cells
P10704499A0682|68 89|fibroblast growth factor
P10704499A0682|127 143|tyrosine kinase p59
P10704499A0682|177 207|phorbol-12-myristate-13-acetate
P10704853T0000|0 15|Cooperative roles
P10704853T0000|18 31|Bozozok/Dharma
P10704853T0000|75 89|dorsal organizer
P10704975A0479|0 16|Thiopentone sodium
P10704975A0479|129 141|neurotoxicity
P10705380A0629|34 51|Xretpos transcripts
P10705380A0629|110 123|UV-irradiation
P10705380A0629|127 145|BMP-4 overexpression
P10705783A0433|55 69|labyrinthectomy
P10705783A0433|95 117|concentration gentamicin
P10706688A0376|11 22|TCR signaling
P10706688A0376|30 40|AP-1 binding
P10706688A0376|66 85|fasl promoter function
P10706688A0376|107 122|NF-kappaB binding
P10706887A0281|78 90|abnormalities
P10706887A0281|110 122|ALK expression
P10706887A1457|136 147|methotrexate
P10708243A0000|69 81|pregnancy loss
P10708243A0000|85 96|preeclampsia
P10708424A0800|38 56|autophosphorylation
P10709705T0000|5 28|point feature registration
P10710499A0000|0 11|Methysergide
P10710499A0000|15 33|serotonin antagonist
P10710499A0000|64 77|wound blood flow
P10710499A0000|81 94|edema formation
P10710742T0000|0 24|Serum leptin concentrations
P10710742T0000|38 66|gonadotropin stimulation cycles
P10710985T0000|21 32|work practice
P10710985T0000|50 69|strengths perspective
P10712512A0506|22 35|plasma membrane
P10712512A0506|67 79|thioacylation
P10712618A0181|12 29|sequence comparison
P10712618A0181|42 64|Bacillus YM55-1 aspartase
P10712618A0181|85 109|Bacillus subtilis aspartase
P10713083A0560|73 84|TraR function
P10713083A0560|102 120|transcription factor
P10713083A0560|134 151|DNA recognition site
P10713155A0151|14 33|IIIa pre-mRNA splicing
P10713161A0985|0 11|Inactivation
P10713161A0985|88 109|Smt3-protein conjugates
P10713175A1399|112 126|ARF-Mdm2 complex
P10713175A1399|143 157|cell cycle arrest
P10713176A0422|0 16|Cyclin A expression
P10713176A0422|75 97|pocket protein partners Rb
P10713176A0422|189 205|E2F-p107 complexes
P10713176A0422|220 236|mitogen withdrawal
P10713176A0885|0 19|D-cyclin-cdk activity
P10713176A0885|33 49|Rb phosphorylation
P10713176A0885|121 132|inhibitor p16
P10713176A0885|149 160|DNA synthesis
P10713176A0885|164 180|cell proliferation
P10713239A0988|41 56|capsulorhexis rim
P10713453A0172|40 50|antibody Q18
P10713453A0172|81 99|polytene chromosomes
P10714985A1057|1 22|RNA boundary experiments
P10714985A1057|102 121|leader RNA association
P10715322A0000|0 12|Gene silencing
P10715322A0000|35 46|DNA sequences
P10715325A0834|62 77|stress conditions
P10715325A0834|120 140|ETHYLENE-INSENSITIVE2
P10715602A0149|22 34|dexamethasone
P10715602A0149|68 95|surfactant preparation Exosurf
P10715602A0149|100 112|phospholipids
P10715602A0149|133 144|Wellcome GmbH
P10717612A0000|44 56|response rates
P10717612A0000|120 136|stimulating factor
P10717612A0000|160 172|interleukin-2
P10717612A0000|220 232|cell carcinoma
P10720434A0291|85 96|cyclin B1 mRNA
P10721698A1195|35 49|dodecamer repeat
P10721698A1195|141 153|transcription
P10721704A1155|19 30|organization
P10721704A1155|93 107|promoter element
P10721704A1155|134 149|sequence analysis
P10721704X0000|22 32|mouse Elavl1
P10721704X0000|111 122|organization
P10721704X0000|255 267|proliferation
P10721704X0000|290 302|mRNA stability
P10721714A1087|15 33|mobility shift assays
P10721717A0676|29 44|sequence identity
P10721717A0676|67 83|amino acid residues
P10721726T0000|18 43|mouse thioredoxin reductases
P10722063A0328|23 43|octadecylsilane column
P10722661A0146|32 47|sequence identity
P10722661A0146|53 73|Neurospora crassa PREG1
P10722661A0146|92 102|PHO80 cyclin
P10722661A0406|116 127|TY epitope tag
P10722661A0406|145 161|trypanosome genome
P10722737A1726|93 111|transcription factor
P10723723A0781|15 27|mouse promoter
P10723723A0781|47 74|CT dinucleotide repeat sequence
P10723727A0713|74 103|polyadenylation signal sequences
P10724436A0085|31 48|reference materials
P10724483A0540|20 30|cAMP control
P10725017A0673|71 84|specialisation
P10725017A0673|100 115|healthcare record
P10725017A0673|144 171|Healthcare Record Architecture
P10725382A0398|0 15|Sequence analyses
P10725433A0543|54 71|Wp reporter activity
P10725433A0543|86 95|B cell lines
P10725433A0543|182 197|promoter function
P10727247A0461|39 55|expression pattern
P10727247A0461|69 84|characterization
P10727247A0461|95 107|TEF-1 isoforms
P10727413A1244|12 23|binding sites
P10727413A1244|60 72|hamster CYP7A1
P10727413A1244|192 208|tissue restriction
P10727426A1280|3 16|kinase activity
P10727426A1280|37 49|CDK inhibitors
P10727428A0000|57 73|cell proliferation
P10727428A0000|77 91|differentiation
P10727433A0560|0 11|Transfection
P10727433A0560|17 39|CSF-1R expression plasmid
P10727433A0560|79 95|signalling pathway
P10727433A0560|114 129|activator protein
P10727433A0560|143 153|uPA promoter
P10727433A0560|208 229|protein kinase C pathways
P10727433T0000|12 57|urokinase plasminogen activator gene transcription
P10727433T0000|75 92|macrophage cell line
P10727511A0294|90 106|signaling pathways
P10727515A1202|0 11|Coactivation
P10727515A1202|92 103|stimulations
P10727515A1202|154 167|pertussis toxin
P10728945A0233|41 59|Platelet Aggregation
P10728945A0233|71 83|Thrombosis-II
P10728986A0000|3 21|Wnt signaling pathway
P10728986A0000|50 66|animal development
P10728986A0000|76 92|cell fate decisions
P10729151A1160|73 90|reporter expression
P10729155A0653|73 84|beta-strand I
P10729220A0000|37 48|growth factor
P10729221A0798|18 35|expression patterns
P10729221A0798|46 61|Kv4 family members
P10729221A0798|67 84|subtype specificity
P10730292T0000|5 22|treatment mechanics
P10730292T0000|28 42|Class II division
P10730292T0000|44 55|malocclusion
P10730763A1491|19 47|Nottingham Eczema Severity Score
P10730763A1491|81 92|research tool
P10730763A1491|115 129|disease severity
P10731411A0958|94 113|DEAD-box RNA helicases
P10731926A0775|0 14|Advanced adenoma
P10732669A0510|63 81|particle bombardment
P10732669A0510|150 171|reporter gene constructs
P10732669A0510|184 201|HD-Zip binding sites
P10732669A1336|43 61|mobility shift assays
P10732669A1336|138 149|heterodimers
P10733569A0364|77 96|stress gene expression
P10733569A0364|123 136|stress response
P10733581A1391|99 111|TTF-1 activity
P10733591A0146|54 70|actin cytoskeleton
P10733591A0146|135 147|transcription
P10733591A0146|151 167|cell proliferation
P10733591A0533|21 32|Cdc42 results
P10733591A0533|38 50|translocation
P10733591A0533|125 138|plasma membrane
P10733880X1783|13 25|Academic Press
P10734312A0503|19 33|Shc localization
P10734312A0503|36 48|membrane rafts
P10734312A0503|71 81|Shc function
P10734312A0503|119 146|Ras membrane localization motif
P10735272A0649|0 15|Southern blotting
P10735272A0649|25 62|strand conformation polymorphism analyses
P10735272A0649|120 132|RT-PCR studies
P10735272A0649|151 165|glioma cell lines
P10735272A0649|193 230|chromosome 19q glioma tumor suppressor gene
P10735848A1440|41 58|tol-oprL expression
P10736161T0000|12 30|phosphoenolpyruvate
P10736161T0000|30 58|sugar phosphotransferase system
P10736223A1227|30 42|transcription
P10736223A1227|106 118|transcription
P10736223A1227|174 186|mRNA stability
P10737366A0280|108 119|formalin test
P10738139A0681|34 61|cytokine response pathway genes
P10739408A0896|0 16|Family environment
P10739408A0896|55 67|relationships
P10739408A0896|68 79|substance use
P10739671A0136|2 35|electrophoresis mobility shift assays
P10739671A0136|97 107|c-myb intron
P10739671A0136|109 132|transcription pause region
P10739671A0136|177 188|fibroblast WI
P10739671A0136|268 279|binding sites
P10740602A0141|0 10|STUDY DESIGN
P10740602A0141|11 30|Fine needle aspiration
P10741850A0452|0 27|Electrophile Response Elements
P10741850A0452|75 90|GCSl subunit genes
P10741850A0452|131 143|gene induction
P10742114A0486|96 107|SD phenotypes
P10743608A1154|0 15|TbRAB31 behaviour
P10743608A1154|136 148|daughter cells
P10743608A1154|224 235|microtubules
P10743719A0223|105 124|rejection nephropathy
P10744749A0315|123 133|MyoD protein
P10744749T0000|77 89|transcription
P10744974T0000|0 14|Phosphorylation
P10744974T0000|18 44|spindle pole body localization
P10744974T0000|73 85|protein kinase
P10745563A0409|35 47|complications
P10745563A0409|166 180|neo-endothelium
P10747099A0507|67 85|adaptor proteins p130
P10747099A0507|163 174|cell invasion
P10747099A0507|223 236|collagen matrix
P10747782A0390|137 154|DNA binding activity
P10747782A0390|168 178|core domains
P10747879A0607|54 65|reading frame
P10747879A0607|104 115|reading frame
P10747890A1096|43 55|protein sensor
P10747890A1096|70 87|groove interactions
P10747890A1096|106 125|base pair interactions
P10748054T0048|23 40|B lymphocyte antigen
P10748054T0048|57 67|calcium flux
P10748125A0000|54 88|protein serine/threonine phosphatases
P10748164A1284|0 16|Scanning mutations
P10748175A0000|16 30|glycan synthesis
P10748175A0000|129 140|transporters
P10748194T0000|34 53|density protein PSD-95
P10748194T0000|79 95|trafficking signal
P10748672A0130|25 35|Vipera aspis
P10748672A0130|39 49|Vipera berus
P10749145T0000|25 36|PCPH proteins
P10749145T0000|50 70|diphosphatase activity
P10749166A0991|164 176|A. tumefaciens
P10749849A0000|30 47|tumor suppressor p53
P10749849A0000|83 97|cell cycle arrest
P10749849A0000|136 153|kinase inhibitor p21
P10749932A0000|16 30|adaptor molecule
P10749932A0000|33 49|integrin signaling
P10750020A0843|4 25|growth factor activation
P10750020A0843|40 54|transactivation
P10750020A0843|57 69|ER/Sp1 binding
P10750021A0728|21 55|deletion promoter-reporter constructs
P10751398A1135|13 25|transcription
P10751398A1135|28 41|c-IAP2 promoter
P10751398A1135|98 112|membrane protein
P10752450A0288|37 52|fluoride products
P10752450A0288|71 93|fluoride delivery systems
P10752475A1376|32 56|signal-transduction events
P10752475A1376|257 272|tumor regressions
P10752475A1376|283 293|mouse models
P10752807A1598|53 74|factor antagonist BB-882
P10752807A1598|151 168|organ failure scores
P10756007A0575|17 28|RBE sequences
P10756007A1512|58 71|ch-19 target DNA
P10756020A0571|35 56|vaccinia virus particles
P10756020A0571|119 136|electron microscopy
P10756032A0599|6 32|dimethyl sulfate footprinting
P10756032A0599|38 52|cyclin E promoter
P10756032A0599|90 105|hypersensitivity
P10756094A0671|52 67|marker resolution
P10756100A0457|22 35|amino-terminus
P10756225A1464|142 155|ethmoid sinuses
P10757983A0733|19 29|CRS sequence
P10757983A0733|59 72|identification
P10757983A0733|76 92|zinc finger protein
P10757983A0733|134 150|zinc finger protein
P10757983A0733|152 171|mouse ZBP-89 homologue
P10758289A0141|20 31|muscle fibres
P10758289A0141|57 69|finger flexors
P10758289A0141|95 106|pisiform bone
P10758726T0000|28 39|arrangements
P10759693A0201|174 189|agents ranitidine
P10759693A0201|253 264|theophylline
P10760109A1050|15 26|malnutrition
P10760109A1050|136 146|plasma IGF-1
P10760109A1050|147 161|serum creatinine
P10760109A1050|168 182|blood hemoglobin
P10760132A1169|68 85|protein prenylation
P10760132A1169|110 128|vesicle polarization
P10760169A1142|56 83|transcription initiation sites
P10760950A1133|9 23|staining pattern
P10760950A1133|92 108|actin stress fibers
P10761263A1108|41 51|T2 statistic
P10761263A1108|98 109|displacement
P10761263A1108|118 133|prostate patients
P10762254A0954|12 32|TMA methyltransferases
P10762254A0954|61 84|MMA methyltransferase gene
P10762254A0954|110 130|TMA methyltransferases
P10762348A0269|5 19|phosphorylation
P10762348A0269|20 31|STAT proteins
P10763823A0824|0 13|Overexpression
P10763823A0824|63 74|transfection
P10763827A1158|20 37|senescence pathways
P10763827A1158|63 73|ras oncogene
P10763827A1158|74 85|inactivation
P10763827A1158|88 104|TGFbeta1 secretion
P10763827A1158|137 153|senescence program
P10764150A0000|89 106|cytokine dependency
P10764150A0000|109 119|FDC-P1 cells
P10764574A0718|60 78|Arabidopsis thaliana
P10764574A0718|109 126|prediction accuracy
P10764574A0718|152 167|alignment methods
P10764729A1846|11 22|cDNA sequence
P10764729A1846|30 42|betaV spectrin
P10764729A1846|68 82|accession number
P10764760T0000|0 14|Transactivation
P10764760T0000|64 82|JNK signaling pathway
P10764802A1258|66 80|Cip/Kip proteins
P10764802A1258|211 223|family members
P10764802A1258|247 261|differentiation
P10764970A1009|21 45|quinupristin/dalfopristin
P10764970A1009|154 165|introduction
P10765095A0308|31 42|PRL secretion
P10765095A0308|55 76|prostate cancer patients
P10765095A0308|122 135|metoclopramide
P10765095A0308|199 210|PRL secretion
P10766246A0000|0 24|Integrin adhesion receptors
P10766246A0000|59 71|cell functions
P10766246A0000|99 112|gene expression
P10766246A0000|119 131|proliferation
P10766246A0000|132 146|differentiation
P10766493T0000|0 12|Recombination
P10766556T0000|3 21|somatoform conundrum
P10767091A0133|72 83|difficulties
P10767091A0133|122 142|inter-user variability
P10767091A0133|146 162|image obliteration
P10767251A1046|103 116|lung resections
P10767553A0100|66 89|helix transcription factor
P10767553A0100|107 117|Factor 3beta
P10767560A0105|28 43|characterization
P10767560A0105|60 71|organization
P10767560A0105|77 88|mouse Pkr gene
P10767560A0105|125 146|mouse Pkr promoter region
P10767560A0105|171 183|transcription
P10769144A0000|37 53|consensus sequence
P10769144A0000|96 109|gene expression
P10770041A0731|0 11|Kidney length
P10770041A0731|63 73|kidney width
P10770065A0264|29 49|S2 sleeve segmentectomy
P10770065A0264|54 72|lymph node dissection
P10770471T0000|33 43|night sweats
P10771528T0036|18 36|alkaline phosphatase
P10771709A0291|59 72|seroconversion
P10771709A0291|129 144|IgG antibody titer
P10771709A0291|155 170|Coxiella burnetii
P10771709A0291|198 210|questionnaire
P10772856X1492|13 25|Academic Press
P10772977A0222|27 37|PVX CP mutant
P10772977A0222|55 72|Nicotiana tabacum cv
P10773351A0672|11 24|CD86 expression
P10773351A0672|99 128|gamma-interferon activation site
P10773455A1268|97 114|mouse ALAS2 promoter
P10773455A1268|179 193|differentiation
P10773458A0000|44 61|vesicle trafficking
P10773667A0351|18 30|HMG20 proteins
P10773951A0000|21 35|B antibody status
P10773951A0000|50 62|O group mothers
P10773951A0000|72 85|O group husbands
P10775038A0142|23 36|Wee1 regulation
P10775267A0363|10 21|transduction
P10775267A0363|80 99|bone marrow transplant
P10775267A0363|125 136|long-latency
P10775585A0754|0 12|Ab-MLV strains
P10775585A0754|46 56|NIH 3T3 cells
P10775585A0754|104 118|signaling events
P10775585A0754|176 188|kinase pathway
P10777217A0536|3 20|p53-homolog p73beta
P10777217A0536|37 48|PIG3 promoter
P10777217A0536|136 147|PIG3 promoter
P10777499A0883|78 89|phytochromes
P10777586A1022|0 21|Co-immunoprecipitation
P10777586A1022|25 49|DNA affinity chromatography
P10777586A1022|101 115|silencer element
P10777586A1022|213 227|band shift assays
P10777669A0582|29 39|marker RP S28
P10777669A0582|51 72|chromosome 19qter region
P10778740A1493|13 27|Cdk2 truncations
P10778757A0000|135 151|cell wall invertase
P10779313A1842|39 52|Xenopus oocytes
P10779313A1842|103 114|GIRK channels
P10779313A1842|151 165|phosphorylation
P10779329T0000|70 90|cell morphology changes
P10779352T0000|0 13|Identification
P10779352T0000|22 32|E2F3 product
P10779508A0452|8 37|footprinting protection analysis
P10779508A0452|74 120|glutathione S-transferase-ERRalpha1 fusion protein
P10779508T0000|24 36|receptor alpha
P10779508T0000|91 114|estrogen response elements
P10779508T0000|125 139|lactoferrin gene
P10780018A0539|47 58|response time
P10780518A1270|28 42|protein function
P10780883T0000|114 129|interferon-alpha
P10781109T0000|27 38|interference
P10781109T0000|61 79|Arabidopsis thaliana
P10781423A0993|45 65|consensus binding sites
P10781423A0993|72 129|homeodomain transcription factor thyroid transcription factor-1
P10781541A1063|143 155|transcription
P10781552A0000|91 104|photosynthesis
P10781604A0827|45 55|CTD sequence
P10781604A0827|89 100|Rsp5 WW domain
P10781990A0455|74 92|hyperintense lesions
P10781990A0455|98 111|globus pallidus
P10782640A0444|29 47|aberration constants
P10782640A0444|51 71|CM300 FEG/UT microscope
P10782989A0575|66 81|DNA binding domain
P10782989A0575|87 104|amino acid sequences
P10782989A0575|115 130|DNA binding domain
P10784367A0133|40 71|Suffolk County Mental Health Project
P10784393A0000|0 14|Marrow dysplasia
P10784393A0000|23 36|characteristic
P10784393A0000|86 100|marrow blastosis
P10785294A0720|24 36|inlays/onlays
P10785294A0720|55 66|restorations
P10785294A0720|112 125|resin composite
P10785880A0947|41 53|complications
P10785880A0947|101 113|HELLP syndrome
P10786671A0182|23 40|telomerase activity
P10786671A0182|129 141|transcriptase
P10786742A0670|5 16|control group
P10786742A0670|17 31|platelet markers
P10787437A1616|30 51|transcription start site
P10788320A1034|23 33|TPR elements
P10788320A1034|79 90|interactions
P10788320A1034|107 118|102kD protein
P10788320A1034|162 172|U4/U6 snRNPs
P10788476A0891|43 67|Sec31A co-precipitate Sec13
P10788476A0891|78 94|ER-Golgi transport
P10788476A0891|126 143|stomatitis G protein
P10788480T0000|51 76|protein gene expression links
P10788480T0000|100 113|DNA replication
P10790390X0000|34 69|position effect variegation modifier mod
P10790390X0000|163 175|gene silencing
P10790390X0000|178 202|position effect variegation
P10790390X0000|218 240|gypsy insulator sequences
P10790390X0000|261 274|gene expression
P10791819A0771|34 54|nucleotide composition
P10791819A0771|60 74|asparagus genome
P10791901A0609|0 11|Transduction
P10791901A0609|30 41|cell line K562
P10791901A0609|57 77|MRP1-PG13 supernatants
P10791901A0609|125 139|target K562 cells
P10791901A0609|216 229|concentrations
P10792583A0000|21 43|vasopressin V1b receptors
P10792718T0000|0 13|Identification
P10792718T0000|18 30|AfsA homologue
P10792718T0000|94 118|autoregulator biosynthesis
P10792718T0000|119 143|virginiamycin biosynthesis
P10792718T0000|147 171|virginiamycin M1 resistance
P10793143A1533|164 177|DNA replication
P10793991A0569|33 46|TIE researchers
P10793991A0569|89 100|telemedicine
P10794405A0000|99 111|understanding
P10794936A0241|3 15|recovery rates
P10794936A0241|86 97|mycobacteria
P10794936A0241|101 113|recovery rates
P10794936A0241|148 168|M. tuberculosis complex
P10794936A0241|224 235|mycobacteria
P10796465A0373|0 16|SELECTION CRITERIA
P10796486A0817|0 16|SELECTION CRITERIA
P10796486A0817|113 128|asthma medication
P10796486A0817|147 162|asthma medication
P10797125A0000|59 73|core temperature
P10797125A0000|80 103|core temperature threshold
P10797125A0000|107 119|sweating onset
P10797125A0000|174 185|degrees C rest
P10797125A0000|199 212|passive heating
P10797586A0402|44 55|disturbances
P10798607A1359|38 49|meningococci
P10798607A1359|84 102|antibody titer levels
P10799501A1391|74 87|SPRK activation
P10799590A0431|64 77|EBNA-3C protein
P10799590A0431|105 117|transcription
P10799590A0431|181 193|transcription
P10799595A1454|73 87|HPV-6 E1 promoter
P10799595A1454|101 112|HPV life cycle
P10799863T0000|20 36|metallopeptidases
P10799863T0000|73 87|HIV-1 ENV epitope
P10799863T0000|110 128|antigen presentation
P10799879T0000|10 25|characterization
P10799879T0000|38 51|adaptor protein
P10799879T0000|56 73|pleckstrin homology
P10799879T0000|77 87|Src homology
P10799879T0000|110 124|T cell activation
P10801244A0578|0 13|Vancomycin data
P10801244A0578|71 86|NONMEM population
P10801330A1714|35 63|membrane cytoskeleton fractions
P10801330A1714|107 125|platelet aggregation
P10801482A0968|118 130|kappaB targets
P10801809T0000|30 46|yeast PHO8 promoter
P10801809T0000|75 86|PHO5 promoter
P10801860A0000|38 70|immunoglobulin superfamily proteins
P10802909A0478|15 26|PARTICIPANTS
P10804379T0001|50 64|cytomegalovirus
P10805286A0233|32 43|cis-elements
P10805286A0233|137 156|rat PCI mRNA expression
P10805286A0914|12 28|PCI mRNA expression
P10805286A0914|65 74|rat PCI cDNA
P10805286A0914|115 131|PCI mRNA expression
P10805390A0340|26 37|measurements
P10805390A0340|40 56|photoluminescence
P10805390A0340|59 85|GaAs/AlGaAs heterostructures
P10805729A0987|3 15|stoichiometry
P10805729A0987|149 167|acid binding surfaces
P10805737T0000|29 55|translation initiation factor
P10805737T0000|88 98|beta subunit
P10805737T0000|114 125|eIF5 function
P10805738A0799|48 64|p38 kinase activity
P10805738A0799|176 197|Gal4-MyoD fusion protein
P10805739A0343|26 41|complex formation
P10805739A0343|54 66|eIF2B subunits
P10805739A0640|13 29|nonsense mutations
P10805739A0640|57 68|eIF2Bepsilon
P10805747A0633|113 130|septin organization
P10807900A0933|5 18|non-cirrhotics
P10807900A0933|31 47|vein visualisation
P10807900A0933|53 64|% sensitivity
P10807900A0933|66 77|% specificity
P10807900A0933|167 178|hypertension
P10807903A0362|15 37|tail substitution mutants
P10807903A0362|69 85|agonist affinities
P10807903A0362|115 125|D1 receptors
P10807903A0362|141 153|ligand binding
P10807903A0362|176 197|cAMP accumulation assays
P10807903A0362|212 222|D1 receptors
P10807903A0362|229 243|exhibit receptor
P10807903A0362|266 279|responsiveness
P10810083A1283|57 71|zinc finger motif
P10810294A0730|0 13|Stat activation
P10810294A0730|50 70|reporter gene induction
P10811079A0555|15 29|color perception
P10811079A0555|47 62|epilepsy patients
P10811079A0555|74 94|vigabatrin monotherapy
P10811079A0555|105 120|epilepsy patients
P10811079A0555|132 155|carbamazepine monotherapy
P10811079A1277|5 21|SPP2 screening test
P10811804A0000|27 45|kinase phosphatase-3
P10811804A0000|58 79|specificity phosphatase
P10811804A0800|48 59|docking sites
P10811804A0800|69 89|target substrates Elk-1
P10811908A0938|0 24|HPLC phosphopeptide mapping
P10811908A0938|25 43|amino acid sequencing
P10814989T0000|0 23|Hepatitis C virus infection
P10815410A0000|41 60|neuroendocrine system
P10815807A1271|23 35|transcription
P10815807A1271|53 65|c-Myb promoter
P10815807A1271|103 113|T-cell lines
P10819327T0000|0 14|C. elegans KLP-11
P10819327T0000|37 55|sea urchin kinesin-II
P10819327T0000|59 94|mouse KIF3A/KIFB/KAP3 kinesin complexes
P10820829T0000|14 32|Brosimum acutifolium
P10820904A0000|17 30|encephalopathy
P10820904A0000|77 88|liver failure
P10820904A0000|107 118|liver disease
P10821836A0842|21 32|S transcripts
P10821836A0842|64 80|sense S transcripts
P10822117A1386|69 80|observations
P10822117A1386|114 127|subject-models
P10823837A1213|35 50|YLL031c transfers
P10823837A1213|54 74|ethanolaminephosphate
P10823837A1213|131 144|GPI lipid anchor
P10823837A1213|170 203|Gpi7p transfer ethanolaminephosphate
P10823961A0664|58 77|DRIP/TRAP/ARC complex
P10823961A0664|110 122|transcription
P10823961A0664|136 147|interactions
P10824485A0393|60 76|T lymphocyte counts
P10824958A1109|86 100|broiler breeders
P10825000A1245|3 24|gene amplification model
P10825200T0000|11 32|protein tyrosine kinases
P10825200T0000|35 47|interleukin-2
P10825200T0000|138 151|STAT activation
P10825293T0000|19 38|N-cadherin-Fc chimera
P10825293T0000|61 80|cell contact formation
P10825293T0000|81 92|contribution
P10825294A0473|71 82|BSP promoters
P10825294A0473|153 164|AML C terminus
P10825294A0473|202 218|pentapeptide VWRPY
P10826861A0000|13 34|immunoglobulin products
P10826861A0000|37 54|plasma cell neoplasm
P10826861A0000|78 91|manifestations
P10826861A0000|101 114|hyperviscosity
P10826861A0000|126 141|cryoglobulinemia
P10826946A1198|0 12|Investigation
P10827952A0158|66 83|bromodomain modules
P10827952A0158|123 139|histone H4 peptides
P10828022A0877|0 18|Endostatin treatment
P10828022A0877|47 69|tyrosine phosphorylation
P10828591A0080|45 56|cDNA sequence
P10828591A0080|83 95|transcript map
P10828591A0080|114 128|markers D11S1765
P10829973T0000|0 24|Iodine deficiency disorders
P10830395A0408|3 18|network evolution
P10831972A0744|58 70|endometriosis
P10831972A1091|32 44|endometriosis
P10831972A1091|110 135|leuprolide acetate injection
P10833461A0603|71 87|length UGT2B7 probe
P10833486A0598|41 53|triglycerides
P10833486A0598|70 92|alanine aminotransferase
P10834707A1533|32 55|platelet activating factor
P10834707A1533|95 107|treatment time
P10834781A0693|51 64|residence times
P10834781A0693|77 91|plasma clearance
P10835355A0225|17 37|zinc finger protein Gis1
P10835355A0225|76 91|rim15Delta defect
P10835355A0225|135 146|derepression
P10835485A0941|27 38|linker domain
P10835485A0941|70 85|sequence identity
P10835485A0941|97 113|amino acid residues
P10835732A0911|20 36|cholesterol levels
P10836542A0363|41 52|UV-A waveband
P10836786A0516|33 43|RNA subunits
P10836786A0516|46 59|enzyme function
P10836786A0516|63 82|substrate specificity
P10836786A0516|95 111|hairpin structures
P10836786A0516|128 138|RNase MRP RNA
P10837126A1004|44 58|signaling factor
P10837126A1004|90 100|marker genes
P10838139A1447|13 23|Ha-ras codon
P10838399A0525|33 45|lung infection
P10838399A0525|58 68|bone disease
P10838399A0525|72 93|reconstruction artifact
P10838531A0675|0 10|Tumor stages
P10839470A1148|21 40|percentage reductions
P10839470A1148|88 102|measure analysis
P10839547A0978|22 32|CTCF binding
P10839547A0978|46 59|DNA methylation
P10839593A0000|42 54|amphotericin B
P10839593A0000|139 150|HIV infection
P10840001A0188|0 18|Mucin gene expression
P10841537A0669|51 62|interactions
P10841593A0780|38 57|cigarette consumption
P10841593A0780|77 88|availability
P10841593A0780|91 105|nicotine patches
P10843716A0406|3 15|tryptase locus
P10843810A0802|80 98|tyrosine phosphatase
P10845522A0000|56 87|99mTc-sestamibi scintimammography
P10845522A0000|118 130|breast lesions
P10846054A0573|91 102|accumulation
P10846054A0573|105 118|progeny LIYV RNA
P10846054A0573|177 194|LIYV RNA replication
P10846069T0000|51 72|parainfluenza virus type
P10846069T0000|76 88|transcription
P10848605T0000|0 14|Phosphorylation
P10848605T0000|17 32|tyrosine residues
P10848605T0000|38 49|kinase domain
P10848605T0000|53 71|juxtamembrane region
P10848605T0000|118 129|Eph receptors
P10848993A0000|7 19|DNA sequencing
P10848993A0000|35 61|methylmalonyl-CoA mutase gene
P10848993A0000|93 120|Amycolatopsis mediterranei U32
P10848993A0000|175 203|serine/threonine protein kinase
P10850329A0248|62 73|chemotherapy
P10850329A0248|139 151|cell carcinoma
P10850453A0713|111 129|TGF-beta1 inhibition
P10850453A0713|163 183|V12Ha-Ras transfection
P10850453A1292|31 48|prostate carcinomas
P10850453A1292|56 80|Ras/MAPK pathway activation
P10850453A1292|100 114|growth advantage
P10850453A1292|126 144|TGF-beta1 production
P10850719A0680|0 12|Vbeta segments
P10850719A0680|26 45|DJbeta rearrangements
P10850719A0680|97 109|compatibility
P10850719A0680|112 123|Vbeta 23-RSSs
P10850719A0680|127 138|Jbeta12-RSSs
P10850849A0730|7 20|administration
P10850849A0730|21 33|AUC0-infinity
P10850849A0730|48 58|microg x h/ml
P10850849A0730|85 104|maximum concentration
P10850849A0730|162 175|absorption time
P10850849A0730|196 210|bioavailability
P10851089A1248|23 42|cell cycle progression
P10851089A1248|61 74|ubiquitination
P10851267A0000|8 26|transcription factor
P10851267A0000|40 59|cell cycle progression
P10852460A0170|3 15|relationships
P10852460A0170|21 39|blood concentrations
P10852460A0170|42 56|thyroid hormones
P10852460A0170|82 97|alpha-tocopherol
P10852460A0170|195 209|SENIEUR protocol
P10852485A0477|41 62|chromosome deletion line
P10852953A0000|0 13|Investigations
P10852953A0000|92 106|field potentials
P10852953A0000|112 130|gamma frequency range
P10853778A0316|6 21|surgery bone cysts
P10853850A1103|82 102|inhalation provocation
P10854004A0788|49 60|FVR responses
P10854004A0788|63 75|noradrenaline
P10854004A0788|89 101|acetylcholine
P10854004A0788|105 117|nitroprusside
P10854699A0424|5 15|FGF-AS cDNAs
P10854699A0424|69 82|splice variants
P10854699A0424|112 125|FGF-AS sequence
P10855690A0870|59 71|hPL-B enhancer
P10855793A1418|0 15|Characterization
P10855793A1418|102 115|identification
P10855796A1160|13 35|RNA hybridization studies
P10855796A1160|66 84|EphA8 gene expression
P10856298A0798|0 11|Transfection
P10856298A0798|60 76|hamster ovary cells
P10856491A0178|19 34|Paris VII hospital
P10856491A0178|61 72|embolization
P10856805T0000|0 29|Improving fissure sealant quality
P10857215A0000|3 24|Menopause-Rating-Scale
P10857262A0186|22 35|fruA transcript
P10857262A0186|72 83|type A protein
P10857751A0304|13 25|mouse ortholog
P10857751A0304|26 39|Mharp/Smarcal1
P10857751A0304|55 83|Caenorhabditis elegans ortholog
P10857751A0304|108 122|GenBank database
P10858355A0920|0 11|Sparfloxacin
P10858355A0920|15 27|clinafloxacin
P10858355A0920|48 72|Enterococcus faecium SF2149
P10858355A0920|76 100|Enterococcus faecalis WH245
P10858988A0786|6 19|tryptase levels
P10860131A0847|0 15|Tolterodine users
P10860752A1601|29 41|binding domain
P10860752A1601|74 87|autoregulation
P10860752A1601|90 126|bacteriophage T4 DNA polymerase synthesis
P10860827A0399|101 114|CSX1 expression
P10860827A0399|117 130|cardiomyocytes
P10860846A0480|46 65|AP2 core binding region
P10860846A0480|74 98|cotransfection experiments
P10860846A0480|106 124|AP2 expression vector
P10860846A0480|166 188|HGF gene promoter activity
P10861080A0433|25 36|IkappaBalpha
P10861080A0433|37 62|IkappaBalpha overexpression
P10861086A0259|2 26|reconstitution experiments
P10861086A0259|135 153|gain-of-function Csk
P10861086A0259|203 214|phagocytosis
P10861086A0904|110 130|phagocytosis signaling
P10861906A0999|3 20|delta srb10 mutation
P10861906A0999|40 55|transcript levels
P10861906A0999|118 132|transcript level
P10861906A0999|196 207|DNA synthesis
P10861906A1479|65 80|transcript levels
P10861906A1479|103 120|nitrogen starvation
P10861906A1479|151 162|alkalization
P10861909A0502|162 173|nmt1 promoter
P10861909A0502|215 237|transcription efficiency
P10861909A0502|265 275|cloning site
P10861909A0502|305 320|restriction sites
P10863048A0000|34 44|cord lesions
P10863352T0001|0 12|Franz Schubert
P10864271A0504|30 42|S. argyrostoma
P10864271A0504|48 60|dissemination
P10864271A0504|63 79|Trichinella larvae
P10864496A0401|3 32|equilibrium dissociation binding
P10864496A0401|71 91|nrgAB promoter fragment
P10864641A1400|103 122|influenza virus growth
P10864989A0484|10 21|introduction
P10864989A0484|157 174|separation efficacy
P10864989A0484|180 193|separation time
P10865422A0138|16 28|serum ferritin
P10865422A0138|90 108|iron supplementation
P10865838A0000|19 30|growth factor
P10865940A0000|14 44|agent pyrrolidine dithiocarbamate
P10865940A0000|138 156|NF-kappaB activation
P10866323A0666|28 48|SIE-1 hypermethylation
P10866323A0666|51 66|p21WAF1 induction
P10866323A0666|69 82|STAT activation
P10866689A0295|8 21|SAOS-2 cell line
P10866689A0295|49 63|reporter plasmid
P10866689A0295|77 92|tal-1 binding site
P10866689A0295|132 145|tal-1-E12-Lmo2
P10866689A0295|149 176|tal-1-E12-Lmo2-Ldb1 complexes
P10866689A0295|190 209|tal-1-E12 heterodimer
P10866886A1277|60 77|mu-receptor agonist
P10867199A0230|128 139|insect orders
P10867496T0001|0 16|Neurofibromatosis
P10867496T0001|42 64|Morbus von Recklinghausen
P10868488A0921|73 89|testosterone level
P10869076A1384|140 163|transcription termination
P10869465A1054|6 18|hybridization
P10869465A1054|63 79|expression changes
P10869465A1054|128 141|germ cell stages
P10870043A0621|3 16|administration
P10870043A0621|22 32|GnRH agonist
P10870043A0621|43 60|bone mineral density
P10870043A0621|93 104|control group
P10870391T0034|43 56|travel diarrhea
P10871045A1221|43 54|C/EBP isoform
P10871045A1221|71 83|stellate cells
P10871045A1221|100 115|C/EBPbeta protein
P10871045A1221|119 134|C/EBPbeta binding
P10871045A1221|146 161|C/EBP binding site
P10871045A1221|204 215|acetaldehyde
P10871347A0477|0 15|Mutation analysis
P10871347A0477|35 45|motif TCCCCT
P10871347A0477|59 74|PyRo1 interaction
P10871379A0261|13 35|transactivation function
P10871412A0369|37 55|focus formation assay
P10871842A0988|21 40|proteasome inhibition
P10871842A0988|48 59|upregulation
P10871842A0988|79 105|transcription factor families
P10871842A0988|125 138|stress response
P10871842A0988|142 154|proliferation
P10872473A2286|3 15|ATR-X syndrome
P10872473A2286|60 70|X chromosome
P10872473A2286|120 133|gene expression
P10872535A0000|72 83|birthweights
P10872535A0000|104 117|susceptibility
P10872535A0000|170 189|glucose tolerance test
P10872535A0000|238 259|birthweight differences
P10872535A0000|272 284|abnormalities
P10872756A1325|12 33|randomization imbalance
P10872756A1325|94 105|motor deficit
P10872756A1325|147 162|dose control group
P10872827A0000|0 16|Penicillin acylase
P10872831A0000|16 26|sequence tag
P10872831A0000|49 70|erythropoietin receptor
P10872831A0000|93 103|EST database
P10873158A0000|60 73|gene expression
P10873286X0000|0 11|GAP JUNCTIONS
P10873386A0000|74 86|20S proteasome
P10873387A0816|39 53|Cacna1f gene maps
P10873387A0816|77 98|mouse synaptophysin gene
P10873388A0623|12 23|Rhotekin cDNA
P10873388A0623|32 52|Northern hybridization
P10873388A0623|186 196|lung tissues
P10874044A0647|9 21|co-expression
P10874044A0647|114 128|pE1-luc activity
P10874151A0000|10 31|Gamma knife radiosurgery
P10878398A0542|40 51|leptin levels
P10878398A0542|89 100|CAPD patients
P10878606A0876|97 108|interactions
P10878675A1278|30 47|antagonist idazoxan
P10878675A1278|97 113|energy expenditure
P10878944A0000|8 37|diphtheria toxin polymer particle
P10878944A0000|134 152|Childhood Infections
P10880702A0966|113 125|sensitization
P10881275T0000|10 24|serum IgM binding
P10881275T0000|27 40|GM1 ganglioside
P10882163A1077|0 17|Objective responses
P10882163A1077|90 106|aminoglutethimide
P10882163A1077|151 169|aromatase inhibitors
P10882213A0163|117 131|myositis patient
P10882213A0163|171 197|dermatomyositis sine myositis
P10882213A0163|249 263|classifications
P10882213A0163|404 419|myositis patients
P10882213A0163|468 482|disease activity
P10882462T0000|12 28|tissue engineering
P10882850A0000|0 11|Endonuclease
P10882850A0000|38 51|DNA glycosylase
P10882850A0000|84 105|pyrimidine base residues
P10885708T0000|8 23|bile duct blockage
P10885731A0915|38 56|synthesis conditions
P10885731A0915|59 69|block length
P10885731A0915|73 85|crystallinity
P10885731A0915|117 129|crystallinity
P10885750A0236|80 94|organ physiology
P10887912A0740|17 34|maximum EMG activity
P10887912A0740|71 87|temporalis muscles
P10887912A0740|137 147|subjects bit
P10889399A0243|3 22|detection success rate
P10890911A0470|47 58|HMG box domain
P10890911A0470|82 92|Wnt pathways
P10890911A0470|112 124|transcription
P10890911A0470|130 152|Xenopus homeobox gene twin
P10891093A0000|3 23|transmembrane topology
P10891093A0000|28 40|exchanger NHE3
P10891093A0000|67 91|transcription/translation
P10891093A0000|104 116|fusion vectors
P10891093A0000|131 157|membrane insertion properties
P10891093A0000|160 172|cDNA sequences
P10891093A0000|189 200|NHE3 membrane
P10891286A0000|12 23|titin/myosin
P10891286A0000|29 45|chain kinase family
P10891286A0000|70 81|organization
P10891286A0000|87 110|actin/myosin cytoskeleton
P10891441A0871|12 35|pTyr317 Shc phosphopeptide
P10891441A0871|87 106|phosphatidylinositol
P10891441A0871|144 159|mass spectrometry
P10891489A0152|32 46|HMG-I/Y proteins
P10891489A0152|71 83|proliferation
P10891489A0152|94 107|transformation
P10891489A0152|157 168|pathogenesis
P10891632A0435|3 34|naltrexone/lofexidine combination
P10891632A0435|83 100|withdrawal syndrome
P10891632A0435|126 142|treatment schedule
P10891632A0435|172 189|withdrawal symptoms
P10891632A0435|203 214|side-effects
P10892300A0268|82 103|locomotor abnormalities
P10893243T0000|44 89|chaperonin subunit gene Ccta/t-complex polypeptide
P10893243T0000|93 127|selenocysteine tRNA gene transcription
P10893243T0000|138 167|factor family zinc finger proteins
P10893258T0000|11 25|protein response
P10893258T0000|64 88|membrane protein biogenesis
P10893258T0000|103 125|reticulum quality control
P10894149T0000|124 141|orphan receptors SF1
P10894149T0000|189 203|receptor alpha-1
P10894816A0836|13 27|reporter plasmid
P10895417A0000|84 109|DepoFoam drug delivery system
P10895417A0669|32 46|DepoFoam vehicle
P10895417A0669|81 95|food consumption
P10895417A0669|103 120|hindlimb muscle tone
P10895417A0669|124 138|body temperature
P10895851A0696|0 16|Bailey Instruments
P10895851A0696|20 39|Owen Mumford filaments
P10896008A0531|0 11|PARTICIPANTS
P10896859A0000|11 26|water deprivation
P10896859A0000|40 50|Na excretion
P10896859A0000|162 173|steroid sheep
P10896859A0838|48 58|Na retention
P10897233A1057|29 40|Nazareth area
P10897973T0001|0 24|Antithrombin III deficiency
P10897973T0001|60 72|Thrombosis ABC
P10897973T0001|83 94|antithrombin
P10898795A0527|19 37|histone deacetylases
P10899128A0661|34 59|transcription factor complex
P10899128A0661|87 101|forkhead protein
P10899128A0661|119 130|implications
P10899128A0661|158 171|gene expression
P10899142A0000|35 55|Genome Project database
P10900129A0138|0 16|Degenerate primers
P10900129A0138|58 71|CYP3A sequences
P10900269A0396|56 69|polypurine site
P10900269A0396|98 110|recombination
P10901133A0381|0 15|Methyllevamisole
P10902348A0566|0 15|Resistance ratios
P10902348A0566|27 38|field strains
P10902348A0566|135 148|glass jar method
P10903440A0515|53 65|testes tissues
P10903495A0533|3 21|gel retardation assay
P10903583T0000|51 69|spine motion analyser
P10903733A0540|0 31|Coimmunoprecipitation experiments
P10903733A0540|121 140|TRAF3 adaptor proteins
P10903837A1208|39 54|goldfish Vsx1 gene
P10903837A1208|83 107|Gene Nomenclature Committee
P10903843A0447|14 25|localization
P10903877A0879|65 75|calphostin C
P10903877A0879|108 118|3TP activity
P10903877A0879|134 150|ERK kinase activity
P10904191A0000|71 91|Gen-Probe Incorporated
P10905349A0329|44 69|XPF endonuclease superfamily
P10905352A0000|9 20|plasmid pCLU1
P10905352A0000|111 122|plasmid pGKL2
P10906176A0000|84 94|mouse genome
P10906999T0000|42 58|chemiluminescence
P10907348A0508|11 22|examinations
P10907348A0508|68 84|PTH concentrations
P10907348A0508|113 125|bone isoenzyme
P10907971A0806|0 11|Atorvastatin
P10907971A0806|36 60|HMG-CoA reductase inhibitor
P10907971T0000|28 59|HMG-CoA reductase inhibitor therapy
P10907971T0000|80 90|CURVES study
P10908317A1459|134 153|estradiol sensitivity
P10908317A1459|183 197|transactivation
P10908364A0000|21 32|DNA structure
P10908462A3159|3 15|effectiveness
P10908478A0717|0 16|SELECTION CRITERIA
P10908478A0717|51 63|schizophrenia
P10909973A1508|49 62|cotransfection
P10909973A1508|93 114|consensus serine residue
P10909973A1508|148 162|phosphorylation
P10910073A0876|10 25|PDGFbetaR fusions
P10910073A0876|97 109|amplification
P10910439A1196|22 33|hypertension
P10910439A1196|41 51|protein load
P10910908A0767|27 51|PI3K-Akt activation pathway
P10913094A0424|4 15|DNA fragments
P10913094A0424|99 124|gel mobility shift-PCR method
P10913172A0442|51 63|Rad24 function
P10913276A0510|77 95|PLC-gamma1 SH3 domain
P10913276A0684|13 29|expression studies
P10913304A1180|2 13|kb transcript
P10915780A1063|0 18|Wnt-1 overexpression
P10915780A1063|50 61|cyclin D1 mRNA
P10915780A1063|73 86|overexpression
P10915780A1063|140 150|ILK activity
P10915780A1063|154 167|cyclin D1 levels
P10917402T0000|21 34|administration
P10917402T0000|37 49|amitriptyline
P10918164A0878|8 25|regression analysis
P10918164A0878|129 147|% confidence interval
P10918440T0000|0 28|Erythema exsudativum multiforme
P10918440T0000|97 114|blood stem cell donor
P10918572A1547|5 16|interactions
P10918572A1547|63 77|ErbB2 activation
P10918572A1547|108 119|consequences
P10918572A1547|144 162|TGF-alpha precursors
P10918572A1547|185 197|ErbB signaling
P10918596A0000|26 38|p53 C-terminus
P10918599A0071|53 64|G1/S boundary
P10918612A0000|3 24|transcription factor Jun
P10918612A0000|66 78|growth signals
P10918612A0000|108 121|gene expression
P10918943T0000|48 62|agent almokalant
P10919971A0606|36 53|neutrophil response
P10919971A0606|116 137|creatine kinase activity
P10919971A0606|172 183|muscle repair
P10920186A0528|50 60|fusion point
P10921197A0179|0 11|Measurements
P10921197A0179|43 66|treatment planning systems
P10921197A0179|83 97|ADAC Pinnacle3 V4
P10925159A1353|146 165|salt-wash preparation
P10925207A0634|29 40|kb transcript
P10926776A0731|9 20|PDP1 isoforms
P10926776A0731|32 43|substitution
P10928179A0101|50 67|sentinel lymph nodes
P10928337A0590|45 58|erythropoietin
P10928477A0764|28 42|PFA-100 analyzer
P10928477A0764|75 90|platelet function
P10928477A0764|105 119|platelet defects
P10928477A0764|129 139|shear stress
P10928477A0764|149 166|patient populations
P10930526A0174|40 51|PL scramblase
P10930526A0174|70 80|mouse origin
P10931927A0655|7 20|oligomer duplex
P10931927A0655|38 52|template-primer
P10931927A0655|70 83|Klenow fragment
P10931927A0655|101 113|DNA polymerase
P10931927A0655|128 140|transcriptase
P10931927A0655|152 171|telomere DNA sequences
P10931927A0655|215 225|template DNA
P10931950A0869|36 47|tumor lysates
P10931950A0869|94 104|T187A mutant
P10931960A0630|9 26|avirulence activity
P10931960A0630|71 86|activation domain
P10931960A0630|113 128|activation domain
P10931960A0630|136 148|herpes simplex
P10931960A0630|154 164|protein VP16
P10932196A0359|55 66|XLRP patients
P10932196A0359|82 95|linkage studies
P10932329A0597|67 91|sulcus cecocolicus dorsalis
P10932527A0947|59 75|epithelialization
P10932527A0947|95 106|inflammation
P10932527T0000|3 15|effectiveness
P10932527T0000|21 44|haemodialysate Solcoseryl
P10932527T0000|64 75|wound healing
P10932679A0049|33 47|diet composition
P10933154A1118|64 79|donor transplants
P10933728A1398|59 78|EBNA2 transactivation
P10933728A1398|94 109|hnRNP protein AUF1
P10933728A1398|190 207|CBF1 binding element
P10933728A1398|226 239|responsiveness
P10933732A0000|58 70|reading frames
P10933732A0000|116 135|transcription factors
P10934073A1433|26 37|CHIME monitor
P10934310A0698|0 12|DATA SYNTHESIS
P10934640A1114|0 9|TB bone area
P10934751T0001|0 12|CREST syndrome
P10934751T0001|30 41|significance
P10935488A1033|0 11|Troglitazone
P10935488A1033|35 53|PPARgamma target gene
P10935488A1033|83 100|acid binding protein
P10935488A1033|141 168|bladder cancer differentiation
P10935880A1049|44 54|NCP BVDV type
P10936051T0000|13 25|megasatellite
P10938102A0265|44 67|NS1 influenza virus protein
P10938102A0265|81 98|translation factors
P10938102A1359|174 197|influenza virus messengers
P10938102T0000|10 39|translation initiation factor 4GI
P10938102T0000|95 108|influenza virus
P10938105A0000|38 67|fibroblast growth factor receptor
P10938105A0000|102 113|sequence IAS1
P10938109A1361|87 98|growth factor
P10938113A0388|47 58|isoforms Vav2
P10938113A0388|150 160|Vav isoforms
P10938120A1093|27 48|fbp1 promoter constructs
P10938120A1093|94 107|MAPK regulation
P10938130A0338|36 52|PLZF BTB/POZ domain
P10938135A0259|36 55|transcription factors
P10938135A0259|118 148|tyrosine kinase signaling pathways
P10938135A0259|184 203|growth factor receptor
P10939030A0986|37 49|response rate p
P10939030A0986|99 115|granulocytopenia p
P10939030A0986|133 144|neutropenia p
P10939785A0540|46 68|ACE inhibitor perindopril
P10939785A0540|130 145|contraindication
P10940413A1153|76 101|stress concentration effects
P10940553A0912|41 58|tissue-specificity
P10940553A0912|94 115|hPer1 gene transcription
P10940557A1687|30 70|Broad Complex Z2 transcription factor elements
P10940562A0379|0 15|Sequence analysis
P10940562T0000|20 35|characterization
P10940562T0000|41 53|oas gene family
P10940562T0000|62 75|O-acetylserine
P10940562T0000|118 137|cysteine biosynthesis
P10940562T0000|140 158|Arabidopsis thaliana
P10940892A0573|20 37|susceptibility loci
P10942587A0981|18 37|phosphorylation state
P10942587A0981|98 110|HPV E6/E7 genes
P10942599A1298|7 22|characterization
P10942599A1298|38 54|Hoxa-1 target genes
P10942599A1298|92 104|Hoxa-1 protein
P10942599A1298|110 133|differentiation processes
P10942599A1298|150 162|embryogenesis
P10943891A1062|12 24|U6-U57 mutants
P10943891A1062|67 87|splice site recognition
P10945010T0001|9 20|daunorubicin
P10945010T0001|23 38|induction therapy
P10945781A0412|9 24|Aeromonas strains
P10945781A0412|33 47|V cholerae non-O1
P10945781A0412|63 81|enterotoxin activity
P10946303A0000|48 63|cyclooxygenase-2
P10946303A0000|82 94|PGE2 formation
P10947274A0839|3 13|therapy time
P10947840A0762|29 42|18S ribosome RNA
P10950398T0100|0 19|Losartan Intervention
P10950415A0866|43 56|Terson syndrome
P10950924A0393|9 21|hybridization
P10950924A0393|24 36|brain sections
P10950935A0111|12 23|manipulation
P10951579A1238|5 21|gamma-irradiation
P10951579A1238|103 116|gene expression
P10951848A0230|0 11|Mobilization
P10951848A0230|16 31|cyclophosphamide
P10951848A0230|53 69|stimulating factor
P10951848A0230|131 146|quality autograft
P10951848A0230|186 201|megachemotherapy
P10952828A2638|82 107|ejection fraction estimation
P10952828A2638|110 129|heart failure patients
P10952828A2638|189 200|image quality
P10954093A0000|11 23|DNA transposon
P10954093A0000|93 115|fungus Podospora anserina
P10954564A1262|71 81|gene product
P10954913A0152|31 51|Atlantic halibut Mx gene
P10954913A0152|68 83|liver cDNA library
P10955998A1124|25 43|glycosylase activity
P10955998A1124|96 107|DNA mutations
P10958271A0365|52 63|measurements
P10958271A0365|81 96|ejection fraction
P10958271A0365|151 164|perfusion SPECT
P10958271A0365|169 208|equilibrium radionuclide angiocardiography
P10958271A0365|263 278|echocardiography
P10958456A0529|140 160|polyadenylation signal
P10958673A0142|44 58|protein response
P10958673A0142|87 109|ER stress response element
P10958688A0265|1 23|Y. lipolytica Kar2p mutant
P10958688A0265|64 74|Sls1p mutant
P10958688A0265|135 146|conformation
P10958698A0280|59 72|Cse4p N terminus
P10958698A0485|109 121|Cse4p function
P10959838A0153|2 14|invertebrates
P10959838A0153|31 43|fusion protein
P10959838A0153|63 82|nitrilase superfamily
P10961046A0342|0 13|Platelet counts
P10961046A0342|46 64|von Willebrand factor
P10961585A0273|3 16|manifestations
P10961585A0273|38 53|thrombocytopenia
P10962564A0883|1 26|beta2 RARE reporter construct
P10962564A0883|74 84|sense strand
P10962738A0000|0 12|Consciousness
P10963735A0193|132 146|dialysis session
P10963735A0193|177 205|polyacrylonitrile membrane AN69
P10963735A0651|8 23|plasma parameters
P10964833A1696|11 22|participants
P10965135A0735|0 15|Promoter activity
P10965135A0735|46 59|cotransfection
P10965135A0735|75 86|mos oncogenes
P10965135A0735|90 107|oncogene inhibition
P10965135A0735|176 190|MAP kinase kinase
P10965135A0735|194 209|inhibitor PD98059
P10965135A1207|83 100|cell transformation
P10965135A1207|151 178|transcription factor complexes
P10965830A0305|0 12|INTERVENTIONS
P10965830A0305|37 48|PCO2 tensions
P10965905A1618|17 29|Akt activation
P10965905A1618|72 84|concentration
P10965905A1618|123 143|wortmannin sensitivity
P10965905A1618|192 210|MAP kinase activation
P10965905A1618|306 324|MAP kinase activation
P10965905T0000|0 14|Insulin receptor
P10965905T0000|86 108|protein kinase activation
P10967361A0000|18 33|resonance imaging
P10967361A0000|76 88|brain function
P10967531A1025|54 66|fibre necrosis
P10967531A1025|97 112|muscle fibre areas
P10967890A1120|25 36|relationship
P10967890A1120|44 56|comprehension
P10970048A0352|78 89|contrariwise
P10970048A0352|93 105|voltage values
P10972688A1272|67 82|hospitalizations
P10972980A0295|60 79|phosphatidylinositol
P10972980A0295|90 104|protein kinases A
P10972990A0526|12 22|p53 function
P10972990A0526|63 81|mutation frequencies
P10972990A0526|99 113|thymidine kinase
P10972990A0526|142 178|hypoxanthine phosphoribosyl transferase
P10972990A0966|33 50|chromosome painting
P10972990A0966|126 144|chromosome deletions
P10972990A0966|145 158|amplifications
P10972990A0966|170 183|translocations
P10973151A0883|46 60|schistosomiasis
P10973151A0883|135 146|interference
P10973385A1423|122 132|artery nodes
P10973385A1423|133 145|esophagectomy
P10973385A1423|155 169|survival benefit
P10973400A0664|65 88|flexion-distraction Stage
P10974541A0389|11 25|K562 cDNA library
P10975465A0134|8 21|cDNA clone NFBD1
P10975465A0134|135 145|BRCT domains
P10975465A0134|151 165|carboxy terminus
P10975465A0134|166 182|amino acid residues
P10980416T0000|11 27|hormone regulation
P10980416T0000|30 45|bone sialoprotein
P10980416T0000|49 65|gene transcription
P10980416T0000|102 122|transcription factor-1
P10980416T0000|138 155|rat BSP gene promoter
P10981094A0779|6 18|target BP goals
P10981094A0779|35 45|Sixth Report
P10981094A0779|53 74|Joint National Committee
P10981094A0779|162 177|pretreatment risk
P10982076A0000|32 49|morbidity recording
P10982076A0000|169 185|influenza activity
P10982391A0425|156 167|membrane core
P10982391A0425|190 207|transmembrane spans
P10982825A0363|49 63|Mot3 binding site
P10983857A0923|46 56|PD reduction
P10983979T0000|50 60|U5 tri-snRNP
P10983979T0000|98 116|spliceosome assembly
P10984122A0911|36 46|DNA mixtures
P10984122A0911|57 68|vector mU6-C1
P10987280A0604|3 19|amino acid sequence
P10987280A0604|22 33|matrilysin-2
P10987280A0604|47 62|threonine residue
P10987301A0332|124 134|herpes virus
P10987301A0332|143 153|herpes virus
P10987301A0332|179 190|angiogenesis
P10987301A0332|236 247|growth factor
P10991648T0000|38 50|half syndromes
P10992299A0745|29 42|gene expression
P10992299A0745|58 70|tumorigenesis
P10992299A0745|71 84|PI12 expression
P10992299A0745|113 129|tumor brain tissues
P10992299A0745|138 157|brain cancer cell lines
P10993773A0717|44 54|min ischemia
P10993773A0717|92 104|control values
P10993773A0717|142 152|min ischemia
P10993787A0369|17 28|MSNA increase
P10995121A0569|10 38|Standard Reference Material 1846
P10995121A0569|39 51|Infant Formula
P10995121A0569|78 90|mg vitamin K/kg
P10995751A0093|51 62|protein-beta
P10995751A0093|80 96|gene transcription
P10995751A0093|110 127|IFN response element
P10997330A0361|0 19|Northern blot analysis
P10997863A0753|5 15|TLE patients
P10997863A0753|47 58|seizure focus
P10997863A0753|69 79|FLE patients
P10997863A0753|109 120|seizure focus
P10997904A1258|3 15|Spo0F residues
P10997904A1258|62 79|response regulators
P10997904A1258|153 181|response regulator-kinase pairs
P11000203A0752|107 118|K-Rev mutants
P11000250A0200|20 33|plasma membrane
P11000250A0200|58 69|JAK molecules
P11000266T0000|0 13|Identification
P11000266T0000|71 91|alpha-fetoprotein gene
P11000521A0588|21 37|signaling pathways
P11000521A0588|67 80|transformation
P11000521A0588|100 110|NIH3T3 cells
P11000521A0588|145 159|phosphorylation
P11000521A0588|162 187|insulin receptor substrate-2
P11000521A0588|220 247|phosphatidylinositol 3-kinase
P11000521A0588|261 274|protein kinase B
P11002236A0328|65 83|retrospective search
P11002236A0328|104 115|Associations
P11002236A0328|119 137|Pediatric Hematology
P11002236A0328|141 155|Oncology centers
P11003471A1149|33 45|ToLCV isolates
P11003641A0811|163 175|transcription
P11003652A0961|48 64|pheromone response
P11003653A0198|61 85|beta-globin locus construct
P11003653A0198|114 133|beta-globin switching
P11003669A0000|94 112|ErbB-2 juxtamembrane
P11003669A0000|116 128|kinase domains
P11003805A0443|117 128|oesophagitis
P11003807A0303|42 53|oesophagitis
P11003807A0303|100 116|oesophageal damage
P11004369A0000|22 33|relationship
P11004369A0000|70 91|color Doppler ultrasound
P11004369A0000|92 109|microvessel density
P11004369A0000|132 149|growth factor levels
P11005808A1082|44 60|ERK MAPK activation
P11005808A1082|70 82|cell viability
P11005831A0242|23 35|leucine zipper
P11005831A0242|155 175|element binding protein
P11006283A1180|66 77|homopolymers
P11006283A1180|119 143|mRNA maturation/metabolism
P11006284T0000|70 95|insulin receptor substrate-1
P11006284T0000|99 126|phosphatidylinositol 3-kinase
P11006331A0319|25 39|allotetraploids
P11006331A0319|72 84|abnormalities
P11007509A1271|5 17|PMR target area
P11007509A1271|76 86|flow reserve
P11007509A1271|95 106|wall segments
P11007509A1271|147 161|stress perfusion
P11007777A0813|10 30|intron/exon boundaries
P11007777A0813|85 108|aspartyl beta-hydroxylase
P11007949A1395|20 38|inactivation mutants
P11007954A0170|3 14|growth factor
P11007954A0170|85 98|exchange factor
P11007961A0930|24 37|PR65/A subunits
P11007961A0930|92 104|PP2A inhibitor
P11007968A0255|92 107|oligonucleotides
P11008139T0000|22 46|pattern discrimination task
P11008420A0580|41 57|segment deviations
P11008420A0580|71 84|complex changes
P11008420A0580|107 122|characterization
P11011139A0000|32 46|SIN4 gene product
P11011139A0000|62 76|mediator complex
P11011139A0000|91 103|RNA polymerase
P11011139A0000|176 193|chromatin structure
P11012568A0192|14 29|hypersensitivity
P11012671A0576|49 67|Gadd45gamma promoter
P11012671A0576|134 151|mobility shift assay
P11012671A0576|159 178|reporter gene analysis
P11012680A0676|0 12|Src activation
P11012680A1020|50 72|calcium chelator BAPTA-AM
P11012680A1020|164 182|PLCgamma binding site
P11012680A1020|199 217|ERK2 phosphorylation
P11013079A0927|8 30|transcription start sites
P11013079A0927|45 67|primer extension analysis
P11013079A0927|85 106|transfection constructs
P11013079A0927|192 203|SV40 promoter
P11014197A0339|7 24|inhibitor scaffolds
P11014213A1019|76 93|receptor activation
P11014213A1019|147 161|receptors GAL-ER
P11014213A1019|236 258|transcription factor GAL4
P11014213A1019|278 292|CAT reporter gene
P11014215A1092|13 27|deletion studies
P11014215A1092|51 61|DNA fragment
P11014215A1092|86 105|translation start site
P11014215A1092|181 195|down-regulation
P11014215A1092|203 223|GnRHR promoter activity
P11014465A0479|38 50|echodensities
P11014821T0000|3 21|LAMMER protein kinase
P11014821T0000|80 92|germline cells
P11016014A0181|55 68|susceptibility
P11016014A0181|71 84|apolipoprotein
P11016014A0181|97 108|lipoproteins
P11016014A0181|181 194|angina pectoris
P11016724A0536|26 45|99mTc-HSA nanocolloid
P11016850A0423|9 19|DNA fragment
P11017876A0787|13 31|localization studies
P11017876A0787|45 61|EGFP fusion protein
P11017876A0787|62 78|cell fractionation
P11017876A0787|82 110|protease protection experiments
P11018028A0263|48 60|protein kinase
P11018028A0263|69 83|phosphorylation
P11018264A0397|0 29|Reporter gene expression analyses
P11018264A0397|46 58|WASP promoters
P11020375A0134|20 36|Ross broiler chicks
P11020375A0134|52 66|treatment groups
P11023832A1038|91 103|lipid products
P11023832A1038|135 147|protein kinase
P11023832A1038|160 178|NF-kappaB signalling
P11023853A0188|23 39|weather conditions
P11023853A0188|91 104|laboratory data
P11023853A0188|180 196|energy expenditure
P11023853A0188|225 236|energy budget
P11023934A0855|33 46|filling pattern
P11024026A0133|98 109|dissociation
P11024036A0984|35 60|C/EBP alpha expression vector
P11024036A0984|61 82|reporter gene expression
P11024047A0626|64 89|luciferase reporter activity
P11024182A0781|12 23|collagen mRNA
P11024182A0781|81 101|pHbetaAPr-1-neo vector
P11024300A1579|23 40|amino acid sequences
P11024300A1579|43 58|peptide fragments
P11024300A1579|118 135|chromatin structure
P11024300A1579|177 188|reading frame
P11025367A1009|0 12|Abnormalities
P11025367A1009|15 35|plasma cholecystokinin
P11027027A0061|1 15|Sunset Yellow FCF
P11027027A0061|41 71|chromatography/mass spectrometry
P11027027A0061|81 102|electrospray ionization
P11027267A0752|11 30|40S ribosome fractions
P11027280A0536|24 38|phosphorylation
P11027289A0000|75 91|RNA binding protein
P11027289A0000|117 131|RNA accumulation
P11027289A0000|169 188|transposon insertions
P11027289A0321|69 86|RNA binding activity
P11027294A0483|26 57|histone acetyltransferase activity
P11027294A0483|104 121|histone acetylation
P11027294A0483|137 154|chromatin structure
P11027833A0362|0 11|Flow cytomery
P11027833A0362|22 38|cell cycle analysis
P11028131A1374|33 55|measure treatment effects
P11028131A1374|56 67|modification
P11028131T0000|0 17|Cost-effectiveness
P11028131T0000|20 36|interferon beta-1b
P11028131T0000|54 83|sclerosis disability progression
P11029045A0000|0 14|Hyperactivation
P11029045A0000|23 34|fission yeast
P11029459A0000|12 29|growth factor-beta1
P11029459A0000|48 62|tumor suppressor
P11029459A0000|66 78|tumor promoter
P11029459A0000|93 107|characteristics
P11029467T0000|91 102|factor-kappa
P11029467T0000|114 127|gene activation
P11029467T0000|163 175|cell line THP-1
P11029656A0640|19 33|junction binding
P11029704A0378|24 42|particle bombardment
P11029704A0378|45 63|tobacco leaf sections
P11029704A0378|125 139|transactivation
P11029704A0378|206 216|RY/G complex
P11029704A0378|272 286|transactivation
P11030066A0142|20 33|manifestations
P11030066A0142|36 46|brain injury
P11030066A0142|70 82|motor deficits
P11030476A0685|10 27|Rhizopus stolonifer
P11030744A0763|0 13|Overexpression
P11030744A0763|85 103|DPM synthase activity
P11031252A0646|26 41|PKC epsilon levels
P11031366T0001|0 17|Helicobacter pylori
P11031366T0001|21 35|stomach diseases
P11031773A0174|41 60|formalin induced-pain
P11032599T0000|12 26|recommendations
P11032599T0000|98 115|practice guidelines
P11032677A0230|28 39|pancreatitis
P11034392A1072|40 55|survival pathways
P11034392A1072|90 102|NF-kappaB/Rel
P11034392A1072|136 148|proliferation
P11034547A0674|117 143|homeodomain recognition sites
P11034547A1355|118 128|DBH promoter
P11034933A0389|49 63|guinea pig hearts
P11034933A0389|101 112|prolongation
P11034933A0389|122 135|repolarization
P11034933A0389|141 157|nmol/L domperidone
P11035037A0183|27 37|yeast TAF145
P11035037A0183|73 83|TBP function
P11035867A0000|59 83|wrist blood pressure monitor
P11035867A0000|84 103|Braun PrecisionSensor
P11035867A0000|142 169|ANSI/AAMI SP10-1992 guidelines
P11035867A0000|241 259|blood pressure values
P11035867A0000|280 298|blood pressure curves
P11036786A0628|50 62|target animals
P11036786A0628|76 97|Drinking Water Standards
P11036938A1162|51 63|erbB receptors
P11036938A1162|92 103|augmentation
P11036938A1162|113 128|steroid secretion
P11036938A1162|180 192|gonadotropins
P11036939A2149|52 72|planar polarity pathway
P11037759T0000|0 13|Catch-up growth
P11037759T0000|48 61|administration
P11037759T0000|81 96|agent vincristine
P11037823A1134|11 26|LSCC malformation
P11037823A1134|41 56|ear malformations
P11038042A0948|44 62|blood cell nadir count
P11038042A0948|76 93|platelet nadir count
P11038118A0000|0 12|Methyl formate
P11038118A0000|77 88|microspheres
P11038118A0000|111 122|serum albumin
P11038317A0000|41 52|RAB subfamily
P11038317A0000|103 117|membrane traffic
P11038366A1417|97 108|PP2A function
P11039341A0180|44 58|characteristics
P11039780A0770|68 79|animal models
P11039780A0770|82 95|osteoarthritis
P11039780A0770|101 111|gene therapy
P11039780A0770|170 180|gene therapy
P11039780A0770|183 205|osteoarthritis treatment
P11040101A1180|47 64|VEGF gene expression
P11040101A1180|142 154|JNK signalings
P11040101A1180|178 190|transcription
P11040219A0548|65 80|S1 homology region
P11041308A0156|54 69|gambling criteria
P11041308A0156|101 123|South Oaks Gambling Screen
P11042197A0386|60 71|dimerization
P11042199A0572|163 178|calcium elevation
P11042204A0186|24 43|phosphatidylinositol
P11042204A0186|62 80|p38 kinase activation
P11042204A0186|90 107|Akt phosphorylation
P11042703A0875|30 39|W/A Z scores
P11043469A0440|13 27|border sequences
P11043469A0440|148 160|Amadoriopines
P11044097A0422|97 115|transcription factor
P11044097T0000|47 66|transcription factors
P11044097T0000|90 114|immunodeficiency virus type
P11044105A0616|30 47|splicing suppressor
P11045180A1892|46 65|blood pressure reading
P11045180A1892|80 91|hypertension
P11045180A1892|109 122|classification
P11045607A0239|0 11|RACE analysis
P11045607A0239|28 54|transcription initiation site
P11046146A1202|4 19|diamide treatment
P11046146A1202|64 74|NFI proteins
P11046146A1202|97 110|concentrations
P11046146A1202|113 126|dithiothreitol
P11046146A1202|171 184|NFI-DNA binding
P11046148A0716|19 35|Syk ubiquitination
P11046148A0716|78 95|Nedd4 family members
P11046148A0716|113 127|destabilization
P11046148A0716|133 149|Lyn tyrosine kinase
P11046153A1052|75 89|p300 coactivator
P11049241A0659|25 47|serum PP14 concentrations
P11049889A1271|0 18|Thromboelastography
P11049889A1271|70 84|anticoagulation
P11049889A1271|107 119|weight heparin
P11050084A0000|51 63|receptor alpha
P11050084A0000|135 148|lipid oxidation
P11050168A1185|48 61|susceptibility
P11050168A1185|164 184|stability determinants
P11051364A0890|69 87|variceal eradication
P11051370A1906|54 64|HCV genotype
P11053009A0000|62 75|cyclooxygenase
P11053009A0000|90 111|prostaglandin synthesis
P11053370A0708|13 25|hybrid protein
P11053370A0708|77 100|glutathione S-transferase
P11053370A0708|122 133|Uhp signaling
P11054011A1685|68 86|locoregional control
P11054011A1685|140 157|oncology department
P11054341A0599|7 22|Glaucoma suspects
P11054341A0599|86 102|SWAP abnormalities
P11054539A0114|60 71|reading frame
P11054539A0114|132 148|amino acid residues
P11054565A0654|159 170|conservation
P11054970A0282|3 23|plexiform neurofibroma
P11054970A0282|44 56|neurofibromas
P11056007A0224|119 135|Enhancer-of-zeste
P11056019A0926|12 30|glycosylase activity
P11056019A0926|51 64|ethenocytosine
P11056019A0926|78 90|vinyl chloride
P11056019A0926|94 107|ethyl carbamate
P11058008A0159|27 38|flap necrosis
P11058008A0159|61 72|tip ischaemia
P11058119A0957|69 80|localization
P11058132A0264|19 33|% match sequences
P11058132A0264|55 70|Bacillus subtilis
P11058406A0447|52 66|circulation time
P11058406A0447|96 113|tobramycin solution
P11059777A0813|8 23|deoxynucleotidyl
P11059777A0813|44 64|nick end labeling assays
P11059777A0813|100 113|PAX3 repressors
P11059777A0813|157 171|down-regulation
P11059786A0682|0 19|VEGF promoter activity
P11059786A0682|31 43|transfections
P11059786A0682|109 128|phosphatidylinositol
P11059786T0000|9 28|growth factor receptor
P11059786T0000|77 98|growth factor expression
P11059786T0000|106 122|glioblastoma cells
P11059786T0000|143 162|phosphatidylinositol
P11062047A1208|27 38|densoviruses
P11062047A1208|44 63|genus Brevidensovirus
P11062047A1208|69 86|family Parvoviridae
P11062047A1208|120 153|virus Penaeus stylirostris densovirus
P11062067A0000|16 28|protein kinase
P11062068T0000|48 66|kinase phosphatase-1
P11062068T0000|78 89|p38 MAP kinase
P11062257A0977|7 23|class C-Vps complex
P11062257A0977|161 176|transport process
P11062274T0000|47 72|tissue plasminogen activator
P11062705A0658|55 68|cancer cell line
P11063127A0000|0 17|Signal transduction
P11063127A0000|33 47|phosphorylation
P11063127A0000|74 91|protein phosphatase
P11063169T0000|0 14|Botulinum toxin A
P11063252A0437|36 58|HSL translation start site
P11063742A0000|27 45|transcription factor
P11064829T0058|0 24|Cardiovascular risk factors
P11066245T0000|20 35|compliance review
P11067797A1306|11 24|EBCT technology
P11067797A1306|134 147|BV distribution
P11067928A0532|28 39|gene segments
P11067928A0532|62 72|Jkappa genes
P11069011A0224|0 13|SSF experiments
P11069075T0000|0 15|Characterization
P11069075T0000|19 51|Xenopus laevis CXC chemokine receptor
P11069075T0000|53 64|implications
P11069075T0000|81 95|cell development
P11069075T0000|101 116|vertebrate embryo
P11069223A0593|38 52|marrow functions
P11069307A0546|12 26|RNA2 translation
P11069307A0546|109 127|replication factor 1a
P11069307A0546|171 182|DED1 function
P11069756A2618|0 12|Abbreviations
P11069756A2618|88 110|Papillomavirus E6 protein
P11069756A2618|119 132|adhesion kinase
P11069756A2618|136 148|GRK interacter
P11069756A2618|196 227|G-protein-coupled-receptor kinase
P11069756A2618|249 261|protein kinase
P11069756A2618|339 352|exchange factor
P11069756A2618|356 375|paxillin kinase linker
P11069756A2618|394 406|phosphoserine
P11069756A2618|409 424|phosphothreonine
P11069756A2618|427 441|phosphotyrosine
P11069756A2618|445 478|growth factor receptor tyrosine kinase
P11069788A0531|67 80|difference PEEP
P11069825A0530|19 30|tuberculosis
P11069999A1602|19 30|gene products
P11070007A0136|0 12|Transcription
P11070056A0704|3 17|Cili-2 sequences
P11070056A0704|40 51|RNaseH domain
P11070056A0704|78 92|retrotransposon
P11070078A1153|48 72|Rb tumor suppressor pathways
P11071651A1308|57 71|differentiation
P11071651A1308|91 107|retinoid induction
P11071651A1308|110 126|FR-beta expression
P11071789T0000|33 45|ACE inhibitors
P11071789T0000|55 66|heart failure
P11071852A0297|95 107|chain reaction
P11071924A0588|24 40|RING finger domains
P11071924A0588|86 102|RING finger domains
P11071974A0155|97 108|lipid profile
P11071974A0155|123 141|fibrinolysis markers
P11071974A0155|145 168|plasma homocysteine levels
P11072155A0764|65 84|cell radiosensitivity
P11072155A0764|85 97|lymphocyte SF2
P11072388T0000|28 51|smoking reduction strategy
P11072388T0000|66 78|schizophrenia
P11073163A0131|57 72|cell cycle control
P11073163A0131|113 129|cell proliferation
P11073163A0131|133 144|cell survival
P11073870A0375|122 133|response task
P11073870A0375|157 168|memory delays
P11073919A0631|12 28|amino acid residues
P11073919A0631|133 149|mouse ODC numbering
P11073919A0631|258 275|dimer stabilization
P11073919A0631|316 331|S. ruminantium LDC
P11073954A0337|26 37|reading frame
P11073954A0337|50 66|CP2 family proteins
P11074210A0623|47 71|insulin resistance syndrome
P11074210A0623|86 103|insulin sensitivity
P11075678A0298|89 101|approximation
P11075944A0691|49 61|MMTV insertion
P11076860A0872|172 183|localization
P11078726X0000|14 28|phosphorylation
P11078726X0000|70 82|transcription
P11078726X0000|94 111|p53 protein activity
P11078726X0000|115 133|transcription factor
P11078726X0000|300 313|gene expression
P11080796A1277|3 25|Tax/IKKgamma interaction
P11082587X0000|48 66|brillouin scattering
P11082587X0000|116 133|laser beam smoothing
P11082587X0000|146 168|Brillouin backscattering
P11082715X0001|12 24|determination
P11082715X0001|27 38|theophylline
P11082715X0001|84 97|chromatography
P11082715X0001|142 154|determination
P11082715X0001|157 168|theophylline
P11083154A0881|21 34|test conditions
P11083154A0881|38 52|oxygen uptake VO2
P11083154A0881|62 80|minute ventilation VE
P11083868A0386|13 36|glutathione S-transferase
P11083868A0386|110 130|transactivation domain
P11084022A1178|12 24|ALK7 signaling
P11084022A1178|52 65|cell morphology
P11084022A1178|81 94|cell flattening
P11084022A1178|121 133|cell processes
P11084334A0590|3 14|swa2-1 allele
P11084334A0590|53 65|point mutation
P11084334A0590|71 93|tetratricopeptide repeat
P11084556T0000|85 99|progenitor cells
P11084649A0497|84 95|gastrulation
P11085267A0562|0 13|Transformation
P11085267A0562|19 30|sconC3 mutant
P11086872A0000|11 22|oil emulsions
P11086872A0000|85 102|Citrus aurantifolia
P11087141A0977|24 36|GT transcripts
P11087141A0977|64 79|splicing patterns
P11087141A0977|125 140|splicing activity
P11088635A0200|8 37|Kubo-Martin-Schwinger condition
P11088635A0200|117 129|usage patterns
P11089911A1267|75 87|transcription
P11089911A1267|94 111|retrotransposition
P11089911A1267|117 128|ATLN elements
P11090172A0612|15 29|RNA1 replication
P11090172A0612|33 45|RNA3 synthesis
P11090172A0612|103 114|FHV virion RNA
P11090272A1240|3 15|transcription
P11090762A0527|137 149|power increase
P11090762A0527|170 182|parietal locus
P11092850A1023|7 33|16S rRNA gene sequence analysis
P11092886A0341|12 36|protein kinase A stimulation
P11092886A0341|92 123|phosphoenolpyruvate carboxykinase
P11093745A0563|43 53|NF1/CTF site
P11094066A0505|57 90|forkhead transcription factor FKHR-L1
P11094066A0505|107 121|FKHR-L1 activity
P11094066A1194|18 29|observations
P11094066A1194|60 72|transcription
P11094066A1194|92 113|FKHR-L1 phosphorylation
P11094066A1194|177 189|proliferation
P11094072A0842|13 24|footprinting
P11094072A1234|31 43|RAG-2 promoter
P11094072A1234|67 80|consensus c-Myb
P11094073A0000|31 47|Vav family proteins
P11094073A0000|72 103|Ros receptor protein tyrosine kinase
P11094075A0257|25 36|reexpression
P11094075A0257|42 53|r-PTPeta gene
P11094075A0257|71 85|rat thyroid cells
P11094075A0257|99 110|retroviruses
P11094075A0257|130 146|v-ras-Ki oncogenes
P11094087T0000|39 52|transformation
P11094087T0000|121 133|kinase pathway
P11094091A0000|16 38|transcription factor CREB
P11094091A0000|87 101|phosphorylation
P11094091A0000|113 125|serine residue
P11094109A0600|19 30|symptom onset
P11094590A0617|31 42|relationship
P11094590A0617|81 92|Gram staining
P11095248A0423|63 74|glycoprotein
P11095248A1523|61 72|prerequisite
P11095981A0254|21 32|cis-elements
P11096662T0000|31 43|Artery Disease
P11097040A0000|70 82|TRIS-extender
P11097040A0000|158 169|interactions
P11097040A0000|216 229|dog spermatozoa
P11098217A0674|23 43|mouse chromosome 7A2-A3
P11098217A0674|63 75|hybridization
P11099377T0000|36 47|UDP-d-Xylose
P11099377T0000|47 94|proteoglycan core protein beta-d-xylosyltransferase
P11099377T0000|106 117|isoform XT-II
P11100515A0282|0 13|Thyrotoxicosis
P11100515A0282|100 113|thyrotoxicosis
P11100515A0282|151 170|amiodarone withdrawal
P11101008A0649|0 14|Chaperones/HSPs
P11101008A0649|43 60|cell cycle processes
P11101847A0159|48 60|stabilization
P11101847A0159|79 97|tumour suppressor p53
P11102458A0000|13 26|identification
P11102458A0000|37 52|characterization
P11102458A0000|55 66|neurobeachin
P11102458A0000|174 187|protein kinase A
P11103472A0802|40 53|CNV-1 amplitude
P11103792A0755|0 13|Overexpression
P11105129T0000|13 26|Susceptibility
P11105129T0000|49 88|Producing Extended-Spectrum beta-lactamase
P11105716A0782|31 47|AIF peak saturation
P11105716A0782|87 99|determination
P11105716A0782|181 198|MR perfusion studies
P11105717A0123|87 110|susceptibility difference
P11105717A0123|172 187|microvasculature
P11106216A0918|5 16|COPD patients
P11106428A0635|132 156|glutathione-S-transferase
P11106667A1061|35 54|membrane localization
P11106667A1061|70 83|Cox2p synthesis
P11106667A1061|90 101|mitochondria
P11106668A0875|11 22|transfection
P11106668A0875|37 53|spacer-RING domain
P11107637X0001|3 15|determination
P11107637X0001|35 50|blood serum lipids
P11107637X0001|74 88|pathophysiology
P11107637X0001|102 113|significance
P11107637X0001|223 237|atherosclerosis
P11107637X0001|249 260|heart disease
P11107637X0001|265 276|use titration
P11108151A0560|13 27|fibronectin mRNA
P11108151A0560|44 56|PKC inhibitors
P11108151A0560|59 70|PKC depletion
P11108151A0560|98 110|EGF-R function
P11108151A0560|130 140|EGF-R mutant
P11108151A0560|144 159|tyrphostin AG1478
P11108151A0560|180 194|fibronectin mRNA
P11108523A0326|0 10|Video images
P11108523A0326|158 174|internostril angle
P11108548A0710|0 16|MS characteristics
P11108548A0710|77 96|substitution patterns
P11108548A0710|149 161|APcI interface
P11108616A0000|9 30|Oreochromis mossambicus
P11108616A0000|44 55|microgravity
P11108616A0000|80 98|space missions STS-55
P11108616A0000|112 123|hypergravity
P11108720A0124|186 203|localization signal
P11108720A1130|0 11|Pretreatment
P11108720A1130|80 91|kinase kinase
P11108720A1130|95 108|inhibitor U0126
P11108720A1130|118 131|S6K2 activation
P11108839A0401|92 103|localisation
P11110040A0000|30 52|5-HT2 receptor antagonism
P11110040A0000|92 103|% w/v solution
P11110040A0000|123 134|applications
P11110040A0000|211 222|ketanserinol
P11110528A0414|38 53|velocity encoding
P11111051A0051|34 57|histone acetyltransferase
P11112417A1126|23 38|MLSN1 transcripts
P11112417A1126|107 119|melanoma cells
P11112417A1126|134 148|MLSN1 expression
P11112417A1126|179 191|transcription
P11112417A1126|195 208|mRNA processing
P11112438X0847|13 25|Academic Press
P11112700T0000|0 15|Characterization
P11112700T0000|21 44|microtubule binding domain
P11112700T0000|47 80|microtubule actin crosslinking factor
P11112700T0000|85 98|identification
P11113179A0541|49 64|estrogen receptor
P11113179A0541|85 97|SRC1 functions
P11113179A1020|71 81|LXXLL motifs
P11113179A1020|117 135|coactivator activity
P11113199A0800|52 65|MEK interaction
P11113199A0800|94 105|localization
P11113199A0800|108 129|ERK2-Delta19-25 mutants
P11113201A1114|16 32|six-protein family
P11113201A1114|67 80|O mannosylation
P11113201A1114|83 96|target proteins
P11113546A0728|51 61|trial period
P11113546A0728|96 107|nematode eggs
P11113546A0728|111 121|Giardia cyst
P11113692A0169|34 44|risk factors
P11113692A0169|184 196|blood pressure
P11113822A0999|75 85|jaw pathoses
P11113823A0197|19 32|chondromatosis
P11114294A0075|47 79|cytokines tumor necrosis factor alpha
P11114294A0075|83 97|interferon gamma
P11114294A0075|128 168|fibrosis transmembrane conductance regulator
P11114521A0282|81 93|cell spreading
P11114718A0349|12 27|mouse fibroblasts
P11114718A0349|63 75|protein levels
P11114924A0808|56 78|primer extension analysis
P11116084A0000|0 10|Mouse Impact
P11116148A0741|0 18|Coexpression studies
P11116148A0741|52 66|transactivation
P11116148A0741|111 132|transactivation domains
P11117263A0570|35 48|Ids3 expression
P11117523A0650|14 31|COUP-TFI expression
P11117523A0650|50 64|differentiation
P11117523A0650|99 110|cell cultures
P11117826A0788|28 39|pretreatment
P11117826A0788|43 61|follow-up evaluation
P11118062A1691|29 40|localization
P11118062A1691|98 111|aggressiveness
P11118438A0411|35 47|Pin1 homologue
P11118438A0411|55 71|plant species apple
P11118438A0411|72 85|Malus domestica
P11118438A0411|133 152|substrate specificity
P11118440T0000|35 56|alternative transcripts
P11118440T0000|62 89|candidate tumor suppressor ING1
P11118440T0000|123 140|corepressor complex
P11118619A0835|48 75|host cell transcription factors
P11118619A0835|156 169|transformation
P11118712A1296|4 22|sensitivity analysis
P11118712A1296|118 131|herd prevalence
P11118712A1296|148 163|confidence limits
P11118712A1296|174 187|within-herd PTB
P11118712A1296|272 286|herd specificity
P11121043A0074|64 75|neurogenesis
P11121118A0075|43 54|GAF sequences
P11121118T0000|7 18|organization
P11121118T0000|29 55|phosphodiesterase PDE11A gene
P11121397A0587|33 44|rib-2 protein
P11121397A0587|55 94|alpha1,4-N-acetylglucosaminyltransferase
P11121397A0587|145 158|heparan sulfate
P11121434A0915|15 28|Mek/Erk pathway
P11121434A0915|31 43|Rat1/ras cells
P11121434A0915|52 63|Mek inhibitor
P11121490A0000|3 37|transcription factor CHOP/GADD153 gene
P11122381A0908|93 109|GM-CSF stimulation
P11122588A0549|0 18|MAIN OUTCOME MEASURES
P11122588A0549|19 34|Percentage change
P11122588A0549|62 72|apnea events
P11122588A0549|74 87|hypopnea events
P11123089A0362|49 63|characteristics
P11123089A0362|100 111|vasculitides
P11123089A0362|152 165|tissue diseases
P11123316T0000|0 17|Tec kinase signaling
P11123316T0000|39 66|phosphatidylinositol 3-kinase
P11123316T0000|73 99|Tec pleckstrin homology domain
P11123701A0442|141 153|DNA constructs
P11123701A0442|169 188|transcription complex
P11123701A0442|223 235|DNA supercoils
P11123912A0306|111 122|polyomavirus
P11124024A1098|36 51|protein complexes
P11124024A1098|80 90|C+T sequence
P11124902X1337|13 25|Academic Press
P11125151T0000|0 17|Nucleotide sequence
P11125151T0000|18 35|genome organization
P11125151T0000|61 77|pineapple mealybug
P11125363A0525|17 38|pretreatment cystoscopy
P11125363A0525|50 61|tumor mapping
P11125363A0525|140 153|5-fluorouracil
P11125363A0525|177 188|radiotherapy
P11125872A0133|57 73|phosphodiesterase
P11125872A0133|161 174|administration
P11126275A1068|17 46|anticardiolipin immunoglobulin G
P11126806A0206|21 47|antiphospholipid-antibodies
P11127161T0000|14 29|smoking cessation
P11127200A1024|90 113|AP-1 transcription factors
P11127200A1024|170 182|collagen I gene
P11127955X0001|18 28|colon cancer
P11127955X0001|90 101|colon cancers
P11128925A0000|51 63|interleukin-6
P11128925A0000|175 187|periodontitis
P11129515A0000|45 70|Vitex agnus castus L extract Ze
P11129724A0904|38 50|contamination
P11129724A0904|95 106|transmission
P11131321T0000|9 24|Trypanosoma vivax
P11131321T0000|38 49|Yankasa sheep
P11131321T0000|65 91|homidum chloride chemotherapy
P11132063A0250|11 28|treatment exposures
P11132063A0250|159 172|cardiomyopathy
P11132148A0162|54 67|promoter region
P11132195A0000|39 52|Volterra series
P11132195A0000|109 120|nonlinearity
P11132195A0000|157 168|measurements
P11132195A0000|171 186|input/output data
P11132790A0609|151 162|risk children
P11133741A0617|10 23|MCP-1 synthesis
P11133741A0617|136 151|promoter activity
P11133830A0174|56 78|tyrosine phosphorylation
P11133830A0174|124 140|kDa phosphoprotein
P11133830A0174|160 178|proto-oncogene c-Cbl
P11133927T0000|10 24|NIR spectroscopy
P11133986A0350|52 71|transcription factors
P11133986A0350|87 108|PU.1 interaction partner
P11134033A0000|40 54|integration site
P11134033A0000|69 80|tumor viruses
P11134033A0000|97 108|eIF3e subunit
P11134033A0000|111 141|translation initiation factor eIF3
P11134033A0639|2 13|int6 deletion
P11134508A0317|48 60|Arabidopsis HD
P11134822A0629|18 36|accelerations/30 min
P11137296A0923|4 31|transcription initiation sites
P11137296A0923|86 98|amplification
P11137296A0923|142 167|translation initiation codon
P11137296A0923|204 228|transcription-PCR analysis
P11137296A0923|282 293|mouse tissues
P11137367A0297|9 25|Toshiba IIDR system
P11137367A0297|45 57|X-ray TV system
P11138009A1032|63 73|USH1 patient
P11138694A0000|3 24|fluorobenzyltrozamicol
P11138694A0000|63 86|acetylcholine transporter
P11139336A0257|12 23|associations
P11139336A0257|33 46|INCENP behavior
P11139469A0402|25 45|Ang2 mRNA accumulations
P11139469A0402|68 81|Tie2 expression
P11139469A0402|101 124|protein kinase C inhibitors
P11139473A0696|0 15|Promoter analysis
P11139473A0696|106 118|SMemb promoter
P11139473A0696|133 149|Hex responsiveness
P11139567A1440|0 22|LH/CG receptor activation
P11139567A1440|56 83|phosphatidylinositol 3-kinase
P11139567A1440|98 122|G protein beta gamma subunits
P11139605A0811|0 15|Deletion analysis
P11139605A0811|78 93|promoter activity
P11139605A0811|97 111|auto-activation
P11139605A0811|130 148|mobility shift assays
P11140472A0497|199 214|cases improvement
P11141003T0000|9 25|stimulation levels
P11143384A0267|47 66|conference situations
P11143384A0267|72 86|microphone input
P11145562A0000|37 48|growth factor
P11145562A0000|103 116|transformation
P11145562A0468|3 13|P69 cell line
P11145562A0468|26 40|immortalization
P11145563A0202|27 38|StAR promoter
P11145563A0303|30 49|StAR promoter activity
P11145563A0303|82 102|granulosa-lutein cells
P11145566A0000|22 40|lipoprotein receptor
P11145566A0000|61 82|cholesterol homeostasis
P11145566A0000|143 155|understanding
P11145566A0000|158 172|HDL-R regulation
P11145571A0788|14 25|gene factor-3
P11145571A0788|29 43|STAT1 homodimers
P11145571A0788|74 88|response element
P11145590A0217|46 60|TGF-beta1 action
P11145590A0217|63 75|thyroglobulin
P11145590A0217|78 91|gene expression
P11145590A0217|116 134|TGF-beta1 regulation
P11145590A0217|153 172|transcription factors
P11145717A0936|45 55|TPO fragment
P11145743A0170|48 59|thyroid cells
P11145743A0170|71 96|thyroid transcription factor
P11145743A0170|178 196|deiodinase promoters
P11145813A0668|0 16|Regional blood blow
P11145813A0668|37 48|microspheres
P11145813A0668|81 91|L6 vertebrae
P11145887A1393|12 24|transcription
P11145887A1393|45 55|Jurkat cells
P11145887A1393|109 123|c-Fos activation
P11145955A0189|30 50|estrogen receptor alpha
P11145955A0189|78 91|gene expression
P11145955A0189|178 190|protein kinase
P11145955A0189|195 211|pathway activation
P11145955A0189|231 247|growth factor alpha
P11146961T0000|0 17|Perfusion technique
P11146961T0000|53 64|artery bypass
P11148042A1258|90 109|peptide immiscibility
P11148042A1258|119 134|gel state bilayers
P11148589A1124|23 43|immunization practices
P11148589A1124|86 108|Pacific Islander children
P11148589A1124|120 136|United States today
P11148589A1124|195 214|liver carcinoma deaths
P11149472A1257|10 30|NP/NMP4/CIZ expression
P11149472A1257|57 68|chondrocytes
P11150315A0226|40 68|transcription factor activities
P11150315A0226|135 155|oligonucleotide clones
P11150315A0226|161 181|DNA recognition library
P11150315A0226|199 216|DNA binding proteins
P11150315A0844|34 51|ERK phosphorylation
P11150439A0701|0 16|Energy expenditure
P11150439A0701|70 92|enrichment determination
P11150439A0701|95 122|isotope ratio mass spectroscopy
P11150439A0701|151 168|regression equation
P11152070A0573|46 58|A. chrysogenum
P11152070A0573|65 79|expression level
P11152070A0573|97 114|cefEF cephalosporin
P11152070A0573|147 171|cephalosporin fermentation
P11152081A0413|43 55|acidification
P11152081A0413|56 74|metal solubilization
P11152081A0413|78 92|sulfur oxidation
P11152283A0223|42 58|gene transcription
P11152344A0416|63 75|arachnoid scar
P11152451A0529|3 29|Schistosoma mansoni homologue
P11152451A0529|66 86|Sj26-GST fusion protein
P11152451A1580|44 58|TGF-beta signals
P11152451A1580|163 185|target gene transcription
P11152451A1580|216 229|TGF-beta effect
P11152521A0181|17 31|protein products
P11152521A0181|65 81|expression vectors
P11152521A0181|93 110|ORF40/41 transcript
P11152963A0000|15 25|src homology
P11152963A0000|93 115|astrocyte transformation
P11153302A0000|0 22|Naltrexone hydrochloride
P11153302A0000|35 58|opioid receptor antagonist
P11153302A0000|100 113|detoxification
P11154491A0322|131 143|echoendoscope
P11155096A0222|7 19|Thyroid status
P11155096A0222|67 81|serum antibodies
P11155096A0222|84 100|thyroid peroxidase
P11155096A0222|123 136|serum TSH levels
P11155096A0222|170 188|serum thyroxin levels
P11156413T0000|20 35|characterization
P11156413T0000|51 63|tumor cell line
P11156413T0000|75 86|polyomavirus
P11156413T0000|131 148|cancer therapeutics
P11156484A0223|0 10|TBARS levels
P11156484A0223|34 46|capacity assay
P11156618T0000|30 41|mouse SCL loci
P11156618T0000|73 96|restriction endonucleases
P11156789A1669|62 73|CSF pulsation
P11156789A1669|92 105|motion artifact
P11156789A1669|123 141|oxygen concentration
P11156789A1669|224 239|CSF protein levels
P11156789A1669|249 263|propofol binding
P11157035A1405|67 80|determinations
P11157035A1405|107 117|IFN alpha-2b
P11157763T0000|14 25|EMAPII domain
P11157763T0000|33 63|aminoacyl-tRNA synthetase complex
P11157763T0000|83 94|dimer mimicry
P11157774A0789|11 22|dSLBP alleles
P11157784A0141|22 36|chromosome 22q11
P11158236A0000|0 16|Nerve growth factor
P11158288T0000|15 27|RNA polymerase
P11158288T0000|64 79|activation domain
P11158288T0000|101 119|CREB phosphorylation
P11158290A0728|57 70|destruction box
P11158290A0728|73 84|IkappaBalpha
P11158295A0158|30 41|kinase domain
P11158295A0158|57 67|Src homology
P11158324A1073|76 95|lipoprotein secretion
P11158324A1073|135 149|apolipoprotein B
P11158324A1073|163 189|triglyceride transfer protein
P11158324A1073|211 227|cholesterol uptake
P11158324A1073|274 292|lipoprotein receptor
P11158324A1073|293 311|scavenger receptor BI
P11158324A1073|329 342|bile acid uptake
P11158324A1073|358 372|down-regulation
P11158324A1073|394 451|bile acid transporters sodium taurocholate cotransporter protein
P11158324A1073|462 484|anion transporter protein
P11158337A0000|50 61|GnRH receptor
P11158337A0000|93 112|transcription factors
P11158337A0000|175 192|activator protein-1
P11158337A0000|235 245|binding site
P11158456A0223|58 69|consultation
P11158456A0223|163 175|family history
P11159363A1251|17 32|cytosine residues
P11160096A1067|36 49|fliF background
P11160656A0000|20 34|cytomegalovirus
P11160656A0000|153 167|HCMV replication
P11160656A0000|246 260|NTera2 carcinoma
P11160683A1220|32 48|C/EBP dimer binding
P11160683A1220|82 98|CREB-1 recruitment
P11160683A1220|101 113|ATF/CREB sites
P11160688A1726|76 88|translocation
P11160721A0932|9 21|transfections
P11160721A0932|60 79|TBLV enhancer activity
P11160721A0932|108 118|T-cell lines
P11160732A0464|0 11|Vector stocks
P11160732A0464|22 37|envelope proteins
P11160732A0464|56 67|SIVmac clones
P11160732A0464|83 100|T-lymphocyte tropic
P11160732A0464|118 133|macrophage tropic
P11160732A1199|177 194|SIVmac239 infection
P11160732A1199|209 221|transcription
P11160738A1414|57 69|establishment
P11160742A0696|8 18|R expression
P11160742A0696|29 41|PML dispersion
P11160860A0662|26 38|IkappaB kinase
P11160860A0662|74 92|NF-kappaB activation
P11160860A0662|100 121|IkappaB phosphorylation
P11160860A0662|175 201|IkappaBalpha phosphorylation
P11160896A0713|0 24|Immunofluorescence studies
P11160896A0713|27 39|C2C12 myotubes
P11160896A0713|56 71|MEF2A co-localise
P11160896A0713|112 126|differentiation
P11160902A0962|84 109|c-sis/PDGF-B proto-oncogene
P11160929T0000|51 63|endonucleases
P11161455A1286|0 19|Southern blot analysis
P11161455A1286|43 53|cell hybrids
P11161720X1294|13 25|Academic Press
P11161793A1033|22 37|receptor isoforms
P11161793A1033|122 133|EGFR activity
P11161816A0851|16 27|similarities
P11161816A0851|35 52|endophilin proteins
P11161816A0851|80 91|SH3GLB family
P11162576A0213|17 30|identification
P11162666A0442|3 28|glucose/insulin stimulation
P11162936A2727|67 79|antiestrogens
P11162936A2727|118 134|tissue selectivity
P11162936A2727|161 185|hormone replacement therapy
P11162936A2727|216 227|breast cancer
P11163932A0000|36 65|roman garden snail Helix pomatia L.
P11163932A0000|105 121|thermopreferendum
P11163932A0000|196 209|air temperature
P11163968A0152|27 41|genome sequences
P11163968A0152|44 63|Pyrococcus horikoshii
P11163968A0152|67 82|Pyrococcus abyssi
P11163968A0152|128 142|archaebacterium
P11163968A0152|168 186|genome polymorphisms
P11163968A0152|197 232|restriction-modification gene homologs
P11164078A0833|4 14|animal model
P11164078A0833|70 87|treatment-response
P11166478T0000|29 43|antinociception
P11167019A1249|48 79|ATPsynCF6 transcription start sites
P11167111A0957|19 40|lung function parameters
P11167778T0000|8 29|antithrombin deficiency
P11168422A0248|36 52|metal fluoride ions
P11168422A0248|99 109|iron protein
P11168446T0000|9 31|erythropoietin synthesis
P11168446T0000|56 67|heart failure
P11168446T0000|97 109|haemodynamics
P11168588T0000|12 33|herpes simplex virus type
P11168588T0000|48 63|Cdc42/Rac pathway
P11168588T0000|92 107|kinase activation
P11169113A0555|27 37|phi29 mutant
P11170476A1546|34 46|gp96 complexes
P11171118A0836|84 95|interactions
P11171118A0836|103 117|NF-1 DNA elements
P11171320A0894|0 11|Coexpression
P11171320A0894|82 109|tyrosine phosphorylation sites
P11171320A0894|133 153|amino acid substitution
P11171320A0894|169 181|phenylalanine
P11171320A0894|242 254|EalphaCL cells
P11172944A0826|54 67|plasma TNFalpha
P11172944A0826|71 90|radiation pneumonitis
P11175333A0336|19 41|co-precipitation methods
P11176098A0342|50 60|shock groups
P11176290T0000|0 13|Identification
P11176290T0000|25 36|vein stenosis
P11176290T0000|42 63|radiofrequency ablation
P11176290T0000|73 84|fibrillation
P11177538A0655|0 13|Tumor cell lines
P11177538A0655|48 70|% gene transfer efficiency
P11178248A1042|32 50|screening techniques
P11178696A0301|97 109|contrast agent
P11178765A0642|99 117|mouse adenocarcinoma
P11179272T0000|0 14|Cytomegalovirus
P11179272T0000|37 67|Helicobacter pylori IgG antibodies
P11179272T0000|91 102|implantation
P11179272T0000|133 147|ultrasound study
P11179400T0000|22 46|carotid body chemoreceptors
P11179664T0000|0 11|Architecture
P11179664T0000|74 102|transcription factor RUNX1/AML1
P11179687A0280|65 76|phosphatases
P11179687A0280|146 157|receptor PTPs
P11179689A0000|3 15|Sox gene family
P11179689A0000|23 32|HMG box gene
P11179689A0000|60 70|DNA sequence
P11179956A1818|82 98|nucleotide binding
P11179956A1818|122 133|interactions
P11179956A1818|179 193|proton transport
P11180255A0776|35 47|improbability
P11180255A0776|69 82|UHF frequencies
P11180688A0000|11 29|maximum oxygen uptake
P11180688A0000|134 144|Fitness Test
P11180688A0000|174 187|schoolchildren
P11181516A0119|11 52|deletion insulin promoter-reporter constructs
P11181516A0119|64 76|transfections
P11181516A0119|85 99|INS-1 beta-cells
P11181516A0119|148 166|rat insulin I promoter
P11181525T0000|3 18|androgen receptor
P11181525T0000|21 34|amino-terminus
P11181525T0000|71 86|AR gene expression
P11181531A0464|38 49|osteoporosis
P11181531A0464|71 83|transcription
P11181531A0464|86 105|NF-kappa B target genes
P11181531A0464|136 157|cytokines interleukin-6
P11181531A0464|161 173|interleukin-1
P11181548A0214|102 112|mE-RABP gene
P11181548A0214|120 130|DNA fragment
P11181995A1093|13 26|genome sequence
P11181995A1093|176 187|mouse matches
P11182746A0872|55 65|drug therapy
P11187016T0000|22 39|A-bomb survivor data
P11187016T0000|40 51|implications
P11188993A0298|121 143|methenamine silver stains
P11191208A0000|64 77|overexpression
P11191208A0000|97 115|membrane efflux pumps
P11191208A0000|124 135|facilitators
P11191208A0000|142 171|ABC binding cassette transporters
P11191208A0000|192 214|transcription regulators
P11191365A0682|0 13|Susceptibility
P11191365A0682|159 170|fibrillation
P11191365A0682|227 239|non-diabetics
P11193045A1193|69 84|tumor suppression
P11193666A1269|36 56|Babesia carrier animals
P11193704A0000|16 30|pleuropneumonia
P11194101A0532|0 16|Baseline BMD values
P11194147A1496|3 14|distribution
P11194147A1496|20 34|rice cultivation
P11194147A1496|64 75|HIDD villages
P11194183A0866|129 155|procyanidin B-2 group subjects
P11194183A0866|212 238|placebo control group subjects
P11194183A0866|239 252|procyanidin B-2
P11195401A1030|4 18|plasma AVP levels
P11195401A1030|65 76|AVP secretion
P11196191A1789|6 29|T47D breast carcinoma cells
P11196191A1789|51 78|EGF receptor autocrine activity
P11196191A1789|97 113|MAPK/PI3K pathways
P11196199T0000|16 33|yeast Rad23 protein A
P11196199T0000|72 85|element binding
P11196199T0000|89 102|binding protein
P11196340A1046|23 36|identification
P11196340A1046|97 109|aescin analogs
P11197288A0855|21 33|metronidazole
P11197328T0000|62 102|maize C4 phosphoenolpyruvate carboxylase gene
P11197328T0000|125 137|transcription
P11197328T0000|140 153|mesophyll cells
P11197549A0748|16 34|stabilization period
P11197926A0000|74 99|General Health Questionnaire
P11198053T0000|28 46|Hypericum perforatum
P11198053T0000|69 80|constituents
P11198289T0000|9 26|serum ceruloplasmin
P11198289T0000|30 41|copper levels
P11198385A0000|21 32|algerae Vavra
P11198385A0000|80 95|laboratory colony
P11198385A0000|98 111|Culex pipiens L.
P11198385A0000|126 143|Gharbia Governorate
P11198424T0000|19 34|characterization
P11198424T0000|68 87|phytosulfokine-alpha
P11198424T0000|99 119|rice cell proliferation
P11200568A0830|84 96|IgG antibodies
P11201250A0849|0 21|Plasma DHE concentration
P11202434T0000|6 27|amino acid substitutions
P11202434T0000|65 84|palmitoyl-CoA binding
P11202434T0000|132 145|ankyrin repeats
P11202705A1112|0 11|Implications
P11202705A1112|14 26|biomonitoring
P11202705A1112|40 59|accumulation patterns
P11202705A1112|93 109|Posidonia oceanica
P11203702A1307|45 60|activation domain
P11204897A0797|30 41|participants
P11204897A0797|52 70|bridge simulator task
P11207216A0296|75 87|chain reaction
P11207216A0296|91 110|cDNA library screening
P11207216A0719|103 131|phorbol 12-myristate 13-acetate
P11207261A1421|40 53|DT40 B cell lines
P11207261A1421|87 114|Fc gamma RIIB1-PECAM-1 receptor
P11207261A1421|139 149|Src homology
P11207261A1421|169 180|phosphatases
P11207269A0745|61 72|p95 component
P11207282A0729|56 68|chicken Notch1
P11207282A0729|99 113|down-regulation
P11207282A0729|116 135|surface IgM expression
P11207282A0729|170 187|IgH gene transcripts
P11207288A0897|0 12|Substitutions
P11207288A0897|127 142|class Ia molecules
P11207308A0999|17 33|diferuloylmethane
P11207308A0999|82 101|STAT1 phosphorylation
P11207308A0999|146 161|kinase activation
P11207308A0999|199 216|p38 phosphorylation
P11207609A0994|77 90|ER localization
P11207609A0994|102 128|stomatitis virus glycoprotein
P11208017A0070|18 43|C2H2-type zinc finger protein
P11208814A0673|87 103|sequence alignment
P11208814A0673|137 149|consensus site
P11208814A0673|153 167|phosphorylation
P11209100A0069|115 133|cytokine antagonists
P11209100A0069|140 170|interleukin-1 receptor antagonist
P11209814A0243|16 28|investigation
P11209814A0243|55 69|characteristics
P11209814A0243|82 94|tissue capsule
P11209814A0243|111 122|implantation
P11209814A0243|125 148|aluminum calcium phosphate
P11209814A0243|157 170|hydroxyapetite
P11210401A0000|0 21|Sevelamer hydrochloride
P11210401A0000|92 108|hyperphosphatemia
P11210401A0000|133 144|hemodialysis
P11210401A0544|89 102|administration
P11210839A0282|6 22|PO3 administration
P11210839A0282|129 140|oprofloxacin
P11210988T0000|54 67|prostate cancer
P11211759A0165|31 43|Control group A
P11211759A0165|102 121|transtracheal heating
P11211759A0165|125 144|humidification system
P11211759A0165|147 160|ANAMED HUMITUBE
P11211759A0165|181 195|cancer operation
P11211936A1490|65 80|JNK/SAPK activity
P11211936A1490|87 100|SAPK activation
P11211936A1490|137 151|differentiation
P11211936A1490|155 166|growth arrest
P11212249A0993|65 80|activator protein
P11212327A1564|26 38|rat adipocytes
P11212327A1564|63 74|PIG compounds
P11212327A1564|82 110|IRS1/3 tyrosine phosphorylation
P11212327A1564|113 124|p59Lyn kinase
P11213342A0492|10 22|parameters SF2
P11214354A1104|59 75|lipid peroxidation
P11214354A1104|90 102|protein thiols
P11215622A0949|36 47|force sensors
P11220166A0616|51 66|motor performance
P11220166A0616|132 143|interactions
P11220166A0616|168 189|brain dopamine receptors
P11220166A0616|195 206|intervention
P11220166A0616|242 252|cortex loops
P11220306A0911|55 65|sigma factor
P11220487T0000|43 56|trichomoniasis
P11220857T0000|22 36|Veterans Affairs
P11221845A0295|23 39|methylation status
P11221845A0295|61 71|liver tumors
P11221845A0295|74 87|SV40 T/t antigen
P11221845A0295|116 134|Restriction Landmark
P11221845A0295|238 248|liver tumors
P11221845A0800|3 17|Genescan program
P11221845A0800|33 44|reading frame
P11221845A0800|109 128|493-amino acid protein
P11221845A0800|142 159|SNAG repressor motif
P11221845A0800|190 214|C2H2-type zinc finger motifs
P11221845A1370|0 19|Northern blot analysis
P11221845A1713|11 22|N18TG-2 cells
P11221845A1713|46 64|5-aza-deoxycytidine
P11221845A1713|212 229|liver tumorigenesis
P11221845A1713|241 252|SV40 T antigen
P11222387A1497|64 90|ABL tyrosine kinase inhibition
P11222387A1497|91 101|FTI SCH66336
P11222639A1273|37 51|tyrosine residue
P11222639A1273|73 85|L1 endocytosis
P11222720A1699|52 64|Notch activity
P11222720A1699|75 86|interactions
P11222720A1699|109 126|corepressor complex
P11223131A0000|0 15|Folate metabolism
P11223131A0000|26 60|malaria parasite Plasmodium falciparum
P11223153A0533|58 77|microsphere technique
P11223153A0533|94 104|lung anatomy
P11223153A0533|145 155|color schema
P11223164A0000|32 46|differentiation
P11223186A1095|0 14|Transactivation
P11223186A1095|17 50|oIFNtau enhancer-reporter constructs
P11223240A0655|10 30|Menin1 gene transcripts
P11223240A0655|45 64|polyadenylation sites
P11223246A0359|0 15|Sequence analysis
P11223246A0359|29 47|RBP21 shares homology
P11223255A1034|13 35|consensus amino acid motif
P11223255A1034|39 68|serine threonine receptor kinases
P11223256A1212|52 63|pea 33RNP gene
P11223257A0404|34 49|rice seedling leaf
P11223257A0404|100 119|protein phosphatase 2A
P11223257A0404|238 250|cycloheximide
P11223257A0404|285 300|protein synthesis
P11224226A0000|12 27|chlordiazepoxide
P11224226A0000|44 72|benzodiazepine receptor agonist
P11224226A0000|105 133|benzodiazepine receptor agonist
P11226752A0750|11 28|tissue culture cells
P11226752A0750|29 42|overexpression
P11226752A0750|57 75|mouse deltex homologs
P11227182A1475|36 47|correlations
P11227182A1475|91 102|leptin levels
P11227484T0000|12 24|determination
P11227484T0000|27 39|methylmercury
P11227484T0000|44 65|ion-association complex
P11230145A0732|49 74|RBP-Jkappa signaling pathway
P11230145A0732|77 93|cell fate decisions
P11230169A0480|26 53|chromatin immunoprecipitation
P11230169A0480|64 81|array hybridization
P11230169A0480|158 168|20p12 region
P11230169A0480|187 202|marker chromosome
P11230534A0688|20 32|DEAH helicases
P11230889A1151|25 38|arm lymphoedema
P11230889A1151|65 76|improvements
P11231287A0158|21 45|neuroblastoma cells SK-N-SH
P11231287A0158|73 84|thapsigargin
P11232947A1451|12 30|lymph node dissection
P11232947A1451|33 48|radiation therapy
P11233643A0000|56 69|protoporphyrin
P11235777A0878|27 49|serum testosterone levels
P11235777A0878|85 109|dihydrotestosterone levels
P11235817A0000|3 32|histamine H1 receptor antagonists
P11235817A0000|33 46|antihistamines
P11237038A0889|40 58|pressure flow studies
P11237038A0889|102 126|bladder outflow obstruction
P11237491A0000|42 53|fluctuations
P11237491A0000|59 74|tumour markers CEA
P11237491A0000|148 166|serum concentrations
P11237491A0000|185 196|fluctuations
P11237491A0000|215 228|concentrations
P11238105A0959|15 27|alpha subunits
P11238105A0959|143 165|tyrosine phosphorylation
P11238375A0617|33 45|kinase cascade
P11238402A0191|59 79|DAN/TIR gene expression
P11238405A0817|94 112|fbp1-lacZ expression
P11238405A0817|120 142|spc1 MAPK phosphorylation
P11238447A0524|7 20|binding studies
P11238447A0524|88 101|CRM1/exportin1
P11238447A0524|131 152|nucleoporins CAN/nup214
P11238586A0000|41 65|histocompatibility complex
P11238586A0000|94 106|T cell receptor
P11238586A0000|156 168|alpha2 helices
P11238586A0000|212 223|interactions
P11238884A0892|20 30|dlg mutation
P11238884A0892|38 54|growth retardation
P11238916A0838|63 76|tyrosine kinase
P11238916A0838|108 124|macrophage lysates
P11238947A0636|43 56|hnRNP A2 binding
P11238947A0636|85 96|RNA transport
P11239184A1340|0 16|Baseline variables
P11239529A0981|32 43|endometrioma
P11239529A0981|64 76|localizations
P11240600A0523|9 19|drug history
P11240600A0523|63 75|VGB medication
P11241166A0677|16 29|gene expression
P11241166A0677|46 56|FA treatment
P11241166A0677|92 105|leptin receptor
P11241166A0677|152 165|STAT signalling
P11241166A0677|184 201|cytokine signalling
P11241215A0566|49 62|fusion proteins
P11241215A0566|144 157|chromatography
P11241215A0566|183 194|enterokinase
P11241243A0693|56 69|quantification
P11241243A0693|118 130|p53 expression
P11241332A0393|50 66|fixation strengths
P11241332A0393|96 112|bone anchor designs
P11241332A0393|130 140|screw anchor
P11241356T0000|12 26|phosphorylation
P11241356T0000|37 48|localization
P11241356T0000|82 106|collagen gene transcription
P11241356T0000|125 137|stellate cells
P11241672T0000|10 25|characterization
P11241672T0000|41 60|integrin gene promoter
P11241672T0000|61 74|identification
P11241672T0000|79 91|interleukin-4
P11243306A0961|30 44|oxLDL antibodies
P11243306A0961|67 78|hypertension
P11243306A0961|99 111|artery disease
P11243306A0961|137 148|hypertension
P11243336A0000|71 82|applications
P11243336A0000|108 129|brachytherapy dosimetry
P11243777A0000|10 22|CCAAT elements
P11243777A0000|53 67|promoter regions
P11243980A0510|31 45|PET examinations
P11243980A0510|55 71|staging procedures
P11245986T0000|50 73|rat aldolase B gene promoter
P11246887A0000|26 49|cholesteryl ester transfer
P11246887A0000|53 83|cholesteryl ester transfer protein
P11246887A0000|111 125|transfer protein
P11246887A0000|172 190|artery calcification
P11246887A0000|260 272|sex difference
P11247663A1447|38 49|DNAH9 alleles
P11248463A0187|3 13|blood levels
P11248626T0000|91 103|prostatectomy
P11250196A0455|37 55|calcium binding sites
P11250196A0455|103 138|betagamma-crystallin fold family member
P11250942A0626|64 84|VDR activation function
P11251083T0000|33 46|cell morphology
P11251083T0000|50 60|S phase entry
P11251083T0000|72 83|growth factor
P11251083T0000|100 117|MEK/ERK activations
P11251104A0526|15 27|alpha-amylase
P11251104A0526|52 75|transcription factor GAMyb
P11251252A0494|0 17|3D image-processing
P11251252A0494|34 47|ultrasound data
P11251252A0494|84 94|section mode
P11251697T0000|6 33|superoxide scavenging activity
P11251697T0000|70 82|determination
P11251697T0000|85 105|electron spin resonance
P11251697T0000|114 127|spin trap method
P11251951A0000|88 98|skin lesions
P11254134A0648|27 46|background activities
P11254134A0648|121 136|background levels
P11254504A0766|10 23|promoter region
P11254504A0766|84 99|growth response-1
P11254504A0766|100 117|activator protein-2
P11254504A0766|133 145|factor-kappaB
P11254504A0766|153 171|zinc finger protein-1
P11254504A0766|205 228|Cdx protein-2 binding sites
P11254713A1029|178 198|IL-2 gene transcription
P11254864T0000|33 44|breast cancer
P11255035A0331|11 25|progenitor cells
P11255035A0331|36 54|SVZa progenitor cells
P11255252A0961|8 18|ER3 sequence
P11255252A0961|99 111|yeast extracts
P11255423A0211|90 102|CD4 lymphocyte
P11256845A0340|29 59|Scotland Coronary Prevention Study
P11256845A0340|88 102|statin treatment
P11256944A1144|38 51|G13 gene product
P11256944A1144|76 87|point mutants
P11256944A1144|103 125|ER stress response element
P11256962A0233|0 15|Sequence analysis
P11256962A0233|68 82|beta subunit gene
P11256962A0233|124 144|GlyR alpha subunit genes
P11256962A0233|220 231|GlyR beta mRNA
P11257870A0000|112 124|sludge process
P11257870A0000|155 171|trichloroethylene
P11257870A0000|215 227|retention time
P11258906A0743|2 27|DNA strand exchange reactions
P11258906A0743|33 48|oligonucleotides
P11258906A0743|74 84|pairing bias
P11259347A0000|9 20|observations
P11259503A0212|0 17|Forskolin treatment
P11259593A1094|10 23|ace2Delta cells
P11259593A1094|53 66|cell separation
P11260468A1179|80 97|papBA transcription
P11260468A1179|131 141|protein H-NS
P11263622A0683|55 67|wall thickness
P11263622A0683|71 84|vessel wall area
P11263622A0683|98 111|histopathology
P11263664A1085|42 59|XBra gene expression
P11263664T0000|4 25|Smad interacting protein
P11263664T0000|54 74|enhancer binding factor
P11264176A0181|19 32|G1/S transition
P11264176A0181|71 90|cyclin A2/cdk2 complex
P11264177T0000|0 17|Nucleotide sequence
P11264177T0000|18 33|transcription map
P11264177T0000|37 52|mutation analysis
P11264182A0000|5 27|T-cell leukemia virus type
P11264182A0000|152 165|leukemogenesis
P11264182A0000|173 186|T-cell leukemia
P11264372T0000|0 11|Requirements
P11264372T0000|37 49|translocation
P11264372T0000|52 71|infected-cell protein
P11264372T0000|75 92|herpes simplex virus
P11264375A0000|8 22|cytomegalovirus
P11264375A0000|67 80|phosphoprotein
P11265853A0000|25 36|Assist System
P11265853A0000|41 51|Novacor Corp
P11265853A0000|125 137|configuration
P11266184A0000|25 43|signal intensity area
P11266184A0000|59 72|time-of-flight
P11266184A0000|128 144|signal intensities
P11266194A0743|7 18|distribution
P11266227A0295|51 63|donor solution
P11266540A0328|32 51|Groucho family members
P11266540A0328|103 122|Tcf/Lef family members
P11266558A1470|24 43|transcription extract
P11266558A1470|53 67|binding activity
P11266558A1470|88 103|initiator element
P11266558A1470|127 149|recruiting RNA polymerase
P11266558A1470|157 173|SL RNA gene promoter
P11266615A0258|60 71|linker region
P11266615A0258|76 92|amino acid residues
P11267679A0102|6 20|bp EcoRI fragment
P11267679A0102|39 59|Southern hybridization
P11267679A0102|73 84|reading frame
P11268459A0167|38 49|relationship
P11268459A0167|60 76|DOX binding ability
P11268459A0167|119 129|tumor volume
P11268459A0167|145 156|tissue tumors
P11268459A0167|174 185|chemotherapy
P11268887A1174|7 24|misinterpretations
P11268887A1174|32 46|reference values
P11268887A1174|65 78|preadolescents
P11271297T0000|0 13|Nephrotoxicity
P11271297T0000|29 48|liver transplantation
P11271297T0000|51 62|cyclosporin A
P11273995A1148|38 48|TOF patients
P11273995A1148|121 134|relaxation time
P11274109A0129|61 73|carbon sources
P11274179A0610|20 32|Rac/Cdc42/Pak
P11274184A0000|64 78|heme oxygenase-1
P11274184A0000|95 108|detoxification
P11274357A0724|20 33|overexpression
P11274357A0724|165 199|nucleoside diphosphate kinase activity
P11274368A0469|41 56|protein synthesis
P11274368A0469|76 101|histone deacetylase activity
P11274368A0818|22 37|initiator element
P11274368A0818|66 76|p21 promoter
P11275986A0091|5 16|gene products
P11275986A0091|40 64|p53 tumor suppressor protein
P11276426A0501|53 69|% sequence identity
P11277913T0000|82 96|mRNA translation
P11278286A0456|38 52|5-HT1A receptors
P11278286A0456|63 74|inactivation
P11278286A0456|162 176|corticosteroids
P11278290A1220|81 93|Agc expression
P11278290A1220|110 124|Smad2 activation
P11278290A1220|167 179|Agc expression
P11278310A1516|62 81|caspase-3 stimulation
P11278390A0632|7 49|transcriptase-polymerase chain reaction assays
P11278400A0668|76 94|homeodomain proteins
P11278400A0668|120 137|mobility shift assay
P11278440A0095|30 50|S1 transmembrane domain
P11278440A0095|76 89|hydrophobicity
P11278440A0095|101 111|S0-S1 linker
P11278461A0637|99 127|rainbow trout HIF-1alpha protein
P11278461A0637|138 149|rainbow trout
P11278461A0637|153 182|chinook salmon HIF-1alpha protein
P11278461A0637|185 203|Western blot analysis
P11278488T0000|3 16|v-Src SH3 domain
P11278488T0000|73 86|adhesion kinase
P11278521A0849|8 26|pair oligonucleotide
P11278521A0849|55 67|up-regulation
P11278521A0849|157 177|lacZ reporter construct
P11278563A0917|0 15|Deletion analyses
P11278563A0917|61 74|ankyrin repeats
P11278583A0873|44 57|effector motifs
P11278583A0873|91 103|ERK activation
P11278583A0873|115 129|differentiation
P11278583A0873|135 155|phosphotyrosine motifs
P11278583A0873|188 208|phosphotyrosine motifs
P11278594A0618|67 85|TGF-beta1 propeptide
P11278594A0618|182 196|MIC-1 propeptide
P11278604A0300|128 144|Lec20 cell extracts
P11278610A0902|54 67|ubiquitination
P11278671T0000|15 27|Bcl-2 homology
P11278671T0000|40 52|splice variant
P11278713A1054|76 94|instability elements
P11278713A1054|142 164|coding region determinant
P11278819A0565|0 17|Sequence comparison
P11278819A0565|21 34|binding studies
P11278819A0565|94 107|mouse IRBP genes
P11278819A0565|119 130|half sequence
P11278819A0565|145 155|core element
P11278819A0565|159 169|MOK2 binding
P11278848A1316|65 80|promoter activity
P11278848A1316|124 143|Sp1 consensus sequence
P11278855A0205|73 103|coimmunoprecipitation experiment
P11278855A0205|114 124|Western blot
P11278870A0123|49 69|copper transporter gene
P11278870A0123|72 83|fission yeast
P11278870A0123|187 209|transcription factor Cuf1
P11278928A1634|32 44|mRNA structure
P11278928A1634|75 87|mRNA structure
P11278928A1634|114 133|C/EBPepsilon isoforms
P11279038A0194|0 10|WRN helicase
P11279038A0194|28 40|DNA structures
P11279038A0194|75 91|Holliday junctions
P11279086A1350|83 96|tumor processes
P11279086A1350|172 183|cell adhesion
P11279108T0000|9 27|serum response factor
P11279108T0000|30 45|CArG box sequences
P11279108T0000|83 96|gene expression
P11279108T0000|113 123|muscle cells
P11279207A0904|49 60|TCR signaling
P11279324A0710|40 53|creatine kinase
P11279720A0844|0 16|SELECTION CRITERIA
P11279720A0844|142 154|complications
P11279720A0844|157 171|levodopa therapy
P11280495A1330|92 105|Amadori albumin
P11280799A1025|68 81|IL-8 production
P11281268A0000|17 31|arginine kinases
P11281268A0000|94 110|phosphagen kinases
P11281268A0000|130 161|sea anemone Anthopleurura japonicus
P11281268A0000|172 201|clam Pseudocardium sachalinensis
P11282029A0075|24 35|growth factor
P11282029A0075|40 60|beta-receptor promoter
P11282029A0075|112 124|transcription
P11282088A0837|0 10|Baseline MBF
P11282394A0841|14 25|VH/VL-chains
P11282394A0841|59 77|antigen reactivities
P11282394A0841|108 125|cross-reactivities
P11282395A0530|30 43|RAG1/2 proteins
P11282395A0530|53 63|DNA hairpins
P11282395A0530|109 122|protein complex
P11282395A0530|128 160|DNA repair proteins Nbs1/Mre11/Rad50
P11282395A1073|48 60|CDR3 sequences
P11282395A1073|85 103|kappaL chain gene loci
P11282395A1073|124 139|blood lymphocytes
P11282433T0000|90 103|cell lung cancer
P11282761A0531|4 18|supplementation
P11282761A0531|53 70|plasma L-citrulline
P11282761A0531|98 109|NO production
P11283014A0921|34 46|transcription
P11283014A0921|56 69|TCR stimulation
P11283014A0921|122 140|actin polymerization
P11283168A0738|108 122|mid-development
P11283354A0548|49 68|histone modifications
P11283354A0548|79 89|histone code
P11283354A0548|128 150|heterochromatin assembly
P11285054A0781|0 17|Regression analyses
P11285054A0781|28 49|SOREMP dream occurrences
P11285054A0781|100 120|NREMP dream occurrences
P11285235A0466|84 94|GATA factors
P11286833A0959|39 52|5-fluorouracil
P11286833A0959|66 88|maintenance chemotherapy
P11287555A1057|3 16|Delta6CCI virus
P11287555A1057|41 59|replication capacity
P11287555A1057|71 84|infectiousness
P11287578A1311|11 23|interleukin-8
P11287578A1311|52 64|protein 1alpha
P11287578A1311|134 146|keratinocytes
P11287579A1084|64 82|late-gene expression
P11287611A0802|80 91|troglitazone
P11287611A0802|127 138|cyclin D1 gene
P11287623A0286|83 98|signaling pathway
P11287623A0286|146 161|integrin subunits
P11287623A0286|182 195|mouse cell lines
P11288208A0712|36 50|tract infections
P11288208A0712|84 96|CD4 cell counts
P11288930A0000|27 40|administration
P11289135A0975|87 99|protein kinase
P11289135A0975|136 155|protein kinase cascade
P11289135A0975|161 172|PMA treatment
P11289135A0975|226 244|protein kinase kinase
P11289135A0975|246 259|inhibitor U0126
P11289135A0975|273 284|potentiation
P11289149A0658|27 39|transcription
P11289149A0658|66 86|transactivation domain
P11290415A0288|36 54|ICBP90 gene structure
P11290415A0288|99 109|PCR analysis
P11290906T0000|10 21|accumulation
P11290906T0000|24 34|Tl-201 SPECT
P11292335A0852|32 46|mutator mutation
P11292335A0852|58 77|sequence substitution
P11292335A0852|145 162|frameshift mutation
P11292839A0531|3 15|transcription
P11294895A0292|29 39|gene product
P11294895A0292|102 136|phosphatidylinositol transfer protein
P11295470A0954|20 40|linkage disequilibrium
P11295760A1374|0 20|Specimen mass reduction
P11296288A1107|37 51|pCMVJS21DeltaGP
P11297419A0894|6 17|W21F rGST A1-1
P11297419A0894|45 61|fluorescence probe
P11297514A0218|12 23|hos1 mutation
P11297514A0218|52 74|CBF transcription factors
P11297545A0948|6 17|transfection
P11297545A0948|44 57|carcinoma cells
P11297866A0484|17 27|I. argentina
P11298326A0677|26 36|Vkappa genes
P11298326A0677|123 136|point mutations
P11301189A1396|86 99|B-lineage cells
P11302072A0508|62 77|Boston Naming Test
P11302072A0508|82 104|Word List Recognition Task
P11302072A0508|113 124|intervention
P11302072A0508|154 165|significance
P11302566A1318|47 73|dopamine receptor sensitivity
P11302566A1318|77 94|psychomotor slowing
P11302704T0000|0 19|Homo-oligomerisation
P11302704T0000|30 41|localisation
P11302704T0000|44 66|mouse histone deacetylase
P11303027A0954|32 43|interactions
P11303638A0559|4 20|NEU overexpression
P11305129T0000|10 20|booster dose
P11305129T0000|23 35|tetanus toxoid
P11305129T0000|77 88|implications
P11306101A0000|5 18|RACE techniques
P11306101A0000|51 62|hamster liver
P11306101A0000|85 98|dehydrogenases
P11306101A0000|140 162|17beta-hydroxy-steroids
P11306101A0000|166 187|3alpha-hydroxysteroids
P11306463A0383|70 91|cdk4/D1 phosphorylation
P11306511A1476|105 124|progesterone receptor
P11306845A0168|57 72|blister formation
P11306845A0168|85 97|keratinocytes
P11308851A0333|13 28|response function
P11308851A0333|77 90|frequency range
P11308851A0333|106 123|material parameters
P11308877A0213|68 78|input phases
P11308877A0213|92 105|discharge times
P11308877A0213|143 172|orientation preserving circle map
P11309373A0783|84 95|mCTR isoforms
P11309389A0273|63 103|phorbol ester phorbol 12-myristate 13-acetate
P11309389A0273|117 139|metalloprotease activity
P11309389A0273|213 225|domain remnant
P11309389A0273|239 253|down-regulation
P11309389A0273|256 267|GHR abundance
P11309389A0273|271 281|GH signaling
P11309400T0000|10 30|terminus modifications
P11309400T0000|65 80|protein synthesis
P11309677A0000|70 83|Gulf War Illness
P11309678A0489|7 31|transcription-PCR analysis
P11311153T0000|3 14|relationship
P11311153T0000|20 40|factor V Leiden mutation
P11311153T0000|63 74|polymorphism
P11311153T0000|122 141|thromboembolic events
P11311153T0000|161 172|arthroplasty
P11311464A0362|33 48|saddle anesthesia
P11311464A0362|70 82|motor weakness
P11311464A0362|126 143|bladder dysfunction
P11311480A0079|5 15|nerve biopsy
P11311480A0079|87 102|cell infiltration
P11311550A0253|39 50|rat eIF4E gene
P11311550A0253|61 82|rat eIF4E promoter region
P11311550A0253|98 109|contribution
P11311550A0253|140 152|transcription
P11311550A0253|185 198|rat cardiocytes
P11311550A0253|213 228|myoblast cell line
P11311563A0423|44 60|promoter construct
P11311563A0423|61 71|OA induction
P11311687A0231|42 52|RLS severity
P11311909A0938|72 85|A1 fenestration
P11312120A1311|0 25|NF-kappaB pathway activation
P11312120A1311|38 51|transformation
P11312326A0169|55 80|complementation experiments
P11312326A0169|202 217|virus replication
P11312584X1846|13 25|Academic Press
P11313249T0000|88 103|activation domain
P11313342A0224|24 43|alanine substitutions
P11313342A0224|55 73|center cleft residues
P11313342A0224|96 107|depurinating
P11313386A0704|0 18|SH2D1A protein levels
P11313386A0704|36 52|CD40 cross-linking
P11313386A0704|72 92|B cell receptor ligation
P11313398A0687|0 20|Cross-linking FcalphaR
P11313398A0687|32 44|IIA-ITAM cells
P11313946T0000|73 85|gene induction
P11314030A1264|113 126|signal pathways
P11314046A0000|25 36|determinants
P11314046A0000|47 66|cell cycle progression
P11314428A0651|37 50|hydroxyapatite
P11314428A0651|81 92|significance
P11314428A0651|101 122|months width differences
P11315633A0920|3 14|cleavage site
P11315633A0920|40 52|RNA polymerase
P11315633A0920|88 112|amino acid sequence analysis
P11315633A0920|142 154|sobemoviruses
P11316127A0485|73 85|Control groups
P11317256A0361|19 31|S. intermedius
P11317256A0361|49 62|S. constellatus
P11317256A0361|81 91|S. anginosus
P11318608A0669|5 29|brain cDNA library screening
P11318608A0669|39 51|amplification
P11318608A0669|112 123|reading frame
P11318608A0669|187 205|localization signals
P11318608A1155|0 11|Transfection
P11318608A1155|25 50|DENTT NLS deletion constructs
P11319098A0164|17 32|tryptophanyl tRNA
P11319098A0164|36 66|protein translocase component SecE
P11319098A0164|84 94|protein NusG
P11319098A0164|110 120|proteins L11
P11319098A0164|173 187|LacI-GalR family
P11319880A1108|9 26|FRAP/mTOR inhibitor
P11319880A1108|34 54|4E-BP1 phosphorylation
P11319880A1108|63 74|predominance
P11323411A0505|0 21|Far Western blot analysis
P11323411A0505|102 112|N-SH2 domain
P11323411A0505|120 134|phosphotyrosine
P11323411A0505|147 157|C-SH2 domain
P11323419T0000|56 70|blood group alpha
P11323419T0000|73 95|fucosyltransferase genes
P11323419T0000|121 142|mouse uterine epithelium
P11323716A0413|46 57|interactions
P11324516A0159|25 38|administration
P11324516A0159|45 69|D2 receptor agonist LY171555
P11324516A0159|72 102|D1/D2 receptor agonist apomorphine
P11324516A0159|112 124|pain threshold
P11324516A0159|132 149|potentiating effect
P11325195A0661|61 75|pork longissimus
P11325391A0498|15 27|d-amphetamine
P11325685A1624|11 30|L-carnitine treatment
P11325685A1624|40 68|plasma carnitine concentrations
P11325685A1624|129 144|exercise capacity
P11325685A1624|147 166|hemodialysis patients
P11325944A0511|47 59|hybrid protein
P11325944A0511|73 96|glutathione S-transferase
P11325944A0511|171 184|uhpT expression
P11327292A0190|29 40|malformation
P11327698A0191|20 40|p44/p42MAPK signalings
P11327698A0191|118 130|PKC activation
P11327698A0191|138 156|PKC expression vector
P11327698A0191|166 183|Sp1 phosphorylation
P11327698A0191|226 238|PKC inhibition
P11327698A0191|241 258|PKC inhibitor Go6976
P11327698A0191|266 283|Sp1 phosphorylation
P11327698A0191|355 367|MEK activation
P11327698A0191|382 399|Sp1 phosphorylation
P11327858A0087|39 53|oncoprotein Hdm2
P11328699A0000|120 132|test situation
P11328853A0644|20 42|promoter deletion mutants
P11328853A0644|82 95|promoter region
P11328853A0644|107 123|promoter sequences
P11331589A0113|41 55|male X chromosome
P11331604A0267|32 44|Gcn4 stability
P11331604A0267|56 70|phosphorylation
P11331604A0267|103 114|srb10 mutants
P11331613A0827|19 30|pVHL function
P11333263A0240|60 73|leader sequence
P11333263A0240|105 120|promoter activity
P11333268A1521|35 46|interactions
P11333268A1521|110 121|consequences
P11333268A1521|256 270|GDP dissociation
P11334124A0903|11 23|dose-response
P11335116A1099|0 19|Bandshift experiments
P11335116A1099|84 112|Orphan receptor Response Element
P11335116A1099|238 251|vitellogenesis
P11335710A0320|44 56|Erk activation
P11336698A0075|57 80|yeast remodeler RSC complex
P11337859A0651|9 21|color removals
P11337859A0651|147 183|hydrogen peroxide oxidation pretreatment
P11340048A0432|42 54|flux densities
P11340048A0432|113 125|flux densities
P11340080A0096|28 46|checkpoint signaling
P11340080A0096|87 105|immunoprecipitation
P11340085A0211|101 112|coactivators
P11340085A0211|126 142|amino acid sequence
P11340085A0211|241 261|transactivation domain
P11340516A0509|35 46|Vicryl suture
P11340525A0737|36 49|study end points
P11340525A0737|125 149|treatment success criterion
P11341349T0000|29 56|breast cancer screening program
P11341405A0146|24 39|racing Greyhounds
P11341405A0146|73 88|MCB abnormalities
P11341405A1154|162 176|dorsal quadrants
P11342479A0430|17 35|Palmaz-Schatz stents
P11342479A0430|75 89|microgram/stent
P11344530A0320|35 47|dilution tests
P11345435A0199|17 29|RNA subdomains
P11345435A0199|88 99|localization
P11345445A0533|64 79|Cd concentrations
P11345445A0533|157 170|concentrations
P11347201X0001|0 16|Nutritional status
P11348318A0940|87 102|characterization
P11349796A0950|0 11|Measurements
P11350038A0459|68 80|stem structure
P11350038A0459|124 136|export process
P11350165A1606|51 63|stem structure
P11350165A1606|84 104|translation efficiency
P11350175A0173|35 47|protein family
P11350175A0173|77 93|chaperone activity
P11350812A0829|15 34|Raf-1 target ERK kinase
P11350812A0829|87 99|ERK activation
P11350812A0829|100 123|caldesmon phosphorylation
P11350812A0829|127 146|stress fiber formation
P11350982A0560|48 67|GCN1-GCN2 interaction
P11352423A0084|9 19|forearm flap
P11352671A0492|47 62|nucleotide change
P11353392A1127|56 69|coding sequence
P11353392A1127|95 106|ASIP mutation
P11353770A0085|64 84|N-glycosylase activity
P11353770A0085|100 119|8-oxoguanine residues
P11353774A0255|27 42|characterization
P11353774A0255|48 64|forkhead homologue
P11353774A0255|67 82|rhabdomyosarcoma
P11353774A0255|133 148|factor 3/forkhead
P11353774A0255|177 191|hormone receptor
P11354406A1373|11 31|CSF outflow conductance
P11354406A1373|97 107|ICP waveform
P11355576A1125|45 59|phosphorylation
P11355576A1125|82 103|tumor suppressor protein
P11355576A1125|133 153|pRb controls commitment
P11355576A1125|222 244|E2F transcription factors
P11355576A1125|259 275|cell proliferation
P11355615A0766|66 77|intervention
P11355615A0766|81 93|incorporation
P11355668T0000|13 24|vasculopathy
P11355668T0000|50 64|porcine neonates
P11355668T0000|113 125|syndrome virus
P11356214A0794|67 91|Knoop hardness measurements
P11356214A0794|124 137|resin specimens
P11356716A0372|54 66|GHS-R variants
P11356835A0000|112 128|protein precursors
P11356835A0000|135 153|amino acid starvation
P11356853A0429|38 59|luciferase reporter gene
P11356853A0429|89 109|pair mouse ho-1 promoter
P11356853A0554|0 15|Mutation analyses
P11356853A0873|12 26|AP-1 superfamily
P11356853A0873|29 54|basic-leucine zipper factors
P11357063A0138|0 11|Descriptions
P11357063A0138|147 159|LH/CGbeta gene
P11357063A0138|173 201|LHbeta-CGbeta gene cluster locus
P11357063A1053|57 71|gpLH/CGbeta gene
P11357063A1053|87 98|TATA sequence
P11357063A1053|116 136|translation start codon
P11358801A1046|42 55|NHEJ deficiency
P11358801A1046|70 83|rearrangements
P11358958A0878|53 68|growth inhibition
P11358962A0344|61 76|mouse development
P11358962A0344|81 95|Foxp2 expression
P11358962A0344|111 126|airway epithelium
P11359568T0000|22 43|pRA2 partitioning region
P11359568T0000|61 78|parAB transcription
P11359568T0000|88 107|nucleoprotein complex
P11359568T0000|115 134|plasmid partition site
P11359827T0000|27 42|characterization
P11359907A0099|7 23|dozen HIF-1 targets
P11359907A0099|75 86|growth factor
P11360190A0178|34 53|cell cycle progression
P11360190A0178|91 103|T-cell line Kit
P11361338A0093|20 33|matrix proteins
P11361338A0093|68 82|targeting signal
P11361338A0093|102 114|tripeptide SKL
P11361338A0447|7 21|PEX5-TPR domains
P11361338A0447|103 116|Pex5p chimaeras
P11361493T0000|8 32|hepatitis B virus infections
P11361493T0000|54 71|security institutes
P11361493T0000|74 84|Buenos Aires
P11367523A1684|0 24|Immunofixation experiments
P11367523A2624|7 17|C4B proteins
P11367523A2624|71 84|concentrations
P11368363A0129|25 44|transcription factors
P11368363A0129|70 84|myeloperoxidase
P11368363A0129|164 187|HMG-Box containing protein
P11368363A0129|205 217|mobility group
P11368363A1103|8 22|protein sequence
P11368363A1103|119 134|repressor domains
P11368787A0180|70 82|annexin A5 gene
P11368787A0180|134 157|transcription start points
P11368911T0000|9 22|identification
P11368911T0000|41 56|mRNA surveillance
P11368914T0071|33 53|complement C3 gene locus
P11369066A1210|34 47|corticosteroid
P11369066A1210|145 163|radiation dermatitis
P11369106A0428|62 73|interactions
P11369106A0428|77 99|transformation processes
P11369410A0949|44 62|stimulus differences
P11369410A0949|136 147|participants
P11369453A1083|20 33|protein binding
P11369453A1083|58 73|peptide treatment
P11369700A0074|28 40|chain isotypes
P11369700A0074|55 69|B cell activators
P11369700A0074|80 92|transcription
P11369700A0074|125 135|region genes
P11369700A0616|55 74|mouse GL alpha promoter
P11369700A0616|82 106|transcription factors Elf-1
P11369700A0616|155 176|luciferase reporter gene
P11369700A0616|188 202|GL alpha promoter
P11370174A0447|7 26|serum creatinine level
P11371115A0962|92 102|MPGN pattern
P11371160A0193|39 53|base-pair C1-G72
P11371160A0193|57 76|discriminator base A73
P11371160A0854|29 41|anticodon loop
P11371160A0854|81 96|TyrRS interaction
P11371160A0854|125 136|tyrosylation
P11371417A0744|23 34|control lungs
P11371417A0744|56 70|chord compliance
P11371417A0744|83 98|lung lavage levels
P11371417A0744|101 119|tumor necrosis factor
P11371417A0744|263 280|preventilation data
P11372882A1143|14 27|beta-HCH levels
P11372959A1447|8 25|regression analysis
P11372959A1447|114 125|relationship
P11372959A1447|126 139|R2 coefficients
P11372959A1447|148 162|habitat category
P11372959A1447|193 205|tick abundance
P11373277A0812|36 49|oncoprotein E1A
P11373277A0812|59 71|transcription
P11373277A0812|89 101|AP-2alpha gene
P11373277A0812|137 148|derepression
P11373277A0812|154 170|AP-2alpha promoter
P11373277A0812|203 218|corepressor CtBP1
P11374051A0437|50 64|corticosteroids
P11374051A0437|67 80|anticoagulants
P11374051A0437|86 103|ulcer complications
P11374559A0103|0 10|SERS spectra
P11374559A0103|25 41|vacuum evaporation
P11374559A0103|69 79|island films
P11374559A0103|91 114|colloidal silver solutions
P11374866X0914|13 25|Academic Press
P11375392T0000|3 14|core promoter
P11375392T0000|22 41|thioredoxin reductase
P11376007A0584|46 66|protein kinase activity
P11376007A0584|135 152|protein phosphatase
P11376007A0584|156 175|protein phosphatase 2A
P11376007A0584|191 202|reactivation
P11376007A0584|223 249|protein phosphatase inhibitor
P11376134A1506|58 76|transcription factor
P11376165T0000|6 27|Cre recombinase function
P11376165T0000|30 43|Xenopus embryos
P11376279A0000|103 119|volume acquisition
P11376687A0344|7 28|nucleotide polymorphism
P11376687A0344|156 170|MTH1 polypeptide
P11376687A0344|212 226|targeting signal
P11377975A0898|55 72|proteinase activity
P11378898A0164|10 21|EMBL databank
P11378898A0164|22 33|Accession No.
P11379106A0372|42 66|deammonification processes
P11380028A0000|66 77|Technetium Tc
P11380028A0000|97 114|orthoiodohippurate
P11380028A0000|127 141|plasma clearance
P11380028A0000|164 175|blood samples
P11380370A0000|23 33|skin lesions
P11380837A1505|0 12|Interventions
P11380837A1505|128 144|access dysfunction
P11381094A0797|39 52|synaptotagmins
P11382701A0688|81 105|plasma sodium concentration
P11382948A0793|58 83|tumor microvessel properties
P11382948A0793|90 106|breast cancer model
P11382948A0793|120 131|permeability
P11383860A0661|51 68|99mTc ciprofloxacin
P11383860A0661|96 111|bone marrow uptake
P11383860A0661|118 128|liver uptake
P11384225A0634|11 28|expression cassette
P11384229A1669|10 21|N63S mutation
P11384229A1669|36 48|VP5 background
P11384229A1669|85 110|beta-galactosidase activity
P11384229A1669|140 150|PR7 mutation
P11384880A0719|28 40|3beta-HSD type
P11384880A0719|42 55|gene expression
P11384880A0719|93 109|breast cancer cells
P11385840A1684|12 23|RTC algorithm
P11385840A1684|35 50|wastewater system
P11385840A1684|113 132|optimization routines
P11387208T0000|0 33|SKP1-SnRK protein kinase interactions
P11387208T0000|62 84|plant SCF ubiquitin ligase
P11387351A0092|75 102|analog 2-chlorodeoxyadenosine
P11387950X0001|86 97|pancreatitis
P11387950X0001|150 170|leukocyte adhesiveness
P11387950X0001|174 192|tumor necrosis factor
P11387950X0001|229 240|pancreatitis
P11387950X0001|361 377|leukocyte adhesion
P11387950X0001|381 392|TNF secretion
P11389077A0000|27 43|signaling pathways
P11389085A0290|13 23|MTC cell line
P11389085A0290|34 45|MEN 2A type RET
P11389085A1032|24 40|NF-kappaB activity
P11389085A1032|77 90|focus formation
P11389085A1032|121 131|NIH 3T3 cells
P11390395A1018|12 27|HMGI-C expression
P11390395A1018|93 107|transactivation
P11390581A1203|20 33|identification
P11390650A0562|10 26|deletion mutations
P11390663A1400|56 80|induction pathway operating
P11390663A1400|87 102|Gcn4p target genes
P11390684A1170|13 33|Northern hybridization
P11390684A1170|47 60|jadM expression
P11390684A1170|77 95|jadomycin B synthesis
P11391303A0807|28 40|interobserver
P11391303A0807|44 71|intraobserver reproducibility
P11391303A1023|27 40|LHR measurement
P11391303A1023|75 86|contribution
P11391303A1023|89 114|Tl-201 lung uptake evaluation
P11391531A1157|13 25|NF-kappaB site
P11391531A1157|31 43|Mdr1b promoter
P11391793A0856|126 138|bacteriophage
P11392772A0182|19 31|biotechnology
P11392772A0182|60 77|surface storm waters
P11392772A0182|95 106|zone Telychka
P11393463A0274|34 47|student samples
P11393463A0274|81 100|NEO-PI-R self-ratings
P11393463A0274|147 160|informant group
P11393463A0274|239 251|month interval
P11393791A1153|0 19|Northern blot analysis
P11393791A1153|39 50|mouse tissues
P11393791A1153|167 189|polymerase chain reaction
P11397652A0381|31 41|spiral assay
P11397652A0381|68 78|test methods
P11397652A0381|116 127|difficulties
P11397652A0381|144 161|sample availability
P11397652A0381|162 176|sample viscosity
P11398134A1565|19 31|alcohol intake
P11398134A1565|116 128|hyperuricemia
P11398899A1183|91 107|PH3 concentrations
P11399064T0000|0 13|Autoregulation
P11399064T0000|47 78|CCAAT/enhancer binding protein beta
P11399064T0000|88 100|transcription
P11399834T0000|14 30|HCV seroconversion
P11399834T0000|49 60|introduction
P11399834T0000|63 77|HCV NAT screening
P11400644A0435|15 27|uncertainties
P11400644A0435|82 95|PCDD/F releases
P11401105T0000|37 50|cancer patients
P11401611A1703|14 26|meta-analysis
P11402674T0000|0 28|Newcastle disease antibody titre
P11402674T0000|42 66|serum calcium concentration
P11403173A0192|31 42|brain tumours
P11403719A1257|50 64|egr-1 expression
P11404016A1922|3 14|co-existence
P11404016A1922|153 168|peptide synthases
P11404019A0532|8 20|understanding
P11404019A0532|26 41|mGSTM2 regulation
P11404019A0532|72 85|promoter region
P11406007A0292|0 16|SELECTION CRITERIA
P11406007A0292|85 98|contraceptives
P11406025A0204|49 61|effectiveness
P11406025A0204|71 83|acceptability
P11406277A0598|50 65|promoter activity
P11406277A0598|79 104|reporter expression activity
P11406277A0598|166 190|parent Hlx promoter sequence
P11407448A0815|71 95|jejunum flap reconstruction
P11407448A0815|124 144|tract voice restoration
P11407448A0815|172 186|voice prosthesis
P11407448A0815|251 264|speech training
P11407650A0661|0 12|Hypercalcemia
P11407650A0661|35 55|serum PTH concentration
P11407650A0661|73 91|hyperparathyroidism
P11407650A0661|151 163|thyroid cancer
P11408099A0518|22 33|correlations
P11408338A1686|132 143|neurologists
P11408575A0000|80 90|kinase Cdc28
P11408591A0000|55 66|cell motility
P11408591A0000|87 98|v-src mutants
P11408604A1440|48 63|ERK kinase cascade
P11408604A1440|95 106|PDGF receptor
P11408604A1440|176 197|receptor tyrosine kinase
P11409425A0000|12 24|plasma samples
P11409425A0000|45 61|National Institute
P11409425A0000|98 123|tissue plasminogen activator
P11409425A0000|128 138|Stroke Trial
P11409425A0000|151 162|relationship
P11409425A0000|172 185|apolipoprotein
P11409425A0000|195 208|Apo E4 phenotype
P11409425A0000|306 316|t-PA therapy
P11410110A0190|82 97|forearm blood flow
P11410563A0363|49 66|regression analysis
P11410563A0363|80 94|body surface area
P11410563A0363|104 124|shop order fracture rate
P11410563A0363|128 146|manufacturing period
P11410563A0363|149 159|risk factors
P11410664A0963|42 70|breast carcinoma MDA-MB231 cells
P11410664A0963|115 127|up-regulation
P11410664A0963|220 235|repair activities
P11410679A0000|38 51|Cre recombinase
P11410679A0000|63 75|rearrangement
P11410679A0000|92 114|LOX recognition sequences
P11411198A0711|54 66|Ashkenazi Jews
P11411198A0711|117 129|stomach cancer
P11411623T0000|11 28|compression therapy
P11411623T0000|52 63|tissue injury
P11411961A0735|0 24|Keratoconjunctivitis sicca
P11411961A0735|49 60|complication
P11413148A0573|0 14|STAT5A mutations
P11413148A0573|20 30|Src homology
P11413148A0573|74 96|tyrosine phosphorylation
P11413277A1121|19 30|chemotherapy
P11413310A0148|76 86|CC chemokine
P11413310A0148|205 216|RSV infection
P11413319A0000|0 12|Reovirus mRNAs
P11413641A0373|20 31|scale matters
P11413641A0373|57 67|quadrat area
P11413760A0000|85 96|ACh receptors
P11414754X1099|13 25|Academic Press
P11415952A0369|30 41|associations
P11415952A0369|89 113|electrocardiogram ischemia
P11415952A0369|140 157|heart disease events
P11416012A1982|47 58|contribution
P11416012A1982|85 95|LDL receptor
P11416012A1982|108 122|reporter plasmid
P11416012A1982|157 190|rabbit muscle protein kinase inhibitor
P11416012A1982|229 248|sarcoma virus promoter
P11416012A2511|35 62|insulin/IGF-I effector pathway
P11416012A2511|95 123|LDL receptor promoter expression
P11416012A2511|205 231|phophatidylinositol 3-kinase
P11416012A2511|287 305|protein kinase kinase
P11416012T0000|42 71|density lipoprotein receptor gene
P11416012T0000|161 173|protein kinase
P11416012T0000|175 202|phosphatidylinositol 3-kinase
P11416012T0000|223 252|protein kinase signaling pathways
P11416132A1351|66 88|repeat binding activities
P11416144A1324|21 33|understanding
P11416144A1324|54 70|cell proliferation
P11416260A0000|149 160|data analysis
P11416393A0000|68 88|lifestyle modification
P11416393A0000|109 130|blood pressure elevation
P11416393A0000|132 146|weight reduction
P11416393A0000|184 195|hypertension
P11416393A0000|254 270|sodium restriction
P11416393A0000|423 440|alcohol consumption
P11416393A0000|478 492|exercise program
P11416393A0000|508 525|tobacco consumption
P11416650T0000|16 27|Hypertension
P11416737T0000|8 25|Tl-201 scintigraphy
P11416737T0000|42 53|plasmacytoma
P11416879A1589|8 23|blood gas tensions
P11416879A1589|44 59|ventilation modes
P11418130A0499|20 32|loxP sequences
P11418130A0499|65 77|recombination
P11418662A0917|37 49|p50 DNA binding
P11419938T0000|32 54|uptake regulation protein
P11419938T0000|59 73|metal activation
P11419938T0000|129 152|diphtheria toxin repressor
P11420612A0303|36 52|sequencing efforts
P11420612A0303|96 107|sequence data
P11422200A0000|40 53|administration
P11422200A0000|84 100|defence mechanisms
P11423991A1393|54 64|p53 variants
P11423991A1393|145 159|cancer therapies
P11425076A0364|99 112|Reynolds number
P11425076A0364|157 181|perturbation theory results
P11425877A1026|115 135|fluid phase pinocytosis
P11425877A1026|217 230|F-actin content
P11427329A1077|56 67|correlations
P11427611A0000|3 16|susceptibility
P11427611A0000|41 53|mulundocandin
P11427611A0000|121 137|National Committee
P11427611A0000|149 167|Laboratory Standards
P11427611A0000|173 183|M38-P method
P11427611A0000|222 233|phenyl-amino
P11427611A0000|241 262|H-tetrazolium hydroxide
P11427611A0000|290 302|determination
P11428276A0352|15 29|syndrome lesions
P11428276A0352|56 66|calcium salt
P11428435A0446|20 30|chart review
P11428435A0446|79 91|period January
P11428487T0000|53 64|vein stenosis
P11429702A0917|105 116|FGFR3 mutants
P11429702A0917|163 176|K650E receptors
P11429702A0917|229 251|receptor phosphorylation
P11430042A0000|16 37|Stille coupling reaction
P11430042A0000|83 99|tetrafluoroborate
P11430976X0000|25 36|biosynthesis
P11430976X0000|39 59|woody plant biopolymers
P11431348A0000|0 11|Interactions
P11431348A0000|22 46|checkpoint abrogator UCN-01
P11431348A0000|104 116|protein kinase
P11431348A0000|129 139|MAPK pathway
P11431348A0000|173 189|leukemia cell lines
P11431472A0540|3 17|affinity binding
P11431857A0186|25 38|urine screening
P11431857A0186|75 87|urine analysis
P11431857A0186|123 135|urine analysis
P11432112A0000|46 59|embryo cleavage
P11432112A0000|90 103|sperm injection
P11432112A0000|126 147|embryo selection process
P11432748T0000|12 42|laminin beta2 chain gene expression
P11432748T0000|50 64|cancer cell lines
P11432776A0421|11 29|Western blot analyses
P11433014A0683|44 57|core histone H2A
P11433018A0756|48 59|H/ACA snoRNAs
P11433018A0756|86 97|H/ACA snoRNPs
P11433024A0260|13 36|ribonucleoprotein complex
P11433024A0260|87 98|RNA component
P11433379A0000|32 45|adaptor protein
P11433379A0000|80 93|adaptor protein
P11434084A0508|40 54|microlatex tests
P11435428A0000|9 28|acetyl-CoA synthetase
P11435428A0000|84 97|lipid synthesis
P11435517A0396|5 19|digestibilities
P11435517A0396|146 156|control diet
P11435560A1322|29 38|HFV R region
P11435560A1322|83 95|target HFV mRNA
P11435578A2231|18 31|reconstitution
P11435578A2231|35 46|consensus CRE
P11435578A2231|88 103|CREB/ATF proteins
P11435578A2231|145 157|transcription
P11435605A0587|41 56|CAR residues Leu73
P11435605A0587|89 103|contact residues
P11435605A0587|151 168|binding interaction
P11435605A0587|189 203|Ad41L fiber knobs
P11435688A0262|91 111|transmembrane segments
P11435983T0000|16 30|transplantation
P11437439A0201|3 18|promoter activity
P11437439A0201|71 83|prestalk cells
P11437660A1219|0 11|Substitution
P11437660A1219|14 27|serine residues
P11437660A1219|62 81|phosphorylation sites
P11437660A1219|111 123|transcription
P11438651A1365|4 26|replication fork movement
P11438651A1365|74 94|replication initiation
P11438651A1365|135 154|replication initiator
P11438654A1237|27 37|adapter Gab1
P11438654A1237|49 62|c-Met signaling
P11438654A1237|83 111|c-Akt/Pak1 cell survival pathway
P11438666A0555|18 29|mouse protein
P11438666A0555|55 70|plant homeodomain
P11438666A0555|101 119|immunoprecipitation
P11438666A0555|134 147|TFIID component
P11438838A0788|60 70|RNA promoter
P11439343A0785|35 46|Pc protein M33
P11441311X0001|30 45|radiation therapy
P11441311X0001|113 132|chemotherapy regimens
P11441952A0414|135 148|months post-TBI
P11441952A0414|191 203|avoidance test
P11441974A0320|40 51|hemolymph PO2
P11443509A0293|17 27|cohort study
P11443509A0293|54 72|First National Health
P11443509A0293|76 92|Examination Survey
P11443999A0573|0 19|Mean Hg concentrations
P11443999A0573|94 109|Hg concentrations
P11443999A0573|126 143|government agencies
P11445008A0816|52 71|FGFR expression levels
P11445008A0816|112 125|RNA pool samples
P11448051A0093|52 71|intestine transit time
P11448051A0093|189 201|Eudragit RS100
P11449014A0000|0 13|STUDY OBJECTIVE
P11449014A0000|132 144|participation
P11449014A0000|149 178|epidemiologist/biostatistician
P11450490A0565|53 70|range hand motions/0
P11451682A0190|10 21|chemotherapy
P11451682A0190|38 51|administration
P11451682A0190|54 86|benzimidazole carbamate derivatives
P11451995T0000|82 129|isoprenylcysteine carboxyl methyltransferase family
P11454004T0000|58 94|glycerol-3-phosphate dehydrogenase gene
P11454004T0000|95 108|identification
P11454004T0000|119 141|hormone-response element
P11454190A0000|0 14|BACKGROUND/AIMS
P11454190A0000|40 56|fatty liver disease
P11454190A0000|87 98|liver disease
P11454190A0000|104 115|United States
P11454239A0478|35 76|Pearson Product Moment Correlation Coefficient
P11454239A0478|77 103|Principal Components Analysis
P11454239A0478|107 134|Discriminant Function Analysis
P11454703A0000|72 85|chromosome ends
P11454703A0000|170 184|immortalization
P11454703A0000|194 206|tumorigenesis
P11456259A0142|10 42|TSH binding inhibitor immunoglobulin
P11456259A0142|71 82|presentation
P11457139A0604|56 66|affinity Man
P11459048A0485|27 39|uncertainties
P11459048A0485|131 144|rotation states
P11459304T0078|0 19|Enantiomer separation
P11459304T0078|36 57|O-desmethylvenlafaxine
P11459794A1172|0 10|TE-671 cells
P11459794A1172|34 52|cAMP response element
P11459794A1172|110 124|GnRH-II promoter
P11459962A0785|56 68|repair pathway
P11459962A0785|96 112|rad27 Delta strains
P11459962A0785|142 155|semipermissive
P11459962A0785|166 177|temperatures
P11460035A0548|17 34|hydroxychloroquine
P11460035A0548|35 47|carbamazepine
P11460035A0548|72 83|imputability
P11461595A0000|16 31|reaction kinetics
P11461595A0000|75 89|coalescence type
P11462004A0886|80 94|complementation
P11462004A1500|155 166|localization
P11462952A1040|7 19|gastrin levels
P11463359A0167|17 31|phorbol ester PMA
P11463359A0167|92 105|luciferase gene
P11463359A0167|126 139|G6Pase promoter
P11463359A0167|164 181|H4IIE hepatoma cells
P11463834A0606|7 25|deletion mutagenesis
P11463834A0606|119 132|Tax interaction
P11465518A0000|46 58|investigators
P11465655A0439|31 48|antagonist atenolol
P11465844T0000|24 39|Kawasaki syndrome
P11465844T0000|56 72|Rickettsia conorii
P11465844T0000|73 87|Rickettsia typhi
P11465844T0000|88 103|Coxiella burnetii
P11465844T0000|106 133|Ehrlichia phagocytophila group
P11466227A1665|72 87|mTf-CAT construct
P11468958A0122|29 42|policy analysis
P11468958A0122|176 188|travel history
P11469701A0377|18 38|insulin administration
P11469701A0377|76 89|insulin therapy
P11469701A0377|153 172|insulin concentration
P11469737A1791|39 60|muscle function recovery
P11469853A0702|21 35|domain shuffling
P11469926T0000|0 25|Breast cancer risk assessment
P11469926T0000|42 52|crystal ball
P11469970A0873|37 48|hyperalgesia
P11469970A0873|57 71|antidepressants
P11469970A0873|95 117|botulinum toxin injection
P11470914A0305|24 41|STAT3 translocation
P11470914A0305|83 96|gene expression
P11472523A0535|10 25|Extrusion cooking
P11472523A0535|43 54|inactivation
P11472523A0535|92 105|metabisulphite
P11472696A0387|30 45|fibrinogen levels
P11473254A0000|10 24|DNA endonuclease
P11473254A0000|30 42|topoisomerase
P11473254A0000|46 66|recombinase activities
P11473261A0587|36 66|guanine nucleotide exchange factor
P11474642A1451|49 61|hexamethonium
P11478627A0573|3 22|desirability function
P11478627A0573|75 88|transformation
P11479104A0446|96 113|lupus erythematosis
P11479501A0744|26 37|distribution
P11479501A0744|122 139|St Jude Medical valve
P11479501A0744|158 172|Omnicarbon valve
P11480497T0000|22 32|JP-8 jet fuel
P11481625A0202|78 98|interferon alfa-2b dose
P11481625A0202|121 140|peginterferon alfa-2b
P11484028T0000|2 14|cross purposes
P11484578A1132|36 50|measurement data
P11484578A1132|81 95|measurement data
P11484578A1132|140 152|design program
P11486032A1261|8 27|transcription factors
P11486141A0424|83 94|meta analysis
P11486399A0000|64 77|salvage regimen
P11486476A0147|50 64|characteristics
P11486476A0147|103 118|markers troponin T
P11486476A1512|7 22|markers troponin T
P11489597A0379|160 172|malformations
P11489597A0561|84 97|pregnancy rates
P11490862A0141|25 45|bladder neck suspension
P11490862A0141|57 70|Stamey-Pereyra
P11490862A0141|88 98|bone anchors
P11494391A0579|40 59|artery-alone ALT graft
P11494391A0579|126 138|bile secretion
P11495920A0504|7 18|pair mismatch
P11495920A0504|91 106|enhancer activity
P11496495A0000|64 76|possibilities
P11496617A0301|42 55|thyroid surgery
P11496617A0301|153 164|mg dolasetron
P11496617A0301|224 235|mg dolasetron
P11498795A0716|61 75|phosphorylation
P11498795A0716|115 130|S phase transition
P11500512A0000|71 89|transporter proteins
P11500571A0976|27 44|NtmybAS transcripts
P11500571A0976|59 74|gPAL1 transcripts
P11500913A1238|0 11|C/EBPbeta LIP
P11500913A1238|48 62|beta-casein mRNA
P11500913A1238|80 104|cell differentiation marker
P11502738A1457|105 120|cyclin D1 promoter
P11502758A0869|66 78|FGFR signaling
P11502778A0941|34 48|estradiol levels
P11502778A0941|130 150|bone resorption markers
P11502778A0941|174 188|estradiol levels
P11504545A0393|26 38|mobility shift
P11504545A0393|42 58|immunoshift assays
P11505407A0461|96 119|tumor necrosis factor alpha
P11509266A0955|17 47|hazards regression adenocarcinoma
P11509615T0000|0 27|Phosphatidylinositol 3-kinase
P11509615T0000|56 73|T cell proliferation
P11509615T0000|87 98|IL-2 receptor
P11509673A0574|11 23|transfectants
P11509673A0574|58 74|P450 AA epoxygenase
P11511544T0000|15 42|heat shock transcription factor
P11512925A0000|0 16|EXAFS measurements
P11513121T0000|19 32|robustness test
P11513121T0000|51 75|quantum chemical parameters
P11513579A0372|140 155|complex formation
P11516890A0236|24 38|cytochrome P-450
P11517190A0352|13 28|promoter sequence
P11517190T0000|26 39|rat ER alpha gene
P11517190T0000|66 78|transcription
P11517269A0472|24 44|differentiation defect
P11517269A0472|67 78|axon guidance
P11517269A0472|150 161|conservation
P11517399A0858|25 41|protein expression
P11517399A0858|106 117|acceptor site
P11517399A0858|151 161|splice sites
P11517445A0221|34 45|V. cholerae O1
P11518868A0559|43 54|risk behavior
P11518868A0559|78 92|hepatitis C virus
P11518868A0559|96 126|healthcare provider communication
P11521191A0000|38 50|12S E1A protein
P11521191A0000|63 83|phosphorylation status
P11521191A0000|142 156|phosphorylation
P11521191A0000|162 182|retinoblastoma protein
P11522431A0673|15 31|tobacco dependence
P11522431A0673|55 68|ICD-10 criteria
P11522584A0882|76 87|muscle biopsy
P11522626A1374|32 48|gene transcription
P11522626A1374|110 126|estrogen receptors
P11522658A0086|24 43|ErbB1/ErbB2 signaling
P11522658A0086|77 103|ErbB kinase inhibitor AG1478in
P11522658A0086|139 155|breast cancer cells
P11522658A0870|18 32|phosphorylation
P11522658A0870|104 116|stoichiometry
P11522658A0870|132 145|kinase activity
P11523446A0523|8 24|reference solution
P11523446A0523|48 61|time-of-flight
P11523446A0523|100 116|nitrogen detection
P11524015A0937|61 83|CAT reporter gene activity
P11524815A0753|5 16|control rates
P11524823X0001|9 19|OAE screener
P11524823X0001|43 59|distortion product
P11524823X0001|132 145|OAE screener GSI
P11524823X0001|160 174|cochlea function
P11525102A0970|40 53|ACP Journal Club
P11525102A0970|62 75|PubMed strategy
P11525640A0560|19 37|ERK kinase activities
P11525640A0560|114 130|chemical inhibitor
P11525640A0560|169 179|UV induction
P11525640A0560|185 198|GADD45 promoter
P11530684A0667|5 15|nerve injury
P11530684A0667|86 112|drive NK1-receptor mechanisms
P11530684A0667|121 136|pain transmission
P11530684A0667|212 239|drive NMDA receptor-mechanisms
P11530684A0667|304 331|drive NMDA-receptor mechanisms
P11530829A0000|45 56|ECG simulator
P11532556A0000|20 38|angioencephalopathy
P11532856A1175|28 43|N-acetylcysteine
P11532856A1175|78 99|stress kinase activities
P11532856A1175|105 117|p42/44 mitogen
P11532856A1175|212 226|HIF-1 activation
P11533238A1137|13 26|octamer element
P11533238A1137|97 121|HLA-DRA promoter activation
P11533340A1285|97 110|point advantage
P11533340A1285|113 134|Bayley motor score scales
P11533863A0125|67 80|presupposition
P11534132A0219|12 24|search engines
P11534900A0000|20 31|combinations
P11534900A0000|47 76|molluscicides Azadirachta indica
P11534900A0000|80 95|Cedrus deodara oil
P11534900A0000|100 116|synergists MGK-264
P11534900A0000|117 133|piperonyl butoxide
P11534900A0000|139 149|fruit powder
P11534900A0000|152 163|Embelia ribes
P11534900A0000|182 197|Lymnaea acuminata
P11535014A1157|38 48|seizure type
P11535014A1157|102 119|precipitate factors
P11535532A0189|19 29|enzyme DUB-2
P11536063A0178|23 41|lung transplantation
P11536063A0178|74 91|heart-lung-machine
P11538437A0568|90 106|N2 post-discharges
P11538437A0568|156 174|% CH4 post-discharges
P11539522A0612|3 16|NAUSICAA system
P11539522A0612|65 78|space dosimetry
P11540991A0127|52 83|NASA MSFC Neutral Buoyancy Simulator
P11540991A0127|133 143|EASE program
P11540991A0127|153 178|Shuttle Atlantis mission 61-B
P11542677A0411|37 50|Generic Systems
P11542677A0411|71 82|alternatives
P11542677A0411|85 108|composting facility design
P11542780A0086|62 73|contribution
P11542780A0086|88 110|energy transfer component
P11542780A0086|117 130|keV/micrometer
P11542780A0086|148 161|track detectors
P11542780A0086|182 194|energy tranfer
P11543154T0000|77 90|space radiation
P11543317A0203|122 134|track detector
P11545594A1556|94 110|amino acid residues
P11547819A0532|99 118|laser output beam sizes
P11547819A0532|157 172|matter generation
P11547819A0532|224 240|ablation hole sizes
P11547819A0532|244 265|tissue penetration rates
P11547819A0532|314 329|vessel wall injury
P11548027A0163|13 33|performance indicators
P11548027A0163|134 157|service quality indicators
P11548027A0163|158 176|personnel indicators
P11550795A2583|0 13|Overexpression
P11550795A2583|78 92|T cell hybridomas
P11552058A0833|49 62|saline solution
P11552058A0833|67 98|Tris-hydroxy-methyl-aminomethane
P11552058A0833|117 128|barbiturates
P11552724A0527|72 82|vessel lumen
P11552724A0527|185 197|interventions
P11552724A0527|249 261|contrast media
P11552922A0361|0 14|CYP2C19 genotype
P11552922A0361|33 99|polymerase chain reaction-restriction fragment length polymorphism method
P11553091A1472|60 71|relationship
P11553091A1472|129 140|relationship
P11553704A0674|102 115|MAPK activation
P11554469A1386|59 76|cellulose synthases
P11554566A0668|3 19|hatcher incubators
P11554566A0833|6 19|companies sites
P11554727A0890|3 21|mutation experiments
P11554727A0890|79 92|GGGGGAGGGGAG-3
P11555516A0639|59 69|cutoff value
P11555516A0639|103 115|artery disease
P11555669A0464|47 62|Vrinnevi Hospital
P11556809A2085|32 45|enzyme activity
P11556809A2085|72 90|5-epi-aristolochene
P11556809A2085|94 109|1-deoxycapsidiol
P11556809A2085|182 195|hydroxylations
P11556809A2085|201 220|hydrocarbon substrate
P11557127A0991|19 33|Sp1 binding sites
P11557127A0991|76 86|rat mrp2 gene
P11559366T0000|43 75|plasminogen activator inhibitor type
P11559547T0000|48 72|pS2 breast cancer marker gene
P11559564A0459|37 49|topoisomerase
P11559564A0459|81 94|splicing factor
P11559564A0459|108 121|splicing factor
P11559789A0314|64 84|ASF/SF2 splicing factor
P11559789A0314|90 101|progesterone
P11559789A0314|122 133|gene cassette
P11559789A0314|196 211|producer cell line
P11559821A1315|0 15|DNA binding assays
P11559821A1315|28 39|interference
P11559821A1315|63 75|CREB-Tax-p300
P11559821A1315|106 127|repeat oligonucleotides
P11560292A0557|39 49|domain model
P11560292A0557|51 62|prototype DSS
P11560292A0557|66 86|dipslide urine cultures
P11560509T0000|0 13|DNA recognition
P11560509T0000|16 28|F factor TraI36
P11560990A0272|0 15|E47 protein levels
P11560992A0000|7 24|specificity kinases
P11560992A0000|42 54|protein kinase
P11560992A0000|120 132|stress kinases
P11560992A0000|149 162|protein kinases
P11560992A0651|0 17|SAPK/JNK activation
P11560992A0651|112 124|mast cell lines
P11560992A0651|128 142|phosphorylation
P11560992A0651|185 197|stress stimuli
P11560992A1184|57 74|SAPK/JNK activation
P11560992A1184|112 123|growth factor
P11560992A1184|149 161|proliferation
P11561623A0897|8 40|copepod Pseudonychocamptus proximus
P11561623A0897|70 81|Tisbe furcata
P11561623A0897|84 94|sand filters
P11562278A0169|37 48|G1 regulation
P11562278A0169|78 90|proliferation
P11562278A0169|91 105|differentiation
P11562278A0169|118 131|transformation
P11564871A1184|45 64|transcription systems
P11564871A1184|176 187|TATA elements
P11564893A1068|20 31|conformation
P11564893A1068|73 87|DNA repair factor
P11564893A1068|91 112|transcription regulator
P11565747A1020|15 28|splicing assays
P11565747A1020|29 42|UV crosslinking
P11565747A1020|57 78|competition experiments
P11565747A1020|116 132|binding affinities
P11565747A1020|144 157|SELEX sequences
P11565747A1020|193 204|P element IVS3
P11566874T0000|6 16|motor domain
P11566948A1217|14 28|nephrosclerosis
P11566961A0472|0 18|Body weight reduction
P11566961A0472|28 45|insulin sensitivity
P11566961A0472|61 72|blood glucose
P11566961A0472|76 95|blood pressure control
P11566996A1391|27 57|nucleotide excision repair pathway
P11568988A0960|7 21|regression model
P11568988A0960|88 100|antibody titer
P11569800T0000|0 21|Temperature measurement
P11569900A0660|0 13|APC-resistance
P11569900A0660|87 107|factor V Leiden mutation
P11569949A2087|13 29|patient enrollment
P11570735A1097|32 44|feedback group
P11570735A1097|82 100|ground reaction force
P11570735A1097|234 247|feedback groups
P11570820T0000|4 15|casein kinase
P11572377T0000|16 27|lithotripter
P11572377T0000|62 76|cavitation field
P11572388A0000|68 95|solvation energy relationships
P11572388A0000|184 200|method development
P11572467T0000|56 81|tissue plasminogen activator
P11573771T0000|8 21|heat treatments
P11573891A0525|48 65|community outbreaks
P11574088A1687|30 47|pancreas transplant
P11574088A1687|77 89|PAK recipients
P11574105A0727|12 24|antibody peaks
P11574105A0727|60 72|antibody titer
P11574105A0727|92 104|antibody titer
P11574105A0727|132 147|disability scores
P11574105A0727|222 237|IgM antibody peaks
P11574105A0727|262 277|IgM antibody peaks
P11574105A0727|307 320|antibody titers
P11575977A1133|27 44|office hypertension
P11575977A1133|75 87|complications
P11576158A1371|5 16|TVD-patients
P11576158A1371|28 40|skin blood flow
P11576776T0081|19 43|microcrystalline cellulose
P11577094A1226|42 53|HSAL2 pathway
P11577094A1226|82 94|hematopoiesis
P11579100T0000|0 21|Phosphotyrosyl peptides
P11579100T0000|41 58|DNA binding activity
P11579100T0000|59 72|gene regulation
P11579100T0000|76 93|cell transformation
P11580173A0181|0 16|Plane wave geometry
P11580173A0181|98 112|P3 approximation
P11580301A1161|14 25|HCV arthritis
P11580301A1161|86 98|polyarthritis
P11580757A0304|34 45|TFCD patients
P11583880T0000|12 25|aneurysm repair
P11583880T0000|33 49|AneuRx stent-graft
P11584328A0532|0 15|Drug interactions
P11584328A0532|59 74|CYP450 isoenzymes
P11585856A0285|71 88|scanning line source
P11585856A0285|92 108|scatter correction
P11585856A0285|109 128|photon energy recovery
P11585856A0285|152 165|backprojection
P11586096A0699|22 43|patient characteristics
P11586096A0699|44 62|control measurements
P11587514A0758|10 26|abi1-1 gene product
P11587514A0758|43 56|ABA suppression
P11587514A0758|73 89|alpha-amylase gene
P11587980A1039|70 89|interrupter technique
P11587980A1039|139 154|resistance values
P11587980A1039|191 205|bronchodilation
P11589568A0744|24 41|checkpoint response
P11589568A0744|53 64|proteins Mad1
P11589568A0744|93 104|counterparts
P11589568A0744|125 136|kinetochores
P11589779T0000|52 67|strongyloidiasis
P11590364A1056|10 28|beta5L splice variant
P11592532A0188|7 32|Humphrey Field Analyzer model
P11592532A0188|77 87|degrees grid
P11593394A0000|12 28|growth factor-beta
P11593394A0000|44 55|growth arrest
P11593394A0000|112 132|cyclin kinase complexes
P11593394A0000|194 215|cyclin kinase inhibitors
P11595170A0582|105 116|organization
P11595176T0000|63 84|close promoter proximity
P11595176T0000|90 110|AF1q translocation gene
P11595478A1014|84 95|Hp negativity
P11595478A1014|103 117|cancer relatives
P11595813A0633|136 151|5alpha-reductase
P11595813A0633|178 194|androgen receptors
P11595840A0000|22 39|fluorodeoxyglucose
P11595840A0000|76 92|blood glucose level
P11596104A0614|0 19|Northern blot analysis
P11596838A1357|28 48|fluticasone propionate
P11596838A1357|151 163|beta2-agonist
P11597185A0477|32 45|metapopulation
P11597185A0477|62 80|computer simulations
P11597185A0477|133 154|metapopulation dynamics
P11597936A0570|5 15|CAD patients
P11597936A0570|74 91|density lipoprotein
P11597936A0570|102 114|triglycerides
P11599079A1040|16 30|orifice voltages
P11600314A0000|13 24|polarography
P11600365A0471|87 98|tosufloxacin
P11600365A0471|124 141|reference compounds
P11600467A1436|57 68|permeability
P11602353A0770|99 116|expression profiles
P11603271T0001|18 33|vertigo syndromes
P11604152A0526|10 21|MCBFV signals
P11604152A0526|83 100|low-frequency range
P11605207T0001|19 30|heart disease
P11605598A0785|13 32|C seroprevalence rates
P11605598A0785|92 104|US populations
P11605598A0785|132 149|prevention programs
P11606538A1002|50 71|receptor tyrosine kinase
P11606538A1002|91 104|neuropeptidase
P11639485A0478|112 122|day students
P11642687T0000|18 33|language versions
P11642687T0000|86 100|prostate disease
P11653491T0000|21 32|DNA violation
P11669281A0653|10 21|cytotoxicity
P11669476A0346|24 48|tumor necrosis factor-alpha
P11669476A0346|138 154|insulin resistance
P11675912A0131|89 101|acetaminophen
P11676899A0704|16 26|risk factors
P11676899A0704|66 78|mononucleosis
P11676899A0704|101 116|immunodeficiency
P11676899A0704|141 152|wood industry
P11677363A0775|117 129|PP variability
P11678437A0000|16 26|oil spillage
P11678437A0000|35 46|productivity
P11678437A0000|50 63|nutrient uptake
P11678437A0000|94 106|pot experiment
P11678437A0000|121 134|manifold sample
P11678437A0000|138 164|petroleum development company
P11679441A0429|0 12|NO metabolites
P11679441A0429|45 59|nitrate/nitrite
P11679441A0429|63 85|micromol/mmol creatinine
P11679441A0429|95 116|guanosine monophosphate
P11679441A0429|121 139|nmol/mmol creatinine
P11683558A0446|35 48|macronutrients
P11683558A0446|60 73|micronutrients
P11684665A0000|0 21|C. elegans embryogenesis
P11684665A0000|64 76|cell divisions
P11684665A0000|120 135|nematode body plan
P11685047A0301|39 56|thrombin inhibition
P11685047A0301|63 77|substrate S-2238
P11685284X0000|0 11|Diabetologia
P11686239A0464|119 136|sequence similarity
P11686239A0464|192 209|Dictyostelium genes
P11686378A0326|110 123|concentrations
P11686378A0326|144 154|E coli/cfu mL
P11687083A0218|57 84|prophylactic prostaglandin use
P11687517A1619|29 41|mouse promoter
P11687737A0000|18 29|heart disease
P11689217T0000|0 30|Cholesteryl ester transfer protein
P11689217T0000|34 48|atherosclerosis
P11691585A1174|15 33|mobility shift assays
P11691585A1174|37 64|coimmunoprecipitation studies
P11691585A1174|83 100|heterodimerization
P11691585A1174|114 131|cKrox family members
P11691585T0000|3 18|hcKrox gene family
P11691585T0000|49 59|matrix genes
P11692004A1200|90 101|relationship
P11693461A1649|5 19|utilisation data
P11693461A1649|77 90|TNF antagonists
P11695481A0310|21 36|combination O3/UV
P11695481A0310|53 67|degradation rate
P11697760A0000|57 72|17beta-estradiol
P11697760A0000|107 117|bone quality
P11703464A0560|19 30|subjects rCBF
P11703464A0560|152 164|reinforcement
P11704829A0312|0 23|Subtraction hybridization
P11704829A0312|34 56|melanoma differentiation
P11704829A0312|130 142|melanoma cells
P11705093A2016|9 26|vitamin D3 analogues
P11706668A0000|96 107|intervention
P11706949T0000|0 12|Growth hormone
P11706949T0000|28 49|growth factor I receptors
P11707977A0750|29 43|infusion therapy
P11708032A0183|58 69|levoforinate
P11708032A0183|82 95|5-fluorouracil
P11708032A0183|227 237|infuser pump
P11708362A0889|3 15|astronaut crew
P11708431A0904|19 30|introduction
P11708431A0904|58 71|oligoarthritis
P11708431A0904|118 130|patient groups
P11708761A1388|57 69|ACE inhibitors
P11708761A1388|93 108|diabetes mellitus
P11709561T0000|34 44|antibody 3F8
P11709561T0000|97 109|neuroblastoma
P11709890T0000|18 28|food handler
P11709890T0000|54 65|food facility
P11709890T0000|72 97|health protection strategies
P11710233T0000|12 28|tissue engineering
P11710685A0994a|37 50|ASCUS/SIL ratio
P11710685A0994a|100 115|Papanicolaou test
P11710685A0994b|37 50|ASCUS/SIL ratio
P11710685A0994b|100 115|Papanicolaou test
P11711701A0602|10 27|medicine physicians
P11711701A0602|95 121|Tc-99m MIBI image combinations
P11711701A0602|228 254|pertechnetate thyroid imaging
P11714429X0000|135 149|thienopyridines
P11714429X0000|282 292|Events trial
P11715079A1016|17 30|proprioception
P11715079A1016|54 66|efference copy
P11715079A1016|99 111|perturbations
P11715079A1016|149 170|eye movement information
P11716043A0380|82 114|Helsinki University Central Hospital
P11716441A0585|34 49|health evaluation
P11722993A0276|0 10|Paul Monagle
P11722993A0276|23 34|epidemiology
P11723500X0000|26 40|characteristics
P11723500X0000|51 63|cell carcinoma
P11723500X0000|104 116|cell carcinoma
P11723511A0780|50 62|category A risk
P11723675A1022|119 131|APACHE II score
P11723928A0294|29 44|river reclamation
P11723928A0294|47 60|Yangpu District
P11723928A0294|63 74|Shanghai City
P11726022A0909|69 80|calculations
P11726022A0909|93 108|time calculations
P11726164A0215|16 29|food processors
P11726164A0215|46 58|cross-contact
P11726164A0215|61 72|food products
P11726164A0215|161 171|food allergy
P11726262A0692|0 22|Lactate accumulation peak
P11726262A0692|38 52|supplementation
P11726574A1304|36 54|baseline assumptions
P11727073A0842|35 47|MIST-VR yields
P11728771A0187|50 65|contrast material
P11730182A0984|76 87|pollen levels
P11730182A0984|90 101|Philadelphia
P11730182A0984|167 178|Cupressaceae
P11730262A0874|28 46|etidronate/fluoride
P11730262A0874|66 77|osteoporosis
P11730262A0874|135 146|osteoporosis
P11730262A0874|204 219|calcium/vitamin D
P11730712A0416|0 16|Treadmill training
P11730712A0416|45 58|infarction size
P11730712A0416|75 86|MCA occlusion
P11732088A0471|58 75|sphincter manometry
P11732417A0571|10 34|percentage positivity value
P11732417A0571|103 114|serum samples
P11736254A0000|96 107|partitioning
P11736792A0204|9 20|semen samples
P11736792A0204|85 115|World Health Organization criteria
P11737158A1517|43 55|fusiform gyrus
P11737158A1517|102 113|computations
P11738404A0120|5 22|chemical structures
P11738404A0120|46 81|alpha-diacetoxy-8 beta-isobutanoyloxy
P11738404A0120|83 101|alpha-benzoyloxy-13
P11738404A0120|101 112|alpha-methyl
P11738404A0120|112 128|butanoyloxy-4 beta
P11738404A0120|130 166|beta-dihydroxy-beta-dihydroagarofuran
P11738404A0120|175 195|alpha-diacetoxy-8 beta
P11738404A0120|199 214|furancarbonyloxy
P11738404A0120|216 255|alpha-benzoyloxy-13-isobutanoyloxy-4 beta
P11738404A0120|257 293|beta-dihydroxy-beta-dihydroagarofuran
P11738404A0120|310 386|alpha,13-tetraacetoxy-9 alpha-benzoyloxy-2 alpha-hydroxy-beta-dihydroagarofuran
P11738404A0120|396 406|analyses NMR
P11740571A0114|55 67|concentration
P11740571A0114|87 107|glutathione peroxidase
P11740571A0114|110 120|brain tissue
P11740571A0114|145 170|chemiluminescence intensity
P11740806X0810|0 14|Saunders Company
P11741554T0000|24 43|lipoprotein particles
P11741554T0000|87 99|artery disease
P11741554T0000|120 132|artery disease
P11742432A0798|73 86|MAC prophylaxis
P11742432A0798|201 212|colonization
P11742432A0798|256 270|discontinuation
P11742432A0798|273 292|macrolide prophylaxis
P11742432A0798|298 309|AIDS patients
P11742432A0798|341 352|cells/microL
P11743612A1179|17 29|meconium ileus
P11743612A1179|81 92|survival rate
P11743612A1179|113 124|CF population
P11744290T0045|9 19|waste matter
P11744953A0878|0 10|Skin cancers
P11744953A0878|81 91|age patients
P11752821A1365|61 79|Adamantiades-Behcet
P11755894A0466|180 192|bowel function
P11755894A0466|206 217|hospital stay
P11760398A0553|188 198|ISG criteria
P11760796A0698|20 33|PHACES syndrome
P11760796A0698|65 76|phakomatosis
P11761601A0133|1 15|computer program
P11761601A0133|50 63|airflow pattern
P11761601A0133|67 77|time history
P11761601A0133|83 107|contaminant concentrations
P11761601A0133|131 149|inhalation exposures
P11763176A0918|25 44|antithrombin activity
P11764062A0000|3 29|Penn State Worry Questionnaire
P11764062A0000|57 80|self-report questionnaire
P11764226A0798|0 13|Classification
P11764226A0798|28 39|ILAR criteria
P11764226A0798|79 93|disease duration
P11764226A0798|136 148|EULAR criteria
P11765448A0588|9 23|X-ray projection
P11768467A0000|0 21|Pyrethroid insecticides
P11769229A0357|3 20|sorption mechanisms
P11771979A1141|199 211|heterogeneity
P11773921A0397|7 26|P-selectin expression
P11773921A0397|173 185|artery disease
P11773921A0397|240 251|implantation
P11775180A0379|54 73|gamma-detecting probe
P11775301A0797|13 24|intervention
P11775301A0797|27 42|depression scores
P11777575A0363|39 52|S. thermophilus
P11777632A1678|155 166|AF expression
P11777632A1678|194 205|breast cancer
P11778044A0000|13 43|probability density distributions
P11778044A0000|79 91|climate system
P11778044A0000|106 127|fingerprinting approach
P11778044A0000|164 185|complexity climate model
P11778044A0000|222 240|climate observations
P11781615A0000|44 55|complication
P11781615A0000|81 99|cell transplantation
P11782218A0349|10 23|white-on-white
P11782218A0349|123 137|media absorption
P11782218A0349|147 165|examination duration
P11782218A0349|181 194|learning effect
P11783457A0000|0 12|Preservatives
P11783457A0000|48 59|preparations
P11783457A0000|114 126|decomposition
P11785085X0001|148 163|vacuum aspiration
P11785085X0001|164 175|Introl-4 unit
P11785085X0001|190 207|pneumovibromassage
P11785827A0986|154 170|selection pressure
P11785827A0986|174 189|transmissibility
P11785827A0986|197 209|communication
P11786248A1162|126 137|sham controls
P11787322X0001|29 48|chemical disinfection
P11787322X0001|140 153|prosthodontics
P11787322X0001|253 264|transmission
P11787746A0374|30 42|lens fragments
P11789206A1182|31 42|Qi deficiency
P11789206A1182|46 56|blood stasis
P11789206A1182|116 126|blood stasis
P11789216T0001|19 34|blood circulation
P11789216T0001|43 53|blood stasis
P11789216T0001|56 68|barrier action
P11790897T0000|104 115|breast cancer
P11791571T0000|1 48|high-efficiency cross-flow micronebulizer interface
P11791571T0000|61 75|electrophoresis
P11791571T0000|97 118|plasma mass spectrometry
P11791853A0532|35 69|coagulation-electrooxidation process
P11792586A0290|85 96|tissue matrix
P11793172A0545|71 89|friction coefficient
P11793614A0000|49 62|concentrations
P11793614A0000|83 99|phosphodiesterase
P11793614A0000|179 193|anticoagulation
P11796977T0000|26 39|mainland Europe
P11800119A0814|3 17|design principle
P11800119A0814|33 45|vibration mode
P11800586A1090|137 148|tuberculosis
P11800878T0000|0 13|Dynamic imaging
P11800878T0000|23 35|wave functions
P11800878T0000|40 62|ultrashort UV laser pulses
P11801459T0000|52 67|atherothrombosis
P11802580A0000|3 33|General Practice Research Database
P11802580A0000|56 75|computerized database
P11802580A0000|100 113|patient records
P11802580A0000|151 168|health research tool
P11802601A0107|29 43|laboratory study
P11802601A0107|75 89|aldicarb sulfone
P11802601A0107|93 109|aldicarb sulfoxide
P11803325A0868|7 21|DC cardioversion
P11804100A0365a|17 29|disappearance
P11804100A0365b|17 29|disappearance
P11804510A0730|8 20|dichlofluanid
P11804510A0730|23 34|chlozolinate
P11806132A0253|3 13|TB incidence
P11806132A0253|39 49|% TB patients
P11810685A0147|16 39|displacement distribution
P11810685A0147|74 85|displacement
P11810685A0147|102 116|long-wavelength
P11810685A0147|152 175|displacement distribution
P11811743A0800|58 67|Class III FI
P11811825A0972|23 49|cross-validation experiments
P11811825A0972|127 142|sensitivity level
P11815644A0081|11 25|characteristics
P11815644A0081|116 132|muscle recruitment
P11815644A0081|139 150|echolocation
P11816458A0319|21 32|Explanations
P11816458A0319|96 108|review article
P11816458A0319|109 122|journal article
P11816458A0319|145 158|journal article
P11816779A0343|3 13|drug packets
P11816779A0343|23 35|acetyl aspirin
P11816779A0343|36 48|acetaminophen
P11816779A0343|52 66|chloramphenicol
P11819326A0000|88 101|encephalopathy
P11821098A0269|0 17|MAIN OUTCOME MEASURE
P11821098A0269|18 28|Serum levels
P11822790A0907|97 111|study population
P11822790A0907|187 206|reproducibility noise
P11822811A0319|50 72|microg/kg ivermectin p.o.
P11822811A0319|109 120|intoxication
P11824701A0894|52 67|behavior patterns
P11824701A0894|77 89|Bortner scores
P11824801A0661|13 24|continuation
P11824801A0661|30 46|interferon therapy
P11824801A0661|79 90|exacerbation
P11824801A0661|149 164|organ involvement
P11826141T0000|20 40|lidocaine inactivation
P11826141T0000|100 112|reinstatement
P11828186A0239|77 88|heart disease
P11828186A0239|95 109|CRP measurements
P11828186A0239|115 133|Third National Health
P11828186A0239|137 162|Nutrition Examination Survey
P11830544A0335|105 116|WIBC-9 tumors
P11830544A0335|137 153|control MC-5 tumors
P11830544A0335|176 187|angiogenesis
P11831512A0468|108 125|carbohydrate source
P11831512A0468|160 177|dextrose equivalent
P11832019A0668|42 57|emergency disease
P11833863A0987|22 34|apnea duration
P11834476A1187|17 27|animal model
P11834476A1187|116 136|hemoglobin transfusion
P11834476A1187|147 161|oxygen transport
P11836046A0549|47 62|calcium carbonate
P11836046A0549|125 140|calcium carbonate
P11836046A0549|201 221|mg medrogestone acetate
P11836303A0518|40 58|culture supernatants
P11836303A1191|81 95|cytokine biology
P11837409A0584|20 44|National Longitudinal Study
P11837409A0584|47 62|Adolescent Health
P11837409A0584|87 100|symptomatology
P11838058A0084|39 53|tissue expansion
P11838058A0084|98 112|tissue expansion
P11838102T0001|8 21|granulomatosis
P11840365A0949|43 60|General Health scale
P11842037A0327|27 49|% urine-plasma difference
P11842728X0001|18 32|schistosomiasis
P11842728X0001|33 46|Schistosomosis
P11842728X0001|75 85|blood flukes
P11842728X0001|91 106|Schistosoma genus
P11843252A0907|7 18|response rate
P11843252A0907|25 43|% confidence interval
P11844812A0915|33 43|ANN ROC curve
P11844812A0915|138 151|prostate volume
P11845547A0449|36 56|KATP channel activators
P11845547A0449|60 75|21-aminosteroids
P11846167A0000|60 73|microorganisms
P11846187A0894|3 21|GT-foreign-pictures
P11846187A0894|81 102|permeability directions
P11847580T0000|13 25|cholecystitis
P11849417A0900|91 108|dialysis PD patients
P11849796A0452|64 75|improvements
P11851941A0372|32 49|serumalbumin method
P11851941A0372|61 71|blood volume
P11851941A0372|77 89|haemodilution
P11851941A0372|145 161|reference solution
P11851941A0372|164 181|hydroxyethyl starch
P11852907A0871|3 30|equilibrium phosphorus content
P11852907A0871|37 47|surface soil
P11852907A0871|85 97|drainage water
P11853943A0122|45 65|R-R interval estimation
P11858548A0241|76 91|mass spectrometry
P11858635A0896|61 79|LOO cross-validation
P11859400A0229|31 42|valacyclovir
P11859400A0229|55 69|HSV reactivation
P11859400A0229|100 128|progenitor cell transplantation
P11859400A0229|193 206|HSV prophylaxis
P11859943A0150|21 37|outpatient clinics
P11859943A0150|101 126|General Health Questionnaire
P11860097A1695|6 18|prosthesis use
P11860097A1695|100 114|prosthesis users
P11860723A0182|13 26|Georgia members
P11860723A0182|32 46|American College
P11860723A0182|49 61|Obstetricians
P11860723A0182|65 77|Gynecologists
P11860876A0409|0 12|HIV-1 C subtype
P11861092A0730|98 110|scanning modes
P11861092A0730|145 157|colour Doppler
P11861092A0730|172 183|power Doppler
P11861092A0730|221 233|inversion mode
P11861092A0730|244 257|HDI5000 scanner
P11862350T0000|31 43|carbamazepine
P11862350T0000|50 81|NMDA receptor antagonist remacemide
P11862350T0000|84 95|road tracking
P11863811A0259|21 33|Nusselt number
P11864173T0000|45 57|exacerbations
P11865218A0069|44 55|wax softening
P11866130A0419|23 38|2-phenoxyethanol
P11866130A0419|48 65|complement activity
P11866130A0419|69 80|phagocytosis
P11866130A0419|94 111|quinaldine sulphate
P11867388A0502|40 52|concentration
P11867388A0502|75 90|fear conditioning
P11867388A0502|144 159|fear conditioning
P11870646A0668|37 67|ceramic/substrate bilayer systems
P11872359A0000|21 37|insulin resistance
P11872359A0000|83 93|risk factors
P11873003X0000|0 13|HIV-1 infection
P11873003X0000|162 177|progression times
P11873003X0000|180 193|HIV-1 infection
P11873003X0000|198 211|seroconversion
P11874637A0212|70 81|improvements
P11874637A0212|98 109|HIV infection
P11874637A0212|176 193|deficiency syndrome
P11874637A0212|204 215|malignancies
P11875695A0718|59 70|registration
P11879108A0719|0 17|MAIN OUTCOME MEASURE
P11879108A0719|76 99|ligase chain reaction assay
P11879108A0719|109 122|outcome measure
P11879108A0719|153 173|immunodeficiency virus
P11881268A0000|65 98|exercise self-efficacy questionnaire
P11881923A1256|9 23|lymphocyte ratio
P11881923A1256|24 40|plasma haptoglobin
P11881923A1256|110 120|POST periods
P11882054A0568|188 199|lesion volume
P11882054A0568|206 217|mirror region
P11882054A1250|63 77|spiking activity
P11882054A1250|191 205|epileptogenesis
P11882747A0354|23 42|Farnsworth D-15 method
P11883682A0162|58 69|distribution
P11883682A0162|88 105|estuarine sediments
P11883763A1062|170 180|Pu transport
P11883763A1062|207 218|East China Sea
P11884014A0665|8 25|treatment protocols
P11884014A0665|29 40|diet delivery
P11885053A1897|133 146|memorial shrine
P11885737A1713|25 42|spermatozoa/microl
P11886473A0796|0 13|Gastritis score
P11887803A1455|3 15|mean thickness
P11888183A0541|48 63|maximum intensity
P11890354A0000|0 16|Genetics Institute
P11893403A0252|31 46|safety evaluation
P11893403A0252|49 65|flavor ingredients
P11893403A0252|108 123|pharmacokinetics
P11893767A0356|23 39|minute ventilation
P11893767A0356|111 126|breathing pattern
P11894605A1429|0 13|INTERPRETATION
P11894605A1429|65 81|health information
P11895024A1054|44 58|AFP surveillance
P11895024A1054|76 91|hospital searches
P11895184A0000|56 67|object-place
P11895184A0000|125 148|cheeseboard maze apparatus
P11897449A0566|21 34|activation site
P11897449A0566|40 53|administration
P11897888A0590|0 11|Urine samples
P11897888A0590|29 42|administration
P11897950A0617|11 28|Lymphoscintigraphy
P11897950A0617|34 56|cynomolgus monkey eyelids
P11897950A0617|81 96|drainage pathways
P11898018T0000|0 13|Data management
P11898797A0124|39 70|choline acetyltransferase activity
P11899479A0122|77 90|denture surface
P11899479A0122|93 107|cotton wool swabs
P11899479A0122|139 149|glucose agar
P11899479A0122|153 168|CHROMagar Candida
P11899479A0122|179 190|yeast species
P11899479A0122|230 246|assimilation tests
P11899479A0122|269 280|kit AuxaColor
P11900770T0000|66 91|dopamine receptor antagonism
P11902738A0185|43 53|cohort study
P11902738A0185|147 161|neutrophil count
P11902781A0550|0 13|Concentrations
P11907691A0214|3 14|orientations
P11907691A0214|20 34|contact surfaces
P11908529A0553|94 105|AgCl crystals
P11912261A0284|33 44|PTH secretion
P11913427A0290|62 74|accelerations
P11915436A0491|11 24|incidence rates
P11917061A0922|119 131|remission rate
P11917882A0326|119 135|adhesion-strategy
P11920455X1195|13 33|American Cancer Society
